<SEC-DOCUMENT>0001628280-25-043232.txt : 20250930
<SEC-HEADER>0001628280-25-043232.hdr.sgml : 20250930
<ACCEPTANCE-DATETIME>20250930161943
ACCESSION NUMBER:		0001628280-25-043232
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		116
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250930
DATE AS OF CHANGE:		20250930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nanobiotix S.A.
		CENTRAL INDEX KEY:			0001760854
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39777
		FILM NUMBER:		251360722

	BUSINESS ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
		BUSINESS PHONE:		33140260470

	MAIL ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>nbx-20250630.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e10ad955-f4fb-4992-aa6a-58056e28f5e0,g:51b53987-7aad-4161-819f-cbfd12ac6608,d:a72c30516b7642d5b908b439c54b9466-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbx="http://nanobiotix.com/20250630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbx-20250630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-9">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-10">0001760854</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-11">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-12">6/30/2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-13">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-14">Q2</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbx-20250630.xsd"/></ix:references><ix:resources><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="subsidiary"><xbrli:measure>nbx:subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="security"><xbrli:measure>nbx:security</xbrli:measure></xbrli:unit><xbrli:unit id="quarterly_installment"><xbrli:measure>nbx:quarterly_installment</xbrli:measure></xbrli:unit><xbrli:unit id="loan"><xbrli:measure>nbx:loan</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>nbx:employee</xbrli:measure></xbrli:unit><xbrli:unit id="benefeciary"><xbrli:measure>nbx:benefeciary</xbrli:measure></xbrli:unit><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:NanobiotixCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nbx:NettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ThirdPartyServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ThirdPartyServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ClinicalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ClinicalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:SuppliersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2025TaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2025TaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2024TaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-27</xbrli:startDate><xbrli:endDate>2025-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-18</xbrli:startDate><xbrli:endDate>2025-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-16</xbrli:startDate><xbrli:endDate>2025-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-16</xbrli:startDate><xbrli:endDate>2025-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nbx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nbx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:PGELoanAgreementBPIFranceAndHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:PGELoanAgreementBPIFranceAndHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:LiabilitiesRelatedToFinancingActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:LiabilitiesRelatedToFinancingActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:LiabilitiesRelatedToFinancingActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BanquePubliqueDInvestissementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-10</xbrli:startDate><xbrli:endDate>2020-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:DebtDetailsAxis">nbx:PrincipalAndFixedRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:DebtDetailsAxis">nbx:MilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:ClinicalStudiesAxis">nbx:NANORAY312Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:ClinicalStudiesAxis">nbx:NANORAY312Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:ClinicalStudiesAxis">nbx:NANORAY312Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:ClinicalStudiesAxis">nbx:NANORAY312Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:ClinicalStudiesAxis">nbx:A1100StudyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:NANORAY312Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:RechargeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:TechnologyTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServiceRechargeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:SupplyServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentArrangement1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OperatingExpenseAxis">nbx:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OperatingExpenseAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentArrangement1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentArrangement1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentArrangement1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:NonRecurringExpenseTypeAxis">nbx:EmploymentTerminationIndemnitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-10</xbrli:startDate><xbrli:endDate>2015-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:LaurentLevyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:LaurentLevyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:LaurentLevyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:LaurentLevyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:LaurentLevyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-10</xbrli:startDate><xbrli:endDate>2015-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-27</xbrli:startDate><xbrli:endDate>2018-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneMarieGraffinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneMarieGraffinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneMarieGraffinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:EnnoSpillnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:EnnoSpillnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:EnnoSpillnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AlainHerreraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AlainHerreraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AlainHerreraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-27</xbrli:startDate><xbrli:endDate>2018-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-03</xbrli:startDate><xbrli:endDate>2016-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-06</xbrli:startDate><xbrli:endDate>2018-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-24</xbrli:startDate><xbrli:endDate>2019-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-24</xbrli:startDate><xbrli:endDate>2019-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-24</xbrli:startDate><xbrli:endDate>2019-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-03</xbrli:startDate><xbrli:endDate>2016-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-06</xbrli:startDate><xbrli:endDate>2018-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LouisKayitalireMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LouisKayitalireMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-23</xbrli:startDate><xbrli:endDate>2024-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">nbx:HSBCBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbx:NBTXR3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbx:TechnologyTransferAndTechnicalAssistanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">nbx:NanobiotixCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:JohnsonJohnsonInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia72c30516b7642d5b908b439c54b9466_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:80%">____________________________________________________________________________________________________________________________________________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">6-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________ </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-16 OR 15d-16</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Date of report: September&#160;30, 2025</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-2" continuedAt="f-2-1"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-3" continuedAt="f-3-1">0</ix:nonNumeric></ix:nonNumeric></span><span style="background-color:#ffffff;color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:continuation id="f-2-1"><ix:continuation id="f-3-1">01-39777</ix:continuation></ix:continuation></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:17pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-4">NANOBIOTIX S.A.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nanobiotix S.A.</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-5">60 rue de Wattignies</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-6">75012</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-7">Paris</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-8">France</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive office)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.053%"><tr><td style="width:1.0%"/><td style="width:45.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center;text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9746; Form 20-F</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744; Form 40-F</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744; </span></div><div><span><br/></span></div><div style="text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:80%">______________________________________________________________________________________________</span></div><div><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:80%">______________________________________________________________________________________________</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_7"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This Form 6-K, including Exhibits 99.1 and 101, is incorporated by reference into the Company&#8217;s Registration Statements on Form F-3 (File No. 333-285604) and Form S-8 (File Nos. 333-253062, 333-257239, 333-272947 and 333-287272).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our Half-Year Report, filed as Exhibit 99.1 hereto, includes references to the Company&#8217;s website at </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">http://www.nanobiotix.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Such reference to the Company&#8217;s website is an inactive textual reference only, and the information contained in, or that can be accessed through, the Company&#8217;s website, including the Company&#8217;s universal registration document filed with the French Financial Markets Authority (Autorit&#233; des March&#233;s Financiers &#8211; the AMF), is not filed as a part of this Form 6-K.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_13">99.1</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_13">Half-Year Financial Report From January 1, 2025 to June 30, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The following materials from Exhibit 99.1 (Nanobiotix S.A.&#8217;s Half-Year Financial Report From January 1, 2025 to June 30, 2025) filed on this on Form 6-K formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the unaudited interim condensed statements of consolidated financial position, (ii) the unaudited interim condensed statements of consolidated operations, (iii) the unaudited interim condensed statements of consolidated comprehensive loss, (iv) the unaudited interim condensed statements of consolidated changes in shareholders&#8217; equity, (v) the unaudited interim condensed statements of consolidated cash flows, and (vi) the notes to the unaudited interim condensed financial consolidated statements.</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_10"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.665%"><tr><td style="width:1.0%"/><td style="width:14.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.279%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">NANOBIOTIX S.A.</span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">/s/ LAURENT LEVY</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Laurent Levy, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chairman of the Executive Board</span></td></tr></table></div><div style="text-align:right"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Date: September&#160;30, 2025</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_13"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div style="padding-left:72pt;text-align:right;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 99.1</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt;padding-left:92.12pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:46.06pt;padding-right:46.06pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:48pt;font-weight:700;line-height:120%">NANOBIOTIX</span></div><div style="padding-left:46.06pt;padding-right:46.06pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">HALF-YEAR FINANCIAL REPORT</span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From January&#160;1, 2025 to June&#160;30, 2025</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">September&#160;30, 2025</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div style="padding-left:72pt;text-align:right;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 99.1</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:2.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">I.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_22">Interim activity report</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_22">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_25">Company information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_25">3</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_28">Significant events during the six-month period ended June 30, 2025</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_28">3</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_31">Company activity over the six-month ended June 30, 2025</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_31">5</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_34">Future prospects</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_34">6</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_37">Main risks and uncertainties for the remaining six months</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_40">7</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_40">Key transactions with related parties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_40">7</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_43">Liquidity and capital resources</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_43">8</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">II. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_46">Unaudited interim condensed consolidated financial statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_46">10</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_49">Unaudited interim condensed statements of consolidated financial position</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_49">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_52">Unaudited interim condensed statements of consolidated operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_52">2</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_55">Unaudited interim condensed statements of consolidated comprehensive loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_55">3</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_58">Unaudited interim condensed statements of consolidated changes in shareholders' equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_58">4</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_61">Unaudited interim condensed statements of consolidated cash flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_61">5</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_64">Notes to the unaudited interim condensed consolidated financial statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_64">6</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_19"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This interim and semi-annual report (the &#8220;Report&#8221;) contains &#8220;forward-looking statements&#8221; within the meaning of applicable federal securities laws, including the Private Securities Litigation Reform Act of 1995. All statements other than present and historical facts and conditions contained in this Report, including statements regarding our future results of operations and financial position, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this Report, the words &#8220;consider,&#8221; &#8220;anticipate,&#8221; &#8220;think,&#8220;, &#8220;aim&#8220;, &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;ambition,&#8220; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;is designed to,&#8221; &#8221;wish,&#8221; &#8220;may,&#8221; &#8221;is designated to,&#8221;,&#8220;might,&#8221;&#8220;on track,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;objective,&#8221; &#8220;should,&#8221; &#8220;scheduled,&#8221; &#8220;would&#8221; or &#8220;will,&#8221; or the negative of these and similar expressions identify forward-looking statements. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those described in our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the SEC) on April 02, 2025 under &#8220;Item 3.D. Risk Factors&#8221; (copy of which are available on www.nanobiotix.com). These risks and uncertainties include factors relating to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our reliance on Janssen to conduct the JNJ-1900 (product formerly coded NBTXR3) development and commercialization activities worldwide in accordance with the Janssen Agreement and the Asia Licensing Agreement;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to successfully develop JNJ-1900 (NBTXR3), including by expanding JNJ-1900 (NBTXR3) pipeline, through the license agreement with Janssen Pharmaceutica NV (&#8220;Janssen&#8221;), dated July 7 2023 (the &#8220;License Agreement&#8221;), and to commercialize JNJ-1900 (NBTXR3) through such License Agreement;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the expected timeline of our clinical trial completion, including our ability, and the ability of our development partners, to successfully conduct, supervise and monitor clinical trials for our product candidates and to complete clinical trial NANORAY-312&#160;within&#160;the expected&#160;timeline considering a number of factors, including the rate of patient enrollment and the potential delays related to the transfer of the sponsorship of this clinical trial NANORAY-312 from Nanobiotix to Janssen;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the completion of applicable pre-marketing regulatory requirements and/or our ability to maintain regulatory approvals and certifications for our products and product candidates in the United States, the European Union (the &#8220;EU&#8221;), and other countries, and the rate and degree of market acceptance of our product candidates, including JNJ-1900 (NBTXR3) through Janssen according to the License Agreement;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the initiation, timing, progress and results of our preclinical studies and clinical trials, including those trials to be conducted under our collaborations with the MD Anderson Cancer Center of the University of Texas (&#8220;MD Anderson&#8221;) and under the License Agreement;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to obtain raw materials, to maintain and operate our facilities to manufacture our product candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to implement our strategic plan, beyond JNJ-1900 (NBTXR3) product, for our platform(s), product candidates and technology; including to expand into additional innovative therapies, including through our Curadigm Nanoprimer platform, and to advance such technologies directly or through collaboration agreements;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to effectively execute under our collaboration agreements, including the License Agreement, and to effectively resolve disputes, if any;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to obtain funding for our operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to attract and retain key management and other qualified personnel;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our global operations and exposure to global markets;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to protect and maintain our intellectual property rights, manufacturing know-how and proprietary technologies and our ability to operate our business without infringing upon the intellectual property rights and proprietary technologies of third parties;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to effectively deploy our capital resources;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">future revenue, expenses, capital expenditures, capital requirements and performance of our publicly traded equity securities;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to compete with institutions with greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing and marketing;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our status as a foreign private issuer and the reduced disclosure requirements associated with maintaining this status.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; or &#8220;the Company believes&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to the Company as of the date of this Report, and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and the Company statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these factors, the Company cannot assure that the forward-looking statements in this Report will prove to be accurate. Furthermore, if the forward-looking statements of the Company prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements these statements should not be regarded or considered as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This Report should be read with the understanding that the Company&#8217;s actual future results may be materially different from what is expected. The Company qualifies all of the forward-looking statements by these cautionary statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_22"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">INTERIM ACTIVITY REPORT</span></div><div style="text-align:center"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1. COMPANY INFORMATION </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nanobiotix, a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> registered with the Paris registry of trade and companies under number 447 521 600 and having its registered office at 60 rue de Wattignies, 75012, Paris (&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nanobiotix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221; and, with its subsidiaries, the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Group</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;), is a late-stage clinical biotechnology company pioneering disruptive, nanophysics-based therapeutic approaches to the treatment of cancer and other major diseases with the express intent of favorably  impacting the lives of millions of patients.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The Company also has subsidiaries in Cambridge, Massachusetts (United States), Spain, and Germany. The Group has been listed on Euronext: Paris under the ticker symbol &#8220;NANO&#8221; since 2012 (ISIN: FR0011341205, Bloomberg Code: NANO:FP) and on the Nasdaq Global Select Market in the United States under the ticker symbol &#8220;NBTX&#8221; since December 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Group is the owner of more than 25 patent families associated with three nanotechnology platforms: 1) radioenhancer platform, from which JNJ-1900 (NBTXR3) is the first product candidate, designed to physically destroy tumor cells locally and prime immune response systemically; 2) Curadigm nanoprimer platform designed to redefine the design and application of therapeutic classes challenged by liver clearance; and 3) OOcuity neurological disease program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s efforts are concentrated on advancing JNJ-1900 (NBTXR3).</span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_28"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2. SIGNIFICANT EVENTS DURING THE SIX-MONTH PERIOD ENDED JUNE 30, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The clinical development during the first half of 2025 continued to focus on building a therapeutic foundation for JNJ-1900 (NBTXR3) in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) as areas of strategic priority. In both indications, radiotherapy remains a cornerstone of care, offering a rational setting for the integration of a locally administered radioenhancer such as JNJ-1900 (NBTXR3). In head and neck cancer, the focus was on the ongoing Phase 3 NANORAY-312 trial with the transfer of trial sponsorship to our licensee Janssen Pharmaceutica NV, a Johnson &amp; Johnson Company (&#8220;J&amp;J&#8221;), moving toward completion. In parallel, Nanobiotix strengthened its financial position through an amendment to the License Agreement with J&amp;J, providing additional support for the advancement of the ongoing Phase 3 NANORAY-312 trial. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expansion into additional tumor types where radiation alone or in combination with immunotherapy is part of the standard of care is also ongoing and has yielded evidence of anti-tumor activity while confirming the safety profile of JNJ-1900 (NBTXR3), such as in re-irradiation for NSCLC and in patients with locally advanced or borderline resectable pancreatic cancer, as reported in the first half of 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lung Cancer (NSCLC): First Randomized Trial in Lung </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Through our collaboration with J&amp;J, NSCLC has become another key area of development together with HNSCC. In the first quarter of 2025, J&amp;J dosed the first patient in CONVERGE, a randomized global Phase 2 trial evaluating JNJ-1900 (NBTXR3) activated by radiotherapy for patients with Stage III unresectable NSCLC patients receiving standard of care chemoradiation followed by consolidation durvalumab. This trial is the first randomized study of JNJ-1900 (NBTXR3) in lung cancer and, if positive per protocol, may represent a significant milestone in the expansion of the development pipeline under the Nanobiotix-J&amp;J License Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lung Cancer (NSCLC): First Phase 1 Results</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, results from the completed dose escalation part of an investigator-sponsored Phase 1 trial (Study 2020-0123) conducted by The University of Texas MD Anderson Cancer Center were presented at the 2025 European Lung Cancer Conference (ELCC). This study evaluates JNJ-1900 (NBTXR3) in patients with locoregional recurrent, previously irradiated, inoperable NSCLC, thus exploring the opportunity to use JNJ-1900 (NBTXR3) in a re-irradiation setting. Twelve patients were evaluated for safety, feasibility and preliminary review of survival data:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">No JNJ-1900 (NBTXR3)-related dose-limiting toxicities and no Grade 3 or higher SAEs related to JNJ-1900 (NBTXR3) were reported </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Promising early efficacy signals were observed: a preliminary review of survival data showed 12-month LPFS of 64% (median 18.6 months) and 12-month OS of 83% (median 30.2 months)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These results support the feasibility and therapeutic potential of using JNJ-1900 (NBTXR3) in a re-irradiation setting, which represents a patient population with few effective treatment options. The expansion part is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pancreatic Cancer: Full Phase 1 Data and Study Expansion</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2025, Nanobiotix announced full data from its Phase 1 trial evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer, a population with high unmet need. The study demonstrated in 22 patients:</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Median overall survival of 23.0 months vs 19.2 months from historical control</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Median local progression-free survival of 13.3 months ;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">CA19-9 normalization in 59% of patients ;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Two patients with locally advanced pancreatic cancer (LAPC) achieved R0 surgical resection.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These results suggest that radiotherapy-activated JNJ-1900 (NBTXR3), after induction chemotherapy, may enhance local tumor control and improve the likelihood of successful resection. An expansion cohort combining JNJ-1900 (NBTXR3) with standard chemoradiation, after induction chemotherapy, was initiated in the first half of 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amendment of the License Agreement with J&amp;J</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2025, Nanobiotix and J&amp;J executed an amendment to the License Agreement which is transferring almost full financial responsibility for NANORAY-312, the ongoing global Phase 3 study evaluating JNJ-1900 (NBTXR3) for locally advanced head and neck cancer from Nanobiotix to J&amp;J, less a small portion of costs that will remain covered by Nanobiotix. Nanobiotix continues to support the execution of NANORAY-312 during and after the sponsorship transition. Selected and limited future milestone obligations previously owed by J&amp;J to Nanobiotix were reduced in consideration of this amendment.</span></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> An MD Anderson historical review of 144 patients with  locally advanced pancreatic cancer (LAPC) treated at the same center showed a mOS of 19.2 months. Patients in the historical review received induction chemotherapy followed by RT with or without concurrent or maintenance chemotherapy (80% received RT with concurrent chemotherapy)</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3. COMPANY ACTIVITY OVER THE SIX MONTHS ENDED 2025</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">3.1. Revenue and other income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Revenue and other income for the six month period ended June&#160;30, 2025 was &#8364;26.6 million, compared to &#8364;9.3 million for the six months ended June&#160;30, 2024, mainly driven by the revenue recognized in connection with the contract modification of Janssen Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the Total Revenue reached </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8364;24.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, composed of:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the line &#8216;Services&#8217; includes (i) a one-off positive revenue of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8364;21.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> directly attributable to the contract modification impact occurred during the first half of 2025, that counterbalances the negative revenue impact recognized in fiscal year 2024 : the amendments signed during the last quarter of 2024 had significantly reduced the transaction price of the license agreement as the R&amp;D service performance obligation was replaced with a funding obligation for the Company towards Janssen, while the amendment letter executed in March 2025 did not impact the scope of the Company's performance obligations but increased the remaining transaction price of the global license agreement, (ii) and other &#8216;Services&#8217; revenue linked to technology transfer and technical assistance recharge to Janssen for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8364;0.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">&#8364;3.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> of &#8216;Other Sales&#8217; related to products clinical supplies to Janssen for the six-month period ended June 30, 2025.</span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2024, the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8364;6.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Total Revenue mainly includes (i) &#8216;Services&#8217; revenue linked to the assignment of the license to Janssen and the rendered R&amp;D services in proportion of the completion of the ongoing studies, totaling </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8364;2.7&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">; (ii) &#8216;Services&#8217; revenue linked to technology transfer and technical assistance recharge for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8364;1.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">; (iii) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8364;2.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> of &#8216;Other Sales&#8217; related to products clinical supplies to Janssen.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Total other income amounts to &#8364;1.7 million for the period ended June 30, 2025 as compared to &#8364;3.1 million for the period ended June 30, 2024, the &#8364;1.4 million decrease mainly relating to (i) the research tax credit for &#8364;1.6 million, compared to &#8364;2.3 million for the period ended June 30, 2024, mainly due to the exclusion of a major vendor from the CIR scope and (ii) the services recharge in connection with the global trial collaboration agreement (or &#8220;GTCA&#8221;) totalling &#8364;26&#160;thousand as compared to &#8364;0.5&#160;million in the prior-year period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For further details, see Note 16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> - Revenues and other income </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the unaudited interim condensed consolidated financial statements included in this report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of our revenue and other income of the Company are set forth in the table below:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,376&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">24,928</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,163</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,616&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,334&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">756&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,710</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,126</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenue and other income</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">26,638</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,289</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">3.2 Operating Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The operating expenses for the first half of 2025 totaled &#8364;25.8 million compared to &#8364;32.9 million in the first half of 2024. The relative weight of R&amp;D and SG&amp;A expenses as percentage of total operating expenses changed from 67% and 33%, respectively, in the first half of 2024 to 56% and 44% in the first half of 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the first half of 2025, the &#8364;7.5 million decrease of R&amp;D expenses is mainly due to a decrease of &#8364;7.7&#160;million  of our purchases, sub-contracting and other expenses reflecting the transfer of sponsorship of the 312 study to Janssen, including the amendment of the Janssen Agreement signed in March 2025, resulting in the removal of funding obligations on the 312 study, partially offset by the increase of &#8364;0.2 million in R&amp;D Payroll costs.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Overall, SG&amp;A expenses slightly increased by &#8364;0.5 million, up to &#8364;11.3 million for the first half of 2025,compared to &#8364;10.8 million for the first half of 2024. This is due to SG&amp;A payroll costs increase by &#8364;0.7&#160;million related to social charges related on stock options granting occurred in June 2025 (vs July in 2024), which is partially offset by &#8364;0.4 million decrease related to litigation provision settlement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.190%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Relative weight</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Relative weight</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SG&amp;A expenses</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,819&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operating income and expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">25,829</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">32,940</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">3.3 Net Results</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The operating result is an income of &#8364;0.8 million for the six-month period ended June&#160;30, 2025 compared to a loss of &#8364;23.7 million for the same period in 2024. Operating result comprises revenue and other income and operating expenses. (See section II Note 16 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue and other income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Note 17 -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Operating Expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the unaudited interim condensed consolidated financial statements included in this report).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The financial result is a loss of &#8364;6.2 million for the six-month period ended June&#160;30, 2025 compared to an income of &#8364;1.9 million for the same period in 2024. (See Section II Note 19 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net financial income (loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the unaudited interim condensed consolidated financial statements included in this report).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net loss for the six-month period ended June&#160;30, 2025 amounts to &#8364;5.4 million compared to a net loss of &#8364;21.9 million for the same period in 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_34"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4. FUTURE PROSPECTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nanobiotix is developing three nanoparticle-based therapy platforms. The first therapeutic candidate from the first platform, potential first-in-class radioenhancer JNJ-1900 (NBTXR3), is being developed and potentially commercialized in collaboration with global licensee </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">J&amp;J</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Nanobiotix plans to leverage the sustainable revenue it expects to come from the development and, to the extent JNJ-1900 (NBTXR3) hits certain development and regulatory milestones, the commercialization of JNJ-1900 (NBTXR3) to further advance development of Curadigm and OOcuity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The global licensing agreement between Nanobiotix and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">J&amp;J</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> established a framework for potential, complementary co-development of relevant indications in the near, medium, and long term. This framework includes the potential for Nanobiotix to lead new randomized Phase 2 JNJ-1900 (NBTXR3) studies, subject to a prior approval of J&amp;J. The joint strategic committee (inter-clinical development body) will ultimately determine the next indications beyond the immediate operational priorities in locally-advanced head and neck squamous cell carcinoma (LA-HNSCC) and stage 3 NSCLC.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nanobiotix Beyond the JNJ-1900 (NBTXR3) Collaboration</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As the JNJ-1900 (NBTXR3) program moves toward the ultimate goal of significantly improving outcomes for patients with cancer around the world through the execution of NANORAY-312 sponsored by </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">J&amp;J</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> from January 1, 2025, Nanobiotix plans to expand the impact of nanoparticle-based therapies in healthcare through continued development of Curadigm and OOcuity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Curadigm &#8220;Nanoprimer&#8221; platform features nanoparticles designed with specific physico-chemical properties that allow temporary occupation of the liver cells responsible for therapeutic clearance. This mechanism is intended to increase the blood bioavailability and subsequent accumulation of therapeutics in the targeted tissues, potentially providing the opportunity to increase the efficacy or decrease the toxicity of intravenously-administered medicines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The OOcuity platform is based on the principle that nanoparticle materials can interact with and influence neuronal networks through their electrical properties, potentially enabling the modulation of malfunctioning neuronal networks toward a &#8220;normal&#8221; state, for example, by reducing the neuronal hyperexcitability associated with neuropathic pain.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5. MAIN RISKS AND UNCERTAINTIES FOR THE REMAINING SIX MONTHS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company estimates are derived from publicly available information released by independent industry analysts and third-party sources, as well as data from internal research, and are based on assumptions made by management, which management believes to be reasonable, based on such data and its knowledge of such industry and market. In addition, while management believes the market opportunity information included in this semi-annual report is generally reliable and is based on reasonable assumptions, such data and Company&#8217;s activities involve risks and uncertainties that the Company may face in the remaining six months of the financial year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span id="i59280db93ab24b72914d626601be2ed7_1867"></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These main risks and uncertainties for the remaining six months are identical to those presented in the Company&#8217;s Annual Report on Form 20-F under &#8220;Item 3.D Risk Factors&#8221;, as amended, for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission on April 02, 2025 (copy available on the Company&#8217;s website (www.nanobiotix.com)).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6. TRANSACTIONS WITH RELATED PARTIES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compensation of executive and supervisory board members has been implemented within this first half of 2025 according to applicable corporate governance law (See Section II Note 23 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Related Parties</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the unaudited interim condensed consolidated financial statements included in this report) with no significant change compared to the terms during the financial year ended December 31, 2024. Such related-party transactions entered into during the financial year ended December 31, 2024 are mentioned in Note 23 to the consolidated financial statements for the financial year ended December 31, 2024 and Note 23 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Related parties</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the unaudited interim condensed consolidated financial statements included in this report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_43"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">7. LIQUIDITY AND CAPITAL RESOURCES</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">7.1 Introduction</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the six-month period ended June&#160;30, 2025, our operations have focused on our organization needs, manufacturing, financing and compliance costs, business development and maintaining our intellectual property portfolio and conducting preclinical studies and clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Since our inception, we have consistently generated negative operating cash flows and we have financed our operations and growth primarily through successive capital increases, debt issuances, collaboration and license agreements and payment of research tax credit (CIR) receivables.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nanobiotix&#8217; ordinary shares have been traded on the Euronext Growth market of Euronext in Paris since September 10, 2012, and ADSs have traded on the Nasdaq Global Market in New York since December 20, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For more information about these financing agreements, please see Section II Note 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the unaudited interim condensed consolidated financial statements included in this report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">7.2 Historical Changes in Cash Flows</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below summarizes the cash inflows and outflows of the Company for the six months ended June&#160;30, 2025 and 2024:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:61.904%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="background-color:#cceeff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash flows from (used in) operating activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,836)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash flows from (used in) investing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="background-color:#ffffff;color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="background-color:#ffffff;color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="background-color:#cceeff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash flows from (used in) financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates changes on cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="background-color:#ffffff;color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(515)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="background-color:#ffffff;color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="background-color:#cceeff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(20,919)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(8,948)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash Flows from / used in operating activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our net cash flows used in operating activities were &#8364;17.4 million and &#8364;5.8 million for the six-month period ended June 30, 2025 and 2024, respectively. The unfavorable change in cash flows used in operating activities of -&#8364;11.6 million is mainly driven by:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">a -&#8364;15.2 million net unfavorable impact resulting from lower cash inflows received from Janssen during the first half of 2025 as compared to the same period in 2024. Indeed, in the first half of 2024, the Group received the first Janssen milestone payment of &#8364;18,6 million, which results in a negative -&#8364;18.6 million effect, which is partially offset by higher cash collection from other revenues from Janssen for +3.4M&#8364; between first half of 2025 and first half of 2024.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">partially offset by a +&#8364;3.6 million net favorable impact resulting from lower operating cash outflows during the first half of 2025 as compared to the same period in 2024, mainly related to the transfer of sponsorship of the 312 study to Janssen and to the removal of funding obligations of the study costs </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(see </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note 17.1 -</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> R&amp;D operating expenses </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the unaudited interim condensed consolidated financial statements included in this report</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash Flows from /  used in investing activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Our net cash flows used in investing activities for the six months ended June 2025 were &#8364;0.2 million mainly relating to acquisition of property, plant and equipment. (See Note 6 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Property, plant and equipment</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> to the unaudited interim condensed consolidated financial statements included in this report). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">For the six months ended  June&#160;30, 2024, net cash flows used in investing activities amounted to &#8364;0.5 million also relating to acquisition of property, plant and equipment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash Flows from / used in financing activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our net cash flows used in financing activities were &#8364;2.8 million for the six months ended June 30, 2025 as compared with &#8364;2.7 million for the six months ended June 30, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash flows used in financing activities for the six months ended June 30, 2025 were primarily attributable to loans reimbursement including interest for respectively &#8364;1.3&#160;million to PGE, &#8364;0.2&#160;million to EIB, &#8364;0.7&#160;million to BPI and to payments related to lease liabilities &#8364;0.6 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash flows used in financing activities for the six months ended June&#160;30, 2024 were primarily attributable to loan reimbursement including interest for respectively &#8364;1.3 million to PGE, &#8364;0.5 million to EIB and &#8364;0.3 million to BPI and to payments related to lease liabilities &#8364;0.5 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">7.3 Repayable advances, loans and lease liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable advances, loans and lease liabilities of the Company are displayed in Section II Note 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the unaudited interim condensed consolidated financial statements included in this report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">7.4 Operating Capital Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since our inception, we have recorded operating losses every year, due primarily to research and development expenses incurred in connection with our efforts to advance the Company&#8217;s development program for JNJ-1900  (NBTXR3). Our net losses were &#8364;5.4 million and &#8364;21.9 million for the six months ended June 30, 2025 and 2024, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of June 30, 2025, we had &#8364;28.8 million of available cash and cash equivalents, consisting of cash and short-term bank deposits that are liquid and easily convertible within 3 months without penalty or risk of change in value (see Note 9. &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Cash and cash equivalents</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> to the unaudited interim condensed consolidated financial statements included in this report).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of the date of authorization of the issuance of these unaudited interim condensed consolidated financial statements, the Company estimates, given its current cost structure and its projected expenditure commitments, that it should have sufficient funds to finance its activities into mid-2026. Accordingly, the Company&#8217;s current cash and cash equivalents will not be sufficient to cover its operating needs for at least the next 12 months following the date of issuance of these financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on its current business plan, the Company estimates that to meet its obligations over the next 12 months, it will require additional liquidity in the range of &#8364;8 to &#8364;10 million. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company&#8217;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This estimate is based on the Company&#8217;s current business plan and excludes (i) other expenses resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing. Besides, the Company may have based this estimate on incorrect assumptions and may have to use its resources sooner than anticipated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">To finance its activity, the Company needs to raise additional funds and is in active discussions regarding non-dilutive financing intended to meaningfully extend its cash runway beyond the 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In addition, further to the current discussions, the Company may seek to raise additional funds to achieve its development goals for its research and development programs through: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">other potential public or private securities offerings; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">potential strategic transactions such as business development partnerships; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">R&amp;D project subsidies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company cannot guarantee that it will be able to obtain the necessary financing, through any of the foregoing measures or otherwise, to meet its needs or to obtain funds at acceptable terms and conditions, on a timely basis, or at all, especially taking into account the generally challenging environment for financing of biotech companies. If the Company is unable to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any approved product or be unable to expand its operations or otherwise capitalize on its business opportunities, as desired, which would impair the Company&#8217;s prospects and business operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our present and future funding requirements will depend on many factors, including, among other things:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the number, size, progress, timing and completion of our clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the monitoring of capital allocation and incurred costs, including employee related staff costs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the number of potential new product candidates we identify and decide to develop, including through the development of our Curadigm and OOcuity platforms;</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims or infringements raised by third parties;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of these product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">selling and marketing activities undertaken in connection with the potential commercialization of future product candidates and costs involved in the creation of an effective sales and marketing organization; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the amount of revenue, if any, we may derive either directly or in the form of milestones or royalty payments from our existing or future partnership or collaboration agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_46"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:3.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_49">INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_49">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_52">INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_52">2</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_55">INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_55">3</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_58">INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS&#8217; EQUITY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_58">4</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_61">INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_61">5</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline" href="#ia72c30516b7642d5b908b439c54b9466_64">NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ia72c30516b7642d5b908b439c54b9466_64">6</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_49"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">(Amounts in thousands of euros)</span></div><div><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:53.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-15">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-16">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-17">4,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-18">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="f-19">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="f-20">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-21">5,284</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-22">5,951</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-23">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-24">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-25">9,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-26">8,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-27">28,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-28">49,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-29">39,889</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-30">61,466</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-31">45,174</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-32">67,418</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:52.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.190%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDER&#8217;S EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-33">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-34">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Premiums related to share capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-35">312,743</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-36">312,743</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="3" id="f-37">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="3" id="f-38">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Treasury shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:TreasuryShares" scale="3" id="f-39">228</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:TreasuryShares" scale="3" id="f-40">228</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserve</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="f-41">378,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="f-42">312,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss for the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-43">5,383</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-44">68,132</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-45">68,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-46">65,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentProvisions" scale="3" id="f-47">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentProvisions" scale="3" id="f-48">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-49">46,505</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-50">45,978</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current refund liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-51">4,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-52">27,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-53">51,089</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-54">74,187</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current provisions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentProvisions" scale="3" id="f-55">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentProvisions" scale="3" id="f-56">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-57">4,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-58">4,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-59">11,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-60">20,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-61">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-62">7,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" scale="3" id="f-63">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" scale="3" id="f-64">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-65">36,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-66">18,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current refund liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentRefundsProvision" format="ixt:num-dot-decimal" scale="3" id="f-67">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentRefundsProvision" format="ixt:num-dot-decimal" scale="3" id="f-68">7,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-69">63,037</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-70">58,935</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-71">114,126</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-72">133,122</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-73">45,174</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-74">67,418</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_52"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">(Amounts in thousands of euros, except per share numbers)</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:53.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues and other income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-75">24,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-76">6,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-77">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-78">3,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues and other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-79">26,638</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-80">9,289</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-81">14,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-82">21,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-83">11,294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-84">10,819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operating incomes and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-85">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-86">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-87">25,829</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-88">32,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" id="f-89">808</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-90">23,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="f-91">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-92">3,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-93">6,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-94">1,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-95">6,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-96">1,924</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-97">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-98">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-99">5,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-100">21,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basic loss per share (euros/share)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-101">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-102">0.46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diluted loss per share (euros/share)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-103">0.11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-104">0.46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_55"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">(Amounts in thousands of euros)</span></div><div><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:54.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.190%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net loss for the period</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">5,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-106">21,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial gains and losses on retirement benefit obligations (IAS 19)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="f-107">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="f-108">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax impact</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="f-109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="f-110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other comprehensive loss that will not be reclassified subsequently to income or loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" format="ixt:fixed-zero" scale="3" id="f-111">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" format="ixt:fixed-zero" scale="3" id="f-112">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" scale="3" id="f-113">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" scale="3" id="f-114">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax impact</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="f-115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="f-116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other comprehensive loss that may be reclassified subsequently to loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="f-117">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="f-118">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-119">5,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-120">21,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_58"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">INTERIM CONDENSED STATEMENT OF CONSOLIDATED CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">(Amounts in thousands of euros, except number of shares)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.659%"><tr><td style="width:1.0%"/><td style="width:20.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.517%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share capital<br/>Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>&#160;shares </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Premiums </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">related to </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">share capital</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">comprehensive </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">income (loss) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reserve</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">for the </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">period</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">shareholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">equity</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-121">47,426,851</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-122">1,423</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-123">312,743</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-124">712</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="f-125">228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-126">312,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-127">68,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-128">65,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-129">5,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">5,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-131">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-132">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial gains and losses (IAS 19)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-134">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-135">5,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-136">5,409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of prior period loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10.1</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-137">68,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-138">68,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:fixed-zero" scale="3" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Capital increase</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10.1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-140">809,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-141">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-3" sign="-" name="ifrs-full:IssueOfEquity" scale="3" id="f-142">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:fixed-zero" scale="3" id="f-143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subscription of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10.2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" format="ixt:fixed-zero" scale="3" id="f-144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share based payment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-145">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-146">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-147">48,236,671</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-148">1,447</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-149">312,743</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-150">686</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="f-151">228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-152">378,217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-153">5,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-154">68,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:20.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share capital<br/>Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>&#160;shares </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Premiums </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">related to </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">share capital</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">comprehensive </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">income (loss) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reserve</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">for the </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">period</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">shareholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">equity</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-155">47,133,328</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-156">1,414</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-157">312,742</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-158">738</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-24" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="f-159">228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-25" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-160">276,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-26" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-161">39,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-27" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-162">1,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">21,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">21,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-165">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-166">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial gains and losses (IAS 19)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations" format="ixt:fixed-zero" scale="3" id="f-167">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-168">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-169">21,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-170">21,874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of prior period loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-171">39,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-172">39,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:fixed-zero" scale="3" id="f-173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Capital increase</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10.1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-174">293,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-175">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-3" sign="-" name="ifrs-full:IssueOfEquity" scale="3" id="f-176">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:fixed-zero" scale="3" id="f-177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subscription of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10.2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" format="ixt:fixed-zero" scale="3" id="f-178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" format="ixt:fixed-zero" scale="3" id="f-179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" format="ixt:fixed-zero" scale="3" id="f-180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share based payment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-181">1,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-182">1,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-183">47,426,851</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-184">1,423</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-185">312,743</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-186">736</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="f-187">228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-188">314,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-189">21,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-190">21,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_61"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">(Amounts in thousands of euros)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.913%"><tr><td style="width:1.0%"/><td style="width:58.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash flows used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-191">5,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-192">21,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Elimination of other non-cash, non-operating income and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-193">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-194">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForProvisions" scale="3" id="f-195">231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForProvisions" scale="3" id="f-196">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expenses related to share-based payments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-197">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-198">1,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of net debt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="f-199">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-200">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on disposal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" scale="3" id="f-202">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting financial liabilities and amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-203">2,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" scale="3" id="f-204">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-205">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-206">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non cash income and expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" id="f-207">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherAdjustmentsForNoncashItems" format="ixt:fixed-zero" scale="3" id="f-208">&#8212;</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of the Janssen amendment on profit or loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="nbx:ImpactOfAmendmentOnProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">19,823</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:ImpactOfAmendmentOnProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-210">&#8212;</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash flows from (used in) operations, before tax and changes in working capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-211">18,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-212">17,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax Paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="f-213">205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="f-214">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash flow from (used in) operating activities after tax and before changes in working capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="nbx:CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement" format="ixt:num-dot-decimal" scale="3" id="f-215">19,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="nbx:CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement" format="ixt:num-dot-decimal" scale="3" id="f-216">18,084</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Increase) / Decrease in trade receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="f-217">1,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="f-218">2,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Receipt of research tax credit receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="f-219">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" format="ixt:fixed-zero" scale="3" id="f-220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Increase) / Decrease in other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables" scale="3" id="f-221">620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables" scale="3" id="f-222">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase / (Decrease) in trade and other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-223">1,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-224">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase / (Decrease) in other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="f-225">260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="f-226">436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase in deferred revenues and contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" scale="3" id="f-227">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-228">13,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Changes in operating working capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-229">1,666</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-230">12,248</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash flows from (used in) operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-231">17,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-232">5,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash flows from (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="f-233">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="f-234">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions of property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-235">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-236">489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Increase) / Decrease in non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" scale="3" id="f-237">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" scale="3" id="f-238">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash flows from (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="f-239">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="f-240">500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash flows from (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase in loans and conditional advances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loans repayments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-243">1,926</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-244">1,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payment of lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-245">568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-246">521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" id="f-247">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" id="f-248">609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash flows from (used in) financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-249">2,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-250">2,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates changes on cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-251">515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-252">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-253">20,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-254">8,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-255">49,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-27" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-256">75,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-257">28,818</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-258">66,335</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</span></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_64"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:109%">AS OF JUNE 30, 2025</span></div><div style="text-align:center"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_67"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfNotesAndOtherExplanatoryInformationTextBlock" id="f-259" continuedAt="f-259-1" escape="true">COMPANY INFORMATION </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-259-1"><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nanobiotix, a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> registered with the Paris registry of trade and companies under number 447 521 600 and having its registered office at 60 rue de Wattignies, 75012, Paris (&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nanobiotix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221; and, with its subsidiaries, the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Group</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;), is a late-stage clinical biotechnology company pioneering disruptive, nanophysics-based therapeutic approaches to the treatment of cancer and other major diseases with the express intent of favorably  impacting the lives of millions of patients.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The Company also has subsidiaries in Cambridge, Massachusetts (United States), Spain, and Germany. The Group has been listed on Euronext: Paris under the ticker symbol &#8220;NANO&#8221; since 2012 (ISIN: FR0011341205, Bloomberg Code: NANO:FP) and on the Nasdaq Global Select Market in the United States under the ticker symbol &#8220;NBTX&#8221; since December 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Group is the owner of more than 25 patent families associated with three nanotechnology platforms: 1) radioenhancer platform, from which JNJ-1900 (NBTXR3) is the first product candidate, designed to physically destroy tumor cells locally and prime immune response systemically; 2) Curadigm nanoprimer platform designed to redefine the design and application of therapeutic classes challenged by liver clearance; and 3) OOcuity neurological disease program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s efforts are concentrated on advancing JNJ-1900 (NBTXR3).</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant events of the period</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Amendment to the Janssen agreement</span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">An amendment of the Janssen Agreement has been signed as of March 17, 2025 with Janssen; this amendment of the global licensing agreement partially removes the Company&#8217;s funding obligation for NANORAY-312 and releases Janssen from select future milestone payments, while facilitating the Company&#8217;s path to sustainable cash flow through significant potential milestone payments over the next few years.</span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total expected payments under the agreement related to the Janssen Agreement is adjusted from approximately $<ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-8" name="nbx:CollaborationAgreementTotalConsideration" format="ixt:num-dot-decimal" scale="9" id="f-260">2.7</ix:nonFraction>&#160;billion to approximately $<ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-8" name="nbx:CollaborationAgreementTotalConsideration" format="ixt:num-dot-decimal" scale="9" id="f-261">2.6</ix:nonFraction>&#160;billion:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Revisions to potential future milestone payments in the amendment total $<ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-6" name="nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-262">105</ix:nonFraction>&#160;million while maintaining eligibility to hundreds of millions in the next 2-3 years potential milestone payments related to the first two programs (cisplatin-ineligible head and neck cancer and stage 3 unresectable lung cancer), </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Beyond the hundreds of millions of the next 2-3 years potential milestone payments for the first two programs to the extent JNJ-1900 (NBTXR3) will hit the related milestone events , the remainder of the $<ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-8" name="nbx:CollaborationAgreementTotalConsideration" format="ixt:num-dot-decimal" scale="9" id="f-263">2.6</ix:nonFraction>&#160;billion is related to medium-to-long-term potential development, regulatory, and sales milestones for the first two programs and potential payments for new indications that may be developed by Janssen, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">There are no changes to the potential $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication" format="ixt:num-dot-decimal" scale="6" id="f-264">220</ix:nonFraction>&#160;million per new indication that may be developed by Nanobiotix, and potential royalties expected from commercial sales of JNJ-1900 (NBTXR3) remain in the low 10s to low 20s. Potential payments for new indications that may be developed by the Company are in addition to the $<ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-8" name="nbx:CollaborationAgreementTotalConsideration" format="ixt:num-dot-decimal" scale="9" id="f-265">2.6</ix:nonFraction>&#160;billion deal value, next to potential related royalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The amendment provides that Janssen will assume almost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">full financial responsibility for NANORAY-312, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">the ongoing pivotal Phase 3 trial through completion,, less a small portion of costs that will remain covered by the Company, allowing the Company to strengthen its financial position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For further details, see Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenues and other Income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_70"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="f-266" continuedAt="f-266-1" escape="true">General information, statement of compliance and basis of presentation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:StatementOfIFRSCompliance" id="f-267" continuedAt="f-267-1" escape="true"><ix:continuation id="f-266-1" continuedAt="f-266-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements as of June&#160;30, 2025 and for the six-month period ended June&#160;30, 2025 were prepared under the supervision of the management of the Company and were submitted by the Executive Board to the review of the Supervisory Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All amounts in the unaudited interim condensed consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated  financial statements of the Company have been prepared in compliance with IAS 34 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Interim Financial Reporting&#8221; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which provides for the presentation of selected explanatory notes. As they are unaudited interim condensed consolidated  financial statements, the accompanying notes do not contain all the disclosures required for annual consolidated financial statements and should therefore be read in conjunction with the Company&#8217;s consolidated financial statements prepared in accordance with IFRS &#174; Accounting Standards, as of and for the year ended December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of the unaudited interim condensed consolidated financial statements in accordance with IAS 34 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Interim Financial Reporting&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> requires the use of estimates and assumptions that affect the amounts and information disclosed in the condensed consolidated financial statements. See Note 3.2 Use of judgement, estimates and assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June&#160;30, 2025 are identical to those used for the year ended December&#160;31, 2024 except for the standards listed below that required adoption in 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2025 in the European Union primarily concern:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.47pt">Amendment to IAS 21 Lack of Exchangeability, the Effects of Changes in Foreign Exchange Rates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">This amendment had no material impact on the Company&#8217;s unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable are:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">Amendments to IFRS 9 and IFRS 7 &#8211; Classification and Measurement of Financial Instruments &#8211; as of January 1, 2026</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">Amendments to IFRS 9 and IFRS 7 &#8211; Contracts Referencing Nature-dependent Electricity &#8211; as of January 1, 2026</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">Annual Improvements to IFRS Accounting Standards, as of January 1, 2026&#8211; Amendments to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 1 First-time Adoption of International Financial Reporting Standards;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 9 Financial Instruments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 10 Consolidated Financial Statements; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IAS 7 Statement of Cash flows</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">New standard &#8211; IFRS 18 &#8211; Presentation and Disclosure in Financial Statements &#8211; as of January 1, 2027</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">New standard &#8211; IFRS 19 &#8211; Subsidiaries without Public Accountability: Disclosures&#8211; as of January 1, 2027</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company is currently assessing the applicability and impact of these new standards, interpretations and amendments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Seasonality of the Company&#8217;s activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">According to IAS 34 &#8211; &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;, an entity whose business is highly seasonal should present financial information for the twelve months up to the end of the interim period and additional comparative information for the prior twelve-month period in the interim condensed consolidated financial statements in order to provide a better understanding and comparison of its interim consolidated financial statements. </span></div></ix:continuation></ix:nonNumeric><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-267-1" continuedAt="f-267-2"><ix:continuation id="f-266-2" continuedAt="f-266-3"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As mentioned in Note 16 Revenue and other income, as most of the income from the Company is generated by ongoing contracts that primarily depend on performance obligations not correlated to seasonal trends, it is considered that the Company activities are not seasonal. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Therefore, the following unaudited interim condensed consolidated financial statements and corresponding notes will not include comparative information other than that mentioned in IAS 34.20.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and payment of research tax credit (CIR) receivables. The Company continues to pursue its research and development activities for its product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning multiple years. The Company does not expect to generate revenue from product sales in the near future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In March 2025, the Company and Janssen executed an amendment to the License Agreement. The amendment provides that Janssen will assume almost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">full financial responsibility for NANORAY-312</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, the ongoing pivotal Phase 3 trial through completion, less a small portion of costs that will remain covered by the Company, allowing the Company to extend its cash runway and to reduce its operating cash outflows post this amendment, including the period beyond mid-2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of June 30, 2025, the Company had &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-268">28.8</ix:nonFraction>&#160;million of available cash and cash equivalents, consisting of cash and short-term bank deposits that are liquid and easily convertible within 3 months without penalty or risk of change in value (see Note 9. &#8211; Cash and cash equivalents).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of the date of authorization of the issuance of these interim condensed consolidated financial statements, the Company estimates, given its current cost structure and its projected expenditure commitments, that it should have sufficient funds to finance its activities into mid-2026. Accordingly, the Company&#8217;s current cash and cash equivalents will not be sufficient to cover its operating needs for at least the next 12 months following the date of the issuance of these financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on its current business plan, the Company estimates that to meet its obligations over the next 12 months, it will require additional liquidity in the range of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-5" name="nbx:AdditionalLiquidityBusinessObligations" scale="6" id="f-269">8</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-5" name="nbx:AdditionalLiquidityBusinessObligations" format="ixt:num-dot-decimal" scale="6" id="f-270">10</ix:nonFraction>&#160;million. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company&#8217;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This estimate is based on the Company&#8217;s current business plan and excludes (i) other expenses resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing. The Company may have based this estimate on incorrect assumptions and may have to use its resources sooner than anticipated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">To finance its activities beyond mid-2026, the Co</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">mpany needs to raise additional funds and is in active discussions regarding non-dilutive financing, intended to meaningfully extend its c</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">ash runway beyond the 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In addition, further to the current discussions, the Company may seek to raise additional funds to achieve its development goals for its research and development programs through: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">other potential public or private securities offerings, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">potential strategic transactions such as business development partnerships; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">R&amp;D project subsidies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on the above, the interim condensed consolidated financial statements as of and for the six-month period ended June 30, 2025, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future and to address its liquidity challenges by pursuing activities to generate additional cash inflows and by closely managing its operating expenditures. As such, they do not include any adjustments related to the value or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company cannot guarantee that it will be able to obtain the necessary financing, through any of the foregoing measures or otherwise, to meet its needs or to obtain funds at acceptable terms and conditions, on a timely basis, or at all, especially considering the generally challenging environment for financing of biotech companies. If the Company is unable to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any approved product or be unable </span></div></ix:continuation></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-267-2"><ix:continuation id="f-266-3"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">to expand its operations or otherwise capitalize on its business opportunities, as desired, which would impair the Company&#8217;s prospects and business operations.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_73"></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfConsolidationExplanatory" id="f-271" continuedAt="f-271-1" escape="true">Consolidated principles and methods</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-271-1" continuedAt="f-271-2"><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">3.1 <ix:nonNumeric contextRef="c-1" name="nbx:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" id="f-272" continuedAt="f-272-1" escape="true">BASIS OF CONSOLIDATION</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-272-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Consolidated entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the consolidation scope is comprised of one parent entity and is similar to that of December&#160;31, 2024 as Nanobiotix S.A. has <ix:nonFraction unitRef="subsidiary" contextRef="c-2" decimals="INF" name="nbx:NumberOfSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="f-273">three</ix:nonFraction> wholly owned subsidiaries: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Nanobiotix Corp., incorporated in the State of Delaware in September 2014 and located in the USA,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Nanobiotix Germany GmbH, created in October 2017 and located in Germany,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Nanobiotix Spain S.L.U., created in December 2017 and located in Spain.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accordingly, the unaudited interim condensed consolidated financial statements as of June&#160;30, 2025 include the operations of each of these subsidiaries, to the extent applicable, from the date of their incorporation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements are presented in thousands of euros, which is the Group&#8217;s presentation currency and the functional currency of the parent company, Nanobiotix S.A. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate for the statement of financial position, whereas, items of the statement of operations, statement of comprehensive loss and statement of cash flow are converted at the average exchange rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The dollar-to-euro exchange rate used in the unaudited interim condensed consolidated financial statements to convert the Group transactions denominated in US dollars were a closing of $<ix:nonFraction unitRef="number" contextRef="c-2" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-274">1.1720</ix:nonFraction> as of June&#160;30, 2025 and an average of $<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-275">1.0930</ix:nonFraction> for the six-month period ended June&#160;30, 2025 compared with $<ix:nonFraction unitRef="number" contextRef="c-39" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-276">1.0705</ix:nonFraction> and $<ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-277">1.0812</ix:nonFraction> respectively, as of and for the six-month period ended June&#160;30, 2024 (source: Banque de France).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">3.2. <ix:nonNumeric contextRef="c-1" name="nbx:DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" id="f-278" continuedAt="f-278-1" escape="true">USE OF JUDGEMENT, ESTIMATES AND ASSUMPTIONS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-278-1" continuedAt="f-278-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed consolidated financial statements in accordance with IAS 34 requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. A sensitivity analysis may be presented if the results differ materially based on the application of different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the measurement of financial instruments (fair value and amortized costs).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Measurement of share-based payments </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures the fair value of stock options (OSA), founders&#8217; warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Executive and Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., option vesting terms) and market data (e.g., to determine expected share volatility) (See Note 18 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-based payments</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Deferred tax assets </span></div></ix:continuation></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-278-2" continuedAt="f-278-3"><ix:continuation id="f-271-2" continuedAt="f-271-3"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company&#8217;s assets and liabilities that appear in its financial statements. The primary source of deferred tax assets are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow for sufficiently reliable income projections to be made, the Company has not recognized deferred tax assets in relation to tax losses carry forwards in the statements of consolidated financial position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial accruals </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clinical trial expenses, although not yet billed in full, are estimated quarterly for each study and a provision is recognized accordingly. (See Note 14.1 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Trade and other payables</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for information regarding the clinical trial accruals as of June 30, 2025 and December 31, 2024).</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to determine the amount and timing of revenue under the contract with customers, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company, determining the stand alone selling price of the performance obligations, the transaction price allocation and the timing of satisfaction of support services provided to customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Determining the distinctiveness of performance obligations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; A promised good or service will need to be recognized separately in revenue if it is distinct as defined in IFRS 15. In determining whether the performance obligation is separate, the Company analyses if (i) the good or service is distinct in absolute terms, i.e. it can be useful to the customer, either on its own or in combination with resources that the customer can obtain separately; and if (ii) the good or service is distinct in the context of the contract, i.e. it can be identified separately from the other goods and services in the contract because there is not a high degree of interdependence or integration between this element and the other goods or services promised in the contract. If either of these two conditions is not met, the good or service is not distinct, and the Company must group it with other promised goods or services until it becomes a distinct group of goods or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Allocation of transaction price to performance obligations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For contracts with multiple performance obligations, the Company allocates the contract&#8217;s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable consideration</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; Due to the nature of the work required to be performed on many of the Company&#8217;s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration and license agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals). The Company includes the related amounts in the estimated transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue on a cumulative catch&#8209;up basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognized over time and input method</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; Some of the Company&#8217;s performance obligations are satisfied over time as work progresses, thus revenue is recognized over time, using an input measure of progress as it best depicts the transfer of control to the customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contract modification</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. The effect that the contract modification has on the transaction price, and on the entity's measure of progress towards complete satisfaction of the performance obligation, is recognized as an adjustment to revenue at the date of the contract modification (i.e. on a cumulative catch-up basis). The Company is required to use significant judgments with respect to identifying and determining the amended standalone selling price of the performance obligations, the transaction price allocation and the adjusted timing of satisfaction of the remaining services provided to customers.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-278-3"><ix:continuation id="f-271-3"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 16 - to the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2024 for additional detail regarding the Company&#8217;s accounting policies and specific judgments made with regard to revenue recognition, and for its additional sources of revenue and other income.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Measurement of financial assets and liabilities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At the renegotiation date in October 2022, the fair value measurement of the EIB loan required the Company to determine:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">the discount rate of the new liability executed in October 2022. The discount rate reflects the company&#8217;s credit risk at the Amendment Agreement date as well as a premium to reflect uncertainties associated with the timing and the amount of the royalties&#8217; payment. The Company involved external financial instruments valuation specialists to support in determining the average discount rate;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">the amount of additional interest (&#8220;royalties&#8221;, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing upon commercialization. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to annual sales turnover relating to JNJ-1900 (NBTXR3) through specific Company&#8217;s license agreement. For the purpose of measuring the fair value of the EIB loan, the Company forecasts expected sales relating to JNJ-1900 (NBTXR3) during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see Notes 4.4 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financing Agreement with the European Investment Bank (&#8220;EIB&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2024, for details about this loan and the accounting treatment applied).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Subsequent to the estimate of the fair value of the EIB loan performed at the renegotiation date, the debt has been measured at amortized cost based on the revised best estimate of the future cash flows related to the debt at each closing date. Accordingly, the Company determines the amount of additional interest as described above. Any subsequent adjustment of flows indexed to turnover are discounted at the original effective interest rate and the adjustment is recognized in profit or loss under the &#8220;catch-up&#8221; method. As of June 30, 2025, the fair value measurement of the EIB loan has been reassessed by the Company for disclosure purpose.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_76"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfSignificantTransactionsTextBlock" id="f-279" continuedAt="f-279-1" escape="true">Significant transactions</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="f-279-1"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The significant transactions are those described in the consolidated financial statements prepared in accordance with IFRS &#174; Accounting Standards for the year ended December 31, 2024, except regarding the Janssen Amendment Agreement which was signed on March 17, 2025 and described in Note 1 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Company Information</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues and Other Income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_79"></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="f-280" continuedAt="f-280-1" escape="true">Intangible assets</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" id="f-281" escape="true"><ix:continuation id="f-280-1" continuedAt="f-280-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in intangible assets breaks down as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-282">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-283">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-286">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-287">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-288">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-291">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-292">734</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-293">8</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-294">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-295">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-296">742</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-297">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-301">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-302">662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-303">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-59" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-306">663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of intangible assets (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-60" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-307">727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-308">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-310">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-311">729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-312">7</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-313">6</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-314">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-316">13</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt">Expenses for the period are detailed in Note 17.4 Depreciation, amortization and provisions expenses</span></div></ix:continuation></ix:nonNumeric><div style="text-indent:3.83pt"><span><br/></span></div><div><ix:continuation id="f-280-2" continuedAt="f-280-3"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="INF" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="0" id="f-317">No</ix:nonFraction> impairment losses were recognized in application of IAS 36 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Assets</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-280-3"> in the period presented.</ix:continuation> </span></div><div><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_82"></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-318" continuedAt="f-318-1" escape="true">Property, plant and equipment</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-318-1" continuedAt="f-318-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="f-319" continuedAt="f-319-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in property, plant and equipment is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">movements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&amp; transfer.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-320">3,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-321">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-65" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-325">3,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-66" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-326">9,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-67" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-67" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-67" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="f-329">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-67" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-68" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-331">8,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-69" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-332">2,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-333">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-337">2,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-72" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-338">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-339">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-340">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-342">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-343">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-75" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-344">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-76" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-76" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-346">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-76" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-76" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-349">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments on tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-350">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-355">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-356">16,559</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-357">150</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-358">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="f-359">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-360">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-361">16,504</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-362">2,582</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-363">134</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-83" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-367">2,716</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-84" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-368">5,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-369">522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="f-371">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-373">5,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-374">1,945</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-375">90</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-379">2,035</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-380">1,021</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-381">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-382">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-384">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-92" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-385">961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of tangible assets(1)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-60" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-386">11,021</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-387">798</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-388">108</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="f-389">65</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-390">4</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-391">11,641</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-392">5,538</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-93" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-393">647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-93" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-394">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="f-395">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-396">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-397">4,863</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><ix:continuation id="f-319-1" continuedAt="f-319-2"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.59pt"><ix:continuation id="f-319-2">Expenses for the period are detailed in Note 17.4 Depreciation, amortization and provisions expenses</ix:continuation> </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><ix:continuation id="f-318-2" continuedAt="f-318-3"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="INF" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="f-398">No</ix:nonFraction> impairment losses were recognized in application of IAS 36 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Assets</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-318-3"> in the period presented.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_85"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock" id="f-399" continuedAt="f-399-1" escape="true">Non-current financial assets </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" id="f-400" continuedAt="f-400-1" escape="true"><ix:continuation id="f-399-1" continuedAt="f-399-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in non-current financial assets breaks down as follows:</span></div></ix:continuation></ix:nonNumeric><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-400-1"><ix:continuation id="f-399-2"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.122%"><tr><td style="width:1.0%"/><td style="width:73.283%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Security <br/>deposits paid</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of Net book value as of December 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-94" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="f-401">406</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-95" decimals="-3" name="ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets" scale="3" id="f-402">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-95" decimals="-3" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reclassification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-95" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherMovementsFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-95" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" scale="3" id="f-405">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-96" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="f-406">409</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_88"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" id="f-407" continuedAt="f-407-1" escape="true">Trade receivables and other current assets</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-407-1" continuedAt="f-407-2"><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">8.1 TRADE RECEIVABLES</span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" id="f-408" escape="true"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-409">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-410">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-411">1,837</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-412">2,977</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, trade receivables balance mainly relates to Janssen revenue not yet collected, which is comprised of product supplies for <ix:nonFraction unitRef="eur" contextRef="c-97" decimals="-5" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-413">1.7</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">8.2 OTHER CURRENT ASSETS</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" id="f-414" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets break down as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit receivable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-415">4,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-416">3,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="f-417">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="f-418">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-419">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-420">3,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:OtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-421">1,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-422">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-423">9,234</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-424">8,753</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" scale="6" id="f-425">1.9</ix:nonFraction> million prepaid expenses mainly relate to research agreements with MD Anderson for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-98" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="f-426">1.1</ix:nonFraction>&#160;million as compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-99" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="f-427">1.2</ix:nonFraction>&#160;million as of December 31, 2024, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-100" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="f-428">0.8</ix:nonFraction>&#160;million related to invoices received for third party services beyond the current closing period, mainly related to IT, insurance and other invoices related to annual administrative contracts as compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="f-429">1.1</ix:nonFraction>&#160;million as of December 31, 2024, and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-430">46</ix:nonFraction>&#160;thousand related to purchases of clinical product not yet consumed as of closing date as compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="f-431">0.6</ix:nonFraction>&#160;million as of December 31, 2024, this significant decrease is explained by the sales dynamics of clinical products sold.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Other receivables increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-5" name="nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-432">0.2</ix:nonFraction>&#160;million and mainly comprised of advance payments to suppliers amounting of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-5" name="ifrs-full:CurrentAdvancesToSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-433">1.3</ix:nonFraction>&#160;million as of June&#160;30, 2025, as compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentAdvancesToSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-434">1.1</ix:nonFraction>&#160;million as of December&#160;31, 2024. Most of these advance payments have been made to Contract Research Organization (CRO) and to Clinical Services Providers in connection with the execution of the clinical trial NANORAY-312.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research tax credit </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is eligible for the Research Tax Credit - CIR (Cr&#233;dit d&#8217;Imp&#244;t Recherche) issued by the French and U.S. tax authorities.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" id="f-435" continuedAt="f-435-1" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in research tax credit receivables breaks down as follows:</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-435-1"><ix:continuation id="f-407-2"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:84.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-436">3,369</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 research tax credit &#8211; Nanobiotix S.A. (1)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-105" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-437">1,616</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 research tax credit &#8211; Nanobiotix Corp (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-3" sign="-" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit" scale="3" id="f-438">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receipt of 2024 research tax credit - Nanobiotix Corp</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-3" sign="-" name="nbx:ProceedsFromIncomeTaxCredit" scale="3" id="f-439">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-440">4,792</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See Note 16 - Revenue and other income.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_91"></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="f-441" continuedAt="f-441-1" escape="true">Cash and cash equivalents</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-441-1"><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" id="f-442" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalent break down as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and bank accounts</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-443">4,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-444">5,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term bank deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-445">24,125</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-446">44,427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net Cash and cash equivalents</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-447">28,818</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-448">49,737</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, net cash and cash equivalents decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-449">20.9</ix:nonFraction>&#160;million as compared to December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The short-term bank deposits correspond exclusively to term deposit transactions that have been settled in July 2025.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_94"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-450" continuedAt="f-450-1" escape="true">Share Capital</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-450-1" continuedAt="f-450-2"><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">10.1 CAPITAL ISSUED</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-451" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Detail of share capital transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands or number of shares)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nature of transaction</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Premiums related to share capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-452">1,423</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-453">312,743</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-454">47,426,851</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 27, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase AGA 2023-P1 and AGA 2023-P2</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-108" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-455">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-456">809,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-457">1,447</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-458">312,743</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-459">48,236,671</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the share capital was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-460">1,447</ix:nonFraction>&#160;thousand divided into <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-461">48,236,671</ix:nonFraction></span><span style="background-color:#ffffff;color:#202124;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">fully paid up ordinary shares, each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-2" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-462">0.03</ix:nonFraction>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Allocation of prior period (loss)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The negative net result for the year 2023 of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-110" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-463">68.1</ix:nonFraction>&#160;million has been fully allocated to reserves.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">10.2 FOUNDER&#8217;S WARRANTS, WARRANTS, STOCK OPTIONS AND FREE SHARES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, there are <ix:nonFraction unitRef="security" contextRef="c-2" decimals="INF" name="nbx:NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes" format="ixt-sec:numwordsen" scale="0" id="f-464">three</ix:nonFraction> different types of securities and other valid instruments entitling their holders to a stake in the Company's share capital: warrant (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">bons de souscription d&#8217;actions</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> or BSA), founders&#8217; warrant (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">bons de souscription de parts de cr&#233;ateur d&#8217;entreprise</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> or BSPCE) and stock option (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">options de souscription ou d&#8217;achat d&#8217;actions</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> or OSA).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At a meeting on February 18, 2025, the Executive Board, acting pursuant to delegations granted by the Company&#8217;s shareholders&#8217; meeting held on May 28, 2024, granted to certain employees of the Group <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-465">8,000</ix:nonFraction> stock options, each giving its holder the right to subscribe one ordinary share, each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-112" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-466">0.03</ix:nonFraction> and at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-111" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-467">3.36</ix:nonFraction> (share premium included). Such stock options are governed by the 2025 stock option plan, adopted by the Executive Board on February 18, 2025 (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025 Stock Option Plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ordinary stock options are exercisable as follows:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt">up to one-third of the ordinary stock options as from February 18, 2026;</span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;      an additional one-third of the ordinary stock options as from February 18, 2027,</span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;      the balance, i.e., one-third of the ordinary stock options as from February 18, 2028,</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">subject to, for each increment, a continued service condition, and in any case, no later than <ix:nonNumeric contextRef="c-113" name="nbx:ShareBasedPaymentArrangementStockOptionTerm" format="ixt-sec:duryear" id="f-468">10</ix:nonNumeric> years after the date of grant, it being specified that stock options which have not been exercised by the end of this <ix:nonNumeric contextRef="c-114" name="nbx:ShareBasedPaymentArrangementStockOptionTerm" format="ixt-sec:duryear" id="f-469">10</ix:nonNumeric>-year period will be forfeited by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At a meeting on May 16, 2025, the Executive Board, acting pursuant to delegations granted by the Company&#8217;s shareholders&#8217; meeting held on May 28, 2024,, granted to certain employees of the Group and members of the Executive Board <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-470">1,241,005</ix:nonFraction> stock options, each giving its holder the right to subscribe one ordinary share, each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-115" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-471">0.03</ix:nonFraction> and at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-114" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-472">2.97</ix:nonFraction> (share premium included). Such stock options are governed by the 2025 Stock Option Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ordinary stock options are exercisable as follows:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt">up to one-third of the ordinary stock options as from May 16, 2026;</span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;      an additional one-third of the ordinary stock options as from May 16, 2027,</span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;      the balance, i.e., one-third of the ordinary stock options as from May 16, 2028,</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">subject to, for each increment, a continued service condition, and in any case, no later than <ix:nonNumeric contextRef="c-113" name="nbx:ShareBasedPaymentArrangementStockOptionTerm" format="ixt-sec:duryear" id="f-473">10</ix:nonNumeric> years after the date of grant, it being specified that stock options which have not been exercised by the end of this <ix:nonNumeric contextRef="c-114" name="nbx:ShareBasedPaymentArrangementStockOptionTerm" format="ixt-sec:duryear" id="f-474">10</ix:nonNumeric>-year period will be forfeited by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Free Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No free shares were granted in the first half of 2025.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-450-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the assumptions related to the estimated vesting of the founders&#8217; warrants, the warrants and performance stock options have been updated (See Note 18 Share-based payments).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_486"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="f-475" continuedAt="f-475-1" escape="true">Retirement Obligations</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-475-1"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherProvisionsExplanatory" id="f-476" continuedAt="f-476-1" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:25.232%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lump-sum retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-116" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="f-477">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-117" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="f-478">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-117" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" format="ixt:fixed-zero" scale="3" id="f-479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-117" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-118" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="f-481">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Non-current provisions</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-119" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="f-482">432</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-120" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="f-483">47</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-120" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" format="ixt:fixed-zero" scale="3" id="f-484">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-120" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" format="ixt:fixed-zero" scale="3" id="f-485">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-121" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="f-486">479</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to measure lump-sum retirement benefits as of June 30, 2025 remain unchanged from the assumptions used as of December 31, 2024. See Note 11 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Retirement Obligations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the consolidated financial statements as of and for the period ended December 31, 2024.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_97"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfProvisionsExplanatory" id="f-487" continuedAt="f-487-1" escape="true">Provisions</ix:nonNumeric></span></div><ix:continuation id="f-487-1"><ix:continuation id="f-476-1" continuedAt="f-476-2"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:29.433%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-122" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="f-488">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-123" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="f-489">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-123" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" scale="3" id="f-490">230</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-123" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" format="ixt:fixed-zero" scale="3" id="f-491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-124" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="f-492">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-125" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="f-493">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-126" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="f-494">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-126" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" scale="3" id="f-495">90</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-126" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" format="ixt:fixed-zero" scale="3" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-127" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="f-497">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current provisions </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-128" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="f-498">438</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-129" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="f-499">49</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-129" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" scale="3" id="f-500">320</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-129" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" format="ixt:fixed-zero" scale="3" id="f-501">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-130" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="f-502">167</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><ix:continuation id="f-476-2" continuedAt="f-476-3"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt"><ix:continuation id="f-476-3">See Note 17.4 Depreciation, amortization and provision expenses for the nature of these decreases</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes exclusively include ongoing employee disputes. The &#8364;<ix:nonFraction unitRef="eur" contextRef="c-123" decimals="-5" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" format="ixt:num-dot-decimal" scale="6" id="f-503">0.2</ix:nonFraction>&#160;million net decrease recorded in the first half of 2025 resulted from the settlement of disputes.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  &#160;&#160;&#160;&#160;13. <ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfFinancialLiabilitiesFootnoteTextBlock" id="f-504" continuedAt="f-504-1" escape="true">Financial liabilities </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-504-1" continuedAt="f-504-2"><div style="padding-left:72pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">13.1 DETAILS OF FINANCIAL LIABILITIES </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="f-505" continuedAt="f-505-1" escape="true"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Short term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-506">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-132" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-507">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-133" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" scale="3" id="f-508">535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-134" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" scale="3" id="f-509">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE loans *</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-135" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-510">2,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-511">2,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" scale="3" id="f-512">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" scale="3" id="f-513">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-514">4,735</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-515">4,924</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Long term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-516">2,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-132" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-517">2,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-133" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" scale="3" id="f-518">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-134" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-519">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE loans *</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-135" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" scale="3" id="f-520">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-521">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-522">43,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-523">40,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-524">46,505</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-525">45,978</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-526">51,240</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-527">50,902</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(*)&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" id="f-528" continuedAt="f-528-1" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">The table below shows the detail of changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes.</span></div></ix:nonNumeric></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-504-2" continuedAt="f-504-3"><ix:continuation id="f-528-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:25.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.434%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands of euros)</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Liabilities</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Repayable BPI Loan Advances</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PGE Loans</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EIB Loan</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance advance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Curadigm Bpi advance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HSBC<br/>&#8220;PGE&#8221;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance<br/>&#8220;PGE&#8221;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-529">4,230</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-530">1,606</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="f-531">342</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-532">1,891</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-533">2,198</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-144" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-534">40,635</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-145" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-535">50,902</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal received</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in loans and conditional advances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-544">600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-545">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-546">626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-547">626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" name="nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-549">1,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" id="f-550">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" id="f-553">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" id="f-554">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" id="f-555">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" id="f-556">335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-557">568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-563">568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows used in<br/>financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="f-564">637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="f-565">600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="f-566">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="f-567">638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="f-568">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="f-569">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-570">2,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indexation effect on current lease commitment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" name="nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" name="nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" name="nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" name="nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of discounting and catch-up</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-578">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" scale="3" id="f-579">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" scale="3" id="f-580">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" scale="3" id="f-581">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" scale="3" id="f-582">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-583">1,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-584">1,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="f-585">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="f-586">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="f-588">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="f-589">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="f-590">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="f-591">822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-596">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-597">3,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-598">3,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash from financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="nbx:CashFlowsFromUsedInNonFinancingActivities" scale="3" id="f-599">38</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" name="nbx:CashFlowsFromUsedInNonFinancingActivities" scale="3" id="f-600">13</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" name="nbx:CashFlowsFromUsedInNonFinancingActivities" scale="3" id="f-601">8</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="nbx:CashFlowsFromUsedInNonFinancingActivities" scale="3" id="f-602">7</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" name="nbx:CashFlowsFromUsedInNonFinancingActivities" scale="3" id="f-603">19</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" name="nbx:CashFlowsFromUsedInNonFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-604">3,083</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="nbx:CashFlowsFromUsedInNonFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-605">3,169</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-153" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-606">3,632</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-154" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-607">1,019</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="f-608">275</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-609">1,260</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-157" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-610">1,569</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-611">43,484</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-159" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-612">51,240</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Of which Current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-153" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-613">1,247</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-154" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesCurrent" scale="3" id="f-614">438</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesCurrent" scale="3" id="f-615">97</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-616">1,260</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-157" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-617">1,262</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesCurrent" scale="3" id="f-618">430</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-159" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-619">4,735</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Of which Non-Current</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-153" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-620">2,385</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-154" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent" scale="3" id="f-621">581</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent" scale="3" id="f-622">178</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent" format="ixt:fixed-zero" scale="3" id="f-623">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-157" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent" scale="3" id="f-624">307</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-625">43,054</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-159" decimals="-3" name="nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-626">46,505</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lease Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities correspond to the discounted amount of the rentals to be paid over the lease terms for all outstanding contracts falling within the scope of IFRS 16. For the period presented, the main contracts relate to the buildings rented in Paris and in Villejuif</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Repayable BPI loan advances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company received repayable advance from Banque Publique d&#8217;Investissement (&#8220;Bpifrance&#8221;, formerly known as &#8220;OSEO Innovation&#8221;). The advance bears <ix:nonFraction unitRef="number" contextRef="c-160" decimals="4" name="nbx:AdvancesReceivedInterestRate" scale="-2" id="f-627">1.56</ix:nonFraction>% interest. The repayment of the period amounts to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-160" decimals="-5" name="ifrs-full:RepaymentsOfCurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-628">0.6</ix:nonFraction>&#160;million while the amount to be reimbursed corresponds to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-160" decimals="-5" name="nbx:ReimbursedAmountOfCorresponds" format="ixt:num-dot-decimal" scale="6" id="f-629">1.0</ix:nonFraction>&#160;million (as detailed in table Note 13.2 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Due dates of the financial liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below)</span><span style="background-color:#ffffff;color:#ff0090;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2020, the Company obtained a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-5" name="nbx:AdvancesAuthorizedAmountToBeAdvanced" format="ixt:num-dot-decimal" scale="6" id="f-630">0.5</ix:nonFraction>&#160;million conditional advance from Bpifrance, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-5" name="ifrs-full:Advances" format="ixt:num-dot-decimal" scale="6" id="f-631">0.4</ix:nonFraction>&#160;million of which was received at the signature date. The advance is interest-free. The repayment of the period amounts to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-162" decimals="-5" name="ifrs-full:RepaymentsOfCurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-632">0.1</ix:nonFraction>&#160;million while the amount to be reimbursed corresponds to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-162" decimals="-5" name="nbx:ReimbursedAmountOfCorresponds" format="ixt:num-dot-decimal" scale="6" id="f-633">0.3</ix:nonFraction>&#160;million (as detailed in table Note 13.2 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Due dates of the financial liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">PGE loan (&#8220;Pr&#234;ts Garantis par l&#8217;Etat&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company announced in June 2020 that it has received approval for financing from both HSBC and Bpifrance for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-163" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-634"><ix:nonFraction unitRef="eur" contextRef="c-164" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-635">5</ix:nonFraction></ix:nonFraction>&#160;million each in the form of state-guaranteed loans (&#8220;Pr&#234;ts Garantis par l&#8217;Etat&#8221;, or &#8220;PGE&#8221; in France).</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This loan is booked at amortized cost using an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-163" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-636">0.31</ix:nonFraction>%. Reimbursement of the loan started in September 2022 and will continue through mid-2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2025, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-165" decimals="-5" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-637">0.6</ix:nonFraction>&#160;million was repaid on the HSBC PGE loan.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-504-3" continuedAt="f-504-4"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 10, 2020, the Company entered into the second &#8364;<ix:nonFraction unitRef="eur" contextRef="c-166" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-638">5</ix:nonFraction>&#160;million PGE loan with Bpifrance (the &#8216;&#8216;Bpifrance PGE Loan&#8217;&#8217;). The Bpifrance PGE loan has a <ix:nonNumeric contextRef="c-166" name="nbx:BorrowingMaturityTerm" format="ixt-sec:durwordsen" id="f-639">6-year</ix:nonNumeric> term and is <ix:nonFraction unitRef="number" contextRef="c-167" decimals="2" name="nbx:BorrowingPercentageOfStateGuaranteedLoan" scale="-2" id="f-640">90</ix:nonFraction>% guaranteed by the French State. Starting after its first year anniversary, the Bpifrance PGE loan bears an interest rate of <ix:nonFraction unitRef="number" contextRef="c-167" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-641">2.25</ix:nonFraction>% per annum, inclusive of an annual State guarantee fee of <ix:nonFraction unitRef="number" contextRef="c-167" decimals="4" name="nbx:BorrowingGuaranteeFee" scale="-2" id="f-642">1.61</ix:nonFraction>% per annum. The principal and interest of the Bpifrance PGE loan is being reimbursed in <ix:nonFraction unitRef="quarterly_installment" contextRef="c-166" decimals="INF" name="nbx:BorrowingNumberOfQuarterlyInstallments" scale="0" id="f-643">20</ix:nonFraction> quarterly installments as from October 31, 2021 through July 26, 2026. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2025, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-168" decimals="-5" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-644">0.6</ix:nonFraction>&#160;million was repaid on the Bpifrance PGE loan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">EIB loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the Company accounted for the debt at amortized cost using the original  effective interest rate (&#8220;EIR&#8221;) of <ix:nonFraction unitRef="number" contextRef="c-169" decimals="3" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-645">21.3</ix:nonFraction>% and adjusting the estimated debt outflows in accordance with the revised forecasts of annual sales turnover relating to JNJ-1900 (NBTXR3) through specific Company&#8217;s license agreement (value and timing).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The EIB loan amounts to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-646">43.5</ix:nonFraction>&#160;million as of June 30, 2025 compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-170" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-647">40.6</ix:nonFraction>&#160;million as of December 31, 2024. The increase of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-5" name="nbx:IncreaseDecreaseInOutstandingLoans" format="ixt:num-dot-decimal" scale="6" id="f-648">2.8</ix:nonFraction>&#160;million over the six months ended June 30 2024 comprises:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Fixed and variable interest expenses accrual for an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-5" name="ifrs-full:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-649">4.1</ix:nonFraction>&#160;million which are partially offset by</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the interest repayments of  &#8364;<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-5" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-650">0.2</ix:nonFraction>&#160;million in accordance with the repayment schedule </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the P&amp;L net positive impact of accretion and discounting on EIB loan of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-5" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-651">1.0</ix:nonFraction>&#160;million corresponding to : </span></div><div style="padding-left:36pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(i) the decrease in estimated debt outflows beyond 2024 - before discounting effect - for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-5" name="nbx:AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" format="ixt:num-dot-decimal" scale="6" id="f-652">2.4</ix:nonFraction>&#160;million positive P&amp;L effect</span></div><div style="padding-left:36pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(ii) partially offset by - &#8364;<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-5" name="nbx:IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" format="ixt:num-dot-decimal" scale="6" id="f-653">1.4</ix:nonFraction>&#160;million of discounting negative effect). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025 the fair value of the debt is estimated at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-654">46.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#2d2d2d;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company estimated the fair value of the debt using the same methodology as the one performed at renegotiation date. In doing so, the Company kept the same assumption of CCC credit rating. However, essentially because of a increase in spreads observed as of June 30, 2025 (compared to December 2024), the estimated fair market rate was estimated at <ix:nonFraction unitRef="number" contextRef="c-158" decimals="3" name="ifrs-full:DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" scale="-2" id="f-655">19.2</ix:nonFraction>%.</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">13.2 DUE DATES OF THE FINANCIAL LIABILITIES </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock" id="f-656" continuedAt="f-656-1" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The due dates for repayment of the financial liabilities at their nominal value and including fixed rate interests and future variable interest payments have been estimated based on the milestone and royalties forecasts at the reporting date are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.959%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1&#160;year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and <br/>3&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 3 and <br/>5&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5 years</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-172" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-657">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-173" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-658">595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-174" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-175" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-176" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-661">1,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curadigm interest-free Bpifrance advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-177" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-662">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-178" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-663">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-179" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-664">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-180" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-181" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-666">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HSBC &#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-182" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-667">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-183" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-184" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-186" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-671">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance &#8220;PGE&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-672">1,275</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-673">314</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-190" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-191" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-676">1,589</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB fixed rate loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-192" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-677">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-193" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-678">22,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-194" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-679">44,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-680">30,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-681">97,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-196" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-682">1,282</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-197" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-683">1,707</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-198" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-684">866</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-199" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-685">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-200" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-686">3,855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-687">4,831</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-202" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-688">24,843</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-203" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-689">45,781</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-690">30,366</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-691">105,822</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Company plans according to contractual terms to reimburse the <ix:nonFraction unitRef="loan" contextRef="c-205" decimals="INF" name="nbx:BorrowingScheduledForReimbursementNumber" format="ixt-sec:numwordsen" scale="0" id="f-692">two</ix:nonFraction> &#8220;PGE&#8221; (&#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; or state-guaranteed loans) from HSBC and BPI over <ix:nonNumeric contextRef="c-205" name="nbx:BorrowingMaturityTerm" format="ixt-sec:duryear" id="f-693">5</ix:nonNumeric> years with a deferral of <ix:nonNumeric contextRef="c-205" name="nbx:BorrowingDefermentPeriod" format="ixt-sec:duryear" id="f-694">1</ix:nonNumeric> year (last reimbursement being in 2026).</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-504-4"><ix:continuation id="f-656-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.959%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1&#160;year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and <br/>3&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 3 and <br/>5&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5 years</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-695">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-696">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-698">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-699">1,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curadigm interest-free Bpifrance advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-700">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-701">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-702">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-704">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HSBC &#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-705">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-706">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-709">1,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance &#8220;PGE&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-710">1,289</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-711">948</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-712">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-713">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-714">2,237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB fixed rate loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-715">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-716">19,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-717">40,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-718">39,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-170" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-719">100,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-720">1,282</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-721">2,131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-232" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-722">866</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-233" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-723">216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-724">4,495</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-725">5,210</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-236" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-726">24,689</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-727">41,725</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-728">39,412</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-729">111,036</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Company plans according to contractual terms to reimburse the <ix:nonFraction unitRef="loan" contextRef="c-239" decimals="INF" name="nbx:BorrowingScheduledForReimbursementNumber" format="ixt-sec:numwordsen" scale="0" id="f-730">two</ix:nonFraction> &#8220;PGE&#8221; (&#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; or state-guaranteed loans) from HSBC and BPI over <ix:nonNumeric contextRef="c-239" name="nbx:BorrowingMaturityTerm" format="ixt-sec:durwordsen" id="f-731">five years</ix:nonNumeric> with a deferral of <ix:nonNumeric contextRef="c-239" name="nbx:BorrowingDefermentPeriod" format="ixt-sec:duryear" id="f-732">1</ix:nonNumeric> year (last reimbursement being in 2026).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The debt obligations indicated above relate to the fixed and variable rate interests and principal payable on repayable advances, the interest-free Bpifrance loan, EIB loan, PGE loans and the lease liabilities. These amounts reflect the committed amounts under those contracts as of June&#160;30, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the table above indicates that the EIB loan's total expected cash outflows (undiscounted) is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-5" name="ifrs-full:Borrowings" scale="6" id="f-733">97.8</ix:nonFraction> million, which includes :</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-734">33.7</ix:nonFraction>&#160;million for the principal and fixed rate interest to be paid over the term of the loan,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-735">19.0</ix:nonFraction>&#160;million remaining milestones to be prepaid under the following mechanisms: </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">should the company secure future non-dilutive capital through the execution of any business development deal, an accelerated redemption of this milestone payment would be triggered resulting in a prorated payment amount not exceeding 10% of any upfront or milestone payment received by the Company; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">should the Company contract future equity or debt financing transactions which will require prepayments equal to a tiered low single digit percentage of raising up to an aggregate of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-6" name="nbx:BorrowingsCumulativeMilestonePrepaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-736">100</ix:nonFraction>&#160;million, on a cumulative basis, increasing to a mid-single digit percentage for such financings greater than &#8364;<ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-6" name="nbx:BorrowingsCumulativeMilestonePrepaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-737">100</ix:nonFraction>&#160;million.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-5" name="nbx:EstimatedRoyaltyPayments" format="ixt:num-dot-decimal" scale="6" id="f-738">45.1</ix:nonFraction>&#160;million for the estimated royalty payments to be made in the future, based on the forecasted sales expected to be generated by the Company&#8217;s partners during the <ix:nonNumeric contextRef="c-151" name="nbx:ConsolidatedForecastedSalesPeriod" format="ixt-sec:durwordsen" id="f-739">six-year</ix:nonNumeric> period beginning upon JNJ-1900 (NBTXR3) commercialization. (See Notes 4.4 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financing Agreement with the European Investment Bank (&#8220;EIB&#8221;) and 13.1 - Conditional advance, bank loan and loans from government and public authorities in the consolidated financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2024).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_103"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" id="f-740" continuedAt="f-740-1" escape="true">Trade payables and other current liabilities</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-740-1" continuedAt="f-740-2"><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">14.1 TRADE AND OTHER PAYABLES</span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" id="f-741" escape="true"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses - clinical trials</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-742">7,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-743">15,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-744">4,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-745">4,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total trade and other payables</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-746">11,639</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-747">20,036</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables are not discounted, as none of the amounts has a maturity date above one year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accrued Expenses related to clinical trials balance decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-5" sign="-" name="nbx:AdjustmentsForIncreaseDecreaseInAccruedExpenses" format="ixt:num-dot-decimal" scale="6" id="f-748"><ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-5" sign="-" name="nbx:AdjustmentsForIncreaseDecreaseInAccruedExpenses" format="ixt:num-dot-decimal" scale="6" id="f-749">8.1</ix:nonFraction></ix:nonFraction>&#160;million between December 31, 2024 and June 30, 2025. This decrease is mainly explained by (i) the NANORAY-312 development in 2025, amounting to a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-5" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-750">1.8</ix:nonFraction>&#160;million accrual as of June 30, 2025, compared to the <ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-5" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-751">11.1</ix:nonFraction>&#160;million accrual as of December 31, 2024. This reduction reflects  the amendment letter signed in March 2025, removing the Company&#8217;s funding obligations for the 312 study in the frame of the transfer of sponsorship to Janssen; partially offset by (ii) the study 1100 development, increasing to a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-247" decimals="-5" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-752">5.3</ix:nonFraction>&#160;million accrual as of June 30, 2025, compared to the <ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-5" name="nbx:IncreaseDecreaseInOtherCurrentPayables" format="ixt:num-dot-decimal" scale="6" id="f-753">4.4</ix:nonFraction>&#160;million accrual as of December 31, 2024.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-740-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The trade payables and other accruals are quite stable between December 2024 and June 2025. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">14.2 OTHER CURRENT LIABILITIES</span></div><ix:nonNumeric contextRef="c-1" name="nbx:DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" id="f-754" escape="true"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="3" id="f-755">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="3" id="f-756">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll tax and other payroll liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-757">5,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-758">6,334</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="nbx:OtherMiscellaneousCurrentLiabilities" scale="3" id="f-759">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="nbx:OtherMiscellaneousCurrentLiabilities" scale="3" id="f-760">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-761">7,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-762">7,543</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll tax and other payroll liabilities primarily consist of payroll taxes and social charges, namely the employer withholdings relating to free shares, as well as accrued bonuses, vacation day accruals and related social charges. Payroll tax and other payroll liabilities have decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="nbx:IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" format="ixt:num-dot-decimal" scale="6" id="f-763">0.5</ix:nonFraction>&#160;million during the first half of 2025, mainly due to the payment in the first half of bonuses payable accrued at the previous year-end for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="nbx:IncreaseDecreaseInBonusAccrual" format="ixt:num-dot-decimal" scale="6" id="f-764">0.9</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">14.3 DEFERRED INCOME AND CONTRACT LIABILITIES</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="nbx:DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" id="f-765" escape="true"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" scale="3" id="f-766">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" scale="3" id="f-767">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities - Current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-768">36,172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-769">18,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred income and current contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-770">36,222</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-771">18,161</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The current contract liabilities are accounted for in accordance with IFRS 15.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current contract liabilities increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-772">18.1</ix:nonFraction>&#160;million to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-5" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-773">36.2</ix:nonFraction>&#160;million as of June 30, 2025. The initial payment received in 2021 from LianBio was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-248" decimals="-5" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-774">16.5</ix:nonFraction>&#160;million was recognized as a contract liability since the delivery of the related performance obligation has not yet commenced. The increase of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-775">18.1</ix:nonFraction>&#160;million results from the combined effects of the amendments on the Janssen License Agreement and the Asia Licensing Agreement (formerly Lianbio) in the allocation of the constrained transaction price (See Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues and other income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">14.4 REFUND LIABILITIES</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="nbx:DetailedInformationAboutRefundLiabilitiesTableTextBlock" id="f-776" escape="true"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current refund liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-777">4,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-778">27,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current refund liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentRefundsProvision" format="ixt:num-dot-decimal" scale="3" id="f-779">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentRefundsProvision" format="ixt:num-dot-decimal" scale="3" id="f-780">7,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Refund liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:RefundsProvision" format="ixt:num-dot-decimal" scale="3" id="f-781">7,378</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:RefundsProvision" format="ixt:num-dot-decimal" scale="3" id="f-782">35,613</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The refund liability, recognized as of December 2024, reflects the refund obligation related to the amendments of the Janssen Agreement, signed in the fourth quarter of 2024.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the refund liabilities decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="nbx:IncreaseDecreaseRefundLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-783">28.2</ix:nonFraction>&#160;million according to the amendment of the Janssen Agreement, signed on March 17, 2025.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These amendments were accounted for as a contract modification under IFRS 15, and resulted in a change in the transaction price, as well as a change in scope of the performance obligations, recorded as a cumulative catch-up in the statement of consolidated operations and refund liabilities in the consolidated statement of financial position. (Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues and other income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_106"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="f-784" continuedAt="f-784-1" escape="true">Financial instruments included in the statement of financial position and impact on income</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="f-785" continuedAt="f-785-1" escape="true"><ix:continuation id="f-784-1" continuedAt="f-784-2"><ix:continuation id="f-505-1" continuedAt="f-505-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Detail of financial instruments included in the statements of financial position and impact on income</span></div></ix:continuation></ix:continuation></ix:nonNumeric><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-784-2" continuedAt="f-784-3"><ix:continuation id="f-785-1"><ix:continuation id="f-505-2"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="f-786">409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-787">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="f-788">409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="f-789">409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-790">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-792">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-793">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-794">28,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-256" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-795">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-257" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-796">28,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-797">28,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-798">31,064</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-799">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-259" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-800">31,064</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-801">31,064</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-802">46,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:fixed-zero" scale="3" id="f-803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-262" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-804">46,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-805">49,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-263" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-806">4,735</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-264" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:fixed-zero" scale="3" id="f-807">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-265" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-808">4,735</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-263" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-809">4,753</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-266" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-810">11,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-267" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:fixed-zero" scale="3" id="f-811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-268" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-812">11,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-266" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-813">11,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Total liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-814">62,879</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-269" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:fixed-zero" scale="3" id="f-815">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-270" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-816">62,879</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-817">65,900</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-271" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="f-818">406</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-272" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-819">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-273" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="f-820">406</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-271" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="f-821">406</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-274" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-822">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-275" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-276" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-824">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-274" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-825">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-826">49,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-827">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-279" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-828">49,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-829">49,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-830">53,120</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-280" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-831">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-832">53,120</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-833">53,120</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-834">45,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:fixed-zero" scale="3" id="f-835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-836">45,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-837">48,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-838">4,924</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-286" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:fixed-zero" scale="3" id="f-839">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-287" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-840">4,924</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-841">4,924</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-288" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-842">20,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:fixed-zero" scale="3" id="f-843">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-844">20,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-288" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-845">20,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Total liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-846">70,936</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-291" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:fixed-zero" scale="3" id="f-847">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-292" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-848">70,936</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-849">73,402</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Management of financial risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The principal financial instruments held by the Company are instruments classified as cash and cash equivalents. These instruments are managed with the objective of enabling the Company to finance its business activities. The Company's policy is to not use financial instruments for speculative purposes. It does not use derivative financial instruments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The principal financial risks faced by the Company are liquidity, foreign currency exchange, interest rate and credit risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Liquidity risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Liquidity risk arises from the Company&#8217;s financial liabilities and significant expenses related to development and manufacturing of nanotechnology products and conducting clinical studies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company&#8217;s operations have consumed substantial amounts of cash since its inception. Developing pharmaceutical product candidates, including conducting clinical trials, is expensive, lengthy and risky, and the Company expects to continue to incur significant losses in the near term. Accordingly, the Company will continue to </span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-784-3"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">require substantial additional capital to continue its clinical development activities and potentially engage in commercialization activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Liquidity risk management aims to ensure that the Company has access to sufficient liquidity and financial resources to be able to meet present and future obligations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company prepares short&#8209;term cash forecasts and annual operating cash flow forecasts as part of its budget procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Prudent liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate credit facilities and being able to unwind market positions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">At the date of these consolidated financial statements, the Company estimates, given its current cost structure and its projected expenditure commitments, to be able to finance its activities into mid-2026 (see Note 2. &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">General information, statement of compliance and basis of presentation</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> for more details).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The functional currency of Nanobiotix S.A. is the euro. Exposure to foreign currency exchange risk is mainly derived from certain of its revenue and bank accounts denominated in U.S dollars. Under the global license Agreement  with Janssen, and the Asia Licensing Agreement (former LianBio contract) the Company has received payments in U.S dollars. Additionally, the Company is also exposed through intragroup transactions between Nanobiotix S.A. and its U.S. subsidiary for which the functional currency is the U.S. dollar, as well as trade relations with customers and suppliers outside the euro zone. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At this stage of its development, the Company does not use hedging to protect its business against exchange rate fluctuations. However, a significant increase in its business activity outside the euro zone could lead to a greater exposure to foreign currency exchange risk as the Company&#8217;s operating capital requirements are mainly denominated in euro. If this occurs, the Company may implement a suitable hedging policy for these risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Credit risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The credit risk related to cash and cash equivalents and to current financial instruments is not material given the rating and size of the relevant financial institutions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s exposure to credit risk chiefly stems from trade receivables related to its customer (Janssen) as of June 30, 2025. Due to the limited number of customers, the Company appropriately monitors its receivables and their payment and clearance. The Company enters into such transactions only with highly reputable, financially sound counterparts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest rate risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's exposure to interest rate risk is primarily related to cash equivalents and investment securities, which consist of term deposits. Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, loans issued by the Company are exclusively fixed rate loans and thus our exposure to interest rate and market risk is deemed low. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable interests on the EIB loan are royalty-based and are not subject to market rate risks.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_109"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRevenueExplanatory" id="f-850" continuedAt="f-850-1" escape="true">Revenue and other income </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="f-851" continuedAt="f-851-1" escape="true"><ix:continuation id="f-850-1" continuedAt="f-850-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The revenue recognition accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June&#160;30, 2025, are identical to those used for the year ended December&#160;31, 2024, as completed below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Further to the agreements signed during the fourth quarter of 2024 detailing the terms for the transfer of the sponsorship of the ongoing NANORAY-312 Phase 3 pivotal trial in head and neck cancer to Janssen (See Note 16 &#8211; </span></div></ix:continuation></ix:nonNumeric><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-850-2" continuedAt="f-850-3"><ix:continuation id="f-851-1"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenues and other income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> to the consolidated financial statements as of and for the year ended December 31, 2024), the Company signed an amendment letter with Janssen BV on March 17, 2025. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The amendment letter provides that Janssen will ultimately assume nearly all remaining costs for the ongoing pivotal Phase 3 trial through completion, except for a limited portion of costs that will continue to be covered by the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This amendment aims to improve the Company&#8217;s short-term cash runway by:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">reducing its obligation to make payments that were probable in the short term for the ongoing NANORAY-312 Phase 3 pivotal trial development costs; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">revising potential future milestone payments for a total of $<ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-6" name="nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-852">105</ix:nonFraction>&#160;million under both the Janssen License Agreement and the Asia Licensing Agreement, </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This amendment letter has been considered and accounted for as a contract modification under IFRS 15, which modifies the remaining transaction prices of both Janssen License Agreement and Asia Licensing Agreement, originally treated as separate contracts for IFRS 15 purposes. As there are price interdependencies between the two effects of the amendment as described above, the contract modification has been applied to both agreements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The amendment does not change the scope of the initial contracts but the overall impact of the contract modification is a significant increase in the remaining constrained transaction price of the combined agreements (Janssen Agreement and Asia Licensing Agreement) while the constraint continues to apply to milestone payments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The net positive impact on the constrained transaction price on the Janssen Agreement was recognized as a cumulative catch-up adjustment, as the remaining goods or services under the license agreement are not distinct. As a result, revenue for the six-month period ended June 30, 2025, included a one-off positive impact of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-294" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-853">21.2</ix:nonFraction>&#160;million, directly attributable to the contract modification as described above.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 15, the funding obligation towards Janssen was reduced to a net refund liability amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-295" decimals="-5" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-854">7.4</ix:nonFraction>&#160;million as of June 30, 2025. See Note 14.4 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Refund liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The combined effects of the amendment on the two license agreements resulted also in the allocation of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-855">18.1</ix:nonFraction>&#160;million of the constrained transaction price to the Asia Licensing Agreement, which was recognized as the related contract liability since the delivery of the related performance obligation has not yet commenced. See Note 14.3 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Deferred income and Contract liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Detail of revenue and other income</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" id="f-856" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s revenue and other income per category for the six-month period ended June 30, 2025 and 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-857">21,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-858">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-859">3,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-299" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-860">2,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-861">24,928</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-862">6,163</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-863">1,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-864">2,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="f-865">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="f-866">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="f-867">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="f-868">756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-869">1,710</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-870">3,126</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenue and other income</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-871">26,638</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-872">9,289</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Revenues</span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the Total Revenue reached &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-873">24.9</ix:nonFraction>&#160;million, composed of:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the line &#8216;Services&#8217; includes (i) a one-off positive revenue of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-5" name="nbx:AdjustmentsToRevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-874">21.2</ix:nonFraction>&#160;million recognized over the six-month period ended June 30, 2025 directly attributable to the contract modification impact occurred during the first half of 2025, that counterbalances the negative revenue impact recognized in fiscal year 2024 : the amendments signed during the last quarter of 2024 had significantly reduced the transaction price of the license agreement as the R&amp;D service performance obligation was replaced with a funding obligation for the Company towards Janssen, while the amendment letter executed in March 2025 did not impact the scope of the Company's performance obligations but increased the remaining transaction price of the global </span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-850-3" continuedAt="f-850-4"><div style="margin-top:3pt;padding-left:36pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">license agreement, (ii) and other &#8216;Services&#8217; revenue linked to technology transfer and technical assistance recharge to Janssen for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-300" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-875">0.4</ix:nonFraction>&#160;million. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-301" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-876">3.4</ix:nonFraction>&#160;million of &#8216;Other Sales&#8217; related to products clinical supplies to Janssen for the six-month period ended June 30, 2025.</span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2024, the &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-877">6.2</ix:nonFraction>&#160;million Total Revenue mainly includes (i) &#8216;Services&#8217; revenue linked to the assignment of the license to Janssen and the rendered R&amp;D services in proportion of the completion of the ongoing studies, totaling &#8364;<ix:nonFraction unitRef="eur" contextRef="c-302" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-878">2.7</ix:nonFraction>&#160;million; (ii) &#8216;Services&#8217; revenue linked to technology transfer and technical assistance recharge for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-303" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-879">1.1</ix:nonFraction>&#160;million; (iii) and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-304" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-880">2.4</ix:nonFraction>&#160;million of &#8216;Other Sales&#8217; related to products clinical supplies to Janssen.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research tax credit</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit decreased from &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-5" name="nbx:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="6" id="f-881">2.3</ix:nonFraction>&#160;million in 2024 to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="nbx:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="6" id="f-882">1.6</ix:nonFraction>&#160;million in 2025 due mainly due to the exclusion of a major vendor from the CIR scope in 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subsidies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidies include the Bpifrance Deep Tech Grant received by the Company, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-168" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="f-883">67</ix:nonFraction>&#160;thousand recognized as other income for the half-year ended June 30, 2025, as compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-305" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="f-884">36</ix:nonFraction>&#160;thousand for the half-year ended June 30, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-850-4">The line item &#8216;Other&#8217; mainly includes income for services recharge, in the framework of the &#8216;GTCA&#8217; totaling &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="f-885">26</ix:nonFraction> thousand as of June 30, 2025 compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-5" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-886">0.5</ix:nonFraction>&#160;million for services recharge and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-5" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-887">0.2</ix:nonFraction>&#160;million for supply services as of June 30, 2024</ix:continuation>.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_112"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory" id="f-888" continuedAt="f-888-1" escape="true">Operating expenses</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-888-1" continuedAt="f-888-2"><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">17.1 RESEARCH AND DEVELOPMENT EXPENSES</span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" id="f-889" escape="true"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month  period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, sub-contracting and other expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="f-890">7,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="f-891">15,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:ResearchAndDevelopmentExpensePayrollCosts" format="ixt:num-dot-decimal" scale="3" id="f-892">6,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:ResearchAndDevelopmentExpensePayrollCosts" format="ixt:num-dot-decimal" scale="3" id="f-893">6,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" scale="3" id="f-894">610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" scale="3" id="f-895">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-896">14,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-897">21,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt">see Note 17.4 Depreciation, amortization and provision expenses</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, sub-contracting and other expenses decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-5" name="nbx:IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" format="ixt:num-dot-decimal" scale="6" id="f-898">7.6</ix:nonFraction>&#160;million for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024. This favorable variance is mainly related to the transfer of sponsorship of the 312 study to Janssen, including the amendment of the Janssen Agreement signed in March 2025, resulting in the removal of funding obligations on the 312 study.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D Payroll costs increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="nbx:IncreaseDecreasePayrollExpense" format="ixt:num-dot-decimal" scale="6" id="f-899">0.2</ix:nonFraction>&#160;million, or by <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="nbx:IncreaseDecreasePayrollExpensePercentage" scale="-2" id="f-900">3.7</ix:nonFraction>% for the six-month period ended June&#160;30, 2025 as compared with the same period in 2024, which is mainly due to the phasing of social charges expenses related to stock options granted between 2025 and 2024 for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-309" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="6" id="f-901">0.2</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">17.2 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" id="f-902" escape="true"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, fees and other expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" format="ixt:num-dot-decimal" scale="3" id="f-903">4,334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" format="ixt:num-dot-decimal" scale="3" id="f-904">4,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpensePayrollCosts" format="ixt:num-dot-decimal" scale="3" id="f-905">7,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpensePayrollCosts" format="ixt:num-dot-decimal" scale="3" id="f-906">6,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" scale="3" id="f-907">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" scale="3" id="f-908">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total SG&amp;A expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-909">11,294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-910">10,819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt">see Note 17.4 Depreciation, amortization and provision expenses</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, fees and other expenses increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-5" sign="-" name="nbx:IncreaseDecreaseInPurchasesFeesAndOtherExpenses" format="ixt:num-dot-decimal" scale="6" id="f-911">0.2</ix:nonFraction>&#160;million for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024, as SG&amp;A expenses were closely monitored and remained overall in line with prior year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SG&amp;A payroll costs increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-5" name="nbx:IncreaseDecreasePayrollExpense" format="ixt:num-dot-decimal" scale="6" id="f-912">0.7</ix:nonFraction>&#160;million, or <ix:nonFraction unitRef="number" contextRef="c-310" decimals="3" name="nbx:IncreaseDecreasePayrollExpensePercentage" scale="-2" id="f-913">11.1</ix:nonFraction>%, for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024. This variation is mainly due to the phasing of social charges expenses related to stock options granted for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-311" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="6" id="f-914">0.3</ix:nonFraction>&#160;million, and severance expenses following some resources reallocation for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="nbx:SeveranceExpenses" format="ixt:num-dot-decimal" scale="6" id="f-915">0.2</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SG&amp;A depreciation expenses decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="nbx:IncreaseDecreaseInDepreciationExpense" format="ixt:num-dot-decimal" scale="6" id="f-916">0.4</ix:nonFraction>&#160;million following reversal of provision recorded during the first half off 2025 due to litigation settlement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">17.3 PAYROLL COSTS </span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" id="f-917" escape="true"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Wages and salaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="f-918">7,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="f-919">7,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="3" id="f-920">4,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="3" id="f-921">3,324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-922">2,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-923">1,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement benefit obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" scale="3" id="f-924">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" scale="3" id="f-925">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total payroll costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-926">13,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-927">12,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average headcount</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="c-1" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-928">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="c-4" decimals="0" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="f-929">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End-of-period headcount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="c-2" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-930">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="c-39" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-931">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-888-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had <ix:nonFraction unitRef="employee" contextRef="c-2" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-932">103</ix:nonFraction> employees, including <ix:nonFraction unitRef="employee" contextRef="c-312" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-933">72</ix:nonFraction> in R&amp;D and <ix:nonFraction unitRef="employee" contextRef="c-313" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-934">31</ix:nonFraction> in selling, general and administrative expenses, compared to <ix:nonFraction unitRef="employee" contextRef="c-39" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-935">110</ix:nonFraction> as of June&#160;30, 2024,  including <ix:nonFraction unitRef="employee" contextRef="c-314" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-936">77</ix:nonFraction> in R&amp;D and <ix:nonFraction unitRef="employee" contextRef="c-315" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-937">33</ix:nonFraction> in selling, general and administrative expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Wages and salaries remained stable for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first half of 2025, related payroll taxes increased by <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="nbx:IncreaseDecreaseInEmployeeBenefitExpensePercentage" scale="-2" id="f-938">22.9</ix:nonFraction>%, or by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="nbx:IncreaseDecreaseInEmployeeBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="f-939">0.8</ix:nonFraction>&#160;million, mainly due to the phasing of social charges expenses related to stock options granting for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-316" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-940">0.5</ix:nonFraction> million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In accordance with IFRS 2 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-based Payment</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, the share-based payment expense recognized in the statement of consolidated operations reflects the amortization of the fair value of the granted awards over the service period. The share-based payment expenses amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="6" id="f-941">2.2</ix:nonFraction>&#160;million for the period ended June&#160;30, 2025, as compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="6" id="f-942">1.9</ix:nonFraction>&#160;million as of  June&#160;30, 2024 (see Note 18 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-based payments</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">17.4 DEPRECIATION, AMORTIZATION AND PROVISION EXPENSES</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" id="f-943" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses by function are detailed as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six month period ended June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-944">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-945">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-946">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-3" name="ifrs-full:DepreciationExpense" scale="3" id="f-947">645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-3" name="ifrs-full:DepreciationExpense" scale="3" id="f-948">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationExpense" scale="3" id="f-949">798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reversal of provision for disputes and charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-3" sign="-" name="nbx:LitigationExpense" scale="3" id="f-950">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-3" sign="-" name="nbx:LitigationExpense" scale="3" id="f-951">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="nbx:LitigationExpense" scale="3" id="f-952">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for disputes and charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="f-953">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="f-954">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="f-955">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses (except IAS 19)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19" scale="3" id="f-956">610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-3" sign="-" name="nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19" scale="3" id="f-957">80</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19" scale="3" id="f-958">529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Provision for retirement benefit obligations&#160;(IAS 19) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-3" name="nbx:ProvisionForRetirementBenefitObligationsNet" scale="3" id="f-959">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-3" name="nbx:ProvisionForRetirementBenefitObligationsNet" scale="3" id="f-960">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:ProvisionForRetirementBenefitObligationsNet" scale="3" id="f-961">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" scale="3" id="f-962">637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-3" sign="-" name="nbx:DepreciationAmortizationAndProvisionExpenses" scale="3" id="f-963">68</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" scale="3" id="f-964">569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six month period ended June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-965">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-3" name="ifrs-full:AmortisationExpense" format="ixt:fixed-zero" scale="3" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-967">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-3" name="ifrs-full:DepreciationExpense" scale="3" id="f-968">621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-3" name="ifrs-full:DepreciationExpense" scale="3" id="f-969">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:DepreciationExpense" scale="3" id="f-970">785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reversal of provision for disputes and charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-3" name="nbx:LitigationExpense" format="ixt:fixed-zero" scale="3" id="f-971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-3" sign="-" name="nbx:LitigationExpense" scale="3" id="f-972">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="nbx:LitigationExpense" scale="3" id="f-973">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for disputes and charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="f-974">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="f-975">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="f-976">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total depreciation, amortization and provision expenses (except IAS 19)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19" scale="3" id="f-977">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19" scale="3" id="f-978">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19" scale="3" id="f-979">983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Provision for retirement benefit obligations&#160;(IAS 19) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-3" name="nbx:ProvisionForRetirementBenefitObligationsNet" scale="3" id="f-980">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-3" name="nbx:ProvisionForRetirementBenefitObligationsNet" scale="3" id="f-981">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:ProvisionForRetirementBenefitObligationsNet" scale="3" id="f-982">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" scale="3" id="f-983">705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" scale="3" id="f-984">311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" format="ixt:num-dot-decimal" scale="3" id="f-985">1,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Details of the provision for retirement benefit obligations are provided in note 11</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">17.5 OTHER OPERATING INCOME AND EXPENSES</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" id="f-986" escape="true"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non recurring expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:OtherNonrecurringExpenses" scale="3" id="f-987">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:OtherNonrecurringExpenses" scale="3" id="f-988">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non recurring  income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:OtherNonrecurringsIncome" scale="3" id="f-989">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="nbx:OtherNonrecurringsIncome" scale="3" id="f-990">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other operating income and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-991">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-992">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company has not recorded any material other operating income and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2024, the other non recurring expenses mainly relates to some employment termination indemnities for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-3" name="nbx:OtherNonrecurringExpenses" scale="3" id="f-993">129</ix:nonFraction> thousand.</span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_115"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                   18. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="f-994" continuedAt="f-994-1" escape="true">Share-based payments</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-994-1" continuedAt="f-994-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Detail of share-based payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has granted stock options (OSA), founders&#8217; warrants (BSPCE), warrants (BSA), and free shares (AGA) to corporate officers, employees, members of the Executive and Supervisory Board and consultants of the Group. In certain cases, exercise of the stock options, founders&#8217; warrants and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" id="f-995" continuedAt="f-995-1" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of stock options, founders&#8217; warrants, warrants and free shares outstanding on June&#160;30, 2025 and their main characteristics, are detailed below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Founders&#8217; warrants outstanding as of June 30, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.070%"><tr><td style="width:1.0%"/><td style="width:45.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2015-1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2015-3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2016 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2016 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2017 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSCPE 2017</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders' meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Feb-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Jun-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-Feb-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-Feb-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7-Jan-17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7-Jan-17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSPCEs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-320" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-996">450,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-997">450,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-322" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-998">450,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-323" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-999">450,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-324" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1000">450,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-325" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1001">450,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSPCEs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-320" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1002">71,650</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1003">53,050</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-322" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1004">126,400</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-323" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1005">129,250</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-324" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1006">117,650</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-325" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1007">80,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the BSPCE were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-320" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1008">71,650</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1009">53,050</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-322" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1010">126,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-323" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1011">129,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-324" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1012">117,650</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-325" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1013">80,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number of which that may be subscribed by corporate officers:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-326" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1014">24,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-327" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1015">23,500</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-328" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1016">23,500</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-329" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1017">26,400</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-330" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1018">32,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1019">24,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-332" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1020">23,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-333" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1021">23,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-334" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1022">26,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1023">32,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-336" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1024">13</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-337" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1025">42</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-338" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1026">43</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-339" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1027">50</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-340" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1028">42</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-341" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1029">3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the BSPCE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/10/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSPCE expiry date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/10/2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSPCE exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-320" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1030">18.57</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-321" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1031">20.28</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-322" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1032">14.46</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-323" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1033">14.46</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-324" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1034">15.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-325" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1035">15.93</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-342" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1036">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-343" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1037">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-344" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="f-1038">333</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-345" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1039">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-346" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1040">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-347" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1041">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSPCEs lapsed or cancelled as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-342" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1042">71,650</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-343" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1043">53,050</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-344" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1044">29,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-345" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1045">31,150</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-346" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1046">20,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-347" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1047">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of BSPCEs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-348" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1048">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-349" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1049">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-350" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1050">96,817</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-351" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1051">98,100</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-352" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1052">97,050</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-353" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1053">80,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares available for subscription as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-348" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1054">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-349" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1055">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-350" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1056">96,817</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-351" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1057">98,100</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-352" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1058">97,050</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-353" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1059">80,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of the related BSPCEs are met)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-348" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1060">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-349" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1061">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-350" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1062">96,817</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-351" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1063">98,100</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-352" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1064">97,050</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-353" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1065">80,000</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-994-2" continuedAt="f-994-3"><ix:continuation id="f-995-1" continuedAt="f-995-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Warrants outstanding as of June 30, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"/><td style="width:43.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.187%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2015-1 </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2015-2 (a) </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2018-2</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2019-1</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2020</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2021 (a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-18</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-18</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Apr-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Feb-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jul-18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29-Mar-19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17-Mar-20</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Apr-21</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum number of BSAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-354" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1066">100,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-355" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1067">100,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-356" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1068">140,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-357" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1069">140,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-358" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1070">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-359" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1071">650,000</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSAs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-354" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1072">26,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-355" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1073">64,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-356" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1074">5,820</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-357" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1075">18,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-358" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1076">18,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-359" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1077">48,103</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares to which the BSA were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-354" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1078">26,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-355" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1079">64,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-356" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1080">5,820</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-357" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1081">18,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-358" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1082">18,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-359" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1083">48,103</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the total number of shares that may subscribed by the corporate officers of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-360" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1084">15,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-361" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1085">12,700</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-362" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1086">14,024</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relevant officers:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anne-Marie GRAFFIN</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-363" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1087">5,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-364" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1088">2,900</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-365" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1089">3,843</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enno SPILLNER</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-366" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1090">3,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-367" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1091">4,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-368" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1092">3,829</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alain HERRERA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-369" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1093">5,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-370" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1094">2,900</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-371" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1095">3,195</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gary PHILLIPS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-372" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1096">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-373" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1097">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-374" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1098">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-375" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1099">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-376" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1100">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-377" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1101">1</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the BSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/25/2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">07/27/18</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/29/19</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/17/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/21</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSA expiry date (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/25/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">07/27/28</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/29/29</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/17/30</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSA issue price</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-354" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="f-1102">4.87</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-355" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="f-1103">5.00</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-356" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="f-1104">2.36</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-357" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="f-1105">1.15</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-358" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="f-1106">0.29</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-359" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="f-1107">2.95</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise price per BSA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-354" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1108">17.67</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-355" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1109">19.54</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-356" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1110">16.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-357" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1111">11.66</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-358" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1112">6.59</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-359" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1113">13.47</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-378" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1114">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-379" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1115">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-380" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1116">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-381" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1117">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-382" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1118">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-383" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1119">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of forfeited or cancelled BSAs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-378" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1120">26,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-379" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1121">64,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-380" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1122">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-381" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1123">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-382" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1124">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-383" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1125">33,672</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of BSAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-384" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1126">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-385" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1127">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-386" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1128">5,820</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-387" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1129">18,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-388" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1130">18,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-389" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1131">14,431</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares available for subscription as of June&#160;30, 2025 (considering the conditions of exercise of the BSAs)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-384" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1132">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-385" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1133">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-386" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1134">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-387" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1135">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-388" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1136">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-389" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1137">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-384" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1138">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-385" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1139">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-386" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1140">5,820</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-387" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1141">18,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-388" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1142">18,000</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-389" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1143">14,431</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="f-1144" continuedAt="f-1144-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> outstanding </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">as of June 30, 2025</span></div></ix:nonNumeric></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1144-1" continuedAt="f-1144-2"><ix:continuation id="f-994-3" continuedAt="f-994-4"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"/><td style="width:25.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.079%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2016-1 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2016-2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2017 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2018 </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2019-1 </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2019 LLY </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2020</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-04 O</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14-Jun-17</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-18</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Apr-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Apr-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02-Feb-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03-Nov-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">07-Jan-17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6-Mar-18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29-Mar-19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24-Oct-19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Mar-20</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Apr-21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-390" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1145">450,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-391" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1146">450,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-392" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1147">450,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-393" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1148">526,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-394" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1149">648,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-395" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1150">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-396" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1151">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-397" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1152">850,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-390" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1153">6,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-391" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1154">4,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-392" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1155">3,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-393" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1156">62,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-394" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1157">37,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-395" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1158">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-396" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1159">407,972</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-397" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1160">143,200</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the OSAs were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-390" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1161">6,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-391" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1162">4,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-392" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1163">3,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-393" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1164">62,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-394" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1165">37,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-395" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1166">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-396" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1167">407,972</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-397" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1168">143,200</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the number that may be subscribed or purchased by corporate officers:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-398" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1169">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-399" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1170">180,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-400" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1171">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-401" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1172">120,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Anne-Juliette HERMANT</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-402" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1173">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Bart VAN RHIJN</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Louis KAYITALIRE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-403" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" id="f-1174">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-404" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" id="f-1175">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-405" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" id="f-1176">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-406" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" id="f-1177">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-407" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" id="f-1178">12</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-408" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" id="f-1179">104</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-409" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" id="f-1180">13</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/03/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/08/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/07/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/30/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/24/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/11/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/22</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSA expiry date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/03/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/06/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/29/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/24/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/11/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise price per OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-390" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1181">13.05</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-391" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1182">14.26</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-392" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1183">14.97</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-393" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1184">12.87</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-394" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1185">11.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-395" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1186">6.41</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-396" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1187">6.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-397" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1188">13.74</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-410" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1189">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-411" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1190">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-412" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1191">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-413" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1192">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-414" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1193">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-415" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1194">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-416" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1195">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-417" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1196">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of lapsed or cancelled OSAs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-410" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1197">6,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-411" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1198">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-412" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1199">3,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-413" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1200">12,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-414" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1201">12,750</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-415" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1202">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-416" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1203">47,265</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-417" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1204">104,668</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of OSAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-418" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="f-1205">400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-419" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1206">4,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-420" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="f-1207">500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-421" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1208">50,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-422" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1209">24,750</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-423" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1210">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-424" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1211">360,707</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-425" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1212">38,532</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum number of shares available for subscription as of June&#160;30, 2025 (given the vesting conditions of the OSAs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-418" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="f-1213">400</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-419" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1214">4,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-420" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="f-1215">500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-421" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1216">50,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-422" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1217">24,750</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-423" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1218">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-424" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1219">360,707</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-425" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1220">38,532</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-418" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" scale="0" id="f-1221">400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-419" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1222">4,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-420" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" scale="0" id="f-1223">500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-421" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1224">50,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-422" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1225">24,750</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-423" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1226">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-424" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1227">360,707</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-425" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1228">38,532</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1144-2" continuedAt="f-1144-3"><ix:continuation id="f-994-4" continuedAt="f-994-5"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"/><td style="width:19.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.760%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.760%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.760%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.866%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.866%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-04 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-06 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-06 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2022-06 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2022-06 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2023-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2024-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2025-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2025-02 O</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-Apr-21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-Apr-21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-jun-2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Jul-23</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-May-2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-May-2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Apr-21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21-Jun-21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21-Jun-21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22-Jun-22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22-Jun-22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Jul-23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-24</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18-Feb-25</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16-May-25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-426" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1229">1,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-427" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1230">1,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-428" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1231">850,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-429" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1232">1,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-430" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1233">850,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-431" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1234">1,700,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-432" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1235">1,700,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-433" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1236">1,700,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-434" decimals="INF" name="nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1237">1,700,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-426" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1238">428,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-427" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1239">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-428" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1240">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-429" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1241">170,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-430" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1242">410,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-431" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1243">338,860</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-432" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1244">1,224,780</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-433" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1245">8,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-434" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1246">1,241,005</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the OSAs were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-426" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1247">428,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-427" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1248">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-428" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1249">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-429" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1250">170,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-430" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1251">410,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-431" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1252">338,860</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-432" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1253">1,224,780</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-433" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1254">8,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-434" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1255">1,241,005</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the number that may be subscribed or purchased by corporate officers:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-435" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1256">240,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-436" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1257">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-437" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1258">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-438" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1259">245,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-439" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1260">298,860</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-440" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1261">930,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-441" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1262">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-442" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1263">945,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-443" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1264">180,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-444" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1265">150,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-445" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1266">200,116</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-446" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1267">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-447" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1268">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-448" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1269">505,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Anne-Juliette HERMANT</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-449" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1270">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-450" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1271">35,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-451" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1272">33,354</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-452" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1273">90,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-453" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1274">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-454" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1275">100,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Bart VAN RHIJN</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-455" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1276">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-456" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1277">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-457" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1278">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-458" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1279">65,390</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-459" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1280">180,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-460" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1281">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-461" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1282">190,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Louis KAYITALIRE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-462" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1283">160,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-463" decimals="INF" name="nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1284">150,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-464" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" scale="0" id="f-1285">14</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-465" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" scale="0" id="f-1286">83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-466" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" scale="0" id="f-1287">49</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-467" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" scale="0" id="f-1288">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-468" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" scale="0" id="f-1289">107</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-469" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" scale="0" id="f-1290">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-470" decimals="INF" name="nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" scale="0" id="f-1291">105</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/20/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/23/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/18/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/16/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSA expiry date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/32</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/32</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/20/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/23/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/18/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/16/2035</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise price per OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-426" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1292">13.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-427" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1293">12.99</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-428" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1294">12.99</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-429" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1295">4.16</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-430" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1296">4.16</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-431" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1297">5.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-432" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1298">5.81</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-433" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1299">3.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-434" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1300">2.97</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-471" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1301">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-472" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1302">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-473" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1303">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-474" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1304">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-475" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1305">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-476" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1306">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-477" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1307">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-478" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1308">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-479" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1309">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of lapsed or cancelled OSAs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-471" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1310">87,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-472" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1311">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-473" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1312">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-474" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1313">46,620</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-475" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1314">30,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-476" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1315">20,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-477" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1316">5,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-478" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1317">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-479" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" id="f-1318">1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of OSAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-480" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1319">340,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-481" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1320">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-482" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1321">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-483" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1322">123,780</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-484" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1323">380,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-485" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1324">318,860</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-486" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1325">1,219,530</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-487" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1326">8,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-488" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1327">1,241,004</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum number of shares available for subscription as of June&#160;30, 2025 (given the vesting conditions of the OSAs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-482" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1328">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-484" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1329">380,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-485" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1330">106,288</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-486" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1331">406,510</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-487" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1332">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-488" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1333">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-480" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1334">340,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-481" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1335">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-482" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1336">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-483" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1337">123,780</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-484" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1338">380,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-485" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1339">318,860</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-486" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1340">1,219,530</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-487" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1341">8,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-488" decimals="INF" name="nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1342">1,241,004</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-995-2" continuedAt="f-995-3"><ix:continuation id="f-994-5" continuedAt="f-994-6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Free shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> outstanding </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">as at June 30, 2025</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"/><td style="width:48.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA 2023 - P1</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA 2023 - P2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of AGAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-489" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1343">1,200,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-490" decimals="INF" name="nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1344">1,200,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of AGAs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-489" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1345">427,110</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-490" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1346">439,210</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the AGAs were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-489" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1347">427,110</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-490" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1348">439,210</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the number that can be subscribed by corporate officers:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-491" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1349">298,860</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-492" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1350">293,470</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-493" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1351">200,116</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-494" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1352">200,116</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Anne-Juliette HERMANT</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-495" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1353">33,354</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-496" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1354">33,354</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Bart VAN RHIJN</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-497" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1355">65,390</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-498" decimals="INF" name="nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1356">65,390</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-499" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1357">88</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="benefeciary" contextRef="c-500" decimals="INF" name="nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" scale="0" id="f-1358">87</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of acquisition (end of the acquisition period)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/27/25</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/27/25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-501" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1359">392,060</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-502" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1360">417,760</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of AGAs lapsed or cancelled as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-501" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1361">35,050</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-502" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1362">21,450</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of AGAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-503" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1363">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-504" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1364">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares that may be subscribed</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-503" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1365">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-504" decimals="INF" name="nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1366">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Duration of the holding period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-489" name="nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" format="ixt-sec:duryear" id="f-1367">1</ix:nonNumeric> year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-490" name="nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" format="ixt-sec:duryear" id="f-1368">1</ix:nonNumeric> year</span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-31</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_118"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-994-6" continuedAt="f-994-7"><ix:continuation id="f-1144-3"><ix:continuation id="f-995-3"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.139%"><tr><td style="width:1.0%"/><td style="width:48.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.275%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-505" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1369">371,967</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-506" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1370">56,251</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-507" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1371">4,730,663</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1372">5,158,881</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The measurement methods used to estimate the fair value of stock options and warrants are described below:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The exercise price is based on the share price at the grant date;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The risk-free rate was determined based on the average life of the instruments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Volatility was determined based on a sample of listed companies in the biotechnology sector at the grant date and for a period equal to the life of the warrant or option.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The performance conditions for all of the plans were assessed as follows:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Performance conditions unrelated to the market were analyzed to determine the likely exercise date of the warrants and options and expense was recorded accordingly based on the probability these conditions would be met; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Market-related performance conditions were directly included in the calculation of the fair value of the instruments.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" id="f-1373" continuedAt="f-1373-1" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of June&#160;30, 2025, the details of active share-based payment plans with remaining IFRS 2 expense are presented in the tables below, reflecting the assumptions related to the probability that the non-market performance conditions will be  and the ongoing accounting impact for the period:</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="f-1374" continuedAt="f-1374-1" escape="true"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"/><td style="width:11.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2025</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 O</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-397" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1375">13.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-397" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1376">13.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-508" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1377">38.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-509" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1378">37.8</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-510" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1379">38.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="y" contextRef="c-511" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1380">5.5</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="c-512" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1381">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="c-513" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1382">6.5</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-508" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1383">0.38</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-509" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1384">0.33</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-510" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1385">0.28</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-397" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-1386">0.00</ix:nonFraction></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-397" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="f-1387">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-514" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-1388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-515" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1389">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 P</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-426" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1390">13.60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-426" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1391">13.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-426" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1392">39.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="c-426" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="3" id="f-1393">10</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-426" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1394">0.03</ix:nonFraction></span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-426" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-1395">0.00</ix:nonFraction></span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="f-1396">1,816</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-516" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1397">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-517" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1398">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 O</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-428" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1399">12.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-428" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1400">12.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-518" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1401">39.2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-519" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1402">37.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-520" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1403">38.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="y" contextRef="c-521" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1404">5.5</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="c-522" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1405">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="c-523" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1406">6.5</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-518" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1407">0.35</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-519" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1408">0.30</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-520" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1409">0.26</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-428" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-1410">0.00</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-428" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="f-1411">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-524" xsi:nil="true" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" id="f-1412"></ix:nonFraction></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-525" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1413">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 P</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-427" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1414">12.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-427" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1415">12.99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-427" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1416">39.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="c-427" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="3" id="f-1417">10</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-427" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1418">0.13</ix:nonFraction></span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-427" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-1419">0.00</ix:nonFraction></span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-427" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="f-1420">212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-526" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1421">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-527" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1422">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2022-06 P </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-429" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1423">3.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-429" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1424">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-429" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" format="ixt:num-dot-decimal" id="f-1425">0.4008</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="c-429" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-1426">10</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-429" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" format="ixt:num-dot-decimal" id="f-1427">0.0228</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-429" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-1428">0.00</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-429" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="f-1429">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-528" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-1430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-529" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1431">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2022-06 O </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-430" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1432">3.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-430" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1433">4.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-530" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1434">42.06</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-531" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1435">41.21</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-532" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1436">40.65</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="y" contextRef="c-533" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1437">5.5</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="c-534" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1438">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="c-535" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1439">6.5</ix:nonFraction> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-530" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1440">1.83</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-531" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1441">1.87</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-532" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1442">1.90</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-430" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-1443">0.00</ix:nonFraction></span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-430" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="f-1444">580</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-536" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1445">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-537" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1446">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2023-01 O</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-538" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1447">6.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-538" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1448">5.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-539" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1449">45.07</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-540" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1450">44.11</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-541" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1451">43.41</ix:nonFraction>% </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="y" contextRef="c-542" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1452">5.5</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="c-543" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1453">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="c-544" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1454">6.5</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-539" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1455">2.85</ix:nonFraction>% /<ix:nonFraction unitRef="number" contextRef="c-540" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1456">2.83</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-541" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1457">2.82</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-538" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-1458">0.00</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-538" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="f-1459">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-545" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1460">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-546" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1461">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2024-01 O</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-547" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1462">5.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-547" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1463">5.81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-548" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1464">53.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-549" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1465">51.90</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-550" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1466">50.70</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="c-551" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1467">5.4</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="c-552" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1468">5.9</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="c-553" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1469">6.4</ix:nonFraction></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-548" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1470">3.00</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-549" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1471">3.02</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-550" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1472">3.02</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-547" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-1473">0.00</ix:nonFraction></span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-547" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="f-1474">3,107</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-554" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1475">837</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-555" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1476">194</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2025-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-556" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" id="f-1477">3.65</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-556" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" id="f-1478">3.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-557" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1479">47.18</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-558" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1480">47.43</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-559" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1481">47.57</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="c-557" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1482">5.4</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="c-558" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1483">5.9</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="c-559" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1484">6.4</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-557" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1485">2.83</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-558" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1486">2.91</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-559" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1487">2.98</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-556" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-1488">0.00</ix:nonFraction></span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-556" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="f-1489">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-556" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1490">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-560" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-1491">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2025-02 O</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-561" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" id="f-1492">3.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-561" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" id="f-1493">2.97</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-562" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1494">47.56</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-563" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1495">47.32</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-564" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1496">47.43</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="c-562" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1497">5.4</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="c-563" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1498">5.9</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="c-564" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1499">6.4</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-562" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1500">2.53</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-563" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1501">2.61</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-564" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1502">2.70</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-561" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-1503">0.00</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-561" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="f-1504">2,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-561" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1505">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-1506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total OSA</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;n.a. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1507">1,273</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1508">708</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><ix:continuation id="f-1373-1" continuedAt="f-1373-2"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.823%"><tr><td style="width:1.0%"/><td style="width:10.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2025</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2023 - P1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-568" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="f-1509">4.87</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-568" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="f-1510">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-569" decimals="2" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1511">3</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="c-570" decimals="3" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1512">3.2</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-568" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="f-1513">0.00</ix:nonFraction></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="f-1514">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-571" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1515">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-572" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1516">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2023 - P2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-573" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" id="f-1517">4.87</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-573" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" id="f-1518">0</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-574" decimals="2" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1519">3</ix:nonFraction>% /<ix:nonFraction unitRef="number" contextRef="c-575" decimals="3" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-1520">3.2</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-573" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="f-1521">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-573" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="f-1522">2,130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-576" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1523">442</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-577" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1524">507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total AGA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-578" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1525">888</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-579" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1526">1,232</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1374-1"><ix:continuation id="f-1373-2"><ix:continuation id="f-994-7"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-580" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-1527">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-581" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-1528">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1529">1,273</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-578" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1530">888</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1531">2,161</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-582" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-1532">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-583" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-1533">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-1534">708</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-579" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1535">1,232</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1536">1,940</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-33</span></div></div></div><div id="ia72c30516b7642d5b908b439c54b9466_121"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="f-1537" continuedAt="f-1537-1" escape="true">Net financial income (loss)</ix:nonNumeric></span></div><ix:continuation id="f-1537-1"><ix:nonNumeric contextRef="c-1" name="nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock" id="f-1538" escape="true"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the six month period ended June 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks" scale="3" id="f-1539">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks" format="ixt:num-dot-decimal" scale="3" id="f-1540">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:NetForeignExchangeGain" scale="3" id="f-1541">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:NetForeignExchangeGain" format="ixt:num-dot-decimal" scale="3" id="f-1542">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="f-1543">645</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-1544">3,386</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest costs </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1545">4,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1546">3,772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net impact of accretion, discounting and catch-up on EIB loan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="nbx:DebtAccretionAndDiscountingImpact" format="ixt:num-dot-decimal" scale="3" id="f-1547">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="nbx:DebtAccretionAndDiscountingImpact" format="ixt:num-dot-decimal" scale="3" id="f-1548">2,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease debt interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-1549">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-1550">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:NetForeignExchangeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1551">3,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:NetForeignExchangeLoss" scale="3" id="f-1552">324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-1553">6,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-1554">1,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net financial income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-1555">6,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-1556">1,924</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from cash and cash equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">For the six month period ended June 30, 2025, the &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1557">0.6</ix:nonFraction>&#160;million income  from cash and cash equivalents was related to short-term deposits compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-5" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1558">1.5</ix:nonFraction>&#160;million for the six month period ended June&#160;30, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interests costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2025, total interest costs amount to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-1559">4.2</ix:nonFraction>&#160;million, mainly due to interest costs on the EIB loan (see Note 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) which consists of fixed and variable rate interests of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-584" decimals="-5" sign="-" name="ifrs-full:InterestRevenueExpense" format="ixt:num-dot-decimal" scale="6" id="f-1560">4.1</ix:nonFraction>&#160;million. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2024, total interest costs amount to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-5" name="ifrs-full:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-1561">3.8</ix:nonFraction>&#160;million, mainly due to interest costs on the EIB loan which consists of fixed and variable rate interests of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-585" decimals="-5" sign="-" name="ifrs-full:InterestRevenueExpense" format="ixt:num-dot-decimal" scale="6" id="f-1562">3.7</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net impact of accretion and discounting and catch-up on EIB loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2025, the P&amp;L net positive impact of accretion and discounting on EIB loan of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-5" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1563">1.0</ix:nonFraction>&#160;million corresponding to (i) the decrease in estimated debt outflows beyond 2024 - before discounting effect - resulting in a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-5" name="nbx:AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" format="ixt:num-dot-decimal" scale="6" id="f-1564">2.4</ix:nonFraction>&#160;million positive P&amp;L effect, (ii) partially offset by -&#8364;<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-5" name="nbx:IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" format="ixt:num-dot-decimal" scale="6" id="f-1565">1.4</ix:nonFraction>&#160;million of discounting negative effect (See Note 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Liabilitie</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">s).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2024, the P&amp;L net positive impact of accretion and discounting on EIB loan of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-5" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1566">2.7</ix:nonFraction>&#160;million corresponding to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-5" name="nbx:IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" format="ixt:num-dot-decimal" scale="6" id="f-1567">13.5</ix:nonFraction>&#160;million discounting positive effect, partially offset by the increase in estimated debt outflows beyond 2023 - before discounting effect - resulting in a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-5" name="nbx:AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" format="ixt:num-dot-decimal" scale="6" id="f-1568">10.8</ix:nonFraction>&#160;million negative P&amp;L effect, due to the revised forecasts of net sales and the revised forecasts of the upfront and milestone payments related to the consideration of the license agreement signed with Janssen signed on July 7, 2023. (See Note 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">Foreign exchange gains and losses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">For the six month period ended June 30, 2025, the company incurred net foreign exchange exchange loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-587" decimals="-5" name="ifrs-full:NetForeignExchangeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1569">3.6</ix:nonFraction>&#160;million, mainly related to the EUR conversion impact on short term USD deposits for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-588" decimals="-5" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1570">3.5</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">For the six month period ended June 30, 2024, the Company incurred net foreign exchange gains of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-589" decimals="-5" name="ifrs-full:NetForeignExchangeGain" format="ixt:num-dot-decimal" scale="6" id="f-1571">1.6</ix:nonFraction>&#160;million mainly related to the short term USD deposits for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-5" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="6" id="f-1572">1.1</ix:nonFraction> million, and to the appreciation of the USD on HSBC bank current account denominated in U.S. dollars for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-5" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="6" id="f-1573">0.5</ix:nonFraction> million.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_124"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="f-1574" continuedAt="f-1574-1" escape="true">Segment reporting</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-1574-1" continuedAt="f-1574-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In accordance with IFRS 8 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Operating Segments</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, reporting by operating segment is derived from the internal organization of the Company&#8217;s activities; it reflects management&#8217;s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company&#8217;s Chairman and the members of the Executive and Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform </span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><ix:continuation id="f-1574-2" continuedAt="f-1574-3"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">cancer treatment. The positive net revenue, as disclosed in the &#8216;Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue and other Income</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-1574-3">&#8217;, is primarily recognized by the Company towards one principal customer, Janssen, located in Belgium. The assets, liabilities and operating loss realized are primarily located in France.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_127"></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">21. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-1575" continuedAt="f-1575-1" escape="true">Loss per share </ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="f-1575-1"><ix:nonNumeric contextRef="c-1" name="ifrs-full:EarningsPerShareExplanatory" id="f-1576" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the six month period ended June 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss for the period (in thousands of euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-1577">5,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-1578">21,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average number of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-1579">47,418,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-1580">47,124,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basic loss per share (in euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-1581">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-1582">0.46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diluted loss per share (in euros)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-1583">0.11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-1584">0.46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instruments providing deferred access to the capital (stock options, founders' warrants and warrants) are considered to be anti-dilutive because they result in a decrease in the loss per share. Therefore, diluted loss per share is identical to basic loss per share as all equity instruments issued, representing a total of <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" format="ixt:num-dot-decimal" scale="0" id="f-1585">5,158,881</ix:nonFraction> potential additional ordinary shares, have been considered antidilutive.</span></div></ix:continuation><div><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_130"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">22. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCommitmentsExplanatory" id="f-1586" continuedAt="f-1586-1" escape="true">Commitments </ix:nonNumeric></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="f-1586-1"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The off-balance sheet commitments have not changed significantly since December, 31, 2024, except for the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commitments related to the master services agreement with Janssen dedicated to the clinical manufacturing of JNJ-1900 (NBTXR3)</span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 22, 2023, the Company entered into a master services agreement (&#8220;MSA&#8221;) with Janssen which includes the clinical manufacturing and the supply of products to be provided by the Company, as well as technical expertise and development services in the field of the territory, as defined in the global  licensing, co-development, and commercialization agreement signed in July 2023.</span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under this MSA, the Company already received as of June 30, 2025 purchase orders from Janssen (a) for the delivery of raw materials and JNJ-1900 (NBTXR3) clinical and technical batches planned to be delivered during the second half of 2025 amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-5" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1587">6.1</ix:nonFraction>&#160;million and (b) for the technology transfer and related technical assistance services amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-5" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1588">0.2</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_133"></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">23. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="f-1589" continuedAt="f-1589-1" escape="true">Related parties </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-1589-1" continuedAt="f-1589-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Key management personnel compensation</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-1590" continuedAt="f-1590-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the six-month period ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1591">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1592">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-1593">1,723</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-1594">1,517</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supervisory Board&#8217;s fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:DirectorsRemunerationExpense" scale="3" id="f-1595">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:DirectorsRemunerationExpense" scale="3" id="f-1596">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total compensation to related parties</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1597">3,094</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1598">2,722</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The methods used to measure share-based payments are presented in Note 18 -</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-based payments </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Related parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of June 30, 2025, Johnson &amp; Johnson Innovation &#8211; JJDC, an affiliate of Janssen, beneficially owns approximately <ix:nonFraction unitRef="number" contextRef="c-594" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-1599">11.66</ix:nonFraction>% of the outstanding ordinary shares of Nanobiotix. Nanobiotix and Janssen are parties to the Janssen Agreement, the &#8220;TSA&#8221; and the &#8220;AAA&#8221;, each as described in the consolidated financial statements prepared for the year ended December 31, 2024). Accordingly Janssen may be considered a related party of Nanobiotix.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1589-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">For the six month period ended June 30, 2025, the Company continued to support Janssen in execution of NANORAY-312 clinical study during the transition process and following the sponsorship transfer and conducted transactions with Janssen (see Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">Revenues and other income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">). <ix:continuation id="f-1590-1" continuedAt="f-1590-2">The payments between the two companies as well as the liabilities and receivables are as follows:</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-1590-2"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:54.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets/(Liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Collection (Janssen towards Nanobiotix SA) / Receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-1600">7,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1601">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments (Nanobiotix SA towards Janssen) / Payables</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" format="ixt:fixed-zero" scale="3" id="f-1602">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1603">7,905</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="nbx:NetCollectionsPaymentsFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-1604">7,387</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" sign="-" name="nbx:NetAmountsReceivablePayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1605">6,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ia72c30516b7642d5b908b439c54b9466_136"></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">24. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" id="f-1606" continuedAt="f-1606-1" escape="true">Subsequent events </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-1606-1"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-36</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>nbx-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e10ad955-f4fb-4992-aa6a-58056e28f5e0,g:51b53987-7aad-4161-819f-cbfd12ac6608-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbx="http://nanobiotix.com/20250630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://nanobiotix.com/20250630">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbx-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbx-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbx-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbx-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://nanobiotix.com/role/Coverpage">
        <link:definition>0000001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION">
        <link:definition>9952151 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS" roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS">
        <link:definition>9952152 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS" roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS">
        <link:definition>9952153 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>9952154 - Statement - INTERIM CONDENSED STATEMENT OF CONSOLIDATED CHANGES IN SHAREHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS" roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS">
        <link:definition>9952155 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1" roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1">
        <link:definition>9952155 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Companyinformation" roleURI="http://nanobiotix.com/role/Companyinformation">
        <link:definition>9952156 - Disclosure - Company information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Generalinformationstatementofcomplianceandbasisofpresentation" roleURI="http://nanobiotix.com/role/Generalinformationstatementofcomplianceandbasisofpresentation">
        <link:definition>9952157 - Disclosure - General information, statement of compliance and basis of presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedprinciplesandmethods" roleURI="http://nanobiotix.com/role/Consolidatedprinciplesandmethods">
        <link:definition>9952158 - Disclosure - Consolidated principles and methods</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significanttransactions" roleURI="http://nanobiotix.com/role/Significanttransactions">
        <link:definition>9952159 - Disclosure - Significant transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassets" roleURI="http://nanobiotix.com/role/Intangibleassets">
        <link:definition>9952160 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipment" roleURI="http://nanobiotix.com/role/Propertyplantandequipment">
        <link:definition>9952161 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Noncurrentfinancialassets" roleURI="http://nanobiotix.com/role/Noncurrentfinancialassets">
        <link:definition>9952162 - Disclosure - Non-current financial assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Tradereceivablesandothercurrentassets" roleURI="http://nanobiotix.com/role/Tradereceivablesandothercurrentassets">
        <link:definition>9952163 - Disclosure - Trade receivables and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cashandcashequivalents" roleURI="http://nanobiotix.com/role/Cashandcashequivalents">
        <link:definition>9952164 - Disclosure - Cash and cash equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://nanobiotix.com/role/ShareCapital">
        <link:definition>9952165 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementObligations" roleURI="http://nanobiotix.com/role/RetirementObligations">
        <link:definition>9952166 - Disclosure - Retirement Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Provisions" roleURI="http://nanobiotix.com/role/Provisions">
        <link:definition>9952167 - Disclosure - Provisions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialliabilities" roleURI="http://nanobiotix.com/role/Financialliabilities">
        <link:definition>9952168 - Disclosure - Financial liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Tradepayablesandothercurrentliabilities" roleURI="http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities">
        <link:definition>9952169 - Disclosure - Trade payables and other current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome" roleURI="http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome">
        <link:definition>9952170 - Disclosure - Financial instruments included in the statement of financial position and impact on income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenueandotherincome" roleURI="http://nanobiotix.com/role/Revenueandotherincome">
        <link:definition>9952171 - Disclosure - Revenue and other income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Operatingexpenses" roleURI="http://nanobiotix.com/role/Operatingexpenses">
        <link:definition>9952172 - Disclosure - Operating expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedpayments" roleURI="http://nanobiotix.com/role/Sharebasedpayments">
        <link:definition>9952173 - Disclosure - Share-based payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netfinancialincomeloss" roleURI="http://nanobiotix.com/role/Netfinancialincomeloss">
        <link:definition>9952174 - Disclosure - Net financial income (loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentreporting" roleURI="http://nanobiotix.com/role/Segmentreporting">
        <link:definition>9952175 - Disclosure - Segment reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Losspershare" roleURI="http://nanobiotix.com/role/Losspershare">
        <link:definition>9952176 - Disclosure - Loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://nanobiotix.com/role/Commitments">
        <link:definition>9952177 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedparties" roleURI="http://nanobiotix.com/role/Relatedparties">
        <link:definition>9952178 - Disclosure - Related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Subsequentevents" roleURI="http://nanobiotix.com/role/Subsequentevents">
        <link:definition>9952179 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedprinciplesandmethodsPolicies" roleURI="http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsPolicies">
        <link:definition>9955511 - Disclosure - Consolidated principles and methods (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsTables" roleURI="http://nanobiotix.com/role/IntangibleassetsTables">
        <link:definition>9955512 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentTables" roleURI="http://nanobiotix.com/role/PropertyplantandequipmentTables">
        <link:definition>9955513 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentfinancialassetsTables" roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsTables">
        <link:definition>9955514 - Disclosure - Non-current financial assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothercurrentassetsTables" roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables">
        <link:definition>9955515 - Disclosure - Trade receivables and other current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsTables" roleURI="http://nanobiotix.com/role/CashandcashequivalentsTables">
        <link:definition>9955516 - Disclosure - Cash and cash equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://nanobiotix.com/role/ShareCapitalTables">
        <link:definition>9955517 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementObligationsTables" roleURI="http://nanobiotix.com/role/RetirementObligationsTables">
        <link:definition>9955518 - Disclosure - Retirement Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsTables" roleURI="http://nanobiotix.com/role/ProvisionsTables">
        <link:definition>9955519 - Disclosure - Provisions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesTables" roleURI="http://nanobiotix.com/role/FinancialliabilitiesTables">
        <link:definition>9955520 - Disclosure - Financial liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesTables" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables">
        <link:definition>9955521 - Disclosure - Trade payables and other current liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables" roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables">
        <link:definition>9955522 - Disclosure - Financial instruments included in the statement of financial position and impact on income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandotherincomeTables" roleURI="http://nanobiotix.com/role/RevenueandotherincomeTables">
        <link:definition>9955523 - Disclosure - Revenue and other income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesTables" roleURI="http://nanobiotix.com/role/OperatingexpensesTables">
        <link:definition>9955524 - Disclosure - Operating expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsTables" roleURI="http://nanobiotix.com/role/SharebasedpaymentsTables">
        <link:definition>9955525 - Disclosure - Share-based payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetfinancialincomelossTables" roleURI="http://nanobiotix.com/role/NetfinancialincomelossTables">
        <link:definition>9955526 - Disclosure - Net financial income (loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LosspershareTables" roleURI="http://nanobiotix.com/role/LosspershareTables">
        <link:definition>9955527 - Disclosure - Loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesTables" roleURI="http://nanobiotix.com/role/RelatedpartiesTables">
        <link:definition>9955528 - Disclosure - Related parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyinformationDetails" roleURI="http://nanobiotix.com/role/CompanyinformationDetails">
        <link:definition>9955529 - Disclosure - Company information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralinformationstatementofcomplianceandbasisofpresentationDetails" roleURI="http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails">
        <link:definition>9955530 - Disclosure - General information, statement of compliance and basis of presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedprinciplesandmethodsDetails" roleURI="http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsDetails">
        <link:definition>9955531 - Disclosure - Consolidated principles and methods (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsScheduleofIntangibleAssetsDetails" roleURI="http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails">
        <link:definition>9955532 - Disclosure - Intangible assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsNarrativeDetails" roleURI="http://nanobiotix.com/role/IntangibleassetsNarrativeDetails">
        <link:definition>9955533 - Disclosure - Intangible assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" roleURI="http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>9955534 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentNarrativeDetails" roleURI="http://nanobiotix.com/role/PropertyplantandequipmentNarrativeDetails">
        <link:definition>9955535 - Disclosure - Property, plant and equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails" roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails">
        <link:definition>9955536 - Disclosure - Non-current financial assets - Schedule of Changes in Non-current Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothercurrentassetsScheduleofTradeReceivablesDetails" roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofTradeReceivablesDetails">
        <link:definition>9955537 - Disclosure - Trade receivables and other current assets - Schedule of Trade Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothercurrentassetsNarrativeDetails" roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails">
        <link:definition>9955538 - Disclosure - Trade receivables and other current assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails" roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails">
        <link:definition>9955539 - Disclosure - Trade receivables and other current assets - Schedule of Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails" roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails">
        <link:definition>9955540 - Disclosure - Trade receivables and other current assets - Schedule of Changes in Research Tax Credit Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsScheduleofCashandCashEquivalentsDetails" roleURI="http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails">
        <link:definition>9955541 - Disclosure - Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsNarrativeDetails" roleURI="http://nanobiotix.com/role/CashandcashequivalentsNarrativeDetails">
        <link:definition>9955542 - Disclosure - Cash and cash equivalents - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalTransactionsDetails" roleURI="http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails">
        <link:definition>9955543 - Disclosure - Share Capital - Schedule of Share Capital Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalCapitalIssuedDetails" roleURI="http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails">
        <link:definition>9955544 - Disclosure - Share Capital - Capital Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" roleURI="http://nanobiotix.com/role/ShareCapitalFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails">
        <link:definition>9955545 - Disclosure - Share Capital - Founder's Warrants, Warrants, Stock Options and Free Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalStockOptionPlansDetails" roleURI="http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails">
        <link:definition>9955546 - Disclosure - Share Capital - Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementObligationsDisclosureofChangesinProvisionsDetails" roleURI="http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails">
        <link:definition>9955547 - Disclosure - Retirement Obligations - Disclosure of Changes in Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsScheduleofChangesinProvisionsDetails" roleURI="http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails">
        <link:definition>9955548 - Disclosure - Provisions - Schedule of Changes in Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails">
        <link:definition>9955549 - Disclosure - Provisions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails" roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails">
        <link:definition>9955550 - Disclosure - Financial liabilities - Schedule of Changes in Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesNarrativeDetails" roleURI="http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails">
        <link:definition>9955551 - Disclosure - Financial liabilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails">
        <link:definition>9955552 - Disclosure - Financial liabilities - Schedule of Changes in Liabilities Arising from Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails">
        <link:definition>9955553 - Disclosure - Financial liabilities - Schedule of Maturity Analysis for Advances Loans and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails">
        <link:definition>9955554 - Disclosure - Trade payables and other current liabilities - Schedule of Trade and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesNarrativeDetails" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails">
        <link:definition>9955555 - Disclosure - Trade payables and other current liabilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails">
        <link:definition>9955556 - Disclosure - Trade payables and other current liabilities - Schedule of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails">
        <link:definition>9955557 - Disclosure - Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1">
        <link:definition>9955558 - Disclosure - Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails" roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails">
        <link:definition>9955559 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Schedule of Financial Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeNarrativeDetails" roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeNarrativeDetails">
        <link:definition>9955560 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandotherincomeNarrativeDetails" roleURI="http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails">
        <link:definition>9955561 - Disclosure - Revenue and other income - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails" roleURI="http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails">
        <link:definition>9955562 - Disclosure - Revenue and other income - Schedule of Revenues and Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails">
        <link:definition>9955563 - Disclosure - Operating expenses - Schedule of Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesNarrativeDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesNarrativeDetails">
        <link:definition>9955564 - Disclosure - Operating expenses - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails">
        <link:definition>9955565 - Disclosure - Operating expenses - Schedule of Selling, General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesScheduleofPayrollCostsDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails">
        <link:definition>9955566 - Disclosure - Operating expenses - Schedule of Payroll Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails">
        <link:definition>9955567 - Disclosure - Operating expenses - Schedule of Depreciation, Amortization and Provision Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails">
        <link:definition>9955568 - Disclosure - Operating expenses - Schedule of Other Operating Income (Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails">
        <link:definition>9955569 - Disclosure - Share-based payments - Schedule of Changes in Founder's Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsScheduleofWarrantsOutstandingDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails">
        <link:definition>9955570 - Disclosure - Share-based payments - Schedule of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsScheduleofChangesinShareOptionsDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails">
        <link:definition>9955571 - Disclosure - Share-based payments - Schedule of Changes in Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsScheduleofFreeSharesOutstandingDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails">
        <link:definition>9955572 - Disclosure - Share-based payments - Schedule of Free Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails">
        <link:definition>9955573 - Disclosure - Share-based payments - Schedule of Number and Weighted Average Remaining Contractual Life of Outstanding Other Equity Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsScheduleofShareBasedAssumptionsDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails">
        <link:definition>9955574 - Disclosure - Share-based payments - Schedule of Share Based Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsScheduleofExpensefromEquityDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails">
        <link:definition>9955575 - Disclosure - Share-based payments - Schedule of Expense from Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails" roleURI="http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails">
        <link:definition>9955576 - Disclosure - Net financial income (loss) - Schedule of Net Financial Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetfinancialincomelossNarrativeDetails" roleURI="http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails">
        <link:definition>9955577 - Disclosure - Net financial income (loss) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LosspershareScheduleofBasicandDilutedLossPerShareDetails" roleURI="http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails">
        <link:definition>9955578 - Disclosure - Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LosspershareNarrativeDetails" roleURI="http://nanobiotix.com/role/LosspershareNarrativeDetails">
        <link:definition>9955579 - Disclosure - Loss per share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsDetails" roleURI="http://nanobiotix.com/role/CommitmentsDetails">
        <link:definition>9955580 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails" roleURI="http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails">
        <link:definition>9955581 - Disclosure - Related parties - Schedule of Key Management Personnel Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesNarrativeDetails" roleURI="http://nanobiotix.com/role/RelatedpartiesNarrativeDetails">
        <link:definition>9955582 - Disclosure - Related parties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" roleURI="http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails">
        <link:definition>9955583 - Disclosure - Related parties - Schedule of Disclosure of Transactions Between Liabilities and Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nbx_NetLossForThePeriodMember" abstract="true" name="NetLossForThePeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations" abstract="false" name="OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" abstract="false" name="IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ImpactOfAmendmentOnProfitOrLoss" abstract="false" name="ImpactOfAmendmentOnProfitOrLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement" abstract="false" name="CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" abstract="false" name="AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" abstract="false" name="AdjustmentsForDecreaseIncreaseInOtherReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_LeaseDebtInterestPaidClassifiedAsFinancingActivities" abstract="false" name="LeaseDebtInterestPaidClassifiedAsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" abstract="true" name="DisclosureOfInformationRelatedToTheCompanyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock" abstract="false" name="DisclosureOfNotesAndOtherExplanatoryInformationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" abstract="true" name="GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_SignificantAccountingPoliciesAbstract" abstract="true" name="SignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_DisclosureOfSignificantTransactionsTextBlock" abstract="false" name="DisclosureOfSignificantTransactionsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" abstract="false" name="DisclosureOfNonCurrentFinancialAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" abstract="false" name="DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_RetirementObligationAbstract" abstract="true" name="RetirementObligationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock" abstract="false" name="DisclosureOfFinancialLiabilitiesFootnoteTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" abstract="false" name="DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_NetFinancialIncomeLossAbstract" abstract="true" name="NetFinancialIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" abstract="false" name="DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock" abstract="false" name="DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" abstract="false" name="DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock" abstract="false" name="DetailedInformationAboutRefundLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" abstract="false" name="DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" abstract="false" name="DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" abstract="false" name="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" abstract="false" name="DetailedInformationAboutFinanceIncomeCostTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfInformationRelatedToTheCompanyTable" abstract="true" name="DisclosureOfInformationRelatedToTheCompanyTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_CollaborationAgreementAxis" abstract="true" name="CollaborationAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_CollaborationAgreementDomain" abstract="true" name="CollaborationAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_JanssenPharmaceuticaNVMember" abstract="true" name="JanssenPharmaceuticaNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NanobiotixCorpMember" abstract="true" name="NanobiotixCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" abstract="true" name="DisclosureOfInformationRelatedToTheCompanyLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_CollaborationAgreementTotalConsideration" abstract="false" name="CollaborationAgreementTotalConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" abstract="false" name="CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication" abstract="false" name="CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AdditionalLiquidityBusinessObligations" abstract="false" name="AdditionalLiquidityBusinessObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_NumberOfSubsidiaries" abstract="false" name="NumberOfSubsidiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_NettingMember" abstract="true" name="NettingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_RightOfUseBuildingsMember" abstract="true" name="RightOfUseBuildingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_PrepaymentsOnTangibleAssetsMember" abstract="true" name="PrepaymentsOnTangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NonCurrentLiquidityContractMember" abstract="true" name="NonCurrentLiquidityContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_SecurityDepositsRollForward" abstract="true" name="SecurityDepositsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" abstract="true" name="DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_MDAndersonCancerCenterNBTXR3Member" abstract="true" name="MDAndersonCancerCenterNBTXR3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_TechnologyTransferAndTechnicalAssistanceMember" abstract="true" name="TechnologyTransferAndTechnicalAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_IntellectualPropertyServicesMember" abstract="true" name="IntellectualPropertyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_ThirdPartyServicesMember" abstract="true" name="ThirdPartyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_ClinicalProductsMember" abstract="true" name="ClinicalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_SuppliersMember" abstract="true" name="SuppliersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" abstract="true" name="DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_NanobiotixSAMember" abstract="true" name="NanobiotixSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OpenTaxYearAxis" abstract="true" name="OpenTaxYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_OpenTaxYearDomain" abstract="true" name="OpenTaxYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_A2025TaxYearMember" abstract="true" name="A2025TaxYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_A2024TaxYearMember" abstract="true" name="A2024TaxYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit" abstract="false" name="CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ProceedsFromIncomeTaxCredit" abstract="false" name="ProceedsFromIncomeTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AGA2023Member" abstract="true" name="AGA2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes" abstract="false" name="NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_ExecutiveBoardAndEmployeesMember" abstract="true" name="ExecutiveBoardAndEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_ShareBasedPaymentArrangementStockOptionTerm" abstract="false" name="ShareBasedPaymentArrangementStockOptionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_LumpSumRetirementBenefitsMember" abstract="true" name="LumpSumRetirementBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NonCurrentOtherProvisionsMember" abstract="true" name="NonCurrentOtherProvisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OtherProvisionsRollForward" abstract="true" name="OtherProvisionsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" abstract="false" name="ProvisionUsedAndUnusedProvisionReversedOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_CurrentOtherProvisionsMember" abstract="true" name="CurrentOtherProvisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_ProvisionsForDisputesMember" abstract="true" name="ProvisionsForDisputesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_ProvisionsForChargesMember" abstract="true" name="ProvisionsForChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" abstract="true" name="PGELoanAgreementBPIFranceAndHSBCFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_EuropeanInvestmentBankLoanAgreementMember" abstract="true" name="EuropeanInvestmentBankLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_ConditionalAdvancesMember" abstract="true" name="ConditionalAdvancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" abstract="true" name="DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_BanquePubliqueDInvestissementMember" abstract="true" name="BanquePubliqueDInvestissementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BPIFranceMember" abstract="true" name="BPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NonDilutiveFinancingAgreementHSBCFranceMember" abstract="true" name="NonDilutiveFinancingAgreementHSBCFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NonDilutiveFinancingAgreementBPIFranceMember" abstract="true" name="NonDilutiveFinancingAgreementBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_DebtDetailsAxis" abstract="true" name="DebtDetailsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_DebtDetailsDomain" abstract="true" name="DebtDetailsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_PrincipalAndFixedRateMember" abstract="true" name="PrincipalAndFixedRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_MilestonePaymentMember" abstract="true" name="MilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_AdvancesReceivedInterestRate" abstract="false" name="AdvancesReceivedInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nbx_ReimbursedAmountOfCorresponds" abstract="false" name="ReimbursedAmountOfCorresponds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AdvancesAuthorizedAmountToBeAdvanced" abstract="false" name="AdvancesAuthorizedAmountToBeAdvanced" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BorrowingMaturityTerm" abstract="false" name="BorrowingMaturityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_BorrowingPercentageOfStateGuaranteedLoan" abstract="false" name="BorrowingPercentageOfStateGuaranteedLoan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="nbx_BorrowingGuaranteeFee" abstract="false" name="BorrowingGuaranteeFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nbx_BorrowingNumberOfQuarterlyInstallments" abstract="false" name="BorrowingNumberOfQuarterlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInOutstandingLoans" abstract="false" name="IncreaseDecreaseInOutstandingLoans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" abstract="false" name="AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" abstract="false" name="IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BorrowingsCumulativeMilestonePrepaymentAmount" abstract="false" name="BorrowingsCumulativeMilestonePrepaymentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_EstimatedRoyaltyPayments" abstract="false" name="EstimatedRoyaltyPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ConsolidatedForecastedSalesPeriod" abstract="false" name="ConsolidatedForecastedSalesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_BPIFranceAdvanceMember" abstract="true" name="BPIFranceAdvanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_ConditionalAdvanceBPIFranceMember" abstract="true" name="ConditionalAdvanceBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_LiabilitiesRelatedToFinancingActivitiesMember" abstract="true" name="LiabilitiesRelatedToFinancingActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_LiabilitiesArisingFromFinancingActivitiesRollForward" abstract="true" name="LiabilitiesArisingFromFinancingActivitiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_CashFlowsFromUsedInNonFinancingActivities" abstract="false" name="CashFlowsFromUsedInNonFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_LiabilitiesArisingFromFinancingActivitiesCurrent" abstract="false" name="LiabilitiesArisingFromFinancingActivitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent" abstract="false" name="LiabilitiesArisingFromFinancingActivitiesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" abstract="true" name="InterestFreeAdvanceToCuradigmBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" abstract="true" name="NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BorrowingScheduledForReimbursementNumber" abstract="false" name="BorrowingScheduledForReimbursementNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_BorrowingDefermentPeriod" abstract="false" name="BorrowingDefermentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" abstract="true" name="DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_ClinicalStudiesAxis" abstract="true" name="ClinicalStudiesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_ClinicalStudiesDomain" abstract="true" name="ClinicalStudiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_A312StudyMember" abstract="true" name="A312StudyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_A1100StudyMember" abstract="true" name="A1100StudyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NANORAY312Member" abstract="true" name="NANORAY312Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_LianBioNBTXR3Member" abstract="true" name="LianBioNBTXR3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" abstract="true" name="DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses" abstract="false" name="AdjustmentsForIncreaseDecreaseInAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInOtherCurrentPayables" abstract="false" name="IncreaseDecreaseInOtherCurrentPayables" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" abstract="false" name="IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInBonusAccrual" abstract="false" name="IncreaseDecreaseInBonusAccrual" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseRefundLiabilities" abstract="false" name="IncreaseDecreaseRefundLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OtherMiscellaneousCurrentLiabilities" abstract="false" name="OtherMiscellaneousCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_NonCurrentFinancialAssetsMember" abstract="true" name="NonCurrentFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_CashAndCashEquivalents1Member" abstract="true" name="CashAndCashEquivalents1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NonCurrentFinancialLiabilitiesMember" abstract="true" name="NonCurrentFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_CurrentFinancialLiabilitiesMember" abstract="true" name="CurrentFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_TradeAndOtherPayablesMember" abstract="true" name="TradeAndOtherPayablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" abstract="false" name="TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" abstract="false" name="TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_JanssenPharmaceuticaBVMember" abstract="true" name="JanssenPharmaceuticaBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OtherSalesMember" abstract="true" name="OtherSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_ServicesMember" abstract="true" name="ServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_TechnologyTransferMember" abstract="true" name="TechnologyTransferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_ServiceRechargeMember" abstract="true" name="ServiceRechargeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_SupplyServicesMember" abstract="true" name="SupplyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_RechargeMember" abstract="true" name="RechargeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_AdjustmentsToRevenueFromContractsWithCustomers" abstract="false" name="AdjustmentsToRevenueFromContractsWithCustomers" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentTaxCredit" abstract="false" name="ResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" abstract="false" name="ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentExpensePayrollCosts" abstract="false" name="ResearchAndDevelopmentExpensePayrollCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" abstract="false" name="ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DisclosureOfOperatingExpensesTable" abstract="true" name="DisclosureOfOperatingExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentArrangement1Member" abstract="true" name="ResearchAndDevelopmentArrangement1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NonRecurringExpenseTypeAxis" abstract="true" name="NonRecurringExpenseTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_NonRecurringExpenseTypeDomain" abstract="true" name="NonRecurringExpenseTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_EmploymentTerminationIndemnitiesMember" abstract="true" name="EmploymentTerminationIndemnitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OperatingExpenseAxis" abstract="true" name="OperatingExpenseAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_OperatingExpenseDomain" abstract="true" name="OperatingExpenseDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_DisclosureOfOperatingExpensesLineItems" abstract="true" name="DisclosureOfOperatingExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" abstract="false" name="IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreasePayrollExpense" abstract="false" name="IncreaseDecreasePayrollExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreasePayrollExpensePercentage" abstract="false" name="IncreaseDecreasePayrollExpensePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nbx_StockOptionsGranted" abstract="false" name="StockOptionsGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" abstract="false" name="IncreaseDecreaseInPurchasesFeesAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_SeveranceExpenses" abstract="false" name="SeveranceExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInDepreciationExpense" abstract="false" name="IncreaseDecreaseInDepreciationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_PaymentOfAdvisoryFees" abstract="false" name="PaymentOfAdvisoryFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInSocialTax" abstract="false" name="IncreaseDecreaseInSocialTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage" abstract="false" name="IncreaseDecreaseInEmployeeBenefitExpensePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInEmployeeBenefitExpense" abstract="false" name="IncreaseDecreaseInEmployeeBenefitExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OtherNonrecurringExpenses" abstract="false" name="OtherNonrecurringExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" abstract="false" name="SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" abstract="false" name="SellingGeneralAndAdministrativeExpensePayrollCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" abstract="false" name="SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_LitigationExpense" abstract="false" name="LitigationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19" abstract="false" name="DepreciationAmortizationAndProvisionExpensesExcludingIAS19" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ProvisionForRetirementBenefitObligationsNet" abstract="false" name="ProvisionForRetirementBenefitObligationsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DepreciationAmortizationAndProvisionExpenses" abstract="false" name="DepreciationAmortizationAndProvisionExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OtherNonrecurringsIncome" abstract="false" name="OtherNonrecurringsIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" abstract="true" name="DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_BSPCE20151Member" abstract="true" name="BSPCE20151Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSPCE20153Member" abstract="true" name="BSPCE20153Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSPCE2016OrdinaryMember" abstract="true" name="BSPCE2016OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSPCE2016PerformanceMember" abstract="true" name="BSPCE2016PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSPCE2017OrdinaryMember" abstract="true" name="BSPCE2017OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSPCE2017Member" abstract="true" name="BSPCE2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_CorporateOfficersMember" abstract="true" name="CorporateOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_LaurentLevyMember" abstract="true" name="LaurentLevyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BeneficiariesOtherThanCorporateOfficersMember" abstract="true" name="BeneficiariesOtherThanCorporateOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" abstract="false" name="NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" abstract="false" name="NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" abstract="false" name="NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" abstract="false" name="MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nbx_BSA20151Member" abstract="true" name="BSA20151Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSA20152Member" abstract="true" name="BSA20152Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSA20182Member" abstract="true" name="BSA20182Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSA20191Member" abstract="true" name="BSA20191Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSA2020Member" abstract="true" name="BSA2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSA2021Member" abstract="true" name="BSA2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OfficersNameAxis" abstract="true" name="OfficersNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_OfficersNameDomain" abstract="true" name="OfficersNameDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_AnneMarieGraffinMember" abstract="true" name="AnneMarieGraffinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_EnnoSpillnerMember" abstract="true" name="EnnoSpillnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_AlainHerreraMember" abstract="true" name="AlainHerreraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA20161PerformanceMember" abstract="true" name="OSA20161PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA20162Member" abstract="true" name="OSA20162Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA2017OrdinaryMember" abstract="true" name="OSA2017OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA2018Member" abstract="true" name="OSA2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA20191Member" abstract="true" name="OSA20191Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSALLY2019Member" abstract="true" name="OSALLY2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA2020Member" abstract="true" name="OSA2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA202104OrdinaryMember" abstract="true" name="OSA202104OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA202104PerformanceMember" abstract="true" name="OSA202104PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA202106PerformanceMember" abstract="true" name="OSA202106PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA202106OrdinaryMember" abstract="true" name="OSA202106OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA202206PerformanceMember" abstract="true" name="OSA202206PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA202206OrdinaryMember" abstract="true" name="OSA202206OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA202301OrdinaryMember" abstract="true" name="OSA202301OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA202401OrdinaryMember" abstract="true" name="OSA202401OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA202501OrdinaryMember" abstract="true" name="OSA202501OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA202502OrdinaryMember" abstract="true" name="OSA202502OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_AnneJulietteHermantMember" abstract="true" name="AnneJulietteHermantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BartVanRhijnMember" abstract="true" name="BartVanRhijnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_LouisKayitalireMember" abstract="true" name="LouisKayitalireMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" abstract="false" name="NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" abstract="false" name="NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" abstract="false" name="MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nbx_AGA2023P1Member" abstract="true" name="AGA2023P1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_AGA2023P2Member" abstract="true" name="AGA2023P2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" abstract="true" name="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_BSPCEMember" abstract="true" name="BSPCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_BSAMember" abstract="true" name="BSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSAMember" abstract="true" name="OSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" abstract="true" name="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_BSA2021AMember" abstract="true" name="BSA2021AMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_OSA20192Member" abstract="true" name="OSA20192Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_AGAMember" abstract="true" name="AGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_AGA2023Performance1Member" abstract="true" name="AGA2023Performance1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_AGA2023Performance2Member" abstract="true" name="AGA2023Performance2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_TranchesAxis" abstract="true" name="TranchesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_TranchesDomain" abstract="true" name="TranchesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_TrancheOneMember" abstract="true" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_TrancheTwoMember" abstract="true" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_TrancheThreeMember" abstract="true" name="TrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_TrancheFourMember" abstract="true" name="TrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_VestingPeriodAxis" abstract="true" name="VestingPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_VestingPeriodDomain" abstract="true" name="VestingPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" abstract="false" name="WeightedAverageSharePriceOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="nbx_ExercisePriceOtherEquityInstrumentsGranted" abstract="false" name="ExercisePriceOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" abstract="false" name="RiskFreeInterestRateOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" abstract="false" name="ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DebtAccretionAndDiscountingImpact" abstract="false" name="DebtAccretionAndDiscountingImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_HSBCBankMember" abstract="true" name="HSBCBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NBTXR3Member" abstract="true" name="NBTXR3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_JohnsonJohnsonInnovationsMember" abstract="true" name="JohnsonJohnsonInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbx_NetCollectionsPaymentsFromRelatedParty" abstract="false" name="NetCollectionsPaymentsFromRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_NetAmountsReceivablePayableRelatedPartyTransactions" abstract="false" name="NetAmountsReceivablePayableRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>nbx-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e10ad955-f4fb-4992-aa6a-58056e28f5e0,g:51b53987-7aad-4161-819f-cbfd12ac6608-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_bc1a0849-5ba7-4ee5-8ad8-cdb596b1f292" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_bdcf87cc-5e53-445c-b0b1-990685cd1b7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_bc1a0849-5ba7-4ee5-8ad8-cdb596b1f292" xlink:to="loc_ifrs-full_CurrentTradeReceivables_bdcf87cc-5e53-445c-b0b1-990685cd1b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_ed6446c3-a212-4d18-b92d-97c70991b969" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_bc1a0849-5ba7-4ee5-8ad8-cdb596b1f292" xlink:to="loc_ifrs-full_OtherCurrentAssets_ed6446c3-a212-4d18-b92d-97c70991b969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_7b101f61-20a3-4ca1-aef2-21386fbe8afd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_bc1a0849-5ba7-4ee5-8ad8-cdb596b1f292" xlink:to="loc_ifrs-full_CashAndCashEquivalents_7b101f61-20a3-4ca1-aef2-21386fbe8afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_7554e5ee-1c65-4f2b-a9d4-dd47525116d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_0102b466-ac1f-408d-b89c-bc71ad84931b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_7554e5ee-1c65-4f2b-a9d4-dd47525116d1" xlink:to="loc_ifrs-full_IssuedCapital_0102b466-ac1f-408d-b89c-bc71ad84931b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_60e45b19-ec04-4ea5-8471-bf1358de80b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_7554e5ee-1c65-4f2b-a9d4-dd47525116d1" xlink:to="loc_ifrs-full_SharePremium_60e45b19-ec04-4ea5-8471-bf1358de80b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_99ab1ccf-15e2-46c6-9891-0b1c5676b5b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_7554e5ee-1c65-4f2b-a9d4-dd47525116d1" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_99ab1ccf-15e2-46c6-9891-0b1c5676b5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_e5201edd-5afa-46cb-bf84-d9ae74308425" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasuryShares"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_7554e5ee-1c65-4f2b-a9d4-dd47525116d1" xlink:to="loc_ifrs-full_TreasuryShares_e5201edd-5afa-46cb-bf84-d9ae74308425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_ccbca319-c4f8-4968-b33a-93a3caa24e6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_7554e5ee-1c65-4f2b-a9d4-dd47525116d1" xlink:to="loc_ifrs-full_OtherReserves_ccbca319-c4f8-4968-b33a-93a3caa24e6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_9441580f-f589-4ed2-bb76-07428ab414b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_7554e5ee-1c65-4f2b-a9d4-dd47525116d1" xlink:to="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_9441580f-f589-4ed2-bb76-07428ab414b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_d86f8345-cc6b-42b4-b020-8b3d221c7603" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_fb5d893c-ae6b-439e-8cc1-04e8b29278bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_d86f8345-cc6b-42b4-b020-8b3d221c7603" xlink:to="loc_ifrs-full_NoncurrentAssets_fb5d893c-ae6b-439e-8cc1-04e8b29278bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_5398307e-12ea-458e-8d41-1ac0bd38b1fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_d86f8345-cc6b-42b4-b020-8b3d221c7603" xlink:to="loc_ifrs-full_CurrentAssets_5398307e-12ea-458e-8d41-1ac0bd38b1fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_1bc412da-fabe-40c9-81b4-0b50f71c8847" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_8a274efa-80de-4a68-b8d0-4caff4b7d1f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1bc412da-fabe-40c9-81b4-0b50f71c8847" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_8a274efa-80de-4a68-b8d0-4caff4b7d1f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_5f91c61b-49a5-4a09-a8b6-a229f923a90c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1bc412da-fabe-40c9-81b4-0b50f71c8847" xlink:to="loc_ifrs-full_NoncurrentProvisions_5f91c61b-49a5-4a09-a8b6-a229f923a90c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_afc25119-41c7-44a9-813a-0184f1f7253f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1bc412da-fabe-40c9-81b4-0b50f71c8847" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_afc25119-41c7-44a9-813a-0184f1f7253f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_9495a7a5-b7ce-4f6b-881b-131b744724f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_81adb641-58c3-43fa-ab17-a45d0a0e2f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_9495a7a5-b7ce-4f6b-881b-131b744724f1" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_81adb641-58c3-43fa-ab17-a45d0a0e2f1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_342d2a4e-c484-4529-a9d3-c396c12c8518" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_9495a7a5-b7ce-4f6b-881b-131b744724f1" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_342d2a4e-c484-4529-a9d3-c396c12c8518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_5d168607-53e4-480b-9705-9dcc9b22d12c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_9495a7a5-b7ce-4f6b-881b-131b744724f1" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_5d168607-53e4-480b-9705-9dcc9b22d12c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_d7344256-0cec-4fc1-9e65-1ef8528d8450" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_4f498401-5f49-4c4f-aaa0-697850219543" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_d7344256-0cec-4fc1-9e65-1ef8528d8450" xlink:to="loc_ifrs-full_CurrentProvisions_4f498401-5f49-4c4f-aaa0-697850219543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_87d353b4-b113-4998-ab0b-7437852b1d4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_d7344256-0cec-4fc1-9e65-1ef8528d8450" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_87d353b4-b113-4998-ab0b-7437852b1d4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_94387964-92a3-4725-a47d-92eae5e46847" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_d7344256-0cec-4fc1-9e65-1ef8528d8450" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_94387964-92a3-4725-a47d-92eae5e46847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_9c8d4a9e-339a-46b8-af73-e3b34669023c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_d7344256-0cec-4fc1-9e65-1ef8528d8450" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_9c8d4a9e-339a-46b8-af73-e3b34669023c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_1e625b07-2e72-47e2-8389-c3826b6b5849" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_d7344256-0cec-4fc1-9e65-1ef8528d8450" xlink:to="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_1e625b07-2e72-47e2-8389-c3826b6b5849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_bb7fc41a-ebaa-4195-a225-180c84242828" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_d7344256-0cec-4fc1-9e65-1ef8528d8450" xlink:to="loc_ifrs-full_CurrentContractLiabilities_bb7fc41a-ebaa-4195-a225-180c84242828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRefundsProvision_eb34820a-0446-447f-9195-bb42ed088635" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRefundsProvision"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_d7344256-0cec-4fc1-9e65-1ef8528d8450" xlink:to="loc_ifrs-full_CurrentRefundsProvision_eb34820a-0446-447f-9195-bb42ed088635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_bf447888-5407-48fd-b9a3-1d8c695704eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_e7c451d2-5c1f-432a-a5fe-8e1e31d7c84a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_bf447888-5407-48fd-b9a3-1d8c695704eb" xlink:to="loc_ifrs-full_Equity_e7c451d2-5c1f-432a-a5fe-8e1e31d7c84a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_e34c9654-cf4d-4cb6-8d16-1202abd13adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_bf447888-5407-48fd-b9a3-1d8c695704eb" xlink:to="loc_ifrs-full_Liabilities_e34c9654-cf4d-4cb6-8d16-1202abd13adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_f62a3c7e-0ac0-4a4b-a2ad-35e2e2f328e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_4ff88522-30c9-4984-92d3-395ea027b3d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_f62a3c7e-0ac0-4a4b-a2ad-35e2e2f328e2" xlink:to="loc_ifrs-full_NoncurrentLiabilities_4ff88522-30c9-4984-92d3-395ea027b3d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_5260f528-aefd-4514-9e89-dd316583805e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_f62a3c7e-0ac0-4a4b-a2ad-35e2e2f328e2" xlink:to="loc_ifrs-full_CurrentLiabilities_5260f528-aefd-4514-9e89-dd316583805e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_09b3e2b7-f506-4317-8530-41e67db615b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_f89314b9-d60a-4ff3-99c2-8acf97c6f86e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_09b3e2b7-f506-4317-8530-41e67db615b7" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_f89314b9-d60a-4ff3-99c2-8acf97c6f86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_efcbaa11-4a41-47fe-a90b-a3748415823a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_09b3e2b7-f506-4317-8530-41e67db615b7" xlink:to="loc_ifrs-full_OtherIncome_efcbaa11-4a41-47fe-a90b-a3748415823a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_d9690c82-cad7-4035-b833-a80e2721e2da" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_38d868a4-f205-4f0c-84d5-5b1ea435d632" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_d9690c82-cad7-4035-b833-a80e2721e2da" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_38d868a4-f205-4f0c-84d5-5b1ea435d632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_5cecd315-eb27-4a3d-b107-64592990d325" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_d9690c82-cad7-4035-b833-a80e2721e2da" xlink:to="loc_ifrs-full_FinanceIncomeCost_5cecd315-eb27-4a3d-b107-64592990d325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1bede72e-cfa2-47fa-86fa-c250f6cb1e2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_d9690c82-cad7-4035-b833-a80e2721e2da" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1bede72e-cfa2-47fa-86fa-c250f6cb1e2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_469957f0-39f4-402b-ae83-a5af2abf0363" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_15aad64e-5e04-4b6e-a6e1-03ffac761a93" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_469957f0-39f4-402b-ae83-a5af2abf0363" xlink:to="loc_ifrs-full_FinanceCosts_15aad64e-5e04-4b6e-a6e1-03ffac761a93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_dea40fa8-5468-4f0e-9414-454d6b6d0041" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_469957f0-39f4-402b-ae83-a5af2abf0363" xlink:to="loc_ifrs-full_FinanceIncome_dea40fa8-5468-4f0e-9414-454d6b6d0041" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_261bbf5d-89cc-4fea-be04-d6fa0925d4d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_fe688af2-acda-43e7-a28e-785aa3500a8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_261bbf5d-89cc-4fea-be04-d6fa0925d4d0" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_fe688af2-acda-43e7-a28e-785aa3500a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_2a1b9adf-3e31-40c9-9ea1-d338bc2aa479" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_261bbf5d-89cc-4fea-be04-d6fa0925d4d0" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_2a1b9adf-3e31-40c9-9ea1-d338bc2aa479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_ff4fcb86-cc7a-44d5-87d4-985296790e77" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_261bbf5d-89cc-4fea-be04-d6fa0925d4d0" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_ff4fcb86-cc7a-44d5-87d4-985296790e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_9b60f0b3-5d68-491f-921e-cedac5a5d77f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_89630d66-5e49-40fd-828e-369e146841ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_9b60f0b3-5d68-491f-921e-cedac5a5d77f" xlink:to="loc_ifrs-full_Revenue_89630d66-5e49-40fd-828e-369e146841ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_47f0d1f8-a394-4985-b699-7a1884ef74c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_9b60f0b3-5d68-491f-921e-cedac5a5d77f" xlink:to="loc_ifrs-full_OperatingExpense_47f0d1f8-a394-4985-b699-7a1884ef74c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_24c416b0-69ba-4414-ba15-477052cf72df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_e65b1826-245e-4b17-a538-5e9e811e6923" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_24c416b0-69ba-4414-ba15-477052cf72df" xlink:to="loc_ifrs-full_ProfitLoss_e65b1826-245e-4b17-a538-5e9e811e6923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_ffa63122-29ad-4586-9742-a2c63ee1d3c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_24c416b0-69ba-4414-ba15-477052cf72df" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_ffa63122-29ad-4586-9742-a2c63ee1d3c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_5eb0f054-9af8-473f-a589-1938142cee7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_24c416b0-69ba-4414-ba15-477052cf72df" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_5eb0f054-9af8-473f-a589-1938142cee7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_aab41aee-d7ef-40e2-9c80-5320dd648857" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_78962452-1582-42e1-8aec-c5e9e3da6704" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_aab41aee-d7ef-40e2-9c80-5320dd648857" xlink:to="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_78962452-1582-42e1-8aec-c5e9e3da6704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_b071608f-2e8d-4944-98ba-1dd7ec36556f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_aab41aee-d7ef-40e2-9c80-5320dd648857" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_b071608f-2e8d-4944-98ba-1dd7ec36556f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_a161bb2d-fd89-4387-a584-318650cb26e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_38227e68-bce3-4951-98fd-9c57d4c1b880" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_a161bb2d-fd89-4387-a584-318650cb26e8" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_38227e68-bce3-4951-98fd-9c57d4c1b880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_e65db07d-963e-49ae-be93-61bca39fbacb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_a161bb2d-fd89-4387-a584-318650cb26e8" xlink:to="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_e65db07d-963e-49ae-be93-61bca39fbacb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_1df42151-fd43-467b-8539-d8645fe92e94" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_b06ae67e-0a79-4bac-b77f-eec7cb26df10" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_1df42151-fd43-467b-8539-d8645fe92e94" xlink:to="loc_ifrs-full_ProfitLoss_b06ae67e-0a79-4bac-b77f-eec7cb26df10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_6cdc74f5-0aac-42a4-9c58-7c315b3d42bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_1df42151-fd43-467b-8539-d8645fe92e94" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_6cdc74f5-0aac-42a4-9c58-7c315b3d42bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e03879bb-7822-484e-8ed0-dd92e12770f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_8ba11110-789c-4eef-9368-523550008076" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e03879bb-7822-484e-8ed0-dd92e12770f0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_8ba11110-789c-4eef-9368-523550008076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_0086adf9-ceac-4ec1-893b-fdfc09d5c193" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e03879bb-7822-484e-8ed0-dd92e12770f0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_0086adf9-ceac-4ec1-893b-fdfc09d5c193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_64553454-1f28-4a87-88d7-274a1f3b5ed5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e03879bb-7822-484e-8ed0-dd92e12770f0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_64553454-1f28-4a87-88d7-274a1f3b5ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_37717fee-1473-414e-a6cd-5c223a79d96c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e03879bb-7822-484e-8ed0-dd92e12770f0" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_37717fee-1473-414e-a6cd-5c223a79d96c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_4860983e-528b-4460-8b58-c3cb21ff9259" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_5a25ff20-e7eb-469a-81ef-1052dd058905" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_4860983e-528b-4460-8b58-c3cb21ff9259" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_5a25ff20-e7eb-469a-81ef-1052dd058905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_dea9cc3c-4070-4d96-b411-9ed054544134" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_4860983e-528b-4460-8b58-c3cb21ff9259" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_dea9cc3c-4070-4d96-b411-9ed054544134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_e07f0390-1e06-4726-a5cc-551c5b58ba03" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_4860983e-528b-4460-8b58-c3cb21ff9259" xlink:to="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_e07f0390-1e06-4726-a5cc-551c5b58ba03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_84adb7d4-3674-40c5-81f3-2b39f5922a7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement_9f6d5e8e-74e6-487f-9412-d0a840a7cc25" xlink:href="nbx-20250630.xsd#nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_84adb7d4-3674-40c5-81f3-2b39f5922a7e" xlink:to="loc_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement_9f6d5e8e-74e6-487f-9412-d0a840a7cc25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_26de2c10-5ca1-497f-bf55-9c04711888c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_84adb7d4-3674-40c5-81f3-2b39f5922a7e" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_26de2c10-5ca1-497f-bf55-9c04711888c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_933b8848-04cc-4ec2-9e4b-0323a33fe7a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_6ff29864-3943-45bb-928a-9dca0947143a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_933b8848-04cc-4ec2-9e4b-0323a33fe7a5" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_6ff29864-3943-45bb-928a-9dca0947143a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_c7ba00f3-f850-4094-b934-5f3dbd200323" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_933b8848-04cc-4ec2-9e4b-0323a33fe7a5" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_c7ba00f3-f850-4094-b934-5f3dbd200323" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_b3c71f11-e99b-48f7-8ad9-5a569101b0c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_933b8848-04cc-4ec2-9e4b-0323a33fe7a5" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_b3c71f11-e99b-48f7-8ad9-5a569101b0c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_a60e501a-7966-4ce5-bade-1e5f753c8c65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_933b8848-04cc-4ec2-9e4b-0323a33fe7a5" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_a60e501a-7966-4ce5-bade-1e5f753c8c65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseDebtInterestPaidClassifiedAsFinancingActivities_cf42758a-f9cc-405f-919c-b0a070d7114a" xlink:href="nbx-20250630.xsd#nbx_LeaseDebtInterestPaidClassifiedAsFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_933b8848-04cc-4ec2-9e4b-0323a33fe7a5" xlink:to="loc_nbx_LeaseDebtInterestPaidClassifiedAsFinancingActivities_cf42758a-f9cc-405f-919c-b0a070d7114a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_8abac6b8-0593-4ac0-b2b8-547d9fa46345" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_303fa428-2ef1-4831-8241-73726a1a8585" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_8abac6b8-0593-4ac0-b2b8-547d9fa46345" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_303fa428-2ef1-4831-8241-73726a1a8585" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_6dce66a5-47b5-4ce0-8df4-44def5b6288b" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_8abac6b8-0593-4ac0-b2b8-547d9fa46345" xlink:to="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_6dce66a5-47b5-4ce0-8df4-44def5b6288b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_3ef0a1f9-88b3-4033-b3ac-e616ab162642" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_8abac6b8-0593-4ac0-b2b8-547d9fa46345" xlink:to="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_3ef0a1f9-88b3-4033-b3ac-e616ab162642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_6493b486-add4-4f02-b5a5-f5e5c0bf0264" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_8abac6b8-0593-4ac0-b2b8-547d9fa46345" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_6493b486-add4-4f02-b5a5-f5e5c0bf0264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_c14fdb99-00d1-4f4a-be06-9825c65603ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_8abac6b8-0593-4ac0-b2b8-547d9fa46345" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_c14fdb99-00d1-4f4a-be06-9825c65603ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_60241be2-1b91-4cc2-8ed3-06a77a147a1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_8abac6b8-0593-4ac0-b2b8-547d9fa46345" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_60241be2-1b91-4cc2-8ed3-06a77a147a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_02d42f46-a1d5-4f91-b260-c730b76ba0c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7a9f0a33-d8a1-421c-877f-29bd9967cbc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_02d42f46-a1d5-4f91-b260-c730b76ba0c8" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7a9f0a33-d8a1-421c-877f-29bd9967cbc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_e6ff224d-1295-494f-85ff-ec2d6fe868b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_02d42f46-a1d5-4f91-b260-c730b76ba0c8" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_e6ff224d-1295-494f-85ff-ec2d6fe868b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_885f3a2b-8148-4a32-9c35-a263e0253604" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_02d42f46-a1d5-4f91-b260-c730b76ba0c8" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_885f3a2b-8148-4a32-9c35-a263e0253604" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_576cf9bf-8fbb-439a-a904-d33f7e51541d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:to="loc_ifrs-full_ProfitLoss_576cf9bf-8fbb-439a-a904-d33f7e51541d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_f487129e-e85c-4e63-b42d-978cb1a2c6d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_f487129e-e85c-4e63-b42d-978cb1a2c6d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_a090ba89-09a9-43d9-ab6a-f07a69d33751" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_a090ba89-09a9-43d9-ab6a-f07a69d33751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_441c97a3-795a-4006-a04a-b6f63b0bcfdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_441c97a3-795a-4006-a04a-b6f63b0bcfdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_0127049d-c98d-49c2-8516-1ab621ee0d35" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_0127049d-c98d-49c2-8516-1ab621ee0d35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_322018cc-7d53-4074-886d-5414f89ced4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_322018cc-7d53-4074-886d-5414f89ced4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_6ee660e4-731b-4d7b-8751-6eae037c999f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:to="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_6ee660e4-731b-4d7b-8751-6eae037c999f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_60b28100-3077-4629-a9f8-60e6390ac6d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_60b28100-3077-4629-a9f8-60e6390ac6d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ImpactOfAmendmentOnProfitOrLoss_2614693d-0752-4a57-b2a5-20e8dda1dad9" xlink:href="nbx-20250630.xsd#nbx_ImpactOfAmendmentOnProfitOrLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:to="loc_nbx_ImpactOfAmendmentOnProfitOrLoss_2614693d-0752-4a57-b2a5-20e8dda1dad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_06edf26d-ed74-439a-979e-17c693e1f8bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9ee603b0-54d7-487b-87d8-3d827a7f7a2f" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_06edf26d-ed74-439a-979e-17c693e1f8bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_3551aa32-2cc6-41ea-b2be-858061f6e4c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_d77fee64-4c12-4ac8-8190-c03355764e9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_3551aa32-2cc6-41ea-b2be-858061f6e4c6" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_d77fee64-4c12-4ac8-8190-c03355764e9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_b1670745-f5a6-4caf-841e-13bfc74bf8da" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_3551aa32-2cc6-41ea-b2be-858061f6e4c6" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_b1670745-f5a6-4caf-841e-13bfc74bf8da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_bd07b0d1-9ad4-444a-b86b-c3c29c1b931c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_3551aa32-2cc6-41ea-b2be-858061f6e4c6" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_bd07b0d1-9ad4-444a-b86b-c3c29c1b931c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_07c208a2-ea81-4144-9c38-425d9996900b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_3551aa32-2cc6-41ea-b2be-858061f6e4c6" xlink:to="loc_ifrs-full_OtherCurrentReceivables_07c208a2-ea81-4144-9c38-425d9996900b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#CashandcashequivalentsScheduleofCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_3ddb70e3-d3ce-43c7-a24d-89be1bcdac3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_23f8b8c3-bc81-4d95-9cdc-89085935e92e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_3ddb70e3-d3ce-43c7-a24d-89be1bcdac3c" xlink:to="loc_ifrs-full_Cash_23f8b8c3-bc81-4d95-9cdc-89085935e92e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_b788a1b5-691c-4be1-ab02-60347ac241fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_3ddb70e3-d3ce-43c7-a24d-89be1bcdac3c" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_b788a1b5-691c-4be1-ab02-60347ac241fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_564e3373-e21a-446b-883c-32854a895907" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_e0ba43bd-4493-43b9-b47d-018d08c4b174" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_564e3373-e21a-446b-883c-32854a895907" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_e0ba43bd-4493-43b9-b47d-018d08c4b174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_e310ace6-b8f1-4866-bad5-1ae787060876" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_564e3373-e21a-446b-883c-32854a895907" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_e310ace6-b8f1-4866-bad5-1ae787060876" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_389a6bd4-33de-40c2-a01a-1f4da59beac3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent_0e9f5a0d-8f7c-48ed-9eb3-3d5fbf84d971" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_389a6bd4-33de-40c2-a01a-1f4da59beac3" xlink:to="loc_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent_0e9f5a0d-8f7c-48ed-9eb3-3d5fbf84d971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent_4b263de1-3ca8-4e25-8c15-43b2159812e5" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_389a6bd4-33de-40c2-a01a-1f4da59beac3" xlink:to="loc_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent_4b263de1-3ca8-4e25-8c15-43b2159812e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_d4bce4db-ddda-4635-8584-85f886317e4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_2bff6dd0-7f50-4ca6-aecd-e3d4aa9ae2d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_d4bce4db-ddda-4635-8584-85f886317e4d" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_2bff6dd0-7f50-4ca6-aecd-e3d4aa9ae2d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_be237aa0-e4bd-4ada-8c62-cd58e1945187" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_d4bce4db-ddda-4635-8584-85f886317e4d" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_be237aa0-e4bd-4ada-8c62-cd58e1945187" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_fba33e69-3213-4743-8cac-3f92a3534619" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_b9f60b82-d160-44cc-986d-abbaa11a0db1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_fba33e69-3213-4743-8cac-3f92a3534619" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_b9f60b82-d160-44cc-986d-abbaa11a0db1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_be3e1c0d-072a-4b03-9574-a2dc0259f5f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_fba33e69-3213-4743-8cac-3f92a3534619" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_be3e1c0d-072a-4b03-9574-a2dc0259f5f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherMiscellaneousCurrentLiabilities_54635004-0c96-4b74-b70f-cde94fe281c0" xlink:href="nbx-20250630.xsd#nbx_OtherMiscellaneousCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_fba33e69-3213-4743-8cac-3f92a3534619" xlink:to="loc_nbx_OtherMiscellaneousCurrentLiabilities_54635004-0c96-4b74-b70f-cde94fe281c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_dc2c45a2-f949-4cf5-bf85-bdd5b213ef59" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_830d4d03-907e-457a-a61a-515696b9894d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_dc2c45a2-f949-4cf5-bf85-bdd5b213ef59" xlink:to="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_830d4d03-907e-457a-a61a-515696b9894d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_7bf0a265-e657-4a96-b210-ec6710028408" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_dc2c45a2-f949-4cf5-bf85-bdd5b213ef59" xlink:to="loc_ifrs-full_CurrentContractLiabilities_7bf0a265-e657-4a96-b210-ec6710028408" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RefundsProvision_55f42a6b-65fb-4aab-8a4a-c4719d8cb009" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RefundsProvision"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_55d74790-1397-4fde-ab33-7b4327fffe88" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_RefundsProvision_55f42a6b-65fb-4aab-8a4a-c4719d8cb009" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_55d74790-1397-4fde-ab33-7b4327fffe88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRefundsProvision_6e61a403-6370-493f-8f3a-e38f570b7b5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRefundsProvision"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_RefundsProvision_55f42a6b-65fb-4aab-8a4a-c4719d8cb009" xlink:to="loc_ifrs-full_CurrentRefundsProvision_6e61a403-6370-493f-8f3a-e38f570b7b5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_36e2f5fa-affc-4827-afb8-58f19b37f794" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_1c523ec7-b9d5-496e-8a00-04fa89c9f4c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_36e2f5fa-affc-4827-afb8-58f19b37f794" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_1c523ec7-b9d5-496e-8a00-04fa89c9f4c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_8c78c522-99f7-47d7-ae8a-e95cce32599b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_36e2f5fa-affc-4827-afb8-58f19b37f794" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_8c78c522-99f7-47d7-ae8a-e95cce32599b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentTaxCredit_fbad948a-d02d-407d-8873-28b510f08bb3" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentTaxCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_36e2f5fa-affc-4827-afb8-58f19b37f794" xlink:to="loc_nbx_ResearchAndDevelopmentTaxCredit_fbad948a-d02d-407d-8873-28b510f08bb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_446c6d31-8b58-4f78-afe3-431e2cbd4261" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_9b42a035-65d2-4e1f-8ce0-3e282ed387fc" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_446c6d31-8b58-4f78-afe3-431e2cbd4261" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_9b42a035-65d2-4e1f-8ce0-3e282ed387fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts_897571e0-eee2-40fe-9998-6017f9404fda" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentExpensePayrollCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_446c6d31-8b58-4f78-afe3-431e2cbd4261" xlink:to="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts_897571e0-eee2-40fe-9998-6017f9404fda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_65d3e98a-d9e6-4d49-84cf-671d57794218" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_446c6d31-8b58-4f78-afe3-431e2cbd4261" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_65d3e98a-d9e6-4d49-84cf-671d57794218" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_18734afd-535f-451c-823a-fad882e6f57d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_4311a42a-b3f0-403d-9871-9380132ee9e1" xlink:href="nbx-20250630.xsd#nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_18734afd-535f-451c-823a-fad882e6f57d" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_4311a42a-b3f0-403d-9871-9380132ee9e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_e2929270-57b1-49e0-b341-e137e29049b7" xlink:href="nbx-20250630.xsd#nbx_SellingGeneralAndAdministrativeExpensePayrollCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_18734afd-535f-451c-823a-fad882e6f57d" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_e2929270-57b1-49e0-b341-e137e29049b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_fba30919-a000-4d50-8fb8-10454fe91444" xlink:href="nbx-20250630.xsd#nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_18734afd-535f-451c-823a-fad882e6f57d" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_fba30919-a000-4d50-8fb8-10454fe91444" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofPayrollCostsDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_a5b0c0e3-597f-44cc-9769-30247375933c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_9286db32-cdfb-4f5e-a3a1-b0691fa3b85d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_a5b0c0e3-597f-44cc-9769-30247375933c" xlink:to="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_9286db32-cdfb-4f5e-a3a1-b0691fa3b85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions_cd8af20a-447f-4d98-8464-71e4e7638894" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_a5b0c0e3-597f-44cc-9769-30247375933c" xlink:to="loc_ifrs-full_SocialSecurityContributions_cd8af20a-447f-4d98-8464-71e4e7638894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_3c72d1cb-955c-4b1a-afba-9ae55dbf3488" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WagesAndSalaries"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_a5b0c0e3-597f-44cc-9769-30247375933c" xlink:to="loc_ifrs-full_WagesAndSalaries_3c72d1cb-955c-4b1a-afba-9ae55dbf3488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ebb1b5e7-4e70-4a24-a341-ebc4936f97a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_a5b0c0e3-597f-44cc-9769-30247375933c" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ebb1b5e7-4e70-4a24-a341-ebc4936f97a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_5ce41778-5f69-4575-ba50-5f17901bed03" xlink:href="nbx-20250630.xsd#nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_525f1424-23d7-488d-bcfe-fef2481a21ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_5ce41778-5f69-4575-ba50-5f17901bed03" xlink:to="loc_ifrs-full_AmortisationExpense_525f1424-23d7-488d-bcfe-fef2481a21ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationExpense_0acf86ee-5445-4543-af39-adfc5d0d113f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_5ce41778-5f69-4575-ba50-5f17901bed03" xlink:to="loc_ifrs-full_DepreciationExpense_0acf86ee-5445-4543-af39-adfc5d0d113f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LitigationExpense_e06b96fa-cd77-4115-8347-5d75e25749a6" xlink:href="nbx-20250630.xsd#nbx_LitigationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_5ce41778-5f69-4575-ba50-5f17901bed03" xlink:to="loc_nbx_LitigationExpense_e06b96fa-cd77-4115-8347-5d75e25749a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_37541ccb-2d6c-4db5-89ef-6bf83174eced" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_5ce41778-5f69-4575-ba50-5f17901bed03" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_37541ccb-2d6c-4db5-89ef-6bf83174eced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpenses_6b6e0dbb-9d2e-40b4-9a6e-18d3cf58a190" xlink:href="nbx-20250630.xsd#nbx_DepreciationAmortizationAndProvisionExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_57725b4c-4a06-4cbd-8435-29e74188b5ed" xlink:href="nbx-20250630.xsd#nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbx_DepreciationAmortizationAndProvisionExpenses_6b6e0dbb-9d2e-40b4-9a6e-18d3cf58a190" xlink:to="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_57725b4c-4a06-4cbd-8435-29e74188b5ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionForRetirementBenefitObligationsNet_2ac4adad-9656-4a80-ab1b-414794041375" xlink:href="nbx-20250630.xsd#nbx_ProvisionForRetirementBenefitObligationsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbx_DepreciationAmortizationAndProvisionExpenses_6b6e0dbb-9d2e-40b4-9a6e-18d3cf58a190" xlink:to="loc_nbx_ProvisionForRetirementBenefitObligationsNet_2ac4adad-9656-4a80-ab1b-414794041375" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_73854945-17a6-40c3-bea5-3b3ec60087f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherNonrecurringExpenses_73a1f102-88c7-4068-94f5-cb0442dfe55d" xlink:href="nbx-20250630.xsd#nbx_OtherNonrecurringExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense_73854945-17a6-40c3-bea5-3b3ec60087f1" xlink:to="loc_nbx_OtherNonrecurringExpenses_73a1f102-88c7-4068-94f5-cb0442dfe55d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherNonrecurringsIncome_511b1e39-3deb-4530-8cbb-a1cf4fc0b294" xlink:href="nbx-20250630.xsd#nbx_OtherNonrecurringsIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense_73854945-17a6-40c3-bea5-3b3ec60087f1" xlink:to="loc_nbx_OtherNonrecurringsIncome_511b1e39-3deb-4530-8cbb-a1cf4fc0b294" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_44a0ce25-be0c-434b-b4b9-a6874b44884b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense_b2ce0219-d596-421d-a52b-ecf79e656919" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_44a0ce25-be0c-434b-b4b9-a6874b44884b" xlink:to="loc_ifrs-full_InterestExpense_b2ce0219-d596-421d-a52b-ecf79e656919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_0c6758bd-8fe9-4b85-82cd-92887e07cc73" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_44a0ce25-be0c-434b-b4b9-a6874b44884b" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_0c6758bd-8fe9-4b85-82cd-92887e07cc73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_d4de8dfd-0dc9-445c-ab34-8dad37534aa5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_44a0ce25-be0c-434b-b4b9-a6874b44884b" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_d4de8dfd-0dc9-445c-ab34-8dad37534aa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DebtAccretionAndDiscountingImpact_3e56fb67-c135-4db4-9bd6-34309cee3ca5" xlink:href="nbx-20250630.xsd#nbx_DebtAccretionAndDiscountingImpact"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_44a0ce25-be0c-434b-b4b9-a6874b44884b" xlink:to="loc_nbx_DebtAccretionAndDiscountingImpact_3e56fb67-c135-4db4-9bd6-34309cee3ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_8a73f8e4-5d56-4417-acf5-bf702e65c222" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_a1d92ac0-18c8-4312-9408-ec3abd7a461e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_8a73f8e4-5d56-4417-acf5-bf702e65c222" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_a1d92ac0-18c8-4312-9408-ec3abd7a461e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_e427583a-1fa4-442b-9036-8374d8283fc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_8a73f8e4-5d56-4417-acf5-bf702e65c222" xlink:to="loc_ifrs-full_NetForeignExchangeGain_e427583a-1fa4-442b-9036-8374d8283fc2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_1cb9b1f7-8727-4103-934c-322d949aa592" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_e175f032-d17e-4459-b01b-dd5c390bb933" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_1cb9b1f7-8727-4103-934c-322d949aa592" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_e175f032-d17e-4459-b01b-dd5c390bb933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_341b2964-c6ff-4105-9840-47536123e65f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_1cb9b1f7-8727-4103-934c-322d949aa592" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_341b2964-c6ff-4105-9840-47536123e65f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DirectorsRemunerationExpense_10ac8b45-09ae-4fb4-9441-3fcd215002a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_1cb9b1f7-8727-4103-934c-322d949aa592" xlink:to="loc_ifrs-full_DirectorsRemunerationExpense_10ac8b45-09ae-4fb4-9441-3fcd215002a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetCollectionsPaymentsFromRelatedParty_fb7d5a4e-891e-4362-8134-7e054532ee32" xlink:href="nbx-20250630.xsd#nbx_NetCollectionsPaymentsFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties_14217881-e079-45a0-955d-80e48634bdb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbx_NetCollectionsPaymentsFromRelatedParty_fb7d5a4e-891e-4362-8134-7e054532ee32" xlink:to="loc_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties_14217881-e079-45a0-955d-80e48634bdb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_8f206b89-32e9-4ac4-bbca-aa2813f6e8f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbx_NetCollectionsPaymentsFromRelatedParty_fb7d5a4e-891e-4362-8134-7e054532ee32" xlink:to="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_8f206b89-32e9-4ac4-bbca-aa2813f6e8f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetAmountsReceivablePayableRelatedPartyTransactions_cb789c9e-ba40-4801-ab54-8143c2e7c204" xlink:href="nbx-20250630.xsd#nbx_NetAmountsReceivablePayableRelatedPartyTransactions"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_3ca7b6a4-e9f2-4f19-88b8-810b47c4d97e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbx_NetAmountsReceivablePayableRelatedPartyTransactions_cb789c9e-ba40-4801-ab54-8143c2e7c204" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_3ca7b6a4-e9f2-4f19-88b8-810b47c4d97e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_d5168d43-6f04-449d-aece-56eec5659a85" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbx_NetAmountsReceivablePayableRelatedPartyTransactions_cb789c9e-ba40-4801-ab54-8143c2e7c204" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_d5168d43-6f04-449d-aece-56eec5659a85" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>nbx-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e10ad955-f4fb-4992-aa6a-58056e28f5e0,g:51b53987-7aad-4161-819f-cbfd12ac6608-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_3ff90c78-36c2-4205-ae68-cacbc0e90838" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_a364bf94-2a5a-42a7-8bcc-d1df7da5273a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3ff90c78-36c2-4205-ae68-cacbc0e90838" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_a364bf94-2a5a-42a7-8bcc-d1df7da5273a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_f6bf64c2-8088-45b9-8c50-72833d1c1b16" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_a364bf94-2a5a-42a7-8bcc-d1df7da5273a" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_f6bf64c2-8088-45b9-8c50-72833d1c1b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_f6bf64c2-8088-45b9-8c50-72833d1c1b16_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_f6bf64c2-8088-45b9-8c50-72833d1c1b16" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_f6bf64c2-8088-45b9-8c50-72833d1c1b16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_f6bf64c2-8088-45b9-8c50-72833d1c1b16" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_de283480-c0d8-46d4-9005-9ae05b7488b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_ifrs-full_IssuedCapitalMember_de283480-c0d8-46d4-9005-9ae05b7488b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_b450e0a3-4c0c-4521-8dd1-516ef178f4ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_ifrs-full_SharePremiumMember_b450e0a3-4c0c-4521-8dd1-516ef178f4ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_8ee65bbf-05c9-4132-ae6c-4064eca39662" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_8ee65bbf-05c9-4132-ae6c-4064eca39662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_6e6c2a05-64ed-4716-9b5a-cf7d8e72b849" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_ifrs-full_TreasurySharesMember_6e6c2a05-64ed-4716-9b5a-cf7d8e72b849" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserveMember_8d53a022-ad06-48a8-afeb-8a93c581928b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_ifrs-full_CapitalReserveMember_8d53a022-ad06-48a8-afeb-8a93c581928b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetLossForThePeriodMember_2af91a67-7d7b-4ac9-8705-25cb350f00a0" xlink:href="nbx-20250630.xsd#nbx_NetLossForThePeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_nbx_NetLossForThePeriodMember_2af91a67-7d7b-4ac9-8705-25cb350f00a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3ff90c78-36c2-4205-ae68-cacbc0e90838" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_16696b02-1cce-417c-a6db-9acf97a9f2e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_16696b02-1cce-417c-a6db-9acf97a9f2e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_1562250b-1a81-48bf-9899-666f692e6f0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_Equity_1562250b-1a81-48bf-9899-666f692e6f0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_1ec21fa5-97f4-431a-b598-63a03ede0022" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_ProfitLoss_1ec21fa5-97f4-431a-b598-63a03ede0022" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_77169ce4-6053-4ecc-aea4-a2277f690051" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_77169ce4-6053-4ecc-aea4-a2277f690051" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations_279c1d3e-0ab9-4aed-8bf5-ff002ba271b9" xlink:href="nbx-20250630.xsd#nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations_279c1d3e-0ab9-4aed-8bf5-ff002ba271b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_939319e3-5a38-4b5c-ae84-6366e59733a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_ComprehensiveIncome_939319e3-5a38-4b5c-ae84-6366e59733a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_26b66153-fd12-4642-b709-4825782685a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_26b66153-fd12-4642-b709-4825782685a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_54c35afb-63b7-4829-9e53-b208fa34169b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_NumberOfSharesIssued_54c35afb-63b7-4829-9e53-b208fa34169b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_7e5e23ee-c4fd-438d-9463-175a8f376166" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_IssueOfEquity_7e5e23ee-c4fd-438d-9463-175a8f376166" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_8c2b69cb-9fec-4d6a-8e47-d5253367a47b" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_8c2b69cb-9fec-4d6a-8e47-d5253367a47b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_e0b76d0a-c6c0-441f-8fd0-2ad81d090abe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_e0b76d0a-c6c0-441f-8fd0-2ad81d090abe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_50a3c4cc-a90e-4113-976e-109349c2fe92" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_b92622cc-790c-4d67-9ba8-6c23c580ffbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CompanyinformationDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#CompanyinformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/CompanyinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_ed6613ae-a29e-4b69-a640-1eef696e832f" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_ed6613ae-a29e-4b69-a640-1eef696e832f" xlink:to="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_2c286284-dad8-4776-b771-d8609ec228fa" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:to="loc_nbx_CollaborationAgreementAxis_2c286284-dad8-4776-b771-d8609ec228fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_2c286284-dad8-4776-b771-d8609ec228fa_default" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_2c286284-dad8-4776-b771-d8609ec228fa" xlink:to="loc_nbx_CollaborationAgreementDomain_2c286284-dad8-4776-b771-d8609ec228fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_5a673bb4-7afb-4dc4-a753-c483d0c1c3bf" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_2c286284-dad8-4776-b771-d8609ec228fa" xlink:to="loc_nbx_CollaborationAgreementDomain_5a673bb4-7afb-4dc4-a753-c483d0c1c3bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_660470ca-53c1-4b45-951a-91a3883c0b60" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_5a673bb4-7afb-4dc4-a753-c483d0c1c3bf" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_660470ca-53c1-4b45-951a-91a3883c0b60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c8e7d202-355a-4f61-8403-4f22d1ef492e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c8e7d202-355a-4f61-8403-4f22d1ef492e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_c8e7d202-355a-4f61-8403-4f22d1ef492e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c8e7d202-355a-4f61-8403-4f22d1ef492e" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_c8e7d202-355a-4f61-8403-4f22d1ef492e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_85791e72-655f-4f59-bf5e-1fa3103e1a9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c8e7d202-355a-4f61-8403-4f22d1ef492e" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_85791e72-655f-4f59-bf5e-1fa3103e1a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_6dd954c7-92b0-4833-b062-4bd211f00646" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_85791e72-655f-4f59-bf5e-1fa3103e1a9e" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_6dd954c7-92b0-4833-b062-4bd211f00646" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2fa0a077-d155-4888-acd3-348efd551dca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:to="loc_srt_CounterpartyNameAxis_2fa0a077-d155-4888-acd3-348efd551dca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fa0a077-d155-4888-acd3-348efd551dca_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2fa0a077-d155-4888-acd3-348efd551dca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fa0a077-d155-4888-acd3-348efd551dca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_64cef72d-979d-4e95-9488-ddd6f99ea77c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2fa0a077-d155-4888-acd3-348efd551dca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_64cef72d-979d-4e95-9488-ddd6f99ea77c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixCorpMember_518eaade-b883-48c1-98a8-7492281a3f8e" xlink:href="nbx-20250630.xsd#nbx_NanobiotixCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_64cef72d-979d-4e95-9488-ddd6f99ea77c" xlink:to="loc_nbx_NanobiotixCorpMember_518eaade-b883-48c1-98a8-7492281a3f8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_d14717a2-4361-4f97-9a9d-f0a46b2ffef5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:to="loc_ifrs-full_RangeAxis_d14717a2-4361-4f97-9a9d-f0a46b2ffef5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_d14717a2-4361-4f97-9a9d-f0a46b2ffef5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_d14717a2-4361-4f97-9a9d-f0a46b2ffef5" xlink:to="loc_ifrs-full_RangeDomain_d14717a2-4361-4f97-9a9d-f0a46b2ffef5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_d16f84f2-9591-4d9d-8624-982921140978" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_d14717a2-4361-4f97-9a9d-f0a46b2ffef5" xlink:to="loc_ifrs-full_RangeDomain_d16f84f2-9591-4d9d-8624-982921140978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_015d2a12-f924-4524-ac3b-efad6c8704d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_d16f84f2-9591-4d9d-8624-982921140978" xlink:to="loc_ifrs-full_TopOfRangeMember_015d2a12-f924-4524-ac3b-efad6c8704d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementTotalConsideration_dd91be4b-680c-48b5-8071-0960df9bd58d" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementTotalConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_ed6613ae-a29e-4b69-a640-1eef696e832f" xlink:to="loc_nbx_CollaborationAgreementTotalConsideration_dd91be4b-680c-48b5-8071-0960df9bd58d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_58035911-516f-4ec4-85eb-60266868d6ca" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_ed6613ae-a29e-4b69-a640-1eef696e832f" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_58035911-516f-4ec4-85eb-60266868d6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication_9d43e4bb-1240-4bc4-b5f1-8c4d33fa356e" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_ed6613ae-a29e-4b69-a640-1eef696e832f" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication_9d43e4bb-1240-4bc4-b5f1-8c4d33fa356e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#GeneralinformationstatementofcomplianceandbasisofpresentationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_bebc8d14-ce6d-4a8d-97cd-706da81bc2ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_189d6376-94ba-459e-8c9e-1dce234ef3c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_bebc8d14-ce6d-4a8d-97cd-706da81bc2ad" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_189d6376-94ba-459e-8c9e-1dce234ef3c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_953fc0b8-1b48-405b-b485-dde618b03e20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_189d6376-94ba-459e-8c9e-1dce234ef3c6" xlink:to="loc_ifrs-full_RangeAxis_953fc0b8-1b48-405b-b485-dde618b03e20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_953fc0b8-1b48-405b-b485-dde618b03e20_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_953fc0b8-1b48-405b-b485-dde618b03e20" xlink:to="loc_ifrs-full_RangeDomain_953fc0b8-1b48-405b-b485-dde618b03e20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_78b228f1-2fa9-4f70-88fd-01606b80cdd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_953fc0b8-1b48-405b-b485-dde618b03e20" xlink:to="loc_ifrs-full_RangeDomain_78b228f1-2fa9-4f70-88fd-01606b80cdd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_89e07836-3c71-4a94-b717-4ab7d102a062" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_78b228f1-2fa9-4f70-88fd-01606b80cdd3" xlink:to="loc_ifrs-full_TopOfRangeMember_89e07836-3c71-4a94-b717-4ab7d102a062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_423f36b5-6a23-4eed-929a-b29354d40fce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_78b228f1-2fa9-4f70-88fd-01606b80cdd3" xlink:to="loc_ifrs-full_BottomOfRangeMember_423f36b5-6a23-4eed-929a-b29354d40fce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_aee87084-85fb-4185-93b4-daa6e9db584d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_bebc8d14-ce6d-4a8d-97cd-706da81bc2ad" xlink:to="loc_ifrs-full_CashAndCashEquivalents_aee87084-85fb-4185-93b4-daa6e9db584d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdditionalLiquidityBusinessObligations_2ed32d91-782e-46ec-a221-65ebff5598a7" xlink:href="nbx-20250630.xsd#nbx_AdditionalLiquidityBusinessObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_bebc8d14-ce6d-4a8d-97cd-706da81bc2ad" xlink:to="loc_nbx_AdditionalLiquidityBusinessObligations_2ed32d91-782e-46ec-a221-65ebff5598a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#IntangibleassetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_b41ac70e-a226-406d-9732-e963ce020584" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_b41ac70e-a226-406d-9732-e963ce020584" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_18b1b9e7-4480-4924-9365-9783ef44c7e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_b41ac70e-a226-406d-9732-e963ce020584" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_18b1b9e7-4480-4924-9365-9783ef44c7e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_18b1b9e7-4480-4924-9365-9783ef44c7e6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_18b1b9e7-4480-4924-9365-9783ef44c7e6" xlink:to="loc_ifrs-full_CarryingAmountMember_18b1b9e7-4480-4924-9365-9783ef44c7e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_83ab355e-9f93-4993-9fc3-670ed420e446" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_18b1b9e7-4480-4924-9365-9783ef44c7e6" xlink:to="loc_ifrs-full_CarryingAmountMember_83ab355e-9f93-4993-9fc3-670ed420e446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_15846ac4-c67c-4eec-bc93-837b4f8182ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_83ab355e-9f93-4993-9fc3-670ed420e446" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_15846ac4-c67c-4eec-bc93-837b4f8182ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2c42c8b1-9505-4bf3-8a73-129d441440aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_83ab355e-9f93-4993-9fc3-670ed420e446" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2c42c8b1-9505-4bf3-8a73-129d441440aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6ff29ab3-1713-493f-b560-ee12eff218ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_b41ac70e-a226-406d-9732-e963ce020584" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6ff29ab3-1713-493f-b560-ee12eff218ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_6ff29ab3-1713-493f-b560-ee12eff218ff_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6ff29ab3-1713-493f-b560-ee12eff218ff" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_6ff29ab3-1713-493f-b560-ee12eff218ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_a173c53c-6bc3-430b-a7af-408f48be09f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6ff29ab3-1713-493f-b560-ee12eff218ff" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_a173c53c-6bc3-430b-a7af-408f48be09f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0c95da73-0cf6-4b6f-92a3-99e4442d9411" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_a173c53c-6bc3-430b-a7af-408f48be09f0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0c95da73-0cf6-4b6f-92a3-99e4442d9411" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_d523e3b4-3303-4602-91de-3e8de9a0547d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0c95da73-0cf6-4b6f-92a3-99e4442d9411" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_d523e3b4-3303-4602-91de-3e8de9a0547d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_53f61350-b349-4c31-ba01-c95899f20e18" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0c95da73-0cf6-4b6f-92a3-99e4442d9411" xlink:to="loc_ifrs-full_ComputerSoftwareMember_53f61350-b349-4c31-ba01-c95899f20e18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_2b1c32bb-28dc-47aa-b71e-55b975a4482d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_2b1c32bb-28dc-47aa-b71e-55b975a4482d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_7a35bb4f-5bdb-4b9e-b325-fcc59de207dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_7a35bb4f-5bdb-4b9e-b325-fcc59de207dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_a828dbf2-23d7-4ac5-93e7-b3fb99177cf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_a828dbf2-23d7-4ac5-93e7-b3fb99177cf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_7858e973-3727-4797-9273-9662b0d1d9d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_7858e973-3727-4797-9273-9662b0d1d9d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_8930432a-eb5c-4532-8ff3-e8dd1c1515ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5a79b3fb-4d2f-4ccc-9a50-ee32bbb9f109" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_ad019b54-fe23-4a26-ab5e-e35fcee436c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5a79b3fb-4d2f-4ccc-9a50-ee32bbb9f109" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_ad019b54-fe23-4a26-ab5e-e35fcee436c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12084897-80dd-4f7e-a277-eb6684fdff95" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_ad019b54-fe23-4a26-ab5e-e35fcee436c5" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12084897-80dd-4f7e-a277-eb6684fdff95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_12084897-80dd-4f7e-a277-eb6684fdff95_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12084897-80dd-4f7e-a277-eb6684fdff95" xlink:to="loc_ifrs-full_CarryingAmountMember_12084897-80dd-4f7e-a277-eb6684fdff95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_aa7185d6-980a-4eef-91f2-0dacbef0d8e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12084897-80dd-4f7e-a277-eb6684fdff95" xlink:to="loc_ifrs-full_CarryingAmountMember_aa7185d6-980a-4eef-91f2-0dacbef0d8e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_b96d8ce1-7f82-4c90-85ad-985c43437968" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_aa7185d6-980a-4eef-91f2-0dacbef0d8e9" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_b96d8ce1-7f82-4c90-85ad-985c43437968" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_b95d62f1-4882-41aa-961a-4de626b0c0d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_aa7185d6-980a-4eef-91f2-0dacbef0d8e9" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_b95d62f1-4882-41aa-961a-4de626b0c0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NettingMember_7d6b3460-8a75-4930-9e03-38599a91514b" xlink:href="nbx-20250630.xsd#nbx_NettingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_aa7185d6-980a-4eef-91f2-0dacbef0d8e9" xlink:to="loc_nbx_NettingMember_7d6b3460-8a75-4930-9e03-38599a91514b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_359821f0-b5e1-4da8-a27e-aedfd22abe05" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_ad019b54-fe23-4a26-ab5e-e35fcee436c5" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_359821f0-b5e1-4da8-a27e-aedfd22abe05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_359821f0-b5e1-4da8-a27e-aedfd22abe05_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_359821f0-b5e1-4da8-a27e-aedfd22abe05" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_359821f0-b5e1-4da8-a27e-aedfd22abe05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_359821f0-b5e1-4da8-a27e-aedfd22abe05" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_c7f1fdaf-7a55-4681-880a-97176281158c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_c7f1fdaf-7a55-4681-880a-97176281158c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseBuildingsMember_d00e0f4c-db7a-4b5d-9fde-d4495b0df3a1" xlink:href="nbx-20250630.xsd#nbx_RightOfUseBuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_nbx_RightOfUseBuildingsMember_d00e0f4c-db7a-4b5d-9fde-d4495b0df3a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MachineryMember_db978fc5-5dd3-49ae-92ec-110ab4fbeced" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MachineryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_ifrs-full_MachineryMember_db978fc5-5dd3-49ae-92ec-110ab4fbeced" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_234512f2-da44-4368-8a20-6a1b33861de2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_ifrs-full_OfficeEquipmentMember_234512f2-da44-4368-8a20-6a1b33861de2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConstructionInProgressMember_379a16e6-2973-4c2d-9d6d-bd6309706dc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_ifrs-full_ConstructionInProgressMember_379a16e6-2973-4c2d-9d6d-bd6309706dc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PrepaymentsOnTangibleAssetsMember_7691e435-a271-496b-8ce4-3a3822ce8b6d" xlink:href="nbx-20250630.xsd#nbx_PrepaymentsOnTangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_nbx_PrepaymentsOnTangibleAssetsMember_7691e435-a271-496b-8ce4-3a3822ce8b6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5a79b3fb-4d2f-4ccc-9a50-ee32bbb9f109" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_a302349c-c2f1-48a8-94f8-a055d74e12ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_a302349c-c2f1-48a8-94f8-a055d74e12ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_12bf666e-bf19-4203-a2dc-6659a70e588f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_12bf666e-bf19-4203-a2dc-6659a70e588f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_7c65799a-cea2-4aaf-b770-53fb9a1b184d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_7c65799a-cea2-4aaf-b770-53fb9a1b184d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_d3d421e3-9ff0-4225-b997-ed0da965286d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_d3d421e3-9ff0-4225-b997-ed0da965286d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_7653ea34-8843-4334-b8d5-4999a3ae863c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_7653ea34-8843-4334-b8d5-4999a3ae863c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_eee65ed0-9261-41fd-9b12-d869a3ae4c64" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_85f425e8-75bb-469a-a305-097091fdb626" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_10bd386b-1860-4cfd-b6a1-434f53afed68" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_85f425e8-75bb-469a-a305-097091fdb626" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_10bd386b-1860-4cfd-b6a1-434f53afed68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0dfad0a8-d7fc-4650-b017-44c0970d720b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_10bd386b-1860-4cfd-b6a1-434f53afed68" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0dfad0a8-d7fc-4650-b017-44c0970d720b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_0dfad0a8-d7fc-4650-b017-44c0970d720b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0dfad0a8-d7fc-4650-b017-44c0970d720b" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_0dfad0a8-d7fc-4650-b017-44c0970d720b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_fe0cef10-1174-477f-b46d-4aabe6049a94" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0dfad0a8-d7fc-4650-b017-44c0970d720b" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_fe0cef10-1174-477f-b46d-4aabe6049a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentLiquidityContractMember_8036c26f-8c4c-40b8-ae5f-cb3e23ee912e" xlink:href="nbx-20250630.xsd#nbx_NonCurrentLiquidityContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_fe0cef10-1174-477f-b46d-4aabe6049a94" xlink:to="loc_nbx_NonCurrentLiquidityContractMember_8036c26f-8c4c-40b8-ae5f-cb3e23ee912e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:href="nbx-20250630.xsd#nbx_SecurityDepositsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_85f425e8-75bb-469a-a305-097091fdb626" xlink:to="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_6dc7234c-06d1-4218-b4d4-aae0b638ac8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_6dc7234c-06d1-4218-b4d4-aae0b638ac8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_8f7b747b-37e8-492a-80ad-5ecdccb141e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_8f7b747b-37e8-492a-80ad-5ecdccb141e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_ad30b49d-7538-4366-aebf-8547ef1e2e57" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_ad30b49d-7538-4366-aebf-8547ef1e2e57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets_6dc6b658-3acd-4e12-8718-f63cf6f7604c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets_6dc6b658-3acd-4e12-8718-f63cf6f7604c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_7d198f42-7c13-4303-a701-1f52c7aa21e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_7d198f42-7c13-4303-a701-1f52c7aa21e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_f46bf57c-912c-4181-84f9-ac6a1a39e860" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradereceivablesandothercurrentassetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_fdc2b183-1b8a-41b3-8f21-d55cbf6463cc" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:to="loc_nbx_CollaborationAgreementAxis_fdc2b183-1b8a-41b3-8f21-d55cbf6463cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_fdc2b183-1b8a-41b3-8f21-d55cbf6463cc_default" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_fdc2b183-1b8a-41b3-8f21-d55cbf6463cc" xlink:to="loc_nbx_CollaborationAgreementDomain_fdc2b183-1b8a-41b3-8f21-d55cbf6463cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_81841482-3686-49c5-91cf-3e76092c6443" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_fdc2b183-1b8a-41b3-8f21-d55cbf6463cc" xlink:to="loc_nbx_CollaborationAgreementDomain_81841482-3686-49c5-91cf-3e76092c6443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_f10f8e60-84c6-4d15-97a9-f33136b97c76" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_81841482-3686-49c5-91cf-3e76092c6443" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_f10f8e60-84c6-4d15-97a9-f33136b97c76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MDAndersonCancerCenterNBTXR3Member_bd4b021f-0cd6-489f-b9e3-6d370e4f0ec9" xlink:href="nbx-20250630.xsd#nbx_MDAndersonCancerCenterNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_81841482-3686-49c5-91cf-3e76092c6443" xlink:to="loc_nbx_MDAndersonCancerCenterNBTXR3Member_bd4b021f-0cd6-489f-b9e3-6d370e4f0ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_c0c578d3-109e-4297-a11a-7a22b49fc80d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_c0c578d3-109e-4297-a11a-7a22b49fc80d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_c0c578d3-109e-4297-a11a-7a22b49fc80d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_c0c578d3-109e-4297-a11a-7a22b49fc80d" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_c0c578d3-109e-4297-a11a-7a22b49fc80d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_c0c578d3-109e-4297-a11a-7a22b49fc80d" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TechnologyTransferAndTechnicalAssistanceMember_8d681ab4-2c7e-447a-9c80-6bbb366c4a39" xlink:href="nbx-20250630.xsd#nbx_TechnologyTransferAndTechnicalAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:to="loc_nbx_TechnologyTransferAndTechnicalAssistanceMember_8d681ab4-2c7e-447a-9c80-6bbb366c4a39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IntellectualPropertyServicesMember_35838250-4fb0-4f04-ba91-b40a69cf5f5b" xlink:href="nbx-20250630.xsd#nbx_IntellectualPropertyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:to="loc_nbx_IntellectualPropertyServicesMember_35838250-4fb0-4f04-ba91-b40a69cf5f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ThirdPartyServicesMember_e1a34ec7-c323-4c52-9d42-58efa0a07ca9" xlink:href="nbx-20250630.xsd#nbx_ThirdPartyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:to="loc_nbx_ThirdPartyServicesMember_e1a34ec7-c323-4c52-9d42-58efa0a07ca9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ClinicalProductsMember_adc76a6a-2726-4b42-8a8e-59cb10059d85" xlink:href="nbx-20250630.xsd#nbx_ClinicalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:to="loc_nbx_ClinicalProductsMember_adc76a6a-2726-4b42-8a8e-59cb10059d85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4d2fa6e0-b70a-4d25-bd36-79345b650b0a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:to="loc_srt_CounterpartyNameAxis_4d2fa6e0-b70a-4d25-bd36-79345b650b0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d2fa6e0-b70a-4d25-bd36-79345b650b0a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4d2fa6e0-b70a-4d25-bd36-79345b650b0a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d2fa6e0-b70a-4d25-bd36-79345b650b0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77419518-7717-47d6-acc0-3967fc8017ef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4d2fa6e0-b70a-4d25-bd36-79345b650b0a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77419518-7717-47d6-acc0-3967fc8017ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_6c8d04e1-d1b8-40b2-a106-b4bcdbfe0b0f" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77419518-7717-47d6-acc0-3967fc8017ef" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_6c8d04e1-d1b8-40b2-a106-b4bcdbfe0b0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SuppliersMember_dfa8b8ad-5728-4bfe-ad43-9b7d26c8bdfd" xlink:href="nbx-20250630.xsd#nbx_SuppliersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77419518-7717-47d6-acc0-3967fc8017ef" xlink:to="loc_nbx_SuppliersMember_dfa8b8ad-5728-4bfe-ad43-9b7d26c8bdfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_a9e0e8e4-7f4c-429c-9d3a-2b2aace4b5d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:to="loc_ifrs-full_CurrentTradeReceivables_a9e0e8e4-7f4c-429c-9d3a-2b2aace4b5d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_e04e89a3-8059-4b4a-9578-f9a5cc14285c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_e04e89a3-8059-4b4a-9578-f9a5cc14285c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_14738591-2186-4cbd-8250-bfcd7b1b0a60" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:to="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_14738591-2186-4cbd-8250-bfcd7b1b0a60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_ed47d2ba-6e91-40f5-bb73-51232e8b715c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_ed47d2ba-6e91-40f5-bb73-51232e8b715c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_db42df92-6853-41aa-be7c-c8c2d9c29790" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_db42df92-6853-41aa-be7c-c8c2d9c29790" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d6041e3a-f573-4c25-8311-cbb4138b0d01" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_db42df92-6853-41aa-be7c-c8c2d9c29790" xlink:to="loc_dei_LegalEntityAxis_d6041e3a-f573-4c25-8311-cbb4138b0d01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d6041e3a-f573-4c25-8311-cbb4138b0d01_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d6041e3a-f573-4c25-8311-cbb4138b0d01" xlink:to="loc_dei_EntityDomain_d6041e3a-f573-4c25-8311-cbb4138b0d01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b6a0f1aa-daff-4cb4-bb57-544f1cc5cb20" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d6041e3a-f573-4c25-8311-cbb4138b0d01" xlink:to="loc_dei_EntityDomain_b6a0f1aa-daff-4cb4-bb57-544f1cc5cb20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixSAMember_a2184c84-b8ee-4391-b5a8-7ac26f164b7b" xlink:href="nbx-20250630.xsd#nbx_NanobiotixSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b6a0f1aa-daff-4cb4-bb57-544f1cc5cb20" xlink:to="loc_nbx_NanobiotixSAMember_a2184c84-b8ee-4391-b5a8-7ac26f164b7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixCorpMember_00651e75-d058-4d15-9d7d-d875fb67dca4" xlink:href="nbx-20250630.xsd#nbx_NanobiotixCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b6a0f1aa-daff-4cb4-bb57-544f1cc5cb20" xlink:to="loc_nbx_NanobiotixCorpMember_00651e75-d058-4d15-9d7d-d875fb67dca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearAxis_7168c609-3e67-4886-a561-b721409fe0a2" xlink:href="nbx-20250630.xsd#nbx_OpenTaxYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_db42df92-6853-41aa-be7c-c8c2d9c29790" xlink:to="loc_nbx_OpenTaxYearAxis_7168c609-3e67-4886-a561-b721409fe0a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain_7168c609-3e67-4886-a561-b721409fe0a2_default" xlink:href="nbx-20250630.xsd#nbx_OpenTaxYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_OpenTaxYearAxis_7168c609-3e67-4886-a561-b721409fe0a2" xlink:to="loc_nbx_OpenTaxYearDomain_7168c609-3e67-4886-a561-b721409fe0a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain_f8133dc0-4ad3-4429-aff1-8aa963c7a115" xlink:href="nbx-20250630.xsd#nbx_OpenTaxYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_OpenTaxYearAxis_7168c609-3e67-4886-a561-b721409fe0a2" xlink:to="loc_nbx_OpenTaxYearDomain_f8133dc0-4ad3-4429-aff1-8aa963c7a115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2025TaxYearMember_2c6d8af2-d2f4-44a9-bc47-9679cfa94349" xlink:href="nbx-20250630.xsd#nbx_A2025TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OpenTaxYearDomain_f8133dc0-4ad3-4429-aff1-8aa963c7a115" xlink:to="loc_nbx_A2025TaxYearMember_2c6d8af2-d2f4-44a9-bc47-9679cfa94349" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2024TaxYearMember_d4bd1133-42b8-4859-88c5-380562165868" xlink:href="nbx-20250630.xsd#nbx_A2024TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OpenTaxYearDomain_f8133dc0-4ad3-4429-aff1-8aa963c7a115" xlink:to="loc_nbx_A2024TaxYearMember_d4bd1133-42b8-4859-88c5-380562165868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_dc26c0fa-f5e1-4590-82a8-0c16aa0e9298" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_dc26c0fa-f5e1-4590-82a8-0c16aa0e9298" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit_09607a86-b4a5-41cd-ba73-1cb9956148e6" xlink:href="nbx-20250630.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:to="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit_09607a86-b4a5-41cd-ba73-1cb9956148e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProceedsFromIncomeTaxCredit_d9f82340-dc7f-42bb-b97a-4ab03bc8d9b8" xlink:href="nbx-20250630.xsd#nbx_ProceedsFromIncomeTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:to="loc_nbx_ProceedsFromIncomeTaxCredit_d9f82340-dc7f-42bb-b97a-4ab03bc8d9b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_f81f8f51-9986-4ac1-987d-a07d30aaac72" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ShareCapitalScheduleofShareCapitalTransactionsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_78763432-174e-4ac3-8330-8772d7c27eb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6f6ebc73-d171-4c3e-ad34-808a4b43de8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_78763432-174e-4ac3-8330-8772d7c27eb1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6f6ebc73-d171-4c3e-ad34-808a4b43de8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5c0be2d2-b788-420c-aa7a-edc41e0feac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6f6ebc73-d171-4c3e-ad34-808a4b43de8e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5c0be2d2-b788-420c-aa7a-edc41e0feac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5c0be2d2-b788-420c-aa7a-edc41e0feac9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5c0be2d2-b788-420c-aa7a-edc41e0feac9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5c0be2d2-b788-420c-aa7a-edc41e0feac9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4891c78b-4e7c-4a6d-904e-d673d4a99ed2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5c0be2d2-b788-420c-aa7a-edc41e0feac9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4891c78b-4e7c-4a6d-904e-d673d4a99ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023Member_de7cfb86-a816-4145-9426-9b46aed84043" xlink:href="nbx-20250630.xsd#nbx_AGA2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4891c78b-4e7c-4a6d-904e-d673d4a99ed2" xlink:to="loc_nbx_AGA2023Member_de7cfb86-a816-4145-9426-9b46aed84043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_c9cc6921-ac05-4f22-800a-0c3d5c8c81ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6f6ebc73-d171-4c3e-ad34-808a4b43de8e" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_c9cc6921-ac05-4f22-800a-0c3d5c8c81ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_c9cc6921-ac05-4f22-800a-0c3d5c8c81ee_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c9cc6921-ac05-4f22-800a-0c3d5c8c81ee" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_c9cc6921-ac05-4f22-800a-0c3d5c8c81ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_10cca365-8b0f-4132-b504-03fcb1ce2fa0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c9cc6921-ac05-4f22-800a-0c3d5c8c81ee" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_10cca365-8b0f-4132-b504-03fcb1ce2fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_f7482e7d-c6cd-475a-ba39-6c7fd912245a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_10cca365-8b0f-4132-b504-03fcb1ce2fa0" xlink:to="loc_ifrs-full_IssuedCapitalMember_f7482e7d-c6cd-475a-ba39-6c7fd912245a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_86d86cd5-202b-42fc-a8ed-e633401fe2e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_10cca365-8b0f-4132-b504-03fcb1ce2fa0" xlink:to="loc_ifrs-full_SharePremiumMember_86d86cd5-202b-42fc-a8ed-e633401fe2e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_88f6f348-ec84-4722-b747-d0975d017f8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_78763432-174e-4ac3-8330-8772d7c27eb1" xlink:to="loc_ifrs-full_EquityAbstract_88f6f348-ec84-4722-b747-d0975d017f8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_e2a35ff9-5338-4b8b-81e9-a605865740d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_88f6f348-ec84-4722-b747-d0975d017f8c" xlink:to="loc_ifrs-full_Equity_e2a35ff9-5338-4b8b-81e9-a605865740d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_fa0c77a9-acc1-4eb0-bd66-c46d4cd67b62" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_88f6f348-ec84-4722-b747-d0975d017f8c" xlink:to="loc_ifrs-full_IssueOfEquity_fa0c77a9-acc1-4eb0-bd66-c46d4cd67b62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_bed23f3d-24d1-40d7-9d93-5dfb6832ebe2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_b3bbe888-dbfe-4fcf-afa6-f3be9622b5c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_78763432-174e-4ac3-8330-8772d7c27eb1" xlink:to="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_b3bbe888-dbfe-4fcf-afa6-f3be9622b5c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_50a310a9-e864-42e9-b724-3645a8715a52" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_b3bbe888-dbfe-4fcf-afa6-f3be9622b5c2" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_50a310a9-e864-42e9-b724-3645a8715a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_9e81d5ea-0a70-4c3f-b1de-832c00cfee25" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_b3bbe888-dbfe-4fcf-afa6-f3be9622b5c2" xlink:to="loc_ifrs-full_NumberOfSharesIssued_9e81d5ea-0a70-4c3f-b1de-832c00cfee25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_69a05bd2-80a5-42e3-8716-e8433580cc15" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ShareCapitalCapitalIssuedDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec8e0dab-38d4-435c-82f9-83aade8d6738" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e916f174-d46d-4117-856c-985323977e0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec8e0dab-38d4-435c-82f9-83aade8d6738" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e916f174-d46d-4117-856c-985323977e0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_8304ec54-914d-4ece-8cc7-44f0f84fb772" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e916f174-d46d-4117-856c-985323977e0a" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_8304ec54-914d-4ece-8cc7-44f0f84fb772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_8304ec54-914d-4ece-8cc7-44f0f84fb772_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8304ec54-914d-4ece-8cc7-44f0f84fb772" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_8304ec54-914d-4ece-8cc7-44f0f84fb772_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_b47113cc-cc61-4cc9-a43c-abe5bbe2a80a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8304ec54-914d-4ece-8cc7-44f0f84fb772" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_b47113cc-cc61-4cc9-a43c-abe5bbe2a80a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_d5e8972c-5b76-4fe7-92d0-23d3b5e44107" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_b47113cc-cc61-4cc9-a43c-abe5bbe2a80a" xlink:to="loc_ifrs-full_IssuedCapitalMember_d5e8972c-5b76-4fe7-92d0-23d3b5e44107" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f1b16409-54a7-41a5-961b-f42cbb0b49f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec8e0dab-38d4-435c-82f9-83aade8d6738" xlink:to="loc_ifrs-full_Equity_f1b16409-54a7-41a5-961b-f42cbb0b49f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_6e512c1b-5c97-4d75-80bc-08ae538995bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec8e0dab-38d4-435c-82f9-83aade8d6738" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_6e512c1b-5c97-4d75-80bc-08ae538995bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_3bfa6e09-143f-41cc-9582-fb3b4296a42e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec8e0dab-38d4-435c-82f9-83aade8d6738" xlink:to="loc_ifrs-full_ParValuePerShare_3bfa6e09-143f-41cc-9582-fb3b4296a42e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ShareCapitalStockOptionPlansDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_433449fe-ea73-4845-84e1-5fef0838c40c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_433449fe-ea73-4845-84e1-5fef0838c40c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a36c861f-0233-4a73-bda9-81f3e88b8090" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_433449fe-ea73-4845-84e1-5fef0838c40c" xlink:to="loc_srt_TitleOfIndividualAxis_a36c861f-0233-4a73-bda9-81f3e88b8090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a36c861f-0233-4a73-bda9-81f3e88b8090_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_a36c861f-0233-4a73-bda9-81f3e88b8090" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a36c861f-0233-4a73-bda9-81f3e88b8090_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_afede4df-9d71-42e5-b033-b32fceb3e866" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_a36c861f-0233-4a73-bda9-81f3e88b8090" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_afede4df-9d71-42e5-b033-b32fceb3e866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExecutiveBoardAndEmployeesMember_275d2b99-3fac-4ccf-8b26-077227f5df4c" xlink:href="nbx-20250630.xsd#nbx_ExecutiveBoardAndEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_afede4df-9d71-42e5-b033-b32fceb3e866" xlink:to="loc_nbx_ExecutiveBoardAndEmployeesMember_275d2b99-3fac-4ccf-8b26-077227f5df4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f6ace8bd-5652-48f3-8d79-e18e34789a4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_433449fe-ea73-4845-84e1-5fef0838c40c" xlink:to="loc_ifrs-full_RangeAxis_f6ace8bd-5652-48f3-8d79-e18e34789a4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_f6ace8bd-5652-48f3-8d79-e18e34789a4e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_f6ace8bd-5652-48f3-8d79-e18e34789a4e" xlink:to="loc_ifrs-full_RangeDomain_f6ace8bd-5652-48f3-8d79-e18e34789a4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_5bd2f9bb-5523-457a-b0e7-749ecdd62d78" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_f6ace8bd-5652-48f3-8d79-e18e34789a4e" xlink:to="loc_ifrs-full_RangeDomain_5bd2f9bb-5523-457a-b0e7-749ecdd62d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_def74dfa-f5ec-4ffd-802d-ade60a01b00f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_5bd2f9bb-5523-457a-b0e7-749ecdd62d78" xlink:to="loc_ifrs-full_TopOfRangeMember_def74dfa-f5ec-4ffd-802d-ade60a01b00f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_43a18b22-f8a1-425e-b64d-87e663b6d1d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_43a18b22-f8a1-425e-b64d-87e663b6d1d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_03ce42ba-e6ad-46dd-af2c-51dca504e55e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:to="loc_ifrs-full_ParValuePerShare_03ce42ba-e6ad-46dd-af2c-51dca504e55e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_a71bb400-45bf-44f1-95bb-2212d927157b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_a71bb400-45bf-44f1-95bb-2212d927157b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedPaymentArrangementStockOptionTerm_b6ce1416-a7fc-4eb7-9244-74da3f12d63b" xlink:href="nbx-20250630.xsd#nbx_ShareBasedPaymentArrangementStockOptionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:to="loc_nbx_ShareBasedPaymentArrangementStockOptionTerm_b6ce1416-a7fc-4eb7-9244-74da3f12d63b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RetirementObligationsDisclosureofChangesinProvisionsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_19111cc0-41f2-4d4d-b6c1-516b11e321b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_a9b1ef06-b85a-4187-8572-9b29d841d362" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_19111cc0-41f2-4d4d-b6c1-516b11e321b8" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_a9b1ef06-b85a-4187-8572-9b29d841d362" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_f3434c9d-a563-4027-b83c-b4ec1038c02c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_a9b1ef06-b85a-4187-8572-9b29d841d362" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_f3434c9d-a563-4027-b83c-b4ec1038c02c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_f3434c9d-a563-4027-b83c-b4ec1038c02c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_f3434c9d-a563-4027-b83c-b4ec1038c02c" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_f3434c9d-a563-4027-b83c-b4ec1038c02c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_ba80a362-43b8-4a3e-a4db-e4e83e3b9c17" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_f3434c9d-a563-4027-b83c-b4ec1038c02c" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_ba80a362-43b8-4a3e-a4db-e4e83e3b9c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LumpSumRetirementBenefitsMember_5e938fbc-af15-4a44-ac0a-c144d8624408" xlink:href="nbx-20250630.xsd#nbx_LumpSumRetirementBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_ba80a362-43b8-4a3e-a4db-e4e83e3b9c17" xlink:to="loc_nbx_LumpSumRetirementBenefitsMember_5e938fbc-af15-4a44-ac0a-c144d8624408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentOtherProvisionsMember_3ea2517d-3077-4e8a-8165-0168ad0700fb" xlink:href="nbx-20250630.xsd#nbx_NonCurrentOtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_ba80a362-43b8-4a3e-a4db-e4e83e3b9c17" xlink:to="loc_nbx_NonCurrentOtherProvisionsMember_3ea2517d-3077-4e8a-8165-0168ad0700fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:href="nbx-20250630.xsd#nbx_OtherProvisionsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_19111cc0-41f2-4d4d-b6c1-516b11e321b8" xlink:to="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_4c40d8b8-a243-442d-84d1-285c13d2e800" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:to="loc_ifrs-full_OtherProvisions_4c40d8b8-a243-442d-84d1-285c13d2e800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_367942b3-9e72-4114-bc43-a8569c424391" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_367942b3-9e72-4114-bc43-a8569c424391" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_b4529a40-1bcf-45a8-b425-f7e830a9c77a" xlink:href="nbx-20250630.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:to="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_b4529a40-1bcf-45a8-b425-f7e830a9c77a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_5f8462ac-fefd-4277-b460-67544e7f7cb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_5f8462ac-fefd-4277-b460-67544e7f7cb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_a1ed260e-4e85-48c1-9893-a2e4c46f18af" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherProvisions"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ProvisionsScheduleofChangesinProvisionsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_11e90c6e-2c47-4a44-98ac-8938172f146c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_899bb0af-7ab0-4a2b-aa74-389ab298df38" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_11e90c6e-2c47-4a44-98ac-8938172f146c" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_899bb0af-7ab0-4a2b-aa74-389ab298df38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_771894c5-3269-4cfd-965e-b491a4ba1cb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_899bb0af-7ab0-4a2b-aa74-389ab298df38" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_771894c5-3269-4cfd-965e-b491a4ba1cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_771894c5-3269-4cfd-965e-b491a4ba1cb7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_771894c5-3269-4cfd-965e-b491a4ba1cb7" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_771894c5-3269-4cfd-965e-b491a4ba1cb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_108ccee3-4cfb-4291-8d37-34bffe505eed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_771894c5-3269-4cfd-965e-b491a4ba1cb7" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_108ccee3-4cfb-4291-8d37-34bffe505eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentOtherProvisionsMember_a0eaa39e-18fd-40fb-bb27-9f5ef4d9846e" xlink:href="nbx-20250630.xsd#nbx_CurrentOtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_108ccee3-4cfb-4291-8d37-34bffe505eed" xlink:to="loc_nbx_CurrentOtherProvisionsMember_a0eaa39e-18fd-40fb-bb27-9f5ef4d9846e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForDisputesMember_afe40ee1-88bd-4a2f-82d5-4acf6c7047b9" xlink:href="nbx-20250630.xsd#nbx_ProvisionsForDisputesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CurrentOtherProvisionsMember_a0eaa39e-18fd-40fb-bb27-9f5ef4d9846e" xlink:to="loc_nbx_ProvisionsForDisputesMember_afe40ee1-88bd-4a2f-82d5-4acf6c7047b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForChargesMember_6fd6064e-1727-46c5-ad14-ccfefdcebac6" xlink:href="nbx-20250630.xsd#nbx_ProvisionsForChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CurrentOtherProvisionsMember_a0eaa39e-18fd-40fb-bb27-9f5ef4d9846e" xlink:to="loc_nbx_ProvisionsForChargesMember_6fd6064e-1727-46c5-ad14-ccfefdcebac6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:href="nbx-20250630.xsd#nbx_OtherProvisionsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_11e90c6e-2c47-4a44-98ac-8938172f146c" xlink:to="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_25410891-e085-4037-b278-d9044284bf54" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:to="loc_ifrs-full_OtherProvisions_25410891-e085-4037-b278-d9044284bf54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_26801643-dcb1-4d4e-9370-476a030b9ff1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_26801643-dcb1-4d4e-9370-476a030b9ff1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_7af1e58c-f01d-45fa-9f7a-0400f3341730" xlink:href="nbx-20250630.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:to="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_7af1e58c-f01d-45fa-9f7a-0400f3341730" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_0ceee2ad-db81-48bc-af64-0f920d898e6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_0ceee2ad-db81-48bc-af64-0f920d898e6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_974ace06-55f4-4793-97f0-722d89223871" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherProvisions"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ProvisionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4d12d508-fbae-462c-b5f1-f992e664f570" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a1f6b6c-141e-4f3f-9141-96e63ba147fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4d12d508-fbae-462c-b5f1-f992e664f570" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a1f6b6c-141e-4f3f-9141-96e63ba147fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_51fd50bf-ebce-4e8a-9fe5-5a36c896e469" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a1f6b6c-141e-4f3f-9141-96e63ba147fa" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_51fd50bf-ebce-4e8a-9fe5-5a36c896e469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_51fd50bf-ebce-4e8a-9fe5-5a36c896e469_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_51fd50bf-ebce-4e8a-9fe5-5a36c896e469" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_51fd50bf-ebce-4e8a-9fe5-5a36c896e469_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_c11acb3b-6ca5-4e3b-b3d9-431a22168cf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_51fd50bf-ebce-4e8a-9fe5-5a36c896e469" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_c11acb3b-6ca5-4e3b-b3d9-431a22168cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForDisputesMember_75be6a2b-c520-4cb4-902d-77c67856e02a" xlink:href="nbx-20250630.xsd#nbx_ProvisionsForDisputesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_c11acb3b-6ca5-4e3b-b3d9-431a22168cf3" xlink:to="loc_nbx_ProvisionsForDisputesMember_75be6a2b-c520-4cb4-902d-77c67856e02a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_14bd6b24-8b7f-4ad6-94f2-2f944286232b" xlink:href="nbx-20250630.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4d12d508-fbae-462c-b5f1-f992e664f570" xlink:to="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_14bd6b24-8b7f-4ad6-94f2-2f944286232b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_390a2fe4-6d73-4e14-add9-1a45370cd31d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2536588f-a117-4a3b-a060-1e20bb982740" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_390a2fe4-6d73-4e14-add9-1a45370cd31d" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2536588f-a117-4a3b-a060-1e20bb982740" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_fd723d1e-0014-4173-9d2a-9eb780306f30" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2536588f-a117-4a3b-a060-1e20bb982740" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_fd723d1e-0014-4173-9d2a-9eb780306f30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_fd723d1e-0014-4173-9d2a-9eb780306f30_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_fd723d1e-0014-4173-9d2a-9eb780306f30" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_fd723d1e-0014-4173-9d2a-9eb780306f30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_2cda0f2a-941e-4a3a-808d-3960d85d324f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_fd723d1e-0014-4173-9d2a-9eb780306f30" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_2cda0f2a-941e-4a3a-808d-3960d85d324f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_930f5d40-9cd9-4c51-8bf5-3e9ac7dc8654" xlink:href="nbx-20250630.xsd#nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_2cda0f2a-941e-4a3a-808d-3960d85d324f" xlink:to="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_930f5d40-9cd9-4c51-8bf5-3e9ac7dc8654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_6f4bb751-dce0-411b-9f2b-3e86a081e689" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_2cda0f2a-941e-4a3a-808d-3960d85d324f" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_6f4bb751-dce0-411b-9f2b-3e86a081e689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_3461d597-dc81-4cf9-aafe-e7112361d7d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2536588f-a117-4a3b-a060-1e20bb982740" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_3461d597-dc81-4cf9-aafe-e7112361d7d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_3461d597-dc81-4cf9-aafe-e7112361d7d3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3461d597-dc81-4cf9-aafe-e7112361d7d3" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_3461d597-dc81-4cf9-aafe-e7112361d7d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_119b0359-8a77-4885-b586-52a80cb802f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3461d597-dc81-4cf9-aafe-e7112361d7d3" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_119b0359-8a77-4885-b586-52a80cb802f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_f525c5bf-6a92-4513-ab32-e9e5679a2eb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_119b0359-8a77-4885-b586-52a80cb802f7" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_f525c5bf-6a92-4513-ab32-e9e5679a2eb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesMember_1d08c1d7-1c72-4a9b-8262-126da4ce1fc1" xlink:href="nbx-20250630.xsd#nbx_ConditionalAdvancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_119b0359-8a77-4885-b586-52a80cb802f7" xlink:to="loc_nbx_ConditionalAdvancesMember_1d08c1d7-1c72-4a9b-8262-126da4ce1fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_70d19ca8-5d12-499b-a43a-aa988ceecbc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_119b0359-8a77-4885-b586-52a80cb802f7" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_70d19ca8-5d12-499b-a43a-aa988ceecbc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_b60b6337-8777-49ca-8d84-15d95c3c0562" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_390a2fe4-6d73-4e14-add9-1a45370cd31d" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_b60b6337-8777-49ca-8d84-15d95c3c0562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_7fea68f3-5fc1-4d30-a324-b5ff2ea51b81" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_390a2fe4-6d73-4e14-add9-1a45370cd31d" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_7fea68f3-5fc1-4d30-a324-b5ff2ea51b81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_84027e92-1e7f-4919-9857-7cf25d931986" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_390a2fe4-6d73-4e14-add9-1a45370cd31d" xlink:to="loc_ifrs-full_FinancialLiabilities_84027e92-1e7f-4919-9857-7cf25d931986" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a0f97726-fdc0-4d05-8f73-5b38c1b57e93" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:to="loc_srt_CounterpartyNameAxis_a0f97726-fdc0-4d05-8f73-5b38c1b57e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0f97726-fdc0-4d05-8f73-5b38c1b57e93_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a0f97726-fdc0-4d05-8f73-5b38c1b57e93" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0f97726-fdc0-4d05-8f73-5b38c1b57e93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d872702b-0661-4dfc-af77-8ffedac7d7e2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a0f97726-fdc0-4d05-8f73-5b38c1b57e93" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d872702b-0661-4dfc-af77-8ffedac7d7e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BanquePubliqueDInvestissementMember_3e9d7b80-1385-4eb5-8d55-9a71eac0e674" xlink:href="nbx-20250630.xsd#nbx_BanquePubliqueDInvestissementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d872702b-0661-4dfc-af77-8ffedac7d7e2" xlink:to="loc_nbx_BanquePubliqueDInvestissementMember_3e9d7b80-1385-4eb5-8d55-9a71eac0e674" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceMember_594e6478-9698-4570-af14-d470dedb47a5" xlink:href="nbx-20250630.xsd#nbx_BPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d872702b-0661-4dfc-af77-8ffedac7d7e2" xlink:to="loc_nbx_BPIFranceMember_594e6478-9698-4570-af14-d470dedb47a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_3b3d81d8-e43e-4512-929a-a3b7bf2fb338" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_3b3d81d8-e43e-4512-929a-a3b7bf2fb338" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_3b3d81d8-e43e-4512-929a-a3b7bf2fb338_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3b3d81d8-e43e-4512-929a-a3b7bf2fb338" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_3b3d81d8-e43e-4512-929a-a3b7bf2fb338_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_c7114389-feae-4983-8276-85a7add7c740" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3b3d81d8-e43e-4512-929a-a3b7bf2fb338" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_c7114389-feae-4983-8276-85a7add7c740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_de093b53-05d8-4292-8c47-d177a7ab7288" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c7114389-feae-4983-8276-85a7add7c740" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_de093b53-05d8-4292-8c47-d177a7ab7288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_7b690d1e-fea4-4950-9fe8-e0e71afdc070" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c7114389-feae-4983-8276-85a7add7c740" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_7b690d1e-fea4-4950-9fe8-e0e71afdc070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_4a9b7d61-c7a2-486e-b098-4c870975e8d5" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c7114389-feae-4983-8276-85a7add7c740" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_4a9b7d61-c7a2-486e-b098-4c870975e8d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_c087e446-6d4a-486f-b9d2-ebdf335d975a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:to="loc_ifrs-full_MeasurementAxis_c087e446-6d4a-486f-b9d2-ebdf335d975a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_c087e446-6d4a-486f-b9d2-ebdf335d975a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_c087e446-6d4a-486f-b9d2-ebdf335d975a" xlink:to="loc_ifrs-full_MeasurementDomain_c087e446-6d4a-486f-b9d2-ebdf335d975a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_b84e9a6d-ec5c-4c78-8ce1-ffdd5383f209" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_c087e446-6d4a-486f-b9d2-ebdf335d975a" xlink:to="loc_ifrs-full_MeasurementDomain_b84e9a6d-ec5c-4c78-8ce1-ffdd5383f209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_af5c605b-9e8e-427d-9c9b-2130cc9ce737" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_b84e9a6d-ec5c-4c78-8ce1-ffdd5383f209" xlink:to="loc_ifrs-full_AtFairValueMember_af5c605b-9e8e-427d-9c9b-2130cc9ce737" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DebtDetailsAxis_93e2646e-0803-46ea-b4f1-c5d2e5492fa3" xlink:href="nbx-20250630.xsd#nbx_DebtDetailsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:to="loc_nbx_DebtDetailsAxis_93e2646e-0803-46ea-b4f1-c5d2e5492fa3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DebtDetailsDomain_93e2646e-0803-46ea-b4f1-c5d2e5492fa3_default" xlink:href="nbx-20250630.xsd#nbx_DebtDetailsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_DebtDetailsAxis_93e2646e-0803-46ea-b4f1-c5d2e5492fa3" xlink:to="loc_nbx_DebtDetailsDomain_93e2646e-0803-46ea-b4f1-c5d2e5492fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DebtDetailsDomain_1356edee-5ced-4133-8ca1-e5f2114c8aa2" xlink:href="nbx-20250630.xsd#nbx_DebtDetailsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_DebtDetailsAxis_93e2646e-0803-46ea-b4f1-c5d2e5492fa3" xlink:to="loc_nbx_DebtDetailsDomain_1356edee-5ced-4133-8ca1-e5f2114c8aa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PrincipalAndFixedRateMember_88b501a7-d9f2-407c-a97c-9d871e1cb6ae" xlink:href="nbx-20250630.xsd#nbx_PrincipalAndFixedRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DebtDetailsDomain_1356edee-5ced-4133-8ca1-e5f2114c8aa2" xlink:to="loc_nbx_PrincipalAndFixedRateMember_88b501a7-d9f2-407c-a97c-9d871e1cb6ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MilestonePaymentMember_5f35b5b5-6505-48bf-be1d-60787dcc9642" xlink:href="nbx-20250630.xsd#nbx_MilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DebtDetailsDomain_1356edee-5ced-4133-8ca1-e5f2114c8aa2" xlink:to="loc_nbx_MilestonePaymentMember_5f35b5b5-6505-48bf-be1d-60787dcc9642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesReceivedInterestRate_b587216b-f465-4d7e-90ed-1875ad817e30" xlink:href="nbx-20250630.xsd#nbx_AdvancesReceivedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_AdvancesReceivedInterestRate_b587216b-f465-4d7e-90ed-1875ad817e30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfCurrentBorrowings_b3b13879-7743-447e-a1a3-b3d94737e0b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfCurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_RepaymentsOfCurrentBorrowings_b3b13879-7743-447e-a1a3-b3d94737e0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ReimbursedAmountOfCorresponds_8043b74e-7788-4d86-b5ef-6de9ca2b0bfb" xlink:href="nbx-20250630.xsd#nbx_ReimbursedAmountOfCorresponds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_ReimbursedAmountOfCorresponds_8043b74e-7788-4d86-b5ef-6de9ca2b0bfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced_34bf8dcf-ee0c-400d-8e21-166d4566017c" xlink:href="nbx-20250630.xsd#nbx_AdvancesAuthorizedAmountToBeAdvanced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced_34bf8dcf-ee0c-400d-8e21-166d4566017c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Advances_10e99f31-228d-46f4-9262-10a3980e128a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Advances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_Advances_10e99f31-228d-46f4-9262-10a3980e128a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_4e39e593-8d0b-47e7-aff4-f726a9549003" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_NotionalAmount_4e39e593-8d0b-47e7-aff4-f726a9549003" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_4ec8a2df-978e-4ba8-9ca5-5877208dcdaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_BorrowingsInterestRate_4ec8a2df-978e-4ba8-9ca5-5877208dcdaa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_522f00a2-d68d-4b98-9e43-2774ee6d9bc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_522f00a2-d68d-4b98-9e43-2774ee6d9bc4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_c5ec7df0-986a-4f70-bc81-f7a7bcf69995" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_c5ec7df0-986a-4f70-bc81-f7a7bcf69995" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm_652e89fd-5f0f-48c6-9671-d1dcb2040b7b" xlink:href="nbx-20250630.xsd#nbx_BorrowingMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_BorrowingMaturityTerm_652e89fd-5f0f-48c6-9671-d1dcb2040b7b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan_ec7c545d-2597-49f3-a2ea-760cd4df5028" xlink:href="nbx-20250630.xsd#nbx_BorrowingPercentageOfStateGuaranteedLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan_ec7c545d-2597-49f3-a2ea-760cd4df5028" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingGuaranteeFee_062ace52-40ec-44ff-b1c5-82f7bf204dc5" xlink:href="nbx-20250630.xsd#nbx_BorrowingGuaranteeFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_BorrowingGuaranteeFee_062ace52-40ec-44ff-b1c5-82f7bf204dc5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingNumberOfQuarterlyInstallments_35ef90ae-a6a5-4187-ad75-8d358373f48c" xlink:href="nbx-20250630.xsd#nbx_BorrowingNumberOfQuarterlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_BorrowingNumberOfQuarterlyInstallments_35ef90ae-a6a5-4187-ad75-8d358373f48c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInOutstandingLoans_6b1177bd-b072-4921-aa44-e88b7dac1ed5" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInOutstandingLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_IncreaseDecreaseInOutstandingLoans_6b1177bd-b072-4921-aa44-e88b7dac1ed5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense_0757b171-3ff1-4f2f-a8d2-88860fe86d5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_InterestExpense_0757b171-3ff1-4f2f-a8d2-88860fe86d5d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_7bf0dbbe-926d-4f3f-b2aa-eb05af761127" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_7bf0dbbe-926d-4f3f-b2aa-eb05af761127" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_b68ea726-59c4-4f60-bb9d-fb0afed57b1f" xlink:href="nbx-20250630.xsd#nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_b68ea726-59c4-4f60-bb9d-fb0afed57b1f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_cf6bf43b-a19e-456c-bf71-ccfa31d5c494" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_cf6bf43b-a19e-456c-bf71-ccfa31d5c494" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse_c87af57a-988f-49f6-871d-edf9e0bdf28f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse_c87af57a-988f-49f6-871d-edf9e0bdf28f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_faf69e29-2b44-4a2d-a5b6-2c9449d7c80d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_Borrowings_faf69e29-2b44-4a2d-a5b6-2c9449d7c80d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingsCumulativeMilestonePrepaymentAmount_c9ed4da6-e919-4832-ae30-d041a281407f" xlink:href="nbx-20250630.xsd#nbx_BorrowingsCumulativeMilestonePrepaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_BorrowingsCumulativeMilestonePrepaymentAmount_c9ed4da6-e919-4832-ae30-d041a281407f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EstimatedRoyaltyPayments_68eaff4a-fca5-4e0f-a52f-e20fbbf9b1b8" xlink:href="nbx-20250630.xsd#nbx_EstimatedRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_EstimatedRoyaltyPayments_68eaff4a-fca5-4e0f-a52f-e20fbbf9b1b8" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConsolidatedForecastedSalesPeriod_57b3643d-e072-4a5e-9b5c-457b4b08efd5" xlink:href="nbx-20250630.xsd#nbx_ConsolidatedForecastedSalesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_ConsolidatedForecastedSalesPeriod_57b3643d-e072-4a5e-9b5c-457b4b08efd5" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_03cf6b68-5779-4e76-bb0e-6070d218e6d9" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_15cd963d-2b0f-4cab-91e2-a4c77b6258f6" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_03cf6b68-5779-4e76-bb0e-6070d218e6d9" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_15cd963d-2b0f-4cab-91e2-a4c77b6258f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_3887c3e9-0d07-482d-8e22-c1a04c49c9d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_15cd963d-2b0f-4cab-91e2-a4c77b6258f6" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_3887c3e9-0d07-482d-8e22-c1a04c49c9d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_3887c3e9-0d07-482d-8e22-c1a04c49c9d0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3887c3e9-0d07-482d-8e22-c1a04c49c9d0" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_3887c3e9-0d07-482d-8e22-c1a04c49c9d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3887c3e9-0d07-482d-8e22-c1a04c49c9d0" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceAdvanceMember_bfef5bf0-1dda-4e87-9e45-f00df009c47f" xlink:href="nbx-20250630.xsd#nbx_BPIFranceAdvanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:to="loc_nbx_BPIFranceAdvanceMember_bfef5bf0-1dda-4e87-9e45-f00df009c47f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvanceBPIFranceMember_1f48d56b-fa9e-4e0c-8d35-9a79fe1310e1" xlink:href="nbx-20250630.xsd#nbx_ConditionalAdvanceBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:to="loc_nbx_ConditionalAdvanceBPIFranceMember_1f48d56b-fa9e-4e0c-8d35-9a79fe1310e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_f04561fe-2efd-4a7e-a5f6-0cb7ddeed22e" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_f04561fe-2efd-4a7e-a5f6-0cb7ddeed22e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_ff49190f-c6ac-41b2-8fa3-783788621bc9" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_ff49190f-c6ac-41b2-8fa3-783788621bc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b091f0cf-7f40-4d48-ba34-016ff9cade85" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b091f0cf-7f40-4d48-ba34-016ff9cade85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_e1d63054-986e-47e3-923e-963b9eafe822" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_15cd963d-2b0f-4cab-91e2-a4c77b6258f6" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_e1d63054-986e-47e3-923e-963b9eafe822" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_e1d63054-986e-47e3-923e-963b9eafe822_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_e1d63054-986e-47e3-923e-963b9eafe822" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_e1d63054-986e-47e3-923e-963b9eafe822_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_1db5e0d1-6125-481b-b93d-01c60ef38963" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_e1d63054-986e-47e3-923e-963b9eafe822" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_1db5e0d1-6125-481b-b93d-01c60ef38963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesRelatedToFinancingActivitiesMember_206127c9-6ade-4f64-b555-ea39f38414ec" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesRelatedToFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_1db5e0d1-6125-481b-b93d-01c60ef38963" xlink:to="loc_nbx_LiabilitiesRelatedToFinancingActivitiesMember_206127c9-6ade-4f64-b555-ea39f38414ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_0b0b8bc0-4cb2-4c64-9a49-137683c1951c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesRelatedToFinancingActivitiesMember_206127c9-6ade-4f64-b555-ea39f38414ec" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_0b0b8bc0-4cb2-4c64-9a49-137683c1951c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_cdc1f9a3-7443-4c22-a648-cbe35ac5de98" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesRelatedToFinancingActivitiesMember_206127c9-6ade-4f64-b555-ea39f38414ec" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_cdc1f9a3-7443-4c22-a648-cbe35ac5de98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_03cf6b68-5779-4e76-bb0e-6070d218e6d9" xlink:to="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_fb35d4f0-1db3-4a8c-8ee4-bcda60a902f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_fb35d4f0-1db3-4a8c-8ee4-bcda60a902f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_09ae2a30-1512-4baa-a3b1-7c03bfc3d451" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_09ae2a30-1512-4baa-a3b1-7c03bfc3d451" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities_15f247f2-e85c-4bf1-9ec8-e3354417b564" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities_15f247f2-e85c-4bf1-9ec8-e3354417b564" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_ea52b1a0-6738-49df-8315-a4baf0b9186e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_ea52b1a0-6738-49df-8315-a4baf0b9186e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_cc0574d4-209d-4eb4-9c16-82bd8d038d2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_cc0574d4-209d-4eb4-9c16-82bd8d038d2f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_fae21d39-3651-4615-9e79-936ce725d28b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_fae21d39-3651-4615-9e79-936ce725d28b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities_433b8f51-23f4-4929-8f15-1f7e8d57dd11" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities_433b8f51-23f4-4929-8f15-1f7e8d57dd11" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities_74fafea8-1085-41d5-99ff-3a2c0c318ff3" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities_74fafea8-1085-41d5-99ff-3a2c0c318ff3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_bf3f0a2b-85b7-4c1e-b43f-f1b7643ddbc6" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_bf3f0a2b-85b7-4c1e-b43f-f1b7643ddbc6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_a1bb0dbe-048f-4b4d-829f-5c9bc234ca7f" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_a1bb0dbe-048f-4b4d-829f-5c9bc234ca7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashFlowsFromUsedInNonFinancingActivities_5aa23baf-9713-40b0-8049-ce949e29c635" xlink:href="nbx-20250630.xsd#nbx_CashFlowsFromUsedInNonFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_CashFlowsFromUsedInNonFinancingActivities_5aa23baf-9713-40b0-8049-ce949e29c635" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_08b55397-c3ea-4948-a02a-c419d0bfc2f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent_072c756b-2d51-41a5-a7b7-37e195551eab" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_03cf6b68-5779-4e76-bb0e-6070d218e6d9" xlink:to="loc_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent_072c756b-2d51-41a5-a7b7-37e195551eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent_3a9b4aac-ab6f-4020-83bd-ecf5e9fe170a" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_03cf6b68-5779-4e76-bb0e-6070d218e6d9" xlink:to="loc_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent_3a9b4aac-ab6f-4020-83bd-ecf5e9fe170a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_11caf830-7cbe-4a78-9f8f-9f88f3ecdaf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_11caf830-7cbe-4a78-9f8f-9f88f3ecdaf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_3c1fa969-e7a5-4c5f-a13d-2d5c479a879c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_11caf830-7cbe-4a78-9f8f-9f88f3ecdaf4" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_3c1fa969-e7a5-4c5f-a13d-2d5c479a879c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_3c1fa969-e7a5-4c5f-a13d-2d5c479a879c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3c1fa969-e7a5-4c5f-a13d-2d5c479a879c" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_3c1fa969-e7a5-4c5f-a13d-2d5c479a879c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3c1fa969-e7a5-4c5f-a13d-2d5c479a879c" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceMember_923ac06a-e168-4222-9de5-0d1893cd1da9" xlink:href="nbx-20250630.xsd#nbx_BPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_BPIFranceMember_923ac06a-e168-4222-9de5-0d1893cd1da9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_e5f41059-2e43-4fb5-9e39-74aa12e7d35a" xlink:href="nbx-20250630.xsd#nbx_InterestFreeAdvanceToCuradigmBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_e5f41059-2e43-4fb5-9e39-74aa12e7d35a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_ae7b97ee-6003-4014-b136-8b83985d1b81" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_ae7b97ee-6003-4014-b136-8b83985d1b81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_919009f9-4166-47f1-9c7e-484d401fce67" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_919009f9-4166-47f1-9c7e-484d401fce67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_54fdc2fa-54cb-48fc-98fd-f2d3ab783948" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_54fdc2fa-54cb-48fc-98fd-f2d3ab783948" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_bbdced53-99d8-4750-ba43-f2dab9953d03" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_bbdced53-99d8-4750-ba43-f2dab9953d03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_c555e612-765b-483c-a1f5-8fea8dd7f30e" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_c555e612-765b-483c-a1f5-8fea8dd7f30e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_c3909732-6b4c-4205-ad84-d95c6e670d60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_11caf830-7cbe-4a78-9f8f-9f88f3ecdaf4" xlink:to="loc_ifrs-full_MaturityAxis_c3909732-6b4c-4205-ad84-d95c6e670d60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_c3909732-6b4c-4205-ad84-d95c6e670d60_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_c3909732-6b4c-4205-ad84-d95c6e670d60" xlink:to="loc_ifrs-full_MaturityDomain_c3909732-6b4c-4205-ad84-d95c6e670d60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_c3909732-6b4c-4205-ad84-d95c6e670d60" xlink:to="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_09616e2a-ed78-487e-ade9-20d77c344608" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_09616e2a-ed78-487e-ade9-20d77c344608" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_4e01bd29-307b-4be2-a080-12df9dc47080" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_4e01bd29-307b-4be2-a080-12df9dc47080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_b31faf61-a36a-40ee-9ff7-f6290e4e9c95" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_b31faf61-a36a-40ee-9ff7-f6290e4e9c95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_5c22b650-d9fd-4cc9-bd98-ad7d0d806513" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_5c22b650-d9fd-4cc9-bd98-ad7d0d806513" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_31dd8262-d190-48b0-b704-ba1a2eabee15" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_31dd8262-d190-48b0-b704-ba1a2eabee15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_ccd09b37-738c-4a33-a56e-7a5d9488ae0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_ccd09b37-738c-4a33-a56e-7a5d9488ae0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_90605bd5-34a2-482f-9c05-16cf518860e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_90605bd5-34a2-482f-9c05-16cf518860e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingScheduledForReimbursementNumber_30c443f1-4378-4e7b-acb7-bbd9f87fe7c0" xlink:href="nbx-20250630.xsd#nbx_BorrowingScheduledForReimbursementNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_nbx_BorrowingScheduledForReimbursementNumber_30c443f1-4378-4e7b-acb7-bbd9f87fe7c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm_2976729a-1d68-41b7-a750-181ff4c9dde5" xlink:href="nbx-20250630.xsd#nbx_BorrowingMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_nbx_BorrowingMaturityTerm_2976729a-1d68-41b7-a750-181ff4c9dde5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriod_182f51e9-399f-4086-a9f7-3fc595d81de7" xlink:href="nbx-20250630.xsd#nbx_BorrowingDefermentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_nbx_BorrowingDefermentPeriod_182f51e9-399f-4086-a9f7-3fc595d81de7" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_778c3ad4-6d42-4943-90b6-d67305cb6886" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_778c3ad4-6d42-4943-90b6-d67305cb6886" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ClinicalStudiesAxis_b953fcd1-04b2-46db-8bce-3bc445f1252f" xlink:href="nbx-20250630.xsd#nbx_ClinicalStudiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_778c3ad4-6d42-4943-90b6-d67305cb6886" xlink:to="loc_nbx_ClinicalStudiesAxis_b953fcd1-04b2-46db-8bce-3bc445f1252f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ClinicalStudiesDomain_b953fcd1-04b2-46db-8bce-3bc445f1252f_default" xlink:href="nbx-20250630.xsd#nbx_ClinicalStudiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_ClinicalStudiesAxis_b953fcd1-04b2-46db-8bce-3bc445f1252f" xlink:to="loc_nbx_ClinicalStudiesDomain_b953fcd1-04b2-46db-8bce-3bc445f1252f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ClinicalStudiesDomain_e67dd2a7-a3a5-45ba-bc5a-76cf5775154d" xlink:href="nbx-20250630.xsd#nbx_ClinicalStudiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_ClinicalStudiesAxis_b953fcd1-04b2-46db-8bce-3bc445f1252f" xlink:to="loc_nbx_ClinicalStudiesDomain_e67dd2a7-a3a5-45ba-bc5a-76cf5775154d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A312StudyMember_7f00897d-795f-4bd1-921a-4c12e964945b" xlink:href="nbx-20250630.xsd#nbx_A312StudyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_ClinicalStudiesDomain_e67dd2a7-a3a5-45ba-bc5a-76cf5775154d" xlink:to="loc_nbx_A312StudyMember_7f00897d-795f-4bd1-921a-4c12e964945b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A1100StudyMember_58a208a1-6c45-4d86-9cd5-0101a8710db6" xlink:href="nbx-20250630.xsd#nbx_A1100StudyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_ClinicalStudiesDomain_e67dd2a7-a3a5-45ba-bc5a-76cf5775154d" xlink:to="loc_nbx_A1100StudyMember_58a208a1-6c45-4d86-9cd5-0101a8710db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NANORAY312Member_7d7b910a-6d93-49a5-9244-c051d933b1bc" xlink:href="nbx-20250630.xsd#nbx_NANORAY312Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_ClinicalStudiesDomain_e67dd2a7-a3a5-45ba-bc5a-76cf5775154d" xlink:to="loc_nbx_NANORAY312Member_7d7b910a-6d93-49a5-9244-c051d933b1bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_c1b1dd8f-acdf-426b-b09d-592142ef40d0" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_778c3ad4-6d42-4943-90b6-d67305cb6886" xlink:to="loc_nbx_CollaborationAgreementAxis_c1b1dd8f-acdf-426b-b09d-592142ef40d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_c1b1dd8f-acdf-426b-b09d-592142ef40d0_default" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_c1b1dd8f-acdf-426b-b09d-592142ef40d0" xlink:to="loc_nbx_CollaborationAgreementDomain_c1b1dd8f-acdf-426b-b09d-592142ef40d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_c4f41ad2-ce36-4566-b510-addb9e2e5627" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_c1b1dd8f-acdf-426b-b09d-592142ef40d0" xlink:to="loc_nbx_CollaborationAgreementDomain_c4f41ad2-ce36-4566-b510-addb9e2e5627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_e1d148f9-94cd-4841-a7fe-dd1a28efa57d" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_c4f41ad2-ce36-4566-b510-addb9e2e5627" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_e1d148f9-94cd-4841-a7fe-dd1a28efa57d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_72d4c544-65b6-459f-a7d1-266745474d76" xlink:href="nbx-20250630.xsd#nbx_LianBioNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_c4f41ad2-ce36-4566-b510-addb9e2e5627" xlink:to="loc_nbx_LianBioNBTXR3Member_72d4c544-65b6-459f-a7d1-266745474d76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses_2f6dc6a8-132d-4f60-a09d-d0bc9235921b" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses_2f6dc6a8-132d-4f60-a09d-d0bc9235921b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_b51edf2d-b5ce-42d5-a694-453df3d11df8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_b51edf2d-b5ce-42d5-a694-453df3d11df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInOtherCurrentPayables_f1114ccf-5bda-4ccd-9895-e69382ef361c" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInOtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_IncreaseDecreaseInOtherCurrentPayables_f1114ccf-5bda-4ccd-9895-e69382ef361c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_0b95f86c-57cd-42c6-bff2-4c8091ba7381" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_0b95f86c-57cd-42c6-bff2-4c8091ba7381" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInBonusAccrual_3a3d0fb4-4462-43c6-aaa3-75a7382db511" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInBonusAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_IncreaseDecreaseInBonusAccrual_3a3d0fb4-4462-43c6-aaa3-75a7382db511" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_64eaa3b3-87fc-49df-9d5c-e583a47debed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_64eaa3b3-87fc-49df-9d5c-e583a47debed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_37df0152-502c-48c1-80ed-b630050199b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_ifrs-full_CurrentContractLiabilities_37df0152-502c-48c1-80ed-b630050199b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseRefundLiabilities_e573da23-4e3d-4760-a359-2824f9c0eb2b" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseRefundLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_IncreaseDecreaseRefundLiabilities_e573da23-4e3d-4760-a359-2824f9c0eb2b" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d8c8752e-6bbc-4c42-bb5d-569e598550fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d8c8752e-6bbc-4c42-bb5d-569e598550fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_d8c8752e-6bbc-4c42-bb5d-569e598550fe_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d8c8752e-6bbc-4c42-bb5d-569e598550fe" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_d8c8752e-6bbc-4c42-bb5d-569e598550fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_cc5c7a6f-95f6-453f-b1f9-346284e0f0f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d8c8752e-6bbc-4c42-bb5d-569e598550fe" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_cc5c7a6f-95f6-453f-b1f9-346284e0f0f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialAssetsMember_2e28ad90-b377-46bb-8cd7-d58cbb02a6a1" xlink:href="nbx-20250630.xsd#nbx_NonCurrentFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_cc5c7a6f-95f6-453f-b1f9-346284e0f0f9" xlink:to="loc_nbx_NonCurrentFinancialAssetsMember_2e28ad90-b377-46bb-8cd7-d58cbb02a6a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_b1cf1e96-6fd3-4d63-905c-3ea3f852a22f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_cc5c7a6f-95f6-453f-b1f9-346284e0f0f9" xlink:to="loc_ifrs-full_TradeReceivablesMember_b1cf1e96-6fd3-4d63-905c-3ea3f852a22f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashAndCashEquivalents1Member_7f6a0602-b16e-4448-9682-951edb191ab0" xlink:href="nbx-20250630.xsd#nbx_CashAndCashEquivalents1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_cc5c7a6f-95f6-453f-b1f9-346284e0f0f9" xlink:to="loc_nbx_CashAndCashEquivalents1Member_7f6a0602-b16e-4448-9682-951edb191ab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2350c267-c837-4cbb-9f93-2020ff736c54" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2350c267-c837-4cbb-9f93-2020ff736c54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_2350c267-c837-4cbb-9f93-2020ff736c54_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2350c267-c837-4cbb-9f93-2020ff736c54" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_2350c267-c837-4cbb-9f93-2020ff736c54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_6fc68430-cc51-4a3e-bc33-d3ad0f34bfc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2350c267-c837-4cbb-9f93-2020ff736c54" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_6fc68430-cc51-4a3e-bc33-d3ad0f34bfc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_53c9fd2a-19d5-4f58-9398-990bca517b09" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_6fc68430-cc51-4a3e-bc33-d3ad0f34bfc4" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_53c9fd2a-19d5-4f58-9398-990bca517b09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_aec312cf-b319-4921-bc33-071174ea5f4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_6fc68430-cc51-4a3e-bc33-d3ad0f34bfc4" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_aec312cf-b319-4921-bc33-071174ea5f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_b6df44d7-40d6-46d4-9d8c-ebe8316864a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_b6df44d7-40d6-46d4-9d8c-ebe8316864a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b6df44d7-40d6-46d4-9d8c-ebe8316864a3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_b6df44d7-40d6-46d4-9d8c-ebe8316864a3" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_b6df44d7-40d6-46d4-9d8c-ebe8316864a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_32432126-c487-4d59-a059-3767990a82c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_b6df44d7-40d6-46d4-9d8c-ebe8316864a3" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_32432126-c487-4d59-a059-3767990a82c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialLiabilitiesMember_bdee3cce-2aea-4ae7-aacb-c5a51e6d3007" xlink:href="nbx-20250630.xsd#nbx_NonCurrentFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_32432126-c487-4d59-a059-3767990a82c6" xlink:to="loc_nbx_NonCurrentFinancialLiabilitiesMember_bdee3cce-2aea-4ae7-aacb-c5a51e6d3007" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentFinancialLiabilitiesMember_b9dd00c0-d562-4da1-9eef-109c1a3806f8" xlink:href="nbx-20250630.xsd#nbx_CurrentFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_32432126-c487-4d59-a059-3767990a82c6" xlink:to="loc_nbx_CurrentFinancialLiabilitiesMember_b9dd00c0-d562-4da1-9eef-109c1a3806f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TradeAndOtherPayablesMember_60008c25-b4d9-4d2a-bda5-b1b22630b8a3" xlink:href="nbx-20250630.xsd#nbx_TradeAndOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_32432126-c487-4d59-a059-3767990a82c6" xlink:to="loc_nbx_TradeAndOtherPayablesMember_60008c25-b4d9-4d2a-bda5-b1b22630b8a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6ecfbbf4-f52d-4e09-b96b-a3abb04a210f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6ecfbbf4-f52d-4e09-b96b-a3abb04a210f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_6ecfbbf4-f52d-4e09-b96b-a3abb04a210f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6ecfbbf4-f52d-4e09-b96b-a3abb04a210f" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_6ecfbbf4-f52d-4e09-b96b-a3abb04a210f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_e647049c-1580-41b6-89a4-e5372bdec247" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6ecfbbf4-f52d-4e09-b96b-a3abb04a210f" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_e647049c-1580-41b6-89a4-e5372bdec247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_a9148180-3f00-4576-b3ab-940ba22a5959" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_e647049c-1580-41b6-89a4-e5372bdec247" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_a9148180-3f00-4576-b3ab-940ba22a5959" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_e4e0bc59-6829-4f8d-918e-f4f44c5a02e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_e647049c-1580-41b6-89a4-e5372bdec247" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_e4e0bc59-6829-4f8d-918e-f4f44c5a02e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_36dd28b0-59bc-45ae-b3df-16a237a3b745" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:to="loc_ifrs-full_FinancialAssets_36dd28b0-59bc-45ae-b3df-16a237a3b745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_a5110cee-6e3e-45c7-8785-fd8793c77a1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_a5110cee-6e3e-45c7-8785-fd8793c77a1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_331ab0a8-21e3-4f35-a61f-fcde39310dfa" xlink:href="nbx-20250630.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:to="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_331ab0a8-21e3-4f35-a61f-fcde39310dfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_2a7cf041-fc16-4834-b809-b6b8efe1f283" xlink:href="nbx-20250630.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:to="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_2a7cf041-fc16-4834-b809-b6b8efe1f283" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RevenueandotherincomeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_2f84ef0a-e870-4980-84c2-c66fa95ffe8e" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:to="loc_nbx_CollaborationAgreementAxis_2f84ef0a-e870-4980-84c2-c66fa95ffe8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_2f84ef0a-e870-4980-84c2-c66fa95ffe8e_default" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_2f84ef0a-e870-4980-84c2-c66fa95ffe8e" xlink:to="loc_nbx_CollaborationAgreementDomain_2f84ef0a-e870-4980-84c2-c66fa95ffe8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_86948590-1bbe-4b4c-ae19-4281f1827902" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_2f84ef0a-e870-4980-84c2-c66fa95ffe8e" xlink:to="loc_nbx_CollaborationAgreementDomain_86948590-1bbe-4b4c-ae19-4281f1827902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NANORAY312Member_7274ec66-4e6d-45e3-b960-4cdf17889f44" xlink:href="nbx-20250630.xsd#nbx_NANORAY312Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_86948590-1bbe-4b4c-ae19-4281f1827902" xlink:to="loc_nbx_NANORAY312Member_7274ec66-4e6d-45e3-b960-4cdf17889f44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaBVMember_e9d7b50d-5ea9-4aff-abb0-1f75bc9f3139" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_86948590-1bbe-4b4c-ae19-4281f1827902" xlink:to="loc_nbx_JanssenPharmaceuticaBVMember_e9d7b50d-5ea9-4aff-abb0-1f75bc9f3139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_92028767-d599-4dc6-bd15-9e5cb8e5cb8c" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_86948590-1bbe-4b4c-ae19-4281f1827902" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_92028767-d599-4dc6-bd15-9e5cb8e5cb8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_963b0bbe-e81a-4e9e-859b-b3040626cc2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_963b0bbe-e81a-4e9e-859b-b3040626cc2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_963b0bbe-e81a-4e9e-859b-b3040626cc2b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_963b0bbe-e81a-4e9e-859b-b3040626cc2b" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_963b0bbe-e81a-4e9e-859b-b3040626cc2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_963b0bbe-e81a-4e9e-859b-b3040626cc2b" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherSalesMember_4a1ed167-3bdb-4c9a-9d93-b2c7da8a2d16" xlink:href="nbx-20250630.xsd#nbx_OtherSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_OtherSalesMember_4a1ed167-3bdb-4c9a-9d93-b2c7da8a2d16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServicesMember_e38995e8-cbca-45c0-a308-0dca4ecca2e4" xlink:href="nbx-20250630.xsd#nbx_ServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_ServicesMember_e38995e8-cbca-45c0-a308-0dca4ecca2e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TechnologyTransferMember_e6dbc4e2-0539-4054-9c6c-d64aae62d1bc" xlink:href="nbx-20250630.xsd#nbx_TechnologyTransferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_TechnologyTransferMember_e6dbc4e2-0539-4054-9c6c-d64aae62d1bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServiceRechargeMember_4c6da207-750f-4b5f-9e11-029307f6078a" xlink:href="nbx-20250630.xsd#nbx_ServiceRechargeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_ServiceRechargeMember_4c6da207-750f-4b5f-9e11-029307f6078a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SupplyServicesMember_9c7f67ef-ede0-47fc-9b5d-e3800686dcda" xlink:href="nbx-20250630.xsd#nbx_SupplyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_SupplyServicesMember_9c7f67ef-ede0-47fc-9b5d-e3800686dcda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RechargeMember_7fe4c4a7-e3e5-4ae0-953c-3eca15e2735c" xlink:href="nbx-20250630.xsd#nbx_RechargeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_RechargeMember_7fe4c4a7-e3e5-4ae0-953c-3eca15e2735c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_9bdd9304-b7b2-4a46-89d9-a3b6207279d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_9bdd9304-b7b2-4a46-89d9-a3b6207279d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_9bdd9304-b7b2-4a46-89d9-a3b6207279d0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_9bdd9304-b7b2-4a46-89d9-a3b6207279d0" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_9bdd9304-b7b2-4a46-89d9-a3b6207279d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_e7ef209d-ef84-4803-b4fd-7d0102909ea9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_9bdd9304-b7b2-4a46-89d9-a3b6207279d0" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_e7ef209d-ef84-4803-b4fd-7d0102909ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_07bafa12-a4db-466e-8558-ce4772bd9ef7" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e7ef209d-ef84-4803-b4fd-7d0102909ea9" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_07bafa12-a4db-466e-8558-ce4772bd9ef7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_947fb1de-9c8c-4f3d-879b-55d777826569" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_947fb1de-9c8c-4f3d-879b-55d777826569" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_f4fa8058-dd13-4d1b-88db-4cec3187c2db" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_f4fa8058-dd13-4d1b-88db-4cec3187c2db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_4ab86aa0-4ba8-472b-9ff1-aa1ea900d388" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_4ab86aa0-4ba8-472b-9ff1-aa1ea900d388" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_e9ce37ec-fc84-4c5b-9310-5bf8fed3303f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_e9ce37ec-fc84-4c5b-9310-5bf8fed3303f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsToRevenueFromContractsWithCustomers_0fec01de-7395-41fa-bdbc-2c83886e839b" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsToRevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_nbx_AdjustmentsToRevenueFromContractsWithCustomers_0fec01de-7395-41fa-bdbc-2c83886e839b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentTaxCredit_20d1e902-9024-46f2-a32a-4b734a5021ce" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_nbx_ResearchAndDevelopmentTaxCredit_20d1e902-9024-46f2-a32a-4b734a5021ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_b6706f4d-f383-4d2c-b811-32cc2d8b8deb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_b6706f4d-f383-4d2c-b811-32cc2d8b8deb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_dc9f0496-4c91-4139-af18-e73bca5287a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_dc9f0496-4c91-4139-af18-e73bca5287a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_d7493b40-ca81-4815-830b-a3bd742a7708" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_OtherRevenue_d7493b40-ca81-4815-830b-a3bd742a7708" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_410a161b-c161-47a2-b28a-b3e51be44085" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_410a161b-c161-47a2-b28a-b3e51be44085" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_8bcd41fe-9a9b-4b03-8675-cf1f5ab518f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_410a161b-c161-47a2-b28a-b3e51be44085" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_8bcd41fe-9a9b-4b03-8675-cf1f5ab518f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_8bcd41fe-9a9b-4b03-8675-cf1f5ab518f1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_8bcd41fe-9a9b-4b03-8675-cf1f5ab518f1" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_8bcd41fe-9a9b-4b03-8675-cf1f5ab518f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_c542bc6e-8bbf-40ea-9d2c-2040b2e76bd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_8bcd41fe-9a9b-4b03-8675-cf1f5ab518f1" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_c542bc6e-8bbf-40ea-9d2c-2040b2e76bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServicesMember_d40ecbe1-fa51-4c21-9e55-2ef9c4afa3e8" xlink:href="nbx-20250630.xsd#nbx_ServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_c542bc6e-8bbf-40ea-9d2c-2040b2e76bd7" xlink:to="loc_nbx_ServicesMember_d40ecbe1-fa51-4c21-9e55-2ef9c4afa3e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherSalesMember_d1273c5e-61fe-4039-b2b5-5e13807905a8" xlink:href="nbx-20250630.xsd#nbx_OtherSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_c542bc6e-8bbf-40ea-9d2c-2040b2e76bd7" xlink:to="loc_nbx_OtherSalesMember_d1273c5e-61fe-4039-b2b5-5e13807905a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_053b506a-24fd-4be4-8be9-c0ac9be23487" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_053b506a-24fd-4be4-8be9-c0ac9be23487" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentTaxCredit_6154662c-018c-4a0f-a848-24bbf613aff4" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_nbx_ResearchAndDevelopmentTaxCredit_6154662c-018c-4a0f-a848-24bbf613aff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_91283083-826e-4f05-802e-19cccfa73209" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_91283083-826e-4f05-802e-19cccfa73209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_82dfc2aa-9156-4c62-b3b9-6c06851d1be2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_82dfc2aa-9156-4c62-b3b9-6c06851d1be2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_800d6f75-818a-4964-b3ef-6cc2766f803c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_OtherIncome_800d6f75-818a-4964-b3ef-6cc2766f803c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_373b65dc-d7be-4509-bc71-a605f5cc24b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_Revenue_373b65dc-d7be-4509-bc71-a605f5cc24b3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/OperatingexpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_f53dd0b5-f1eb-489e-873d-69e271136c91" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_f53dd0b5-f1eb-489e-873d-69e271136c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_f53dd0b5-f1eb-489e-873d-69e271136c91_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_f53dd0b5-f1eb-489e-873d-69e271136c91" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_f53dd0b5-f1eb-489e-873d-69e271136c91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_4920217a-e39a-405f-9bdd-b5ce56f74842" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_f53dd0b5-f1eb-489e-873d-69e271136c91" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_4920217a-e39a-405f-9bdd-b5ce56f74842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentArrangement1Member_c7471ac4-091e-44d8-b53c-60f79e0ff700" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentArrangement1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_4920217a-e39a-405f-9bdd-b5ce56f74842" xlink:to="loc_nbx_ResearchAndDevelopmentArrangement1Member_c7471ac4-091e-44d8-b53c-60f79e0ff700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_229bb464-569a-4528-ad2b-fd842c18374c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_4920217a-e39a-405f-9bdd-b5ce56f74842" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_229bb464-569a-4528-ad2b-fd842c18374c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonRecurringExpenseTypeAxis_6d3159dc-6665-4ed4-86bb-2327fa5dfd1b" xlink:href="nbx-20250630.xsd#nbx_NonRecurringExpenseTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:to="loc_nbx_NonRecurringExpenseTypeAxis_6d3159dc-6665-4ed4-86bb-2327fa5dfd1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonRecurringExpenseTypeDomain_6d3159dc-6665-4ed4-86bb-2327fa5dfd1b_default" xlink:href="nbx-20250630.xsd#nbx_NonRecurringExpenseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_NonRecurringExpenseTypeAxis_6d3159dc-6665-4ed4-86bb-2327fa5dfd1b" xlink:to="loc_nbx_NonRecurringExpenseTypeDomain_6d3159dc-6665-4ed4-86bb-2327fa5dfd1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonRecurringExpenseTypeDomain_989e5077-ba69-42b3-ba3b-a701a09b17d0" xlink:href="nbx-20250630.xsd#nbx_NonRecurringExpenseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_NonRecurringExpenseTypeAxis_6d3159dc-6665-4ed4-86bb-2327fa5dfd1b" xlink:to="loc_nbx_NonRecurringExpenseTypeDomain_989e5077-ba69-42b3-ba3b-a701a09b17d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EmploymentTerminationIndemnitiesMember_6dfc36fd-6d27-4431-9c63-9c717413b842" xlink:href="nbx-20250630.xsd#nbx_EmploymentTerminationIndemnitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_NonRecurringExpenseTypeDomain_989e5077-ba69-42b3-ba3b-a701a09b17d0" xlink:to="loc_nbx_EmploymentTerminationIndemnitiesMember_6dfc36fd-6d27-4431-9c63-9c717413b842" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OperatingExpenseAxis_5857f7b9-973b-467d-8ea0-3412129fbd8a" xlink:href="nbx-20250630.xsd#nbx_OperatingExpenseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:to="loc_nbx_OperatingExpenseAxis_5857f7b9-973b-467d-8ea0-3412129fbd8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OperatingExpenseDomain_5857f7b9-973b-467d-8ea0-3412129fbd8a_default" xlink:href="nbx-20250630.xsd#nbx_OperatingExpenseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_OperatingExpenseAxis_5857f7b9-973b-467d-8ea0-3412129fbd8a" xlink:to="loc_nbx_OperatingExpenseDomain_5857f7b9-973b-467d-8ea0-3412129fbd8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OperatingExpenseDomain_60da605d-f541-4eb5-8b26-3c9191ce34f9" xlink:href="nbx-20250630.xsd#nbx_OperatingExpenseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_OperatingExpenseAxis_5857f7b9-973b-467d-8ea0-3412129fbd8a" xlink:to="loc_nbx_OperatingExpenseDomain_60da605d-f541-4eb5-8b26-3c9191ce34f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentMember_fae8f311-c0d2-4f9b-94ca-a25872720399" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OperatingExpenseDomain_60da605d-f541-4eb5-8b26-3c9191ce34f9" xlink:to="loc_nbx_ResearchAndDevelopmentMember_fae8f311-c0d2-4f9b-94ca-a25872720399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_693ae29d-1437-445e-a246-0dc56cd4f4cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OperatingExpenseDomain_60da605d-f541-4eb5-8b26-3c9191ce34f9" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_693ae29d-1437-445e-a246-0dc56cd4f4cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_a0913718-0d2b-4f8b-aea6-d71989dcd51f" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_a0913718-0d2b-4f8b-aea6-d71989dcd51f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreasePayrollExpense_34ddc5f9-ad87-4deb-b60b-a23d1daec977" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreasePayrollExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreasePayrollExpense_34ddc5f9-ad87-4deb-b60b-a23d1daec977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreasePayrollExpensePercentage_e1860815-a8c2-444d-90fa-a57fd89e226c" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreasePayrollExpensePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreasePayrollExpensePercentage_e1860815-a8c2-444d-90fa-a57fd89e226c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_StockOptionsGranted_7afcb9f9-455e-4143-b21c-fb398180aa79" xlink:href="nbx-20250630.xsd#nbx_StockOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_StockOptionsGranted_7afcb9f9-455e-4143-b21c-fb398180aa79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_2f31e575-36b2-4520-b6c3-ae882b947ea9" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_2f31e575-36b2-4520-b6c3-ae882b947ea9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_97ce6613-9c44-4ae9-8a92-72b358d47b9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_97ce6613-9c44-4ae9-8a92-72b358d47b9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SeveranceExpenses_baaf526a-593a-4662-9779-a4db48fbf4d8" xlink:href="nbx-20250630.xsd#nbx_SeveranceExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_SeveranceExpenses_baaf526a-593a-4662-9779-a4db48fbf4d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInDepreciationExpense_75b0c732-3a5f-498a-9102-579cb0e4ee77" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInDepreciationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInDepreciationExpense_75b0c732-3a5f-498a-9102-579cb0e4ee77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PaymentOfAdvisoryFees_eff24f11-3813-4d69-96de-b4572a7e6ef5" xlink:href="nbx-20250630.xsd#nbx_PaymentOfAdvisoryFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_PaymentOfAdvisoryFees_eff24f11-3813-4d69-96de-b4572a7e6ef5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInSocialTax_c75957c4-af96-403f-a769-4d413518c759" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInSocialTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInSocialTax_c75957c4-af96-403f-a769-4d413518c759" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_0d58fce3-69cd-4d27-ab8a-1288488856d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_ifrs-full_NumberOfEmployees_0d58fce3-69cd-4d27-ab8a-1288488856d0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage_b3996f94-2b05-430c-9986-70d5bdd07a86" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage_b3996f94-2b05-430c-9986-70d5bdd07a86" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_a629f3c4-4d2c-440f-9932-7d12a629a2a4" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_a629f3c4-4d2c-440f-9932-7d12a629a2a4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_446a7284-4630-4158-aa14-27c29d2af1f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_446a7284-4630-4158-aa14-27c29d2af1f7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherNonrecurringExpenses_1ecff216-7fef-421c-af16-79909384e2a0" xlink:href="nbx-20250630.xsd#nbx_OtherNonrecurringExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_OtherNonrecurringExpenses_1ecff216-7fef-421c-af16-79909384e2a0" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_8bc1dc24-d1e9-4f53-8fec-79109a461042" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_8bc1dc24-d1e9-4f53-8fec-79109a461042" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_c6392b86-23ad-4274-aba7-75546d1ddafd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_8bc1dc24-d1e9-4f53-8fec-79109a461042" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_c6392b86-23ad-4274-aba7-75546d1ddafd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_c6392b86-23ad-4274-aba7-75546d1ddafd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_c6392b86-23ad-4274-aba7-75546d1ddafd" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_c6392b86-23ad-4274-aba7-75546d1ddafd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_d85216d4-4ee7-4f1d-bac3-6af359396d36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_c6392b86-23ad-4274-aba7-75546d1ddafd" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_d85216d4-4ee7-4f1d-bac3-6af359396d36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentArrangement1Member_67f724ef-ca30-4952-8505-75e1e44e13be" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentArrangement1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_d85216d4-4ee7-4f1d-bac3-6af359396d36" xlink:to="loc_nbx_ResearchAndDevelopmentArrangement1Member_67f724ef-ca30-4952-8505-75e1e44e13be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_dfadad63-b7fb-48a3-b540-c33cc4260154" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_d85216d4-4ee7-4f1d-bac3-6af359396d36" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_dfadad63-b7fb-48a3-b540-c33cc4260154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_d6f8fa78-d592-47e8-ae4d-3cf610abda92" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_ifrs-full_AmortisationExpense_d6f8fa78-d592-47e8-ae4d-3cf610abda92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationExpense_f00f164b-957f-45bc-9cd5-7a6795b6a5b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_ifrs-full_DepreciationExpense_f00f164b-957f-45bc-9cd5-7a6795b6a5b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LitigationExpense_49a8bd21-63d3-42d0-8eef-a2bc4a376a74" xlink:href="nbx-20250630.xsd#nbx_LitigationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_nbx_LitigationExpense_49a8bd21-63d3-42d0-8eef-a2bc4a376a74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_1906ab0c-1af1-4276-9a03-b4b033a1e867" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_1906ab0c-1af1-4276-9a03-b4b033a1e867" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_dd063edd-c437-4056-9195-d66c09caf0a8" xlink:href="nbx-20250630.xsd#nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_dd063edd-c437-4056-9195-d66c09caf0a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionForRetirementBenefitObligationsNet_cffc75e6-760c-4d6e-872b-746de0436f44" xlink:href="nbx-20250630.xsd#nbx_ProvisionForRetirementBenefitObligationsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_nbx_ProvisionForRetirementBenefitObligationsNet_cffc75e6-760c-4d6e-872b-746de0436f44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpenses_67132871-a856-472e-af14-789e55f70acc" xlink:href="nbx-20250630.xsd#nbx_DepreciationAmortizationAndProvisionExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_nbx_DepreciationAmortizationAndProvisionExpenses_67132871-a856-472e-af14-789e55f70acc" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_264999c5-b731-45ae-a094-09761fa8c497" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_264999c5-b731-45ae-a094-09761fa8c497" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5572447b-8657-4d64-b9a7-0cbe6d5a8d91" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_264999c5-b731-45ae-a094-09761fa8c497" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5572447b-8657-4d64-b9a7-0cbe6d5a8d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5572447b-8657-4d64-b9a7-0cbe6d5a8d91_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5572447b-8657-4d64-b9a7-0cbe6d5a8d91" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5572447b-8657-4d64-b9a7-0cbe6d5a8d91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5572447b-8657-4d64-b9a7-0cbe6d5a8d91" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member_3ab148f9-2fb4-4440-9261-29a2fdd2b916" xlink:href="nbx-20250630.xsd#nbx_BSPCE20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE20151Member_3ab148f9-2fb4-4440-9261-29a2fdd2b916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member_578eb762-a2fc-4d68-82a3-6658e7744c68" xlink:href="nbx-20250630.xsd#nbx_BSPCE20153Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE20153Member_578eb762-a2fc-4d68-82a3-6658e7744c68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016OrdinaryMember_ce13e2a7-5126-4478-b661-f509eab7b3c0" xlink:href="nbx-20250630.xsd#nbx_BSPCE2016OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE2016OrdinaryMember_ce13e2a7-5126-4478-b661-f509eab7b3c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016PerformanceMember_e410757e-be52-4bad-8782-bde1842893b0" xlink:href="nbx-20250630.xsd#nbx_BSPCE2016PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE2016PerformanceMember_e410757e-be52-4bad-8782-bde1842893b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017OrdinaryMember_07dea362-7b35-454c-adfa-62ca2d4a8b05" xlink:href="nbx-20250630.xsd#nbx_BSPCE2017OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE2017OrdinaryMember_07dea362-7b35-454c-adfa-62ca2d4a8b05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017Member_734dabf3-72a0-434a-a972-18fb828fa83c" xlink:href="nbx-20250630.xsd#nbx_BSPCE2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE2017Member_734dabf3-72a0-434a-a972-18fb828fa83c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_81440269-1331-4771-ad72-dfbe678bd57b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_264999c5-b731-45ae-a094-09761fa8c497" xlink:to="loc_srt_TitleOfIndividualAxis_81440269-1331-4771-ad72-dfbe678bd57b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81440269-1331-4771-ad72-dfbe678bd57b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_81440269-1331-4771-ad72-dfbe678bd57b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81440269-1331-4771-ad72-dfbe678bd57b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62c5b622-d500-48e3-a274-7b0f210ada37" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_81440269-1331-4771-ad72-dfbe678bd57b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62c5b622-d500-48e3-a274-7b0f210ada37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CorporateOfficersMember_583db93c-3fed-41d1-b60a-fcfb9304183a" xlink:href="nbx-20250630.xsd#nbx_CorporateOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62c5b622-d500-48e3-a274-7b0f210ada37" xlink:to="loc_nbx_CorporateOfficersMember_583db93c-3fed-41d1-b60a-fcfb9304183a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LaurentLevyMember_57c46f12-226f-4ea2-a412-25345b93e08b" xlink:href="nbx-20250630.xsd#nbx_LaurentLevyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62c5b622-d500-48e3-a274-7b0f210ada37" xlink:to="loc_nbx_LaurentLevyMember_57c46f12-226f-4ea2-a412-25345b93e08b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_e6583fa8-b04b-4dcb-8941-85103a5d029a" xlink:href="nbx-20250630.xsd#nbx_BeneficiariesOtherThanCorporateOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62c5b622-d500-48e3-a274-7b0f210ada37" xlink:to="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_e6583fa8-b04b-4dcb-8941-85103a5d029a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_663f53ff-445f-4b97-b371-4a1424c5803c" xlink:href="nbx-20250630.xsd#nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_663f53ff-445f-4b97-b371-4a1424c5803c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_ba43124d-04b4-4529-8395-86ce9bc2bb6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_ba43124d-04b4-4529-8395-86ce9bc2bb6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_38520d36-e5ad-41f8-8cee-6682c21f3f25" xlink:href="nbx-20250630.xsd#nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_38520d36-e5ad-41f8-8cee-6682c21f3f25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_1eb35767-8bcf-4a14-bdf6-9fe60f51eabf" xlink:href="nbx-20250630.xsd#nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_1eb35767-8bcf-4a14-bdf6-9fe60f51eabf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_38c3bf62-b544-461a-a425-c4ee21d2b194" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_38c3bf62-b544-461a-a425-c4ee21d2b194" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e652a888-15b4-4730-9799-1f6f39495b8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e652a888-15b4-4730-9799-1f6f39495b8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_c5d052ae-bd99-43c9-996d-96f2e8aff427" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_c5d052ae-bd99-43c9-996d-96f2e8aff427" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_f4e125c5-b8f7-4861-9f70-1877ef0e5020" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_f4e125c5-b8f7-4861-9f70-1877ef0e5020" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_895323ce-2d80-4d39-a088-182514ee3ea9" xlink:href="nbx-20250630.xsd#nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_895323ce-2d80-4d39-a088-182514ee3ea9" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8eae201d-d33a-482f-88b5-49a7e52bca37" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8eae201d-d33a-482f-88b5-49a7e52bca37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_8eae201d-d33a-482f-88b5-49a7e52bca37_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8eae201d-d33a-482f-88b5-49a7e52bca37" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_8eae201d-d33a-482f-88b5-49a7e52bca37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8eae201d-d33a-482f-88b5-49a7e52bca37" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member_eafb48da-81c1-4ef9-9641-ec2d566f9e0f" xlink:href="nbx-20250630.xsd#nbx_BSA20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA20151Member_eafb48da-81c1-4ef9-9641-ec2d566f9e0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152Member_d1ca5063-94c0-4ffe-a80a-6075a387e6d3" xlink:href="nbx-20250630.xsd#nbx_BSA20152Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA20152Member_d1ca5063-94c0-4ffe-a80a-6075a387e6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member_fa432df1-0b68-494d-b6ac-10e1fdab8c15" xlink:href="nbx-20250630.xsd#nbx_BSA20182Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA20182Member_fa432df1-0b68-494d-b6ac-10e1fdab8c15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member_a96d5e68-6d7e-479e-8fd2-a2860bbfc925" xlink:href="nbx-20250630.xsd#nbx_BSA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA20191Member_a96d5e68-6d7e-479e-8fd2-a2860bbfc925" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_c5087f49-23cc-4bc1-87bf-8c82da66a676" xlink:href="nbx-20250630.xsd#nbx_BSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA2020Member_c5087f49-23cc-4bc1-87bf-8c82da66a676" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021Member_ae8cf595-68e8-4ecf-b0a8-e431098ddb44" xlink:href="nbx-20250630.xsd#nbx_BSA2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA2021Member_ae8cf595-68e8-4ecf-b0a8-e431098ddb44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cd68b595-90f4-4cd7-a088-0464064a1a2f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:to="loc_srt_TitleOfIndividualAxis_cd68b595-90f4-4cd7-a088-0464064a1a2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cd68b595-90f4-4cd7-a088-0464064a1a2f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_cd68b595-90f4-4cd7-a088-0464064a1a2f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cd68b595-90f4-4cd7-a088-0464064a1a2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1514d77e-8fa8-4df2-b358-25d130a856c1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_cd68b595-90f4-4cd7-a088-0464064a1a2f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1514d77e-8fa8-4df2-b358-25d130a856c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CorporateOfficersMember_f336a7ec-455c-4f2f-9465-e1b250298cd1" xlink:href="nbx-20250630.xsd#nbx_CorporateOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1514d77e-8fa8-4df2-b358-25d130a856c1" xlink:to="loc_nbx_CorporateOfficersMember_f336a7ec-455c-4f2f-9465-e1b250298cd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_dd3fe8c9-2f08-4660-98dc-b92e8063577b" xlink:href="nbx-20250630.xsd#nbx_BeneficiariesOtherThanCorporateOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1514d77e-8fa8-4df2-b358-25d130a856c1" xlink:to="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_dd3fe8c9-2f08-4660-98dc-b92e8063577b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameAxis_7e5ed7f3-3efa-4d19-83ed-52f68101cd2b" xlink:href="nbx-20250630.xsd#nbx_OfficersNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:to="loc_nbx_OfficersNameAxis_7e5ed7f3-3efa-4d19-83ed-52f68101cd2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameDomain_7e5ed7f3-3efa-4d19-83ed-52f68101cd2b_default" xlink:href="nbx-20250630.xsd#nbx_OfficersNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_OfficersNameAxis_7e5ed7f3-3efa-4d19-83ed-52f68101cd2b" xlink:to="loc_nbx_OfficersNameDomain_7e5ed7f3-3efa-4d19-83ed-52f68101cd2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameDomain_34c90580-7d5e-4946-b6bc-b21ea7938336" xlink:href="nbx-20250630.xsd#nbx_OfficersNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_OfficersNameAxis_7e5ed7f3-3efa-4d19-83ed-52f68101cd2b" xlink:to="loc_nbx_OfficersNameDomain_34c90580-7d5e-4946-b6bc-b21ea7938336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneMarieGraffinMember_510aa9eb-a4d1-44f7-9ddb-05db8cdfeb3b" xlink:href="nbx-20250630.xsd#nbx_AnneMarieGraffinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OfficersNameDomain_34c90580-7d5e-4946-b6bc-b21ea7938336" xlink:to="loc_nbx_AnneMarieGraffinMember_510aa9eb-a4d1-44f7-9ddb-05db8cdfeb3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EnnoSpillnerMember_b17e285b-e389-4034-88db-3948150e1bf5" xlink:href="nbx-20250630.xsd#nbx_EnnoSpillnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OfficersNameDomain_34c90580-7d5e-4946-b6bc-b21ea7938336" xlink:to="loc_nbx_EnnoSpillnerMember_b17e285b-e389-4034-88db-3948150e1bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AlainHerreraMember_d72d4eb3-1fff-40b6-93f1-b6761345f1cd" xlink:href="nbx-20250630.xsd#nbx_AlainHerreraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OfficersNameDomain_34c90580-7d5e-4946-b6bc-b21ea7938336" xlink:to="loc_nbx_AlainHerreraMember_d72d4eb3-1fff-40b6-93f1-b6761345f1cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_75178057-2be1-4f16-ae28-441ae7518e1a" xlink:href="nbx-20250630.xsd#nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_75178057-2be1-4f16-ae28-441ae7518e1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_f8a308dc-a48d-4794-9e8b-5325a773ce38" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_f8a308dc-a48d-4794-9e8b-5325a773ce38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_bd1d1ddc-f7e1-4f2b-80ee-b374bd49d210" xlink:href="nbx-20250630.xsd#nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_bd1d1ddc-f7e1-4f2b-80ee-b374bd49d210" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_c04073bc-a8f4-4eb9-9470-9f33d20e5360" xlink:href="nbx-20250630.xsd#nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_c04073bc-a8f4-4eb9-9470-9f33d20e5360" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_30d9e11d-477f-4cbd-a5eb-87bf917c9ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_30d9e11d-477f-4cbd-a5eb-87bf917c9ac2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_4f1ba96e-cb32-4e66-9d0d-75ef1e3fcf8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_4f1ba96e-cb32-4e66-9d0d-75ef1e3fcf8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_74420c0b-fb38-45ca-ab9a-157716a211a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_74420c0b-fb38-45ca-ab9a-157716a211a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_3903e42f-eec5-463e-b755-af171f4e36ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_3903e42f-eec5-463e-b755-af171f4e36ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5d53c1e6-328e-4845-9242-2be343dc1d01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5d53c1e6-328e-4845-9242-2be343dc1d01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_9dcac511-2994-4533-8be6-d92e0c7c6083" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_9dcac511-2994-4533-8be6-d92e0c7c6083" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_ba672e4d-1ec7-4bf0-81ad-c28de8a6ba52" xlink:href="nbx-20250630.xsd#nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_ba672e4d-1ec7-4bf0-81ad-c28de8a6ba52" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofChangesinShareOptionsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_61fc30c5-4c34-43fc-b3bb-0a981c33d075" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_61fc30c5-4c34-43fc-b3bb-0a981c33d075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_61fc30c5-4c34-43fc-b3bb-0a981c33d075_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_61fc30c5-4c34-43fc-b3bb-0a981c33d075" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_61fc30c5-4c34-43fc-b3bb-0a981c33d075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_61fc30c5-4c34-43fc-b3bb-0a981c33d075" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161PerformanceMember_ecb21127-9cd6-46dd-9a4f-ef3cd9414627" xlink:href="nbx-20250630.xsd#nbx_OSA20161PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA20161PerformanceMember_ecb21127-9cd6-46dd-9a4f-ef3cd9414627" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member_95c6b358-d67f-463a-bd87-2d1b3a2dcf20" xlink:href="nbx-20250630.xsd#nbx_OSA20162Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA20162Member_95c6b358-d67f-463a-bd87-2d1b3a2dcf20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017OrdinaryMember_e1c99f4b-61d0-4975-8d88-40fa92f10460" xlink:href="nbx-20250630.xsd#nbx_OSA2017OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA2017OrdinaryMember_e1c99f4b-61d0-4975-8d88-40fa92f10460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member_6fe9afa7-ba54-435c-81ef-117b7d75e913" xlink:href="nbx-20250630.xsd#nbx_OSA2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA2018Member_6fe9afa7-ba54-435c-81ef-117b7d75e913" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member_6632642d-00af-47c1-8f96-6d0f6d6bcaef" xlink:href="nbx-20250630.xsd#nbx_OSA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA20191Member_6632642d-00af-47c1-8f96-6d0f6d6bcaef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSALLY2019Member_f047d27d-dc5d-473a-a68f-b362d2d303a7" xlink:href="nbx-20250630.xsd#nbx_OSALLY2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSALLY2019Member_f047d27d-dc5d-473a-a68f-b362d2d303a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_6d5d3448-0c78-432d-b923-1bd327b8364b" xlink:href="nbx-20250630.xsd#nbx_OSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA2020Member_6d5d3448-0c78-432d-b923-1bd327b8364b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember_0cf177f9-3151-4546-a907-15563d35164e" xlink:href="nbx-20250630.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202104OrdinaryMember_0cf177f9-3151-4546-a907-15563d35164e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104PerformanceMember_de469114-cee9-4cac-b987-3e29dfb2350b" xlink:href="nbx-20250630.xsd#nbx_OSA202104PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202104PerformanceMember_de469114-cee9-4cac-b987-3e29dfb2350b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106PerformanceMember_6f74af20-0991-4ee3-8307-3c361fd4330b" xlink:href="nbx-20250630.xsd#nbx_OSA202106PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202106PerformanceMember_6f74af20-0991-4ee3-8307-3c361fd4330b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember_a6a84cdf-c6f2-4b5f-8d91-3d64b21d2eeb" xlink:href="nbx-20250630.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202106OrdinaryMember_a6a84cdf-c6f2-4b5f-8d91-3d64b21d2eeb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202206PerformanceMember_707b68db-9fc1-4415-85eb-e3e9a0bd00c2" xlink:href="nbx-20250630.xsd#nbx_OSA202206PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202206PerformanceMember_707b68db-9fc1-4415-85eb-e3e9a0bd00c2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202206OrdinaryMember_96e4d012-33ca-4a46-9318-be16896d94c3" xlink:href="nbx-20250630.xsd#nbx_OSA202206OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202206OrdinaryMember_96e4d012-33ca-4a46-9318-be16896d94c3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202301OrdinaryMember_1e78dee7-f07f-4941-9e6e-b3150ed2d5d5" xlink:href="nbx-20250630.xsd#nbx_OSA202301OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202301OrdinaryMember_1e78dee7-f07f-4941-9e6e-b3150ed2d5d5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202401OrdinaryMember_d4c8e2f8-f5f5-4d4e-b443-c041a5d7dd10" xlink:href="nbx-20250630.xsd#nbx_OSA202401OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202401OrdinaryMember_d4c8e2f8-f5f5-4d4e-b443-c041a5d7dd10" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202501OrdinaryMember_f12a443f-a55a-4e4c-a01b-351fab046614" xlink:href="nbx-20250630.xsd#nbx_OSA202501OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202501OrdinaryMember_f12a443f-a55a-4e4c-a01b-351fab046614" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202502OrdinaryMember_0ed33591-84a8-478a-9d51-bee4c8f3621f" xlink:href="nbx-20250630.xsd#nbx_OSA202502OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202502OrdinaryMember_0ed33591-84a8-478a-9d51-bee4c8f3621f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a77cadc4-42ef-4975-a281-65de557ae881" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:to="loc_srt_TitleOfIndividualAxis_a77cadc4-42ef-4975-a281-65de557ae881" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a77cadc4-42ef-4975-a281-65de557ae881_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_a77cadc4-42ef-4975-a281-65de557ae881" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a77cadc4-42ef-4975-a281-65de557ae881_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_842ce310-47fb-4d8f-8c36-e915aa0aa353" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_a77cadc4-42ef-4975-a281-65de557ae881" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_842ce310-47fb-4d8f-8c36-e915aa0aa353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CorporateOfficersMember_7558fe85-13bd-4ac0-89b0-a0e1519b414d" xlink:href="nbx-20250630.xsd#nbx_CorporateOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_842ce310-47fb-4d8f-8c36-e915aa0aa353" xlink:to="loc_nbx_CorporateOfficersMember_7558fe85-13bd-4ac0-89b0-a0e1519b414d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_e0045696-33d0-4aab-9d1d-73226874e25a" xlink:href="nbx-20250630.xsd#nbx_BeneficiariesOtherThanCorporateOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_842ce310-47fb-4d8f-8c36-e915aa0aa353" xlink:to="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_e0045696-33d0-4aab-9d1d-73226874e25a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameAxis_ae85779c-59dc-43b6-be21-f79168fdcc54" xlink:href="nbx-20250630.xsd#nbx_OfficersNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:to="loc_nbx_OfficersNameAxis_ae85779c-59dc-43b6-be21-f79168fdcc54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameDomain_ae85779c-59dc-43b6-be21-f79168fdcc54_default" xlink:href="nbx-20250630.xsd#nbx_OfficersNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_OfficersNameAxis_ae85779c-59dc-43b6-be21-f79168fdcc54" xlink:to="loc_nbx_OfficersNameDomain_ae85779c-59dc-43b6-be21-f79168fdcc54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:href="nbx-20250630.xsd#nbx_OfficersNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_OfficersNameAxis_ae85779c-59dc-43b6-be21-f79168fdcc54" xlink:to="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LaurentLevyMember_767b006f-cf27-4d4a-a0d7-338f2c69eae5" xlink:href="nbx-20250630.xsd#nbx_LaurentLevyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:to="loc_nbx_LaurentLevyMember_767b006f-cf27-4d4a-a0d7-338f2c69eae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantMember_7a02cc47-d91b-4250-a49c-a81023f9962d" xlink:href="nbx-20250630.xsd#nbx_AnneJulietteHermantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:to="loc_nbx_AnneJulietteHermantMember_7a02cc47-d91b-4250-a49c-a81023f9962d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BartVanRhijnMember_18129f00-5054-4ac8-9ea1-6440fa68d13a" xlink:href="nbx-20250630.xsd#nbx_BartVanRhijnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:to="loc_nbx_BartVanRhijnMember_18129f00-5054-4ac8-9ea1-6440fa68d13a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LouisKayitalireMember_2fbbfa49-d299-4c42-8315-f10a71a0f449" xlink:href="nbx-20250630.xsd#nbx_LouisKayitalireMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:to="loc_nbx_LouisKayitalireMember_2fbbfa49-d299-4c42-8315-f10a71a0f449" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement_4545ec95-0df7-4de3-b6f6-6e5d545fa71a" xlink:href="nbx-20250630.xsd#nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement_4545ec95-0df7-4de3-b6f6-6e5d545fa71a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_3003869e-9a44-408e-a451-202663a0741d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_3003869e-9a44-408e-a451-202663a0741d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement_d1d98866-4e0b-499e-9daf-c5767e41f295" xlink:href="nbx-20250630.xsd#nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement_d1d98866-4e0b-499e-9daf-c5767e41f295" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement_a925e25a-3811-454a-a222-146235c4cc42" xlink:href="nbx-20250630.xsd#nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement_a925e25a-3811-454a-a222-146235c4cc42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_31dc140b-a41a-4907-aff9-77ed4ce2059f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_31dc140b-a41a-4907-aff9-77ed4ce2059f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_a767d3c5-78b4-4842-8ffc-b453a5188839" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_a767d3c5-78b4-4842-8ffc-b453a5188839" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_2d31aa62-0390-4ace-8b9c-82319d09871f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_2d31aa62-0390-4ace-8b9c-82319d09871f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_778137b8-24ef-471e-85ce-9fd5fde267cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_778137b8-24ef-471e-85ce-9fd5fde267cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_08a1a00c-c9e6-4d3b-b3db-be5593802223" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_08a1a00c-c9e6-4d3b-b3db-be5593802223" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement_50a0a76a-0fe5-4cb3-9d08-e842a479978a" xlink:href="nbx-20250630.xsd#nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement_50a0a76a-0fe5-4cb3-9d08-e842a479978a" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofFreeSharesOutstandingDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0ecf6b3f-79d8-4c02-88da-f996c14a479e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0ecf6b3f-79d8-4c02-88da-f996c14a479e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0ecf6b3f-79d8-4c02-88da-f996c14a479e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0ecf6b3f-79d8-4c02-88da-f996c14a479e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0ecf6b3f-79d8-4c02-88da-f996c14a479e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5d875f7e-14e2-424f-9c81-c7c1761683b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0ecf6b3f-79d8-4c02-88da-f996c14a479e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5d875f7e-14e2-424f-9c81-c7c1761683b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023P1Member_4646441f-2862-4bf4-abb4-cadc3ab04e43" xlink:href="nbx-20250630.xsd#nbx_AGA2023P1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5d875f7e-14e2-424f-9c81-c7c1761683b8" xlink:to="loc_nbx_AGA2023P1Member_4646441f-2862-4bf4-abb4-cadc3ab04e43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023P2Member_29df5827-fa7c-494c-8add-053a05f1e55c" xlink:href="nbx-20250630.xsd#nbx_AGA2023P2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5d875f7e-14e2-424f-9c81-c7c1761683b8" xlink:to="loc_nbx_AGA2023P2Member_29df5827-fa7c-494c-8add-053a05f1e55c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_87734a49-8165-47c6-9393-542f38996823" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:to="loc_srt_TitleOfIndividualAxis_87734a49-8165-47c6-9393-542f38996823" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_87734a49-8165-47c6-9393-542f38996823_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_87734a49-8165-47c6-9393-542f38996823" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_87734a49-8165-47c6-9393-542f38996823_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6a786fa-4293-4764-8251-4c085067818d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_87734a49-8165-47c6-9393-542f38996823" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6a786fa-4293-4764-8251-4c085067818d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CorporateOfficersMember_31926fe2-3793-4c2b-9575-d1cf99309108" xlink:href="nbx-20250630.xsd#nbx_CorporateOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6a786fa-4293-4764-8251-4c085067818d" xlink:to="loc_nbx_CorporateOfficersMember_31926fe2-3793-4c2b-9575-d1cf99309108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_6f2fed00-ba15-4281-9252-1b185c4991ef" xlink:href="nbx-20250630.xsd#nbx_BeneficiariesOtherThanCorporateOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6a786fa-4293-4764-8251-4c085067818d" xlink:to="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_6f2fed00-ba15-4281-9252-1b185c4991ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameAxis_a18cfad1-a297-41ed-b785-bdac85008fed" xlink:href="nbx-20250630.xsd#nbx_OfficersNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:to="loc_nbx_OfficersNameAxis_a18cfad1-a297-41ed-b785-bdac85008fed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameDomain_a18cfad1-a297-41ed-b785-bdac85008fed_default" xlink:href="nbx-20250630.xsd#nbx_OfficersNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_OfficersNameAxis_a18cfad1-a297-41ed-b785-bdac85008fed" xlink:to="loc_nbx_OfficersNameDomain_a18cfad1-a297-41ed-b785-bdac85008fed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameDomain_0e2085aa-e790-4a65-9358-26617bde186f" xlink:href="nbx-20250630.xsd#nbx_OfficersNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_OfficersNameAxis_a18cfad1-a297-41ed-b785-bdac85008fed" xlink:to="loc_nbx_OfficersNameDomain_0e2085aa-e790-4a65-9358-26617bde186f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LaurentLevyMember_08789718-a2bf-48c5-a440-3b59d42cc655" xlink:href="nbx-20250630.xsd#nbx_LaurentLevyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OfficersNameDomain_0e2085aa-e790-4a65-9358-26617bde186f" xlink:to="loc_nbx_LaurentLevyMember_08789718-a2bf-48c5-a440-3b59d42cc655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantMember_fb9d6c5b-4c18-4c98-a6b5-78fb88f4e75a" xlink:href="nbx-20250630.xsd#nbx_AnneJulietteHermantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OfficersNameDomain_0e2085aa-e790-4a65-9358-26617bde186f" xlink:to="loc_nbx_AnneJulietteHermantMember_fb9d6c5b-4c18-4c98-a6b5-78fb88f4e75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BartVanRhijnMember_15f11c08-b78b-433e-bff0-04519f6ae0e6" xlink:href="nbx-20250630.xsd#nbx_BartVanRhijnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OfficersNameDomain_0e2085aa-e790-4a65-9358-26617bde186f" xlink:to="loc_nbx_BartVanRhijnMember_15f11c08-b78b-433e-bff0-04519f6ae0e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_8bd0db7f-3b75-410e-8221-f19f065651be" xlink:href="nbx-20250630.xsd#nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_8bd0db7f-3b75-410e-8221-f19f065651be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b8404d1c-bde8-4e9b-8b7e-ec5a230935ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b8404d1c-bde8-4e9b-8b7e-ec5a230935ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_bc8a3a01-386e-436b-b799-6599fc0cc6b3" xlink:href="nbx-20250630.xsd#nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_bc8a3a01-386e-436b-b799-6599fc0cc6b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_55513891-6b0a-431a-b922-c568dc758f1b" xlink:href="nbx-20250630.xsd#nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_55513891-6b0a-431a-b922-c568dc758f1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4a6c83c4-d12e-41ec-8d5d-357e216bc5f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4a6c83c4-d12e-41ec-8d5d-357e216bc5f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_86191dd8-f7a4-4d6f-9eeb-6f23c107b391" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_86191dd8-f7a4-4d6f-9eeb-6f23c107b391" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3b9a71bb-41cc-40e6-8641-b5f62fa3f58c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3b9a71bb-41cc-40e6-8641-b5f62fa3f58c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_00ef37ea-f61c-437c-af12-8a3540a35013" xlink:href="nbx-20250630.xsd#nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_00ef37ea-f61c-437c-af12-8a3540a35013" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_e513ba80-3f42-44e2-b2b4-b178971f3ff6" xlink:href="nbx-20250630.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_e513ba80-3f42-44e2-b2b4-b178971f3ff6" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_de942185-a9e9-4c9b-9d21-5d33b5840726" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_ff071e12-7874-4dfd-81e7-c16744e92a62" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_de942185-a9e9-4c9b-9d21-5d33b5840726" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_ff071e12-7874-4dfd-81e7-c16744e92a62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4618a5e2-ba74-426f-b240-c8e208e90ee1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_ff071e12-7874-4dfd-81e7-c16744e92a62" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4618a5e2-ba74-426f-b240-c8e208e90ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4618a5e2-ba74-426f-b240-c8e208e90ee1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4618a5e2-ba74-426f-b240-c8e208e90ee1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4618a5e2-ba74-426f-b240-c8e208e90ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0616c099-c67f-4f12-8e61-935d26b1a7b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4618a5e2-ba74-426f-b240-c8e208e90ee1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0616c099-c67f-4f12-8e61-935d26b1a7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_65e3f8b5-ad6e-48b9-a13b-9e694d3b5411" xlink:href="nbx-20250630.xsd#nbx_BSPCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0616c099-c67f-4f12-8e61-935d26b1a7b4" xlink:to="loc_nbx_BSPCEMember_65e3f8b5-ad6e-48b9-a13b-9e694d3b5411" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_db99864e-ba23-4975-9753-8ef5f87b6bc8" xlink:href="nbx-20250630.xsd#nbx_BSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0616c099-c67f-4f12-8e61-935d26b1a7b4" xlink:to="loc_nbx_BSAMember_db99864e-ba23-4975-9753-8ef5f87b6bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_ce8d9afd-2e0a-4e8b-856b-1fbbfe692d17" xlink:href="nbx-20250630.xsd#nbx_OSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0616c099-c67f-4f12-8e61-935d26b1a7b4" xlink:to="loc_nbx_OSAMember_ce8d9afd-2e0a-4e8b-856b-1fbbfe692d17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_23ef80f4-d9cb-439d-8f6b-8cc37cd42d53" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_de942185-a9e9-4c9b-9d21-5d33b5840726" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_23ef80f4-d9cb-439d-8f6b-8cc37cd42d53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_cfddd9e5-cf73-4adb-a084-6b1ecbc16bc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_de942185-a9e9-4c9b-9d21-5d33b5840726" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_cfddd9e5-cf73-4adb-a084-6b1ecbc16bc5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d9f3e956-fa91-4870-98f0-ef6625f48927" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d9f3e956-fa91-4870-98f0-ef6625f48927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d9f3e956-fa91-4870-98f0-ef6625f48927_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d9f3e956-fa91-4870-98f0-ef6625f48927" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d9f3e956-fa91-4870-98f0-ef6625f48927_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d9f3e956-fa91-4870-98f0-ef6625f48927" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:href="nbx-20250630.xsd#nbx_BSPCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:to="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member_2d93e6d0-e28d-43aa-b015-ca1f752b688d" xlink:href="nbx-20250630.xsd#nbx_BSPCE20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE20151Member_2d93e6d0-e28d-43aa-b015-ca1f752b688d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member_9d364478-2a0b-49cf-ad6a-e50ee105d72e" xlink:href="nbx-20250630.xsd#nbx_BSPCE20153Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE20153Member_9d364478-2a0b-49cf-ad6a-e50ee105d72e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016OrdinaryMember_9ebbdebc-8336-4976-803a-599610c3803a" xlink:href="nbx-20250630.xsd#nbx_BSPCE2016OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE2016OrdinaryMember_9ebbdebc-8336-4976-803a-599610c3803a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016PerformanceMember_f9f5e063-41f9-4c2b-ba53-91ab1f278da1" xlink:href="nbx-20250630.xsd#nbx_BSPCE2016PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE2016PerformanceMember_f9f5e063-41f9-4c2b-ba53-91ab1f278da1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017OrdinaryMember_3d941b7d-02f0-4d86-808e-fbcb18ad14eb" xlink:href="nbx-20250630.xsd#nbx_BSPCE2017OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE2017OrdinaryMember_3d941b7d-02f0-4d86-808e-fbcb18ad14eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017Member_13bdd9aa-9fe4-4f46-842a-7167972f1daf" xlink:href="nbx-20250630.xsd#nbx_BSPCE2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE2017Member_13bdd9aa-9fe4-4f46-842a-7167972f1daf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:href="nbx-20250630.xsd#nbx_BSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:to="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member_3e8e9e4f-3f91-49cd-9c00-472e76b2678e" xlink:href="nbx-20250630.xsd#nbx_BSA20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA20151Member_3e8e9e4f-3f91-49cd-9c00-472e76b2678e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152Member_94f29a39-8fc4-4cac-b3af-73f591c8ae65" xlink:href="nbx-20250630.xsd#nbx_BSA20152Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA20152Member_94f29a39-8fc4-4cac-b3af-73f591c8ae65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member_e7251ce5-4905-4ac5-aed5-9742136faac7" xlink:href="nbx-20250630.xsd#nbx_BSA20182Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA20182Member_e7251ce5-4905-4ac5-aed5-9742136faac7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member_ad4f8bda-6dea-44cd-a783-98cb23e7236f" xlink:href="nbx-20250630.xsd#nbx_BSA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA20191Member_ad4f8bda-6dea-44cd-a783-98cb23e7236f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_adbfa0bb-e854-4987-a123-90b01b1dc9bc" xlink:href="nbx-20250630.xsd#nbx_BSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA2020Member_adbfa0bb-e854-4987-a123-90b01b1dc9bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember_7c6333e0-cee9-4d1c-9e91-dc6939df4e61" xlink:href="nbx-20250630.xsd#nbx_BSA2021AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA2021AMember_7c6333e0-cee9-4d1c-9e91-dc6939df4e61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:href="nbx-20250630.xsd#nbx_OSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:to="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161PerformanceMember_d7a7097a-cba4-4fd3-b692-cc3ac51f22e5" xlink:href="nbx-20250630.xsd#nbx_OSA20161PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA20161PerformanceMember_d7a7097a-cba4-4fd3-b692-cc3ac51f22e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member_f9f36d9f-8ebc-4868-a95d-0e1e95b224ef" xlink:href="nbx-20250630.xsd#nbx_OSA20162Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA20162Member_f9f36d9f-8ebc-4868-a95d-0e1e95b224ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017OrdinaryMember_a6100001-fc54-464a-a2ae-cda466a2a96d" xlink:href="nbx-20250630.xsd#nbx_OSA2017OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA2017OrdinaryMember_a6100001-fc54-464a-a2ae-cda466a2a96d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member_688c68f4-484e-477a-b593-cbf1bb1b1adb" xlink:href="nbx-20250630.xsd#nbx_OSA2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA2018Member_688c68f4-484e-477a-b593-cbf1bb1b1adb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member_56dbf133-f615-4870-b6b0-cafd23091340" xlink:href="nbx-20250630.xsd#nbx_OSA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA20191Member_56dbf133-f615-4870-b6b0-cafd23091340" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20192Member_ef856b21-6b5c-4dd7-98f1-03c24145bc09" xlink:href="nbx-20250630.xsd#nbx_OSA20192Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA20192Member_ef856b21-6b5c-4dd7-98f1-03c24145bc09" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_f59af712-67e5-494b-b61d-a2670852d6ee" xlink:href="nbx-20250630.xsd#nbx_OSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA2020Member_f59af712-67e5-494b-b61d-a2670852d6ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember_efdfcced-044f-429a-afcd-6a511cc99d6e" xlink:href="nbx-20250630.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202104OrdinaryMember_efdfcced-044f-429a-afcd-6a511cc99d6e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104PerformanceMember_df1fb12b-8d6b-4fc1-83e2-3258a7a430da" xlink:href="nbx-20250630.xsd#nbx_OSA202104PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202104PerformanceMember_df1fb12b-8d6b-4fc1-83e2-3258a7a430da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember_ecf9499b-ce63-4d6b-94de-b1419f0ef062" xlink:href="nbx-20250630.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202106OrdinaryMember_ecf9499b-ce63-4d6b-94de-b1419f0ef062" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106PerformanceMember_2939d78b-4380-443e-8922-fd7361c8c02d" xlink:href="nbx-20250630.xsd#nbx_OSA202106PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202106PerformanceMember_2939d78b-4380-443e-8922-fd7361c8c02d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202206PerformanceMember_37ee2651-83b8-444f-ae16-711ef1c3990b" xlink:href="nbx-20250630.xsd#nbx_OSA202206PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202206PerformanceMember_37ee2651-83b8-444f-ae16-711ef1c3990b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202206OrdinaryMember_24d763ba-4a63-43bc-889c-e8d5efafc17c" xlink:href="nbx-20250630.xsd#nbx_OSA202206OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202206OrdinaryMember_24d763ba-4a63-43bc-889c-e8d5efafc17c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202301OrdinaryMember_a7e11ded-206f-4bd2-99cd-6a09f81196d1" xlink:href="nbx-20250630.xsd#nbx_OSA202301OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202301OrdinaryMember_a7e11ded-206f-4bd2-99cd-6a09f81196d1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202401OrdinaryMember_31b8ac5e-aabf-4f1f-b2bb-8723a2f5b9e9" xlink:href="nbx-20250630.xsd#nbx_OSA202401OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202401OrdinaryMember_31b8ac5e-aabf-4f1f-b2bb-8723a2f5b9e9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202501OrdinaryMember_8e84b156-b191-488d-a40f-57fe73cb9424" xlink:href="nbx-20250630.xsd#nbx_OSA202501OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202501OrdinaryMember_8e84b156-b191-488d-a40f-57fe73cb9424" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202502OrdinaryMember_cb1f4122-1777-47ee-9225-a3e46a0297d0" xlink:href="nbx-20250630.xsd#nbx_OSA202502OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202502OrdinaryMember_cb1f4122-1777-47ee-9225-a3e46a0297d0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_724a2412-c22c-481d-84d1-d717dd555d13" xlink:href="nbx-20250630.xsd#nbx_AGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:to="loc_nbx_AGAMember_724a2412-c22c-481d-84d1-d717dd555d13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023Performance1Member_e0c6f283-8833-4316-a7c3-5db4dc4e0c1f" xlink:href="nbx-20250630.xsd#nbx_AGA2023Performance1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_724a2412-c22c-481d-84d1-d717dd555d13" xlink:to="loc_nbx_AGA2023Performance1Member_e0c6f283-8833-4316-a7c3-5db4dc4e0c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023Performance2Member_9496e0b5-6fa3-431c-b0a1-930577c0805b" xlink:href="nbx-20250630.xsd#nbx_AGA2023Performance2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_724a2412-c22c-481d-84d1-d717dd555d13" xlink:to="loc_nbx_AGA2023Performance2Member_9496e0b5-6fa3-431c-b0a1-930577c0805b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesAxis_5971ee02-d310-4fe3-ad94-632c74316497" xlink:href="nbx-20250630.xsd#nbx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:to="loc_nbx_TranchesAxis_5971ee02-d310-4fe3-ad94-632c74316497" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain_5971ee02-d310-4fe3-ad94-632c74316497_default" xlink:href="nbx-20250630.xsd#nbx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_TranchesAxis_5971ee02-d310-4fe3-ad94-632c74316497" xlink:to="loc_nbx_TranchesDomain_5971ee02-d310-4fe3-ad94-632c74316497_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:href="nbx-20250630.xsd#nbx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_TranchesAxis_5971ee02-d310-4fe3-ad94-632c74316497" xlink:to="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_99098a1c-c7b1-4a0f-a4cf-0d4be6ddddc3" xlink:href="nbx-20250630.xsd#nbx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:to="loc_nbx_TrancheOneMember_99098a1c-c7b1-4a0f-a4cf-0d4be6ddddc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_18efdddd-be74-43b0-94b3-a1ab403ead01" xlink:href="nbx-20250630.xsd#nbx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:to="loc_nbx_TrancheTwoMember_18efdddd-be74-43b0-94b3-a1ab403ead01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_9a92caec-6e63-4447-8f18-8d87531e2040" xlink:href="nbx-20250630.xsd#nbx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:to="loc_nbx_TrancheThreeMember_9a92caec-6e63-4447-8f18-8d87531e2040" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember_8804101f-9ab3-4eed-bb2b-a2a87f4f7f83" xlink:href="nbx-20250630.xsd#nbx_TrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:to="loc_nbx_TrancheFourMember_8804101f-9ab3-4eed-bb2b-a2a87f4f7f83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingPeriodAxis_93fc3531-d44b-4943-82c1-4699dfb476a7" xlink:href="nbx-20250630.xsd#nbx_VestingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:to="loc_nbx_VestingPeriodAxis_93fc3531-d44b-4943-82c1-4699dfb476a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingPeriodDomain_93fc3531-d44b-4943-82c1-4699dfb476a7_default" xlink:href="nbx-20250630.xsd#nbx_VestingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_VestingPeriodAxis_93fc3531-d44b-4943-82c1-4699dfb476a7" xlink:to="loc_nbx_VestingPeriodDomain_93fc3531-d44b-4943-82c1-4699dfb476a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:href="nbx-20250630.xsd#nbx_VestingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_VestingPeriodAxis_93fc3531-d44b-4943-82c1-4699dfb476a7" xlink:to="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_a9780b39-32de-4b89-9d25-2015ad8e61d8" xlink:href="nbx-20250630.xsd#nbx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:to="loc_nbx_TrancheOneMember_a9780b39-32de-4b89-9d25-2015ad8e61d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_f01e19f2-82e5-4b22-a30f-9ed941f85a6c" xlink:href="nbx-20250630.xsd#nbx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:to="loc_nbx_TrancheTwoMember_f01e19f2-82e5-4b22-a30f-9ed941f85a6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_fa457aad-57f7-4d44-b2eb-bb361beea6c5" xlink:href="nbx-20250630.xsd#nbx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:to="loc_nbx_TrancheThreeMember_fa457aad-57f7-4d44-b2eb-bb361beea6c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember_168b0159-a115-4f01-9735-3720a56a601b" xlink:href="nbx-20250630.xsd#nbx_TrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:to="loc_nbx_TrancheFourMember_168b0159-a115-4f01-9735-3720a56a601b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_46fea0ca-b821-4bbe-a6a3-816d04789c56" xlink:href="nbx-20250630.xsd#nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_46fea0ca-b821-4bbe-a6a3-816d04789c56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted_e7c404d7-e3e4-4f55-b1cd-29da240a46d8" xlink:href="nbx-20250630.xsd#nbx_ExercisePriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted_e7c404d7-e3e4-4f55-b1cd-29da240a46d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_ff79dec4-fb9f-486e-9f75-b454ddc5303c" xlink:href="nbx-20250630.xsd#nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_ff79dec4-fb9f-486e-9f75-b454ddc5303c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_daa15d0b-bd94-431b-80c9-c48bcca61ee6" xlink:href="nbx-20250630.xsd#nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_daa15d0b-bd94-431b-80c9-c48bcca61ee6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_4d1edad4-b952-428a-8f50-79143aa0a489" xlink:href="nbx-20250630.xsd#nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_4d1edad4-b952-428a-8f50-79143aa0a489" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_254f5d8b-2dfe-4544-9065-74b87029140b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_254f5d8b-2dfe-4544-9065-74b87029140b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_285fdf42-baaf-43a4-8e89-11cd74aaaef0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_285fdf42-baaf-43a4-8e89-11cd74aaaef0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_6e5c2984-251d-4ec2-b3b0-1a8204733c61" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_6e5c2984-251d-4ec2-b3b0-1a8204733c61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2fa56876-9505-4348-b722-a45862cc461a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2fa56876-9505-4348-b722-a45862cc461a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_a861f6ec-b126-47f4-942d-fd55ca90d2ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_a861f6ec-b126-47f4-942d-fd55ca90d2ac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_fb27fd69-5c80-4f46-a450-80ae90b2e05b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_fb27fd69-5c80-4f46-a450-80ae90b2e05b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_d44ddf74-34f5-458f-8c68-ffd736b6eef4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_d44ddf74-34f5-458f-8c68-ffd736b6eef4" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofExpensefromEquityDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_89607d6f-7c3a-47fa-940c-8a125958f8a9" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_c0bad435-34b5-4238-b961-5b7ec5bb316f" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_89607d6f-7c3a-47fa-940c-8a125958f8a9" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_c0bad435-34b5-4238-b961-5b7ec5bb316f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_37556bea-a415-4fe0-a1f5-c389969aef16" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_c0bad435-34b5-4238-b961-5b7ec5bb316f" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_37556bea-a415-4fe0-a1f5-c389969aef16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_37556bea-a415-4fe0-a1f5-c389969aef16_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_37556bea-a415-4fe0-a1f5-c389969aef16" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_37556bea-a415-4fe0-a1f5-c389969aef16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_37556bea-a415-4fe0-a1f5-c389969aef16" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_80e821f1-4c4e-49d9-bcde-3ffecb5c7b39" xlink:href="nbx-20250630.xsd#nbx_BSPCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:to="loc_nbx_BSPCEMember_80e821f1-4c4e-49d9-bcde-3ffecb5c7b39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_f5f6a7c0-63ab-4db0-9c13-34ed38204cd9" xlink:href="nbx-20250630.xsd#nbx_BSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:to="loc_nbx_BSAMember_f5f6a7c0-63ab-4db0-9c13-34ed38204cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_cfb828e7-8bf8-4a95-b144-b2349c4ed4c9" xlink:href="nbx-20250630.xsd#nbx_OSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:to="loc_nbx_OSAMember_cfb828e7-8bf8-4a95-b144-b2349c4ed4c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_23575310-8ee1-48bf-9e82-e3fa5b5cc9b9" xlink:href="nbx-20250630.xsd#nbx_AGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:to="loc_nbx_AGAMember_23575310-8ee1-48bf-9e82-e3fa5b5cc9b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8c6c026d-f2b3-455b-a96a-78c77a0d6ae1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_89607d6f-7c3a-47fa-940c-8a125958f8a9" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8c6c026d-f2b3-455b-a96a-78c77a0d6ae1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#NetfinancialincomelossNarrativeDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_a351faf5-3d5f-4476-b2fd-47a0c9de6e2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_a351faf5-3d5f-4476-b2fd-47a0c9de6e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_a351faf5-3d5f-4476-b2fd-47a0c9de6e2e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a351faf5-3d5f-4476-b2fd-47a0c9de6e2e" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_a351faf5-3d5f-4476-b2fd-47a0c9de6e2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_8aaa9c80-6bc3-44c1-b806-630b4a32a90e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a351faf5-3d5f-4476-b2fd-47a0c9de6e2e" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_8aaa9c80-6bc3-44c1-b806-630b4a32a90e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_5cc99bcc-f0a8-4287-b179-15ec70a2d093" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_8aaa9c80-6bc3-44c1-b806-630b4a32a90e" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_5cc99bcc-f0a8-4287-b179-15ec70a2d093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_fd0285d8-e44e-40b7-bab8-f0feb762b188" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_fd0285d8-e44e-40b7-bab8-f0feb762b188" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_fd0285d8-e44e-40b7-bab8-f0feb762b188_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_fd0285d8-e44e-40b7-bab8-f0feb762b188" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_fd0285d8-e44e-40b7-bab8-f0feb762b188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_a653a2f2-2c8a-4296-9eb5-fa6c3e406458" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_fd0285d8-e44e-40b7-bab8-f0feb762b188" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_a653a2f2-2c8a-4296-9eb5-fa6c3e406458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_1ed49683-9b81-41e6-b930-b3d572613895" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain_a653a2f2-2c8a-4296-9eb5-fa6c3e406458" xlink:to="loc_ifrs-full_FixedInterestRateMember_1ed49683-9b81-41e6-b930-b3d572613895" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember_7cf7f384-623d-445b-8adb-92ca27d4ff00" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain_a653a2f2-2c8a-4296-9eb5-fa6c3e406458" xlink:to="loc_ifrs-full_FloatingInterestRateMember_7cf7f384-623d-445b-8adb-92ca27d4ff00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_cd222cae-7057-400a-969d-19f4756f7542" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:to="loc_srt_CurrencyAxis_cd222cae-7057-400a-969d-19f4756f7542" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_cd222cae-7057-400a-969d-19f4756f7542_default" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_cd222cae-7057-400a-969d-19f4756f7542" xlink:to="loc_currency_AllCurrenciesDomain_cd222cae-7057-400a-969d-19f4756f7542_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_aea10fa0-d2c7-4d8d-ad79-2fad73f3e34b" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_cd222cae-7057-400a-969d-19f4756f7542" xlink:to="loc_currency_AllCurrenciesDomain_aea10fa0-d2c7-4d8d-ad79-2fad73f3e34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_49932dc6-e65b-4521-9e85-1558d6bf836c" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_aea10fa0-d2c7-4d8d-ad79-2fad73f3e34b" xlink:to="loc_currency_USD_49932dc6-e65b-4521-9e85-1558d6bf836c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_d6b47f16-3e1f-43c6-9b82-6f27bc728cd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:to="loc_ifrs-full_CounterpartiesAxis_d6b47f16-3e1f-43c6-9b82-6f27bc728cd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_d6b47f16-3e1f-43c6-9b82-6f27bc728cd4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_d6b47f16-3e1f-43c6-9b82-6f27bc728cd4" xlink:to="loc_ifrs-full_CounterpartiesDomain_d6b47f16-3e1f-43c6-9b82-6f27bc728cd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_eb72cfe5-a930-4357-8e1d-f4d785df78a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_d6b47f16-3e1f-43c6-9b82-6f27bc728cd4" xlink:to="loc_ifrs-full_CounterpartiesDomain_eb72cfe5-a930-4357-8e1d-f4d785df78a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_HSBCBankMember_5936b05a-aa6f-49d0-873d-e9dad55db38f" xlink:href="nbx-20250630.xsd#nbx_HSBCBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_eb72cfe5-a930-4357-8e1d-f4d785df78a5" xlink:to="loc_nbx_HSBCBankMember_5936b05a-aa6f-49d0-873d-e9dad55db38f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_193eaf6a-9ce6-4611-8b97-1097b88a34b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_193eaf6a-9ce6-4611-8b97-1097b88a34b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense_dec43031-4a08-406c-8ea8-b87780886cc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_InterestExpense_dec43031-4a08-406c-8ea8-b87780886cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_3754ddcb-1c35-475c-8a9a-2af4d8cca4c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_InterestRevenueExpense_3754ddcb-1c35-475c-8a9a-2af4d8cca4c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_e61685a7-2857-4c31-a62f-f329890ce7bd" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_e61685a7-2857-4c31-a62f-f329890ce7bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_51615cbb-4a3d-40a2-b312-b7e1cde745e8" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_51615cbb-4a3d-40a2-b312-b7e1cde745e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_6969fca9-c344-4b69-bda6-30b36214b22e" xlink:href="nbx-20250630.xsd#nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_6969fca9-c344-4b69-bda6-30b36214b22e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_471f5771-193a-4353-b246-4799f8434027" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_471f5771-193a-4353-b246-4799f8434027" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_bcc94433-2ac3-4e6c-962f-d05c552b939d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_bcc94433-2ac3-4e6c-962f-d05c552b939d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_94bb5341-2c6d-4807-88d3-32a00e9d6ecf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_NetForeignExchangeGain_94bb5341-2c6d-4807-88d3-32a00e9d6ecf" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#CommitmentsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_8e4e43a3-5032-4405-bf3a-832daa2a9372" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_020167aa-aeef-4a67-804f-15c87323a266" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_8e4e43a3-5032-4405-bf3a-832daa2a9372" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_020167aa-aeef-4a67-804f-15c87323a266" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_e2f64e44-d6a9-425c-9f75-96b03ff97653" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_020167aa-aeef-4a67-804f-15c87323a266" xlink:to="loc_nbx_CollaborationAgreementAxis_e2f64e44-d6a9-425c-9f75-96b03ff97653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_e2f64e44-d6a9-425c-9f75-96b03ff97653_default" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_e2f64e44-d6a9-425c-9f75-96b03ff97653" xlink:to="loc_nbx_CollaborationAgreementDomain_e2f64e44-d6a9-425c-9f75-96b03ff97653_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_76723cfe-c68e-49f1-83e4-77e433f07c2e" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_e2f64e44-d6a9-425c-9f75-96b03ff97653" xlink:to="loc_nbx_CollaborationAgreementDomain_76723cfe-c68e-49f1-83e4-77e433f07c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_5e01f7b4-38da-43e5-8a59-6bef3747fd1a" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_76723cfe-c68e-49f1-83e4-77e433f07c2e" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_5e01f7b4-38da-43e5-8a59-6bef3747fd1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eef3fb98-9853-4724-92b6-b02269876ce2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_020167aa-aeef-4a67-804f-15c87323a266" xlink:to="loc_srt_ProductOrServiceAxis_eef3fb98-9853-4724-92b6-b02269876ce2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eef3fb98-9853-4724-92b6-b02269876ce2_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_eef3fb98-9853-4724-92b6-b02269876ce2" xlink:to="loc_srt_ProductsAndServicesDomain_eef3fb98-9853-4724-92b6-b02269876ce2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2dc0fd3-a13d-4d35-a054-eb0a9b730292" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_eef3fb98-9853-4724-92b6-b02269876ce2" xlink:to="loc_srt_ProductsAndServicesDomain_d2dc0fd3-a13d-4d35-a054-eb0a9b730292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NBTXR3Member_b848b660-4ffb-4292-b042-438f3b2dbb61" xlink:href="nbx-20250630.xsd#nbx_NBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2dc0fd3-a13d-4d35-a054-eb0a9b730292" xlink:to="loc_nbx_NBTXR3Member_b848b660-4ffb-4292-b042-438f3b2dbb61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TechnologyTransferAndTechnicalAssistanceMember_f80d879b-f838-45d8-bb74-92911538d992" xlink:href="nbx-20250630.xsd#nbx_TechnologyTransferAndTechnicalAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2dc0fd3-a13d-4d35-a054-eb0a9b730292" xlink:to="loc_nbx_TechnologyTransferAndTechnicalAssistanceMember_f80d879b-f838-45d8-bb74-92911538d992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_82cc9f01-b9cb-45ab-8fcf-a2ed043334b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_8e4e43a3-5032-4405-bf3a-832daa2a9372" xlink:to="loc_ifrs-full_CurrentTradeReceivables_82cc9f01-b9cb-45ab-8fcf-a2ed043334b8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RelatedpartiesNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RelatedpartiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/RelatedpartiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2a23df68-9c08-45f3-b6a2-d59c3644b8c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_28710aca-c6b0-4f68-945a-db639c996f0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2a23df68-9c08-45f3-b6a2-d59c3644b8c7" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_28710aca-c6b0-4f68-945a-db639c996f0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_84068209-cee6-4119-9585-a4718e18cf78" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_28710aca-c6b0-4f68-945a-db639c996f0b" xlink:to="loc_srt_OwnershipAxis_84068209-cee6-4119-9585-a4718e18cf78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_84068209-cee6-4119-9585-a4718e18cf78_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_84068209-cee6-4119-9585-a4718e18cf78" xlink:to="loc_srt_OwnershipDomain_84068209-cee6-4119-9585-a4718e18cf78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_392bf8a9-63b6-4f68-98d1-0182f9469758" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_84068209-cee6-4119-9585-a4718e18cf78" xlink:to="loc_srt_OwnershipDomain_392bf8a9-63b6-4f68-98d1-0182f9469758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixCorpMember_34635985-b699-44f9-9892-98339af3153b" xlink:href="nbx-20250630.xsd#nbx_NanobiotixCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_392bf8a9-63b6-4f68-98d1-0182f9469758" xlink:to="loc_nbx_NanobiotixCorpMember_34635985-b699-44f9-9892-98339af3153b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d870c252-2f82-4f60-85fe-7c3fdd172d7e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_28710aca-c6b0-4f68-945a-db639c996f0b" xlink:to="loc_dei_LegalEntityAxis_d870c252-2f82-4f60-85fe-7c3fdd172d7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d870c252-2f82-4f60-85fe-7c3fdd172d7e_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d870c252-2f82-4f60-85fe-7c3fdd172d7e" xlink:to="loc_dei_EntityDomain_d870c252-2f82-4f60-85fe-7c3fdd172d7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_39982ef1-5aac-4a44-a3c6-3dc8a9495c68" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d870c252-2f82-4f60-85fe-7c3fdd172d7e" xlink:to="loc_dei_EntityDomain_39982ef1-5aac-4a44-a3c6-3dc8a9495c68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JohnsonJohnsonInnovationsMember_b0b0ddef-8c7a-4159-94cc-4de94a8461a3" xlink:href="nbx-20250630.xsd#nbx_JohnsonJohnsonInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_39982ef1-5aac-4a44-a3c6-3dc8a9495c68" xlink:to="loc_nbx_JohnsonJohnsonInnovationsMember_b0b0ddef-8c7a-4159-94cc-4de94a8461a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_3202342d-f45b-44d4-989e-1bbc338500c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2a23df68-9c08-45f3-b6a2-d59c3644b8c7" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_3202342d-f45b-44d4-989e-1bbc338500c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>nbx-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e10ad955-f4fb-4992-aa6a-58056e28f5e0,g:51b53987-7aad-4161-819f-cbfd12ac6608-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_nbx_LouisKayitalireMember_2169acde-1695-4b67-9145-2a53760ec281_terseLabel_en-US" xlink:label="lab_nbx_LouisKayitalireMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Louis Kayitalire</link:label>
    <link:label id="lab_nbx_LouisKayitalireMember_label_en-US" xlink:label="lab_nbx_LouisKayitalireMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Louis Kayitalire [Member]</link:label>
    <link:label id="lab_nbx_LouisKayitalireMember_documentation_en-US" xlink:label="lab_nbx_LouisKayitalireMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Louis Kayitalire</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LouisKayitalireMember" xlink:href="nbx-20250630.xsd#nbx_LouisKayitalireMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LouisKayitalireMember" xlink:to="lab_nbx_LouisKayitalireMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValue_e56bfc4c-013c-47d7-b4a4-67f235062323_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total financial assets, at fair value</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValue_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_ded1d55d-dc33-4ac1-8c3c-a7af09c4f7e9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpense_e7a44b96-485b-44b8-bb76-0ee7d2b6613e_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest costs</link:label>
    <link:label id="lab_ifrs-full_InterestExpense_89940547-5e66-44dc-a190-4dc17679df8f_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest costs</link:label>
    <link:label id="lab_ifrs-full_InterestExpense_label_en-US" xlink:label="lab_ifrs-full_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpense" xlink:to="lab_ifrs-full_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_fe617c80-c030-49da-a331-a0e2ddd13360_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential additional ordinary shares that are considered antidilutive (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_label_en-US" xlink:label="lab_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of potential ordinary shares that are antidilutive in period presented</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:to="lab_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE2016PerformanceMember_c086d79a-b86c-430a-bf1a-4243f4b9fa00_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2016PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSPCE 2016 P</link:label>
    <link:label id="lab_nbx_BSPCE2016PerformanceMember_label_en-US" xlink:label="lab_nbx_BSPCE2016PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSPCE 2016 Performance [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2016PerformanceMember_documentation_en-US" xlink:label="lab_nbx_BSPCE2016PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSPCE 2016 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016PerformanceMember" xlink:href="nbx-20250630.xsd#nbx_BSPCE2016PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2016PerformanceMember" xlink:to="lab_nbx_BSPCE2016PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CurrentOtherProvisionsMember_5d9f5e92-1031-459e-a7aa-e2165ab33331_terseLabel_en-US" xlink:label="lab_nbx_CurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current provisions</link:label>
    <link:label id="lab_nbx_CurrentOtherProvisionsMember_label_en-US" xlink:label="lab_nbx_CurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Other Provisions [Member]</link:label>
    <link:label id="lab_nbx_CurrentOtherProvisionsMember_documentation_en-US" xlink:label="lab_nbx_CurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentOtherProvisionsMember" xlink:href="nbx-20250630.xsd#nbx_CurrentOtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CurrentOtherProvisionsMember" xlink:to="lab_nbx_CurrentOtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_88607c98-2fb0-45f8-8635-464b974cd45a_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital [Abstract]</link:label>
    <link:label id="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInDepreciationExpense_3b3f8341-10e2-4f87-b2ea-a49922c526c1_negatedTerseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInDepreciationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in depreciation expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInDepreciationExpense_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInDepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Depreciation Expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInDepreciationExpense_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInDepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Depreciation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInDepreciationExpense" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInDepreciationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInDepreciationExpense" xlink:to="lab_nbx_IncreaseDecreaseInDepreciationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreasePayrollExpense_73c31ee8-d59f-425f-9b58-afa488744712_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreasePayrollExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in employee benefit expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreasePayrollExpense_label_en-US" xlink:label="lab_nbx_IncreaseDecreasePayrollExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Payroll Expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreasePayrollExpense_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreasePayrollExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Payroll Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreasePayrollExpense" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreasePayrollExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreasePayrollExpense" xlink:to="lab_nbx_IncreaseDecreasePayrollExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_70d01d65-09be-4dee-aa49-513c0a99e0c7_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_label_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:to="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_6c21fc61-d5d3-414a-868f-dc8921343cca_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Current Assets Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Current Assets Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_b540d65b-d4ec-4a71-800d-dc5ecdfad927_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OtherNonrecurringsIncome_a92f592f-3e49-4b6d-bcd1-c70f96102a95_terseLabel_en-US" xlink:label="lab_nbx_OtherNonrecurringsIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non recurring income</link:label>
    <link:label id="lab_nbx_OtherNonrecurringsIncome_label_en-US" xlink:label="lab_nbx_OtherNonrecurringsIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonrecurrings Income</link:label>
    <link:label id="lab_nbx_OtherNonrecurringsIncome_documentation_en-US" xlink:label="lab_nbx_OtherNonrecurringsIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Nonrecurrings Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherNonrecurringsIncome" xlink:href="nbx-20250630.xsd#nbx_OtherNonrecurringsIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OtherNonrecurringsIncome" xlink:to="lab_nbx_OtherNonrecurringsIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_73bcc719-4869-41bb-9214-416155b61bef_verboseLabel_en-US" xlink:label="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">PGE loans</link:label>
    <link:label id="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_label_en-US" xlink:label="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PGE Loan Agreement, BPI France And HSBC France [Member]</link:label>
    <link:label id="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_documentation_en-US" xlink:label="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PGE Loan Agreement, BPI France And HSBC France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:href="nbx-20250630.xsd#nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:to="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInBonusAccrual_c0ad6d7b-d888-4c03-b767-221be20cdda4_negatedTerseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInBonusAccrual" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in bonus accrual</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInBonusAccrual_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInBonusAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Bonus Accrual</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInBonusAccrual_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInBonusAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Bonus Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInBonusAccrual" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInBonusAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInBonusAccrual" xlink:to="lab_nbx_IncreaseDecreaseInBonusAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_e921e5ed-0437-4bcb-b7b5-6ef1f8467333_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) related to adjustments for income forecast projections</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Related To Adjustments For Income Forecast Projections</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Related To Adjustments For Income Forecast Projections</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" xlink:to="lab_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WagesAndSalaries_e16fd122-7f93-4c1f-991c-3b632b311c13_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Wages and salaries</link:label>
    <link:label id="lab_ifrs-full_WagesAndSalaries_label_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wages and salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WagesAndSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries" xlink:to="lab_ifrs-full_WagesAndSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8978f0ba-5a61-4b11-a7bd-9a36c2f1fa97_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b0a7b2a4-e756-4bbf-91dc-b025f86f1e69_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_3af61d9f-7dc3-44a1-9e88-91cef2337ccb_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PaymentOfAdvisoryFees_92fbfdf0-01b1-4ecb-8075-e39dd23c56db_terseLabel_en-US" xlink:label="lab_nbx_PaymentOfAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of advisory fees</link:label>
    <link:label id="lab_nbx_PaymentOfAdvisoryFees_label_en-US" xlink:label="lab_nbx_PaymentOfAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Advisory Fees</link:label>
    <link:label id="lab_nbx_PaymentOfAdvisoryFees_documentation_en-US" xlink:label="lab_nbx_PaymentOfAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Of Advisory Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PaymentOfAdvisoryFees" xlink:href="nbx-20250630.xsd#nbx_PaymentOfAdvisoryFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PaymentOfAdvisoryFees" xlink:to="lab_nbx_PaymentOfAdvisoryFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingExpense_ebf0044a-7b5d-475a-8e2a-56a06be962bd_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_429baede-ab5b-4473-bf47-bc03f843cbb3_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of prior period loss</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through appropriation of retained earnings, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_A312StudyMember_07801448-7ff4-4b98-9e26-c8e2d916f4f3_terseLabel_en-US" xlink:label="lab_nbx_A312StudyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">312 study</link:label>
    <link:label id="lab_nbx_A312StudyMember_label_en-US" xlink:label="lab_nbx_A312StudyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">312 Study [Member]</link:label>
    <link:label id="lab_nbx_A312StudyMember_documentation_en-US" xlink:label="lab_nbx_A312StudyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">312 Study</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A312StudyMember" xlink:href="nbx-20250630.xsd#nbx_A312StudyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_A312StudyMember" xlink:to="lab_nbx_A312StudyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_e5360d2f-e762-4522-aa46-ee5bb44226ac_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares subscribed (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_37b18d77-6b55-4236-8a4f-7f6769489da1_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses - clinical trials</link:label>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_644a8998-0cdc-44d4-934f-3e5db5c5eb29_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in accrued expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current accrued expenses and other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AnneJulietteHermantMember_50de65ea-2203-4e92-b66b-3e4b7499987c_terseLabel_en-US" xlink:label="lab_nbx_AnneJulietteHermantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anne-Juliette HERMANT</link:label>
    <link:label id="lab_nbx_AnneJulietteHermantMember_label_en-US" xlink:label="lab_nbx_AnneJulietteHermantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anne-Juliette Hermant [Member]</link:label>
    <link:label id="lab_nbx_AnneJulietteHermantMember_documentation_en-US" xlink:label="lab_nbx_AnneJulietteHermantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Anne-Juliette Hermant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantMember" xlink:href="nbx-20250630.xsd#nbx_AnneJulietteHermantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AnneJulietteHermantMember" xlink:to="lab_nbx_AnneJulietteHermantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_99c4edc8-8830-4227-822e-bb83da38e12a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated principles and methods</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of consolidation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NettingMember_3ccd273f-0883-4180-8269-fc9175d5708d_terseLabel_en-US" xlink:label="lab_nbx_NettingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Netting</link:label>
    <link:label id="lab_nbx_NettingMember_label_en-US" xlink:label="lab_nbx_NettingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Netting [Member]</link:label>
    <link:label id="lab_nbx_NettingMember_documentation_en-US" xlink:label="lab_nbx_NettingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Netting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NettingMember" xlink:href="nbx-20250630.xsd#nbx_NettingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NettingMember" xlink:to="lab_nbx_NettingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_7a41c71d-21cc-4a81-a56c-42ccdf30a2ba_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Information Related To The Company [Abstract]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_label_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Information Related To The Company [Abstract]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_documentation_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Information Related To The Company [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:to="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted_9ce28630-eec7-4c7c-a2c4-15888e80a1f2_terseLabel_en-US" xlink:label="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in euro per share)</link:label>
    <link:label id="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price, Other Equity Instruments Granted</link:label>
    <link:label id="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:href="nbx-20250630.xsd#nbx_ExercisePriceOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:to="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_90d6df8c-a283-4004-8891-abb4d6f6ebb3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Lease Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_f43d2044-364d-4d9a-b3c8-161a995ffe95_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_Equity_c8c0c491-3181-4b70-98a4-fcdc0ea80c2e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Equity_5257f63c-623a-407b-946c-22fd6b6757da_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity at end of period</link:label>
    <link:label id="lab_ifrs-full_Equity_6ba56fc0-0241-445c-a494-2d8fecbc3a1d_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_RightOfUseBuildingsMember_d995ad31-40e6-4037-a2eb-3da10222a414_terseLabel_en-US" xlink:label="lab_nbx_RightOfUseBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use &#8211; Buildings</link:label>
    <link:label id="lab_nbx_RightOfUseBuildingsMember_label_en-US" xlink:label="lab_nbx_RightOfUseBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right Of Use, Buildings [Member]</link:label>
    <link:label id="lab_nbx_RightOfUseBuildingsMember_documentation_en-US" xlink:label="lab_nbx_RightOfUseBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right Of Use, Buildings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseBuildingsMember" xlink:href="nbx-20250630.xsd#nbx_RightOfUseBuildingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_RightOfUseBuildingsMember" xlink:to="lab_nbx_RightOfUseBuildingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_60d9d763-beac-4743-bdac-f639b200409f_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_d66b18f4-2d5c-45de-9ff3-d351fb5615aa_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment at beginning of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_707137d0-a957-43e2-a518-b7395162c9cb_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment at end of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_70249955-e8c3-42b0-bd9b-48967620699c_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial income (loss)</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="lab_ifrs-full_FinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_c67adbcb-28d8-4618-a846-2bf618a435e3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_002b76b4-eac4-4f3e-a62a-a3b5822e37b5_netLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Number of shares subscribed (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInSocialTax_7336be02-9567-4403-977c-1d8e2b6cf15e_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInSocialTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in social tax</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInSocialTax_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInSocialTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Social Tax</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInSocialTax_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInSocialTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Social Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInSocialTax" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInSocialTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInSocialTax" xlink:to="lab_nbx_IncreaseDecreaseInSocialTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_07b27fa4-6c8c-490f-85c8-b0bf89a58901_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_94a63233-c0b3-4b15-a401-b0d1d9bbcaa0_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_d3390904-dff6-43be-b16d-ef380eaf1e9d_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CashFlowsFromUsedInNonFinancingActivities_4e63e21b-d46d-45d6-8af3-d8e6f79623e3_terseLabel_en-US" xlink:label="lab_nbx_CashFlowsFromUsedInNonFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash from financing activities</link:label>
    <link:label id="lab_nbx_CashFlowsFromUsedInNonFinancingActivities_label_en-US" xlink:label="lab_nbx_CashFlowsFromUsedInNonFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows From (Used In) Non Financing Activities</link:label>
    <link:label id="lab_nbx_CashFlowsFromUsedInNonFinancingActivities_documentation_en-US" xlink:label="lab_nbx_CashFlowsFromUsedInNonFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flows From (Used In) Non Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashFlowsFromUsedInNonFinancingActivities" xlink:href="nbx-20250630.xsd#nbx_CashFlowsFromUsedInNonFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CashFlowsFromUsedInNonFinancingActivities" xlink:to="lab_nbx_CashFlowsFromUsedInNonFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromGovernmentGrants_99888325-06e0-4bbf-b6de-87ff4e47c4a3_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidies</link:label>
    <link:label id="lab_ifrs-full_RevenueFromGovernmentGrants_label_en-US" xlink:label="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income from government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromGovernmentGrants" xlink:to="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_39e33748-feb1-4925-937e-57319fe16376_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of share options granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_295061d4-4330-4daa-8402-935afdb0ddc8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_2596123b-f3d6-4c0a-b431-26b677007eaa_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings, profit (loss) for reporting period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:to="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NetLossForThePeriodMember_ce217f05-6bbf-4eea-9636-012d1aab333c_terseLabel_en-US" xlink:label="lab_nbx_NetLossForThePeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_nbx_NetLossForThePeriodMember_label_en-US" xlink:label="lab_nbx_NetLossForThePeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Loss For The Period [Member]</link:label>
    <link:label id="lab_nbx_NetLossForThePeriodMember_documentation_en-US" xlink:label="lab_nbx_NetLossForThePeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Loss For The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetLossForThePeriodMember" xlink:href="nbx-20250630.xsd#nbx_NetLossForThePeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NetLossForThePeriodMember" xlink:to="lab_nbx_NetLossForThePeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CurrentFinancialLiabilitiesMember_b1d1b382-2666-43e9-b3fb-0700117747bc_terseLabel_en-US" xlink:label="lab_nbx_CurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial liabilities</link:label>
    <link:label id="lab_nbx_CurrentFinancialLiabilitiesMember_label_en-US" xlink:label="lab_nbx_CurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Financial Liabilities [Member]</link:label>
    <link:label id="lab_nbx_CurrentFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_nbx_CurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentFinancialLiabilitiesMember" xlink:href="nbx-20250630.xsd#nbx_CurrentFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CurrentFinancialLiabilitiesMember" xlink:to="lab_nbx_CurrentFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_b11d15f3-d9ea-4938-bac2-73526309ed44_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) / Decrease in trade receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TechnologyTransferMember_865ed7a2-4ec7-4a84-9a81-5612e33cd82a_terseLabel_en-US" xlink:label="lab_nbx_TechnologyTransferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology Transfer</link:label>
    <link:label id="lab_nbx_TechnologyTransferMember_label_en-US" xlink:label="lab_nbx_TechnologyTransferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology Transfer [Member]</link:label>
    <link:label id="lab_nbx_TechnologyTransferMember_documentation_en-US" xlink:label="lab_nbx_TechnologyTransferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technology Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TechnologyTransferMember" xlink:href="nbx-20250630.xsd#nbx_TechnologyTransferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TechnologyTransferMember" xlink:to="lab_nbx_TechnologyTransferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_7f01e988-1d10-4fca-acb3-1816916b5262_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated variable interest expense accrual</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_24f467cb-61ac-44ff-94c4-67f0fc2d0aa9_terseLabel_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixtures, fittings and installations</link:label>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_label_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixtures and fittings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixturesAndFittingsMember" xlink:to="lab_ifrs-full_FixturesAndFittingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PrincipalAndFixedRateMember_303786f3-e7a8-4efd-a72a-cd8acf35100a_terseLabel_en-US" xlink:label="lab_nbx_PrincipalAndFixedRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal and Fixed Rate</link:label>
    <link:label id="lab_nbx_PrincipalAndFixedRateMember_label_en-US" xlink:label="lab_nbx_PrincipalAndFixedRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal And Fixed Rate [Member]</link:label>
    <link:label id="lab_nbx_PrincipalAndFixedRateMember_documentation_en-US" xlink:label="lab_nbx_PrincipalAndFixedRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal And Fixed Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PrincipalAndFixedRateMember" xlink:href="nbx-20250630.xsd#nbx_PrincipalAndFixedRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PrincipalAndFixedRateMember" xlink:to="lab_nbx_PrincipalAndFixedRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_304bf15c-a809-4843-a530-3ace96233664_terseLabel_en-US" xlink:label="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:label id="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:href="nbx-20250630.xsd#nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:to="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_7fb2c36b-713d-4fe4-8a3f-8f7bf43bc697_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period (in thousands of euros)</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_142681f2-cb20-48fc-a78c-cef93036fbac_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets carried at fair value through profit or loss</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_4c404ee8-9928-42e2-8b41-658fbe063dbf_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA20161PerformanceMember_1c8cc644-f3a8-479c-9827-d13de70818b6_terseLabel_en-US" xlink:label="lab_nbx_OSA20161PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2016-1 P</link:label>
    <link:label id="lab_nbx_OSA20161PerformanceMember_label_en-US" xlink:label="lab_nbx_OSA20161PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2016-1 Performance [Member]</link:label>
    <link:label id="lab_nbx_OSA20161PerformanceMember_documentation_en-US" xlink:label="lab_nbx_OSA20161PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2016-1 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161PerformanceMember" xlink:href="nbx-20250630.xsd#nbx_OSA20161PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA20161PerformanceMember" xlink:to="lab_nbx_OSA20161PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_3f703313-dda3-4485-8719-caecb8a66893_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_95901b54-1f6d-4222-9875-03f3bb5dc909_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in contract liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_d44fadc5-c85c-4cce-a76e-11a9aa89fc6e_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other operating incomes and expenses</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_c4f511e3-5b69-4a3f-bda6-eff6805df2fb_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other operating income and expenses</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_2003535f-65e4-4526-985f-dd31f6d88e13_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForProvisions" xlink:to="lab_ifrs-full_AdjustmentsForProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_07d64657-4cc9-43de-a691-9c45adc3c3da_terseLabel_en-US" xlink:label="lab_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities Arising From Financing Activities [Roll Forward]</link:label>
    <link:label id="lab_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_label_en-US" xlink:label="lab_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Arising From Financing Activities [Roll Forward]</link:label>
    <link:label id="lab_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_documentation_en-US" xlink:label="lab_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward" xlink:to="lab_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_90cc975e-ba36-4773-88da-a8f7fcdd2d67_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:to="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_02f59984-d6f5-4a80-aad9-81a5d0ee283a_terseLabel_en-US" xlink:label="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed Information About Other Current Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Detailed Information About Other Current Liabilities Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20152Member_e7af4eaf-7b83-4a0f-9f2a-cc454aaec025_terseLabel_en-US" xlink:label="lab_nbx_BSA20152Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2015-2</link:label>
    <link:label id="lab_nbx_BSA20152Member_label_en-US" xlink:label="lab_nbx_BSA20152Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2015-2 [Member]</link:label>
    <link:label id="lab_nbx_BSA20152Member_documentation_en-US" xlink:label="lab_nbx_BSA20152Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA 2015-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152Member" xlink:href="nbx-20250630.xsd#nbx_BSA20152Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20152Member" xlink:to="lab_nbx_BSA20152Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_a7047f8c-9620-4237-91b0-2e67a3e00dd4_terseLabel_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) / Decrease in other receivables</link:label>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_13c7e4cc-4f0b-4197-a044-d71c009b4401_verboseLabel_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other receivables</link:label>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_label_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Decrease (Increase) In Other Receivables</link:label>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_documentation_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Decrease (Increase) In Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:to="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities_4ecd1225-fc31-4bfd-94b6-ddcca03f45f9_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indexation effect on current lease commitment</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Indexation Effect On Current Lease Commitment, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Indexation Effect On Current Lease Commitment, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_b86d8be6-4845-4b4a-9eca-7ada030539dd_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non cash income and expenses</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments for non-cash items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_5c10868b-36af-414c-80a1-38a189f2aa1c_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock_03cf97d5-c559-4fa6-91cf-59fac25b7d31_terseLabel_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of judgement, estimates and assumptions</link:label>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock_label_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions [Policy Text Block]</link:label>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock_documentation_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:href="nbx-20250630.xsd#nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:to="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_75c260c6-2b39-41b6-b534-22c99938f44c_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_nbx_SignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_nbx_SignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_nbx_SignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SignificantAccountingPoliciesAbstract" xlink:href="nbx-20250630.xsd#nbx_SignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract" xlink:to="lab_nbx_SignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202206OrdinaryMember_30eb9d83-6b73-4eb8-a2ff-6ada24ec9da5_terseLabel_en-US" xlink:label="lab_nbx_OSA202206OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2022-06 O</link:label>
    <link:label id="lab_nbx_OSA202206OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA202206OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2022-06 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA202206OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA202206OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2022-06 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202206OrdinaryMember" xlink:href="nbx-20250630.xsd#nbx_OSA202206OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202206OrdinaryMember" xlink:to="lab_nbx_OSA202206OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremium_05488b0c-cfe9-4f14-88a1-fcd50731a034_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premiums related to share capital</link:label>
    <link:label id="lab_ifrs-full_SharePremium_label_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremium" xlink:to="lab_ifrs-full_SharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_625fb509-f751-4409-839a-be6ada460652_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSALLY2019Member_45403980-da70-4d80-b6b5-0a81390ca524_terseLabel_en-US" xlink:label="lab_nbx_OSALLY2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2019 LLY</link:label>
    <link:label id="lab_nbx_OSALLY2019Member_label_en-US" xlink:label="lab_nbx_OSALLY2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA LLY 2019 [Member]</link:label>
    <link:label id="lab_nbx_OSALLY2019Member_documentation_en-US" xlink:label="lab_nbx_OSALLY2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA LLY 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSALLY2019Member" xlink:href="nbx-20250630.xsd#nbx_OSALLY2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSALLY2019Member" xlink:to="lab_nbx_OSALLY2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_aa4dbef0-25c2-4a19-93ce-c69019c4ae3d_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll tax and other payroll liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current payables on social security and taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesTable_5c913bf6-895d-4dab-b83a-df118ded48e2_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Expenses [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesTable_label_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Expenses [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable" xlink:to="lab_nbx_DisclosureOfOperatingExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesDomain_6d9478d5-f703-4038-951c-5d7b376170d1_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_196677b3-b350-4530-854b-ba94e1761589_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other operating expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_4b6d19f2-2827-41b8-b9d9-91ab4ea990c3_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RefundsProvision_a09f1bdb-76b2-4cc2-9f89-207f5ad81a4a_totalLabel_en-US" xlink:label="lab_ifrs-full_RefundsProvision" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Refund liabilities</link:label>
    <link:label id="lab_ifrs-full_RefundsProvision_label_en-US" xlink:label="lab_ifrs-full_RefundsProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refunds provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RefundsProvision" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RefundsProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RefundsProvision" xlink:to="lab_ifrs-full_RefundsProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementDomain_07281b58-31bb-4673-9412-88c615a61a19_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated measurement [member]</link:label>
    <link:label id="lab_ifrs-full_MeasurementDomain_label_en-US" xlink:label="lab_ifrs-full_MeasurementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementDomain" xlink:to="lab_ifrs-full_MeasurementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ProvisionsForChargesMember_855c0830-3151-40b3-856f-4e16dd079bf6_terseLabel_en-US" xlink:label="lab_nbx_ProvisionsForChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for charges</link:label>
    <link:label id="lab_nbx_ProvisionsForChargesMember_label_en-US" xlink:label="lab_nbx_ProvisionsForChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Charges [Member]</link:label>
    <link:label id="lab_nbx_ProvisionsForChargesMember_documentation_en-US" xlink:label="lab_nbx_ProvisionsForChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions For Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForChargesMember" xlink:href="nbx-20250630.xsd#nbx_ProvisionsForChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ProvisionsForChargesMember" xlink:to="lab_nbx_ProvisionsForChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_7f23854f-c4bb-4973-b19a-eb157a94e588_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreases</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through derecognition, financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:to="lab_ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock_207b9a54-9b0f-4bd9-9f70-1ed32275dc6d_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Founders' Warrants, Warrants and Free Shares</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of outstanding other equity Instruments [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:to="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations_f241e730-25b8-4899-8744-2deea7f0f7bd_verboseLabel_en-US" xlink:label="lab_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains and losses (IAS 19)</link:label>
    <link:label id="lab_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations_label_en-US" xlink:label="lab_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income, Before Tax, Gains (Losses) on Actuarial Gains and Losses on Retirement Benefit Obligations</link:label>
    <link:label id="lab_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations_documentation_en-US" xlink:label="lab_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income, Before Tax, Gains (Losses) on Actuarial Gains and Losses on Retirement Benefit Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations" xlink:href="nbx-20250630.xsd#nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations" xlink:to="lab_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LitigationExpense_5d127d72-0a3b-424d-bcef-207a05fd408f_negatedTerseLabel_en-US" xlink:label="lab_nbx_LitigationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reversal of provision for disputes and charges</link:label>
    <link:label id="lab_nbx_LitigationExpense_label_en-US" xlink:label="lab_nbx_LitigationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Expense</link:label>
    <link:label id="lab_nbx_LitigationExpense_documentation_en-US" xlink:label="lab_nbx_LitigationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LitigationExpense" xlink:href="nbx-20250630.xsd#nbx_LitigationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LitigationExpense" xlink:to="lab_nbx_LitigationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_49ece16d-5a88-4857-b576-87bc9b7644da_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e302199c-6dcb-4d5b-927a-048340428c2c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DebtAccretionAndDiscountingImpact_22ac5542-a91c-42e5-b9c7-b6fcf9167b39_negatedTerseLabel_en-US" xlink:label="lab_nbx_DebtAccretionAndDiscountingImpact" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net impact of accretion, discounting and catch-up on EIB loan</link:label>
    <link:label id="lab_nbx_DebtAccretionAndDiscountingImpact_label_en-US" xlink:label="lab_nbx_DebtAccretionAndDiscountingImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt (Accretion) And Discounting Impact</link:label>
    <link:label id="lab_nbx_DebtAccretionAndDiscountingImpact_documentation_en-US" xlink:label="lab_nbx_DebtAccretionAndDiscountingImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt (Accretion) And Discounting Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DebtAccretionAndDiscountingImpact" xlink:href="nbx-20250630.xsd#nbx_DebtAccretionAndDiscountingImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DebtAccretionAndDiscountingImpact" xlink:to="lab_nbx_DebtAccretionAndDiscountingImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_9f92ddc7-f89d-4f8e-b554-c959ed30c3be_negatedTerseLabel_en-US" xlink:label="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreases</link:label>
    <link:label id="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_5bc786b6-67fa-4908-8217-c4e7d6782221_verboseLabel_en-US" xlink:label="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_label_en-US" xlink:label="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision Used And Unused Provision Reversed, Other Provisions</link:label>
    <link:label id="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_documentation_en-US" xlink:label="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision Used And Unused Provision Reversed, Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:href="nbx-20250630.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:to="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_add6281e-24db-47d4-8d79-06050818a07c_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_661b0c5e-2383-497c-a454-518c61c41678_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total number of awards granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ConditionalAdvanceBPIFranceMember_6f0baa90-6c67-4b83-aa12-04761790d792_terseLabel_en-US" xlink:label="lab_nbx_ConditionalAdvanceBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Curadigm Bpi advance</link:label>
    <link:label id="lab_nbx_ConditionalAdvanceBPIFranceMember_label_en-US" xlink:label="lab_nbx_ConditionalAdvanceBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conditional Advance, BPI France [Member]</link:label>
    <link:label id="lab_nbx_ConditionalAdvanceBPIFranceMember_documentation_en-US" xlink:label="lab_nbx_ConditionalAdvanceBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conditional Advance, BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvanceBPIFranceMember" xlink:href="nbx-20250630.xsd#nbx_ConditionalAdvanceBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ConditionalAdvanceBPIFranceMember" xlink:to="lab_nbx_ConditionalAdvanceBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_e677d69f-ebdb-49c0-ab06-486ba2d601c9_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock_c5fd5cde-f1d1-4864-9352-78d510fe26db_terseLabel_en-US" xlink:label="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Financial Income (Loss)</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock_label_en-US" xlink:label="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed Information About Finance Income (Cost) [Table Text Block]</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Detailed Information About Finance Income (Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:to="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20182Member_2bb2e915-4ed4-4cbc-ae28-b657e77815b4_terseLabel_en-US" xlink:label="lab_nbx_BSA20182Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2018-2</link:label>
    <link:label id="lab_nbx_BSA20182Member_label_en-US" xlink:label="lab_nbx_BSA20182Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2018-2 [Member]</link:label>
    <link:label id="lab_nbx_BSA20182Member_documentation_en-US" xlink:label="lab_nbx_BSA20182Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA 2018-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member" xlink:href="nbx-20250630.xsd#nbx_BSA20182Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20182Member" xlink:to="lab_nbx_BSA20182Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdjustmentsToRevenueFromContractsWithCustomers_8f8fbe47-46f2-47fe-88de-d67dc690048a_terseLabel_en-US" xlink:label="lab_nbx_AdjustmentsToRevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract modification adjustment</link:label>
    <link:label id="lab_nbx_AdjustmentsToRevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_nbx_AdjustmentsToRevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Revenue From Contracts With Customers</link:label>
    <link:label id="lab_nbx_AdjustmentsToRevenueFromContractsWithCustomers_documentation_en-US" xlink:label="lab_nbx_AdjustmentsToRevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Revenue From Contracts With Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsToRevenueFromContractsWithCustomers" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsToRevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdjustmentsToRevenueFromContractsWithCustomers" xlink:to="lab_nbx_AdjustmentsToRevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_ff86406d-f326-42ad-b621-39a3fd8ed6a6_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b79ff750-83b3-4822-af32-031f039163e3_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of awards outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_10e63de1-abab-45ce-919b-5bb365a34cae_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Payroll Costs</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_0db5d1ba-de2e-4613-9fa8-28ab6c9e4216_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements &amp; transfer.</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers and other changes, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_17a0f698-0964-4652-a60a-0f3ee56fdfe8_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts receivable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ShareBasedPaymentArrangementStockOptionTerm_c4aa7eba-e3ed-4300-9036-95d92ab2deee_terseLabel_en-US" xlink:label="lab_nbx_ShareBasedPaymentArrangementStockOptionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum term of options granted for share-based payment arrangement</link:label>
    <link:label id="lab_nbx_ShareBasedPaymentArrangementStockOptionTerm_label_en-US" xlink:label="lab_nbx_ShareBasedPaymentArrangementStockOptionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Stock Option Term</link:label>
    <link:label id="lab_nbx_ShareBasedPaymentArrangementStockOptionTerm_documentation_en-US" xlink:label="lab_nbx_ShareBasedPaymentArrangementStockOptionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Stock Option Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedPaymentArrangementStockOptionTerm" xlink:href="nbx-20250630.xsd#nbx_ShareBasedPaymentArrangementStockOptionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ShareBasedPaymentArrangementStockOptionTerm" xlink:to="lab_nbx_ShareBasedPaymentArrangementStockOptionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_501ef849-8f13-4a2c-9483-86b6355879db_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Revenue_6657f12c-8e12-4324-aa17-2a62aea0d200_totalLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues and other income</link:label>
    <link:label id="lab_ifrs-full_Revenue_label_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_9f79c5bc-22c9-423c-9dd5-de1aa878aa55_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Financial Liabilities [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_77f07059-3e88-4573-9509-a5ef57ce8d9f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingDefermentPeriod_7ee21c43-9aba-4c95-9473-b16182770817_terseLabel_en-US" xlink:label="lab_nbx_BorrowingDefermentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, deferment period</link:label>
    <link:label id="lab_nbx_BorrowingDefermentPeriod_label_en-US" xlink:label="lab_nbx_BorrowingDefermentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Deferment Period</link:label>
    <link:label id="lab_nbx_BorrowingDefermentPeriod_documentation_en-US" xlink:label="lab_nbx_BorrowingDefermentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Deferment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriod" xlink:href="nbx-20250630.xsd#nbx_BorrowingDefermentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingDefermentPeriod" xlink:to="lab_nbx_BorrowingDefermentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock_9961ccd9-da7e-490f-a013-5bbb209d0fe2_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Trade Receivables</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Trade Receivables Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Trade Receivables Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_303ad52f-7906-481e-9c41-7fccd423326a_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital Ordinary shares</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_f58559aa-3541-475e-a447-9d06ec0b53a3_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfOtherProvisionsDomain_e231de58-f9d3-4919-b20f-f986303701b9_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provisions [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfOtherProvisionsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_3146591e-ee81-43fa-b67c-201ded5e0bb7_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities at beginning of period</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_0896b63b-0f5b-416b-a969-3b7ce16e7617_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities at end of period</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSAMember_e1730653-189d-4027-8977-9d3eed40ef63_terseLabel_en-US" xlink:label="lab_nbx_BSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA</link:label>
    <link:label id="lab_nbx_BSAMember_label_en-US" xlink:label="lab_nbx_BSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA [Member]</link:label>
    <link:label id="lab_nbx_BSAMember_documentation_en-US" xlink:label="lab_nbx_BSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember" xlink:href="nbx-20250630.xsd#nbx_BSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSAMember" xlink:to="lab_nbx_BSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_deea2921-6b26-48e3-8891-9046d6cfcf9a_negatedTotalLabel_en-US" xlink:label="lab_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total depreciation, amortization and provision expenses (except IAS 19)</link:label>
    <link:label id="lab_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_label_en-US" xlink:label="lab_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization And Provision Expenses Excluding IAS 19</link:label>
    <link:label id="lab_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_documentation_en-US" xlink:label="lab_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization And Provision Expenses Excluding IAS 19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19" xlink:href="nbx-20250630.xsd#nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19" xlink:to="lab_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_367c1e5c-026f-4d07-bab1-3cf4e96ffcf5_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal received</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through financing cash flows, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA2023Performance1Member_963da791-2418-4309-bf78-7eb2ab54530a_terseLabel_en-US" xlink:label="lab_nbx_AGA2023Performance1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA 2023 - P1</link:label>
    <link:label id="lab_nbx_AGA2023Performance1Member_label_en-US" xlink:label="lab_nbx_AGA2023Performance1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA 2023 Performance1 [Member]</link:label>
    <link:label id="lab_nbx_AGA2023Performance1Member_documentation_en-US" xlink:label="lab_nbx_AGA2023Performance1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA 2023 Performance1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023Performance1Member" xlink:href="nbx-20250630.xsd#nbx_AGA2023Performance1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA2023Performance1Member" xlink:to="lab_nbx_AGA2023Performance1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_c8203b16-09e7-4e4b-8ec8-ec7b68e55efe_terseLabel_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total financial liabilities, at fair value</link:label>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_label_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value</link:label>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_documentation_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:href="nbx-20250630.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:to="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_EuropeanInvestmentBankLoanAgreementMember_cc2a2459-f8b0-4d3b-aa85-35a54932af25_terseLabel_en-US" xlink:label="lab_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EIB Loan</link:label>
    <link:label id="lab_nbx_EuropeanInvestmentBankLoanAgreementMember_6bd680f3-202e-4c65-ab17-6218d1297ee8_verboseLabel_en-US" xlink:label="lab_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EIB fixed rate loan</link:label>
    <link:label id="lab_nbx_EuropeanInvestmentBankLoanAgreementMember_label_en-US" xlink:label="lab_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Investment Bank Loan Agreement [Member]</link:label>
    <link:label id="lab_nbx_EuropeanInvestmentBankLoanAgreementMember_documentation_en-US" xlink:label="lab_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">European Investment Bank Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:to="lab_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TranchesDomain_dd38f9de-0284-4dc1-823f-e064dc37e976_terseLabel_en-US" xlink:label="lab_nbx_TranchesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranches [Domain]</link:label>
    <link:label id="lab_nbx_TranchesDomain_label_en-US" xlink:label="lab_nbx_TranchesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranches [Domain]</link:label>
    <link:label id="lab_nbx_TranchesDomain_documentation_en-US" xlink:label="lab_nbx_TranchesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranches [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain" xlink:href="nbx-20250630.xsd#nbx_TranchesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TranchesDomain" xlink:to="lab_nbx_TranchesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_1b326018-326a-4ace-92fc-7868e1af8cfc_terseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SG&amp;A</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingsCumulativeMilestonePrepaymentAmount_79471f64-490e-4228-bcf8-49abf5b815e8_terseLabel_en-US" xlink:label="lab_nbx_BorrowingsCumulativeMilestonePrepaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, cumulative milestone prepayment amount</link:label>
    <link:label id="lab_nbx_BorrowingsCumulativeMilestonePrepaymentAmount_label_en-US" xlink:label="lab_nbx_BorrowingsCumulativeMilestonePrepaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Cumulative Milestone Prepayment Amount</link:label>
    <link:label id="lab_nbx_BorrowingsCumulativeMilestonePrepaymentAmount_documentation_en-US" xlink:label="lab_nbx_BorrowingsCumulativeMilestonePrepaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Cumulative Milestone Prepayment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingsCumulativeMilestonePrepaymentAmount" xlink:href="nbx-20250630.xsd#nbx_BorrowingsCumulativeMilestonePrepaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingsCumulativeMilestonePrepaymentAmount" xlink:to="lab_nbx_BorrowingsCumulativeMilestonePrepaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_6f3a644c-55a9-4b49-88f7-848807b6ee46_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OtherProvisionsRollForward_57fd6d4d-9145-494b-b0fe-81387e8d0a2e_terseLabel_en-US" xlink:label="lab_nbx_OtherProvisionsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Provisions [Roll Forward]</link:label>
    <link:label id="lab_nbx_OtherProvisionsRollForward_label_en-US" xlink:label="lab_nbx_OtherProvisionsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Provisions [Roll Forward]</link:label>
    <link:label id="lab_nbx_OtherProvisionsRollForward_documentation_en-US" xlink:label="lab_nbx_OtherProvisionsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherProvisionsRollForward" xlink:href="nbx-20250630.xsd#nbx_OtherProvisionsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OtherProvisionsRollForward" xlink:to="lab_nbx_OtherProvisionsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_56b6362a-4cd9-46c8-8022-96cf77c1ac94_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Increase) / Decrease in non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of other long-term assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_fefaf1ab-8b8d-40f0-8f31-cceb69841aae_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_d96f11eb-2adc-48cb-940c-4f7f83956aea_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Intangible assets at beginning of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_8c68ca24-f70a-4a33-8c00-a6df728e9d44_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Intangible assets at end of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_5675c34e-4520-4bb2-abde-26756cdd60e8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General information, statement of compliance and basis of presentation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesLineItems_975a6952-4142-406b-be53-d8808a436e5f_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Expenses</link:label>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Expenses [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems" xlink:to="lab_nbx_DisclosureOfOperatingExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_e066900d-958b-43a1-a053-ef6a54aa3cb2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreases</link:label>
    <link:label id="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_e524a468-4dce-4357-9a9d-321780d6bc6b_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TrancheFourMember_ed55175b-b5c3-494e-b321-65a873f40026_terseLabel_en-US" xlink:label="lab_nbx_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche four</link:label>
    <link:label id="lab_nbx_TrancheFourMember_label_en-US" xlink:label="lab_nbx_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Four [Member]</link:label>
    <link:label id="lab_nbx_TrancheFourMember_documentation_en-US" xlink:label="lab_nbx_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember" xlink:href="nbx-20250630.xsd#nbx_TrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TrancheFourMember" xlink:to="lab_nbx_TrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_2dc806a4-f97a-4cc1-ac34-452e171cd15e_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_c75567bb-5fa7-4675-adc6-e631bb9a143f_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Net cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_9e8e61e1-8da5-4496-87fe-864e21a66baf_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Net cash and cash equivalents at end of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_c222677f-1635-4fd5-9e90-1c8e38e32adc_totalLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_e56c5b13-a4df-47c0-9199-2f881735df3e_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreases</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MachineryMember_b1a6e760-93c9-45fd-a437-1688362dc3c9_terseLabel_en-US" xlink:label="lab_ifrs-full_MachineryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technical equipment</link:label>
    <link:label id="lab_ifrs-full_MachineryMember_label_en-US" xlink:label="lab_ifrs-full_MachineryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MachineryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MachineryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MachineryMember" xlink:to="lab_ifrs-full_MachineryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_ec90a3d2-40e1-4155-ba10-fa386daad8b0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Share Options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_47e3eeb8-d427-414e-bad7-dca026261f23_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfCurrentBorrowings_bbea82d5-c451-4b83-8e6e-4e08ca17b93e_terseLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of current borrowings</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfCurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfCurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfCurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfCurrentBorrowings" xlink:to="lab_ifrs-full_RepaymentsOfCurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ConstructionInProgressMember_e4fcb68a-cba1-4d11-8431-68eb7b016304_terseLabel_en-US" xlink:label="lab_ifrs-full_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tangible assets in progress</link:label>
    <link:label id="lab_ifrs-full_ConstructionInProgressMember_label_en-US" xlink:label="lab_ifrs-full_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in progress [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConstructionInProgressMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConstructionInProgressMember" xlink:to="lab_ifrs-full_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent_787850d8-3391-4dca-95ca-7f1a9f84458c_terseLabel_en-US" xlink:label="lab_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Of which Non-Current</link:label>
    <link:label id="lab_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent_label_en-US" xlink:label="lab_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Arising from Financing Activities Non Current</link:label>
    <link:label id="lab_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent_documentation_en-US" xlink:label="lab_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Arising from Financing Activities Non Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent" xlink:to="lab_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInOutstandingLoans_1cdb44a7-088c-4fc4-a248-a49dbdeb3c74_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInOutstandingLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in outstanding loans</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInOutstandingLoans_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInOutstandingLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Outstanding Loans</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInOutstandingLoans_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInOutstandingLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Outstanding Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInOutstandingLoans" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInOutstandingLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInOutstandingLoans" xlink:to="lab_nbx_IncreaseDecreaseInOutstandingLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_3ecc08f9-5349-4808-a94d-223491e242c7_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_6f672d44-36d2-425c-ab73-d6cfeac067d6_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, potential development and commercial milestones payments</link:label>
    <link:label id="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_label_en-US" xlink:label="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Potential Milestones Payments To Be Received</link:label>
    <link:label id="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Potential Milestones Payments To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:to="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement_f0a311d4-5c5e-4d00-8800-555eb77f5159_terseLabel_en-US" xlink:label="lab_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of beneficiaries who are not corporate officers</link:label>
    <link:label id="lab_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Beneficiaries Of Share Options, Share-Based Payment Arrangement</link:label>
    <link:label id="lab_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Beneficiaries Of Share Options, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" xlink:href="nbx-20250630.xsd#nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" xlink:to="lab_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2020Member_08ea3f9e-c952-4d2e-a06e-e9fd985d3efb_terseLabel_en-US" xlink:label="lab_nbx_BSA2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2020</link:label>
    <link:label id="lab_nbx_BSA2020Member_label_en-US" xlink:label="lab_nbx_BSA2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2020 [Member]</link:label>
    <link:label id="lab_nbx_BSA2020Member_documentation_en-US" xlink:label="lab_nbx_BSA2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member" xlink:href="nbx-20250630.xsd#nbx_BSA2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2020Member" xlink:to="lab_nbx_BSA2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_83e3b277-595e-43c6-9606-fb93c4bb971a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Key Management Personnel Compensation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_18038685-08b0-45ee-a909-f6c74e53eec0_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonCurrentFinancialLiabilitiesMember_77352fe3-c883-482d-8af8-ef0c61174f15_terseLabel_en-US" xlink:label="lab_nbx_NonCurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial liabilities</link:label>
    <link:label id="lab_nbx_NonCurrentFinancialLiabilitiesMember_label_en-US" xlink:label="lab_nbx_NonCurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Current Financial Liabilities [Member]</link:label>
    <link:label id="lab_nbx_NonCurrentFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_nbx_NonCurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Current Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialLiabilitiesMember" xlink:href="nbx-20250630.xsd#nbx_NonCurrentFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonCurrentFinancialLiabilitiesMember" xlink:to="lab_nbx_NonCurrentFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_d7e272ad-3ae0-44cf-866f-2cec917c5128_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_965a3715-970e-4bd1-bc09-b8f941c00b28_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_96dd6238-c9b7-4bdc-9b66-c41f9f004a27_terseLabel_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receipt of research tax credit receivable</link:label>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax</link:label>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_documentation_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:to="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDepositsFromCustomers_e57f70e5-ec49-4fe2-8fdd-f9323352300b_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDepositsFromCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current deposits from customers</link:label>
    <link:label id="lab_ifrs-full_CurrentDepositsFromCustomers_label_en-US" xlink:label="lab_ifrs-full_CurrentDepositsFromCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current deposits from customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDepositsFromCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDepositsFromCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDepositsFromCustomers" xlink:to="lab_ifrs-full_CurrentDepositsFromCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_70a19fc2-4c31-4b82-8176-e387cca36b04_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average share price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_f607d1fd-46b1-45e2-9f24-3148dcc57ca3_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_13b7539b-e936-45cd-82c7-4a7065213dbd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_JanssenPharmaceuticaNVMember_dc54e4db-5a41-43fb-85c8-305cae5b1609_terseLabel_en-US" xlink:label="lab_nbx_JanssenPharmaceuticaNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceutica NV</link:label>
    <link:label id="lab_nbx_JanssenPharmaceuticaNVMember_label_en-US" xlink:label="lab_nbx_JanssenPharmaceuticaNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceutica NV [Member]</link:label>
    <link:label id="lab_nbx_JanssenPharmaceuticaNVMember_documentation_en-US" xlink:label="lab_nbx_JanssenPharmaceuticaNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceutica NV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_JanssenPharmaceuticaNVMember" xlink:to="lab_nbx_JanssenPharmaceuticaNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAbstract_a879beb3-e823-4396-94e3-7727e991406b_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues and other income</link:label>
    <link:label id="lab_ifrs-full_RevenueAbstract_label_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_a9760142-35e3-4db9-a8cc-e72abdae1bff_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_3b2a617e-472c-424a-877c-da4c93f90943_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues and other income</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_02c8e6de-db03-463c-b35b-d587a5dbb2a6_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowingsMember_a6ed5985-4347-41d9-bf82-de483e19a426_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term borrowings</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowingsMember_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term borrowings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowingsMember" xlink:to="lab_ifrs-full_LongtermBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OtherNonrecurringExpenses_dd2c6386-83a8-462b-a33d-518720a1689a_terseLabel_en-US" xlink:label="lab_nbx_OtherNonrecurringExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non recurring expenses</link:label>
    <link:label id="lab_nbx_OtherNonrecurringExpenses_ed54e3fa-ac31-4356-b206-ae6a1e621b9e_negatedTerseLabel_en-US" xlink:label="lab_nbx_OtherNonrecurringExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non recurring expenses</link:label>
    <link:label id="lab_nbx_OtherNonrecurringExpenses_label_en-US" xlink:label="lab_nbx_OtherNonrecurringExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonrecurring Expenses</link:label>
    <link:label id="lab_nbx_OtherNonrecurringExpenses_documentation_en-US" xlink:label="lab_nbx_OtherNonrecurringExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Nonrecurring Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherNonrecurringExpenses" xlink:href="nbx-20250630.xsd#nbx_OtherNonrecurringExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OtherNonrecurringExpenses" xlink:to="lab_nbx_OtherNonrecurringExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationExpense_357d346e-661e-45bd-ba01-f1e08f15c19c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense of tangible assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationExpense_label_en-US" xlink:label="lab_ifrs-full_DepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationExpense" xlink:to="lab_ifrs-full_DepreciationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_EmploymentTerminationIndemnitiesMember_73d7b824-5948-420d-863d-86394561b666_terseLabel_en-US" xlink:label="lab_nbx_EmploymentTerminationIndemnitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Termination Indemnities</link:label>
    <link:label id="lab_nbx_EmploymentTerminationIndemnitiesMember_label_en-US" xlink:label="lab_nbx_EmploymentTerminationIndemnitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Termination Indemnities [Member]</link:label>
    <link:label id="lab_nbx_EmploymentTerminationIndemnitiesMember_documentation_en-US" xlink:label="lab_nbx_EmploymentTerminationIndemnitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employment Termination Indemnities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EmploymentTerminationIndemnitiesMember" xlink:href="nbx-20250630.xsd#nbx_EmploymentTerminationIndemnitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_EmploymentTerminationIndemnitiesMember" xlink:to="lab_nbx_EmploymentTerminationIndemnitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities_30a676fb-24fb-4627-b469-9fc07b2ff2e4_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA2020Member_5fa54429-7aed-4c38-87c5-05a72154c820_terseLabel_en-US" xlink:label="lab_nbx_OSA2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2020</link:label>
    <link:label id="lab_nbx_OSA2020Member_label_en-US" xlink:label="lab_nbx_OSA2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2020 [Member]</link:label>
    <link:label id="lab_nbx_OSA2020Member_documentation_en-US" xlink:label="lab_nbx_OSA2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member" xlink:href="nbx-20250630.xsd#nbx_OSA2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA2020Member" xlink:to="lab_nbx_OSA2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ProceedsFromIncomeTaxCredit_1fee214a-a1a5-4f12-8de9-2fa8216c6ed2_terseLabel_en-US" xlink:label="lab_nbx_ProceedsFromIncomeTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receipt of 2024 research tax credit - Nanobiotix Corp</link:label>
    <link:label id="lab_nbx_ProceedsFromIncomeTaxCredit_label_en-US" xlink:label="lab_nbx_ProceedsFromIncomeTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Income Tax Credit</link:label>
    <link:label id="lab_nbx_ProceedsFromIncomeTaxCredit_documentation_en-US" xlink:label="lab_nbx_ProceedsFromIncomeTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Income Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProceedsFromIncomeTaxCredit" xlink:href="nbx-20250630.xsd#nbx_ProceedsFromIncomeTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ProceedsFromIncomeTaxCredit" xlink:to="lab_nbx_ProceedsFromIncomeTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CapitalCommitmentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CapitalCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital commitments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalCommitmentsAbstract" xlink:to="lab_ifrs-full_CapitalCommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_09a67eea-6304-4926-9095-a1eacf46b3d9_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock_1739b4d1-e8c7-471d-b258-fd27c1cdf88f_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Advances Loans and Lease Liabilities</link:label>
    <link:label id="lab_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Advances Loans And Lease Liabilities [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Advances Loans And Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock" xlink:to="lab_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingPeriodDomain_ccd5fd6b-ab1c-4aa1-acce-ed3f38add033_terseLabel_en-US" xlink:label="lab_nbx_VestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_nbx_VestingPeriodDomain_label_en-US" xlink:label="lab_nbx_VestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period [Domain]</link:label>
    <link:label id="lab_nbx_VestingPeriodDomain_documentation_en-US" xlink:label="lab_nbx_VestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingPeriodDomain" xlink:href="nbx-20250630.xsd#nbx_VestingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingPeriodDomain" xlink:to="lab_nbx_VestingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OtherMiscellaneousCurrentLiabilities_c8d02328-e259-4ce3-a1f8-50d491c388dd_terseLabel_en-US" xlink:label="lab_nbx_OtherMiscellaneousCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other payables</link:label>
    <link:label id="lab_nbx_OtherMiscellaneousCurrentLiabilities_label_en-US" xlink:label="lab_nbx_OtherMiscellaneousCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Miscellaneous Current Liabilities</link:label>
    <link:label id="lab_nbx_OtherMiscellaneousCurrentLiabilities_documentation_en-US" xlink:label="lab_nbx_OtherMiscellaneousCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Miscellaneous Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherMiscellaneousCurrentLiabilities" xlink:href="nbx-20250630.xsd#nbx_OtherMiscellaneousCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OtherMiscellaneousCurrentLiabilities" xlink:to="lab_nbx_OtherMiscellaneousCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_2d672998-38ce-45b7-87ce-ccf3940bb01e_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">USD</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ConsolidatedForecastedSalesPeriod_948b9ddf-4663-4be7-b74e-279e6fd80c35_terseLabel_en-US" xlink:label="lab_nbx_ConsolidatedForecastedSalesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated forecasted sales, period</link:label>
    <link:label id="lab_nbx_ConsolidatedForecastedSalesPeriod_label_en-US" xlink:label="lab_nbx_ConsolidatedForecastedSalesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Forecasted Sales, Period</link:label>
    <link:label id="lab_nbx_ConsolidatedForecastedSalesPeriod_documentation_en-US" xlink:label="lab_nbx_ConsolidatedForecastedSalesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Forecasted Sales, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConsolidatedForecastedSalesPeriod" xlink:href="nbx-20250630.xsd#nbx_ConsolidatedForecastedSalesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ConsolidatedForecastedSalesPeriod" xlink:to="lab_nbx_ConsolidatedForecastedSalesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_dffa38bd-08d2-4a49-a2e4-3f31c990e88b_negatedTerseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in payroll tax and other payroll liabilities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:to="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202301OrdinaryMember_8fbde833-7dee-4618-93d0-5d929f92caf1_terseLabel_en-US" xlink:label="lab_nbx_OSA202301OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2023-01 O</link:label>
    <link:label id="lab_nbx_OSA202301OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA202301OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2023-01 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA202301OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA202301OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2023-01 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202301OrdinaryMember" xlink:href="nbx-20250630.xsd#nbx_OSA202301OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202301OrdinaryMember" xlink:to="lab_nbx_OSA202301OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Cash_ae5afa48-0e02-40ca-a3e9-783148fc4de3_terseLabel_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and bank accounts</link:label>
    <link:label id="lab_ifrs-full_Cash_label_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RelatedPartyTransactionsAbstract_2927ab70-135d-43cf-b13f-0c1a6c7c5a42_terseLabel_en-US" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transactions [abstract]</link:label>
    <link:label id="lab_ifrs-full_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related party transactions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_50f1ec45-7cbd-44d6-9663-fa5491a1c11e_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, category [member]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_56b5c53a-3122-4970-a91e-80d2bf5adab8_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than 5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_34983149-41ba-4c15-b58d-9ff75d0d15ff_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_8ac0880e-135b-4faf-88fc-2f50f2e920fd_terseLabel_en-US" xlink:label="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of initial plan</link:label>
    <link:label id="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_label_en-US" xlink:label="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan</link:label>
    <link:label id="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_documentation_en-US" xlink:label="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:href="nbx-20250630.xsd#nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:to="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OfficersNameDomain_4a68b180-5eaa-47e7-96d2-ff6c875ecfa3_terseLabel_en-US" xlink:label="lab_nbx_OfficersNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Officers Name [Domain]</link:label>
    <link:label id="lab_nbx_OfficersNameDomain_label_en-US" xlink:label="lab_nbx_OfficersNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officers Name [Domain]</link:label>
    <link:label id="lab_nbx_OfficersNameDomain_documentation_en-US" xlink:label="lab_nbx_OfficersNameDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Officers Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameDomain" xlink:href="nbx-20250630.xsd#nbx_OfficersNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OfficersNameDomain" xlink:to="lab_nbx_OfficersNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_bcc308ee-326b-4908-ae2e-0d5d6faa26bf_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsDomain_ba842e7d-07bc-4215-8eee-5f517b7ff0f7_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, class</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ServiceRechargeMember_4cc6d290-5b45-4356-91c4-26c7ba39acd2_terseLabel_en-US" xlink:label="lab_nbx_ServiceRechargeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service Recharge</link:label>
    <link:label id="lab_nbx_ServiceRechargeMember_label_en-US" xlink:label="lab_nbx_ServiceRechargeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Recharge [Member]</link:label>
    <link:label id="lab_nbx_ServiceRechargeMember_documentation_en-US" xlink:label="lab_nbx_ServiceRechargeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service Recharge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServiceRechargeMember" xlink:href="nbx-20250630.xsd#nbx_ServiceRechargeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ServiceRechargeMember" xlink:to="lab_nbx_ServiceRechargeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense_b2f5c021-fd80-475b-a6b0-f2aada8ce303_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in employee benefit expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Employee Benefit Expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Employee Benefit Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:to="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_19a07fb1-79eb-4ead-aac2-098968245b47_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_ed90b869-60a8-45d8-9611-823317fe0d03_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_807d65cb-d6dd-4119-b25c-517f0864bf90_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General principles and statement of compliance and basis of presentation</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NetFinancialIncomeLossAbstract_label_en-US" xlink:label="lab_nbx_NetFinancialIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Financial Income (Loss) [Abstract]</link:label>
    <link:label id="lab_nbx_NetFinancialIncomeLossAbstract_documentation_en-US" xlink:label="lab_nbx_NetFinancialIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Financial Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetFinancialIncomeLossAbstract" xlink:href="nbx-20250630.xsd#nbx_NetFinancialIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract" xlink:to="lab_nbx_NetFinancialIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_fd466c1a-25ba-403e-a6af-75cd35d4c007_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value added tax receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_4449d4ce-7c01-419e-876d-f46643a4854e_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease debt interests</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_6d9343b4-3cc2-4a18-8fd8-4680f5e980c0_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of number of shares outstanding [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:to="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_7a735693-38a8-4060-a7be-c1f2c05ad43b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based payment</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TrancheTwoMember_e3dc6789-a10c-4478-ab32-9494b5171681_terseLabel_en-US" xlink:label="lab_nbx_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche two</link:label>
    <link:label id="lab_nbx_TrancheTwoMember_label_en-US" xlink:label="lab_nbx_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_nbx_TrancheTwoMember_documentation_en-US" xlink:label="lab_nbx_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember" xlink:href="nbx-20250630.xsd#nbx_TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TrancheTwoMember" xlink:to="lab_nbx_TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_80bfab14-644e-4a26-9be5-7eeef3482dbe_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_91cfe6ba-c942-4ca9-9627-7db4e168eab9_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_56698d4c-8031-426b-be07-ccf82bc1ea2a_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_2a8b6a69-e9c9-4a97-9cb8-3fce39b69c21_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SecurityDepositsRollForward_fc122c2e-92bd-4dec-8c0c-3c8cc14502fb_terseLabel_en-US" xlink:label="lab_nbx_SecurityDepositsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposits paid</link:label>
    <link:label id="lab_nbx_SecurityDepositsRollForward_label_en-US" xlink:label="lab_nbx_SecurityDepositsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposits [Roll Forward]</link:label>
    <link:label id="lab_nbx_SecurityDepositsRollForward_documentation_en-US" xlink:label="lab_nbx_SecurityDepositsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Security Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SecurityDepositsRollForward" xlink:href="nbx-20250630.xsd#nbx_SecurityDepositsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SecurityDepositsRollForward" xlink:to="lab_nbx_SecurityDepositsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OperatingExpenseDomain_1a378f8e-4c83-46f1-afb0-01667ab95aba_terseLabel_en-US" xlink:label="lab_nbx_OperatingExpenseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expense [Domain]</link:label>
    <link:label id="lab_nbx_OperatingExpenseDomain_label_en-US" xlink:label="lab_nbx_OperatingExpenseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Domain]</link:label>
    <link:label id="lab_nbx_OperatingExpenseDomain_documentation_en-US" xlink:label="lab_nbx_OperatingExpenseDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Expense [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OperatingExpenseDomain" xlink:href="nbx-20250630.xsd#nbx_OperatingExpenseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OperatingExpenseDomain" xlink:to="lab_nbx_OperatingExpenseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_af527497-74b5-47e9-8e49-d04207edda59_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_02206d76-d6ca-46e3-b315-644c5f42d1b0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_6df7d6fd-ce01-4879-b462-56db65e4d5f8_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_435c71ea-cc70-40fc-8ef3-609d816e3b71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_cee30600-751d-4c8b-a5cc-43823deb7092_negatedTerseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization, and provision expenses</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Depreciation, Amortization And Provision Expense</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Depreciation, Amortization And Provision Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:to="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA2018Member_000655e3-e722-4709-84f7-4fd4402578e9_terseLabel_en-US" xlink:label="lab_nbx_OSA2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2018</link:label>
    <link:label id="lab_nbx_OSA2018Member_label_en-US" xlink:label="lab_nbx_OSA2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2018 [Member]</link:label>
    <link:label id="lab_nbx_OSA2018Member_documentation_en-US" xlink:label="lab_nbx_OSA2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member" xlink:href="nbx-20250630.xsd#nbx_OSA2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA2018Member" xlink:to="lab_nbx_OSA2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_22b0ad63-fa4c-4c60-96c7-d51f32b03d1e_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_label_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:to="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_99452e75-4c6d-4874-a434-1fcc69b416de_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major ordinary share transactions</link:label>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_label_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_c0b95b92-4de7-43af-a230-102e52e8e6b4_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated fixed interest expense accrual</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_d351be30-e4ef-49a9-b31f-ccfad7b2dcfc_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity (in years)</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_095655d5-8999-4b7c-b180-ec3ceab22468_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates changes on cash</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_077abdda-0240-4bfc-9d16-6613fb222cc8_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in purchases, sub-contracting and other expenses</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:to="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_1df4e3c3-e7c4-4664-8cf3-ed65ad108951_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_HSBCBankMember_b0459386-3067-441a-8557-efbdb028ea14_terseLabel_en-US" xlink:label="lab_nbx_HSBCBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HSBC Bank</link:label>
    <link:label id="lab_nbx_HSBCBankMember_label_en-US" xlink:label="lab_nbx_HSBCBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HSBC Bank [Member]</link:label>
    <link:label id="lab_nbx_HSBCBankMember_documentation_en-US" xlink:label="lab_nbx_HSBCBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HSBC Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_HSBCBankMember" xlink:href="nbx-20250630.xsd#nbx_HSBCBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_HSBCBankMember" xlink:to="lab_nbx_HSBCBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_5e3a5e3f-22a3-46fd-8b2c-c72e412aa89b_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from (used in) operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_08337a4f-b586-43eb-a6e2-5fa3e394198d_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of awards lapsed, cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9412a93e-9918-4446-8177-b7ee584dca6b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_97f17e00-5005-4451-95f5-c3df95a4ad43_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_0cc0ec0f-6dea-4efb-83bf-7dedb2a060bb_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit receivable</link:label>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_027b3206-8635-4828-ae80-b2fbb023c431_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Research tax credit receivable at beginning of period</link:label>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_317fc2ad-0650-49f6-bc42-d5092ca08a68_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Research tax credit receivable at end of period</link:label>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current receivables from taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_dce6255d-52c6-4e53-8a70-7df498c989a9_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_ee0cd588-bc77-4d90-a9f5-1186d862e1d4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SupplyServicesMember_0b4232aa-7642-42eb-b91f-685c43d2db7e_terseLabel_en-US" xlink:label="lab_nbx_SupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply Services</link:label>
    <link:label id="lab_nbx_SupplyServicesMember_label_en-US" xlink:label="lab_nbx_SupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supply Services [Member]</link:label>
    <link:label id="lab_nbx_SupplyServicesMember_documentation_en-US" xlink:label="lab_nbx_SupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supply Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SupplyServicesMember" xlink:href="nbx-20250630.xsd#nbx_SupplyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SupplyServicesMember" xlink:to="lab_nbx_SupplyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_ad5b6c90-81b3-4b54-8db1-baaa9b64811e_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current refund liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_3d88cc65-9bd6-4de1-881e-b0e7294719b1_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current refund liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_67d354f1-5e40-4f2e-b99e-c57bc6a20931_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_d37835a5-4448-402c-99fd-79f060d51cfc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PrepaymentsOnTangibleAssetsMember_0edba4c5-8722-485b-a00f-89c3a9965429_terseLabel_en-US" xlink:label="lab_nbx_PrepaymentsOnTangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayments on tangible assets</link:label>
    <link:label id="lab_nbx_PrepaymentsOnTangibleAssetsMember_label_en-US" xlink:label="lab_nbx_PrepaymentsOnTangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments On Tangible Assets [Member]</link:label>
    <link:label id="lab_nbx_PrepaymentsOnTangibleAssetsMember_documentation_en-US" xlink:label="lab_nbx_PrepaymentsOnTangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayments On Tangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PrepaymentsOnTangibleAssetsMember" xlink:href="nbx-20250630.xsd#nbx_PrepaymentsOnTangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PrepaymentsOnTangibleAssetsMember" xlink:to="lab_nbx_PrepaymentsOnTangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets_1201ff82-0c1e-4191-834a-2eabf9dbb70c_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other movements, financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_e346deae-a10b-4104-9cc6-26c5a3eb99fe_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue and other income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b129151a-b47d-401b-ba7e-0e59105d73bd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonCurrentFinancialAssetsMember_7891eebe-8005-4b73-be66-712fc035d115_terseLabel_en-US" xlink:label="lab_nbx_NonCurrentFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
    <link:label id="lab_nbx_NonCurrentFinancialAssetsMember_label_en-US" xlink:label="lab_nbx_NonCurrentFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Financial Assets [Member]</link:label>
    <link:label id="lab_nbx_NonCurrentFinancialAssetsMember_documentation_en-US" xlink:label="lab_nbx_NonCurrentFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialAssetsMember" xlink:href="nbx-20250630.xsd#nbx_NonCurrentFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonCurrentFinancialAssetsMember" xlink:to="lab_nbx_NonCurrentFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_01fb5be8-1017-4098-a582-f9d3f5870f9c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elimination of other non-cash, non-operating income and expenses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TrancheThreeMember_19a4b3c2-9252-4074-a5a4-8dd81e0b39ac_terseLabel_en-US" xlink:label="lab_nbx_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche three</link:label>
    <link:label id="lab_nbx_TrancheThreeMember_label_en-US" xlink:label="lab_nbx_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Three [Member]</link:label>
    <link:label id="lab_nbx_TrancheThreeMember_documentation_en-US" xlink:label="lab_nbx_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember" xlink:href="nbx-20250630.xsd#nbx_TrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TrancheThreeMember" xlink:to="lab_nbx_TrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_19dd81e3-831e-4628-a58c-9940fa9899ad_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Maturity Analysis for Advances Loans and Lease Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_EstimatedRoyaltyPayments_b845cbd0-f59f-4578-9aca-d3464b5be3c1_terseLabel_en-US" xlink:label="lab_nbx_EstimatedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated royalty payments</link:label>
    <link:label id="lab_nbx_EstimatedRoyaltyPayments_label_en-US" xlink:label="lab_nbx_EstimatedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Royalty Payments</link:label>
    <link:label id="lab_nbx_EstimatedRoyaltyPayments_documentation_en-US" xlink:label="lab_nbx_EstimatedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EstimatedRoyaltyPayments" xlink:href="nbx-20250630.xsd#nbx_EstimatedRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_EstimatedRoyaltyPayments" xlink:to="lab_nbx_EstimatedRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OpenTaxYearAxis_7d3f1f07-1e40-4e5d-8f59-c1c9fcccd653_terseLabel_en-US" xlink:label="lab_nbx_OpenTaxYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year [Axis]</link:label>
    <link:label id="lab_nbx_OpenTaxYearAxis_label_en-US" xlink:label="lab_nbx_OpenTaxYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open Tax Year [Axis]</link:label>
    <link:label id="lab_nbx_OpenTaxYearAxis_documentation_en-US" xlink:label="lab_nbx_OpenTaxYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearAxis" xlink:href="nbx-20250630.xsd#nbx_OpenTaxYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OpenTaxYearAxis" xlink:to="lab_nbx_OpenTaxYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseRefundLiabilities_c5ee4cee-60b3-4233-9107-2c60c67de0ee_negatedTerseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseRefundLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in refund liabilities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseRefundLiabilities_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseRefundLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Refund Liabilities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseRefundLiabilities_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseRefundLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Refund Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseRefundLiabilities" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseRefundLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseRefundLiabilities" xlink:to="lab_nbx_IncreaseDecreaseRefundLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NANORAY312Member_15360a0b-4230-489a-ae30-28634ebd8616_terseLabel_en-US" xlink:label="lab_nbx_NANORAY312Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NANORAY-312</link:label>
    <link:label id="lab_nbx_NANORAY312Member_label_en-US" xlink:label="lab_nbx_NANORAY312Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NANORAY-312 [Member]</link:label>
    <link:label id="lab_nbx_NANORAY312Member_documentation_en-US" xlink:label="lab_nbx_NANORAY312Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NANORAY-312</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NANORAY312Member" xlink:href="nbx-20250630.xsd#nbx_NANORAY312Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NANORAY312Member" xlink:to="lab_nbx_NANORAY312Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock_16a8a60b-82dc-4eca-b31f-da6deecd0dda_terseLabel_en-US" xlink:label="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Income and Contract Liabilities</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed Information About Deferred Income And Contract Liabilities [Table Text Block]</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Detailed Information About Deferred Income And Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:to="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_5bd03837-74c5-4757-9434-177a040a605d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax Paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentFinancialLiabilities_dd2cbcb4-ce92-4b0a-bff5-4d44343e5ac4_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentFinancialLiabilities_0595939a-c124-453c-ad9f-54e52dcb70a2_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total current financial liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_c7ae5858-d4a7-4cda-9004-a38a0c68c70d_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of accretion and discounting</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SeveranceExpenses_ce999a74-0d80-4f2f-8b19-e631af31d386_terseLabel_en-US" xlink:label="lab_nbx_SeveranceExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance expenses</link:label>
    <link:label id="lab_nbx_SeveranceExpenses_label_en-US" xlink:label="lab_nbx_SeveranceExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Expenses</link:label>
    <link:label id="lab_nbx_SeveranceExpenses_documentation_en-US" xlink:label="lab_nbx_SeveranceExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Severance Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SeveranceExpenses" xlink:href="nbx-20250630.xsd#nbx_SeveranceExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SeveranceExpenses" xlink:to="lab_nbx_SeveranceExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_940c2f39-82dd-48b2-85a6-cf6b18b4f323_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on cash and bank balances at central banks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_152d7763-3b3d-4a7b-88f8-e8896e3bfb36_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_2eba577c-f98a-413a-b2d2-990d1bb6b7f6_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_79007c63-f3ba-4014-99a8-e794b5401043_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesDomain_5f46e04f-213d-4367-aa7c-f261136db5d6_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate types [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of interest rates [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain" xlink:to="lab_ifrs-full_TypesOfInterestRatesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_fd4115eb-ef2d-4fb3-8353-0f5fe92cf753_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIncome_1eb05254-f0a8-4c90-beef-4024c4c854a7_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_ifrs-full_OtherIncome_dd00128c-2d17-4219-bc3f-1ef488386a7e_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_ifrs-full_OtherIncome_label_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="lab_ifrs-full_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_22d8f196-2710-48db-8697-441205be4621_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MilestonePaymentMember_69d68ffa-da3e-4d77-b31f-c44be366e000_terseLabel_en-US" xlink:label="lab_nbx_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_nbx_MilestonePaymentMember_label_en-US" xlink:label="lab_nbx_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment [Member]</link:label>
    <link:label id="lab_nbx_MilestonePaymentMember_documentation_en-US" xlink:label="lab_nbx_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MilestonePaymentMember" xlink:href="nbx-20250630.xsd#nbx_MilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MilestonePaymentMember" xlink:to="lab_nbx_MilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan_0e4a0534-fa6a-4ede-8996-345c269d4eb1_terseLabel_en-US" xlink:label="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of state-guaranteed loan</link:label>
    <link:label id="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan_label_en-US" xlink:label="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Percentage Of State-Guaranteed Loan</link:label>
    <link:label id="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan_documentation_en-US" xlink:label="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Percentage Of State-Guaranteed Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:href="nbx-20250630.xsd#nbx_BorrowingPercentageOfStateGuaranteedLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:to="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_21d8b14a-7385-4e7d-9a7d-452d1756addd_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_label_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:to="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_ef5ee023-60aa-4a4e-a3a2-af604f69a791_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ProvisionsForDisputesMember_2acdafa5-a28e-4c3b-8abd-c404cfdb76cb_terseLabel_en-US" xlink:label="lab_nbx_ProvisionsForDisputesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for disputes</link:label>
    <link:label id="lab_nbx_ProvisionsForDisputesMember_label_en-US" xlink:label="lab_nbx_ProvisionsForDisputesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Disputes [Member]</link:label>
    <link:label id="lab_nbx_ProvisionsForDisputesMember_documentation_en-US" xlink:label="lab_nbx_ProvisionsForDisputesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions For Disputes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForDisputesMember" xlink:href="nbx-20250630.xsd#nbx_ProvisionsForDisputesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ProvisionsForDisputesMember" xlink:to="lab_nbx_ProvisionsForDisputesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentMember_771b4f93-a720-4cc6-a6ec-e14511d1b55f_terseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentMember" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentMember" xlink:to="lab_nbx_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingNumberOfQuarterlyInstallments_a4a41add-a712-44d2-8111-c692e00f4edd_terseLabel_en-US" xlink:label="lab_nbx_BorrowingNumberOfQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of quarterly instalments</link:label>
    <link:label id="lab_nbx_BorrowingNumberOfQuarterlyInstallments_label_en-US" xlink:label="lab_nbx_BorrowingNumberOfQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Number Of Quarterly Installments</link:label>
    <link:label id="lab_nbx_BorrowingNumberOfQuarterlyInstallments_documentation_en-US" xlink:label="lab_nbx_BorrowingNumberOfQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Number Of Quarterly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingNumberOfQuarterlyInstallments" xlink:href="nbx-20250630.xsd#nbx_BorrowingNumberOfQuarterlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingNumberOfQuarterlyInstallments" xlink:to="lab_nbx_BorrowingNumberOfQuarterlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_10aaa44b-0b9a-4ea9-90cb-aa75deccc08c_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains and losses on retirement benefit obligations (IAS 19)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before tax, gains (losses) on remeasurements of defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_c12b47cb-d737-4166-9ffc-20c668b7bad9_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other accruals</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_f796b70e-7e5e-44f7-b5d8-31df03535b21_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax impact</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to remeasurements of defined benefit plans included in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_2498797b-e7f8-4f5f-9d5d-beb271291032_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_5d22106e-036d-441e-bcba-d91f65727743_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total compensation to related parties</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities_0e11818a-e99c-48ed-9406-dc7780f9d849_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in loans and conditional advances</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Decrease In Loans And Conditional Advances, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Decrease In Loans And Conditional Advances, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f5f5d23f-3211-49eb-b74e-3a0da1838091_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_77e114cf-bfe2-4797-9e67-adf33aa5b8fe_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss that may be reclassified subsequently to loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_acfd8882-2180-485f-8caa-6f2be14c52f7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_6eec850a-ab16-4a07-9f56-0a36146646a6_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of share options outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_6340ba38-54e6-4e49-94a0-5e3a2592ce42_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AlainHerreraMember_d575ab7a-c859-4daf-bc17-75267a380725_terseLabel_en-US" xlink:label="lab_nbx_AlainHerreraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alain HERRERA</link:label>
    <link:label id="lab_nbx_AlainHerreraMember_label_en-US" xlink:label="lab_nbx_AlainHerreraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alain Herrera [Member]</link:label>
    <link:label id="lab_nbx_AlainHerreraMember_documentation_en-US" xlink:label="lab_nbx_AlainHerreraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alain Herrera</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AlainHerreraMember" xlink:href="nbx-20250630.xsd#nbx_AlainHerreraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AlainHerreraMember" xlink:to="lab_nbx_AlainHerreraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_260bbaea-8c52-4c67-9e4b-dd02ab7b58f4_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_44b1fdff-6a09-4446-93b8-5c91071c4df0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_1253d09a-3119-4c68-a3e3-909ae859741c_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross book value of intangible assets</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_711c7238-5653-4865-98de-059af1ae06c2_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_ef5792c6-86fc-4cf2-b3e5-8c118fe2f754_totalLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total trade and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_6a780064-cea5-41f0-875f-cedf3322b87e_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND SHAREHOLDER&#8217;S EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses_66cc1d47-5885-49de-8b4e-a20c0a0dd71f_negatedTerseLabel_en-US" xlink:label="lab_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in accrued expenses</link:label>
    <link:label id="lab_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses_label_en-US" xlink:label="lab_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Accrued Expenses</link:label>
    <link:label id="lab_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses_documentation_en-US" xlink:label="lab_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:to="lab_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ThirdPartyServicesMember_ae509c8a-df69-4045-b228-1a2c8c927427_terseLabel_en-US" xlink:label="lab_nbx_ThirdPartyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third party services</link:label>
    <link:label id="lab_nbx_ThirdPartyServicesMember_label_en-US" xlink:label="lab_nbx_ThirdPartyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Party Services [Member]</link:label>
    <link:label id="lab_nbx_ThirdPartyServicesMember_documentation_en-US" xlink:label="lab_nbx_ThirdPartyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third Party Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ThirdPartyServicesMember" xlink:href="nbx-20250630.xsd#nbx_ThirdPartyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ThirdPartyServicesMember" xlink:to="lab_nbx_ThirdPartyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties_b97fc2fb-7c0d-46b7-a319-c6048518c791_terseLabel_en-US" xlink:label="lab_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collections</link:label>
    <link:label id="lab_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties_label_en-US" xlink:label="lab_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash receipts from repayment of advances and loans made to related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties" xlink:to="lab_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_12aeb2cf-c569-4476-ab0f-a369ea8054ae_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of net debt</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:to="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRevenueExpense_39512fb0-4f7c-4ce0-afe0-ef5e37fe1f2b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestRevenueExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_ifrs-full_InterestRevenueExpense_label_en-US" xlink:label="lab_ifrs-full_InterestRevenueExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRevenueExpense" xlink:to="lab_ifrs-full_InterestRevenueExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes_26fd9b13-b9e9-4305-8a2f-c54c1d5e18e8_terseLabel_en-US" xlink:label="lab_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of security types (security)</link:label>
    <link:label id="lab_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes_label_en-US" xlink:label="lab_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share-Based Payment Arrangement, Number Of Security Types</link:label>
    <link:label id="lab_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes_documentation_en-US" xlink:label="lab_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share-Based Payment Arrangement, Number Of Security Types</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes" xlink:href="nbx-20250630.xsd#nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes" xlink:to="lab_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_A2025TaxYearMember_55a98cf0-c781-41ef-af01-507fd920c75c_terseLabel_en-US" xlink:label="lab_nbx_A2025TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Tax Year</link:label>
    <link:label id="lab_nbx_A2025TaxYearMember_label_en-US" xlink:label="lab_nbx_A2025TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Tax Year [Member]</link:label>
    <link:label id="lab_nbx_A2025TaxYearMember_documentation_en-US" xlink:label="lab_nbx_A2025TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2025TaxYearMember" xlink:href="nbx-20250630.xsd#nbx_A2025TaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_A2025TaxYearMember" xlink:to="lab_nbx_A2025TaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_dd47589a-cec6-4821-add4-41e438b53ebb_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_aff18f83-fd3f-402e-af64-727a16b383ae_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than 1&#160;year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement_2b9e73e7-1b02-43d1-a0ef-10f02819ca20_terseLabel_en-US" xlink:label="lab_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares to which the share options were likely to give right (in shares)</link:label>
    <link:label id="lab_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares To Which Options Were Likely To Give Right In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares To Which Options Were Likely To Give Right In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:href="nbx-20250630.xsd#nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:to="lab_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_db014875-5ac0-4991-bc22-28d06ccee5db_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average foreign exchange rate</link:label>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageForeignExchangeRate" xlink:to="lab_ifrs-full_AverageForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_d292c1dd-664a-4e1f-b79a-701e18a9a400_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_a14816b2-7bbc-4663-9388-ec8b824d9c7e_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_dc66c48c-0ef2-4b6f-ab1c-9acc7993e024_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock_ff045cf0-090a-473f-8ccc-53dce3c73f24_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
    <link:label id="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-current Financial Assets [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-current Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:to="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingScheduledForReimbursementNumber_2d292272-d45a-4007-b5c7-b351d1deb981_terseLabel_en-US" xlink:label="lab_nbx_BorrowingScheduledForReimbursementNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, number of PGE</link:label>
    <link:label id="lab_nbx_BorrowingScheduledForReimbursementNumber_label_en-US" xlink:label="lab_nbx_BorrowingScheduledForReimbursementNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing Scheduled For Reimbursement, Number</link:label>
    <link:label id="lab_nbx_BorrowingScheduledForReimbursementNumber_documentation_en-US" xlink:label="lab_nbx_BorrowingScheduledForReimbursementNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing Scheduled For Reimbursement, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingScheduledForReimbursementNumber" xlink:href="nbx-20250630.xsd#nbx_BorrowingScheduledForReimbursementNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingScheduledForReimbursementNumber" xlink:to="lab_nbx_BorrowingScheduledForReimbursementNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE2016OrdinaryMember_f29a1e78-5c1c-4dc3-a6d0-1445373d4ef0_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2016OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSPCE 2016 O</link:label>
    <link:label id="lab_nbx_BSPCE2016OrdinaryMember_label_en-US" xlink:label="lab_nbx_BSPCE2016OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSPCE 2016 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2016OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_BSPCE2016OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSPCE 2016 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016OrdinaryMember" xlink:href="nbx-20250630.xsd#nbx_BSPCE2016OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2016OrdinaryMember" xlink:to="lab_nbx_BSPCE2016OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ffbacba4-604f-4ab1-803e-1b08051846d6_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_90f8e81d-7421-420f-8381-0764c1b7a3e8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ReimbursedAmountOfCorresponds_ea010021-2c51-4c6d-b60e-bc1e80763f67_terseLabel_en-US" xlink:label="lab_nbx_ReimbursedAmountOfCorresponds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursed amount of corresponds</link:label>
    <link:label id="lab_nbx_ReimbursedAmountOfCorresponds_label_en-US" xlink:label="lab_nbx_ReimbursedAmountOfCorresponds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursed Amount of Corresponds</link:label>
    <link:label id="lab_nbx_ReimbursedAmountOfCorresponds_documentation_en-US" xlink:label="lab_nbx_ReimbursedAmountOfCorresponds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursed Amount of Corresponds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ReimbursedAmountOfCorresponds" xlink:href="nbx-20250630.xsd#nbx_ReimbursedAmountOfCorresponds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ReimbursedAmountOfCorresponds" xlink:to="lab_nbx_ReimbursedAmountOfCorresponds" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingMaturityTerm_07611ccb-560e-4f21-9310-88a5113b686f_terseLabel_en-US" xlink:label="lab_nbx_BorrowingMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, maturity</link:label>
    <link:label id="lab_nbx_BorrowingMaturityTerm_label_en-US" xlink:label="lab_nbx_BorrowingMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Maturity Term</link:label>
    <link:label id="lab_nbx_BorrowingMaturityTerm_documentation_en-US" xlink:label="lab_nbx_BorrowingMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Maturity Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm" xlink:href="nbx-20250630.xsd#nbx_BorrowingMaturityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingMaturityTerm" xlink:to="lab_nbx_BorrowingMaturityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9e9bcd24-1182-486f-b0c9-3d2792da0582_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_6d9dff41-a6b7-474a-ba15-1d7d7b7f00ba_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_5d3fb649-3ab6-4240-b8b0-6de6229ce603_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in loans and conditional advances</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_43d72e0f-529e-442b-8dcc-2dc65ab5104b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_2de860cb-ce88-4f4a-a893-0147364f2221_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duration of the holding period</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Holding Period</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Holding Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:href="nbx-20250630.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LiabilitiesRelatedToFinancingActivitiesMember_6142b0e3-b6bd-41b8-9e18-41dbe396b3be_terseLabel_en-US" xlink:label="lab_nbx_LiabilitiesRelatedToFinancingActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities Related to Financing Activities</link:label>
    <link:label id="lab_nbx_LiabilitiesRelatedToFinancingActivitiesMember_label_en-US" xlink:label="lab_nbx_LiabilitiesRelatedToFinancingActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Related To Financing Activities [Member]</link:label>
    <link:label id="lab_nbx_LiabilitiesRelatedToFinancingActivitiesMember_documentation_en-US" xlink:label="lab_nbx_LiabilitiesRelatedToFinancingActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Related To Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesRelatedToFinancingActivitiesMember" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesRelatedToFinancingActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LiabilitiesRelatedToFinancingActivitiesMember" xlink:to="lab_nbx_LiabilitiesRelatedToFinancingActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_9150d9ea-2915-4191-99f3-d5af90528390_terseLabel_en-US" xlink:label="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Yield</link:label>
    <link:label id="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend As Percentage, Other Equity Instruments Granted</link:label>
    <link:label id="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Dividend As Percentage, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:href="nbx-20250630.xsd#nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:to="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_8454e2ee-c6eb-43cf-a115-8acd6a570a0c_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ClinicalStudiesDomain_c9a2ba01-9edd-46f3-93bf-3bc91556a594_terseLabel_en-US" xlink:label="lab_nbx_ClinicalStudiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Studies [Domain]</link:label>
    <link:label id="lab_nbx_ClinicalStudiesDomain_label_en-US" xlink:label="lab_nbx_ClinicalStudiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Studies [Domain]</link:label>
    <link:label id="lab_nbx_ClinicalStudiesDomain_documentation_en-US" xlink:label="lab_nbx_ClinicalStudiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Studies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ClinicalStudiesDomain" xlink:href="nbx-20250630.xsd#nbx_ClinicalStudiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ClinicalStudiesDomain" xlink:to="lab_nbx_ClinicalStudiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_609f2ac0-8fcd-4f75-9389-b92171f17728_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_124f0d78-d162-4887-a179-4074040c658e_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic loss per share (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MDAndersonCancerCenterNBTXR3Member_e40e8b63-b117-4c8b-83fd-d4860d433be8_terseLabel_en-US" xlink:label="lab_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MD Anderson Cancer Center, NBTXR3</link:label>
    <link:label id="lab_nbx_MDAndersonCancerCenterNBTXR3Member_label_en-US" xlink:label="lab_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MD Anderson Cancer Center, NBTXR3 [Member]</link:label>
    <link:label id="lab_nbx_MDAndersonCancerCenterNBTXR3Member_documentation_en-US" xlink:label="lab_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MD Anderson Cancer Center, NBTXR3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:href="nbx-20250630.xsd#nbx_MDAndersonCancerCenterNBTXR3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:to="lab_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_d68b6c34-97d8-49df-a0fe-f4db0cec5bdb_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in deferred revenues and contract liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in deferred income including contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementAxis_8900d002-1ea9-4865-a915-fad19b1458c5_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:label id="lab_ifrs-full_MeasurementAxis_label_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_EnnoSpillnerMember_1ff32ae1-1595-4b07-aab8-027e3041805a_terseLabel_en-US" xlink:label="lab_nbx_EnnoSpillnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enno SPILLNER</link:label>
    <link:label id="lab_nbx_EnnoSpillnerMember_label_en-US" xlink:label="lab_nbx_EnnoSpillnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enno Spillner [Member]</link:label>
    <link:label id="lab_nbx_EnnoSpillnerMember_documentation_en-US" xlink:label="lab_nbx_EnnoSpillnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enno Spillner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EnnoSpillnerMember" xlink:href="nbx-20250630.xsd#nbx_EnnoSpillnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_EnnoSpillnerMember" xlink:to="lab_nbx_EnnoSpillnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LumpSumRetirementBenefitsMember_d2876c33-6289-4d7b-9a35-6136f11cee47_terseLabel_en-US" xlink:label="lab_nbx_LumpSumRetirementBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lump-sum retirement benefits</link:label>
    <link:label id="lab_nbx_LumpSumRetirementBenefitsMember_label_en-US" xlink:label="lab_nbx_LumpSumRetirementBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lump-Sum Retirement Benefits [Member]</link:label>
    <link:label id="lab_nbx_LumpSumRetirementBenefitsMember_documentation_en-US" xlink:label="lab_nbx_LumpSumRetirementBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lump-Sum Retirement Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LumpSumRetirementBenefitsMember" xlink:href="nbx-20250630.xsd#nbx_LumpSumRetirementBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LumpSumRetirementBenefitsMember" xlink:to="lab_nbx_LumpSumRetirementBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonRecurringExpenseTypeDomain_d35b49fc-c2bd-41e4-a56d-4b5edb23bcd8_terseLabel_en-US" xlink:label="lab_nbx_NonRecurringExpenseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Recurring Expense Type [Domain]</link:label>
    <link:label id="lab_nbx_NonRecurringExpenseTypeDomain_label_en-US" xlink:label="lab_nbx_NonRecurringExpenseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Recurring Expense Type [Domain]</link:label>
    <link:label id="lab_nbx_NonRecurringExpenseTypeDomain_documentation_en-US" xlink:label="lab_nbx_NonRecurringExpenseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Recurring Expense Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonRecurringExpenseTypeDomain" xlink:href="nbx-20250630.xsd#nbx_NonRecurringExpenseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonRecurringExpenseTypeDomain" xlink:to="lab_nbx_NonRecurringExpenseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfProvisionsExplanatory_a7aeffc8-0c89-4aa0-be2d-841c87e36237_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE2017OrdinaryMember_79325281-1d14-4269-a8ac-0c2519176ac8_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSPCE 2017 O</link:label>
    <link:label id="lab_nbx_BSPCE2017OrdinaryMember_label_en-US" xlink:label="lab_nbx_BSPCE2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSPCE 2017 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2017OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_BSPCE2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSPCE 2017 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017OrdinaryMember" xlink:href="nbx-20250630.xsd#nbx_BSPCE2017OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2017OrdinaryMember" xlink:to="lab_nbx_BSPCE2017OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_fca8db9a-9cd5-4ca6-b40d-97e12e2f08bb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_93d2f92e-c6a7-4964-ae2b-ae3dd8f9898d_terseLabel_en-US" xlink:label="lab_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of beneficiaries who are not corporate officers</link:label>
    <link:label id="lab_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Beneficiaries Of Other Equity Instruments, Share-Based Payment Arrangement</link:label>
    <link:label id="lab_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Beneficiaries Of Other Equity Instruments, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" xlink:href="nbx-20250630.xsd#nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" xlink:to="lab_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_JanssenPharmaceuticaBVMember_fc5bfd2e-a581-40a5-b8fd-9f526bf73249_terseLabel_en-US" xlink:label="lab_nbx_JanssenPharmaceuticaBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceutica BV</link:label>
    <link:label id="lab_nbx_JanssenPharmaceuticaBVMember_label_en-US" xlink:label="lab_nbx_JanssenPharmaceuticaBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceutica BV [Member]</link:label>
    <link:label id="lab_nbx_JanssenPharmaceuticaBVMember_documentation_en-US" xlink:label="lab_nbx_JanssenPharmaceuticaBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceutica BV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaBVMember" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_JanssenPharmaceuticaBVMember" xlink:to="lab_nbx_JanssenPharmaceuticaBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_7b0c22a7-867d-42eb-a553-2ddb16d77707_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_120bf74e-f35b-41e5-b5ce-2b3adcabc378_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FloatingInterestRateMember_c16b0b1a-26b5-42f9-b45c-47fb3c4cbc92_terseLabel_en-US" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable interest rate</link:label>
    <link:label id="lab_ifrs-full_FloatingInterestRateMember_label_en-US" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Floating interest rate [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FloatingInterestRateMember" xlink:to="lab_ifrs-full_FloatingInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_7c9badfb-4aff-413f-8543-62157ad9a32d_netLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total number of shares available for subscription (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_cee92d07-146d-4318-93c9-201db995b6aa_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of awards available for subscription (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NetCollectionsPaymentsFromRelatedParty_efec1c60-4771-4903-a383-e70aaf6b44fc_totalLabel_en-US" xlink:label="lab_nbx_NetCollectionsPaymentsFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net collections</link:label>
    <link:label id="lab_nbx_NetCollectionsPaymentsFromRelatedParty_label_en-US" xlink:label="lab_nbx_NetCollectionsPaymentsFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Collections (Payments) From Related Party</link:label>
    <link:label id="lab_nbx_NetCollectionsPaymentsFromRelatedParty_documentation_en-US" xlink:label="lab_nbx_NetCollectionsPaymentsFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Collections (Payments) From Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetCollectionsPaymentsFromRelatedParty" xlink:href="nbx-20250630.xsd#nbx_NetCollectionsPaymentsFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NetCollectionsPaymentsFromRelatedParty" xlink:to="lab_nbx_NetCollectionsPaymentsFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20191Member_c3319054-b971-46d3-b5d7-f7152a843a94_terseLabel_en-US" xlink:label="lab_nbx_BSA20191Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2019-1</link:label>
    <link:label id="lab_nbx_BSA20191Member_label_en-US" xlink:label="lab_nbx_BSA20191Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2019-1 [Member]</link:label>
    <link:label id="lab_nbx_BSA20191Member_documentation_en-US" xlink:label="lab_nbx_BSA20191Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA 2019-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member" xlink:href="nbx-20250630.xsd#nbx_BSA20191Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20191Member" xlink:to="lab_nbx_BSA20191Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ProvisionForRetirementBenefitObligationsNet_c8bc4da0-840b-4fc7-a6b2-7b892df02103_negatedTerseLabel_en-US" xlink:label="lab_nbx_ProvisionForRetirementBenefitObligationsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total Provision for retirement benefit obligations (IAS 19)</link:label>
    <link:label id="lab_nbx_ProvisionForRetirementBenefitObligationsNet_label_en-US" xlink:label="lab_nbx_ProvisionForRetirementBenefitObligationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for Retirement Benefit Obligations&#160;Net</link:label>
    <link:label id="lab_nbx_ProvisionForRetirementBenefitObligationsNet_documentation_en-US" xlink:label="lab_nbx_ProvisionForRetirementBenefitObligationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision for Retirement Benefit Obligations&#160;Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionForRetirementBenefitObligationsNet" xlink:href="nbx-20250630.xsd#nbx_ProvisionForRetirementBenefitObligationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ProvisionForRetirementBenefitObligationsNet" xlink:to="lab_nbx_ProvisionForRetirementBenefitObligationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_20dabe3f-4f45-43d8-acca-af563d04c3b7_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock_32bd0956-1e75-4643-b364-3134a3b82c8a_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other current liabilities</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Trade Payables And Other Current Liabilities [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Trade Payables And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:to="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_26d08bf6-33a3-406b-bbac-1fd94aba6008_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_ae462fd2-7d1a-4af7-97fc-78c41338dd27_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:to="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_ac750082-c146-4b62-a254-21231a99422e_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses related to share-based payments</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_A2024TaxYearMember_3f37ca62-c6f6-48b0-9be7-0b004e55cd8e_terseLabel_en-US" xlink:label="lab_nbx_A2024TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Tax Year</link:label>
    <link:label id="lab_nbx_A2024TaxYearMember_label_en-US" xlink:label="lab_nbx_A2024TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Tax Year [Member]</link:label>
    <link:label id="lab_nbx_A2024TaxYearMember_documentation_en-US" xlink:label="lab_nbx_A2024TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2024TaxYearMember" xlink:href="nbx-20250630.xsd#nbx_A2024TaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_A2024TaxYearMember" xlink:to="lab_nbx_A2024TaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ea822fc6-1b8d-44e4-a0c8-c0fee441606d_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20151Member_538ce59e-e95c-4490-85cb-faaf250c3ca5_terseLabel_en-US" xlink:label="lab_nbx_BSA20151Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2015-1</link:label>
    <link:label id="lab_nbx_BSA20151Member_label_en-US" xlink:label="lab_nbx_BSA20151Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2015-1 [Member]</link:label>
    <link:label id="lab_nbx_BSA20151Member_documentation_en-US" xlink:label="lab_nbx_BSA20151Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA 2015-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member" xlink:href="nbx-20250630.xsd#nbx_BSA20151Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20151Member" xlink:to="lab_nbx_BSA20151Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DebtDetailsDomain_7d3602ff-a2e6-4a33-95e0-fee08684b844_terseLabel_en-US" xlink:label="lab_nbx_DebtDetailsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Details [Domain]</link:label>
    <link:label id="lab_nbx_DebtDetailsDomain_label_en-US" xlink:label="lab_nbx_DebtDetailsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Details [Domain]</link:label>
    <link:label id="lab_nbx_DebtDetailsDomain_documentation_en-US" xlink:label="lab_nbx_DebtDetailsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Details [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DebtDetailsDomain" xlink:href="nbx-20250630.xsd#nbx_DebtDetailsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DebtDetailsDomain" xlink:to="lab_nbx_DebtDetailsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementAxis_0ae4b54b-a6f6-45d8-bb72-39576f5be3b9_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Axis]</link:label>
    <link:label id="lab_nbx_CollaborationAgreementAxis_label_en-US" xlink:label="lab_nbx_CollaborationAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Axis]</link:label>
    <link:label id="lab_nbx_CollaborationAgreementAxis_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementAxis" xlink:to="lab_nbx_CollaborationAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA2023Member_b737a176-1991-4ede-91ec-b37c30468019_terseLabel_en-US" xlink:label="lab_nbx_AGA2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA 2023</link:label>
    <link:label id="lab_nbx_AGA2023Member_label_en-US" xlink:label="lab_nbx_AGA2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA 2023 [Member]</link:label>
    <link:label id="lab_nbx_AGA2023Member_documentation_en-US" xlink:label="lab_nbx_AGA2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023Member" xlink:href="nbx-20250630.xsd#nbx_AGA2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA2023Member" xlink:to="lab_nbx_AGA2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_37423113-5f5c-46f3-baad-2a99b2c884e5_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_e3803f5d-551f-4d9d-af79-1a6122653352_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Obligations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of employee benefits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCEMember_f1dbd310-58d4-4d99-9ff9-b424b59e310e_terseLabel_en-US" xlink:label="lab_nbx_BSPCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSPCE</link:label>
    <link:label id="lab_nbx_BSPCEMember_label_en-US" xlink:label="lab_nbx_BSPCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSPCE [Member]</link:label>
    <link:label id="lab_nbx_BSPCEMember_documentation_en-US" xlink:label="lab_nbx_BSPCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSPCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember" xlink:href="nbx-20250630.xsd#nbx_BSPCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCEMember" xlink:to="lab_nbx_BSPCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_ca8b86e5-a0ea-444c-8f6b-ba1763d872b3_negatedTerseLabel_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and provision expenses</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_label_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_documentation_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:href="nbx-20250630.xsd#nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:to="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_5c4a2006-de74-4fa6-9136-662dfe531617_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_c83da7f8-b5b1-4c71-a449-61a61a53444e_negatedTerseLabel_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payroll costs (including share-based payments)</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_label_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling General And Administrative Expense, Payroll Costs</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_documentation_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selling General And Administrative Expense, Payroll Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:href="nbx-20250630.xsd#nbx_SellingGeneralAndAdministrativeExpensePayrollCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:to="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_494a65c3-9096-4587-ab5e-e31a3b179f7b_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_58c8f60a-c039-4493-95b9-505b25d11a47_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_81025fbb-33f0-4976-9de0-ae82bf504300_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_c02bb70f-42d3-4c3b-ac7b-0a35acd84c68_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_8802333c-0d2a-45e9-8af3-a17ed5aecf0a_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retirement benefit obligations</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:to="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_c8161072-dd15-4691-b1f9-136a1f2855a6_terseLabel_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HSBC "PGE" and Bpifrance "PGE"</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_label_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Dilutive Financing Agreement, HSBC France And BPI France [Member]</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_documentation_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Dilutive Financing Agreement, HSBC France And BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:to="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_da0dd2ce-e27a-47ed-85c7-a0748ae7f713_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationExpense_ec9ef854-6cc9-4905-9dc9-27b5516eab37_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense of intangible assets</link:label>
    <link:label id="lab_ifrs-full_AmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense" xlink:to="lab_ifrs-full_AmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202502OrdinaryMember_4aba5a3a-11e7-445d-8ad4-0c56a42dea02_terseLabel_en-US" xlink:label="lab_nbx_OSA202502OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2025-02 O</link:label>
    <link:label id="lab_nbx_OSA202502OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA202502OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2025-02 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA202502OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA202502OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2025-02 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202502OrdinaryMember" xlink:href="nbx-20250630.xsd#nbx_OSA202502OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202502OrdinaryMember" xlink:to="lab_nbx_OSA202502OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_3ef79d68-cbce-425d-8849-d1e47b983065_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_8681287e-d810-4e9d-9af3-8dda701d924a_terseLabel_en-US" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_label_en-US" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-derivative financial liabilities, undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202106PerformanceMember_0381eb9a-2f75-4575-b3de-ac85463fbcfe_terseLabel_en-US" xlink:label="lab_nbx_OSA202106PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2021-06 P</link:label>
    <link:label id="lab_nbx_OSA202106PerformanceMember_label_en-US" xlink:label="lab_nbx_OSA202106PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2021-06 Performance [Member]</link:label>
    <link:label id="lab_nbx_OSA202106PerformanceMember_documentation_en-US" xlink:label="lab_nbx_OSA202106PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2021-06 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106PerformanceMember" xlink:href="nbx-20250630.xsd#nbx_OSA202106PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202106PerformanceMember" xlink:to="lab_nbx_OSA202106PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable_e70639d4-ff7f-40bd-b8ef-a213e716e04b_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Information Related To The Company [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable_label_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Information Related To The Company [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Information Related To The Company [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:to="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BanquePubliqueDInvestissementMember_4f4be327-6185-4b76-9eaf-9b687808c9ab_terseLabel_en-US" xlink:label="lab_nbx_BanquePubliqueDInvestissementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Banque Publique d&#8217;Investissement</link:label>
    <link:label id="lab_nbx_BanquePubliqueDInvestissementMember_label_en-US" xlink:label="lab_nbx_BanquePubliqueDInvestissementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Banque Publique d&#8217;Investissement [Member]</link:label>
    <link:label id="lab_nbx_BanquePubliqueDInvestissementMember_documentation_en-US" xlink:label="lab_nbx_BanquePubliqueDInvestissementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Banque Publique d&#8217;Investissement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BanquePubliqueDInvestissementMember" xlink:href="nbx-20250630.xsd#nbx_BanquePubliqueDInvestissementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BanquePubliqueDInvestissementMember" xlink:to="lab_nbx_BanquePubliqueDInvestissementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Advances_ade16444-5ab0-41cc-b299-8f0bf40dfe79_terseLabel_en-US" xlink:label="lab_ifrs-full_Advances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances received</link:label>
    <link:label id="lab_ifrs-full_Advances_label_en-US" xlink:label="lab_ifrs-full_Advances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advances received, representing contract liabilities for performance obligations satisfied at point in time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Advances" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Advances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Advances" xlink:to="lab_ifrs-full_Advances" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_76e58e47-6285-43ca-9ae1-9f689f0c0a25_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BartVanRhijnMember_9a6389fd-7eb0-4a2c-8efc-6bed97c639fb_terseLabel_en-US" xlink:label="lab_nbx_BartVanRhijnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bart VAN RHIJN</link:label>
    <link:label id="lab_nbx_BartVanRhijnMember_label_en-US" xlink:label="lab_nbx_BartVanRhijnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bart Van Rhijn [Member]</link:label>
    <link:label id="lab_nbx_BartVanRhijnMember_documentation_en-US" xlink:label="lab_nbx_BartVanRhijnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bart Van Rhijn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BartVanRhijnMember" xlink:href="nbx-20250630.xsd#nbx_BartVanRhijnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BartVanRhijnMember" xlink:to="lab_nbx_BartVanRhijnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_3ab7fd1b-dfb2-491c-9c49-ccd8ed9984cf_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_7b3107a4-b8be-4788-b6c9-f9e8c9cf6eb6_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA20162Member_4373690b-2b87-4bb0-b147-6c8bc551b7f8_terseLabel_en-US" xlink:label="lab_nbx_OSA20162Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2016-2</link:label>
    <link:label id="lab_nbx_OSA20162Member_label_en-US" xlink:label="lab_nbx_OSA20162Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2016-2 [Member]</link:label>
    <link:label id="lab_nbx_OSA20162Member_documentation_en-US" xlink:label="lab_nbx_OSA20162Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2016-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member" xlink:href="nbx-20250630.xsd#nbx_OSA20162Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA20162Member" xlink:to="lab_nbx_OSA20162Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_b196faef-b627-4d23-8996-1efc1b9daaa5_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fbb3427a-7b7b-48ae-b4dd-8d617b8c69f2_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, class [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingPeriodAxis_801eb01e-7b32-4143-9009-fba7ea0ded8a_terseLabel_en-US" xlink:label="lab_nbx_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_nbx_VestingPeriodAxis_label_en-US" xlink:label="lab_nbx_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period [Axis]</link:label>
    <link:label id="lab_nbx_VestingPeriodAxis_documentation_en-US" xlink:label="lab_nbx_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingPeriodAxis" xlink:href="nbx-20250630.xsd#nbx_VestingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingPeriodAxis" xlink:to="lab_nbx_VestingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_9b901106-ceb2-4bd2-914f-7dc150633dad_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory_0e0217c3-a51a-400a-8756-149dc48f5daa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Provisions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageNumberOfEmployees_dfdf612b-1a27-43bf-96ae-98757953e261_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average headcount</link:label>
    <link:label id="lab_ifrs-full_AverageNumberOfEmployees_label_en-US" xlink:label="lab_ifrs-full_AverageNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average number of employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageNumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AverageNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageNumberOfEmployees" xlink:to="lab_ifrs-full_AverageNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SocialSecurityContributions_19344eca-1f5c-4797-bb59-06b1f83b8ce6_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SocialSecurityContributions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payroll taxes</link:label>
    <link:label id="lab_ifrs-full_SocialSecurityContributions_label_en-US" xlink:label="lab_ifrs-full_SocialSecurityContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Social security contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SocialSecurityContributions" xlink:to="lab_ifrs-full_SocialSecurityContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock_449cf2f1-6837-433f-ab02-de7a5fabcb69_terseLabel_en-US" xlink:label="lab_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Detailed Information About Refund Liabilities</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed Information About Refund Liabilities [Table Text Block]</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Detailed Information About Refund Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock" xlink:to="lab_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock_0f60c953-99b0-4e0f-ab59-b16bb3d9d412_terseLabel_en-US" xlink:label="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues and Other Income</link:label>
    <link:label id="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosur Of Disaggregation Of Revenues And Other Income [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosur Of Disaggregation Of Revenues And Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:to="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonCurrentLiquidityContractMember_0a29eb40-abb2-4c20-af3f-743ee2f99c24_terseLabel_en-US" xlink:label="lab_nbx_NonCurrentLiquidityContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposits paid</link:label>
    <link:label id="lab_nbx_NonCurrentLiquidityContractMember_label_en-US" xlink:label="lab_nbx_NonCurrentLiquidityContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current, Liquidity Contract [Member]</link:label>
    <link:label id="lab_nbx_NonCurrentLiquidityContractMember_documentation_en-US" xlink:label="lab_nbx_NonCurrentLiquidityContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-current, Liquidity Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentLiquidityContractMember" xlink:href="nbx-20250630.xsd#nbx_NonCurrentLiquidityContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonCurrentLiquidityContractMember" xlink:to="lab_nbx_NonCurrentLiquidityContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_7dfdab06-6b93-4fde-9ef4-6915dca8d67a_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premiums related to share capital</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_58b17e9f-4012-4d55-a7f4-3affecbdd7cb_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisions" xlink:to="lab_ifrs-full_NoncurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202106OrdinaryMember_e7d7c38b-6cd1-4728-ab46-f21241654ca1_terseLabel_en-US" xlink:label="lab_nbx_OSA202106OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2021-06 O</link:label>
    <link:label id="lab_nbx_OSA202106OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA202106OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2021-06 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA202106OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA202106OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2021-06 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember" xlink:href="nbx-20250630.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202106OrdinaryMember" xlink:to="lab_nbx_OSA202106OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AnneMarieGraffinMember_be1fc16e-7a63-46c7-b326-7388a1e8eef1_terseLabel_en-US" xlink:label="lab_nbx_AnneMarieGraffinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anne-Marie GRAFFIN</link:label>
    <link:label id="lab_nbx_AnneMarieGraffinMember_label_en-US" xlink:label="lab_nbx_AnneMarieGraffinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anne-Marie Graffin [Member]</link:label>
    <link:label id="lab_nbx_AnneMarieGraffinMember_documentation_en-US" xlink:label="lab_nbx_AnneMarieGraffinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Anne-Marie Graffin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneMarieGraffinMember" xlink:href="nbx-20250630.xsd#nbx_AnneMarieGraffinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AnneMarieGraffinMember" xlink:to="lab_nbx_AnneMarieGraffinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_573b338f-9e09-490c-b926-6ed8c78490ca_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [member]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_574aead9-b3c9-44d0-a1e6-f418315a9c3e_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_e8407eba-ae59-4a7a-a077-754a9499df79_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_f8a1bf58-6d2b-4eac-a6ad-b371c085ac73_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NanobiotixCorpMember_341a6b8f-1c00-4b7d-b630-8539aae69c7f_terseLabel_en-US" xlink:label="lab_nbx_NanobiotixCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nanobiotix Corp.</link:label>
    <link:label id="lab_nbx_NanobiotixCorpMember_label_en-US" xlink:label="lab_nbx_NanobiotixCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nanobiotix Corp. [Member]</link:label>
    <link:label id="lab_nbx_NanobiotixCorpMember_documentation_en-US" xlink:label="lab_nbx_NanobiotixCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nanobiotix Corp.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixCorpMember" xlink:href="nbx-20250630.xsd#nbx_NanobiotixCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NanobiotixCorpMember" xlink:to="lab_nbx_NanobiotixCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_82652601-743b-4f85-9e0c-c88c10dffbe1_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office and IT equipment</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_StockOptionsGranted_6b1c3371-4697-4e3b-b0a8-d41c0dc44348_terseLabel_en-US" xlink:label="lab_nbx_StockOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted</link:label>
    <link:label id="lab_nbx_StockOptionsGranted_label_en-US" xlink:label="lab_nbx_StockOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Granted</link:label>
    <link:label id="lab_nbx_StockOptionsGranted_documentation_en-US" xlink:label="lab_nbx_StockOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_StockOptionsGranted" xlink:href="nbx-20250630.xsd#nbx_StockOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_StockOptionsGranted" xlink:to="lab_nbx_StockOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_ec9bfbc4-7acc-45a8-9b93-83d4ce6cc2c9_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax impact</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to exchange differences on translation of foreign operations included in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingGuaranteeFee_b68f11a3-9c65-4e0a-a88c-977902dff53a_terseLabel_en-US" xlink:label="lab_nbx_BorrowingGuaranteeFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, guarantee fee</link:label>
    <link:label id="lab_nbx_BorrowingGuaranteeFee_label_en-US" xlink:label="lab_nbx_BorrowingGuaranteeFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Guarantee Fee</link:label>
    <link:label id="lab_nbx_BorrowingGuaranteeFee_documentation_en-US" xlink:label="lab_nbx_BorrowingGuaranteeFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Guarantee Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingGuaranteeFee" xlink:href="nbx-20250630.xsd#nbx_BorrowingGuaranteeFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingGuaranteeFee" xlink:to="lab_nbx_BorrowingGuaranteeFee" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2021AMember_4efe762e-190b-4025-b533-21e333e3ae28_terseLabel_en-US" xlink:label="lab_nbx_BSA2021AMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2021</link:label>
    <link:label id="lab_nbx_BSA2021AMember_label_en-US" xlink:label="lab_nbx_BSA2021AMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2021 (a) [Member]</link:label>
    <link:label id="lab_nbx_BSA2021AMember_documentation_en-US" xlink:label="lab_nbx_BSA2021AMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA 2021 (a)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember" xlink:href="nbx-20250630.xsd#nbx_BSA2021AMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2021AMember" xlink:to="lab_nbx_BSA2021AMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_f4df2e33-a372-407a-82d4-2dd3d8c7c7fc_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_c4ed5eb2-1386-4c1d-849d-be48adf2e735_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_3b182b73-a39c-46e1-a8fc-36cdc991d1d7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202501OrdinaryMember_54ee93fd-2826-4f5a-bad2-0080937b5e16_terseLabel_en-US" xlink:label="lab_nbx_OSA202501OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2025-01 O</link:label>
    <link:label id="lab_nbx_OSA202501OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA202501OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2025-01 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA202501OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA202501OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2025-01 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202501OrdinaryMember" xlink:href="nbx-20250630.xsd#nbx_OSA202501OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202501OrdinaryMember" xlink:to="lab_nbx_OSA202501OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_3fc66238-8d92-4c06-91ae-6d3673d58ad5_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit_28ee7794-2369-4f88-8327-3458df30d100_terseLabel_en-US" xlink:label="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 research tax credit</link:label>
    <link:label id="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit_label_en-US" xlink:label="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Receivables From Taxes Other Than Income Tax, Income Tax Credit</link:label>
    <link:label id="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit_documentation_en-US" xlink:label="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Receivables From Taxes Other Than Income Tax, Income Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit" xlink:href="nbx-20250630.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit" xlink:to="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_263d6fe9-fece-427b-ad7e-4c879c466414_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_8e44e472-1959-4936-aaf6-5afcdb92a84d_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at end of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_16f65bca-b700-49c7-b32f-b78001f15137_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_e825dc6f-f301-495d-9cec-40c8c3a26237_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_18739759-310e-4cfb-8927-aef0dfca0e55_terseLabel_en-US" xlink:label="lab_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of awards authorised (in shares)</link:label>
    <link:label id="lab_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Other Equity Instruments Authorised In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Other Equity Instruments Authorised In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" xlink:href="nbx-20250630.xsd#nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" xlink:to="lab_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisions_8f1067f6-93cf-4714-b19f-56da73b17c50_periodStartLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Other provisions at beginning of period</link:label>
    <link:label id="lab_ifrs-full_OtherProvisions_35572ea0-caf0-462b-b278-5446d8ea3766_periodEndLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Other provisions at end of period</link:label>
    <link:label id="lab_ifrs-full_OtherProvisions_label_en-US" xlink:label="lab_ifrs-full_OtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisions" xlink:to="lab_ifrs-full_OtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_b6fea1fc-bcab-4ac2-8898-bf193bc24d9b_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilities_b9d66d0a-fca5-4ed6-923e-2bafd94de9cb_totalLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2021Member_4623e82b-ee33-4fda-85f1-bce4acf69150_terseLabel_en-US" xlink:label="lab_nbx_BSA2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2021</link:label>
    <link:label id="lab_nbx_BSA2021Member_label_en-US" xlink:label="lab_nbx_BSA2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2021 [Member]</link:label>
    <link:label id="lab_nbx_BSA2021Member_documentation_en-US" xlink:label="lab_nbx_BSA2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021Member" xlink:href="nbx-20250630.xsd#nbx_BSA2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2021Member" xlink:to="lab_nbx_BSA2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA2023Performance2Member_4642b15c-db3f-4f8a-bc93-4efaf10a17e0_terseLabel_en-US" xlink:label="lab_nbx_AGA2023Performance2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA 2023 - P2</link:label>
    <link:label id="lab_nbx_AGA2023Performance2Member_label_en-US" xlink:label="lab_nbx_AGA2023Performance2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA 2023 Performance2 [Member]</link:label>
    <link:label id="lab_nbx_AGA2023Performance2Member_documentation_en-US" xlink:label="lab_nbx_AGA2023Performance2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA 2023 Performance2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023Performance2Member" xlink:href="nbx-20250630.xsd#nbx_AGA2023Performance2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA2023Performance2Member" xlink:to="lab_nbx_AGA2023Performance2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_e52c7862-b8db-4aec-a3da-f0f0e410a722_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_8563444b-f6e1-4ff2-939c-fe651d8bc404_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_ac854efc-20dc-4f64-add2-b50d7f6af917_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred income and current contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current deferred income including current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ImpactOfAmendmentOnProfitOrLoss_990418ce-1093-4111-88b0-95e297137a81_terseLabel_en-US" xlink:label="lab_nbx_ImpactOfAmendmentOnProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of the Janssen amendment on profit or loss</link:label>
    <link:label id="lab_nbx_ImpactOfAmendmentOnProfitOrLoss_label_en-US" xlink:label="lab_nbx_ImpactOfAmendmentOnProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of Amendment on Profit or Loss</link:label>
    <link:label id="lab_nbx_ImpactOfAmendmentOnProfitOrLoss_documentation_en-US" xlink:label="lab_nbx_ImpactOfAmendmentOnProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impact of Amendment on Profit or Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ImpactOfAmendmentOnProfitOrLoss" xlink:href="nbx-20250630.xsd#nbx_ImpactOfAmendmentOnProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ImpactOfAmendmentOnProfitOrLoss" xlink:to="lab_nbx_ImpactOfAmendmentOnProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_1637c04f-c950-43be-bc00-debc48117b35_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdditionalLiquidityBusinessObligations_ce21b68f-bb86-4859-8346-737f4160861b_terseLabel_en-US" xlink:label="lab_nbx_AdditionalLiquidityBusinessObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional liquidity business obligations</link:label>
    <link:label id="lab_nbx_AdditionalLiquidityBusinessObligations_label_en-US" xlink:label="lab_nbx_AdditionalLiquidityBusinessObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Liquidity Business Obligations</link:label>
    <link:label id="lab_nbx_AdditionalLiquidityBusinessObligations_documentation_en-US" xlink:label="lab_nbx_AdditionalLiquidityBusinessObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Liquidity Business Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdditionalLiquidityBusinessObligations" xlink:href="nbx-20250630.xsd#nbx_AdditionalLiquidityBusinessObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdditionalLiquidityBusinessObligations" xlink:to="lab_nbx_AdditionalLiquidityBusinessObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TradeAndOtherPayablesMember_f64036c6-1380-4e2d-a7b7-2a4bb3d42bfc_terseLabel_en-US" xlink:label="lab_nbx_TradeAndOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other payables</link:label>
    <link:label id="lab_nbx_TradeAndOtherPayablesMember_label_en-US" xlink:label="lab_nbx_TradeAndOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade And Other Payables [Member]</link:label>
    <link:label id="lab_nbx_TradeAndOtherPayablesMember_documentation_en-US" xlink:label="lab_nbx_TradeAndOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade And Other Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TradeAndOtherPayablesMember" xlink:href="nbx-20250630.xsd#nbx_TradeAndOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TradeAndOtherPayablesMember" xlink:to="lab_nbx_TradeAndOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BPIFranceAdvanceMember_066552a5-ec20-4cc2-bfc1-fc586b655864_terseLabel_en-US" xlink:label="lab_nbx_BPIFranceAdvanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bpifrance advance</link:label>
    <link:label id="lab_nbx_BPIFranceAdvanceMember_label_en-US" xlink:label="lab_nbx_BPIFranceAdvanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BPI France Advance [Member]</link:label>
    <link:label id="lab_nbx_BPIFranceAdvanceMember_documentation_en-US" xlink:label="lab_nbx_BPIFranceAdvanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BPI France Advance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceAdvanceMember" xlink:href="nbx-20250630.xsd#nbx_BPIFranceAdvanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BPIFranceAdvanceMember" xlink:to="lab_nbx_BPIFranceAdvanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfEmployees_3173a549-6b71-4500-a933-e9bc3cf43a6d_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_ifrs-full_NumberOfEmployees_ae73c55e-c208-4b1a-8ecb-40f7a9bab7c9_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">End-of-period headcount</link:label>
    <link:label id="lab_ifrs-full_NumberOfEmployees_label_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfEmployees" xlink:to="lab_ifrs-full_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_56b8df2f-bffa-482a-8a9e-fc0c8ee600c2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_3dd2b331-39e7-4aa4-8750-84616219cc1e_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ClinicalProductsMember_373164a6-5577-4db7-ba25-3e706283d83b_terseLabel_en-US" xlink:label="lab_nbx_ClinicalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical products</link:label>
    <link:label id="lab_nbx_ClinicalProductsMember_label_en-US" xlink:label="lab_nbx_ClinicalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Products [Member]</link:label>
    <link:label id="lab_nbx_ClinicalProductsMember_documentation_en-US" xlink:label="lab_nbx_ClinicalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ClinicalProductsMember" xlink:href="nbx-20250630.xsd#nbx_ClinicalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ClinicalProductsMember" xlink:to="lab_nbx_ClinicalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_48cbe2c0-2c37-44b4-b451-802495e10e38_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_0d333033-4ff2-442d-9c6e-6757e2a15a4b_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total SG&amp;A expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e7acd539-9815-4110-984a-b9275ac6fbd0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8428f97d-15f4-4f18-b51f-478c40af9653_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense for the year</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from equity-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d039e01c-6969-49e8-90c6-a7d1971c070e_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_69724f17-e806-4c9e-85ab-01060d2e6453_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b24fcf7-9e08-4f7e-b92d-e0476cc01f62_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_86f0f1d4-9ea8-4c44-9a0c-cbfb3e8cdef9_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_8098cb33-ccb0-49d9-a052-203afbc1a50e_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current deferred income other than current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_6cb50c12-559f-42ea-8777-54d510ec117b_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_71f7f5ef-7891-48cd-9c43-208fe41f3e4c_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top of range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DepreciationAmortizationAndProvisionExpenses_de655632-2411-48b7-a5f4-8654db7d5fbb_negatedTotalLabel_en-US" xlink:label="lab_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total depreciation, amortization and provision expenses</link:label>
    <link:label id="lab_nbx_DepreciationAmortizationAndProvisionExpenses_label_en-US" xlink:label="lab_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization And Provision Expenses</link:label>
    <link:label id="lab_nbx_DepreciationAmortizationAndProvisionExpenses_documentation_en-US" xlink:label="lab_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization And Provision Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:href="nbx-20250630.xsd#nbx_DepreciationAmortizationAndProvisionExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:to="lab_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_89b8101f-30f6-4282-81eb-2ad2522254ad_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_3949fb2c-c8c2-421c-a05c-e3423e44fd23_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_72d92970-043c-4a28-8e55-f62a7bf7725d_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_a6548ce1-02c0-419e-9487-9e48a1a9bcd2_terseLabel_en-US" xlink:label="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Curadigm interest-free Bpifrance advance</link:label>
    <link:label id="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_label_en-US" xlink:label="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest-free Advance To Curadigm, BPI France [Member]</link:label>
    <link:label id="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_documentation_en-US" xlink:label="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest-free Advance To Curadigm, BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:href="nbx-20250630.xsd#nbx_InterestFreeAdvanceToCuradigmBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:to="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeGain_8113b78d-ec2e-44a2-9016-632a8cc6e563_terseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeGain_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net foreign exchange gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeGain" xlink:to="lab_ifrs-full_NetForeignExchangeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_12ffa035-1f4b-431f-a238-be366d3aa510_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ab44a50c-599c-440a-897b-0548bf16ac16_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_d5a291d9-5517-468b-bb6e-288e6144d4dc_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_066c1c57-d78d-4549-aaf9-3aedf9d3c057_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_75655e73-4dbd-4295-846f-934373d303ad_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_69be5ecb-49bc-4e38-a5bf-47ee227fe74b_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities" xlink:to="lab_ifrs-full_GrossLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_RechargeMember_bf27a1c2-c3ef-4f4c-b00c-2b1b4f35a76b_terseLabel_en-US" xlink:label="lab_nbx_RechargeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recharge</link:label>
    <link:label id="lab_nbx_RechargeMember_label_en-US" xlink:label="lab_nbx_RechargeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recharge [Member]</link:label>
    <link:label id="lab_nbx_RechargeMember_documentation_en-US" xlink:label="lab_nbx_RechargeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recharge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RechargeMember" xlink:href="nbx-20250630.xsd#nbx_RechargeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_RechargeMember" xlink:to="lab_nbx_RechargeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_544c7c52-d2bc-4a06-bc89-dcc809b15657_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss that will not be reclassified subsequently to income or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentRefundsProvision_68514661-b705-4aa1-8c89-130a909b0773_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentRefundsProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current refund liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentRefundsProvision_label_en-US" xlink:label="lab_ifrs-full_CurrentRefundsProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current refunds provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRefundsProvision" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRefundsProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentRefundsProvision" xlink:to="lab_ifrs-full_CurrentRefundsProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_da388c88-4787-4044-bb3b-c81889d1ecfc_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_1ae861bf-fdfe-4a98-8bd5-57e9665aca67_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities - Current</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_3a53ae5d-d87f-436e-82c5-c240480d769e_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BPIFranceMember_3dd30234-3711-4e89-9ef2-f22e1570d5b2_terseLabel_en-US" xlink:label="lab_nbx_BPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bpifrance</link:label>
    <link:label id="lab_nbx_BPIFranceMember_label_en-US" xlink:label="lab_nbx_BPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BPI France [Member]</link:label>
    <link:label id="lab_nbx_BPIFranceMember_documentation_en-US" xlink:label="lab_nbx_BPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceMember" xlink:href="nbx-20250630.xsd#nbx_BPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BPIFranceMember" xlink:to="lab_nbx_BPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_e35baf88-c5ee-48df-97b8-8089eb4a2f24_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of discounting financial liabilities and amortized cost</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentProvisions_3045c540-3984-4a68-9756-9589d54093c9_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current provisions</link:label>
    <link:label id="lab_ifrs-full_CurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentProvisions" xlink:to="lab_ifrs-full_CurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA20192Member_b70299da-9664-4a9a-8c8a-f3e4ae322631_terseLabel_en-US" xlink:label="lab_nbx_OSA20192Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2019-2</link:label>
    <link:label id="lab_nbx_OSA20192Member_label_en-US" xlink:label="lab_nbx_OSA20192Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2019-2 [Member]</link:label>
    <link:label id="lab_nbx_OSA20192Member_documentation_en-US" xlink:label="lab_nbx_OSA20192Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2019-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20192Member" xlink:href="nbx-20250630.xsd#nbx_OSA20192Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA20192Member" xlink:to="lab_nbx_OSA20192Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_c62e6080-4e50-4d39-82da-3235a579f3c9_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameDomain" xlink:to="lab_ifrs-full_BorrowingsByNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock_bd03001a-5d3d-4eae-8f19-023d0929b06f_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Non-current Financial Assets</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Non-Current Financial Assets [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Non-Current Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_65402964-be00-4a28-91b9-9c1a1c09f4a7_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription of warrants</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:to="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_80616a95-cb6f-4cb9-b710-fe00733c23ab_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfSubsidiaries_1f21d4e3-4fe0-4093-aca9-1ab7cba9e729_terseLabel_en-US" xlink:label="lab_nbx_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of subsidiaries</link:label>
    <link:label id="lab_nbx_NumberOfSubsidiaries_label_en-US" xlink:label="lab_nbx_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Subsidiaries</link:label>
    <link:label id="lab_nbx_NumberOfSubsidiaries_documentation_en-US" xlink:label="lab_nbx_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSubsidiaries" xlink:href="nbx-20250630.xsd#nbx_NumberOfSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfSubsidiaries" xlink:to="lab_nbx_NumberOfSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_5a070345-f42e-4b6f-b382-3ccf691366bc_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_label_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivablesMember" xlink:to="lab_ifrs-full_TradeReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement_05b4de90-b8a8-473a-aa5d-c7e69748bf9c_terseLabel_en-US" xlink:label="lab_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from (used in) operating activities after tax and before changes in working capital</link:label>
    <link:label id="lab_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement_label_en-US" xlink:label="lab_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow From Operating Activities After Tax And Before Change In Working Capital Requirement</link:label>
    <link:label id="lab_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement_documentation_en-US" xlink:label="lab_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow From Operating Activities After Tax And Before Change In Working Capital Requirement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement" xlink:href="nbx-20250630.xsd#nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement" xlink:to="lab_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_41956808-8a0c-4f87-a295-2124ef9eb427_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NetAmountsReceivablePayableRelatedPartyTransactions_43c76938-19e4-4d63-90ff-fd2d46ba8d55_totalLabel_en-US" xlink:label="lab_nbx_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net receivables (liabilities)</link:label>
    <link:label id="lab_nbx_NetAmountsReceivablePayableRelatedPartyTransactions_label_en-US" xlink:label="lab_nbx_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Amounts Receivable Payable Related Party Transactions</link:label>
    <link:label id="lab_nbx_NetAmountsReceivablePayableRelatedPartyTransactions_documentation_en-US" xlink:label="lab_nbx_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Amounts Receivable Payable Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:href="nbx-20250630.xsd#nbx_NetAmountsReceivablePayableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:to="lab_nbx_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_c8cfe3d7-921e-4a67-b0d2-e40e4f4e34ea_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_8cc14f53-00de-4735-b87c-95f3ef773ddc_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixedInterestRateMember_f9d3b673-a97a-4290-b637-397eb1f88dc1_terseLabel_en-US" xlink:label="lab_ifrs-full_FixedInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed interest rate</link:label>
    <link:label id="lab_ifrs-full_FixedInterestRateMember_label_en-US" xlink:label="lab_ifrs-full_FixedInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed interest rate [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixedInterestRateMember" xlink:to="lab_ifrs-full_FixedInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_44e6e1e0-1c98-498d-b056-90d559bbb804_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through foreign exchange, financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_6dab95ff-ba1c-4f74-97c0-7c209b91c862_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Financial Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_153760cb-ddf5-41a7-8e6f-6d82f4befdc5_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_5c7891c8-6a9f-41b3-9a83-9d3b28c5b693_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Financial Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_3355f8cf-816e-4ede-9e35-d9c87ba2e1aa_terseLabel_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_label_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Financial Liabilities Including Trade Payables And Other Payables</link:label>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_documentation_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Financial Liabilities Including Trade Payables And Other Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:href="nbx-20250630.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:to="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember_be3d3de2-d7ff-48bf-bd02-e8cced68cad0_terseLabel_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bpifrance &#8220;PGE&#8221;</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember_f40cf7d6-afca-4f55-8130-c98183039e16_verboseLabel_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Bpifrance "PGE"</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember_label_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Dilutive Financing Agreement, BPI France [Member]</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember_documentation_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Dilutive Financing Agreement, BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:to="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TranchesAxis_5eee1d6a-a75b-4314-adab-8a98d5592d95_terseLabel_en-US" xlink:label="lab_nbx_TranchesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranches [Axis]</link:label>
    <link:label id="lab_nbx_TranchesAxis_label_en-US" xlink:label="lab_nbx_TranchesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranches [Axis]</link:label>
    <link:label id="lab_nbx_TranchesAxis_documentation_en-US" xlink:label="lab_nbx_TranchesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesAxis" xlink:href="nbx-20250630.xsd#nbx_TranchesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TranchesAxis" xlink:to="lab_nbx_TranchesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock_eaf3f32f-338d-458b-8877-93e87ec0a31a_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company information</link:label>
    <link:label id="lab_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of notes and other explanatory information [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of notes and other explanatory information as part of a complete set of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock" xlink:to="lab_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OtherSalesMember_0c9ae450-d93c-4e3b-97c0-a34a5bad9335_terseLabel_en-US" xlink:label="lab_nbx_OtherSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other sales</link:label>
    <link:label id="lab_nbx_OtherSalesMember_label_en-US" xlink:label="lab_nbx_OtherSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sales [Member]</link:label>
    <link:label id="lab_nbx_OtherSalesMember_documentation_en-US" xlink:label="lab_nbx_OtherSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherSalesMember" xlink:href="nbx-20250630.xsd#nbx_OtherSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OtherSalesMember" xlink:to="lab_nbx_OtherSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_23aebd51-d942-4f65-925d-7b91bc5d8b2b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesDomain_f10fac7e-218b-4968-9e37-8d8ae46b62c0_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesDomain_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesDomain" xlink:to="lab_ifrs-full_CounterpartiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasurySharesMember_2cd2af25-aea5-404c-acd5-d55de4eebb5a_terseLabel_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasurySharesMember_label_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasurySharesMember" xlink:to="lab_ifrs-full_TreasurySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonRecurringExpenseTypeAxis_b0ac9d4d-2a49-43a5-a300-b55f46d2d822_terseLabel_en-US" xlink:label="lab_nbx_NonRecurringExpenseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Recurring Expense Type [Axis]</link:label>
    <link:label id="lab_nbx_NonRecurringExpenseTypeAxis_label_en-US" xlink:label="lab_nbx_NonRecurringExpenseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Recurring Expense Type [Axis]</link:label>
    <link:label id="lab_nbx_NonRecurringExpenseTypeAxis_documentation_en-US" xlink:label="lab_nbx_NonRecurringExpenseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Recurring Expense Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonRecurringExpenseTypeAxis" xlink:href="nbx-20250630.xsd#nbx_NonRecurringExpenseTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonRecurringExpenseTypeAxis" xlink:to="lab_nbx_NonRecurringExpenseTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_18a4aac5-2e4c-4d3b-bb83-0fcd8c84ee8d_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_8d6d99ca-d704-4cd8-8c2f-f368d04843c2_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_db7765ab-6630-4fb3-96aa-a7e17f3561b9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock_2168c81e-3922-450e-93ac-914f7d7413ef_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Depreciation, Amortization and Provision Expenses</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA2017OrdinaryMember_8202ee74-bf6f-4cc4-ac5e-d4f1b16c1139_terseLabel_en-US" xlink:label="lab_nbx_OSA2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2017 O</link:label>
    <link:label id="lab_nbx_OSA2017OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2017 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA2017OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2017 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017OrdinaryMember" xlink:href="nbx-20250630.xsd#nbx_OSA2017OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA2017OrdinaryMember" xlink:to="lab_nbx_OSA2017OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_1a2750c4-eac0-471a-8f2a-b751f0f27f65_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital increase</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_8c659b34-9adf-44b3-ae3d-93aceb273ad2_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Allocation of loss 12/31/2024</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_db4d2327-3fd7-479f-a321-f95046d954cb_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_1dbbcc03-54a1-4d86-8eeb-41c5033d8e71_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_f5343102-104e-4d97-944c-0e2044d8d725_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Trade and Other Payables</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Trade And Other Payables Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Trade And Other Payables Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows_afc689a4-4718-4306-96ef-92f0067c07e1_terseLabel_en-US" xlink:label="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows_label_en-US" xlink:label="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank borrowings, undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:to="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202104PerformanceMember_748b821a-5a79-4e77-9db8-5d6bb1cf44cd_terseLabel_en-US" xlink:label="lab_nbx_OSA202104PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2021-04 P</link:label>
    <link:label id="lab_nbx_OSA202104PerformanceMember_label_en-US" xlink:label="lab_nbx_OSA202104PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2021-04 Performance [Member]</link:label>
    <link:label id="lab_nbx_OSA202104PerformanceMember_documentation_en-US" xlink:label="lab_nbx_OSA202104PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2021-04 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104PerformanceMember" xlink:href="nbx-20250630.xsd#nbx_OSA202104PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202104PerformanceMember" xlink:to="lab_nbx_OSA202104PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_78e826ba-5237-4ccc-9005-60a84c0ba478_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentTaxCredit_2699680c-6098-4de9-88dc-66bd1ce3eeba_terseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development, Tax Credit</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development, Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentTaxCredit" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentTaxCredit" xlink:to="lab_nbx_ResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain_232deafe-7f2c-4d8b-9eca-44dacecbfa69_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LaurentLevyMember_857e53c6-3ded-49e0-a630-8e0b8a28938f_terseLabel_en-US" xlink:label="lab_nbx_LaurentLevyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laurent LEVY</link:label>
    <link:label id="lab_nbx_LaurentLevyMember_label_en-US" xlink:label="lab_nbx_LaurentLevyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laurent Levy [Member]</link:label>
    <link:label id="lab_nbx_LaurentLevyMember_documentation_en-US" xlink:label="lab_nbx_LaurentLevyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laurent Levy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LaurentLevyMember" xlink:href="nbx-20250630.xsd#nbx_LaurentLevyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LaurentLevyMember" xlink:to="lab_nbx_LaurentLevyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_7fb34140-a7c6-4499-ba7b-68fcad80d917_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line items by function</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock_c6019a5c-cbda-4459-9d61-ca52f7fb614e_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Liabilities Footnote [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Liabilities Footnote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock" xlink:to="lab_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_2b18cc95-5095-4d77-8dcf-fe05bc472702_negatedLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange losses</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_c8460211-9994-4464-8fb3-6a452a8ec131_terseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss" xlink:to="lab_ifrs-full_NetForeignExchangeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesDomain_82e3c839-584f-47e8-a153-1744e4da61d6_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [member]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesDomain_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesDomain" xlink:to="lab_ifrs-full_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_81837201-cad9-4319-9729-517ba1defbf7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_e0bd1f29-c22e-4cba-ac77-cd2c0453b579_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_d6fe0919-7c3b-4b74-aad3-0e88579bf3a3_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loans repayments</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_c114bf9c-86ff-4914-9810-ce369c161589_terseLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings, classified as financing activities</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_A1100StudyMember_063c5462-edda-45a7-ae8f-1e030b18783f_terseLabel_en-US" xlink:label="lab_nbx_A1100StudyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1100 study</link:label>
    <link:label id="lab_nbx_A1100StudyMember_label_en-US" xlink:label="lab_nbx_A1100StudyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1100 Study [Member]</link:label>
    <link:label id="lab_nbx_A1100StudyMember_documentation_en-US" xlink:label="lab_nbx_A1100StudyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1100 Study</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A1100StudyMember" xlink:href="nbx-20250630.xsd#nbx_A1100StudyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_A1100StudyMember" xlink:to="lab_nbx_A1100StudyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdvancesReceivedInterestRate_a994aeea-0e9b-4c75-9fb2-e6c147b75259_terseLabel_en-US" xlink:label="lab_nbx_AdvancesReceivedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances, interest rate</link:label>
    <link:label id="lab_nbx_AdvancesReceivedInterestRate_label_en-US" xlink:label="lab_nbx_AdvancesReceivedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advances Received, Interest Rate</link:label>
    <link:label id="lab_nbx_AdvancesReceivedInterestRate_documentation_en-US" xlink:label="lab_nbx_AdvancesReceivedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advances Received, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesReceivedInterestRate" xlink:href="nbx-20250630.xsd#nbx_AdvancesReceivedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdvancesReceivedInterestRate" xlink:to="lab_nbx_AdvancesReceivedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_d051b2eb-7fc0-4f8f-9d81-971a9922d487_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DebtDetailsAxis_0b7e1324-d093-4870-9e25-9a48ed9607db_terseLabel_en-US" xlink:label="lab_nbx_DebtDetailsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Details [Axis]</link:label>
    <link:label id="lab_nbx_DebtDetailsAxis_label_en-US" xlink:label="lab_nbx_DebtDetailsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Details [Axis]</link:label>
    <link:label id="lab_nbx_DebtDetailsAxis_documentation_en-US" xlink:label="lab_nbx_DebtDetailsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Details</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DebtDetailsAxis" xlink:href="nbx-20250630.xsd#nbx_DebtDetailsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DebtDetailsAxis" xlink:to="lab_nbx_DebtDetailsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAdvancesToSuppliers_b75a1ba0-bce5-4910-869e-53aed3cec74f_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current advances to suppliers</link:label>
    <link:label id="lab_ifrs-full_CurrentAdvancesToSuppliers_label_en-US" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current advances to suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:to="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ExecutiveBoardAndEmployeesMember_d4fff942-73f0-4812-8ec9-243327612567_terseLabel_en-US" xlink:label="lab_nbx_ExecutiveBoardAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Board and Employees</link:label>
    <link:label id="lab_nbx_ExecutiveBoardAndEmployeesMember_label_en-US" xlink:label="lab_nbx_ExecutiveBoardAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Board And Employees [Member]</link:label>
    <link:label id="lab_nbx_ExecutiveBoardAndEmployeesMember_documentation_en-US" xlink:label="lab_nbx_ExecutiveBoardAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Executive Board And Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExecutiveBoardAndEmployeesMember" xlink:href="nbx-20250630.xsd#nbx_ExecutiveBoardAndEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ExecutiveBoardAndEmployeesMember" xlink:to="lab_nbx_ExecutiveBoardAndEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_a9d539a9-9f7b-4115-ab7d-a93afe600257_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_3646fefa-61ef-40a7-983b-2c931e470844_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share Capital Transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReserves_54e64322-7462-4c02-9ebc-21e21756ec31_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve</link:label>
    <link:label id="lab_ifrs-full_OtherReserves_label_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_fed0e8a8-4f39-44bb-ab3e-505c29ac5ca7_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInOtherCurrentPayables_aac32e5f-bfd5-48fc-989f-1552e7c77891_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase of other trade payables</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInOtherCurrentPayables_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Other Current Payables</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInOtherCurrentPayables_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Other Current Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInOtherCurrentPayables" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInOtherCurrentPayables" xlink:to="lab_nbx_IncreaseDecreaseInOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE2017Member_eb66cc21-42a0-47d1-8e90-d5a6680ba31d_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSCPE 2017</link:label>
    <link:label id="lab_nbx_BSPCE2017Member_label_en-US" xlink:label="lab_nbx_BSPCE2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSPCE 2017 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2017Member_documentation_en-US" xlink:label="lab_nbx_BSPCE2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSPCE 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017Member" xlink:href="nbx-20250630.xsd#nbx_BSPCE2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2017Member" xlink:to="lab_nbx_BSPCE2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_d650a6ce-0f6f-4770-8db9-67453466ffcb_terseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_1ed78d56-ebc6-4747-b7e1-6951caa86ae9_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments, classified as cash equivalents</link:label>
    <link:label id="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term investments, classified as cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_0b65462b-e032-4d3f-8ebb-6e4e1a4f2e9b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments included in the statement of financial position and impact on income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_42619a31-8493-40aa-b14b-0f673b28ce48_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA20191Member_350d3675-fd06-43c1-9c9e-2aa9953a4bf9_terseLabel_en-US" xlink:label="lab_nbx_OSA20191Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2019-1</link:label>
    <link:label id="lab_nbx_OSA20191Member_label_en-US" xlink:label="lab_nbx_OSA20191Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2019-1 [Member]</link:label>
    <link:label id="lab_nbx_OSA20191Member_documentation_en-US" xlink:label="lab_nbx_OSA20191Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2019-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member" xlink:href="nbx-20250630.xsd#nbx_OSA20191Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA20191Member" xlink:to="lab_nbx_OSA20191Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_8d6e9dc9-5e7c-40dc-8d3b-787c490cca43_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares available for subscription (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_05487197-da6d-4a2d-89ba-b6e19d4bb4dd_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, interest rate</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_5df7648a-6a0d-4c9e-a78d-acb6a913584f_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from (used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LianBioNBTXR3Member_ef62aedd-99e1-4110-b6d7-582c36900299_terseLabel_en-US" xlink:label="lab_nbx_LianBioNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LianBio, NBTXR3</link:label>
    <link:label id="lab_nbx_LianBioNBTXR3Member_label_en-US" xlink:label="lab_nbx_LianBioNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LianBio, NBTXR3 [Member]</link:label>
    <link:label id="lab_nbx_LianBioNBTXR3Member_documentation_en-US" xlink:label="lab_nbx_LianBioNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LianBio, NBTXR3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member" xlink:href="nbx-20250630.xsd#nbx_LianBioNBTXR3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LianBioNBTXR3Member" xlink:to="lab_nbx_LianBioNBTXR3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202206PerformanceMember_d2fdb8c6-b67d-4f57-8f56-c0cb06b991a6_terseLabel_en-US" xlink:label="lab_nbx_OSA202206PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2022-06 P</link:label>
    <link:label id="lab_nbx_OSA202206PerformanceMember_label_en-US" xlink:label="lab_nbx_OSA202206PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2022-06 Performance [Member]</link:label>
    <link:label id="lab_nbx_OSA202206PerformanceMember_documentation_en-US" xlink:label="lab_nbx_OSA202206PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2022-06 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202206PerformanceMember" xlink:href="nbx-20250630.xsd#nbx_OSA202206PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202206PerformanceMember" xlink:to="lab_nbx_OSA202206PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_54b98b23-6cda-445a-b218-3d7055da332f_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_18b18ade-75dc-4fd0-b398-cc378ec7702f_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_6f8deb25-7948-4b14-84a9-40e8246cccb7_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_label_en-US" xlink:label="lab_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash advances and loans made to related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:to="lab_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_26adf00f-3c25-46c9-9600-ef80da9e2851_verboseLabel_en-US" xlink:label="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum total number of shares that may be subscribed (in shares)</link:label>
    <link:label id="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_db1c960c-8afe-4e24-a7e8-a16952c29c4d_terseLabel_en-US" xlink:label="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum total number of awards that may be subscribed (in shares)</link:label>
    <link:label id="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_42af99ba-4603-4fe0-b305-a08450e90002_netLabel_en-US" xlink:label="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total number of shares that may be subscribed (in shares)</link:label>
    <link:label id="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Number Of Other Equity Instruments That May Be Subscribed In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Number Of Other Equity Instruments That May Be Subscribed In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:href="nbx-20250630.xsd#nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:to="lab_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TrancheOneMember_3809639d-fa8c-41dd-84c8-9cdae87a77e1_terseLabel_en-US" xlink:label="lab_nbx_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche one</link:label>
    <link:label id="lab_nbx_TrancheOneMember_label_en-US" xlink:label="lab_nbx_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_nbx_TrancheOneMember_documentation_en-US" xlink:label="lab_nbx_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember" xlink:href="nbx-20250630.xsd#nbx_TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TrancheOneMember" xlink:to="lab_nbx_TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA2023P2Member_fe21d91e-188d-4e53-ada3-1fc650b6934c_terseLabel_en-US" xlink:label="lab_nbx_AGA2023P2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA 2023 - P2</link:label>
    <link:label id="lab_nbx_AGA2023P2Member_label_en-US" xlink:label="lab_nbx_AGA2023P2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA 2023 - P2 [Member]</link:label>
    <link:label id="lab_nbx_AGA2023P2Member_documentation_en-US" xlink:label="lab_nbx_AGA2023P2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA 2023 - P2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023P2Member" xlink:href="nbx-20250630.xsd#nbx_AGA2023P2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA2023P2Member" xlink:to="lab_nbx_AGA2023P2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_eefcb3ac-fb95-4e46-9aa3-ef478e73f624_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_ab84476e-6228-4356-8f46-3bcc45b5e4f8_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA issue price (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_421ca465-1f6f-472c-8379-b4c0bc48f35c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_622badec-b6d1-48cd-a8f0-6b3f33163cb2_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from (used in) financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_9d821b3d-812b-4844-ab5a-7ddf72f31a40_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_7d2a81fd-1ab1-4c18-b62f-6d6aba6f8592_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_a6d74e3f-4aa9-4cad-9fb3-00dc0947eef0_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets at beginning of period</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_b0495bc1-d372-4ff6-90c8-0b14f93b06e8_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets at end of period</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialAssets" xlink:to="lab_ifrs-full_NoncurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_2b1ae52f-8b12-4764-a88a-76f714dab572_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total payroll costs</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonCurrentOtherProvisionsMember_4ec0e3ec-eec8-4ff5-bdbb-f0247f5e0e35_terseLabel_en-US" xlink:label="lab_nbx_NonCurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Non-current provisions</link:label>
    <link:label id="lab_nbx_NonCurrentOtherProvisionsMember_label_en-US" xlink:label="lab_nbx_NonCurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Other Provisions [Member]</link:label>
    <link:label id="lab_nbx_NonCurrentOtherProvisionsMember_documentation_en-US" xlink:label="lab_nbx_NonCurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentOtherProvisionsMember" xlink:href="nbx-20250630.xsd#nbx_NonCurrentOtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonCurrentOtherProvisionsMember" xlink:to="lab_nbx_NonCurrentOtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_c8257bbd-1331-4110-bb31-ee11a47fc875_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_7c521b97-e060-458f-9296-8206e1b70eb6_terseLabel_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_label_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Copyrights, patents and other industrial property rights, service and operating rights [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:to="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_f1c6f0be-cc89-4cde-b575-247dc1311932_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Changes in operating working capital</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_139d0c0f-a824-4bc9-867e-6831c4188402_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_e4feee48-c398-428d-8415-e1bae82e7c4e_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Between 1 and 3&#160;years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than three years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasuryShares_92fbf79a-6c8a-4270-85fc-ea80b496de35_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasuryShares_label_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasuryShares" xlink:to="lab_ifrs-full_TreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_5368791f-3fc1-4f48-b40b-4a7f2e805d20_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase through origination or purchase, financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets" xlink:to="lab_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_2d1e0ac2-17a5-4da7-985a-c6203a1693ef_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSAMember_f4e0d0a5-bf7e-4085-8ee2-103395351d58_terseLabel_en-US" xlink:label="lab_nbx_OSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA</link:label>
    <link:label id="lab_nbx_OSAMember_label_en-US" xlink:label="lab_nbx_OSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA [Member]</link:label>
    <link:label id="lab_nbx_OSAMember_documentation_en-US" xlink:label="lab_nbx_OSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember" xlink:href="nbx-20250630.xsd#nbx_OSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSAMember" xlink:to="lab_nbx_OSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_RetirementObligationAbstract_ac41ad6e-115f-428c-b3ce-3e90c65fb884_terseLabel_en-US" xlink:label="lab_nbx_RetirementObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Obligation [Abstract]</link:label>
    <link:label id="lab_nbx_RetirementObligationAbstract_label_en-US" xlink:label="lab_nbx_RetirementObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Obligation [Abstract]</link:label>
    <link:label id="lab_nbx_RetirementObligationAbstract_documentation_en-US" xlink:label="lab_nbx_RetirementObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Retirement Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RetirementObligationAbstract" xlink:href="nbx-20250630.xsd#nbx_RetirementObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_RetirementObligationAbstract" xlink:to="lab_nbx_RetirementObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementDomain_a4e2c9c6-da85-485e-9593-9329eca81e51_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Domain]</link:label>
    <link:label id="lab_nbx_CollaborationAgreementDomain_label_en-US" xlink:label="lab_nbx_CollaborationAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Domain]</link:label>
    <link:label id="lab_nbx_CollaborationAgreementDomain_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementDomain" xlink:to="lab_nbx_CollaborationAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_abbb4c0f-a2d4-4cd1-80bf-8f2465a67a51_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations, before tax and changes in working capital</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_60727d49-ed63-42ea-b713-7a2b7a2cd3c9_terseLabel_en-US" xlink:label="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in euros per share)</link:label>
    <link:label id="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Share Price, Other Equity Instruments Granted</link:label>
    <link:label id="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Share Price, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:href="nbx-20250630.xsd#nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:to="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent_050dcb94-9e26-4565-961e-ccaa6262f574_terseLabel_en-US" xlink:label="lab_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Of which Current</link:label>
    <link:label id="lab_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent_label_en-US" xlink:label="lab_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Arising from Financing Activities Current</link:label>
    <link:label id="lab_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent_documentation_en-US" xlink:label="lab_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Arising from Financing Activities Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent" xlink:to="lab_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities_b9aa1adc-0efc-420a-b06f-aa5f6a289bfe_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of discounting and catch-up</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Impact Of Discounting And Catch up, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Impact Of Discounting And Catch up, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_914ada76-a542-49b0-b95e-f99b5a2834f9_terseLabel_en-US" xlink:label="lab_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares to which the awards were likely to give right (in shares)</link:label>
    <link:label id="lab_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares To Which Other Equity Instruments Were Likely To Give Right In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares To Which Other Equity Instruments Were Likely To Give Right In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:href="nbx-20250630.xsd#nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:to="lab_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3b881f39-2155-4b43-b656-3b3809e3958b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGAMember_30da11cd-4ab3-4382-bde9-9f456d49df3c_terseLabel_en-US" xlink:label="lab_nbx_AGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA</link:label>
    <link:label id="lab_nbx_AGAMember_label_en-US" xlink:label="lab_nbx_AGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA [Member]</link:label>
    <link:label id="lab_nbx_AGAMember_documentation_en-US" xlink:label="lab_nbx_AGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember" xlink:href="nbx-20250630.xsd#nbx_AGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGAMember" xlink:to="lab_nbx_AGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_b16c4626-555e-4ca4-9296-bf16b4abdeb4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication_cf828e68-d242-44c5-956e-da7ef2a5a4c3_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, compensation per indication</link:label>
    <link:label id="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication_label_en-US" xlink:label="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Potential Milestones Payments To Be Received Per Indication</link:label>
    <link:label id="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Potential Milestones Payments To Be Received Per Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication" xlink:to="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_06c1827b-16a0-4c9c-a752-39823efac8fc_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bottom of range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_68caf35b-fe8c-4a75-879f-03fe589d664c_terseLabel_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of consolidation</link:label>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation [Policy Text Block]</link:label>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_documentation_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:href="nbx-20250630.xsd#nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:to="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_25d0ffbd-e5bc-4e94-a4ec-637665ed48cb_negatedTerseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases, sub-contracting and other expenses</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Sub-Contracting And Other Expenses</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Sub-Contracting And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:to="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_5ef0171d-f4fd-4a88-a4c9-0ea9f10e7a12_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Information Related To The Company [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Information Related To The Company [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Information Related To The Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:to="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IntellectualPropertyServicesMember_858f8cd3-6787-47ae-8f9d-85d333f76d72_terseLabel_en-US" xlink:label="lab_nbx_IntellectualPropertyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual Property Services</link:label>
    <link:label id="lab_nbx_IntellectualPropertyServicesMember_label_en-US" xlink:label="lab_nbx_IntellectualPropertyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property Services [Member]</link:label>
    <link:label id="lab_nbx_IntellectualPropertyServicesMember_documentation_en-US" xlink:label="lab_nbx_IntellectualPropertyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intellectual Property Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IntellectualPropertyServicesMember" xlink:href="nbx-20250630.xsd#nbx_IntellectualPropertyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IntellectualPropertyServicesMember" xlink:to="lab_nbx_IntellectualPropertyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TechnologyTransferAndTechnicalAssistanceMember_0410a864-cff9-4eda-a82f-0a4922cf0e8b_terseLabel_en-US" xlink:label="lab_nbx_TechnologyTransferAndTechnicalAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology Transfer and Technical Assistance</link:label>
    <link:label id="lab_nbx_TechnologyTransferAndTechnicalAssistanceMember_label_en-US" xlink:label="lab_nbx_TechnologyTransferAndTechnicalAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology Transfer And Technical Assistance [Member]</link:label>
    <link:label id="lab_nbx_TechnologyTransferAndTechnicalAssistanceMember_documentation_en-US" xlink:label="lab_nbx_TechnologyTransferAndTechnicalAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technology Transfer And Technical Assistance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TechnologyTransferAndTechnicalAssistanceMember" xlink:href="nbx-20250630.xsd#nbx_TechnologyTransferAndTechnicalAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TechnologyTransferAndTechnicalAssistanceMember" xlink:to="lab_nbx_TechnologyTransferAndTechnicalAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_c1f32422-3ceb-4fb5-8d47-3654497aa884_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_a2fc8fe2-903f-48b3-bc35-336dac7f7971_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_0964cc15-ba75-459a-bfc8-2cc6de71de39_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_9daed6ac-ba9f-4799-935f-f5853740dbef_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities carried at amortized cost</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_6b555966-ab25-44f8-9038-f0c2c88d3799_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Between 3 and 5&#160;years</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_db8db9f4-8279-4ba5-a260-d1880ebd603c_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value per share (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_03dd19bf-a08a-4ced-9319-6be1b9265de5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_8e43a4f2-28aa-4c8a-ae40-a7fb11e2ac74_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_b29a4913-6187-411d-9399-c30b19c1a2ad_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRevenue_1b7c4ea2-5094-4445-9c2a-f1f2bedc7a1f_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_ifrs-full_OtherRevenue_label_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue" xlink:to="lab_ifrs-full_OtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssets_28080721-656f-4799-94cb-471845f49398_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_ifrs-full_FinancialAssets_label_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_cdad798f-72a4-480c-96be-6f3f6941a121_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_12cf09ae-6035-40da-addd-0abbaf053a6d_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Operating Income (Expenses)</link:label>
    <link:label id="lab_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income (Expense) [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" xlink:to="lab_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_66cb7968-3b91-4f77-8dea-cd8a53ee7e7f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_JohnsonJohnsonInnovationsMember_752165bb-ad0b-4cbf-a125-9878bb75c8d7_terseLabel_en-US" xlink:label="lab_nbx_JohnsonJohnsonInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson Innovations</link:label>
    <link:label id="lab_nbx_JohnsonJohnsonInnovationsMember_label_en-US" xlink:label="lab_nbx_JohnsonJohnsonInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson Innovations [Member]</link:label>
    <link:label id="lab_nbx_JohnsonJohnsonInnovationsMember_documentation_en-US" xlink:label="lab_nbx_JohnsonJohnsonInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson Innovations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JohnsonJohnsonInnovationsMember" xlink:href="nbx-20250630.xsd#nbx_JohnsonJohnsonInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_JohnsonJohnsonInnovationsMember" xlink:to="lab_nbx_JohnsonJohnsonInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BeneficiariesOtherThanCorporateOfficersMember_2a495cf7-2b03-4144-b65c-cd9462b4d703_terseLabel_en-US" xlink:label="lab_nbx_BeneficiariesOtherThanCorporateOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficiaries other than corporate officers</link:label>
    <link:label id="lab_nbx_BeneficiariesOtherThanCorporateOfficersMember_label_en-US" xlink:label="lab_nbx_BeneficiariesOtherThanCorporateOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficiaries Other Than Corporate Officers [Member]</link:label>
    <link:label id="lab_nbx_BeneficiariesOtherThanCorporateOfficersMember_documentation_en-US" xlink:label="lab_nbx_BeneficiariesOtherThanCorporateOfficersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Beneficiaries Other Than Corporate Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember" xlink:href="nbx-20250630.xsd#nbx_BeneficiariesOtherThanCorporateOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember" xlink:to="lab_nbx_BeneficiariesOtherThanCorporateOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_8e16baf9-0028-4764-9bcc-d77ec0f05ba8_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain" xlink:to="lab_ifrs-full_ComponentsOfEquityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_7efce3f1-4949-4107-8c03-ba3e23ce1e6b_negatedTerseLabel_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases, fees and other expenses</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_label_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling General And Administrative Expense, Purchases, Fees And Other Expense</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_documentation_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selling General And Administrative Expense, Purchases, Fees And Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:href="nbx-20250630.xsd#nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:to="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_3576d5d0-f9b0-4a30-ae34-e6e06420239f_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_7cdc2133-00bb-463b-a6ab-c754ae9b67dc_terseLabel_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_8746c174-127f-4821-ac40-f62d7c0c94e0_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Capital increase (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_9fe3d576-5c2e-4cc5-a230-1b8e746261bc_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital increase (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DirectorsRemunerationExpense_fa19328e-d72d-4cf6-aea0-dbdef55b18c8_terseLabel_en-US" xlink:label="lab_ifrs-full_DirectorsRemunerationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supervisory Board&#8217;s fees</link:label>
    <link:label id="lab_ifrs-full_DirectorsRemunerationExpense_label_en-US" xlink:label="lab_ifrs-full_DirectorsRemunerationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors' remuneration expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DirectorsRemunerationExpense" xlink:to="lab_ifrs-full_DirectorsRemunerationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_be159391-14c5-4d4f-a3b8-f5932c88f061_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision for disputes and charges</link:label>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision used, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:to="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeDomain_3403b89e-9609-4a73-89e9-f22c3622dbd3_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:label id="lab_ifrs-full_RangeDomain_label_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeDomain" xlink:to="lab_ifrs-full_RangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_61f02d40-ea8a-44c6-9151-98f819a26894_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation of intangible assets</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_97933c98-689b-47cf-825a-57971dff0c84_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for gain (loss) on disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_c8857f64-2fdd-49ce-8450-005418364413_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net financial income (loss)</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OfficersNameAxis_aa6bea37-d82b-4b5f-bb76-4f7ca07c9b91_terseLabel_en-US" xlink:label="lab_nbx_OfficersNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Officers Name [Axis]</link:label>
    <link:label id="lab_nbx_OfficersNameAxis_label_en-US" xlink:label="lab_nbx_OfficersNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officers Name [Axis]</link:label>
    <link:label id="lab_nbx_OfficersNameAxis_documentation_en-US" xlink:label="lab_nbx_OfficersNameAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Officers Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameAxis" xlink:href="nbx-20250630.xsd#nbx_OfficersNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OfficersNameAxis" xlink:to="lab_nbx_OfficersNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OpenTaxYearDomain_37d85d70-1e1b-4137-9c6d-0b06e01f804e_terseLabel_en-US" xlink:label="lab_nbx_OpenTaxYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year [Domain]</link:label>
    <link:label id="lab_nbx_OpenTaxYearDomain_label_en-US" xlink:label="lab_nbx_OpenTaxYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open Tax Year [Domain]</link:label>
    <link:label id="lab_nbx_OpenTaxYearDomain_documentation_en-US" xlink:label="lab_nbx_OpenTaxYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Open Tax Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain" xlink:href="nbx-20250630.xsd#nbx_OpenTaxYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OpenTaxYearDomain" xlink:to="lab_nbx_OpenTaxYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock_5c3967b3-0d18-449c-ac7d-c40d7235298b_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Trade Receivables And Other Current Assets [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Trade Receivables And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:to="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_7788b8be-97a5-4a7b-878f-3c88388e1b3d_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase / (Decrease) in trade and other payables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_1c1ecd62-6a02-45ac-979c-adbf6c42e83b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CashAndCashEquivalents1Member_f861c6a6-2a57-4d30-b958-626b635187f3_terseLabel_en-US" xlink:label="lab_nbx_CashAndCashEquivalents1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_nbx_CashAndCashEquivalents1Member_label_en-US" xlink:label="lab_nbx_CashAndCashEquivalents1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents1 [Member]</link:label>
    <link:label id="lab_nbx_CashAndCashEquivalents1Member_documentation_en-US" xlink:label="lab_nbx_CashAndCashEquivalents1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashAndCashEquivalents1Member" xlink:href="nbx-20250630.xsd#nbx_CashAndCashEquivalents1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CashAndCashEquivalents1Member" xlink:to="lab_nbx_CashAndCashEquivalents1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202104OrdinaryMember_a128d351-def8-4eb5-9a74-682c8ae0a156_terseLabel_en-US" xlink:label="lab_nbx_OSA202104OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2021-04 O</link:label>
    <link:label id="lab_nbx_OSA202104OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA202104OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2021-04 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA202104OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA202104OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2021-04 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember" xlink:href="nbx-20250630.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202104OrdinaryMember" xlink:to="lab_nbx_OSA202104OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE20153Member_f24fb06e-4a04-4e31-90b8-71408cfbcff1_terseLabel_en-US" xlink:label="lab_nbx_BSPCE20153Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSPCE 2015-3</link:label>
    <link:label id="lab_nbx_BSPCE20153Member_label_en-US" xlink:label="lab_nbx_BSPCE20153Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSPCE 2015-3 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE20153Member_documentation_en-US" xlink:label="lab_nbx_BSPCE20153Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSPCE 2015-3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member" xlink:href="nbx-20250630.xsd#nbx_BSPCE20153Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE20153Member" xlink:to="lab_nbx_BSPCE20153Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_ed1e8b7e-fb4c-40db-b45d-81dbd40681b4_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts payable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse_1f503578-c422-4817-92a9-6c4db9a15c49_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market rate estimated percent</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate used in current estimate of value in use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" xlink:to="lab_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ConditionalAdvancesMember_3aa93ca2-deb1-413e-a030-f77ffc2ee3ae_terseLabel_en-US" xlink:label="lab_nbx_ConditionalAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conditional advances</link:label>
    <link:label id="lab_nbx_ConditionalAdvancesMember_label_en-US" xlink:label="lab_nbx_ConditionalAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conditional Advances [Member]</link:label>
    <link:label id="lab_nbx_ConditionalAdvancesMember_documentation_en-US" xlink:label="lab_nbx_ConditionalAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conditional Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesMember" xlink:href="nbx-20250630.xsd#nbx_ConditionalAdvancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ConditionalAdvancesMember" xlink:to="lab_nbx_ConditionalAdvancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SuppliersMember_82791ed4-4992-4c5b-a553-c3aa34ecb06b_terseLabel_en-US" xlink:label="lab_nbx_SuppliersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Suppliers</link:label>
    <link:label id="lab_nbx_SuppliersMember_label_en-US" xlink:label="lab_nbx_SuppliersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suppliers [Member]</link:label>
    <link:label id="lab_nbx_SuppliersMember_documentation_en-US" xlink:label="lab_nbx_SuppliersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SuppliersMember" xlink:href="nbx-20250630.xsd#nbx_SuppliersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SuppliersMember" xlink:to="lab_nbx_SuppliersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_5766ecf8-b198-4288-80f2-ddd241e05f36_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialLiabilities_7b883461-62cb-446f-8c95-014e6c34929b_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialLiabilities_705edfd2-62e1-40bc-9aac-26d2d8ce2086_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total non-current financial liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialLiabilities" xlink:to="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_a6c17071-cc25-46ea-a03d-d8c418d1b2e5_negatedTerseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in purchases, fees, and other expenses</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Purchases, Fees, And Other Expenses</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Purchases, Fees, And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:to="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement_b4e4c0c2-1db8-4013-95cc-d7cf3d5668ff_terseLabel_en-US" xlink:label="lab_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum total number of shares that may be subscribed (in shares)</link:label>
    <link:label id="lab_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Number Of Share Options That May Be Subscribed In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Number Of Share Options That May Be Subscribed In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:href="nbx-20250630.xsd#nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:to="lab_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts_067a218a-c6c6-4346-82f7-84f3dfd84554_negatedTerseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payroll costs (including share-based payments)</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Payroll Costs</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Payroll Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentExpensePayrollCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:to="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NanobiotixSAMember_9611a39a-2866-4610-b1e6-f1c7585ea351_terseLabel_en-US" xlink:label="lab_nbx_NanobiotixSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nanobiotix S.A.</link:label>
    <link:label id="lab_nbx_NanobiotixSAMember_label_en-US" xlink:label="lab_nbx_NanobiotixSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nanobiotix S.A. [Member]</link:label>
    <link:label id="lab_nbx_NanobiotixSAMember_documentation_en-US" xlink:label="lab_nbx_NanobiotixSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nanobiotix S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixSAMember" xlink:href="nbx-20250630.xsd#nbx_NanobiotixSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NanobiotixSAMember" xlink:to="lab_nbx_NanobiotixSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsDomain_6e80198a-1176-42fb-aa92-274f5f4fa3e5_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, category</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage_b49dad1f-eff7-4b1a-b63d-ad3ae35020df_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of increase in employee benefit expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Employee Benefit Expense, Percentage</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Employee Benefit Expense, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage" xlink:to="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionsAbstract_4fcea231-ed3d-4664-9d5c-990cf96bbbec_terseLabel_en-US" xlink:label="lab_ifrs-full_ProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions [abstract]</link:label>
    <link:label id="lab_ifrs-full_ProvisionsAbstract_label_en-US" xlink:label="lab_ifrs-full_ProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionsAbstract" xlink:to="lab_ifrs-full_ProvisionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_82d8137e-71d8-4f18-b5b1-2d38cdff9ccb_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NBTXR3Member_98bf316d-1652-47c6-9e61-e9c3e93a0b82_terseLabel_en-US" xlink:label="lab_nbx_NBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NBTXR3</link:label>
    <link:label id="lab_nbx_NBTXR3Member_label_en-US" xlink:label="lab_nbx_NBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NBTXR3 [Member]</link:label>
    <link:label id="lab_nbx_NBTXR3Member_documentation_en-US" xlink:label="lab_nbx_NBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NBTXR3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NBTXR3Member" xlink:href="nbx-20250630.xsd#nbx_NBTXR3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NBTXR3Member" xlink:to="lab_nbx_NBTXR3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalProvisionsOtherProvisions_6df13960-ec40-48a3-bcd0-717962207948_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases</link:label>
    <link:label id="lab_ifrs-full_AdditionalProvisionsOtherProvisions_64442fb6-ca52-4529-86b5-9150a47c5bfc_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increases</link:label>
    <link:label id="lab_ifrs-full_AdditionalProvisionsOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional provisions, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementTotalConsideration_b4800e77-290b-4ebe-9a37-bef8552c51d0_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deal value</link:label>
    <link:label id="lab_nbx_CollaborationAgreementTotalConsideration_label_en-US" xlink:label="lab_nbx_CollaborationAgreementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Total Consideration</link:label>
    <link:label id="lab_nbx_CollaborationAgreementTotalConsideration_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Total Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementTotalConsideration" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementTotalConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementTotalConsideration" xlink:to="lab_nbx_CollaborationAgreementTotalConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotionalAmount_7ec212d1-01ae-42e1-a05f-4c242e65eecd_terseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_label_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock_3e1bc578-40e0-4721-973e-4e32f1bb8473_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Research Tax Credit Receivables</link:label>
    <link:label id="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Research Tax Credit Receivables [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Research Tax Credit Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:to="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_d0b96ab0-d7d1-450c-855b-9f13482c0f8f_terseLabel_en-US" xlink:label="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Information, Statement of Compliance and Basis of Presentation [Abstract]</link:label>
    <link:label id="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_label_en-US" xlink:label="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Information, Statement of Compliance and Basis of Presentation [Abstract]</link:label>
    <link:label id="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_documentation_en-US" xlink:label="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General Information, Statement of Compliance and Basis of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:href="nbx-20250630.xsd#nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:to="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_71974edc-1f46-4c49-ad60-0f2ac7396e63_terseLabel_en-US" xlink:label="lab_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to debt financing related to estimated debt outflows</link:label>
    <link:label id="lab_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_label_en-US" xlink:label="lab_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To Debt Financing Related to Estimated Debt Outflows</link:label>
    <link:label id="lab_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_documentation_en-US" xlink:label="lab_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment To Debt Financing Related to Estimated Debt Outflows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" xlink:href="nbx-20250630.xsd#nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" xlink:to="lab_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInEquityAbstract_9627b5d9-f546-4cc3-9380-ffffeb1becbc_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in equity</link:label>
    <link:label id="lab_ifrs-full_ChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_ChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInEquityAbstract" xlink:to="lab_ifrs-full_ChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_5280df86-f5fa-40e2-a743-149db102388a_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salaries, wages and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfSignificantTransactionsTextBlock_b080a978-1385-404c-b422-a087aec6fad1_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant transactions</link:label>
    <link:label id="lab_nbx_DisclosureOfSignificantTransactionsTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Significant Transactions [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfSignificantTransactionsTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Significant Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfSignificantTransactionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:to="lab_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement_1f0e341b-b418-43c2-b44d-d0206309584c_terseLabel_en-US" xlink:label="lab_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of share options authorised (in shares)</link:label>
    <link:label id="lab_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Options Authorised In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Options Authorised In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" xlink:href="nbx-20250630.xsd#nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" xlink:to="lab_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OperatingExpenseAxis_d2a8ddd4-1584-4bcb-9270-b0f847a37d51_terseLabel_en-US" xlink:label="lab_nbx_OperatingExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expense [Axis]</link:label>
    <link:label id="lab_nbx_OperatingExpenseAxis_label_en-US" xlink:label="lab_nbx_OperatingExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Axis]</link:label>
    <link:label id="lab_nbx_OperatingExpenseAxis_documentation_en-US" xlink:label="lab_nbx_OperatingExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OperatingExpenseAxis" xlink:href="nbx-20250630.xsd#nbx_OperatingExpenseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OperatingExpenseAxis" xlink:to="lab_nbx_OperatingExpenseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ServicesMember_4f5d2fab-de7d-443e-9113-9fc5bcecf5e4_terseLabel_en-US" xlink:label="lab_nbx_ServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services</link:label>
    <link:label id="lab_nbx_ServicesMember_label_en-US" xlink:label="lab_nbx_ServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Services [Member]</link:label>
    <link:label id="lab_nbx_ServicesMember_documentation_en-US" xlink:label="lab_nbx_ServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServicesMember" xlink:href="nbx-20250630.xsd#nbx_ServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ServicesMember" xlink:to="lab_nbx_ServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_16bdd69c-743f-4cd0-b1f3-a2455a7ace2e_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase / (Decrease) in other current liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA2023P1Member_397a1abc-9da0-4536-8d41-db6f2c0a144e_terseLabel_en-US" xlink:label="lab_nbx_AGA2023P1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA 2023 - P1</link:label>
    <link:label id="lab_nbx_AGA2023P1Member_label_en-US" xlink:label="lab_nbx_AGA2023P1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA 2023 - P1 [Member]</link:label>
    <link:label id="lab_nbx_AGA2023P1Member_documentation_en-US" xlink:label="lab_nbx_AGA2023P1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA 2023 - P1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023P1Member" xlink:href="nbx-20250630.xsd#nbx_AGA2023P1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA2023P1Member" xlink:to="lab_nbx_AGA2023P1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_b18c3482-3ca8-4160-86cc-2977eb3b13f0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Number of Founders' Warrants, Warrants and Free Shares Outstanding and Their Characteristics</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_0f1f9390-c7d8-4512-b7e3-bb1bdce7ceda_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentArrangement1Member_e8dc15d6-365a-4d39-8632-0b15e6ff4264_terseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentArrangement1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentArrangement1Member_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentArrangement1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement1 [Member]</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentArrangement1Member_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentArrangement1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentArrangement1Member" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentArrangement1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentArrangement1Member" xlink:to="lab_nbx_ResearchAndDevelopmentArrangement1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_155a4d69-cafc-43a9-9c45-52db84bf6047_terseLabel_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HSBC &#8220;PGE&#8221;</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_75d28eb3-ae03-4e68-a9a6-771756f63633_verboseLabel_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">HSBC "PGE"</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_label_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Dilutive Financing Agreement, HSBC France [Member]</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_documentation_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Dilutive Financing Agreement, HSBC France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:to="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CorporateOfficersMember_0d3d00a8-98f0-4849-be6b-495d7dd3131f_terseLabel_en-US" xlink:label="lab_nbx_CorporateOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate officers</link:label>
    <link:label id="lab_nbx_CorporateOfficersMember_label_en-US" xlink:label="lab_nbx_CorporateOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Officers [Member]</link:label>
    <link:label id="lab_nbx_CorporateOfficersMember_documentation_en-US" xlink:label="lab_nbx_CorporateOfficersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CorporateOfficersMember" xlink:href="nbx-20250630.xsd#nbx_CorporateOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CorporateOfficersMember" xlink:to="lab_nbx_CorporateOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ClinicalStudiesAxis_bf969caf-5fa8-47fe-9ccf-90ed6f62ba80_terseLabel_en-US" xlink:label="lab_nbx_ClinicalStudiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Studies [Axis]</link:label>
    <link:label id="lab_nbx_ClinicalStudiesAxis_label_en-US" xlink:label="lab_nbx_ClinicalStudiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Studies [Axis]</link:label>
    <link:label id="lab_nbx_ClinicalStudiesAxis_documentation_en-US" xlink:label="lab_nbx_ClinicalStudiesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Studies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ClinicalStudiesAxis" xlink:href="nbx-20250630.xsd#nbx_ClinicalStudiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ClinicalStudiesAxis" xlink:to="lab_nbx_ClinicalStudiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock_3a33d711-3d55-4791-918a-3abfba774576_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Expenses</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Research And Development Expense Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Research And Development Expense Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_03815433-c8e4-487d-b222-f2adbf3be55c_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of share options lapsed or cancelled (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced_7045075f-0479-4349-bd5d-e9cd5d2efbd1_terseLabel_en-US" xlink:label="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount to be advanced</link:label>
    <link:label id="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced_label_en-US" xlink:label="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advances, Authorized Amount To Be Advanced</link:label>
    <link:label id="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced_documentation_en-US" xlink:label="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advances, Authorized Amount To Be Advanced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:href="nbx-20250630.xsd#nbx_AdvancesAuthorizedAmountToBeAdvanced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:to="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_0d10503c-a0c4-4f14-8cb9-09184d77a6b3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_bdfd9ea6-3cc5-4ec8-996c-902ea9c7d6ff_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted loss per share (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityDomain_f0d9a364-47a9-428a-bcf2-24c3ccf2d231_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:label id="lab_ifrs-full_MaturityDomain_label_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityDomain" xlink:to="lab_ifrs-full_MaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_57c7a6d3-01e0-41bf-a694-6a1d9e15a1a3_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:to="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_b59420f4-b69b-4af1-b3ce-9f8ad4bbdda0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Number of Shares Options Outstanding and Their Characteristics</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6923eb16-a48e-4e1d-b2a9-b7f6b465e0f5_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CapitalReserveMember_9eca6fd0-30f2-4f02-87d4-649d2189ce61_terseLabel_en-US" xlink:label="lab_ifrs-full_CapitalReserveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve</link:label>
    <link:label id="lab_ifrs-full_CapitalReserveMember_label_en-US" xlink:label="lab_ifrs-full_CapitalReserveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital reserve [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserveMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalReserveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalReserveMember" xlink:to="lab_ifrs-full_CapitalReserveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_825915df-f084-4d50-8334-0de028fc96bc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AtFairValueMember_2f4ed7a6-2b3e-4c26-8d10-ee843208668e_terseLabel_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At fair value</link:label>
    <link:label id="lab_ifrs-full_AtFairValueMember_label_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At fair value [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember" xlink:to="lab_ifrs-full_AtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_2740f4ff-9de4-4492-a0d7-ebf3a444ac43_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term bank deposits</link:label>
    <link:label id="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term deposits, classified as cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202401OrdinaryMember_ae9034b6-9fe9-4fc3-b5ef-02a5a5765924_terseLabel_en-US" xlink:label="lab_nbx_OSA202401OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OSA 2024-01 O</link:label>
    <link:label id="lab_nbx_OSA202401OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA202401OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OSA 2024-01 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA202401OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA202401OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OSA 2024-01 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202401OrdinaryMember" xlink:href="nbx-20250630.xsd#nbx_OSA202401OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202401OrdinaryMember" xlink:to="lab_nbx_OSA202401OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_c106e392-e6f8-4b4a-aff8-3fe3c4afc14b_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Loss Per Share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreasePayrollExpensePercentage_fed6a2f0-4c2b-42b8-9128-d3fb7e89fdf3_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreasePayrollExpensePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage change in employee benefit expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreasePayrollExpensePercentage_label_en-US" xlink:label="lab_nbx_IncreaseDecreasePayrollExpensePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Payroll Expense, Percentage</link:label>
    <link:label id="lab_nbx_IncreaseDecreasePayrollExpensePercentage_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreasePayrollExpensePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Payroll Expense, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreasePayrollExpensePercentage" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreasePayrollExpensePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreasePayrollExpensePercentage" xlink:to="lab_nbx_IncreaseDecreasePayrollExpensePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d03a7c67-61c4-4000-b15e-d666bf2707de_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4295e189-15e7-4435-8386-026d8ddda89d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_0a4598f8-0e23-45e6-9945-fcdf978af1a8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_b46a4979-8ef5-490e-b7cf-7d96e5c7c9fb_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE20151Member_abbaa4a1-13ab-4273-b9de-e1d21ab585d1_terseLabel_en-US" xlink:label="lab_nbx_BSPCE20151Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSPCE 2015-1</link:label>
    <link:label id="lab_nbx_BSPCE20151Member_label_en-US" xlink:label="lab_nbx_BSPCE20151Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSPCE 2015-1 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE20151Member_documentation_en-US" xlink:label="lab_nbx_BSPCE20151Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSPCE 2015-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member" xlink:href="nbx-20250630.xsd#nbx_BSPCE20151Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE20151Member" xlink:to="lab_nbx_BSPCE20151Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>nbx-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e10ad955-f4fb-4992-aa6a-58056e28f5e0,g:51b53987-7aad-4161-819f-cbfd12ac6608-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://nanobiotix.com/role/Coverpage" xlink:type="simple" xlink:href="nbx-20250630.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f03cdc28-ae6b-4e03-939d-caa924ec9018" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_DocumentType_f03cdc28-ae6b-4e03-939d-caa924ec9018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_18f2b6b8-32d7-4183-b28d-6e75cf8d4a56" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_EntityFileNumber_18f2b6b8-32d7-4183-b28d-6e75cf8d4a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8920d1c6-f8aa-48d0-8dde-bd149d42e6a3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_EntityRegistrantName_8920d1c6-f8aa-48d0-8dde-bd149d42e6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4b5ee122-55a0-4ce5-8a51-c1cf6fe19f5e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_EntityAddressAddressLine1_4b5ee122-55a0-4ce5-8a51-c1cf6fe19f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d708fed3-82ef-4ef8-aa05-d2b3aeea6afb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_EntityAddressPostalZipCode_d708fed3-82ef-4ef8-aa05-d2b3aeea6afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2015cf2f-dcab-4acb-9f65-721d75f3d106" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_EntityAddressCityOrTown_2015cf2f-dcab-4acb-9f65-721d75f3d106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_ed95c31b-fe85-41ef-b079-026ade9665da" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_EntityAddressCountry_ed95c31b-fe85-41ef-b079-026ade9665da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e7e186ba-a777-4e68-b0c4-14ea066a1ff3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_AmendmentFlag_e7e186ba-a777-4e68-b0c4-14ea066a1ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e9662099-3f1d-4d3a-9a7a-0ef01e16bd3c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_EntityCentralIndexKey_e9662099-3f1d-4d3a-9a7a-0ef01e16bd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_16a831f1-8dde-452a-a6ef-6d3d745afb54" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_CurrentFiscalYearEndDate_16a831f1-8dde-452a-a6ef-6d3d745afb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7cb2a8ce-0550-4fa9-a6ea-f4cde4bfa3e4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_DocumentPeriodEndDate_7cb2a8ce-0550-4fa9-a6ea-f4cde4bfa3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e559d287-cb2d-43ef-9e21-06cc423d8325" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_DocumentFiscalYearFocus_e559d287-cb2d-43ef-9e21-06cc423d8325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c2f845a9-9bdf-4e0d-85e9-c13b52a0dcbd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0895a8a1-6d40-4884-9959-26cf577a3167" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c2f845a9-9bdf-4e0d-85e9-c13b52a0dcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_f7f37afe-5e3c-4346-b2c3-328b2b1ffe48" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_7dc2f431-df2e-4b45-b03f-81b36a9c7693" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_f7f37afe-5e3c-4346-b2c3-328b2b1ffe48" xlink:to="loc_ifrs-full_AssetsAbstract_7dc2f431-df2e-4b45-b03f-81b36a9c7693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_2d9b5715-d319-447e-856c-bc07cce7a56c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_7dc2f431-df2e-4b45-b03f-81b36a9c7693" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_2d9b5715-d319-447e-856c-bc07cce7a56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_4359a99e-a212-434b-9662-873bbeed84b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_2d9b5715-d319-447e-856c-bc07cce7a56c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_4359a99e-a212-434b-9662-873bbeed84b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_c516d17b-e10b-498b-8971-8318ba692fb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_2d9b5715-d319-447e-856c-bc07cce7a56c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_c516d17b-e10b-498b-8971-8318ba692fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_934712e2-8698-442b-92a3-0cab74097352" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_2d9b5715-d319-447e-856c-bc07cce7a56c" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_934712e2-8698-442b-92a3-0cab74097352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_40ba2099-4d73-4dd6-9eaa-3fd7a4178db7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_2d9b5715-d319-447e-856c-bc07cce7a56c" xlink:to="loc_ifrs-full_NoncurrentAssets_40ba2099-4d73-4dd6-9eaa-3fd7a4178db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_07adb971-fc3e-41c9-a66a-262f00d8d7e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_7dc2f431-df2e-4b45-b03f-81b36a9c7693" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_07adb971-fc3e-41c9-a66a-262f00d8d7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_e09b0d88-821a-408a-90b5-8907aa61015f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_07adb971-fc3e-41c9-a66a-262f00d8d7e1" xlink:to="loc_ifrs-full_CurrentTradeReceivables_e09b0d88-821a-408a-90b5-8907aa61015f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_16bd57e3-ba26-41cf-9b84-e1238d97b338" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_07adb971-fc3e-41c9-a66a-262f00d8d7e1" xlink:to="loc_ifrs-full_OtherCurrentAssets_16bd57e3-ba26-41cf-9b84-e1238d97b338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_35f77368-a5bf-4cbb-857d-0cb01b961333" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_07adb971-fc3e-41c9-a66a-262f00d8d7e1" xlink:to="loc_ifrs-full_CashAndCashEquivalents_35f77368-a5bf-4cbb-857d-0cb01b961333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_55c16a8b-70d7-4d18-b4c5-0edad9bd50d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_07adb971-fc3e-41c9-a66a-262f00d8d7e1" xlink:to="loc_ifrs-full_CurrentAssets_55c16a8b-70d7-4d18-b4c5-0edad9bd50d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_a7406b14-ea03-4707-91a6-1f0d68fe42c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_7dc2f431-df2e-4b45-b03f-81b36a9c7693" xlink:to="loc_ifrs-full_Assets_a7406b14-ea03-4707-91a6-1f0d68fe42c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_f0b10fe4-b798-42b5-a166-363dbbfc7057" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_f7f37afe-5e3c-4346-b2c3-328b2b1ffe48" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_f0b10fe4-b798-42b5-a166-363dbbfc7057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_c61a8073-abef-45a3-a78d-211e0aaffb5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f0b10fe4-b798-42b5-a166-363dbbfc7057" xlink:to="loc_ifrs-full_EquityAbstract_c61a8073-abef-45a3-a78d-211e0aaffb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_d6bb4253-dc07-45b0-b3c3-40615644341e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_c61a8073-abef-45a3-a78d-211e0aaffb5d" xlink:to="loc_ifrs-full_IssuedCapital_d6bb4253-dc07-45b0-b3c3-40615644341e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_a6f986fd-1de9-4c14-8fc1-6b3d08a358f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_c61a8073-abef-45a3-a78d-211e0aaffb5d" xlink:to="loc_ifrs-full_SharePremium_a6f986fd-1de9-4c14-8fc1-6b3d08a358f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_de541f65-6aab-47b0-a578-47627b117430" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_c61a8073-abef-45a3-a78d-211e0aaffb5d" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_de541f65-6aab-47b0-a578-47627b117430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_4f1664e8-163f-4300-8c91-7a87845c07a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasuryShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_c61a8073-abef-45a3-a78d-211e0aaffb5d" xlink:to="loc_ifrs-full_TreasuryShares_4f1664e8-163f-4300-8c91-7a87845c07a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_022517bf-26ff-4518-bc53-64dee25e0c23" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_c61a8073-abef-45a3-a78d-211e0aaffb5d" xlink:to="loc_ifrs-full_OtherReserves_022517bf-26ff-4518-bc53-64dee25e0c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_3f9320aa-bf09-4efa-8d82-94d96e886e38" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_c61a8073-abef-45a3-a78d-211e0aaffb5d" xlink:to="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_3f9320aa-bf09-4efa-8d82-94d96e886e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d35157aa-d55d-415e-8c56-9ffc525bfed3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_c61a8073-abef-45a3-a78d-211e0aaffb5d" xlink:to="loc_ifrs-full_Equity_d35157aa-d55d-415e-8c56-9ffc525bfed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_c825d9c2-3385-4f40-bc20-f8ceeaee3816" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f0b10fe4-b798-42b5-a166-363dbbfc7057" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_c825d9c2-3385-4f40-bc20-f8ceeaee3816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_881868ac-c116-4574-b168-094f3cd082ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_c825d9c2-3385-4f40-bc20-f8ceeaee3816" xlink:to="loc_ifrs-full_NoncurrentProvisions_881868ac-c116-4574-b168-094f3cd082ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_58be6cfa-b3e6-4d4e-bf7f-445a20f5c525" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_c825d9c2-3385-4f40-bc20-f8ceeaee3816" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_58be6cfa-b3e6-4d4e-bf7f-445a20f5c525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_362ff031-f3b4-4820-9807-218ba219ba81" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_c825d9c2-3385-4f40-bc20-f8ceeaee3816" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_362ff031-f3b4-4820-9807-218ba219ba81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_10998328-531d-4aba-b565-93293120f300" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_c825d9c2-3385-4f40-bc20-f8ceeaee3816" xlink:to="loc_ifrs-full_NoncurrentLiabilities_10998328-531d-4aba-b565-93293120f300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_5f2e007d-e8fb-4f40-aac6-573f9a28d76e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f0b10fe4-b798-42b5-a166-363dbbfc7057" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_5f2e007d-e8fb-4f40-aac6-573f9a28d76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_1c994acd-b129-47c9-98e1-ddf0acb3c3d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5f2e007d-e8fb-4f40-aac6-573f9a28d76e" xlink:to="loc_ifrs-full_CurrentProvisions_1c994acd-b129-47c9-98e1-ddf0acb3c3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_148fc456-26ac-44d7-9f4e-e1b81aca3105" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5f2e007d-e8fb-4f40-aac6-573f9a28d76e" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_148fc456-26ac-44d7-9f4e-e1b81aca3105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_6e633f17-9f40-4314-ab74-82330f7cb510" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5f2e007d-e8fb-4f40-aac6-573f9a28d76e" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_6e633f17-9f40-4314-ab74-82330f7cb510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_d63590b8-c737-4a3a-a426-0aa2ebbabaa5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5f2e007d-e8fb-4f40-aac6-573f9a28d76e" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_d63590b8-c737-4a3a-a426-0aa2ebbabaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_4e98721f-1782-4a1d-b0f4-a4e78dfd0851" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5f2e007d-e8fb-4f40-aac6-573f9a28d76e" xlink:to="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_4e98721f-1782-4a1d-b0f4-a4e78dfd0851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_945af22b-7101-41ca-9977-20ba6e73833f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5f2e007d-e8fb-4f40-aac6-573f9a28d76e" xlink:to="loc_ifrs-full_CurrentContractLiabilities_945af22b-7101-41ca-9977-20ba6e73833f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRefundsProvision_6fedd443-e141-40ba-9347-fd164b2032d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRefundsProvision"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5f2e007d-e8fb-4f40-aac6-573f9a28d76e" xlink:to="loc_ifrs-full_CurrentRefundsProvision_6fedd443-e141-40ba-9347-fd164b2032d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_9250aa0a-478b-4fea-9143-0f3f60eb0139" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5f2e007d-e8fb-4f40-aac6-573f9a28d76e" xlink:to="loc_ifrs-full_CurrentLiabilities_9250aa0a-478b-4fea-9143-0f3f60eb0139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_c0cab62f-edce-4f21-a037-0c4738c5a759" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f0b10fe4-b798-42b5-a166-363dbbfc7057" xlink:to="loc_ifrs-full_Liabilities_c0cab62f-edce-4f21-a037-0c4738c5a759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_b17c49e8-53ce-44c9-a0f0-99f81d978cb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f0b10fe4-b798-42b5-a166-363dbbfc7057" xlink:to="loc_ifrs-full_EquityAndLiabilities_b17c49e8-53ce-44c9-a0f0-99f81d978cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_fba7f0b0-1184-4e7a-bb4d-7ad7dfbc2883" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_RevenueAbstract_fba7f0b0-1184-4e7a-bb4d-7ad7dfbc2883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_9b148d97-47c5-488d-a5eb-4d552a448d0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_fba7f0b0-1184-4e7a-bb4d-7ad7dfbc2883" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_9b148d97-47c5-488d-a5eb-4d552a448d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_fe4a759e-7c1f-479b-a283-517e422eee63" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_fba7f0b0-1184-4e7a-bb4d-7ad7dfbc2883" xlink:to="loc_ifrs-full_OtherIncome_fe4a759e-7c1f-479b-a283-517e422eee63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_9029f862-7689-46fa-ac5d-fc640c275a27" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_fba7f0b0-1184-4e7a-bb4d-7ad7dfbc2883" xlink:to="loc_ifrs-full_Revenue_9029f862-7689-46fa-ac5d-fc640c275a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_e2014425-51fc-413f-a32a-8e4aac5bbfa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_e2014425-51fc-413f-a32a-8e4aac5bbfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_cefd5b69-ec81-427a-b352-03f5a50816d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_cefd5b69-ec81-427a-b352-03f5a50816d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_b32c9e5a-0c87-445f-8429-a9be9e73ecaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_b32c9e5a-0c87-445f-8429-a9be9e73ecaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_9ffb5dd8-9586-4009-b403-fad95fd79e74" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_OperatingExpense_9ffb5dd8-9586-4009-b403-fad95fd79e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_9c926399-9a47-48e8-b0d5-7d90130df6d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_9c926399-9a47-48e8-b0d5-7d90130df6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_6fd408d1-02c2-45f3-a69c-417ff08957cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_FinanceIncome_6fd408d1-02c2-45f3-a69c-417ff08957cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_0540581d-93d0-4797-ae21-0f919ba134c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_FinanceCosts_0540581d-93d0-4797-ae21-0f919ba134c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_878a743d-937b-425e-a97a-27d25778800c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_FinanceIncomeCost_878a743d-937b-425e-a97a-27d25778800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_4c860273-a05f-44c1-abb5-f194f934a275" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_4c860273-a05f-44c1-abb5-f194f934a275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_34c379b0-2c73-4d03-8bab-9d8cf48819bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_ProfitLoss_34c379b0-2c73-4d03-8bab-9d8cf48819bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_757573da-3f9f-4677-8b3b-d488d018f5f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_757573da-3f9f-4677-8b3b-d488d018f5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_54be8331-aa74-431b-9c75-2a991c49fa6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_6b50b303-cdc4-447c-8904-95c9c2026177" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_54be8331-aa74-431b-9c75-2a991c49fa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_d07d517b-efd4-412d-8306-68b3deb31729" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_dfc89653-62a9-4ec4-ac16-ff5fb9c02d27" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_d07d517b-efd4-412d-8306-68b3deb31729" xlink:to="loc_ifrs-full_ProfitLoss_dfc89653-62a9-4ec4-ac16-ff5fb9c02d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_29c19a07-b0d2-41c5-81a2-5278d7b1039a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_d07d517b-efd4-412d-8306-68b3deb31729" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_29c19a07-b0d2-41c5-81a2-5278d7b1039a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_5577b8ee-df29-4130-8542-29341540d3b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_d07d517b-efd4-412d-8306-68b3deb31729" xlink:to="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_5577b8ee-df29-4130-8542-29341540d3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1d385b6f-f768-4a1f-ad85-b2d343aa33a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_d07d517b-efd4-412d-8306-68b3deb31729" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1d385b6f-f768-4a1f-ad85-b2d343aa33a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_f8c0bb6c-660e-4793-b3fe-59801501cdb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_d07d517b-efd4-412d-8306-68b3deb31729" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_f8c0bb6c-660e-4793-b3fe-59801501cdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_c839affb-bcf7-4bf6-9d1d-5fb875a4ab5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_d07d517b-efd4-412d-8306-68b3deb31729" xlink:to="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_c839affb-bcf7-4bf6-9d1d-5fb875a4ab5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_da9a7b8f-2089-4aa7-91af-8036926f716d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_d07d517b-efd4-412d-8306-68b3deb31729" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_da9a7b8f-2089-4aa7-91af-8036926f716d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_63c929a3-1f21-4850-bd3d-587a17e5701d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_d07d517b-efd4-412d-8306-68b3deb31729" xlink:to="loc_ifrs-full_ComprehensiveIncome_63c929a3-1f21-4850-bd3d-587a17e5701d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_ef0648ba-1b05-418f-8c67-e572b03c613a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_a364bf94-2a5a-42a7-8bcc-d1df7da5273a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_ef0648ba-1b05-418f-8c67-e572b03c613a" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_a364bf94-2a5a-42a7-8bcc-d1df7da5273a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_f6bf64c2-8088-45b9-8c50-72833d1c1b16" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_a364bf94-2a5a-42a7-8bcc-d1df7da5273a" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_f6bf64c2-8088-45b9-8c50-72833d1c1b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_f6bf64c2-8088-45b9-8c50-72833d1c1b16" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_de283480-c0d8-46d4-9005-9ae05b7488b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_ifrs-full_IssuedCapitalMember_de283480-c0d8-46d4-9005-9ae05b7488b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_b450e0a3-4c0c-4521-8dd1-516ef178f4ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_ifrs-full_SharePremiumMember_b450e0a3-4c0c-4521-8dd1-516ef178f4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_8ee65bbf-05c9-4132-ae6c-4064eca39662" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_8ee65bbf-05c9-4132-ae6c-4064eca39662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_6e6c2a05-64ed-4716-9b5a-cf7d8e72b849" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_ifrs-full_TreasurySharesMember_6e6c2a05-64ed-4716-9b5a-cf7d8e72b849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserveMember_8d53a022-ad06-48a8-afeb-8a93c581928b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalReserveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_ifrs-full_CapitalReserveMember_8d53a022-ad06-48a8-afeb-8a93c581928b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetLossForThePeriodMember_2af91a67-7d7b-4ac9-8705-25cb350f00a0" xlink:href="nbx-20250630.xsd#nbx_NetLossForThePeriodMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6e687d1e-6fc9-4b01-bf4a-e9fbee7dc913" xlink:to="loc_nbx_NetLossForThePeriodMember_2af91a67-7d7b-4ac9-8705-25cb350f00a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_3ff90c78-36c2-4205-ae68-cacbc0e90838" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_a364bf94-2a5a-42a7-8bcc-d1df7da5273a" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_3ff90c78-36c2-4205-ae68-cacbc0e90838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3ff90c78-36c2-4205-ae68-cacbc0e90838" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_16696b02-1cce-417c-a6db-9acf97a9f2e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_16696b02-1cce-417c-a6db-9acf97a9f2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_1562250b-1a81-48bf-9899-666f692e6f0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_Equity_1562250b-1a81-48bf-9899-666f692e6f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_1ec21fa5-97f4-431a-b598-63a03ede0022" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_ProfitLoss_1ec21fa5-97f4-431a-b598-63a03ede0022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_77169ce4-6053-4ecc-aea4-a2277f690051" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_77169ce4-6053-4ecc-aea4-a2277f690051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations_279c1d3e-0ab9-4aed-8bf5-ff002ba271b9" xlink:href="nbx-20250630.xsd#nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations_279c1d3e-0ab9-4aed-8bf5-ff002ba271b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_939319e3-5a38-4b5c-ae84-6366e59733a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_ComprehensiveIncome_939319e3-5a38-4b5c-ae84-6366e59733a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_26b66153-fd12-4642-b709-4825782685a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_26b66153-fd12-4642-b709-4825782685a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_54c35afb-63b7-4829-9e53-b208fa34169b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_NumberOfSharesIssued_54c35afb-63b7-4829-9e53-b208fa34169b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_7e5e23ee-c4fd-438d-9463-175a8f376166" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_IssueOfEquity_7e5e23ee-c4fd-438d-9463-175a8f376166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_8c2b69cb-9fec-4d6a-8e47-d5253367a47b" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_8c2b69cb-9fec-4d6a-8e47-d5253367a47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_e0b76d0a-c6c0-441f-8fd0-2ad81d090abe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_e0b76d0a-c6c0-441f-8fd0-2ad81d090abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_50a3c4cc-a90e-4113-976e-109349c2fe92" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_50a3c4cc-a90e-4113-976e-109349c2fe92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_b92622cc-790c-4d67-9ba8-6c23c580ffbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1dec8a61-5cf1-495a-a658-d215f632f689" xlink:to="loc_ifrs-full_Equity_b92622cc-790c-4d67-9ba8-6c23c580ffbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS" xlink:type="simple" xlink:href="nbx-20250630.xsd#INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_ce2cf30d-02ac-4c01-85e7-580ac70c0faf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1779498c-0b7d-45b8-9879-de40646889a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_ce2cf30d-02ac-4c01-85e7-580ac70c0faf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1779498c-0b7d-45b8-9879-de40646889a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_c063972a-9388-4687-b50b-de8267b991f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1779498c-0b7d-45b8-9879-de40646889a9" xlink:to="loc_ifrs-full_ProfitLoss_c063972a-9388-4687-b50b-de8267b991f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1779498c-0b7d-45b8-9879-de40646889a9" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_e3504259-50c1-4dde-a3b4-5ce12f339b61" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_e3504259-50c1-4dde-a3b4-5ce12f339b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_3e196f4f-0563-4c81-8a22-6325d2547e7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_3e196f4f-0563-4c81-8a22-6325d2547e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_eacd2a06-f588-48cb-9205-c1b18632c819" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_eacd2a06-f588-48cb-9205-c1b18632c819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_9a052fda-35be-437d-b611-6155a202d3ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_9a052fda-35be-437d-b611-6155a202d3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_84d47db9-55cf-4e93-a20f-b4499b5bab6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_84d47db9-55cf-4e93-a20f-b4499b5bab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_d2145b9d-d857-419a-a983-98774af25994" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_d2145b9d-d857-419a-a983-98774af25994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b354cb85-5f2b-4892-8621-e8dcc64bc6a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b354cb85-5f2b-4892-8621-e8dcc64bc6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_dd4aa450-829c-4ddd-88f7-d3b9d7d8c27f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_dd4aa450-829c-4ddd-88f7-d3b9d7d8c27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ImpactOfAmendmentOnProfitOrLoss_ecd54f5f-8ed6-49ce-9df7-8a74cf8ab1b0" xlink:href="nbx-20250630.xsd#nbx_ImpactOfAmendmentOnProfitOrLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_nbx_ImpactOfAmendmentOnProfitOrLoss_ecd54f5f-8ed6-49ce-9df7-8a74cf8ab1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_3fe9ae9e-2c94-4e34-b45d-f06b9b9d0329" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_3fe9ae9e-2c94-4e34-b45d-f06b9b9d0329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_1984291b-5ad8-4643-a076-689aab7621f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_1984291b-5ad8-4643-a076-689aab7621f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement_44fb55c1-b835-4a18-8690-b01db3c90a18" xlink:href="nbx-20250630.xsd#nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement_44fb55c1-b835-4a18-8690-b01db3c90a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_056f34c2-2157-4e06-9a4e-f1c0310462c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_056f34c2-2157-4e06-9a4e-f1c0310462c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_c4fa33af-3cbe-4c5b-ac16-7bc1769372b8" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_c4fa33af-3cbe-4c5b-ac16-7bc1769372b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_6897dcfa-db03-42ab-91dc-44c367151167" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_6897dcfa-db03-42ab-91dc-44c367151167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_6bdd7ad7-3d4a-4cb8-8717-bcc8a426a8d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_6bdd7ad7-3d4a-4cb8-8717-bcc8a426a8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_f4e16f20-b970-4c1a-8fbf-9569d3175080" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_f4e16f20-b970-4c1a-8fbf-9569d3175080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_6d5917f4-4eb9-44ef-8a68-d369901c3a56" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_6d5917f4-4eb9-44ef-8a68-d369901c3a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_c5949403-f717-4bf2-8fad-fe39d730520a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_075f68a5-f756-4307-8551-2f91f63b9fc1" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_c5949403-f717-4bf2-8fad-fe39d730520a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_8feb8136-042a-4220-ba0a-89a46d2cd0a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1779498c-0b7d-45b8-9879-de40646889a9" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_8feb8136-042a-4220-ba0a-89a46d2cd0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_d6b07413-c2cb-4080-afce-8a5bdf30c26f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_ce2cf30d-02ac-4c01-85e7-580ac70c0faf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_d6b07413-c2cb-4080-afce-8a5bdf30c26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_7a97619e-2173-4861-b34e-895968d28195" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_d6b07413-c2cb-4080-afce-8a5bdf30c26f" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_7a97619e-2173-4861-b34e-895968d28195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_e274b9be-fe4c-4a29-a2d7-67710d33220a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_d6b07413-c2cb-4080-afce-8a5bdf30c26f" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_e274b9be-fe4c-4a29-a2d7-67710d33220a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_518d35d4-1702-4dba-8880-3f1553d703d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_d6b07413-c2cb-4080-afce-8a5bdf30c26f" xlink:to="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_518d35d4-1702-4dba-8880-3f1553d703d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_35b16132-24a2-4b61-999b-7b763dba1b40" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_d6b07413-c2cb-4080-afce-8a5bdf30c26f" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_35b16132-24a2-4b61-999b-7b763dba1b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_236fb735-e5f9-404f-8c6b-fa5eecaff480" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_ce2cf30d-02ac-4c01-85e7-580ac70c0faf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_236fb735-e5f9-404f-8c6b-fa5eecaff480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_a1f9ed40-57fc-42a8-a5de-c87c97b1ecfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_236fb735-e5f9-404f-8c6b-fa5eecaff480" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_a1f9ed40-57fc-42a8-a5de-c87c97b1ecfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_abae5948-a3bd-43ea-bb12-65c67811f629" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_236fb735-e5f9-404f-8c6b-fa5eecaff480" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_abae5948-a3bd-43ea-bb12-65c67811f629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_6f110211-dc41-4e20-8f57-9496177d1e44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_236fb735-e5f9-404f-8c6b-fa5eecaff480" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_6f110211-dc41-4e20-8f57-9496177d1e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_0adfd05f-55b8-462b-b585-517b2b70afc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_236fb735-e5f9-404f-8c6b-fa5eecaff480" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_0adfd05f-55b8-462b-b585-517b2b70afc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a4c38306-b5c6-4e41-871d-2e36830c118c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_236fb735-e5f9-404f-8c6b-fa5eecaff480" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a4c38306-b5c6-4e41-871d-2e36830c118c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_df9f4614-2fac-4673-81b2-4b66722319cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_ce2cf30d-02ac-4c01-85e7-580ac70c0faf" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_df9f4614-2fac-4673-81b2-4b66722319cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0ed8518e-ff20-4554-ae66-99fdddcb7bd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_ce2cf30d-02ac-4c01-85e7-580ac70c0faf" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0ed8518e-ff20-4554-ae66-99fdddcb7bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_61758bb7-16db-4e23-a0d2-8f42e42c86c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_ce2cf30d-02ac-4c01-85e7-580ac70c0faf" xlink:to="loc_ifrs-full_CashAndCashEquivalents_61758bb7-16db-4e23-a0d2-8f42e42c86c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_d4afa6b3-9d43-4976-b945-a1c35f633901" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_ce2cf30d-02ac-4c01-85e7-580ac70c0faf" xlink:to="loc_ifrs-full_CashAndCashEquivalents_d4afa6b3-9d43-4976-b945-a1c35f633901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Companyinformation" xlink:type="simple" xlink:href="nbx-20250630.xsd#Companyinformation"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Companyinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_97c863dd-0f06-4364-923a-d3217264040e" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock_47e9f46a-c4a0-4caa-b7a4-fb756db98526" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_97c863dd-0f06-4364-923a-d3217264040e" xlink:to="loc_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock_47e9f46a-c4a0-4caa-b7a4-fb756db98526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Generalinformationstatementofcomplianceandbasisofpresentation" xlink:type="simple" xlink:href="nbx-20250630.xsd#Generalinformationstatementofcomplianceandbasisofpresentation"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Generalinformationstatementofcomplianceandbasisofpresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_2e027736-73e3-42ec-8965-e1872c328add" xlink:href="nbx-20250630.xsd#nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_3b1b00d7-5da3-484e-878d-be8eac072779" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_2e027736-73e3-42ec-8965-e1872c328add" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_3b1b00d7-5da3-484e-878d-be8eac072779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Consolidatedprinciplesandmethods" xlink:type="simple" xlink:href="nbx-20250630.xsd#Consolidatedprinciplesandmethods"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Consolidatedprinciplesandmethods" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SignificantAccountingPoliciesAbstract_a399aeae-60a7-4628-aa82-4ac4051e5b31" xlink:href="nbx-20250630.xsd#nbx_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_ce95730f-c791-439e-aad0-920b65273b59" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_a399aeae-60a7-4628-aa82-4ac4051e5b31" xlink:to="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_ce95730f-c791-439e-aad0-920b65273b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Significanttransactions" xlink:type="simple" xlink:href="nbx-20250630.xsd#Significanttransactions"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Significanttransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0f5720f8-9fac-4483-bab8-6a0d813ad875" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfSignificantTransactionsTextBlock_8d346fcf-ec45-4947-9ceb-c6da080d29d2" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfSignificantTransactionsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0f5720f8-9fac-4483-bab8-6a0d813ad875" xlink:to="loc_nbx_DisclosureOfSignificantTransactionsTextBlock_8d346fcf-ec45-4947-9ceb-c6da080d29d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Intangibleassets" xlink:type="simple" xlink:href="nbx-20250630.xsd#Intangibleassets"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Intangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_30535b17-df38-4fd9-869a-04a232b16166" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_d9d1e9c8-1d18-40d2-885e-b123d57a13c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_30535b17-df38-4fd9-869a-04a232b16166" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_d9d1e9c8-1d18-40d2-885e-b123d57a13c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="nbx-20250630.xsd#Propertyplantandequipment"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Propertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_47b8acff-0252-4089-b97b-c31952ae55de" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_43111f98-b9e0-4a07-a6b3-84a4a8a42944" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_47b8acff-0252-4089-b97b-c31952ae55de" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_43111f98-b9e0-4a07-a6b3-84a4a8a42944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Noncurrentfinancialassets" xlink:type="simple" xlink:href="nbx-20250630.xsd#Noncurrentfinancialassets"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Noncurrentfinancialassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_c515286c-335c-477c-b646-95fb17f7ebc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock_3066c354-4cc5-485e-be26-99296c0683a4" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_c515286c-335c-477c-b646-95fb17f7ebc4" xlink:to="loc_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock_3066c354-4cc5-485e-be26-99296c0683a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Tradereceivablesandothercurrentassets" xlink:type="simple" xlink:href="nbx-20250630.xsd#Tradereceivablesandothercurrentassets"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Tradereceivablesandothercurrentassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_feeffd8d-ec3b-4e08-b9e0-77199ec2e4eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock_066cce19-b5d3-4bd8-8685-646d98f3a252" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_feeffd8d-ec3b-4e08-b9e0-77199ec2e4eb" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock_066cce19-b5d3-4bd8-8685-646d98f3a252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Cashandcashequivalents" xlink:type="simple" xlink:href="nbx-20250630.xsd#Cashandcashequivalents"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Cashandcashequivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_5017452e-4e2a-4c0c-98bc-9dd9a9501896" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_921e5af3-0ed2-4ad1-ac04-c03937b3a765" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_5017452e-4e2a-4c0c-98bc-9dd9a9501896" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_921e5af3-0ed2-4ad1-ac04-c03937b3a765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapital" xlink:type="simple" xlink:href="nbx-20250630.xsd#ShareCapital"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_9f91e8e6-9254-4e4c-a334-21e03f09463f" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_bcabb0a0-09fb-475e-8979-7528e79bed04" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_9f91e8e6-9254-4e4c-a334-21e03f09463f" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_bcabb0a0-09fb-475e-8979-7528e79bed04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RetirementObligations" xlink:type="simple" xlink:href="nbx-20250630.xsd#RetirementObligations"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RetirementObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RetirementObligationAbstract_89916cd9-a210-4156-b613-b8dbc4b8cb01" xlink:href="nbx-20250630.xsd#nbx_RetirementObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_41728858-5e93-48fa-b1ce-7c08dea7f250" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_RetirementObligationAbstract_89916cd9-a210-4156-b613-b8dbc4b8cb01" xlink:to="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_41728858-5e93-48fa-b1ce-7c08dea7f250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Provisions" xlink:type="simple" xlink:href="nbx-20250630.xsd#Provisions"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Provisions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_369b869b-5ccd-4feb-8b4a-412acfbbf6e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory_adaf520a-f9bf-4df8-9e5e-fa22e7af919a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_369b869b-5ccd-4feb-8b4a-412acfbbf6e9" xlink:to="loc_ifrs-full_DisclosureOfProvisionsExplanatory_adaf520a-f9bf-4df8-9e5e-fa22e7af919a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Financialliabilities" xlink:type="simple" xlink:href="nbx-20250630.xsd#Financialliabilities"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Financialliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_9f07c3f5-4841-49f9-b3d9-41ecd9d518b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock_60189858-631d-4219-be9c-1cf8525e1c75" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_9f07c3f5-4841-49f9-b3d9-41ecd9d518b3" xlink:to="loc_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock_60189858-631d-4219-be9c-1cf8525e1c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities" xlink:type="simple" xlink:href="nbx-20250630.xsd#Tradepayablesandothercurrentliabilities"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9f6d1ed4-6780-460e-a905-062c0a80baac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock_0032bbde-1ce5-4b86-a91d-61f73dd179dd" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9f6d1ed4-6780-460e-a905-062c0a80baac" xlink:to="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock_0032bbde-1ce5-4b86-a91d-61f73dd179dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome" xlink:type="simple" xlink:href="nbx-20250630.xsd#Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_993ebada-60cb-4eda-95a5-d4cc201b85c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_f09ced92-654f-4683-b291-6b562396804d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_993ebada-60cb-4eda-95a5-d4cc201b85c1" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_f09ced92-654f-4683-b291-6b562396804d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Revenueandotherincome" xlink:type="simple" xlink:href="nbx-20250630.xsd#Revenueandotherincome"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Revenueandotherincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_8f6ec36c-e22b-4bbe-a5ad-29c6656ce296" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_71f2ed52-073e-4e46-9f92-9661e451cd96" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_8f6ec36c-e22b-4bbe-a5ad-29c6656ce296" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_71f2ed52-073e-4e46-9f92-9661e451cd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Operatingexpenses" xlink:type="simple" xlink:href="nbx-20250630.xsd#Operatingexpenses"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Operatingexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_00296778-8e05-4891-af48-258121a3c79f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_7b973e1a-0927-4c2e-bda4-1560fef05fa4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_00296778-8e05-4891-af48-258121a3c79f" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_7b973e1a-0927-4c2e-bda4-1560fef05fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Sharebasedpayments" xlink:type="simple" xlink:href="nbx-20250630.xsd#Sharebasedpayments"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Sharebasedpayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_a6f2839a-f426-46a0-a31d-fe0c1f98e1e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_f99ff181-4dc4-4c40-bb4c-9a8952097a41" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_a6f2839a-f426-46a0-a31d-fe0c1f98e1e9" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_f99ff181-4dc4-4c40-bb4c-9a8952097a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Netfinancialincomeloss" xlink:type="simple" xlink:href="nbx-20250630.xsd#Netfinancialincomeloss"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Netfinancialincomeloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetFinancialIncomeLossAbstract_76344d85-f540-4fdf-8935-bb91e8496587" xlink:href="nbx-20250630.xsd#nbx_NetFinancialIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_9cc5afb6-6a8b-4a06-8719-1d00ed95df20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_76344d85-f540-4fdf-8935-bb91e8496587" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_9cc5afb6-6a8b-4a06-8719-1d00ed95df20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Segmentreporting" xlink:type="simple" xlink:href="nbx-20250630.xsd#Segmentreporting"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Segmentreporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0c53fe55-b6a3-4ded-ae58-49f0421811ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_18efd68a-353b-4d74-b27d-c74c2e7a5b01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0c53fe55-b6a3-4ded-ae58-49f0421811ec" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_18efd68a-353b-4d74-b27d-c74c2e7a5b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Losspershare" xlink:type="simple" xlink:href="nbx-20250630.xsd#Losspershare"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Losspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_92b96b07-aecb-447b-b1c9-7dc6608b61e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_6822089c-761d-40c8-b4be-8db4956ea1a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_92b96b07-aecb-447b-b1c9-7dc6608b61e5" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_6822089c-761d-40c8-b4be-8db4956ea1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Commitments" xlink:type="simple" xlink:href="nbx-20250630.xsd#Commitments"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalCommitmentsAbstract_6f689331-ab9c-4d49-8ee2-b15b5ba87e54" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_d7543010-fc2d-4217-a8c1-17d261df75ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CapitalCommitmentsAbstract_6f689331-ab9c-4d49-8ee2-b15b5ba87e54" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_d7543010-fc2d-4217-a8c1-17d261df75ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Relatedparties" xlink:type="simple" xlink:href="nbx-20250630.xsd#Relatedparties"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Relatedparties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_54d46b00-ed72-43b9-8c03-c2830fd9d84a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_e9da77e3-148e-41b3-b177-7e11d2ee5b85" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_54d46b00-ed72-43b9-8c03-c2830fd9d84a" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_e9da77e3-148e-41b3-b177-7e11d2ee5b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Subsequentevents" xlink:type="simple" xlink:href="nbx-20250630.xsd#Subsequentevents"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Subsequentevents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_15253c25-00d9-41fa-a33b-915c831e6062" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_e2a075e1-6d87-4b08-8310-5af982bea149" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_15253c25-00d9-41fa-a33b-915c831e6062" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_e2a075e1-6d87-4b08-8310-5af982bea149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsPolicies" xlink:type="simple" xlink:href="nbx-20250630.xsd#ConsolidatedprinciplesandmethodsPolicies"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SignificantAccountingPoliciesAbstract_710ddb46-8c62-4905-b23a-0f16ce0dbc2f" xlink:href="nbx-20250630.xsd#nbx_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_959c381b-ed67-458c-99ae-d84bc76cf272" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_710ddb46-8c62-4905-b23a-0f16ce0dbc2f" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_959c381b-ed67-458c-99ae-d84bc76cf272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_a96a6d7e-d03b-409c-b989-3164dcf6a646" xlink:href="nbx-20250630.xsd#nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_710ddb46-8c62-4905-b23a-0f16ce0dbc2f" xlink:to="loc_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_a96a6d7e-d03b-409c-b989-3164dcf6a646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock_7cc8e5be-a4df-4249-bc2f-984f7b3a6e51" xlink:href="nbx-20250630.xsd#nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_710ddb46-8c62-4905-b23a-0f16ce0dbc2f" xlink:to="loc_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock_7cc8e5be-a4df-4249-bc2f-984f7b3a6e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_ace261ac-f4c0-46f7-bb80-82e1f49062ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_710ddb46-8c62-4905-b23a-0f16ce0dbc2f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_ace261ac-f4c0-46f7-bb80-82e1f49062ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IntangibleassetsTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#IntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/IntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_af25fca7-ce7f-43e7-83f2-d14d173c2753" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_42919e96-740f-42c6-a206-2b8fc2cdd6a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_af25fca7-ce7f-43e7-83f2-d14d173c2753" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_42919e96-740f-42c6-a206-2b8fc2cdd6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#PropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/PropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_23098dc1-d20e-46a9-b10d-9d8801509404" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_3a64ff46-4b3c-46b7-84fb-fb423ffbf181" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_23098dc1-d20e-46a9-b10d-9d8801509404" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_3a64ff46-4b3c-46b7-84fb-fb423ffbf181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#NoncurrentfinancialassetsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NoncurrentfinancialassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_2bbb90b5-dfb6-401a-8c0b-54e9e39601bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock_7be4b519-40cd-467c-b7ae-352f2464f529" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_2bbb90b5-dfb6-401a-8c0b-54e9e39601bd" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock_7be4b519-40cd-467c-b7ae-352f2464f529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradereceivablesandothercurrentassetsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_105bf5ba-ca65-4c43-96f2-a1b95bf8bc72" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock_8faa0a6b-9a86-4b00-a078-08bf969bde26" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_105bf5ba-ca65-4c43-96f2-a1b95bf8bc72" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock_8faa0a6b-9a86-4b00-a078-08bf969bde26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_3a4c1455-e42d-4a54-910e-1fd8094c12a5" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_105bf5ba-ca65-4c43-96f2-a1b95bf8bc72" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_3a4c1455-e42d-4a54-910e-1fd8094c12a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock_94ce367f-07df-4ed0-957e-6d268b939a97" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_105bf5ba-ca65-4c43-96f2-a1b95bf8bc72" xlink:to="loc_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock_94ce367f-07df-4ed0-957e-6d268b939a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CashandcashequivalentsTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#CashandcashequivalentsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/CashandcashequivalentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_39f7d8cf-c298-449b-a45a-d51857ad3222" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_92cb57e0-83d6-40ad-bc98-469835b64b67" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_39f7d8cf-c298-449b-a45a-d51857ad3222" xlink:to="loc_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_92cb57e0-83d6-40ad-bc98-469835b64b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#ShareCapitalTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_4fd7ccc1-ae13-4b28-ba2e-c3dcb38d6af2" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_2855527f-18ae-47d5-9a30-425a9b096615" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_4fd7ccc1-ae13-4b28-ba2e-c3dcb38d6af2" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_2855527f-18ae-47d5-9a30-425a9b096615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RetirementObligationsTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#RetirementObligationsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RetirementObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RetirementObligationAbstract_944573fb-8bee-4dad-88cf-c641bfd09fde" xlink:href="nbx-20250630.xsd#nbx_RetirementObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory_939542a2-c53b-4baa-9fe9-60457cf647ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_RetirementObligationAbstract_944573fb-8bee-4dad-88cf-c641bfd09fde" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory_939542a2-c53b-4baa-9fe9-60457cf647ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#ProvisionsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ProvisionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_ed09da5a-1285-41be-8dc5-f916193687f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory_4cd394b2-3638-4c8e-934f-5d766e43939a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_ed09da5a-1285-41be-8dc5-f916193687f1" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory_4cd394b2-3638-4c8e-934f-5d766e43939a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_616f5c86-e9d6-4a81-91c3-e7ca008d8ef9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_044c14f3-d9cc-419b-a43f-137e7a5e0808" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_616f5c86-e9d6-4a81-91c3-e7ca008d8ef9" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_044c14f3-d9cc-419b-a43f-137e7a5e0808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_5d3784d0-228b-4378-b891-ae87f862bad7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_616f5c86-e9d6-4a81-91c3-e7ca008d8ef9" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_5d3784d0-228b-4378-b891-ae87f862bad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock_efa0467a-882f-456a-9928-4fc05373edcb" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_616f5c86-e9d6-4a81-91c3-e7ca008d8ef9" xlink:to="loc_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock_efa0467a-882f-456a-9928-4fc05373edcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_033523ac-1836-424f-b116-57d688e5150f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_166062ce-e0f7-42e1-bd18-170540ab61fd" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_033523ac-1836-424f-b116-57d688e5150f" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_166062ce-e0f7-42e1-bd18-170540ab61fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_35806a2a-0ddf-44b4-9f48-664cbc276a9d" xlink:href="nbx-20250630.xsd#nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_033523ac-1836-424f-b116-57d688e5150f" xlink:to="loc_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_35806a2a-0ddf-44b4-9f48-664cbc276a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock_75305d4b-127b-4346-a8a6-5e6a9d728594" xlink:href="nbx-20250630.xsd#nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_033523ac-1836-424f-b116-57d688e5150f" xlink:to="loc_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock_75305d4b-127b-4346-a8a6-5e6a9d728594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock_4634c108-e45f-4c51-afee-06aabb5fa95c" xlink:href="nbx-20250630.xsd#nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_033523ac-1836-424f-b116-57d688e5150f" xlink:to="loc_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock_4634c108-e45f-4c51-afee-06aabb5fa95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_2f726e94-3171-4baa-8ab2-88a54d464352" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_308de2f0-5dab-472f-a4eb-958bebc453da" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_2f726e94-3171-4baa-8ab2-88a54d464352" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_308de2f0-5dab-472f-a4eb-958bebc453da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2cae01d3-1423-4630-b9d0-1bca1268f7ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_2f726e94-3171-4baa-8ab2-88a54d464352" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2cae01d3-1423-4630-b9d0-1bca1268f7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenueandotherincomeTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#RevenueandotherincomeTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RevenueandotherincomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_fb70eb5d-b4e2-4345-9d85-fe45449c2158" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock_803de517-eea5-4f04-9d41-01cb1662d7d2" xlink:href="nbx-20250630.xsd#nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_fb70eb5d-b4e2-4345-9d85-fe45449c2158" xlink:to="loc_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock_803de517-eea5-4f04-9d41-01cb1662d7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_65b9f166-9d77-484f-9f46-e1c67815d53e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock_a8dcb56e-bebe-4a2b-9f11-c657da1eb118" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_65b9f166-9d77-484f-9f46-e1c67815d53e" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock_a8dcb56e-bebe-4a2b-9f11-c657da1eb118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_020b82c7-10a4-4d98-b278-eccbb1104cf1" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_65b9f166-9d77-484f-9f46-e1c67815d53e" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_020b82c7-10a4-4d98-b278-eccbb1104cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_091173f6-be21-4012-990b-f668b89d2e03" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_65b9f166-9d77-484f-9f46-e1c67815d53e" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_091173f6-be21-4012-990b-f668b89d2e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock_13db62fd-9d73-4fc0-b283-aea6ab9c450a" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_65b9f166-9d77-484f-9f46-e1c67815d53e" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock_13db62fd-9d73-4fc0-b283-aea6ab9c450a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_f849f4d2-5d33-449d-8886-80b41823e32a" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_65b9f166-9d77-484f-9f46-e1c67815d53e" xlink:to="loc_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_f849f4d2-5d33-449d-8886-80b41823e32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_cbe16453-f368-4f3f-b7d5-741a810434d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock_09f4cf7b-3695-4d8c-8290-ac776153a6d4" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_cbe16453-f368-4f3f-b7d5-741a810434d9" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock_09f4cf7b-3695-4d8c-8290-ac776153a6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_d9568adb-707e-41ab-bd1e-619193744eab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_cbe16453-f368-4f3f-b7d5-741a810434d9" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_d9568adb-707e-41ab-bd1e-619193744eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_50c7dde9-bf93-40bf-8942-789f075be5f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_cbe16453-f368-4f3f-b7d5-741a810434d9" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_50c7dde9-bf93-40bf-8942-789f075be5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_1073addf-f4e0-4d2c-a65c-6458cf62c0ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_cbe16453-f368-4f3f-b7d5-741a810434d9" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_1073addf-f4e0-4d2c-a65c-6458cf62c0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NetfinancialincomelossTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#NetfinancialincomelossTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NetfinancialincomelossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetFinancialIncomeLossAbstract_88a71757-3e28-4877-9012-1a673842b909" xlink:href="nbx-20250630.xsd#nbx_NetFinancialIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock_a6e30cac-d9c3-4641-9bee-0729344e51a4" xlink:href="nbx-20250630.xsd#nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_88a71757-3e28-4877-9012-1a673842b909" xlink:to="loc_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock_a6e30cac-d9c3-4641-9bee-0729344e51a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/LosspershareTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#LosspershareTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/LosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_f7916809-5c3e-4234-8a72-56a97468fb97" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_c31bafd6-89b8-42ee-8cca-a997b9e77107" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_f7916809-5c3e-4234-8a72-56a97468fb97" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_c31bafd6-89b8-42ee-8cca-a997b9e77107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RelatedpartiesTables" xlink:type="simple" xlink:href="nbx-20250630.xsd#RelatedpartiesTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RelatedpartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_e4f519e7-4f56-4889-bca3-22c7731703f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_b2e9e813-507d-4945-adba-2a49c7d590f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e4f519e7-4f56-4889-bca3-22c7731703f0" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_b2e9e813-507d-4945-adba-2a49c7d590f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CompanyinformationDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#CompanyinformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/CompanyinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_bec89db3-3e75-411d-85ea-92ec4d5cfb78" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_bec89db3-3e75-411d-85ea-92ec4d5cfb78" xlink:to="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_2c286284-dad8-4776-b771-d8609ec228fa" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:to="loc_nbx_CollaborationAgreementAxis_2c286284-dad8-4776-b771-d8609ec228fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_5a673bb4-7afb-4dc4-a753-c483d0c1c3bf" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_2c286284-dad8-4776-b771-d8609ec228fa" xlink:to="loc_nbx_CollaborationAgreementDomain_5a673bb4-7afb-4dc4-a753-c483d0c1c3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_660470ca-53c1-4b45-951a-91a3883c0b60" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_5a673bb4-7afb-4dc4-a753-c483d0c1c3bf" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_660470ca-53c1-4b45-951a-91a3883c0b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c8e7d202-355a-4f61-8403-4f22d1ef492e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c8e7d202-355a-4f61-8403-4f22d1ef492e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_85791e72-655f-4f59-bf5e-1fa3103e1a9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c8e7d202-355a-4f61-8403-4f22d1ef492e" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_85791e72-655f-4f59-bf5e-1fa3103e1a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_6dd954c7-92b0-4833-b062-4bd211f00646" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_85791e72-655f-4f59-bf5e-1fa3103e1a9e" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_6dd954c7-92b0-4833-b062-4bd211f00646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2fa0a077-d155-4888-acd3-348efd551dca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:to="loc_srt_CounterpartyNameAxis_2fa0a077-d155-4888-acd3-348efd551dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_64cef72d-979d-4e95-9488-ddd6f99ea77c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2fa0a077-d155-4888-acd3-348efd551dca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_64cef72d-979d-4e95-9488-ddd6f99ea77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixCorpMember_518eaade-b883-48c1-98a8-7492281a3f8e" xlink:href="nbx-20250630.xsd#nbx_NanobiotixCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_64cef72d-979d-4e95-9488-ddd6f99ea77c" xlink:to="loc_nbx_NanobiotixCorpMember_518eaade-b883-48c1-98a8-7492281a3f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_d14717a2-4361-4f97-9a9d-f0a46b2ffef5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:to="loc_ifrs-full_RangeAxis_d14717a2-4361-4f97-9a9d-f0a46b2ffef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_d16f84f2-9591-4d9d-8624-982921140978" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_d14717a2-4361-4f97-9a9d-f0a46b2ffef5" xlink:to="loc_ifrs-full_RangeDomain_d16f84f2-9591-4d9d-8624-982921140978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_015d2a12-f924-4524-ac3b-efad6c8704d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_d16f84f2-9591-4d9d-8624-982921140978" xlink:to="loc_ifrs-full_TopOfRangeMember_015d2a12-f924-4524-ac3b-efad6c8704d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_ed6613ae-a29e-4b69-a640-1eef696e832f" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_f68ec7c3-2039-448c-8f80-f199c95df54c" xlink:to="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_ed6613ae-a29e-4b69-a640-1eef696e832f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementTotalConsideration_dd91be4b-680c-48b5-8071-0960df9bd58d" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementTotalConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_ed6613ae-a29e-4b69-a640-1eef696e832f" xlink:to="loc_nbx_CollaborationAgreementTotalConsideration_dd91be4b-680c-48b5-8071-0960df9bd58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_58035911-516f-4ec4-85eb-60266868d6ca" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_ed6613ae-a29e-4b69-a640-1eef696e832f" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_58035911-516f-4ec4-85eb-60266868d6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication_9d43e4bb-1240-4bc4-b5f1-8c4d33fa356e" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_ed6613ae-a29e-4b69-a640-1eef696e832f" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication_9d43e4bb-1240-4bc4-b5f1-8c4d33fa356e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#GeneralinformationstatementofcomplianceandbasisofpresentationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_2400c970-57f4-4dfa-addd-e3ab20c855ae" xlink:href="nbx-20250630.xsd#nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_189d6376-94ba-459e-8c9e-1dce234ef3c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_2400c970-57f4-4dfa-addd-e3ab20c855ae" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_189d6376-94ba-459e-8c9e-1dce234ef3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_953fc0b8-1b48-405b-b485-dde618b03e20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_189d6376-94ba-459e-8c9e-1dce234ef3c6" xlink:to="loc_ifrs-full_RangeAxis_953fc0b8-1b48-405b-b485-dde618b03e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_78b228f1-2fa9-4f70-88fd-01606b80cdd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_953fc0b8-1b48-405b-b485-dde618b03e20" xlink:to="loc_ifrs-full_RangeDomain_78b228f1-2fa9-4f70-88fd-01606b80cdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_89e07836-3c71-4a94-b717-4ab7d102a062" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_78b228f1-2fa9-4f70-88fd-01606b80cdd3" xlink:to="loc_ifrs-full_TopOfRangeMember_89e07836-3c71-4a94-b717-4ab7d102a062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_423f36b5-6a23-4eed-929a-b29354d40fce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_78b228f1-2fa9-4f70-88fd-01606b80cdd3" xlink:to="loc_ifrs-full_BottomOfRangeMember_423f36b5-6a23-4eed-929a-b29354d40fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_bebc8d14-ce6d-4a8d-97cd-706da81bc2ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_189d6376-94ba-459e-8c9e-1dce234ef3c6" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_bebc8d14-ce6d-4a8d-97cd-706da81bc2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_aee87084-85fb-4185-93b4-daa6e9db584d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_bebc8d14-ce6d-4a8d-97cd-706da81bc2ad" xlink:to="loc_ifrs-full_CashAndCashEquivalents_aee87084-85fb-4185-93b4-daa6e9db584d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdditionalLiquidityBusinessObligations_2ed32d91-782e-46ec-a221-65ebff5598a7" xlink:href="nbx-20250630.xsd#nbx_AdditionalLiquidityBusinessObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_bebc8d14-ce6d-4a8d-97cd-706da81bc2ad" xlink:to="loc_nbx_AdditionalLiquidityBusinessObligations_2ed32d91-782e-46ec-a221-65ebff5598a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ConsolidatedprinciplesandmethodsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SignificantAccountingPoliciesAbstract_7c25c1b1-896d-4851-9d9a-cf80f6459676" xlink:href="nbx-20250630.xsd#nbx_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSubsidiaries_c8d18fa6-8abd-4765-a21b-976958f8d408" xlink:href="nbx-20250630.xsd#nbx_NumberOfSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_7c25c1b1-896d-4851-9d9a-cf80f6459676" xlink:to="loc_nbx_NumberOfSubsidiaries_c8d18fa6-8abd-4765-a21b-976958f8d408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_52ff4f86-2e3a-4196-8649-c697da397d38" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_7c25c1b1-896d-4851-9d9a-cf80f6459676" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_52ff4f86-2e3a-4196-8649-c697da397d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_fa8863ca-3c5a-4b47-83c1-55d8cbb2bcfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_7c25c1b1-896d-4851-9d9a-cf80f6459676" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_fa8863ca-3c5a-4b47-83c1-55d8cbb2bcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#IntangibleassetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_28677dfe-026d-44ed-a201-e58aa9141689" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_b41ac70e-a226-406d-9732-e963ce020584" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_28677dfe-026d-44ed-a201-e58aa9141689" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_b41ac70e-a226-406d-9732-e963ce020584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_18b1b9e7-4480-4924-9365-9783ef44c7e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_b41ac70e-a226-406d-9732-e963ce020584" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_18b1b9e7-4480-4924-9365-9783ef44c7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_83ab355e-9f93-4993-9fc3-670ed420e446" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_18b1b9e7-4480-4924-9365-9783ef44c7e6" xlink:to="loc_ifrs-full_CarryingAmountMember_83ab355e-9f93-4993-9fc3-670ed420e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_15846ac4-c67c-4eec-bc93-837b4f8182ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_83ab355e-9f93-4993-9fc3-670ed420e446" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_15846ac4-c67c-4eec-bc93-837b4f8182ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2c42c8b1-9505-4bf3-8a73-129d441440aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_83ab355e-9f93-4993-9fc3-670ed420e446" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2c42c8b1-9505-4bf3-8a73-129d441440aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6ff29ab3-1713-493f-b560-ee12eff218ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_b41ac70e-a226-406d-9732-e963ce020584" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6ff29ab3-1713-493f-b560-ee12eff218ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_a173c53c-6bc3-430b-a7af-408f48be09f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6ff29ab3-1713-493f-b560-ee12eff218ff" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_a173c53c-6bc3-430b-a7af-408f48be09f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0c95da73-0cf6-4b6f-92a3-99e4442d9411" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_a173c53c-6bc3-430b-a7af-408f48be09f0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0c95da73-0cf6-4b6f-92a3-99e4442d9411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_d523e3b4-3303-4602-91de-3e8de9a0547d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0c95da73-0cf6-4b6f-92a3-99e4442d9411" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_d523e3b4-3303-4602-91de-3e8de9a0547d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_53f61350-b349-4c31-ba01-c95899f20e18" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0c95da73-0cf6-4b6f-92a3-99e4442d9411" xlink:to="loc_ifrs-full_ComputerSoftwareMember_53f61350-b349-4c31-ba01-c95899f20e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_b41ac70e-a226-406d-9732-e963ce020584" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_2b1c32bb-28dc-47aa-b71e-55b975a4482d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_2b1c32bb-28dc-47aa-b71e-55b975a4482d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_7a35bb4f-5bdb-4b9e-b325-fcc59de207dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_7a35bb4f-5bdb-4b9e-b325-fcc59de207dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_a828dbf2-23d7-4ac5-93e7-b3fb99177cf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_a828dbf2-23d7-4ac5-93e7-b3fb99177cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_7858e973-3727-4797-9273-9662b0d1d9d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_7858e973-3727-4797-9273-9662b0d1d9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_8930432a-eb5c-4532-8ff3-e8dd1c1515ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8c495cdc-2a19-4729-aa1c-ff8fc03b1589" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_8930432a-eb5c-4532-8ff3-e8dd1c1515ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IntangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#IntangibleassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/IntangibleassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_d3587131-2c60-41d8-a327-8e4c27b86dad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_12d9f436-2c54-4e23-b1ed-65cabc967abf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_d3587131-2c60-41d8-a327-8e4c27b86dad" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_12d9f436-2c54-4e23-b1ed-65cabc967abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_9d60de34-a8b1-493c-a135-a32fd817ab14" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_ad019b54-fe23-4a26-ab5e-e35fcee436c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_9d60de34-a8b1-493c-a135-a32fd817ab14" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_ad019b54-fe23-4a26-ab5e-e35fcee436c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12084897-80dd-4f7e-a277-eb6684fdff95" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_ad019b54-fe23-4a26-ab5e-e35fcee436c5" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12084897-80dd-4f7e-a277-eb6684fdff95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_aa7185d6-980a-4eef-91f2-0dacbef0d8e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12084897-80dd-4f7e-a277-eb6684fdff95" xlink:to="loc_ifrs-full_CarryingAmountMember_aa7185d6-980a-4eef-91f2-0dacbef0d8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_b96d8ce1-7f82-4c90-85ad-985c43437968" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_aa7185d6-980a-4eef-91f2-0dacbef0d8e9" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_b96d8ce1-7f82-4c90-85ad-985c43437968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_b95d62f1-4882-41aa-961a-4de626b0c0d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_aa7185d6-980a-4eef-91f2-0dacbef0d8e9" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_b95d62f1-4882-41aa-961a-4de626b0c0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NettingMember_7d6b3460-8a75-4930-9e03-38599a91514b" xlink:href="nbx-20250630.xsd#nbx_NettingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_aa7185d6-980a-4eef-91f2-0dacbef0d8e9" xlink:to="loc_nbx_NettingMember_7d6b3460-8a75-4930-9e03-38599a91514b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_359821f0-b5e1-4da8-a27e-aedfd22abe05" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_ad019b54-fe23-4a26-ab5e-e35fcee436c5" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_359821f0-b5e1-4da8-a27e-aedfd22abe05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_359821f0-b5e1-4da8-a27e-aedfd22abe05" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_c7f1fdaf-7a55-4681-880a-97176281158c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_c7f1fdaf-7a55-4681-880a-97176281158c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseBuildingsMember_d00e0f4c-db7a-4b5d-9fde-d4495b0df3a1" xlink:href="nbx-20250630.xsd#nbx_RightOfUseBuildingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_nbx_RightOfUseBuildingsMember_d00e0f4c-db7a-4b5d-9fde-d4495b0df3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MachineryMember_db978fc5-5dd3-49ae-92ec-110ab4fbeced" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MachineryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_ifrs-full_MachineryMember_db978fc5-5dd3-49ae-92ec-110ab4fbeced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_234512f2-da44-4368-8a20-6a1b33861de2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_ifrs-full_OfficeEquipmentMember_234512f2-da44-4368-8a20-6a1b33861de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConstructionInProgressMember_379a16e6-2973-4c2d-9d6d-bd6309706dc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_ifrs-full_ConstructionInProgressMember_379a16e6-2973-4c2d-9d6d-bd6309706dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PrepaymentsOnTangibleAssetsMember_7691e435-a271-496b-8ce4-3a3822ce8b6d" xlink:href="nbx-20250630.xsd#nbx_PrepaymentsOnTangibleAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5868b7a4-2ad8-44af-948c-0c3819b167df" xlink:to="loc_nbx_PrepaymentsOnTangibleAssetsMember_7691e435-a271-496b-8ce4-3a3822ce8b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5a79b3fb-4d2f-4ccc-9a50-ee32bbb9f109" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_ad019b54-fe23-4a26-ab5e-e35fcee436c5" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5a79b3fb-4d2f-4ccc-9a50-ee32bbb9f109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5a79b3fb-4d2f-4ccc-9a50-ee32bbb9f109" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_a302349c-c2f1-48a8-94f8-a055d74e12ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_a302349c-c2f1-48a8-94f8-a055d74e12ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_12bf666e-bf19-4203-a2dc-6659a70e588f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_12bf666e-bf19-4203-a2dc-6659a70e588f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_7c65799a-cea2-4aaf-b770-53fb9a1b184d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_7c65799a-cea2-4aaf-b770-53fb9a1b184d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_d3d421e3-9ff0-4225-b997-ed0da965286d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_d3d421e3-9ff0-4225-b997-ed0da965286d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_7653ea34-8843-4334-b8d5-4999a3ae863c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_7653ea34-8843-4334-b8d5-4999a3ae863c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_eee65ed0-9261-41fd-9b12-d869a3ae4c64" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_9ec735c1-3c65-4b4d-93d6-0923bf608c64" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_eee65ed0-9261-41fd-9b12-d869a3ae4c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#PropertyplantandequipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_80168d45-4254-4414-887c-8a0cae662ffc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_d8287b4d-413f-4c63-8462-2f0609f17afe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_80168d45-4254-4414-887c-8a0cae662ffc" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_d8287b4d-413f-4c63-8462-2f0609f17afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_8cde6dc5-0558-4bc9-87b5-9dbea194c524" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_10bd386b-1860-4cfd-b6a1-434f53afed68" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_8cde6dc5-0558-4bc9-87b5-9dbea194c524" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_10bd386b-1860-4cfd-b6a1-434f53afed68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0dfad0a8-d7fc-4650-b017-44c0970d720b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_10bd386b-1860-4cfd-b6a1-434f53afed68" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0dfad0a8-d7fc-4650-b017-44c0970d720b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_fe0cef10-1174-477f-b46d-4aabe6049a94" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0dfad0a8-d7fc-4650-b017-44c0970d720b" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_fe0cef10-1174-477f-b46d-4aabe6049a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentLiquidityContractMember_8036c26f-8c4c-40b8-ae5f-cb3e23ee912e" xlink:href="nbx-20250630.xsd#nbx_NonCurrentLiquidityContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_fe0cef10-1174-477f-b46d-4aabe6049a94" xlink:to="loc_nbx_NonCurrentLiquidityContractMember_8036c26f-8c4c-40b8-ae5f-cb3e23ee912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_85f425e8-75bb-469a-a305-097091fdb626" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_10bd386b-1860-4cfd-b6a1-434f53afed68" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_85f425e8-75bb-469a-a305-097091fdb626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:href="nbx-20250630.xsd#nbx_SecurityDepositsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_85f425e8-75bb-469a-a305-097091fdb626" xlink:to="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_6dc7234c-06d1-4218-b4d4-aae0b638ac8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_6dc7234c-06d1-4218-b4d4-aae0b638ac8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_8f7b747b-37e8-492a-80ad-5ecdccb141e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_8f7b747b-37e8-492a-80ad-5ecdccb141e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_ad30b49d-7538-4366-aebf-8547ef1e2e57" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_ad30b49d-7538-4366-aebf-8547ef1e2e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets_6dc6b658-3acd-4e12-8718-f63cf6f7604c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets_6dc6b658-3acd-4e12-8718-f63cf6f7604c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_7d198f42-7c13-4303-a701-1f52c7aa21e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_7d198f42-7c13-4303-a701-1f52c7aa21e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_f46bf57c-912c-4181-84f9-ac6a1a39e860" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SecurityDepositsRollForward_fafac5cb-5fa8-4832-8641-606299b76682" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_f46bf57c-912c-4181-84f9-ac6a1a39e860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofTradeReceivablesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradereceivablesandothercurrentassetsScheduleofTradeReceivablesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofTradeReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_a73b5236-a8b6-46aa-af5c-0dbce484238f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_64eb6a02-5a61-4d42-a2e4-69dc1e9ee686" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_a73b5236-a8b6-46aa-af5c-0dbce484238f" xlink:to="loc_ifrs-full_CurrentTradeReceivables_64eb6a02-5a61-4d42-a2e4-69dc1e9ee686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradereceivablesandothercurrentassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_4973609a-2177-4563-8ac6-a457f878cae1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_4973609a-2177-4563-8ac6-a457f878cae1" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_fdc2b183-1b8a-41b3-8f21-d55cbf6463cc" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:to="loc_nbx_CollaborationAgreementAxis_fdc2b183-1b8a-41b3-8f21-d55cbf6463cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_81841482-3686-49c5-91cf-3e76092c6443" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_fdc2b183-1b8a-41b3-8f21-d55cbf6463cc" xlink:to="loc_nbx_CollaborationAgreementDomain_81841482-3686-49c5-91cf-3e76092c6443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_f10f8e60-84c6-4d15-97a9-f33136b97c76" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_81841482-3686-49c5-91cf-3e76092c6443" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_f10f8e60-84c6-4d15-97a9-f33136b97c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MDAndersonCancerCenterNBTXR3Member_bd4b021f-0cd6-489f-b9e3-6d370e4f0ec9" xlink:href="nbx-20250630.xsd#nbx_MDAndersonCancerCenterNBTXR3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_81841482-3686-49c5-91cf-3e76092c6443" xlink:to="loc_nbx_MDAndersonCancerCenterNBTXR3Member_bd4b021f-0cd6-489f-b9e3-6d370e4f0ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_c0c578d3-109e-4297-a11a-7a22b49fc80d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_c0c578d3-109e-4297-a11a-7a22b49fc80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_c0c578d3-109e-4297-a11a-7a22b49fc80d" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TechnologyTransferAndTechnicalAssistanceMember_8d681ab4-2c7e-447a-9c80-6bbb366c4a39" xlink:href="nbx-20250630.xsd#nbx_TechnologyTransferAndTechnicalAssistanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:to="loc_nbx_TechnologyTransferAndTechnicalAssistanceMember_8d681ab4-2c7e-447a-9c80-6bbb366c4a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IntellectualPropertyServicesMember_35838250-4fb0-4f04-ba91-b40a69cf5f5b" xlink:href="nbx-20250630.xsd#nbx_IntellectualPropertyServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:to="loc_nbx_IntellectualPropertyServicesMember_35838250-4fb0-4f04-ba91-b40a69cf5f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ThirdPartyServicesMember_e1a34ec7-c323-4c52-9d42-58efa0a07ca9" xlink:href="nbx-20250630.xsd#nbx_ThirdPartyServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:to="loc_nbx_ThirdPartyServicesMember_e1a34ec7-c323-4c52-9d42-58efa0a07ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ClinicalProductsMember_adc76a6a-2726-4b42-8a8e-59cb10059d85" xlink:href="nbx-20250630.xsd#nbx_ClinicalProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_14723e23-048e-4eee-bcb0-1ec80a3f2c9d" xlink:to="loc_nbx_ClinicalProductsMember_adc76a6a-2726-4b42-8a8e-59cb10059d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4d2fa6e0-b70a-4d25-bd36-79345b650b0a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:to="loc_srt_CounterpartyNameAxis_4d2fa6e0-b70a-4d25-bd36-79345b650b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77419518-7717-47d6-acc0-3967fc8017ef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4d2fa6e0-b70a-4d25-bd36-79345b650b0a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77419518-7717-47d6-acc0-3967fc8017ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_6c8d04e1-d1b8-40b2-a106-b4bcdbfe0b0f" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77419518-7717-47d6-acc0-3967fc8017ef" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_6c8d04e1-d1b8-40b2-a106-b4bcdbfe0b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SuppliersMember_dfa8b8ad-5728-4bfe-ad43-9b7d26c8bdfd" xlink:href="nbx-20250630.xsd#nbx_SuppliersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77419518-7717-47d6-acc0-3967fc8017ef" xlink:to="loc_nbx_SuppliersMember_dfa8b8ad-5728-4bfe-ad43-9b7d26c8bdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_cbf4c8a2-85ee-4234-b79d-ec7fa69507c5" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_a9e0e8e4-7f4c-429c-9d3a-2b2aace4b5d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:to="loc_ifrs-full_CurrentTradeReceivables_a9e0e8e4-7f4c-429c-9d3a-2b2aace4b5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_e04e89a3-8059-4b4a-9578-f9a5cc14285c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_e04e89a3-8059-4b4a-9578-f9a5cc14285c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_14738591-2186-4cbd-8250-bfcd7b1b0a60" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:to="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_14738591-2186-4cbd-8250-bfcd7b1b0a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_ed47d2ba-6e91-40f5-bb73-51232e8b715c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_78d7ff6e-ce36-403e-bb46-777650b5151a" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_ed47d2ba-6e91-40f5-bb73-51232e8b715c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9d45e383-fbc5-4d6c-a5e6-8d65976dbd43" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_961819ad-1bfe-4a98-ab31-57496d656b6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9d45e383-fbc5-4d6c-a5e6-8d65976dbd43" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_961819ad-1bfe-4a98-ab31-57496d656b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_ce8421fb-7866-4854-b08a-6d9ce721220a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9d45e383-fbc5-4d6c-a5e6-8d65976dbd43" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_ce8421fb-7866-4854-b08a-6d9ce721220a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_6d1b9e31-4f79-4729-85d2-105a81b65cc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9d45e383-fbc5-4d6c-a5e6-8d65976dbd43" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_6d1b9e31-4f79-4729-85d2-105a81b65cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_81105890-8f2f-46a4-9511-add341ba0da2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9d45e383-fbc5-4d6c-a5e6-8d65976dbd43" xlink:to="loc_ifrs-full_OtherCurrentReceivables_81105890-8f2f-46a4-9511-add341ba0da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_b2eb254b-177a-4493-bcf5-6653bb810257" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9d45e383-fbc5-4d6c-a5e6-8d65976dbd43" xlink:to="loc_ifrs-full_OtherCurrentAssets_b2eb254b-177a-4493-bcf5-6653bb810257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_05054dc1-4401-47ed-afae-b39c8d2f9e58" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_db42df92-6853-41aa-be7c-c8c2d9c29790" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_05054dc1-4401-47ed-afae-b39c8d2f9e58" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_db42df92-6853-41aa-be7c-c8c2d9c29790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d6041e3a-f573-4c25-8311-cbb4138b0d01" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_db42df92-6853-41aa-be7c-c8c2d9c29790" xlink:to="loc_dei_LegalEntityAxis_d6041e3a-f573-4c25-8311-cbb4138b0d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b6a0f1aa-daff-4cb4-bb57-544f1cc5cb20" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d6041e3a-f573-4c25-8311-cbb4138b0d01" xlink:to="loc_dei_EntityDomain_b6a0f1aa-daff-4cb4-bb57-544f1cc5cb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixSAMember_a2184c84-b8ee-4391-b5a8-7ac26f164b7b" xlink:href="nbx-20250630.xsd#nbx_NanobiotixSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b6a0f1aa-daff-4cb4-bb57-544f1cc5cb20" xlink:to="loc_nbx_NanobiotixSAMember_a2184c84-b8ee-4391-b5a8-7ac26f164b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixCorpMember_00651e75-d058-4d15-9d7d-d875fb67dca4" xlink:href="nbx-20250630.xsd#nbx_NanobiotixCorpMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b6a0f1aa-daff-4cb4-bb57-544f1cc5cb20" xlink:to="loc_nbx_NanobiotixCorpMember_00651e75-d058-4d15-9d7d-d875fb67dca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearAxis_7168c609-3e67-4886-a561-b721409fe0a2" xlink:href="nbx-20250630.xsd#nbx_OpenTaxYearAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_db42df92-6853-41aa-be7c-c8c2d9c29790" xlink:to="loc_nbx_OpenTaxYearAxis_7168c609-3e67-4886-a561-b721409fe0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain_f8133dc0-4ad3-4429-aff1-8aa963c7a115" xlink:href="nbx-20250630.xsd#nbx_OpenTaxYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearAxis_7168c609-3e67-4886-a561-b721409fe0a2" xlink:to="loc_nbx_OpenTaxYearDomain_f8133dc0-4ad3-4429-aff1-8aa963c7a115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2025TaxYearMember_2c6d8af2-d2f4-44a9-bc47-9679cfa94349" xlink:href="nbx-20250630.xsd#nbx_A2025TaxYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearDomain_f8133dc0-4ad3-4429-aff1-8aa963c7a115" xlink:to="loc_nbx_A2025TaxYearMember_2c6d8af2-d2f4-44a9-bc47-9679cfa94349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2024TaxYearMember_d4bd1133-42b8-4859-88c5-380562165868" xlink:href="nbx-20250630.xsd#nbx_A2024TaxYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearDomain_f8133dc0-4ad3-4429-aff1-8aa963c7a115" xlink:to="loc_nbx_A2024TaxYearMember_d4bd1133-42b8-4859-88c5-380562165868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_db42df92-6853-41aa-be7c-c8c2d9c29790" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_dc26c0fa-f5e1-4590-82a8-0c16aa0e9298" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_dc26c0fa-f5e1-4590-82a8-0c16aa0e9298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit_09607a86-b4a5-41cd-ba73-1cb9956148e6" xlink:href="nbx-20250630.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:to="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit_09607a86-b4a5-41cd-ba73-1cb9956148e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProceedsFromIncomeTaxCredit_d9f82340-dc7f-42bb-b97a-4ab03bc8d9b8" xlink:href="nbx-20250630.xsd#nbx_ProceedsFromIncomeTaxCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:to="loc_nbx_ProceedsFromIncomeTaxCredit_d9f82340-dc7f-42bb-b97a-4ab03bc8d9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_f81f8f51-9986-4ac1-987d-a07d30aaac72" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_2ae72097-643b-44c3-a146-0788b887df41" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_f81f8f51-9986-4ac1-987d-a07d30aaac72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#CashandcashequivalentsScheduleofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_059c43cb-b577-495d-8c8d-c8b70b6fa717" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_935a02b8-3d76-4528-ac46-ef81ab00df1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_059c43cb-b577-495d-8c8d-c8b70b6fa717" xlink:to="loc_ifrs-full_Cash_935a02b8-3d76-4528-ac46-ef81ab00df1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_fe50761f-896c-4508-b3ec-ca940116d08c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_059c43cb-b577-495d-8c8d-c8b70b6fa717" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_fe50761f-896c-4508-b3ec-ca940116d08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_dd2ae53c-3f1c-46f7-a825-a09eac433000" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_059c43cb-b577-495d-8c8d-c8b70b6fa717" xlink:to="loc_ifrs-full_CashAndCashEquivalents_dd2ae53c-3f1c-46f7-a825-a09eac433000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CashandcashequivalentsNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#CashandcashequivalentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/CashandcashequivalentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_041a2a6c-4211-4326-95ea-8ac11204860d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_707f7e42-1714-4d4d-9276-344607a014be" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_041a2a6c-4211-4326-95ea-8ac11204860d" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_707f7e42-1714-4d4d-9276-344607a014be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_3ab06e4e-3f15-425f-8024-77bf16e8f097" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_041a2a6c-4211-4326-95ea-8ac11204860d" xlink:to="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_3ab06e4e-3f15-425f-8024-77bf16e8f097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDepositsFromCustomers_0918120d-31a2-49cc-89cc-386a5864b05b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDepositsFromCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_041a2a6c-4211-4326-95ea-8ac11204860d" xlink:to="loc_ifrs-full_CurrentDepositsFromCustomers_0918120d-31a2-49cc-89cc-386a5864b05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ShareCapitalScheduleofShareCapitalTransactionsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_edfc8a35-642c-4b53-8b06-817e90829828" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6f6ebc73-d171-4c3e-ad34-808a4b43de8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_edfc8a35-642c-4b53-8b06-817e90829828" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6f6ebc73-d171-4c3e-ad34-808a4b43de8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5c0be2d2-b788-420c-aa7a-edc41e0feac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6f6ebc73-d171-4c3e-ad34-808a4b43de8e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5c0be2d2-b788-420c-aa7a-edc41e0feac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4891c78b-4e7c-4a6d-904e-d673d4a99ed2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5c0be2d2-b788-420c-aa7a-edc41e0feac9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4891c78b-4e7c-4a6d-904e-d673d4a99ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023Member_de7cfb86-a816-4145-9426-9b46aed84043" xlink:href="nbx-20250630.xsd#nbx_AGA2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4891c78b-4e7c-4a6d-904e-d673d4a99ed2" xlink:to="loc_nbx_AGA2023Member_de7cfb86-a816-4145-9426-9b46aed84043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_c9cc6921-ac05-4f22-800a-0c3d5c8c81ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6f6ebc73-d171-4c3e-ad34-808a4b43de8e" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_c9cc6921-ac05-4f22-800a-0c3d5c8c81ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_10cca365-8b0f-4132-b504-03fcb1ce2fa0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c9cc6921-ac05-4f22-800a-0c3d5c8c81ee" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_10cca365-8b0f-4132-b504-03fcb1ce2fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_f7482e7d-c6cd-475a-ba39-6c7fd912245a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_10cca365-8b0f-4132-b504-03fcb1ce2fa0" xlink:to="loc_ifrs-full_IssuedCapitalMember_f7482e7d-c6cd-475a-ba39-6c7fd912245a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_86d86cd5-202b-42fc-a8ed-e633401fe2e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_10cca365-8b0f-4132-b504-03fcb1ce2fa0" xlink:to="loc_ifrs-full_SharePremiumMember_86d86cd5-202b-42fc-a8ed-e633401fe2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_78763432-174e-4ac3-8330-8772d7c27eb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6f6ebc73-d171-4c3e-ad34-808a4b43de8e" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_78763432-174e-4ac3-8330-8772d7c27eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_88f6f348-ec84-4722-b747-d0975d017f8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_78763432-174e-4ac3-8330-8772d7c27eb1" xlink:to="loc_ifrs-full_EquityAbstract_88f6f348-ec84-4722-b747-d0975d017f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_e2a35ff9-5338-4b8b-81e9-a605865740d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_88f6f348-ec84-4722-b747-d0975d017f8c" xlink:to="loc_ifrs-full_Equity_e2a35ff9-5338-4b8b-81e9-a605865740d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_fa0c77a9-acc1-4eb0-bd66-c46d4cd67b62" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_88f6f348-ec84-4722-b747-d0975d017f8c" xlink:to="loc_ifrs-full_IssueOfEquity_fa0c77a9-acc1-4eb0-bd66-c46d4cd67b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_bed23f3d-24d1-40d7-9d93-5dfb6832ebe2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_88f6f348-ec84-4722-b747-d0975d017f8c" xlink:to="loc_ifrs-full_Equity_bed23f3d-24d1-40d7-9d93-5dfb6832ebe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_b3bbe888-dbfe-4fcf-afa6-f3be9622b5c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_78763432-174e-4ac3-8330-8772d7c27eb1" xlink:to="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_b3bbe888-dbfe-4fcf-afa6-f3be9622b5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_50a310a9-e864-42e9-b724-3645a8715a52" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_b3bbe888-dbfe-4fcf-afa6-f3be9622b5c2" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_50a310a9-e864-42e9-b724-3645a8715a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_9e81d5ea-0a70-4c3f-b1de-832c00cfee25" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_b3bbe888-dbfe-4fcf-afa6-f3be9622b5c2" xlink:to="loc_ifrs-full_NumberOfSharesIssued_9e81d5ea-0a70-4c3f-b1de-832c00cfee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_69a05bd2-80a5-42e3-8716-e8433580cc15" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_b3bbe888-dbfe-4fcf-afa6-f3be9622b5c2" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_69a05bd2-80a5-42e3-8716-e8433580cc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ShareCapitalCapitalIssuedDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_01c9e27a-b5db-4e05-8ad9-f659f5e2dd92" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e916f174-d46d-4117-856c-985323977e0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_01c9e27a-b5db-4e05-8ad9-f659f5e2dd92" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e916f174-d46d-4117-856c-985323977e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_8304ec54-914d-4ece-8cc7-44f0f84fb772" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e916f174-d46d-4117-856c-985323977e0a" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_8304ec54-914d-4ece-8cc7-44f0f84fb772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_b47113cc-cc61-4cc9-a43c-abe5bbe2a80a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8304ec54-914d-4ece-8cc7-44f0f84fb772" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_b47113cc-cc61-4cc9-a43c-abe5bbe2a80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_d5e8972c-5b76-4fe7-92d0-23d3b5e44107" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_b47113cc-cc61-4cc9-a43c-abe5bbe2a80a" xlink:to="loc_ifrs-full_IssuedCapitalMember_d5e8972c-5b76-4fe7-92d0-23d3b5e44107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec8e0dab-38d4-435c-82f9-83aade8d6738" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e916f174-d46d-4117-856c-985323977e0a" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec8e0dab-38d4-435c-82f9-83aade8d6738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f1b16409-54a7-41a5-961b-f42cbb0b49f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec8e0dab-38d4-435c-82f9-83aade8d6738" xlink:to="loc_ifrs-full_Equity_f1b16409-54a7-41a5-961b-f42cbb0b49f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_6e512c1b-5c97-4d75-80bc-08ae538995bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec8e0dab-38d4-435c-82f9-83aade8d6738" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_6e512c1b-5c97-4d75-80bc-08ae538995bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_3bfa6e09-143f-41cc-9582-fb3b4296a42e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec8e0dab-38d4-435c-82f9-83aade8d6738" xlink:to="loc_ifrs-full_ParValuePerShare_3bfa6e09-143f-41cc-9582-fb3b4296a42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ShareCapitalFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_d9b22516-4e88-4baf-9daa-3becda511120" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes_3dc74d8e-bb96-44dd-9ec9-8d9df7c43e11" xlink:href="nbx-20250630.xsd#nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_d9b22516-4e88-4baf-9daa-3becda511120" xlink:to="loc_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes_3dc74d8e-bb96-44dd-9ec9-8d9df7c43e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_eaec3314-938b-49f9-8e73-3cb4135aef59" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_d9b22516-4e88-4baf-9daa-3becda511120" xlink:to="loc_ifrs-full_ProfitLoss_eaec3314-938b-49f9-8e73-3cb4135aef59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ShareCapitalStockOptionPlansDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_f7ce185d-ba43-4938-b864-a09fd21a03b7" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_433449fe-ea73-4845-84e1-5fef0838c40c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_f7ce185d-ba43-4938-b864-a09fd21a03b7" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_433449fe-ea73-4845-84e1-5fef0838c40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a36c861f-0233-4a73-bda9-81f3e88b8090" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_433449fe-ea73-4845-84e1-5fef0838c40c" xlink:to="loc_srt_TitleOfIndividualAxis_a36c861f-0233-4a73-bda9-81f3e88b8090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_afede4df-9d71-42e5-b033-b32fceb3e866" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_a36c861f-0233-4a73-bda9-81f3e88b8090" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_afede4df-9d71-42e5-b033-b32fceb3e866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExecutiveBoardAndEmployeesMember_275d2b99-3fac-4ccf-8b26-077227f5df4c" xlink:href="nbx-20250630.xsd#nbx_ExecutiveBoardAndEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_afede4df-9d71-42e5-b033-b32fceb3e866" xlink:to="loc_nbx_ExecutiveBoardAndEmployeesMember_275d2b99-3fac-4ccf-8b26-077227f5df4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f6ace8bd-5652-48f3-8d79-e18e34789a4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_433449fe-ea73-4845-84e1-5fef0838c40c" xlink:to="loc_ifrs-full_RangeAxis_f6ace8bd-5652-48f3-8d79-e18e34789a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_5bd2f9bb-5523-457a-b0e7-749ecdd62d78" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_f6ace8bd-5652-48f3-8d79-e18e34789a4e" xlink:to="loc_ifrs-full_RangeDomain_5bd2f9bb-5523-457a-b0e7-749ecdd62d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_def74dfa-f5ec-4ffd-802d-ade60a01b00f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_5bd2f9bb-5523-457a-b0e7-749ecdd62d78" xlink:to="loc_ifrs-full_TopOfRangeMember_def74dfa-f5ec-4ffd-802d-ade60a01b00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_433449fe-ea73-4845-84e1-5fef0838c40c" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_43a18b22-f8a1-425e-b64d-87e663b6d1d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_43a18b22-f8a1-425e-b64d-87e663b6d1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_03ce42ba-e6ad-46dd-af2c-51dca504e55e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:to="loc_ifrs-full_ParValuePerShare_03ce42ba-e6ad-46dd-af2c-51dca504e55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_a71bb400-45bf-44f1-95bb-2212d927157b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_a71bb400-45bf-44f1-95bb-2212d927157b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedPaymentArrangementStockOptionTerm_b6ce1416-a7fc-4eb7-9244-74da3f12d63b" xlink:href="nbx-20250630.xsd#nbx_ShareBasedPaymentArrangementStockOptionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_740fd6b2-c9e8-4a9b-acf8-e754385d4bb5" xlink:to="loc_nbx_ShareBasedPaymentArrangementStockOptionTerm_b6ce1416-a7fc-4eb7-9244-74da3f12d63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RetirementObligationsDisclosureofChangesinProvisionsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RetirementObligationAbstract_bbbc76c8-73ac-4f45-bd1e-307fdf371bd9" xlink:href="nbx-20250630.xsd#nbx_RetirementObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_a9b1ef06-b85a-4187-8572-9b29d841d362" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_RetirementObligationAbstract_bbbc76c8-73ac-4f45-bd1e-307fdf371bd9" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_a9b1ef06-b85a-4187-8572-9b29d841d362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_f3434c9d-a563-4027-b83c-b4ec1038c02c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_a9b1ef06-b85a-4187-8572-9b29d841d362" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_f3434c9d-a563-4027-b83c-b4ec1038c02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_ba80a362-43b8-4a3e-a4db-e4e83e3b9c17" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_f3434c9d-a563-4027-b83c-b4ec1038c02c" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_ba80a362-43b8-4a3e-a4db-e4e83e3b9c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LumpSumRetirementBenefitsMember_5e938fbc-af15-4a44-ac0a-c144d8624408" xlink:href="nbx-20250630.xsd#nbx_LumpSumRetirementBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_ba80a362-43b8-4a3e-a4db-e4e83e3b9c17" xlink:to="loc_nbx_LumpSumRetirementBenefitsMember_5e938fbc-af15-4a44-ac0a-c144d8624408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentOtherProvisionsMember_3ea2517d-3077-4e8a-8165-0168ad0700fb" xlink:href="nbx-20250630.xsd#nbx_NonCurrentOtherProvisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_ba80a362-43b8-4a3e-a4db-e4e83e3b9c17" xlink:to="loc_nbx_NonCurrentOtherProvisionsMember_3ea2517d-3077-4e8a-8165-0168ad0700fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_19111cc0-41f2-4d4d-b6c1-516b11e321b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_a9b1ef06-b85a-4187-8572-9b29d841d362" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_19111cc0-41f2-4d4d-b6c1-516b11e321b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:href="nbx-20250630.xsd#nbx_OtherProvisionsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_19111cc0-41f2-4d4d-b6c1-516b11e321b8" xlink:to="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_4c40d8b8-a243-442d-84d1-285c13d2e800" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:to="loc_ifrs-full_OtherProvisions_4c40d8b8-a243-442d-84d1-285c13d2e800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_367942b3-9e72-4114-bc43-a8569c424391" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_367942b3-9e72-4114-bc43-a8569c424391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_b4529a40-1bcf-45a8-b425-f7e830a9c77a" xlink:href="nbx-20250630.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:to="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_b4529a40-1bcf-45a8-b425-f7e830a9c77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_5f8462ac-fefd-4277-b460-67544e7f7cb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_5f8462ac-fefd-4277-b460-67544e7f7cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_a1ed260e-4e85-48c1-9893-a2e4c46f18af" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OtherProvisionsRollForward_a2fb231d-edeb-4c09-9ef4-00f35ee723fd" xlink:to="loc_ifrs-full_OtherProvisions_a1ed260e-4e85-48c1-9893-a2e4c46f18af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ProvisionsScheduleofChangesinProvisionsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_5ede95ab-4bdf-412f-af1c-907a0f5ecec6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_899bb0af-7ab0-4a2b-aa74-389ab298df38" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_5ede95ab-4bdf-412f-af1c-907a0f5ecec6" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_899bb0af-7ab0-4a2b-aa74-389ab298df38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_771894c5-3269-4cfd-965e-b491a4ba1cb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_899bb0af-7ab0-4a2b-aa74-389ab298df38" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_771894c5-3269-4cfd-965e-b491a4ba1cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_108ccee3-4cfb-4291-8d37-34bffe505eed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_771894c5-3269-4cfd-965e-b491a4ba1cb7" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_108ccee3-4cfb-4291-8d37-34bffe505eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentOtherProvisionsMember_a0eaa39e-18fd-40fb-bb27-9f5ef4d9846e" xlink:href="nbx-20250630.xsd#nbx_CurrentOtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_108ccee3-4cfb-4291-8d37-34bffe505eed" xlink:to="loc_nbx_CurrentOtherProvisionsMember_a0eaa39e-18fd-40fb-bb27-9f5ef4d9846e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForDisputesMember_afe40ee1-88bd-4a2f-82d5-4acf6c7047b9" xlink:href="nbx-20250630.xsd#nbx_ProvisionsForDisputesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CurrentOtherProvisionsMember_a0eaa39e-18fd-40fb-bb27-9f5ef4d9846e" xlink:to="loc_nbx_ProvisionsForDisputesMember_afe40ee1-88bd-4a2f-82d5-4acf6c7047b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForChargesMember_6fd6064e-1727-46c5-ad14-ccfefdcebac6" xlink:href="nbx-20250630.xsd#nbx_ProvisionsForChargesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CurrentOtherProvisionsMember_a0eaa39e-18fd-40fb-bb27-9f5ef4d9846e" xlink:to="loc_nbx_ProvisionsForChargesMember_6fd6064e-1727-46c5-ad14-ccfefdcebac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_11e90c6e-2c47-4a44-98ac-8938172f146c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_899bb0af-7ab0-4a2b-aa74-389ab298df38" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_11e90c6e-2c47-4a44-98ac-8938172f146c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:href="nbx-20250630.xsd#nbx_OtherProvisionsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_11e90c6e-2c47-4a44-98ac-8938172f146c" xlink:to="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_25410891-e085-4037-b278-d9044284bf54" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:to="loc_ifrs-full_OtherProvisions_25410891-e085-4037-b278-d9044284bf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_26801643-dcb1-4d4e-9370-476a030b9ff1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_26801643-dcb1-4d4e-9370-476a030b9ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_7af1e58c-f01d-45fa-9f7a-0400f3341730" xlink:href="nbx-20250630.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:to="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_7af1e58c-f01d-45fa-9f7a-0400f3341730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_0ceee2ad-db81-48bc-af64-0f920d898e6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_0ceee2ad-db81-48bc-af64-0f920d898e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_974ace06-55f4-4793-97f0-722d89223871" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OtherProvisionsRollForward_2f411a0b-c813-4faf-829a-158a2a2bf1f3" xlink:to="loc_ifrs-full_OtherProvisions_974ace06-55f4-4793-97f0-722d89223871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#ProvisionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_c023d416-3f67-485b-8a5d-941fc8f73482" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a1f6b6c-141e-4f3f-9141-96e63ba147fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_c023d416-3f67-485b-8a5d-941fc8f73482" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a1f6b6c-141e-4f3f-9141-96e63ba147fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_51fd50bf-ebce-4e8a-9fe5-5a36c896e469" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a1f6b6c-141e-4f3f-9141-96e63ba147fa" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_51fd50bf-ebce-4e8a-9fe5-5a36c896e469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_c11acb3b-6ca5-4e3b-b3d9-431a22168cf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_51fd50bf-ebce-4e8a-9fe5-5a36c896e469" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_c11acb3b-6ca5-4e3b-b3d9-431a22168cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForDisputesMember_75be6a2b-c520-4cb4-902d-77c67856e02a" xlink:href="nbx-20250630.xsd#nbx_ProvisionsForDisputesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_c11acb3b-6ca5-4e3b-b3d9-431a22168cf3" xlink:to="loc_nbx_ProvisionsForDisputesMember_75be6a2b-c520-4cb4-902d-77c67856e02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4d12d508-fbae-462c-b5f1-f992e664f570" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a1f6b6c-141e-4f3f-9141-96e63ba147fa" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4d12d508-fbae-462c-b5f1-f992e664f570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_14bd6b24-8b7f-4ad6-94f2-2f944286232b" xlink:href="nbx-20250630.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4d12d508-fbae-462c-b5f1-f992e664f570" xlink:to="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_14bd6b24-8b7f-4ad6-94f2-2f944286232b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_2624d1d5-eea9-47f1-b7ab-6b87ff08a481" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2536588f-a117-4a3b-a060-1e20bb982740" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_2624d1d5-eea9-47f1-b7ab-6b87ff08a481" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2536588f-a117-4a3b-a060-1e20bb982740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_fd723d1e-0014-4173-9d2a-9eb780306f30" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2536588f-a117-4a3b-a060-1e20bb982740" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_fd723d1e-0014-4173-9d2a-9eb780306f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_2cda0f2a-941e-4a3a-808d-3960d85d324f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_fd723d1e-0014-4173-9d2a-9eb780306f30" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_2cda0f2a-941e-4a3a-808d-3960d85d324f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_930f5d40-9cd9-4c51-8bf5-3e9ac7dc8654" xlink:href="nbx-20250630.xsd#nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_2cda0f2a-941e-4a3a-808d-3960d85d324f" xlink:to="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_930f5d40-9cd9-4c51-8bf5-3e9ac7dc8654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_6f4bb751-dce0-411b-9f2b-3e86a081e689" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_2cda0f2a-941e-4a3a-808d-3960d85d324f" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_6f4bb751-dce0-411b-9f2b-3e86a081e689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_3461d597-dc81-4cf9-aafe-e7112361d7d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2536588f-a117-4a3b-a060-1e20bb982740" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_3461d597-dc81-4cf9-aafe-e7112361d7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_119b0359-8a77-4885-b586-52a80cb802f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3461d597-dc81-4cf9-aafe-e7112361d7d3" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_119b0359-8a77-4885-b586-52a80cb802f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_f525c5bf-6a92-4513-ab32-e9e5679a2eb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_119b0359-8a77-4885-b586-52a80cb802f7" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_f525c5bf-6a92-4513-ab32-e9e5679a2eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesMember_1d08c1d7-1c72-4a9b-8262-126da4ce1fc1" xlink:href="nbx-20250630.xsd#nbx_ConditionalAdvancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_119b0359-8a77-4885-b586-52a80cb802f7" xlink:to="loc_nbx_ConditionalAdvancesMember_1d08c1d7-1c72-4a9b-8262-126da4ce1fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_70d19ca8-5d12-499b-a43a-aa988ceecbc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_119b0359-8a77-4885-b586-52a80cb802f7" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_70d19ca8-5d12-499b-a43a-aa988ceecbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_390a2fe4-6d73-4e14-add9-1a45370cd31d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_2536588f-a117-4a3b-a060-1e20bb982740" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_390a2fe4-6d73-4e14-add9-1a45370cd31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_b60b6337-8777-49ca-8d84-15d95c3c0562" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_390a2fe4-6d73-4e14-add9-1a45370cd31d" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_b60b6337-8777-49ca-8d84-15d95c3c0562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_7fea68f3-5fc1-4d30-a324-b5ff2ea51b81" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_390a2fe4-6d73-4e14-add9-1a45370cd31d" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_7fea68f3-5fc1-4d30-a324-b5ff2ea51b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_84027e92-1e7f-4919-9857-7cf25d931986" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_390a2fe4-6d73-4e14-add9-1a45370cd31d" xlink:to="loc_ifrs-full_FinancialLiabilities_84027e92-1e7f-4919-9857-7cf25d931986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_7a808ac5-3d5e-4a12-9345-7dcbb68a4bf9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_7a808ac5-3d5e-4a12-9345-7dcbb68a4bf9" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a0f97726-fdc0-4d05-8f73-5b38c1b57e93" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:to="loc_srt_CounterpartyNameAxis_a0f97726-fdc0-4d05-8f73-5b38c1b57e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d872702b-0661-4dfc-af77-8ffedac7d7e2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a0f97726-fdc0-4d05-8f73-5b38c1b57e93" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d872702b-0661-4dfc-af77-8ffedac7d7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BanquePubliqueDInvestissementMember_3e9d7b80-1385-4eb5-8d55-9a71eac0e674" xlink:href="nbx-20250630.xsd#nbx_BanquePubliqueDInvestissementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d872702b-0661-4dfc-af77-8ffedac7d7e2" xlink:to="loc_nbx_BanquePubliqueDInvestissementMember_3e9d7b80-1385-4eb5-8d55-9a71eac0e674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceMember_594e6478-9698-4570-af14-d470dedb47a5" xlink:href="nbx-20250630.xsd#nbx_BPIFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d872702b-0661-4dfc-af77-8ffedac7d7e2" xlink:to="loc_nbx_BPIFranceMember_594e6478-9698-4570-af14-d470dedb47a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_3b3d81d8-e43e-4512-929a-a3b7bf2fb338" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_3b3d81d8-e43e-4512-929a-a3b7bf2fb338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_c7114389-feae-4983-8276-85a7add7c740" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3b3d81d8-e43e-4512-929a-a3b7bf2fb338" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_c7114389-feae-4983-8276-85a7add7c740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_de093b53-05d8-4292-8c47-d177a7ab7288" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c7114389-feae-4983-8276-85a7add7c740" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_de093b53-05d8-4292-8c47-d177a7ab7288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_7b690d1e-fea4-4950-9fe8-e0e71afdc070" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c7114389-feae-4983-8276-85a7add7c740" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_7b690d1e-fea4-4950-9fe8-e0e71afdc070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_4a9b7d61-c7a2-486e-b098-4c870975e8d5" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_c7114389-feae-4983-8276-85a7add7c740" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_4a9b7d61-c7a2-486e-b098-4c870975e8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_c087e446-6d4a-486f-b9d2-ebdf335d975a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:to="loc_ifrs-full_MeasurementAxis_c087e446-6d4a-486f-b9d2-ebdf335d975a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_b84e9a6d-ec5c-4c78-8ce1-ffdd5383f209" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_c087e446-6d4a-486f-b9d2-ebdf335d975a" xlink:to="loc_ifrs-full_MeasurementDomain_b84e9a6d-ec5c-4c78-8ce1-ffdd5383f209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_af5c605b-9e8e-427d-9c9b-2130cc9ce737" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_b84e9a6d-ec5c-4c78-8ce1-ffdd5383f209" xlink:to="loc_ifrs-full_AtFairValueMember_af5c605b-9e8e-427d-9c9b-2130cc9ce737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DebtDetailsAxis_93e2646e-0803-46ea-b4f1-c5d2e5492fa3" xlink:href="nbx-20250630.xsd#nbx_DebtDetailsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:to="loc_nbx_DebtDetailsAxis_93e2646e-0803-46ea-b4f1-c5d2e5492fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DebtDetailsDomain_1356edee-5ced-4133-8ca1-e5f2114c8aa2" xlink:href="nbx-20250630.xsd#nbx_DebtDetailsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DebtDetailsAxis_93e2646e-0803-46ea-b4f1-c5d2e5492fa3" xlink:to="loc_nbx_DebtDetailsDomain_1356edee-5ced-4133-8ca1-e5f2114c8aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PrincipalAndFixedRateMember_88b501a7-d9f2-407c-a97c-9d871e1cb6ae" xlink:href="nbx-20250630.xsd#nbx_PrincipalAndFixedRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DebtDetailsDomain_1356edee-5ced-4133-8ca1-e5f2114c8aa2" xlink:to="loc_nbx_PrincipalAndFixedRateMember_88b501a7-d9f2-407c-a97c-9d871e1cb6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MilestonePaymentMember_5f35b5b5-6505-48bf-be1d-60787dcc9642" xlink:href="nbx-20250630.xsd#nbx_MilestonePaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DebtDetailsDomain_1356edee-5ced-4133-8ca1-e5f2114c8aa2" xlink:to="loc_nbx_MilestonePaymentMember_5f35b5b5-6505-48bf-be1d-60787dcc9642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_bd1eff37-3977-4a3c-8751-58a4e3814f47" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesReceivedInterestRate_b587216b-f465-4d7e-90ed-1875ad817e30" xlink:href="nbx-20250630.xsd#nbx_AdvancesReceivedInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_AdvancesReceivedInterestRate_b587216b-f465-4d7e-90ed-1875ad817e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfCurrentBorrowings_b3b13879-7743-447e-a1a3-b3d94737e0b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfCurrentBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_RepaymentsOfCurrentBorrowings_b3b13879-7743-447e-a1a3-b3d94737e0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ReimbursedAmountOfCorresponds_8043b74e-7788-4d86-b5ef-6de9ca2b0bfb" xlink:href="nbx-20250630.xsd#nbx_ReimbursedAmountOfCorresponds"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_ReimbursedAmountOfCorresponds_8043b74e-7788-4d86-b5ef-6de9ca2b0bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced_34bf8dcf-ee0c-400d-8e21-166d4566017c" xlink:href="nbx-20250630.xsd#nbx_AdvancesAuthorizedAmountToBeAdvanced"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced_34bf8dcf-ee0c-400d-8e21-166d4566017c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Advances_10e99f31-228d-46f4-9262-10a3980e128a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Advances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_Advances_10e99f31-228d-46f4-9262-10a3980e128a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_4e39e593-8d0b-47e7-aff4-f726a9549003" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_NotionalAmount_4e39e593-8d0b-47e7-aff4-f726a9549003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_4ec8a2df-978e-4ba8-9ca5-5877208dcdaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_BorrowingsInterestRate_4ec8a2df-978e-4ba8-9ca5-5877208dcdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_522f00a2-d68d-4b98-9e43-2774ee6d9bc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_522f00a2-d68d-4b98-9e43-2774ee6d9bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_c5ec7df0-986a-4f70-bc81-f7a7bcf69995" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_c5ec7df0-986a-4f70-bc81-f7a7bcf69995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm_652e89fd-5f0f-48c6-9671-d1dcb2040b7b" xlink:href="nbx-20250630.xsd#nbx_BorrowingMaturityTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_BorrowingMaturityTerm_652e89fd-5f0f-48c6-9671-d1dcb2040b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan_ec7c545d-2597-49f3-a2ea-760cd4df5028" xlink:href="nbx-20250630.xsd#nbx_BorrowingPercentageOfStateGuaranteedLoan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan_ec7c545d-2597-49f3-a2ea-760cd4df5028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingGuaranteeFee_062ace52-40ec-44ff-b1c5-82f7bf204dc5" xlink:href="nbx-20250630.xsd#nbx_BorrowingGuaranteeFee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_BorrowingGuaranteeFee_062ace52-40ec-44ff-b1c5-82f7bf204dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingNumberOfQuarterlyInstallments_35ef90ae-a6a5-4187-ad75-8d358373f48c" xlink:href="nbx-20250630.xsd#nbx_BorrowingNumberOfQuarterlyInstallments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_BorrowingNumberOfQuarterlyInstallments_35ef90ae-a6a5-4187-ad75-8d358373f48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInOutstandingLoans_6b1177bd-b072-4921-aa44-e88b7dac1ed5" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInOutstandingLoans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_IncreaseDecreaseInOutstandingLoans_6b1177bd-b072-4921-aa44-e88b7dac1ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense_0757b171-3ff1-4f2f-a8d2-88860fe86d5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_InterestExpense_0757b171-3ff1-4f2f-a8d2-88860fe86d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_7bf0dbbe-926d-4f3f-b2aa-eb05af761127" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_7bf0dbbe-926d-4f3f-b2aa-eb05af761127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_b68ea726-59c4-4f60-bb9d-fb0afed57b1f" xlink:href="nbx-20250630.xsd#nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_b68ea726-59c4-4f60-bb9d-fb0afed57b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_cf6bf43b-a19e-456c-bf71-ccfa31d5c494" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_cf6bf43b-a19e-456c-bf71-ccfa31d5c494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse_c87af57a-988f-49f6-871d-edf9e0bdf28f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse_c87af57a-988f-49f6-871d-edf9e0bdf28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_faf69e29-2b44-4a2d-a5b6-2c9449d7c80d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_ifrs-full_Borrowings_faf69e29-2b44-4a2d-a5b6-2c9449d7c80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingsCumulativeMilestonePrepaymentAmount_c9ed4da6-e919-4832-ae30-d041a281407f" xlink:href="nbx-20250630.xsd#nbx_BorrowingsCumulativeMilestonePrepaymentAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_BorrowingsCumulativeMilestonePrepaymentAmount_c9ed4da6-e919-4832-ae30-d041a281407f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EstimatedRoyaltyPayments_68eaff4a-fca5-4e0f-a52f-e20fbbf9b1b8" xlink:href="nbx-20250630.xsd#nbx_EstimatedRoyaltyPayments"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_EstimatedRoyaltyPayments_68eaff4a-fca5-4e0f-a52f-e20fbbf9b1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConsolidatedForecastedSalesPeriod_57b3643d-e072-4a5e-9b5c-457b4b08efd5" xlink:href="nbx-20250630.xsd#nbx_ConsolidatedForecastedSalesPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_5ce1dd13-79ea-4c1d-b5da-f9953008e776" xlink:to="loc_nbx_ConsolidatedForecastedSalesPeriod_57b3643d-e072-4a5e-9b5c-457b4b08efd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b54d6f50-36d0-4941-9c36-dfe1275665cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_15cd963d-2b0f-4cab-91e2-a4c77b6258f6" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b54d6f50-36d0-4941-9c36-dfe1275665cc" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_15cd963d-2b0f-4cab-91e2-a4c77b6258f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_3887c3e9-0d07-482d-8e22-c1a04c49c9d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_15cd963d-2b0f-4cab-91e2-a4c77b6258f6" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_3887c3e9-0d07-482d-8e22-c1a04c49c9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3887c3e9-0d07-482d-8e22-c1a04c49c9d0" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceAdvanceMember_bfef5bf0-1dda-4e87-9e45-f00df009c47f" xlink:href="nbx-20250630.xsd#nbx_BPIFranceAdvanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:to="loc_nbx_BPIFranceAdvanceMember_bfef5bf0-1dda-4e87-9e45-f00df009c47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvanceBPIFranceMember_1f48d56b-fa9e-4e0c-8d35-9a79fe1310e1" xlink:href="nbx-20250630.xsd#nbx_ConditionalAdvanceBPIFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:to="loc_nbx_ConditionalAdvanceBPIFranceMember_1f48d56b-fa9e-4e0c-8d35-9a79fe1310e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_f04561fe-2efd-4a7e-a5f6-0cb7ddeed22e" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_f04561fe-2efd-4a7e-a5f6-0cb7ddeed22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_ff49190f-c6ac-41b2-8fa3-783788621bc9" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_ff49190f-c6ac-41b2-8fa3-783788621bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b091f0cf-7f40-4d48-ba34-016ff9cade85" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e424af00-5495-4a9f-9403-ed240281faa1" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b091f0cf-7f40-4d48-ba34-016ff9cade85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_e1d63054-986e-47e3-923e-963b9eafe822" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_15cd963d-2b0f-4cab-91e2-a4c77b6258f6" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_e1d63054-986e-47e3-923e-963b9eafe822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_1db5e0d1-6125-481b-b93d-01c60ef38963" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_e1d63054-986e-47e3-923e-963b9eafe822" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_1db5e0d1-6125-481b-b93d-01c60ef38963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesRelatedToFinancingActivitiesMember_206127c9-6ade-4f64-b555-ea39f38414ec" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesRelatedToFinancingActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_1db5e0d1-6125-481b-b93d-01c60ef38963" xlink:to="loc_nbx_LiabilitiesRelatedToFinancingActivitiesMember_206127c9-6ade-4f64-b555-ea39f38414ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_0b0b8bc0-4cb2-4c64-9a49-137683c1951c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesRelatedToFinancingActivitiesMember_206127c9-6ade-4f64-b555-ea39f38414ec" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_0b0b8bc0-4cb2-4c64-9a49-137683c1951c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_cdc1f9a3-7443-4c22-a648-cbe35ac5de98" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesRelatedToFinancingActivitiesMember_206127c9-6ade-4f64-b555-ea39f38414ec" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_cdc1f9a3-7443-4c22-a648-cbe35ac5de98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_03cf6b68-5779-4e76-bb0e-6070d218e6d9" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_15cd963d-2b0f-4cab-91e2-a4c77b6258f6" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_03cf6b68-5779-4e76-bb0e-6070d218e6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_03cf6b68-5779-4e76-bb0e-6070d218e6d9" xlink:to="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_fb35d4f0-1db3-4a8c-8ee4-bcda60a902f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_fb35d4f0-1db3-4a8c-8ee4-bcda60a902f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_09ae2a30-1512-4baa-a3b1-7c03bfc3d451" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_09ae2a30-1512-4baa-a3b1-7c03bfc3d451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities_15f247f2-e85c-4bf1-9ec8-e3354417b564" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities_15f247f2-e85c-4bf1-9ec8-e3354417b564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_ea52b1a0-6738-49df-8315-a4baf0b9186e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_ea52b1a0-6738-49df-8315-a4baf0b9186e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_cc0574d4-209d-4eb4-9c16-82bd8d038d2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_cc0574d4-209d-4eb4-9c16-82bd8d038d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_fae21d39-3651-4615-9e79-936ce725d28b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_fae21d39-3651-4615-9e79-936ce725d28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities_433b8f51-23f4-4929-8f15-1f7e8d57dd11" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities_433b8f51-23f4-4929-8f15-1f7e8d57dd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities_74fafea8-1085-41d5-99ff-3a2c0c318ff3" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities_74fafea8-1085-41d5-99ff-3a2c0c318ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_bf3f0a2b-85b7-4c1e-b43f-f1b7643ddbc6" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_bf3f0a2b-85b7-4c1e-b43f-f1b7643ddbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_a1bb0dbe-048f-4b4d-829f-5c9bc234ca7f" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_a1bb0dbe-048f-4b4d-829f-5c9bc234ca7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashFlowsFromUsedInNonFinancingActivities_5aa23baf-9713-40b0-8049-ce949e29c635" xlink:href="nbx-20250630.xsd#nbx_CashFlowsFromUsedInNonFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_nbx_CashFlowsFromUsedInNonFinancingActivities_5aa23baf-9713-40b0-8049-ce949e29c635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_08b55397-c3ea-4948-a02a-c419d0bfc2f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward_476d7a30-3c7d-4f19-8128-b69778ec2caf" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_08b55397-c3ea-4948-a02a-c419d0bfc2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent_072c756b-2d51-41a5-a7b7-37e195551eab" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_03cf6b68-5779-4e76-bb0e-6070d218e6d9" xlink:to="loc_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent_072c756b-2d51-41a5-a7b7-37e195551eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent_3a9b4aac-ab6f-4020-83bd-ecf5e9fe170a" xlink:href="nbx-20250630.xsd#nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_03cf6b68-5779-4e76-bb0e-6070d218e6d9" xlink:to="loc_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent_3a9b4aac-ab6f-4020-83bd-ecf5e9fe170a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_9f6406ed-48a1-4477-94b3-8622ea2202e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_11caf830-7cbe-4a78-9f8f-9f88f3ecdaf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_9f6406ed-48a1-4477-94b3-8622ea2202e3" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_11caf830-7cbe-4a78-9f8f-9f88f3ecdaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_3c1fa969-e7a5-4c5f-a13d-2d5c479a879c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_11caf830-7cbe-4a78-9f8f-9f88f3ecdaf4" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_3c1fa969-e7a5-4c5f-a13d-2d5c479a879c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3c1fa969-e7a5-4c5f-a13d-2d5c479a879c" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceMember_923ac06a-e168-4222-9de5-0d1893cd1da9" xlink:href="nbx-20250630.xsd#nbx_BPIFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_BPIFranceMember_923ac06a-e168-4222-9de5-0d1893cd1da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_e5f41059-2e43-4fb5-9e39-74aa12e7d35a" xlink:href="nbx-20250630.xsd#nbx_InterestFreeAdvanceToCuradigmBPIFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_e5f41059-2e43-4fb5-9e39-74aa12e7d35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_ae7b97ee-6003-4014-b136-8b83985d1b81" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_ae7b97ee-6003-4014-b136-8b83985d1b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_919009f9-4166-47f1-9c7e-484d401fce67" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_919009f9-4166-47f1-9c7e-484d401fce67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_54fdc2fa-54cb-48fc-98fd-f2d3ab783948" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_54fdc2fa-54cb-48fc-98fd-f2d3ab783948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_bbdced53-99d8-4750-ba43-f2dab9953d03" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_bbdced53-99d8-4750-ba43-f2dab9953d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_c555e612-765b-483c-a1f5-8fea8dd7f30e" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_4068b438-c171-4cbd-94eb-87c1982d16d2" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_c555e612-765b-483c-a1f5-8fea8dd7f30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_c3909732-6b4c-4205-ad84-d95c6e670d60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_11caf830-7cbe-4a78-9f8f-9f88f3ecdaf4" xlink:to="loc_ifrs-full_MaturityAxis_c3909732-6b4c-4205-ad84-d95c6e670d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_c3909732-6b4c-4205-ad84-d95c6e670d60" xlink:to="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_09616e2a-ed78-487e-ade9-20d77c344608" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_09616e2a-ed78-487e-ade9-20d77c344608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_4e01bd29-307b-4be2-a080-12df9dc47080" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_4e01bd29-307b-4be2-a080-12df9dc47080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_b31faf61-a36a-40ee-9ff7-f6290e4e9c95" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_b31faf61-a36a-40ee-9ff7-f6290e4e9c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_5c22b650-d9fd-4cc9-bd98-ad7d0d806513" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_dd7ab6e2-60d0-44e9-8a4e-999a21c8daf2" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_5c22b650-d9fd-4cc9-bd98-ad7d0d806513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_11caf830-7cbe-4a78-9f8f-9f88f3ecdaf4" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_31dd8262-d190-48b0-b704-ba1a2eabee15" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_31dd8262-d190-48b0-b704-ba1a2eabee15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_ccd09b37-738c-4a33-a56e-7a5d9488ae0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_ccd09b37-738c-4a33-a56e-7a5d9488ae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_90605bd5-34a2-482f-9c05-16cf518860e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_90605bd5-34a2-482f-9c05-16cf518860e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingScheduledForReimbursementNumber_30c443f1-4378-4e7b-acb7-bbd9f87fe7c0" xlink:href="nbx-20250630.xsd#nbx_BorrowingScheduledForReimbursementNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_nbx_BorrowingScheduledForReimbursementNumber_30c443f1-4378-4e7b-acb7-bbd9f87fe7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm_2976729a-1d68-41b7-a750-181ff4c9dde5" xlink:href="nbx-20250630.xsd#nbx_BorrowingMaturityTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_nbx_BorrowingMaturityTerm_2976729a-1d68-41b7-a750-181ff4c9dde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriod_182f51e9-399f-4086-a9f7-3fc595d81de7" xlink:href="nbx-20250630.xsd#nbx_BorrowingDefermentPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_9a80ae0b-cc02-4de0-82b6-0f0e11558c6a" xlink:to="loc_nbx_BorrowingDefermentPeriod_182f51e9-399f-4086-a9f7-3fc595d81de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ed51a3a5-bc4b-4e75-a084-e7880b45fa1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_68357c06-6329-4431-8503-197969adb01b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ed51a3a5-bc4b-4e75-a084-e7880b45fa1f" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_68357c06-6329-4431-8503-197969adb01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_fab7abd3-2145-40f5-bf95-fd1771beab3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ed51a3a5-bc4b-4e75-a084-e7880b45fa1f" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_fab7abd3-2145-40f5-bf95-fd1771beab3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_514f50d4-7218-4e51-83db-cf324fb71d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ed51a3a5-bc4b-4e75-a084-e7880b45fa1f" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_514f50d4-7218-4e51-83db-cf324fb71d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_539a9887-db53-45aa-b77a-0cf97bd2969a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_778c3ad4-6d42-4943-90b6-d67305cb6886" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_539a9887-db53-45aa-b77a-0cf97bd2969a" xlink:to="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_778c3ad4-6d42-4943-90b6-d67305cb6886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ClinicalStudiesAxis_b953fcd1-04b2-46db-8bce-3bc445f1252f" xlink:href="nbx-20250630.xsd#nbx_ClinicalStudiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_778c3ad4-6d42-4943-90b6-d67305cb6886" xlink:to="loc_nbx_ClinicalStudiesAxis_b953fcd1-04b2-46db-8bce-3bc445f1252f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ClinicalStudiesDomain_e67dd2a7-a3a5-45ba-bc5a-76cf5775154d" xlink:href="nbx-20250630.xsd#nbx_ClinicalStudiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_ClinicalStudiesAxis_b953fcd1-04b2-46db-8bce-3bc445f1252f" xlink:to="loc_nbx_ClinicalStudiesDomain_e67dd2a7-a3a5-45ba-bc5a-76cf5775154d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A312StudyMember_7f00897d-795f-4bd1-921a-4c12e964945b" xlink:href="nbx-20250630.xsd#nbx_A312StudyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_ClinicalStudiesDomain_e67dd2a7-a3a5-45ba-bc5a-76cf5775154d" xlink:to="loc_nbx_A312StudyMember_7f00897d-795f-4bd1-921a-4c12e964945b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A1100StudyMember_58a208a1-6c45-4d86-9cd5-0101a8710db6" xlink:href="nbx-20250630.xsd#nbx_A1100StudyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_ClinicalStudiesDomain_e67dd2a7-a3a5-45ba-bc5a-76cf5775154d" xlink:to="loc_nbx_A1100StudyMember_58a208a1-6c45-4d86-9cd5-0101a8710db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NANORAY312Member_7d7b910a-6d93-49a5-9244-c051d933b1bc" xlink:href="nbx-20250630.xsd#nbx_NANORAY312Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_ClinicalStudiesDomain_e67dd2a7-a3a5-45ba-bc5a-76cf5775154d" xlink:to="loc_nbx_NANORAY312Member_7d7b910a-6d93-49a5-9244-c051d933b1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_c1b1dd8f-acdf-426b-b09d-592142ef40d0" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_778c3ad4-6d42-4943-90b6-d67305cb6886" xlink:to="loc_nbx_CollaborationAgreementAxis_c1b1dd8f-acdf-426b-b09d-592142ef40d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_c4f41ad2-ce36-4566-b510-addb9e2e5627" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_c1b1dd8f-acdf-426b-b09d-592142ef40d0" xlink:to="loc_nbx_CollaborationAgreementDomain_c4f41ad2-ce36-4566-b510-addb9e2e5627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_e1d148f9-94cd-4841-a7fe-dd1a28efa57d" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_c4f41ad2-ce36-4566-b510-addb9e2e5627" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_e1d148f9-94cd-4841-a7fe-dd1a28efa57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_72d4c544-65b6-459f-a7d1-266745474d76" xlink:href="nbx-20250630.xsd#nbx_LianBioNBTXR3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_c4f41ad2-ce36-4566-b510-addb9e2e5627" xlink:to="loc_nbx_LianBioNBTXR3Member_72d4c544-65b6-459f-a7d1-266745474d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_778c3ad4-6d42-4943-90b6-d67305cb6886" xlink:to="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses_2f6dc6a8-132d-4f60-a09d-d0bc9235921b" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses_2f6dc6a8-132d-4f60-a09d-d0bc9235921b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_b51edf2d-b5ce-42d5-a694-453df3d11df8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_b51edf2d-b5ce-42d5-a694-453df3d11df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInOtherCurrentPayables_f1114ccf-5bda-4ccd-9895-e69382ef361c" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_IncreaseDecreaseInOtherCurrentPayables_f1114ccf-5bda-4ccd-9895-e69382ef361c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_0b95f86c-57cd-42c6-bff2-4c8091ba7381" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_0b95f86c-57cd-42c6-bff2-4c8091ba7381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInBonusAccrual_3a3d0fb4-4462-43c6-aaa3-75a7382db511" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInBonusAccrual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_IncreaseDecreaseInBonusAccrual_3a3d0fb4-4462-43c6-aaa3-75a7382db511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_64eaa3b3-87fc-49df-9d5c-e583a47debed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_64eaa3b3-87fc-49df-9d5c-e583a47debed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_37df0152-502c-48c1-80ed-b630050199b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_ifrs-full_CurrentContractLiabilities_37df0152-502c-48c1-80ed-b630050199b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseRefundLiabilities_e573da23-4e3d-4760-a359-2824f9c0eb2b" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseRefundLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_5059bf2b-8cc3-419b-a598-e62632e8a396" xlink:to="loc_nbx_IncreaseDecreaseRefundLiabilities_e573da23-4e3d-4760-a359-2824f9c0eb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3135b319-f7cf-405d-989f-aebcb2e06b2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_5670737f-a372-4b49-81c3-b55994617ee1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3135b319-f7cf-405d-989f-aebcb2e06b2b" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_5670737f-a372-4b49-81c3-b55994617ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_814b580c-90fa-4f02-a249-52591ada3fd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3135b319-f7cf-405d-989f-aebcb2e06b2b" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_814b580c-90fa-4f02-a249-52591ada3fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherMiscellaneousCurrentLiabilities_63ee0499-72fe-4b0c-9b25-44d393f8e085" xlink:href="nbx-20250630.xsd#nbx_OtherMiscellaneousCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3135b319-f7cf-405d-989f-aebcb2e06b2b" xlink:to="loc_nbx_OtherMiscellaneousCurrentLiabilities_63ee0499-72fe-4b0c-9b25-44d393f8e085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_0e8c0ca3-7748-4088-813c-ffd6d27a8334" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3135b319-f7cf-405d-989f-aebcb2e06b2b" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_0e8c0ca3-7748-4088-813c-ffd6d27a8334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_40ea7abc-8a37-428c-89ca-40f1c4377d35" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_7caea79b-6bcf-4209-b125-c1a99acce8e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_40ea7abc-8a37-428c-89ca-40f1c4377d35" xlink:to="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_7caea79b-6bcf-4209-b125-c1a99acce8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_7c27a960-5a9f-4993-bff8-a2f79e4c8b28" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_40ea7abc-8a37-428c-89ca-40f1c4377d35" xlink:to="loc_ifrs-full_CurrentContractLiabilities_7c27a960-5a9f-4993-bff8-a2f79e4c8b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_29933d5c-576b-4efb-84c1-91dedc3aa283" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_40ea7abc-8a37-428c-89ca-40f1c4377d35" xlink:to="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_29933d5c-576b-4efb-84c1-91dedc3aa283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1" xlink:type="simple" xlink:href="nbx-20250630.xsd#TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_65e91899-9ae8-4c6a-9b74-6579ec5633ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_faa88f54-9c63-4fee-9697-9860236b4fa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_65e91899-9ae8-4c6a-9b74-6579ec5633ea" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_faa88f54-9c63-4fee-9697-9860236b4fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRefundsProvision_1023a096-ecea-4c66-bfa3-841fd6968844" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRefundsProvision"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_65e91899-9ae8-4c6a-9b74-6579ec5633ea" xlink:to="loc_ifrs-full_CurrentRefundsProvision_1023a096-ecea-4c66-bfa3-841fd6968844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RefundsProvision_2cd9f76b-fa99-431c-b4cc-a897f0769723" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RefundsProvision"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_65e91899-9ae8-4c6a-9b74-6579ec5633ea" xlink:to="loc_ifrs-full_RefundsProvision_2cd9f76b-fa99-431c-b4cc-a897f0769723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_46b58291-317a-4e0a-b458-84526d080df6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_46b58291-317a-4e0a-b458-84526d080df6" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d8c8752e-6bbc-4c42-bb5d-569e598550fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d8c8752e-6bbc-4c42-bb5d-569e598550fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_cc5c7a6f-95f6-453f-b1f9-346284e0f0f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_d8c8752e-6bbc-4c42-bb5d-569e598550fe" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_cc5c7a6f-95f6-453f-b1f9-346284e0f0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialAssetsMember_2e28ad90-b377-46bb-8cd7-d58cbb02a6a1" xlink:href="nbx-20250630.xsd#nbx_NonCurrentFinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_cc5c7a6f-95f6-453f-b1f9-346284e0f0f9" xlink:to="loc_nbx_NonCurrentFinancialAssetsMember_2e28ad90-b377-46bb-8cd7-d58cbb02a6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_b1cf1e96-6fd3-4d63-905c-3ea3f852a22f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_cc5c7a6f-95f6-453f-b1f9-346284e0f0f9" xlink:to="loc_ifrs-full_TradeReceivablesMember_b1cf1e96-6fd3-4d63-905c-3ea3f852a22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashAndCashEquivalents1Member_7f6a0602-b16e-4448-9682-951edb191ab0" xlink:href="nbx-20250630.xsd#nbx_CashAndCashEquivalents1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_cc5c7a6f-95f6-453f-b1f9-346284e0f0f9" xlink:to="loc_nbx_CashAndCashEquivalents1Member_7f6a0602-b16e-4448-9682-951edb191ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2350c267-c837-4cbb-9f93-2020ff736c54" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2350c267-c837-4cbb-9f93-2020ff736c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_6fc68430-cc51-4a3e-bc33-d3ad0f34bfc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_2350c267-c837-4cbb-9f93-2020ff736c54" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_6fc68430-cc51-4a3e-bc33-d3ad0f34bfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_53c9fd2a-19d5-4f58-9398-990bca517b09" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_6fc68430-cc51-4a3e-bc33-d3ad0f34bfc4" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_53c9fd2a-19d5-4f58-9398-990bca517b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_aec312cf-b319-4921-bc33-071174ea5f4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_6fc68430-cc51-4a3e-bc33-d3ad0f34bfc4" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_aec312cf-b319-4921-bc33-071174ea5f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_b6df44d7-40d6-46d4-9d8c-ebe8316864a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_b6df44d7-40d6-46d4-9d8c-ebe8316864a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_32432126-c487-4d59-a059-3767990a82c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_b6df44d7-40d6-46d4-9d8c-ebe8316864a3" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_32432126-c487-4d59-a059-3767990a82c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialLiabilitiesMember_bdee3cce-2aea-4ae7-aacb-c5a51e6d3007" xlink:href="nbx-20250630.xsd#nbx_NonCurrentFinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_32432126-c487-4d59-a059-3767990a82c6" xlink:to="loc_nbx_NonCurrentFinancialLiabilitiesMember_bdee3cce-2aea-4ae7-aacb-c5a51e6d3007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentFinancialLiabilitiesMember_b9dd00c0-d562-4da1-9eef-109c1a3806f8" xlink:href="nbx-20250630.xsd#nbx_CurrentFinancialLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_32432126-c487-4d59-a059-3767990a82c6" xlink:to="loc_nbx_CurrentFinancialLiabilitiesMember_b9dd00c0-d562-4da1-9eef-109c1a3806f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TradeAndOtherPayablesMember_60008c25-b4d9-4d2a-bda5-b1b22630b8a3" xlink:href="nbx-20250630.xsd#nbx_TradeAndOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_32432126-c487-4d59-a059-3767990a82c6" xlink:to="loc_nbx_TradeAndOtherPayablesMember_60008c25-b4d9-4d2a-bda5-b1b22630b8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6ecfbbf4-f52d-4e09-b96b-a3abb04a210f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6ecfbbf4-f52d-4e09-b96b-a3abb04a210f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_e647049c-1580-41b6-89a4-e5372bdec247" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6ecfbbf4-f52d-4e09-b96b-a3abb04a210f" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_e647049c-1580-41b6-89a4-e5372bdec247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_a9148180-3f00-4576-b3ab-940ba22a5959" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_e647049c-1580-41b6-89a4-e5372bdec247" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_a9148180-3f00-4576-b3ab-940ba22a5959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_e4e0bc59-6829-4f8d-918e-f4f44c5a02e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_e647049c-1580-41b6-89a4-e5372bdec247" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_e4e0bc59-6829-4f8d-918e-f4f44c5a02e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ec9885df-e7a6-4106-9865-92fdd57529fe" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_36dd28b0-59bc-45ae-b3df-16a237a3b745" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:to="loc_ifrs-full_FinancialAssets_36dd28b0-59bc-45ae-b3df-16a237a3b745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_a5110cee-6e3e-45c7-8785-fd8793c77a1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_a5110cee-6e3e-45c7-8785-fd8793c77a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_331ab0a8-21e3-4f35-a61f-fcde39310dfa" xlink:href="nbx-20250630.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:to="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_331ab0a8-21e3-4f35-a61f-fcde39310dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_2a7cf041-fc16-4834-b809-b6b8efe1f283" xlink:href="nbx-20250630.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0758e451-4bd1-432a-9862-fc15d5b5300c" xlink:to="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_2a7cf041-fc16-4834-b809-b6b8efe1f283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_611d2a45-a723-411e-96c4-4c1b7b0f3e00" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_103ce492-8d3e-40d4-98dc-e7e2bad7ed1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_611d2a45-a723-411e-96c4-4c1b7b0f3e00" xlink:to="loc_ifrs-full_CashAndCashEquivalents_103ce492-8d3e-40d4-98dc-e7e2bad7ed1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RevenueandotherincomeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_6384903d-d938-46f7-82e8-9e8bb100a410" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_6384903d-d938-46f7-82e8-9e8bb100a410" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_2f84ef0a-e870-4980-84c2-c66fa95ffe8e" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:to="loc_nbx_CollaborationAgreementAxis_2f84ef0a-e870-4980-84c2-c66fa95ffe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_86948590-1bbe-4b4c-ae19-4281f1827902" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_2f84ef0a-e870-4980-84c2-c66fa95ffe8e" xlink:to="loc_nbx_CollaborationAgreementDomain_86948590-1bbe-4b4c-ae19-4281f1827902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NANORAY312Member_7274ec66-4e6d-45e3-b960-4cdf17889f44" xlink:href="nbx-20250630.xsd#nbx_NANORAY312Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_86948590-1bbe-4b4c-ae19-4281f1827902" xlink:to="loc_nbx_NANORAY312Member_7274ec66-4e6d-45e3-b960-4cdf17889f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaBVMember_e9d7b50d-5ea9-4aff-abb0-1f75bc9f3139" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_86948590-1bbe-4b4c-ae19-4281f1827902" xlink:to="loc_nbx_JanssenPharmaceuticaBVMember_e9d7b50d-5ea9-4aff-abb0-1f75bc9f3139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_92028767-d599-4dc6-bd15-9e5cb8e5cb8c" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_86948590-1bbe-4b4c-ae19-4281f1827902" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_92028767-d599-4dc6-bd15-9e5cb8e5cb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_963b0bbe-e81a-4e9e-859b-b3040626cc2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_963b0bbe-e81a-4e9e-859b-b3040626cc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_963b0bbe-e81a-4e9e-859b-b3040626cc2b" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherSalesMember_4a1ed167-3bdb-4c9a-9d93-b2c7da8a2d16" xlink:href="nbx-20250630.xsd#nbx_OtherSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_OtherSalesMember_4a1ed167-3bdb-4c9a-9d93-b2c7da8a2d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServicesMember_e38995e8-cbca-45c0-a308-0dca4ecca2e4" xlink:href="nbx-20250630.xsd#nbx_ServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_ServicesMember_e38995e8-cbca-45c0-a308-0dca4ecca2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TechnologyTransferMember_e6dbc4e2-0539-4054-9c6c-d64aae62d1bc" xlink:href="nbx-20250630.xsd#nbx_TechnologyTransferMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_TechnologyTransferMember_e6dbc4e2-0539-4054-9c6c-d64aae62d1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServiceRechargeMember_4c6da207-750f-4b5f-9e11-029307f6078a" xlink:href="nbx-20250630.xsd#nbx_ServiceRechargeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_ServiceRechargeMember_4c6da207-750f-4b5f-9e11-029307f6078a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SupplyServicesMember_9c7f67ef-ede0-47fc-9b5d-e3800686dcda" xlink:href="nbx-20250630.xsd#nbx_SupplyServicesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_SupplyServicesMember_9c7f67ef-ede0-47fc-9b5d-e3800686dcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RechargeMember_7fe4c4a7-e3e5-4ae0-953c-3eca15e2735c" xlink:href="nbx-20250630.xsd#nbx_RechargeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_b449133c-5ab6-4657-9743-4253f67603ad" xlink:to="loc_nbx_RechargeMember_7fe4c4a7-e3e5-4ae0-953c-3eca15e2735c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_9bdd9304-b7b2-4a46-89d9-a3b6207279d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_9bdd9304-b7b2-4a46-89d9-a3b6207279d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_e7ef209d-ef84-4803-b4fd-7d0102909ea9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_9bdd9304-b7b2-4a46-89d9-a3b6207279d0" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_e7ef209d-ef84-4803-b4fd-7d0102909ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_07bafa12-a4db-466e-8558-ce4772bd9ef7" xlink:href="nbx-20250630.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_e7ef209d-ef84-4803-b4fd-7d0102909ea9" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_07bafa12-a4db-466e-8558-ce4772bd9ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1066f02c-af47-4b24-b028-ab2fa4141a6a" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_947fb1de-9c8c-4f3d-879b-55d777826569" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_947fb1de-9c8c-4f3d-879b-55d777826569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_f4fa8058-dd13-4d1b-88db-4cec3187c2db" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_f4fa8058-dd13-4d1b-88db-4cec3187c2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_4ab86aa0-4ba8-472b-9ff1-aa1ea900d388" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_4ab86aa0-4ba8-472b-9ff1-aa1ea900d388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_e9ce37ec-fc84-4c5b-9310-5bf8fed3303f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_e9ce37ec-fc84-4c5b-9310-5bf8fed3303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsToRevenueFromContractsWithCustomers_0fec01de-7395-41fa-bdbc-2c83886e839b" xlink:href="nbx-20250630.xsd#nbx_AdjustmentsToRevenueFromContractsWithCustomers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_nbx_AdjustmentsToRevenueFromContractsWithCustomers_0fec01de-7395-41fa-bdbc-2c83886e839b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentTaxCredit_20d1e902-9024-46f2-a32a-4b734a5021ce" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_nbx_ResearchAndDevelopmentTaxCredit_20d1e902-9024-46f2-a32a-4b734a5021ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_b6706f4d-f383-4d2c-b811-32cc2d8b8deb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_b6706f4d-f383-4d2c-b811-32cc2d8b8deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_dc9f0496-4c91-4139-af18-e73bca5287a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_dc9f0496-4c91-4139-af18-e73bca5287a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_d7493b40-ca81-4815-830b-a3bd742a7708" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_09088ed2-76e7-4a9f-9e5d-76dd0eeec2e8" xlink:to="loc_ifrs-full_OtherRevenue_d7493b40-ca81-4815-830b-a3bd742a7708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_eabb1565-6b0e-48d8-89c5-4f5224295609" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_410a161b-c161-47a2-b28a-b3e51be44085" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_eabb1565-6b0e-48d8-89c5-4f5224295609" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_410a161b-c161-47a2-b28a-b3e51be44085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_8bcd41fe-9a9b-4b03-8675-cf1f5ab518f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_410a161b-c161-47a2-b28a-b3e51be44085" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_8bcd41fe-9a9b-4b03-8675-cf1f5ab518f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_c542bc6e-8bbf-40ea-9d2c-2040b2e76bd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_8bcd41fe-9a9b-4b03-8675-cf1f5ab518f1" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_c542bc6e-8bbf-40ea-9d2c-2040b2e76bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServicesMember_d40ecbe1-fa51-4c21-9e55-2ef9c4afa3e8" xlink:href="nbx-20250630.xsd#nbx_ServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_c542bc6e-8bbf-40ea-9d2c-2040b2e76bd7" xlink:to="loc_nbx_ServicesMember_d40ecbe1-fa51-4c21-9e55-2ef9c4afa3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherSalesMember_d1273c5e-61fe-4039-b2b5-5e13807905a8" xlink:href="nbx-20250630.xsd#nbx_OtherSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_c542bc6e-8bbf-40ea-9d2c-2040b2e76bd7" xlink:to="loc_nbx_OtherSalesMember_d1273c5e-61fe-4039-b2b5-5e13807905a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_410a161b-c161-47a2-b28a-b3e51be44085" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_053b506a-24fd-4be4-8be9-c0ac9be23487" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_053b506a-24fd-4be4-8be9-c0ac9be23487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentTaxCredit_6154662c-018c-4a0f-a848-24bbf613aff4" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_nbx_ResearchAndDevelopmentTaxCredit_6154662c-018c-4a0f-a848-24bbf613aff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_91283083-826e-4f05-802e-19cccfa73209" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_91283083-826e-4f05-802e-19cccfa73209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_82dfc2aa-9156-4c62-b3b9-6c06851d1be2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_82dfc2aa-9156-4c62-b3b9-6c06851d1be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_800d6f75-818a-4964-b3ef-6cc2766f803c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_OtherIncome_800d6f75-818a-4964-b3ef-6cc2766f803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_373b65dc-d7be-4509-bc71-a605f5cc24b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_61cb4e83-ff8a-4552-8e67-cd5cb8777c34" xlink:to="loc_ifrs-full_Revenue_373b65dc-d7be-4509-bc71-a605f5cc24b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8807cecf-3018-478c-a3dc-f9c1181bba6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_43ff0d81-e96e-4820-a76d-0cf9dfce8fff" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8807cecf-3018-478c-a3dc-f9c1181bba6f" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_43ff0d81-e96e-4820-a76d-0cf9dfce8fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts_73318f6d-2ea1-43c2-a1fc-f63fec44a30e" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentExpensePayrollCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8807cecf-3018-478c-a3dc-f9c1181bba6f" xlink:to="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts_73318f6d-2ea1-43c2-a1fc-f63fec44a30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_a0f23f39-f421-43d0-a1d8-e16a3e17d91b" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8807cecf-3018-478c-a3dc-f9c1181bba6f" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_a0f23f39-f421-43d0-a1d8-e16a3e17d91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_d18cf289-e66e-40bc-8190-3d9b09e1cf8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8807cecf-3018-478c-a3dc-f9c1181bba6f" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_d18cf289-e66e-40bc-8190-3d9b09e1cf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_62a8211b-6e35-4802-8fc7-4712d4350b64" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_62a8211b-6e35-4802-8fc7-4712d4350b64" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_f53dd0b5-f1eb-489e-873d-69e271136c91" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_f53dd0b5-f1eb-489e-873d-69e271136c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_4920217a-e39a-405f-9bdd-b5ce56f74842" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_f53dd0b5-f1eb-489e-873d-69e271136c91" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_4920217a-e39a-405f-9bdd-b5ce56f74842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentArrangement1Member_c7471ac4-091e-44d8-b53c-60f79e0ff700" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentArrangement1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_4920217a-e39a-405f-9bdd-b5ce56f74842" xlink:to="loc_nbx_ResearchAndDevelopmentArrangement1Member_c7471ac4-091e-44d8-b53c-60f79e0ff700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_229bb464-569a-4528-ad2b-fd842c18374c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_4920217a-e39a-405f-9bdd-b5ce56f74842" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_229bb464-569a-4528-ad2b-fd842c18374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonRecurringExpenseTypeAxis_6d3159dc-6665-4ed4-86bb-2327fa5dfd1b" xlink:href="nbx-20250630.xsd#nbx_NonRecurringExpenseTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:to="loc_nbx_NonRecurringExpenseTypeAxis_6d3159dc-6665-4ed4-86bb-2327fa5dfd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonRecurringExpenseTypeDomain_989e5077-ba69-42b3-ba3b-a701a09b17d0" xlink:href="nbx-20250630.xsd#nbx_NonRecurringExpenseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NonRecurringExpenseTypeAxis_6d3159dc-6665-4ed4-86bb-2327fa5dfd1b" xlink:to="loc_nbx_NonRecurringExpenseTypeDomain_989e5077-ba69-42b3-ba3b-a701a09b17d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EmploymentTerminationIndemnitiesMember_6dfc36fd-6d27-4431-9c63-9c717413b842" xlink:href="nbx-20250630.xsd#nbx_EmploymentTerminationIndemnitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NonRecurringExpenseTypeDomain_989e5077-ba69-42b3-ba3b-a701a09b17d0" xlink:to="loc_nbx_EmploymentTerminationIndemnitiesMember_6dfc36fd-6d27-4431-9c63-9c717413b842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OperatingExpenseAxis_5857f7b9-973b-467d-8ea0-3412129fbd8a" xlink:href="nbx-20250630.xsd#nbx_OperatingExpenseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:to="loc_nbx_OperatingExpenseAxis_5857f7b9-973b-467d-8ea0-3412129fbd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OperatingExpenseDomain_60da605d-f541-4eb5-8b26-3c9191ce34f9" xlink:href="nbx-20250630.xsd#nbx_OperatingExpenseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OperatingExpenseAxis_5857f7b9-973b-467d-8ea0-3412129fbd8a" xlink:to="loc_nbx_OperatingExpenseDomain_60da605d-f541-4eb5-8b26-3c9191ce34f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentMember_fae8f311-c0d2-4f9b-94ca-a25872720399" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OperatingExpenseDomain_60da605d-f541-4eb5-8b26-3c9191ce34f9" xlink:to="loc_nbx_ResearchAndDevelopmentMember_fae8f311-c0d2-4f9b-94ca-a25872720399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_693ae29d-1437-445e-a246-0dc56cd4f4cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OperatingExpenseDomain_60da605d-f541-4eb5-8b26-3c9191ce34f9" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_693ae29d-1437-445e-a246-0dc56cd4f4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_f4f835d4-e594-45c3-b2eb-47fdfcbcbb87" xlink:to="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_a0913718-0d2b-4f8b-aea6-d71989dcd51f" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_a0913718-0d2b-4f8b-aea6-d71989dcd51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreasePayrollExpense_34ddc5f9-ad87-4deb-b60b-a23d1daec977" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreasePayrollExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreasePayrollExpense_34ddc5f9-ad87-4deb-b60b-a23d1daec977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreasePayrollExpensePercentage_e1860815-a8c2-444d-90fa-a57fd89e226c" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreasePayrollExpensePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreasePayrollExpensePercentage_e1860815-a8c2-444d-90fa-a57fd89e226c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_StockOptionsGranted_7afcb9f9-455e-4143-b21c-fb398180aa79" xlink:href="nbx-20250630.xsd#nbx_StockOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_StockOptionsGranted_7afcb9f9-455e-4143-b21c-fb398180aa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_2f31e575-36b2-4520-b6c3-ae882b947ea9" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_2f31e575-36b2-4520-b6c3-ae882b947ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_97ce6613-9c44-4ae9-8a92-72b358d47b9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_97ce6613-9c44-4ae9-8a92-72b358d47b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SeveranceExpenses_baaf526a-593a-4662-9779-a4db48fbf4d8" xlink:href="nbx-20250630.xsd#nbx_SeveranceExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_SeveranceExpenses_baaf526a-593a-4662-9779-a4db48fbf4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInDepreciationExpense_75b0c732-3a5f-498a-9102-579cb0e4ee77" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInDepreciationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInDepreciationExpense_75b0c732-3a5f-498a-9102-579cb0e4ee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PaymentOfAdvisoryFees_eff24f11-3813-4d69-96de-b4572a7e6ef5" xlink:href="nbx-20250630.xsd#nbx_PaymentOfAdvisoryFees"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_PaymentOfAdvisoryFees_eff24f11-3813-4d69-96de-b4572a7e6ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInSocialTax_c75957c4-af96-403f-a769-4d413518c759" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInSocialTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInSocialTax_c75957c4-af96-403f-a769-4d413518c759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_0d58fce3-69cd-4d27-ab8a-1288488856d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_ifrs-full_NumberOfEmployees_0d58fce3-69cd-4d27-ab8a-1288488856d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage_b3996f94-2b05-430c-9986-70d5bdd07a86" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage_b3996f94-2b05-430c-9986-70d5bdd07a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_a629f3c4-4d2c-440f-9932-7d12a629a2a4" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_a629f3c4-4d2c-440f-9932-7d12a629a2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_446a7284-4630-4158-aa14-27c29d2af1f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_446a7284-4630-4158-aa14-27c29d2af1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherNonrecurringExpenses_1ecff216-7fef-421c-af16-79909384e2a0" xlink:href="nbx-20250630.xsd#nbx_OtherNonrecurringExpenses"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_92526c54-6488-4f07-9e73-0609d4e99a38" xlink:to="loc_nbx_OtherNonrecurringExpenses_1ecff216-7fef-421c-af16-79909384e2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b92484ff-ce33-48fd-bba4-da4b165d01eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_a0fb226e-052b-4cdb-8a68-30989efdc221" xlink:href="nbx-20250630.xsd#nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b92484ff-ce33-48fd-bba4-da4b165d01eb" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_a0fb226e-052b-4cdb-8a68-30989efdc221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_7d83a06e-5096-4680-a02b-fa10cbe01bcd" xlink:href="nbx-20250630.xsd#nbx_SellingGeneralAndAdministrativeExpensePayrollCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b92484ff-ce33-48fd-bba4-da4b165d01eb" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_7d83a06e-5096-4680-a02b-fa10cbe01bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_c120b4af-5578-4e16-a318-aee365c5b79d" xlink:href="nbx-20250630.xsd#nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b92484ff-ce33-48fd-bba4-da4b165d01eb" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_c120b4af-5578-4e16-a318-aee365c5b79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_b36a5b2c-b871-47bb-8795-2792f6a1eb26" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b92484ff-ce33-48fd-bba4-da4b165d01eb" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_b36a5b2c-b871-47bb-8795-2792f6a1eb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofPayrollCostsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8b84dfa8-a783-465c-8083-eca002494378" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_ebc8224b-6c78-4c88-a512-a0ab96d8e972" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WagesAndSalaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8b84dfa8-a783-465c-8083-eca002494378" xlink:to="loc_ifrs-full_WagesAndSalaries_ebc8224b-6c78-4c88-a512-a0ab96d8e972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions_5bfc5d96-ad12-4df6-b9cb-9cb0b5bc6a45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8b84dfa8-a783-465c-8083-eca002494378" xlink:to="loc_ifrs-full_SocialSecurityContributions_5bfc5d96-ad12-4df6-b9cb-9cb0b5bc6a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7de7633c-9ab6-4d8c-9315-92ceeb42aded" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8b84dfa8-a783-465c-8083-eca002494378" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7de7633c-9ab6-4d8c-9315-92ceeb42aded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_8f4fddcc-4d13-4c0f-bb9a-0429ffc1cd8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8b84dfa8-a783-465c-8083-eca002494378" xlink:to="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_8f4fddcc-4d13-4c0f-bb9a-0429ffc1cd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_68154097-43a0-4fc2-ab41-30aca47f6ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8b84dfa8-a783-465c-8083-eca002494378" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_68154097-43a0-4fc2-ab41-30aca47f6ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageNumberOfEmployees_4f69299a-e4a9-4373-a0f6-74009004bf35" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AverageNumberOfEmployees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8b84dfa8-a783-465c-8083-eca002494378" xlink:to="loc_ifrs-full_AverageNumberOfEmployees_4f69299a-e4a9-4373-a0f6-74009004bf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_0b19db65-4716-4dc6-a31e-af511e103123" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8b84dfa8-a783-465c-8083-eca002494378" xlink:to="loc_ifrs-full_NumberOfEmployees_0b19db65-4716-4dc6-a31e-af511e103123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_252948f3-9800-482d-bd5c-d0a5f525a2fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_8bc1dc24-d1e9-4f53-8fec-79109a461042" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_252948f3-9800-482d-bd5c-d0a5f525a2fa" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_8bc1dc24-d1e9-4f53-8fec-79109a461042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_c6392b86-23ad-4274-aba7-75546d1ddafd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_8bc1dc24-d1e9-4f53-8fec-79109a461042" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_c6392b86-23ad-4274-aba7-75546d1ddafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_d85216d4-4ee7-4f1d-bac3-6af359396d36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_c6392b86-23ad-4274-aba7-75546d1ddafd" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_d85216d4-4ee7-4f1d-bac3-6af359396d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentArrangement1Member_67f724ef-ca30-4952-8505-75e1e44e13be" xlink:href="nbx-20250630.xsd#nbx_ResearchAndDevelopmentArrangement1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_d85216d4-4ee7-4f1d-bac3-6af359396d36" xlink:to="loc_nbx_ResearchAndDevelopmentArrangement1Member_67f724ef-ca30-4952-8505-75e1e44e13be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_dfadad63-b7fb-48a3-b540-c33cc4260154" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_d85216d4-4ee7-4f1d-bac3-6af359396d36" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_dfadad63-b7fb-48a3-b540-c33cc4260154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_8bc1dc24-d1e9-4f53-8fec-79109a461042" xlink:to="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_d6f8fa78-d592-47e8-ae4d-3cf610abda92" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_ifrs-full_AmortisationExpense_d6f8fa78-d592-47e8-ae4d-3cf610abda92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationExpense_f00f164b-957f-45bc-9cd5-7a6795b6a5b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_ifrs-full_DepreciationExpense_f00f164b-957f-45bc-9cd5-7a6795b6a5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LitigationExpense_49a8bd21-63d3-42d0-8eef-a2bc4a376a74" xlink:href="nbx-20250630.xsd#nbx_LitigationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_nbx_LitigationExpense_49a8bd21-63d3-42d0-8eef-a2bc4a376a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_1906ab0c-1af1-4276-9a03-b4b033a1e867" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_1906ab0c-1af1-4276-9a03-b4b033a1e867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_dd063edd-c437-4056-9195-d66c09caf0a8" xlink:href="nbx-20250630.xsd#nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19_dd063edd-c437-4056-9195-d66c09caf0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionForRetirementBenefitObligationsNet_cffc75e6-760c-4d6e-872b-746de0436f44" xlink:href="nbx-20250630.xsd#nbx_ProvisionForRetirementBenefitObligationsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_nbx_ProvisionForRetirementBenefitObligationsNet_cffc75e6-760c-4d6e-872b-746de0436f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpenses_67132871-a856-472e-af14-789e55f70acc" xlink:href="nbx-20250630.xsd#nbx_DepreciationAmortizationAndProvisionExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_062f9d0f-2c1c-4b26-adad-87c7f6742c68" xlink:to="loc_nbx_DepreciationAmortizationAndProvisionExpenses_67132871-a856-472e-af14-789e55f70acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_98ab24c0-a550-424f-bf4a-4d5d74292024" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherNonrecurringExpenses_20df8027-fce7-4073-b970-87d0a5dc75a3" xlink:href="nbx-20250630.xsd#nbx_OtherNonrecurringExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_98ab24c0-a550-424f-bf4a-4d5d74292024" xlink:to="loc_nbx_OtherNonrecurringExpenses_20df8027-fce7-4073-b970-87d0a5dc75a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherNonrecurringsIncome_e3a21006-88ab-426b-999b-74c18aa1a2af" xlink:href="nbx-20250630.xsd#nbx_OtherNonrecurringsIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_98ab24c0-a550-424f-bf4a-4d5d74292024" xlink:to="loc_nbx_OtherNonrecurringsIncome_e3a21006-88ab-426b-999b-74c18aa1a2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_9c41fbf6-244b-495c-977c-64a1700fee59" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_98ab24c0-a550-424f-bf4a-4d5d74292024" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_9c41fbf6-244b-495c-977c-64a1700fee59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_f1553f9a-3b2e-48f4-ba86-2c560de928e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_264999c5-b731-45ae-a094-09761fa8c497" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_f1553f9a-3b2e-48f4-ba86-2c560de928e0" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_264999c5-b731-45ae-a094-09761fa8c497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5572447b-8657-4d64-b9a7-0cbe6d5a8d91" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_264999c5-b731-45ae-a094-09761fa8c497" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5572447b-8657-4d64-b9a7-0cbe6d5a8d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5572447b-8657-4d64-b9a7-0cbe6d5a8d91" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member_3ab148f9-2fb4-4440-9261-29a2fdd2b916" xlink:href="nbx-20250630.xsd#nbx_BSPCE20151Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE20151Member_3ab148f9-2fb4-4440-9261-29a2fdd2b916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member_578eb762-a2fc-4d68-82a3-6658e7744c68" xlink:href="nbx-20250630.xsd#nbx_BSPCE20153Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE20153Member_578eb762-a2fc-4d68-82a3-6658e7744c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016OrdinaryMember_ce13e2a7-5126-4478-b661-f509eab7b3c0" xlink:href="nbx-20250630.xsd#nbx_BSPCE2016OrdinaryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE2016OrdinaryMember_ce13e2a7-5126-4478-b661-f509eab7b3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016PerformanceMember_e410757e-be52-4bad-8782-bde1842893b0" xlink:href="nbx-20250630.xsd#nbx_BSPCE2016PerformanceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE2016PerformanceMember_e410757e-be52-4bad-8782-bde1842893b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017OrdinaryMember_07dea362-7b35-454c-adfa-62ca2d4a8b05" xlink:href="nbx-20250630.xsd#nbx_BSPCE2017OrdinaryMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE2017OrdinaryMember_07dea362-7b35-454c-adfa-62ca2d4a8b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017Member_734dabf3-72a0-434a-a972-18fb828fa83c" xlink:href="nbx-20250630.xsd#nbx_BSPCE2017Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f23005db-80ee-4679-868c-d24557e63682" xlink:to="loc_nbx_BSPCE2017Member_734dabf3-72a0-434a-a972-18fb828fa83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_81440269-1331-4771-ad72-dfbe678bd57b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_264999c5-b731-45ae-a094-09761fa8c497" xlink:to="loc_srt_TitleOfIndividualAxis_81440269-1331-4771-ad72-dfbe678bd57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62c5b622-d500-48e3-a274-7b0f210ada37" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_81440269-1331-4771-ad72-dfbe678bd57b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62c5b622-d500-48e3-a274-7b0f210ada37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CorporateOfficersMember_583db93c-3fed-41d1-b60a-fcfb9304183a" xlink:href="nbx-20250630.xsd#nbx_CorporateOfficersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62c5b622-d500-48e3-a274-7b0f210ada37" xlink:to="loc_nbx_CorporateOfficersMember_583db93c-3fed-41d1-b60a-fcfb9304183a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LaurentLevyMember_57c46f12-226f-4ea2-a412-25345b93e08b" xlink:href="nbx-20250630.xsd#nbx_LaurentLevyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62c5b622-d500-48e3-a274-7b0f210ada37" xlink:to="loc_nbx_LaurentLevyMember_57c46f12-226f-4ea2-a412-25345b93e08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_e6583fa8-b04b-4dcb-8941-85103a5d029a" xlink:href="nbx-20250630.xsd#nbx_BeneficiariesOtherThanCorporateOfficersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62c5b622-d500-48e3-a274-7b0f210ada37" xlink:to="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_e6583fa8-b04b-4dcb-8941-85103a5d029a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_264999c5-b731-45ae-a094-09761fa8c497" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_663f53ff-445f-4b97-b371-4a1424c5803c" xlink:href="nbx-20250630.xsd#nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_663f53ff-445f-4b97-b371-4a1424c5803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_ba43124d-04b4-4529-8395-86ce9bc2bb6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_ba43124d-04b4-4529-8395-86ce9bc2bb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_38520d36-e5ad-41f8-8cee-6682c21f3f25" xlink:href="nbx-20250630.xsd#nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_38520d36-e5ad-41f8-8cee-6682c21f3f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_1eb35767-8bcf-4a14-bdf6-9fe60f51eabf" xlink:href="nbx-20250630.xsd#nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_1eb35767-8bcf-4a14-bdf6-9fe60f51eabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_38c3bf62-b544-461a-a425-c4ee21d2b194" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_38c3bf62-b544-461a-a425-c4ee21d2b194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e652a888-15b4-4730-9799-1f6f39495b8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e652a888-15b4-4730-9799-1f6f39495b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_c5d052ae-bd99-43c9-996d-96f2e8aff427" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_c5d052ae-bd99-43c9-996d-96f2e8aff427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_f4e125c5-b8f7-4861-9f70-1877ef0e5020" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_f4e125c5-b8f7-4861-9f70-1877ef0e5020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_895323ce-2d80-4d39-a088-182514ee3ea9" xlink:href="nbx-20250630.xsd#nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_25a9003e-01e9-41a3-857f-08d97857c356" xlink:to="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_895323ce-2d80-4d39-a088-182514ee3ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_c1572b4e-320b-4387-835b-dfaccb0807a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_c1572b4e-320b-4387-835b-dfaccb0807a1" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8eae201d-d33a-482f-88b5-49a7e52bca37" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8eae201d-d33a-482f-88b5-49a7e52bca37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8eae201d-d33a-482f-88b5-49a7e52bca37" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member_eafb48da-81c1-4ef9-9641-ec2d566f9e0f" xlink:href="nbx-20250630.xsd#nbx_BSA20151Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA20151Member_eafb48da-81c1-4ef9-9641-ec2d566f9e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152Member_d1ca5063-94c0-4ffe-a80a-6075a387e6d3" xlink:href="nbx-20250630.xsd#nbx_BSA20152Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA20152Member_d1ca5063-94c0-4ffe-a80a-6075a387e6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member_fa432df1-0b68-494d-b6ac-10e1fdab8c15" xlink:href="nbx-20250630.xsd#nbx_BSA20182Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA20182Member_fa432df1-0b68-494d-b6ac-10e1fdab8c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member_a96d5e68-6d7e-479e-8fd2-a2860bbfc925" xlink:href="nbx-20250630.xsd#nbx_BSA20191Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA20191Member_a96d5e68-6d7e-479e-8fd2-a2860bbfc925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_c5087f49-23cc-4bc1-87bf-8c82da66a676" xlink:href="nbx-20250630.xsd#nbx_BSA2020Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA2020Member_c5087f49-23cc-4bc1-87bf-8c82da66a676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021Member_ae8cf595-68e8-4ecf-b0a8-e431098ddb44" xlink:href="nbx-20250630.xsd#nbx_BSA2021Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_d6994434-9d67-4815-b04a-7a8a2f6db226" xlink:to="loc_nbx_BSA2021Member_ae8cf595-68e8-4ecf-b0a8-e431098ddb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cd68b595-90f4-4cd7-a088-0464064a1a2f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:to="loc_srt_TitleOfIndividualAxis_cd68b595-90f4-4cd7-a088-0464064a1a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1514d77e-8fa8-4df2-b358-25d130a856c1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_cd68b595-90f4-4cd7-a088-0464064a1a2f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1514d77e-8fa8-4df2-b358-25d130a856c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CorporateOfficersMember_f336a7ec-455c-4f2f-9465-e1b250298cd1" xlink:href="nbx-20250630.xsd#nbx_CorporateOfficersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1514d77e-8fa8-4df2-b358-25d130a856c1" xlink:to="loc_nbx_CorporateOfficersMember_f336a7ec-455c-4f2f-9465-e1b250298cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_dd3fe8c9-2f08-4660-98dc-b92e8063577b" xlink:href="nbx-20250630.xsd#nbx_BeneficiariesOtherThanCorporateOfficersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1514d77e-8fa8-4df2-b358-25d130a856c1" xlink:to="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_dd3fe8c9-2f08-4660-98dc-b92e8063577b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameAxis_7e5ed7f3-3efa-4d19-83ed-52f68101cd2b" xlink:href="nbx-20250630.xsd#nbx_OfficersNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:to="loc_nbx_OfficersNameAxis_7e5ed7f3-3efa-4d19-83ed-52f68101cd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameDomain_34c90580-7d5e-4946-b6bc-b21ea7938336" xlink:href="nbx-20250630.xsd#nbx_OfficersNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameAxis_7e5ed7f3-3efa-4d19-83ed-52f68101cd2b" xlink:to="loc_nbx_OfficersNameDomain_34c90580-7d5e-4946-b6bc-b21ea7938336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneMarieGraffinMember_510aa9eb-a4d1-44f7-9ddb-05db8cdfeb3b" xlink:href="nbx-20250630.xsd#nbx_AnneMarieGraffinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameDomain_34c90580-7d5e-4946-b6bc-b21ea7938336" xlink:to="loc_nbx_AnneMarieGraffinMember_510aa9eb-a4d1-44f7-9ddb-05db8cdfeb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EnnoSpillnerMember_b17e285b-e389-4034-88db-3948150e1bf5" xlink:href="nbx-20250630.xsd#nbx_EnnoSpillnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameDomain_34c90580-7d5e-4946-b6bc-b21ea7938336" xlink:to="loc_nbx_EnnoSpillnerMember_b17e285b-e389-4034-88db-3948150e1bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AlainHerreraMember_d72d4eb3-1fff-40b6-93f1-b6761345f1cd" xlink:href="nbx-20250630.xsd#nbx_AlainHerreraMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameDomain_34c90580-7d5e-4946-b6bc-b21ea7938336" xlink:to="loc_nbx_AlainHerreraMember_d72d4eb3-1fff-40b6-93f1-b6761345f1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3697288a-bc31-4f25-9c97-21b7b9ae1a23" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_75178057-2be1-4f16-ae28-441ae7518e1a" xlink:href="nbx-20250630.xsd#nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_75178057-2be1-4f16-ae28-441ae7518e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_f8a308dc-a48d-4794-9e8b-5325a773ce38" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_f8a308dc-a48d-4794-9e8b-5325a773ce38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_bd1d1ddc-f7e1-4f2b-80ee-b374bd49d210" xlink:href="nbx-20250630.xsd#nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_bd1d1ddc-f7e1-4f2b-80ee-b374bd49d210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_c04073bc-a8f4-4eb9-9470-9f33d20e5360" xlink:href="nbx-20250630.xsd#nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_c04073bc-a8f4-4eb9-9470-9f33d20e5360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_30d9e11d-477f-4cbd-a5eb-87bf917c9ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_30d9e11d-477f-4cbd-a5eb-87bf917c9ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_4f1ba96e-cb32-4e66-9d0d-75ef1e3fcf8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_4f1ba96e-cb32-4e66-9d0d-75ef1e3fcf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_74420c0b-fb38-45ca-ab9a-157716a211a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_74420c0b-fb38-45ca-ab9a-157716a211a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_3903e42f-eec5-463e-b755-af171f4e36ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_3903e42f-eec5-463e-b755-af171f4e36ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5d53c1e6-328e-4845-9242-2be343dc1d01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5d53c1e6-328e-4845-9242-2be343dc1d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_9dcac511-2994-4533-8be6-d92e0c7c6083" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_9dcac511-2994-4533-8be6-d92e0c7c6083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_ba672e4d-1ec7-4bf0-81ad-c28de8a6ba52" xlink:href="nbx-20250630.xsd#nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_fc9bfe08-aa38-483d-a449-3a7538ccff65" xlink:to="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_ba672e4d-1ec7-4bf0-81ad-c28de8a6ba52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofChangesinShareOptionsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_60385b3a-c8d2-4f25-8a7c-c6a79a2808fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_60385b3a-c8d2-4f25-8a7c-c6a79a2808fc" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_61fc30c5-4c34-43fc-b3bb-0a981c33d075" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_61fc30c5-4c34-43fc-b3bb-0a981c33d075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_61fc30c5-4c34-43fc-b3bb-0a981c33d075" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161PerformanceMember_ecb21127-9cd6-46dd-9a4f-ef3cd9414627" xlink:href="nbx-20250630.xsd#nbx_OSA20161PerformanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA20161PerformanceMember_ecb21127-9cd6-46dd-9a4f-ef3cd9414627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member_95c6b358-d67f-463a-bd87-2d1b3a2dcf20" xlink:href="nbx-20250630.xsd#nbx_OSA20162Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA20162Member_95c6b358-d67f-463a-bd87-2d1b3a2dcf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017OrdinaryMember_e1c99f4b-61d0-4975-8d88-40fa92f10460" xlink:href="nbx-20250630.xsd#nbx_OSA2017OrdinaryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA2017OrdinaryMember_e1c99f4b-61d0-4975-8d88-40fa92f10460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member_6fe9afa7-ba54-435c-81ef-117b7d75e913" xlink:href="nbx-20250630.xsd#nbx_OSA2018Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA2018Member_6fe9afa7-ba54-435c-81ef-117b7d75e913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member_6632642d-00af-47c1-8f96-6d0f6d6bcaef" xlink:href="nbx-20250630.xsd#nbx_OSA20191Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA20191Member_6632642d-00af-47c1-8f96-6d0f6d6bcaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSALLY2019Member_f047d27d-dc5d-473a-a68f-b362d2d303a7" xlink:href="nbx-20250630.xsd#nbx_OSALLY2019Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSALLY2019Member_f047d27d-dc5d-473a-a68f-b362d2d303a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_6d5d3448-0c78-432d-b923-1bd327b8364b" xlink:href="nbx-20250630.xsd#nbx_OSA2020Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA2020Member_6d5d3448-0c78-432d-b923-1bd327b8364b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember_0cf177f9-3151-4546-a907-15563d35164e" xlink:href="nbx-20250630.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202104OrdinaryMember_0cf177f9-3151-4546-a907-15563d35164e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104PerformanceMember_de469114-cee9-4cac-b987-3e29dfb2350b" xlink:href="nbx-20250630.xsd#nbx_OSA202104PerformanceMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202104PerformanceMember_de469114-cee9-4cac-b987-3e29dfb2350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106PerformanceMember_6f74af20-0991-4ee3-8307-3c361fd4330b" xlink:href="nbx-20250630.xsd#nbx_OSA202106PerformanceMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202106PerformanceMember_6f74af20-0991-4ee3-8307-3c361fd4330b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember_a6a84cdf-c6f2-4b5f-8d91-3d64b21d2eeb" xlink:href="nbx-20250630.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202106OrdinaryMember_a6a84cdf-c6f2-4b5f-8d91-3d64b21d2eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202206PerformanceMember_707b68db-9fc1-4415-85eb-e3e9a0bd00c2" xlink:href="nbx-20250630.xsd#nbx_OSA202206PerformanceMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202206PerformanceMember_707b68db-9fc1-4415-85eb-e3e9a0bd00c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202206OrdinaryMember_96e4d012-33ca-4a46-9318-be16896d94c3" xlink:href="nbx-20250630.xsd#nbx_OSA202206OrdinaryMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202206OrdinaryMember_96e4d012-33ca-4a46-9318-be16896d94c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202301OrdinaryMember_1e78dee7-f07f-4941-9e6e-b3150ed2d5d5" xlink:href="nbx-20250630.xsd#nbx_OSA202301OrdinaryMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202301OrdinaryMember_1e78dee7-f07f-4941-9e6e-b3150ed2d5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202401OrdinaryMember_d4c8e2f8-f5f5-4d4e-b443-c041a5d7dd10" xlink:href="nbx-20250630.xsd#nbx_OSA202401OrdinaryMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202401OrdinaryMember_d4c8e2f8-f5f5-4d4e-b443-c041a5d7dd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202501OrdinaryMember_f12a443f-a55a-4e4c-a01b-351fab046614" xlink:href="nbx-20250630.xsd#nbx_OSA202501OrdinaryMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202501OrdinaryMember_f12a443f-a55a-4e4c-a01b-351fab046614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202502OrdinaryMember_0ed33591-84a8-478a-9d51-bee4c8f3621f" xlink:href="nbx-20250630.xsd#nbx_OSA202502OrdinaryMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_78dbbfd0-5a87-4848-a031-ca40fdebb7c7" xlink:to="loc_nbx_OSA202502OrdinaryMember_0ed33591-84a8-478a-9d51-bee4c8f3621f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a77cadc4-42ef-4975-a281-65de557ae881" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:to="loc_srt_TitleOfIndividualAxis_a77cadc4-42ef-4975-a281-65de557ae881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_842ce310-47fb-4d8f-8c36-e915aa0aa353" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_a77cadc4-42ef-4975-a281-65de557ae881" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_842ce310-47fb-4d8f-8c36-e915aa0aa353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CorporateOfficersMember_7558fe85-13bd-4ac0-89b0-a0e1519b414d" xlink:href="nbx-20250630.xsd#nbx_CorporateOfficersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_842ce310-47fb-4d8f-8c36-e915aa0aa353" xlink:to="loc_nbx_CorporateOfficersMember_7558fe85-13bd-4ac0-89b0-a0e1519b414d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_e0045696-33d0-4aab-9d1d-73226874e25a" xlink:href="nbx-20250630.xsd#nbx_BeneficiariesOtherThanCorporateOfficersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_842ce310-47fb-4d8f-8c36-e915aa0aa353" xlink:to="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_e0045696-33d0-4aab-9d1d-73226874e25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameAxis_ae85779c-59dc-43b6-be21-f79168fdcc54" xlink:href="nbx-20250630.xsd#nbx_OfficersNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:to="loc_nbx_OfficersNameAxis_ae85779c-59dc-43b6-be21-f79168fdcc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:href="nbx-20250630.xsd#nbx_OfficersNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameAxis_ae85779c-59dc-43b6-be21-f79168fdcc54" xlink:to="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LaurentLevyMember_767b006f-cf27-4d4a-a0d7-338f2c69eae5" xlink:href="nbx-20250630.xsd#nbx_LaurentLevyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:to="loc_nbx_LaurentLevyMember_767b006f-cf27-4d4a-a0d7-338f2c69eae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantMember_7a02cc47-d91b-4250-a49c-a81023f9962d" xlink:href="nbx-20250630.xsd#nbx_AnneJulietteHermantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:to="loc_nbx_AnneJulietteHermantMember_7a02cc47-d91b-4250-a49c-a81023f9962d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BartVanRhijnMember_18129f00-5054-4ac8-9ea1-6440fa68d13a" xlink:href="nbx-20250630.xsd#nbx_BartVanRhijnMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:to="loc_nbx_BartVanRhijnMember_18129f00-5054-4ac8-9ea1-6440fa68d13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LouisKayitalireMember_2fbbfa49-d299-4c42-8315-f10a71a0f449" xlink:href="nbx-20250630.xsd#nbx_LouisKayitalireMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameDomain_6fd772b4-b4a8-48ae-b79e-f400a56176a8" xlink:to="loc_nbx_LouisKayitalireMember_2fbbfa49-d299-4c42-8315-f10a71a0f449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ceb4fb7d-40d9-4633-84dc-f93471bf7120" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement_4545ec95-0df7-4de3-b6f6-6e5d545fa71a" xlink:href="nbx-20250630.xsd#nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement_4545ec95-0df7-4de3-b6f6-6e5d545fa71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_3003869e-9a44-408e-a451-202663a0741d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_3003869e-9a44-408e-a451-202663a0741d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement_d1d98866-4e0b-499e-9daf-c5767e41f295" xlink:href="nbx-20250630.xsd#nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement_d1d98866-4e0b-499e-9daf-c5767e41f295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement_a925e25a-3811-454a-a222-146235c4cc42" xlink:href="nbx-20250630.xsd#nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement_a925e25a-3811-454a-a222-146235c4cc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_31dc140b-a41a-4907-aff9-77ed4ce2059f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_31dc140b-a41a-4907-aff9-77ed4ce2059f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_a767d3c5-78b4-4842-8ffc-b453a5188839" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_a767d3c5-78b4-4842-8ffc-b453a5188839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_2d31aa62-0390-4ace-8b9c-82319d09871f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_2d31aa62-0390-4ace-8b9c-82319d09871f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_778137b8-24ef-471e-85ce-9fd5fde267cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_778137b8-24ef-471e-85ce-9fd5fde267cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_08a1a00c-c9e6-4d3b-b3db-be5593802223" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_08a1a00c-c9e6-4d3b-b3db-be5593802223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement_50a0a76a-0fe5-4cb3-9d08-e842a479978a" xlink:href="nbx-20250630.xsd#nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_04fac6f8-b6b8-4c96-9e4c-07107920e153" xlink:to="loc_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement_50a0a76a-0fe5-4cb3-9d08-e842a479978a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofFreeSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_5e4fa244-baf7-4378-be74-790a8b7cb97f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_5e4fa244-baf7-4378-be74-790a8b7cb97f" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0ecf6b3f-79d8-4c02-88da-f996c14a479e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0ecf6b3f-79d8-4c02-88da-f996c14a479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5d875f7e-14e2-424f-9c81-c7c1761683b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0ecf6b3f-79d8-4c02-88da-f996c14a479e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5d875f7e-14e2-424f-9c81-c7c1761683b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023P1Member_4646441f-2862-4bf4-abb4-cadc3ab04e43" xlink:href="nbx-20250630.xsd#nbx_AGA2023P1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5d875f7e-14e2-424f-9c81-c7c1761683b8" xlink:to="loc_nbx_AGA2023P1Member_4646441f-2862-4bf4-abb4-cadc3ab04e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023P2Member_29df5827-fa7c-494c-8add-053a05f1e55c" xlink:href="nbx-20250630.xsd#nbx_AGA2023P2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5d875f7e-14e2-424f-9c81-c7c1761683b8" xlink:to="loc_nbx_AGA2023P2Member_29df5827-fa7c-494c-8add-053a05f1e55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_87734a49-8165-47c6-9393-542f38996823" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:to="loc_srt_TitleOfIndividualAxis_87734a49-8165-47c6-9393-542f38996823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6a786fa-4293-4764-8251-4c085067818d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_87734a49-8165-47c6-9393-542f38996823" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6a786fa-4293-4764-8251-4c085067818d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CorporateOfficersMember_31926fe2-3793-4c2b-9575-d1cf99309108" xlink:href="nbx-20250630.xsd#nbx_CorporateOfficersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6a786fa-4293-4764-8251-4c085067818d" xlink:to="loc_nbx_CorporateOfficersMember_31926fe2-3793-4c2b-9575-d1cf99309108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_6f2fed00-ba15-4281-9252-1b185c4991ef" xlink:href="nbx-20250630.xsd#nbx_BeneficiariesOtherThanCorporateOfficersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b6a786fa-4293-4764-8251-4c085067818d" xlink:to="loc_nbx_BeneficiariesOtherThanCorporateOfficersMember_6f2fed00-ba15-4281-9252-1b185c4991ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameAxis_a18cfad1-a297-41ed-b785-bdac85008fed" xlink:href="nbx-20250630.xsd#nbx_OfficersNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:to="loc_nbx_OfficersNameAxis_a18cfad1-a297-41ed-b785-bdac85008fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OfficersNameDomain_0e2085aa-e790-4a65-9358-26617bde186f" xlink:href="nbx-20250630.xsd#nbx_OfficersNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameAxis_a18cfad1-a297-41ed-b785-bdac85008fed" xlink:to="loc_nbx_OfficersNameDomain_0e2085aa-e790-4a65-9358-26617bde186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LaurentLevyMember_08789718-a2bf-48c5-a440-3b59d42cc655" xlink:href="nbx-20250630.xsd#nbx_LaurentLevyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameDomain_0e2085aa-e790-4a65-9358-26617bde186f" xlink:to="loc_nbx_LaurentLevyMember_08789718-a2bf-48c5-a440-3b59d42cc655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantMember_fb9d6c5b-4c18-4c98-a6b5-78fb88f4e75a" xlink:href="nbx-20250630.xsd#nbx_AnneJulietteHermantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameDomain_0e2085aa-e790-4a65-9358-26617bde186f" xlink:to="loc_nbx_AnneJulietteHermantMember_fb9d6c5b-4c18-4c98-a6b5-78fb88f4e75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BartVanRhijnMember_15f11c08-b78b-433e-bff0-04519f6ae0e6" xlink:href="nbx-20250630.xsd#nbx_BartVanRhijnMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OfficersNameDomain_0e2085aa-e790-4a65-9358-26617bde186f" xlink:to="loc_nbx_BartVanRhijnMember_15f11c08-b78b-433e-bff0-04519f6ae0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_3471bdc7-9f8e-4060-97a2-0782b8abbc62" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_8bd0db7f-3b75-410e-8221-f19f065651be" xlink:href="nbx-20250630.xsd#nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement_8bd0db7f-3b75-410e-8221-f19f065651be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b8404d1c-bde8-4e9b-8b7e-ec5a230935ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b8404d1c-bde8-4e9b-8b7e-ec5a230935ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_bc8a3a01-386e-436b-b799-6599fc0cc6b3" xlink:href="nbx-20250630.xsd#nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement_bc8a3a01-386e-436b-b799-6599fc0cc6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_55513891-6b0a-431a-b922-c568dc758f1b" xlink:href="nbx-20250630.xsd#nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement_55513891-6b0a-431a-b922-c568dc758f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4a6c83c4-d12e-41ec-8d5d-357e216bc5f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4a6c83c4-d12e-41ec-8d5d-357e216bc5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_86191dd8-f7a4-4d6f-9eeb-6f23c107b391" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_86191dd8-f7a4-4d6f-9eeb-6f23c107b391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3b9a71bb-41cc-40e6-8641-b5f62fa3f58c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3b9a71bb-41cc-40e6-8641-b5f62fa3f58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_00ef37ea-f61c-437c-af12-8a3540a35013" xlink:href="nbx-20250630.xsd#nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement_00ef37ea-f61c-437c-af12-8a3540a35013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_e513ba80-3f42-44e2-b2b4-b178971f3ff6" xlink:href="nbx-20250630.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_c2b8e354-9c99-44fb-95ad-5ddbabbd6742" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_e513ba80-3f42-44e2-b2b4-b178971f3ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_a001846b-f31b-495c-95e3-57961fddfcef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_ff071e12-7874-4dfd-81e7-c16744e92a62" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_a001846b-f31b-495c-95e3-57961fddfcef" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_ff071e12-7874-4dfd-81e7-c16744e92a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4618a5e2-ba74-426f-b240-c8e208e90ee1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_ff071e12-7874-4dfd-81e7-c16744e92a62" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4618a5e2-ba74-426f-b240-c8e208e90ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0616c099-c67f-4f12-8e61-935d26b1a7b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4618a5e2-ba74-426f-b240-c8e208e90ee1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0616c099-c67f-4f12-8e61-935d26b1a7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_65e3f8b5-ad6e-48b9-a13b-9e694d3b5411" xlink:href="nbx-20250630.xsd#nbx_BSPCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0616c099-c67f-4f12-8e61-935d26b1a7b4" xlink:to="loc_nbx_BSPCEMember_65e3f8b5-ad6e-48b9-a13b-9e694d3b5411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_db99864e-ba23-4975-9753-8ef5f87b6bc8" xlink:href="nbx-20250630.xsd#nbx_BSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0616c099-c67f-4f12-8e61-935d26b1a7b4" xlink:to="loc_nbx_BSAMember_db99864e-ba23-4975-9753-8ef5f87b6bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_ce8d9afd-2e0a-4e8b-856b-1fbbfe692d17" xlink:href="nbx-20250630.xsd#nbx_OSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0616c099-c67f-4f12-8e61-935d26b1a7b4" xlink:to="loc_nbx_OSAMember_ce8d9afd-2e0a-4e8b-856b-1fbbfe692d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_de942185-a9e9-4c9b-9d21-5d33b5840726" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_ff071e12-7874-4dfd-81e7-c16744e92a62" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_de942185-a9e9-4c9b-9d21-5d33b5840726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_23ef80f4-d9cb-439d-8f6b-8cc37cd42d53" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_de942185-a9e9-4c9b-9d21-5d33b5840726" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_23ef80f4-d9cb-439d-8f6b-8cc37cd42d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_cfddd9e5-cf73-4adb-a084-6b1ecbc16bc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_de942185-a9e9-4c9b-9d21-5d33b5840726" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_cfddd9e5-cf73-4adb-a084-6b1ecbc16bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_3b2790bc-124b-48c6-a8d6-93d8c7a19c08" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_3b2790bc-124b-48c6-a8d6-93d8c7a19c08" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d9f3e956-fa91-4870-98f0-ef6625f48927" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d9f3e956-fa91-4870-98f0-ef6625f48927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d9f3e956-fa91-4870-98f0-ef6625f48927" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:href="nbx-20250630.xsd#nbx_BSPCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:to="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member_2d93e6d0-e28d-43aa-b015-ca1f752b688d" xlink:href="nbx-20250630.xsd#nbx_BSPCE20151Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE20151Member_2d93e6d0-e28d-43aa-b015-ca1f752b688d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member_9d364478-2a0b-49cf-ad6a-e50ee105d72e" xlink:href="nbx-20250630.xsd#nbx_BSPCE20153Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE20153Member_9d364478-2a0b-49cf-ad6a-e50ee105d72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016OrdinaryMember_9ebbdebc-8336-4976-803a-599610c3803a" xlink:href="nbx-20250630.xsd#nbx_BSPCE2016OrdinaryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE2016OrdinaryMember_9ebbdebc-8336-4976-803a-599610c3803a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016PerformanceMember_f9f5e063-41f9-4c2b-ba53-91ab1f278da1" xlink:href="nbx-20250630.xsd#nbx_BSPCE2016PerformanceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE2016PerformanceMember_f9f5e063-41f9-4c2b-ba53-91ab1f278da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017OrdinaryMember_3d941b7d-02f0-4d86-808e-fbcb18ad14eb" xlink:href="nbx-20250630.xsd#nbx_BSPCE2017OrdinaryMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE2017OrdinaryMember_3d941b7d-02f0-4d86-808e-fbcb18ad14eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017Member_13bdd9aa-9fe4-4f46-842a-7167972f1daf" xlink:href="nbx-20250630.xsd#nbx_BSPCE2017Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_f49da1d1-c4fc-4005-b7e9-94fd42d04e44" xlink:to="loc_nbx_BSPCE2017Member_13bdd9aa-9fe4-4f46-842a-7167972f1daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:href="nbx-20250630.xsd#nbx_BSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:to="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member_3e8e9e4f-3f91-49cd-9c00-472e76b2678e" xlink:href="nbx-20250630.xsd#nbx_BSA20151Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA20151Member_3e8e9e4f-3f91-49cd-9c00-472e76b2678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152Member_94f29a39-8fc4-4cac-b3af-73f591c8ae65" xlink:href="nbx-20250630.xsd#nbx_BSA20152Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA20152Member_94f29a39-8fc4-4cac-b3af-73f591c8ae65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member_e7251ce5-4905-4ac5-aed5-9742136faac7" xlink:href="nbx-20250630.xsd#nbx_BSA20182Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA20182Member_e7251ce5-4905-4ac5-aed5-9742136faac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member_ad4f8bda-6dea-44cd-a783-98cb23e7236f" xlink:href="nbx-20250630.xsd#nbx_BSA20191Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA20191Member_ad4f8bda-6dea-44cd-a783-98cb23e7236f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_adbfa0bb-e854-4987-a123-90b01b1dc9bc" xlink:href="nbx-20250630.xsd#nbx_BSA2020Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA2020Member_adbfa0bb-e854-4987-a123-90b01b1dc9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember_7c6333e0-cee9-4d1c-9e91-dc6939df4e61" xlink:href="nbx-20250630.xsd#nbx_BSA2021AMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_f1dd0733-3d34-498a-9e38-8ec2714d09f2" xlink:to="loc_nbx_BSA2021AMember_7c6333e0-cee9-4d1c-9e91-dc6939df4e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:href="nbx-20250630.xsd#nbx_OSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:to="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161PerformanceMember_d7a7097a-cba4-4fd3-b692-cc3ac51f22e5" xlink:href="nbx-20250630.xsd#nbx_OSA20161PerformanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA20161PerformanceMember_d7a7097a-cba4-4fd3-b692-cc3ac51f22e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member_f9f36d9f-8ebc-4868-a95d-0e1e95b224ef" xlink:href="nbx-20250630.xsd#nbx_OSA20162Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA20162Member_f9f36d9f-8ebc-4868-a95d-0e1e95b224ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017OrdinaryMember_a6100001-fc54-464a-a2ae-cda466a2a96d" xlink:href="nbx-20250630.xsd#nbx_OSA2017OrdinaryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA2017OrdinaryMember_a6100001-fc54-464a-a2ae-cda466a2a96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member_688c68f4-484e-477a-b593-cbf1bb1b1adb" xlink:href="nbx-20250630.xsd#nbx_OSA2018Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA2018Member_688c68f4-484e-477a-b593-cbf1bb1b1adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member_56dbf133-f615-4870-b6b0-cafd23091340" xlink:href="nbx-20250630.xsd#nbx_OSA20191Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA20191Member_56dbf133-f615-4870-b6b0-cafd23091340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20192Member_ef856b21-6b5c-4dd7-98f1-03c24145bc09" xlink:href="nbx-20250630.xsd#nbx_OSA20192Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA20192Member_ef856b21-6b5c-4dd7-98f1-03c24145bc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_f59af712-67e5-494b-b61d-a2670852d6ee" xlink:href="nbx-20250630.xsd#nbx_OSA2020Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA2020Member_f59af712-67e5-494b-b61d-a2670852d6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember_efdfcced-044f-429a-afcd-6a511cc99d6e" xlink:href="nbx-20250630.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202104OrdinaryMember_efdfcced-044f-429a-afcd-6a511cc99d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104PerformanceMember_df1fb12b-8d6b-4fc1-83e2-3258a7a430da" xlink:href="nbx-20250630.xsd#nbx_OSA202104PerformanceMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202104PerformanceMember_df1fb12b-8d6b-4fc1-83e2-3258a7a430da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember_ecf9499b-ce63-4d6b-94de-b1419f0ef062" xlink:href="nbx-20250630.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202106OrdinaryMember_ecf9499b-ce63-4d6b-94de-b1419f0ef062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106PerformanceMember_2939d78b-4380-443e-8922-fd7361c8c02d" xlink:href="nbx-20250630.xsd#nbx_OSA202106PerformanceMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202106PerformanceMember_2939d78b-4380-443e-8922-fd7361c8c02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202206PerformanceMember_37ee2651-83b8-444f-ae16-711ef1c3990b" xlink:href="nbx-20250630.xsd#nbx_OSA202206PerformanceMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202206PerformanceMember_37ee2651-83b8-444f-ae16-711ef1c3990b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202206OrdinaryMember_24d763ba-4a63-43bc-889c-e8d5efafc17c" xlink:href="nbx-20250630.xsd#nbx_OSA202206OrdinaryMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202206OrdinaryMember_24d763ba-4a63-43bc-889c-e8d5efafc17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202301OrdinaryMember_a7e11ded-206f-4bd2-99cd-6a09f81196d1" xlink:href="nbx-20250630.xsd#nbx_OSA202301OrdinaryMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202301OrdinaryMember_a7e11ded-206f-4bd2-99cd-6a09f81196d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202401OrdinaryMember_31b8ac5e-aabf-4f1f-b2bb-8723a2f5b9e9" xlink:href="nbx-20250630.xsd#nbx_OSA202401OrdinaryMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202401OrdinaryMember_31b8ac5e-aabf-4f1f-b2bb-8723a2f5b9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202501OrdinaryMember_8e84b156-b191-488d-a40f-57fe73cb9424" xlink:href="nbx-20250630.xsd#nbx_OSA202501OrdinaryMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202501OrdinaryMember_8e84b156-b191-488d-a40f-57fe73cb9424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202502OrdinaryMember_cb1f4122-1777-47ee-9225-a3e46a0297d0" xlink:href="nbx-20250630.xsd#nbx_OSA202502OrdinaryMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_efd310aa-37ad-4e83-a1b6-52bca85e7b55" xlink:to="loc_nbx_OSA202502OrdinaryMember_cb1f4122-1777-47ee-9225-a3e46a0297d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_724a2412-c22c-481d-84d1-d717dd555d13" xlink:href="nbx-20250630.xsd#nbx_AGAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_33095623-182c-4d6b-ab68-9301c848019b" xlink:to="loc_nbx_AGAMember_724a2412-c22c-481d-84d1-d717dd555d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023Performance1Member_e0c6f283-8833-4316-a7c3-5db4dc4e0c1f" xlink:href="nbx-20250630.xsd#nbx_AGA2023Performance1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_724a2412-c22c-481d-84d1-d717dd555d13" xlink:to="loc_nbx_AGA2023Performance1Member_e0c6f283-8833-4316-a7c3-5db4dc4e0c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2023Performance2Member_9496e0b5-6fa3-431c-b0a1-930577c0805b" xlink:href="nbx-20250630.xsd#nbx_AGA2023Performance2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_724a2412-c22c-481d-84d1-d717dd555d13" xlink:to="loc_nbx_AGA2023Performance2Member_9496e0b5-6fa3-431c-b0a1-930577c0805b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesAxis_5971ee02-d310-4fe3-ad94-632c74316497" xlink:href="nbx-20250630.xsd#nbx_TranchesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:to="loc_nbx_TranchesAxis_5971ee02-d310-4fe3-ad94-632c74316497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:href="nbx-20250630.xsd#nbx_TranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesAxis_5971ee02-d310-4fe3-ad94-632c74316497" xlink:to="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_99098a1c-c7b1-4a0f-a4cf-0d4be6ddddc3" xlink:href="nbx-20250630.xsd#nbx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:to="loc_nbx_TrancheOneMember_99098a1c-c7b1-4a0f-a4cf-0d4be6ddddc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_18efdddd-be74-43b0-94b3-a1ab403ead01" xlink:href="nbx-20250630.xsd#nbx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:to="loc_nbx_TrancheTwoMember_18efdddd-be74-43b0-94b3-a1ab403ead01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_9a92caec-6e63-4447-8f18-8d87531e2040" xlink:href="nbx-20250630.xsd#nbx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:to="loc_nbx_TrancheThreeMember_9a92caec-6e63-4447-8f18-8d87531e2040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember_8804101f-9ab3-4eed-bb2b-a2a87f4f7f83" xlink:href="nbx-20250630.xsd#nbx_TrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesDomain_48e87d3a-a793-41d4-8e71-65b0b90c1e14" xlink:to="loc_nbx_TrancheFourMember_8804101f-9ab3-4eed-bb2b-a2a87f4f7f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingPeriodAxis_93fc3531-d44b-4943-82c1-4699dfb476a7" xlink:href="nbx-20250630.xsd#nbx_VestingPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:to="loc_nbx_VestingPeriodAxis_93fc3531-d44b-4943-82c1-4699dfb476a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:href="nbx-20250630.xsd#nbx_VestingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingPeriodAxis_93fc3531-d44b-4943-82c1-4699dfb476a7" xlink:to="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_a9780b39-32de-4b89-9d25-2015ad8e61d8" xlink:href="nbx-20250630.xsd#nbx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:to="loc_nbx_TrancheOneMember_a9780b39-32de-4b89-9d25-2015ad8e61d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_f01e19f2-82e5-4b22-a30f-9ed941f85a6c" xlink:href="nbx-20250630.xsd#nbx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:to="loc_nbx_TrancheTwoMember_f01e19f2-82e5-4b22-a30f-9ed941f85a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_fa457aad-57f7-4d44-b2eb-bb361beea6c5" xlink:href="nbx-20250630.xsd#nbx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:to="loc_nbx_TrancheThreeMember_fa457aad-57f7-4d44-b2eb-bb361beea6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember_168b0159-a115-4f01-9735-3720a56a601b" xlink:href="nbx-20250630.xsd#nbx_TrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingPeriodDomain_9bcd85ef-203d-4200-b2e7-10aec2efb73d" xlink:to="loc_nbx_TrancheFourMember_168b0159-a115-4f01-9735-3720a56a601b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_9c0fcb3f-a1f1-44ee-a9d8-d70f71eb7548" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_46fea0ca-b821-4bbe-a6a3-816d04789c56" xlink:href="nbx-20250630.xsd#nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_46fea0ca-b821-4bbe-a6a3-816d04789c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted_e7c404d7-e3e4-4f55-b1cd-29da240a46d8" xlink:href="nbx-20250630.xsd#nbx_ExercisePriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted_e7c404d7-e3e4-4f55-b1cd-29da240a46d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_ff79dec4-fb9f-486e-9f75-b454ddc5303c" xlink:href="nbx-20250630.xsd#nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_ff79dec4-fb9f-486e-9f75-b454ddc5303c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_daa15d0b-bd94-431b-80c9-c48bcca61ee6" xlink:href="nbx-20250630.xsd#nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_daa15d0b-bd94-431b-80c9-c48bcca61ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_4d1edad4-b952-428a-8f50-79143aa0a489" xlink:href="nbx-20250630.xsd#nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_4d1edad4-b952-428a-8f50-79143aa0a489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_254f5d8b-2dfe-4544-9065-74b87029140b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_254f5d8b-2dfe-4544-9065-74b87029140b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_285fdf42-baaf-43a4-8e89-11cd74aaaef0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_285fdf42-baaf-43a4-8e89-11cd74aaaef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_6e5c2984-251d-4ec2-b3b0-1a8204733c61" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_6e5c2984-251d-4ec2-b3b0-1a8204733c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2fa56876-9505-4348-b722-a45862cc461a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2fa56876-9505-4348-b722-a45862cc461a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_a861f6ec-b126-47f4-942d-fd55ca90d2ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_a861f6ec-b126-47f4-942d-fd55ca90d2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_fb27fd69-5c80-4f46-a450-80ae90b2e05b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_fb27fd69-5c80-4f46-a450-80ae90b2e05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_d44ddf74-34f5-458f-8c68-ffd736b6eef4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_c3722714-3e23-4d8f-98cf-67d518a08876" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_d44ddf74-34f5-458f-8c68-ffd736b6eef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#SharebasedpaymentsScheduleofExpensefromEquityDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_8aff8592-e33c-4d8b-8cda-bb3ae6cfca1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_c0bad435-34b5-4238-b961-5b7ec5bb316f" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_8aff8592-e33c-4d8b-8cda-bb3ae6cfca1e" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_c0bad435-34b5-4238-b961-5b7ec5bb316f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_37556bea-a415-4fe0-a1f5-c389969aef16" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_c0bad435-34b5-4238-b961-5b7ec5bb316f" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_37556bea-a415-4fe0-a1f5-c389969aef16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_37556bea-a415-4fe0-a1f5-c389969aef16" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_80e821f1-4c4e-49d9-bcde-3ffecb5c7b39" xlink:href="nbx-20250630.xsd#nbx_BSPCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:to="loc_nbx_BSPCEMember_80e821f1-4c4e-49d9-bcde-3ffecb5c7b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_f5f6a7c0-63ab-4db0-9c13-34ed38204cd9" xlink:href="nbx-20250630.xsd#nbx_BSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:to="loc_nbx_BSAMember_f5f6a7c0-63ab-4db0-9c13-34ed38204cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_cfb828e7-8bf8-4a95-b144-b2349c4ed4c9" xlink:href="nbx-20250630.xsd#nbx_OSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:to="loc_nbx_OSAMember_cfb828e7-8bf8-4a95-b144-b2349c4ed4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_23575310-8ee1-48bf-9e82-e3fa5b5cc9b9" xlink:href="nbx-20250630.xsd#nbx_AGAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6f82293c-4d70-47af-bda6-5947eeb0d9d4" xlink:to="loc_nbx_AGAMember_23575310-8ee1-48bf-9e82-e3fa5b5cc9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_89607d6f-7c3a-47fa-940c-8a125958f8a9" xlink:href="nbx-20250630.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_c0bad435-34b5-4238-b961-5b7ec5bb316f" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_89607d6f-7c3a-47fa-940c-8a125958f8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8c6c026d-f2b3-455b-a96a-78c77a0d6ae1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_89607d6f-7c3a-47fa-940c-8a125958f8a9" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8c6c026d-f2b3-455b-a96a-78c77a0d6ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetFinancialIncomeLossAbstract_82cf6f57-d1e8-4988-a92a-afa4bd819d53" xlink:href="nbx-20250630.xsd#nbx_NetFinancialIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_e5d6db63-3dee-4fcc-b7c7-ef6ea2660470" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_82cf6f57-d1e8-4988-a92a-afa4bd819d53" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_e5d6db63-3dee-4fcc-b7c7-ef6ea2660470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_616a4472-a76d-4742-8471-9b635d38f4db" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_82cf6f57-d1e8-4988-a92a-afa4bd819d53" xlink:to="loc_ifrs-full_NetForeignExchangeGain_616a4472-a76d-4742-8471-9b635d38f4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_29560abc-3fdc-431d-8876-28060e9bf13f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_82cf6f57-d1e8-4988-a92a-afa4bd819d53" xlink:to="loc_ifrs-full_FinanceIncome_29560abc-3fdc-431d-8876-28060e9bf13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense_f7e6a1f3-35fa-4ba0-ad8f-6e82320f53f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_82cf6f57-d1e8-4988-a92a-afa4bd819d53" xlink:to="loc_ifrs-full_InterestExpense_f7e6a1f3-35fa-4ba0-ad8f-6e82320f53f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DebtAccretionAndDiscountingImpact_0542281c-2384-4dda-8b97-a5e591adf686" xlink:href="nbx-20250630.xsd#nbx_DebtAccretionAndDiscountingImpact"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_82cf6f57-d1e8-4988-a92a-afa4bd819d53" xlink:to="loc_nbx_DebtAccretionAndDiscountingImpact_0542281c-2384-4dda-8b97-a5e591adf686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_eb93f61d-a095-4d98-907d-be5ad3a860c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_82cf6f57-d1e8-4988-a92a-afa4bd819d53" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_eb93f61d-a095-4d98-907d-be5ad3a860c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_e0de9e4e-7122-43c6-b1a3-0687c500f986" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_82cf6f57-d1e8-4988-a92a-afa4bd819d53" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_e0de9e4e-7122-43c6-b1a3-0687c500f986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_04b9215e-e5b1-48d2-8096-56342ae1f621" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_82cf6f57-d1e8-4988-a92a-afa4bd819d53" xlink:to="loc_ifrs-full_FinanceCosts_04b9215e-e5b1-48d2-8096-56342ae1f621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_53118293-f906-45b8-8243-477a489c0667" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_82cf6f57-d1e8-4988-a92a-afa4bd819d53" xlink:to="loc_ifrs-full_FinanceIncomeCost_53118293-f906-45b8-8243-477a489c0667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#NetfinancialincomelossNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetFinancialIncomeLossAbstract_0c0069f8-93a8-4f20-93c1-4d2d631e8c8b" xlink:href="nbx-20250630.xsd#nbx_NetFinancialIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NetFinancialIncomeLossAbstract_0c0069f8-93a8-4f20-93c1-4d2d631e8c8b" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_a351faf5-3d5f-4476-b2fd-47a0c9de6e2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_a351faf5-3d5f-4476-b2fd-47a0c9de6e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_8aaa9c80-6bc3-44c1-b806-630b4a32a90e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a351faf5-3d5f-4476-b2fd-47a0c9de6e2e" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_8aaa9c80-6bc3-44c1-b806-630b4a32a90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_5cc99bcc-f0a8-4287-b179-15ec70a2d093" xlink:href="nbx-20250630.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_8aaa9c80-6bc3-44c1-b806-630b4a32a90e" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_5cc99bcc-f0a8-4287-b179-15ec70a2d093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_fd0285d8-e44e-40b7-bab8-f0feb762b188" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_fd0285d8-e44e-40b7-bab8-f0feb762b188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_a653a2f2-2c8a-4296-9eb5-fa6c3e406458" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_fd0285d8-e44e-40b7-bab8-f0feb762b188" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_a653a2f2-2c8a-4296-9eb5-fa6c3e406458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_1ed49683-9b81-41e6-b930-b3d572613895" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain_a653a2f2-2c8a-4296-9eb5-fa6c3e406458" xlink:to="loc_ifrs-full_FixedInterestRateMember_1ed49683-9b81-41e6-b930-b3d572613895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember_7cf7f384-623d-445b-8adb-92ca27d4ff00" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain_a653a2f2-2c8a-4296-9eb5-fa6c3e406458" xlink:to="loc_ifrs-full_FloatingInterestRateMember_7cf7f384-623d-445b-8adb-92ca27d4ff00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_cd222cae-7057-400a-969d-19f4756f7542" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:to="loc_srt_CurrencyAxis_cd222cae-7057-400a-969d-19f4756f7542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_aea10fa0-d2c7-4d8d-ad79-2fad73f3e34b" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_cd222cae-7057-400a-969d-19f4756f7542" xlink:to="loc_currency_AllCurrenciesDomain_aea10fa0-d2c7-4d8d-ad79-2fad73f3e34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_49932dc6-e65b-4521-9e85-1558d6bf836c" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_aea10fa0-d2c7-4d8d-ad79-2fad73f3e34b" xlink:to="loc_currency_USD_49932dc6-e65b-4521-9e85-1558d6bf836c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_d6b47f16-3e1f-43c6-9b82-6f27bc728cd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:to="loc_ifrs-full_CounterpartiesAxis_d6b47f16-3e1f-43c6-9b82-6f27bc728cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_eb72cfe5-a930-4357-8e1d-f4d785df78a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_d6b47f16-3e1f-43c6-9b82-6f27bc728cd4" xlink:to="loc_ifrs-full_CounterpartiesDomain_eb72cfe5-a930-4357-8e1d-f4d785df78a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_HSBCBankMember_5936b05a-aa6f-49d0-873d-e9dad55db38f" xlink:href="nbx-20250630.xsd#nbx_HSBCBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_eb72cfe5-a930-4357-8e1d-f4d785df78a5" xlink:to="loc_nbx_HSBCBankMember_5936b05a-aa6f-49d0-873d-e9dad55db38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_55673d0a-d7f8-43eb-9b1a-cb3210c85cf6" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_193eaf6a-9ce6-4611-8b97-1097b88a34b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_193eaf6a-9ce6-4611-8b97-1097b88a34b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense_dec43031-4a08-406c-8ea8-b87780886cc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_InterestExpense_dec43031-4a08-406c-8ea8-b87780886cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_3754ddcb-1c35-475c-8a9a-2af4d8cca4c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_InterestRevenueExpense_3754ddcb-1c35-475c-8a9a-2af4d8cca4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_e61685a7-2857-4c31-a62f-f329890ce7bd" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_e61685a7-2857-4c31-a62f-f329890ce7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_51615cbb-4a3d-40a2-b312-b7e1cde745e8" xlink:href="nbx-20250630.xsd#nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections_51615cbb-4a3d-40a2-b312-b7e1cde745e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_6969fca9-c344-4b69-bda6-30b36214b22e" xlink:href="nbx-20250630.xsd#nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows_6969fca9-c344-4b69-bda6-30b36214b22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_471f5771-193a-4353-b246-4799f8434027" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_471f5771-193a-4353-b246-4799f8434027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_bcc94433-2ac3-4e6c-962f-d05c552b939d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_bcc94433-2ac3-4e6c-962f-d05c552b939d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_94bb5341-2c6d-4807-88d3-32a00e9d6ecf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_353fa625-4954-4b1e-84d3-ad1c71d945fc" xlink:to="loc_ifrs-full_NetForeignExchangeGain_94bb5341-2c6d-4807-88d3-32a00e9d6ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#LosspershareScheduleofBasicandDilutedLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_b7002ca8-15a9-4957-9c0e-69e84baf6856" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_ba7c6ddd-6ebe-4369-941b-413174d53829" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_b7002ca8-15a9-4957-9c0e-69e84baf6856" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_ba7c6ddd-6ebe-4369-941b-413174d53829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_df104363-76d9-4950-b76f-02fb042fc3f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_b7002ca8-15a9-4957-9c0e-69e84baf6856" xlink:to="loc_ifrs-full_WeightedAverageShares_df104363-76d9-4950-b76f-02fb042fc3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_e5afae06-6039-4b17-be4c-cbde0303ef85" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_b7002ca8-15a9-4957-9c0e-69e84baf6856" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_e5afae06-6039-4b17-be4c-cbde0303ef85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_7ae3fc0d-c00d-4c6c-8361-39de612a5d36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_b7002ca8-15a9-4957-9c0e-69e84baf6856" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_7ae3fc0d-c00d-4c6c-8361-39de612a5d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/LosspershareNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#LosspershareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/LosspershareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_cc5535a0-b2dd-417b-9923-a4143fdb9598" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_a146adc7-dc1a-4d8d-9370-c8fc4c226074" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_cc5535a0-b2dd-417b-9923-a4143fdb9598" xlink:to="loc_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_a146adc7-dc1a-4d8d-9370-c8fc4c226074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#CommitmentsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalCommitmentsAbstract_dccef947-5bde-47f0-a4ca-06d23b2a56a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_020167aa-aeef-4a67-804f-15c87323a266" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CapitalCommitmentsAbstract_dccef947-5bde-47f0-a4ca-06d23b2a56a9" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_020167aa-aeef-4a67-804f-15c87323a266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_e2f64e44-d6a9-425c-9f75-96b03ff97653" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_020167aa-aeef-4a67-804f-15c87323a266" xlink:to="loc_nbx_CollaborationAgreementAxis_e2f64e44-d6a9-425c-9f75-96b03ff97653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_76723cfe-c68e-49f1-83e4-77e433f07c2e" xlink:href="nbx-20250630.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_e2f64e44-d6a9-425c-9f75-96b03ff97653" xlink:to="loc_nbx_CollaborationAgreementDomain_76723cfe-c68e-49f1-83e4-77e433f07c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JanssenPharmaceuticaNVMember_5e01f7b4-38da-43e5-8a59-6bef3747fd1a" xlink:href="nbx-20250630.xsd#nbx_JanssenPharmaceuticaNVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_76723cfe-c68e-49f1-83e4-77e433f07c2e" xlink:to="loc_nbx_JanssenPharmaceuticaNVMember_5e01f7b4-38da-43e5-8a59-6bef3747fd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eef3fb98-9853-4724-92b6-b02269876ce2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_020167aa-aeef-4a67-804f-15c87323a266" xlink:to="loc_srt_ProductOrServiceAxis_eef3fb98-9853-4724-92b6-b02269876ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2dc0fd3-a13d-4d35-a054-eb0a9b730292" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_eef3fb98-9853-4724-92b6-b02269876ce2" xlink:to="loc_srt_ProductsAndServicesDomain_d2dc0fd3-a13d-4d35-a054-eb0a9b730292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NBTXR3Member_b848b660-4ffb-4292-b042-438f3b2dbb61" xlink:href="nbx-20250630.xsd#nbx_NBTXR3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2dc0fd3-a13d-4d35-a054-eb0a9b730292" xlink:to="loc_nbx_NBTXR3Member_b848b660-4ffb-4292-b042-438f3b2dbb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TechnologyTransferAndTechnicalAssistanceMember_f80d879b-f838-45d8-bb74-92911538d992" xlink:href="nbx-20250630.xsd#nbx_TechnologyTransferAndTechnicalAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2dc0fd3-a13d-4d35-a054-eb0a9b730292" xlink:to="loc_nbx_TechnologyTransferAndTechnicalAssistanceMember_f80d879b-f838-45d8-bb74-92911538d992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_8e4e43a3-5032-4405-bf3a-832daa2a9372" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_020167aa-aeef-4a67-804f-15c87323a266" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_8e4e43a3-5032-4405-bf3a-832daa2a9372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_82cc9f01-b9cb-45ab-8fcf-a2ed043334b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_8e4e43a3-5032-4405-bf3a-832daa2a9372" xlink:to="loc_ifrs-full_CurrentTradeReceivables_82cc9f01-b9cb-45ab-8fcf-a2ed043334b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_32e23ac0-c381-419d-b7d7-64e9684051c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_ba98e539-2670-4ca9-9df3-ce05a82c8ce6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_32e23ac0-c381-419d-b7d7-64e9684051c3" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_ba98e539-2670-4ca9-9df3-ce05a82c8ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_fdba14c0-d99c-4db8-aecb-a0553bc1befe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_32e23ac0-c381-419d-b7d7-64e9684051c3" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_fdba14c0-d99c-4db8-aecb-a0553bc1befe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DirectorsRemunerationExpense_fd1ce26f-d9a4-4c9e-bfe1-fd0c24f75b32" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_32e23ac0-c381-419d-b7d7-64e9684051c3" xlink:to="loc_ifrs-full_DirectorsRemunerationExpense_fd1ce26f-d9a4-4c9e-bfe1-fd0c24f75b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_bfdf5e33-cc60-42ac-95b8-e578c0f04462" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_32e23ac0-c381-419d-b7d7-64e9684051c3" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_bfdf5e33-cc60-42ac-95b8-e578c0f04462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RelatedpartiesNarrativeDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RelatedpartiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RelatedpartiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_30984443-6232-4094-83be-20f503b69770" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_28710aca-c6b0-4f68-945a-db639c996f0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_30984443-6232-4094-83be-20f503b69770" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_28710aca-c6b0-4f68-945a-db639c996f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_84068209-cee6-4119-9585-a4718e18cf78" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_28710aca-c6b0-4f68-945a-db639c996f0b" xlink:to="loc_srt_OwnershipAxis_84068209-cee6-4119-9585-a4718e18cf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_392bf8a9-63b6-4f68-98d1-0182f9469758" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_84068209-cee6-4119-9585-a4718e18cf78" xlink:to="loc_srt_OwnershipDomain_392bf8a9-63b6-4f68-98d1-0182f9469758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixCorpMember_34635985-b699-44f9-9892-98339af3153b" xlink:href="nbx-20250630.xsd#nbx_NanobiotixCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_392bf8a9-63b6-4f68-98d1-0182f9469758" xlink:to="loc_nbx_NanobiotixCorpMember_34635985-b699-44f9-9892-98339af3153b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d870c252-2f82-4f60-85fe-7c3fdd172d7e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_28710aca-c6b0-4f68-945a-db639c996f0b" xlink:to="loc_dei_LegalEntityAxis_d870c252-2f82-4f60-85fe-7c3fdd172d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_39982ef1-5aac-4a44-a3c6-3dc8a9495c68" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d870c252-2f82-4f60-85fe-7c3fdd172d7e" xlink:to="loc_dei_EntityDomain_39982ef1-5aac-4a44-a3c6-3dc8a9495c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_JohnsonJohnsonInnovationsMember_b0b0ddef-8c7a-4159-94cc-4de94a8461a3" xlink:href="nbx-20250630.xsd#nbx_JohnsonJohnsonInnovationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_39982ef1-5aac-4a44-a3c6-3dc8a9495c68" xlink:to="loc_nbx_JohnsonJohnsonInnovationsMember_b0b0ddef-8c7a-4159-94cc-4de94a8461a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2a23df68-9c08-45f3-b6a2-d59c3644b8c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_28710aca-c6b0-4f68-945a-db639c996f0b" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2a23df68-9c08-45f3-b6a2-d59c3644b8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_3202342d-f45b-44d4-989e-1bbc338500c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2a23df68-9c08-45f3-b6a2-d59c3644b8c7" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_3202342d-f45b-44d4-989e-1bbc338500c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" xlink:type="simple" xlink:href="nbx-20250630.xsd#RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_65abefdb-276f-4716-ae49-bd0032aa6225" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties_53dead46-746f-42b4-a531-57174e2c53b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_65abefdb-276f-4716-ae49-bd0032aa6225" xlink:to="loc_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties_53dead46-746f-42b4-a531-57174e2c53b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_65b14e33-1a7b-46fc-b805-b4052127e636" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_65abefdb-276f-4716-ae49-bd0032aa6225" xlink:to="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_65b14e33-1a7b-46fc-b805-b4052127e636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetCollectionsPaymentsFromRelatedParty_9a29eeb3-1375-4215-b6df-b7f92e8aa73e" xlink:href="nbx-20250630.xsd#nbx_NetCollectionsPaymentsFromRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_65abefdb-276f-4716-ae49-bd0032aa6225" xlink:to="loc_nbx_NetCollectionsPaymentsFromRelatedParty_9a29eeb3-1375-4215-b6df-b7f92e8aa73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_8cfb4a1d-e5ab-479b-957c-931893bbdd81" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_65abefdb-276f-4716-ae49-bd0032aa6225" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_8cfb4a1d-e5ab-479b-957c-931893bbdd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_ef2862e4-e0ca-4f85-98e2-c25b9f34a058" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_65abefdb-276f-4716-ae49-bd0032aa6225" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_ef2862e4-e0ca-4f85-98e2-c25b9f34a058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetAmountsReceivablePayableRelatedPartyTransactions_02c26ab6-d940-4123-936b-2f74cd4ceba3" xlink:href="nbx-20250630.xsd#nbx_NetAmountsReceivablePayableRelatedPartyTransactions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_65abefdb-276f-4716-ae49-bd0032aa6225" xlink:to="loc_nbx_NetAmountsReceivablePayableRelatedPartyTransactions_02c26ab6-d940-4123-936b-2f74cd4ceba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NANOBIOTIX S.A.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line</a></td>
<td class="text">60 rue de Wattignies<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Paris<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">FR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001760854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">&#8364; 13<span></span>
</td>
<td class="nump">&#8364; 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">4,863<span></span>
</td>
<td class="nump">5,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">5,284<span></span>
</td>
<td class="nump">5,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">9,234<span></span>
</td>
<td class="nump">8,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">28,818<span></span>
</td>
<td class="nump">49,737<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">39,889<span></span>
</td>
<td class="nump">61,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">45,174<span></span>
</td>
<td class="nump">67,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Premiums related to share capital</a></td>
<td class="nump">312,743<span></span>
</td>
<td class="nump">312,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(228)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserve</a></td>
<td class="num">(378,217)<span></span>
</td>
<td class="num">(312,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod', window );">Net loss for the period</a></td>
<td class="num">(5,383)<span></span>
</td>
<td class="num">(68,132)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="num">(68,952)<span></span>
</td>
<td class="num">(65,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Non-current provisions</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">46,505<span></span>
</td>
<td class="nump">45,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current refund liabilities</a></td>
<td class="nump">4,105<span></span>
</td>
<td class="nump">27,778<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">51,089<span></span>
</td>
<td class="nump">74,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Current provisions</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">4,735<span></span>
</td>
<td class="nump">4,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payables and other payables</a></td>
<td class="nump">11,639<span></span>
</td>
<td class="nump">20,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities', window );">Deferred income</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current contract liabilities</a></td>
<td class="nump">36,172<span></span>
</td>
<td class="nump">18,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Current refund liabilities</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">7,835<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">63,037<span></span>
</td>
<td class="nump">58,935<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">114,126<span></span>
</td>
<td class="nump">133,122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">&#8364; 45,174<span></span>
</td>
<td class="nump">&#8364; 67,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for refunds. [Refer: Refunds provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity&#8217;s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarningsProfitLossForReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">&#8364; 24,928<span></span>
</td>
<td class="nump">&#8364; 6,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">3,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenues and other income</a></td>
<td class="nump">26,638<span></span>
</td>
<td class="nump">9,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(14,529)<span></span>
</td>
<td class="num">(21,987)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="num">(11,294)<span></span>
</td>
<td class="num">(10,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating incomes and expenses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="num">(25,829)<span></span>
</td>
<td class="num">(32,941)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income (loss)</a></td>
<td class="nump">808<span></span>
</td>
<td class="num">(23,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">3,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(6,831)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Financial income (loss)</a></td>
<td class="num">(6,186)<span></span>
</td>
<td class="nump">1,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (5,383)<span></span>
</td>
<td class="num">&#8364; (21,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share (in euro per share)</a></td>
<td class="num">&#8364; (0.11)<span></span>
</td>
<td class="num">&#8364; (0.46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share (in euro per share)</a></td>
<td class="num">&#8364; (0.11)<span></span>
</td>
<td class="num">&#8364; (0.46)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (5,383)<span></span>
</td>
<td class="num">&#8364; (21,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains and losses on retirement benefit obligations (IAS 19)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome', window );">Tax impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive loss that will not be reclassified subsequently to income or loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax', window );">Currency translation adjustment</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome', window );">Tax impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive loss that may be reclassified subsequently to loss</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">&#8364; (5,409)<span></span>
</td>
<td class="num">&#8364; (21,874)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to exchange differences on the translation of financial statements of foreign operations. [Refer: Other comprehensive income; Reserve of exchange differences on translation]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to remeasurements of defined benefit plans. [Refer: Other comprehensive income; Reserve of remeasurements of defined benefit plans; Defined benefit plans [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED STATEMENT OF CONSOLIDATED CHANGES IN SHAREHOLDERS&#8217; EQUITY - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share capital Ordinary shares</div></th>
<th class="th"><div>Premiums related to share capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Reserve</div></th>
<th class="th"><div>Net loss for the period</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at beginning of period (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,133,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period at Dec. 31, 2023</a></td>
<td class="num">&#8364; (1,843)<span></span>
</td>
<td class="nump">&#8364; 1,414<span></span>
</td>
<td class="nump">&#8364; 312,742<span></span>
</td>
<td class="nump">&#8364; 738<span></span>
</td>
<td class="num">&#8364; (228)<span></span>
</td>
<td class="num">&#8364; (276,810)<span></span>
</td>
<td class="num">&#8364; (39,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Changes in equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(21,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation adjustments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations', window );">Actuarial gains and losses (IAS 19)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">(21,874)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings', window );">Allocation of prior period loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,700)<span></span>
</td>
<td class="nump">39,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity', window );">Subscription of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payment</a></td>
<td class="nump">1,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,426,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Jun. 30, 2024</a></td>
<td class="num">(21,777)<span></span>
</td>
<td class="nump">&#8364; 1,423<span></span>
</td>
<td class="nump">312,743<span></span>
</td>
<td class="nump">736<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="num">(314,578)<span></span>
</td>
<td class="num">(21,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Changes in equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Capital increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at beginning of period (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,426,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period at Dec. 31, 2024</a></td>
<td class="num">(65,704)<span></span>
</td>
<td class="nump">&#8364; 1,423<span></span>
</td>
<td class="nump">312,743<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="num">(312,221)<span></span>
</td>
<td class="num">(68,132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Changes in equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(5,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,383)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation adjustments</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations', window );">Actuarial gains and losses (IAS 19)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">(5,409)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings', window );">Allocation of prior period loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,132)<span></span>
</td>
<td class="nump">68,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity', window );">Subscription of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payment</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,236,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Jun. 30, 2025</a></td>
<td class="num">&#8364; (68,952)<span></span>
</td>
<td class="nump">&#8364; 1,447<span></span>
</td>
<td class="nump">&#8364; 312,743<span></span>
</td>
<td class="nump">&#8364; 686<span></span>
</td>
<td class="num">&#8364; (228)<span></span>
</td>
<td class="num">&#8364; (378,217)<span></span>
</td>
<td class="num">&#8364; (5,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Changes in equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Capital increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">809,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income, Before Tax, Gains (Losses) on Actuarial Gains and Losses on Retirement Benefit Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (5,383)<span></span>
</td>
<td class="num">&#8364; (21,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Elimination of other non-cash, non-operating income and expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Provisions</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Expenses related to share-based payments</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">1,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Cost of net debt</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment', window );">Loss on disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities', window );">Impact of discounting financial liabilities and amortized cost</a></td>
<td class="nump">2,365<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other non cash income and expenses</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ImpactOfAmendmentOnProfitOrLoss', window );">Impact of the Janssen amendment on profit or loss</a></td>
<td class="num">(19,823)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows from (used in) operations, before tax and changes in working capital</a></td>
<td class="num">(18,873)<span></span>
</td>
<td class="num">(17,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities', window );">Tax Paid</a></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement', window );">Cash flow from (used in) operating activities after tax and before changes in working capital</a></td>
<td class="num">(19,077)<span></span>
</td>
<td class="num">(18,084)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">(Increase) / Decrease in trade receivables</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax', window );">Receipt of research tax credit receivable</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables', window );">(Increase) / Decrease in other receivables</a></td>
<td class="num">(620)<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase / (Decrease) in trade and other payables</a></td>
<td class="nump">1,293<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities', window );">Increase / (Decrease) in other current liabilities</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities', window );">Increase in deferred revenues and contract liabilities</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">13,671<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Changes in operating working capital</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="nump">12,248<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flows from (used in) operating activities</a></td>
<td class="num">(17,411)<span></span>
</td>
<td class="num">(5,836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from (used in) investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of intangible assets</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities', window );">(Increase) / Decrease in non-current financial assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flows from (used in) investing activities</a></td>
<td class="num">(162)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from (used in) financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Increase in loans and conditional advances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Loans repayments</a></td>
<td class="num">(1,926)<span></span>
</td>
<td class="num">(1,525)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="num">(568)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(336)<span></span>
</td>
<td class="num">(609)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flows from (used in) financing activities</a></td>
<td class="num">(2,830)<span></span>
</td>
<td class="num">(2,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rates changes on cash</a></td>
<td class="num">(515)<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(20,919)<span></span>
</td>
<td class="num">(8,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Net cash and cash equivalents at beginning of period</a></td>
<td class="nump">49,737<span></span>
</td>
<td class="nump">75,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Net cash and cash equivalents at end of period</a></td>
<td class="nump">&#8364; 28,818<span></span>
</td>
<td class="nump">&#8364; 66,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in derivative financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for income taxes paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Decrease (Increase) In Other Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow From Operating Activities After Tax And Before Change In Working Capital Requirement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ImpactOfAmendmentOnProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of Amendment on Profit or Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ImpactOfAmendmentOnProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract', window );"><strong>Disclosure Of Information Related To The Company [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock', window );">Company information</a></td>
<td class="text">COMPANY INFORMATION <div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nanobiotix, a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> registered with the Paris registry of trade and companies under number 447 521 600 and having its registered office at 60 rue de Wattignies, 75012, Paris (&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nanobiotix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221; and, with its subsidiaries, the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Group</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;), is a late-stage clinical biotechnology company pioneering disruptive, nanophysics-based therapeutic approaches to the treatment of cancer and other major diseases with the express intent of favorably  impacting the lives of millions of patients.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The Company also has subsidiaries in Cambridge, Massachusetts (United States), Spain, and Germany. The Group has been listed on Euronext: Paris under the ticker symbol &#8220;NANO&#8221; since 2012 (ISIN: FR0011341205, Bloomberg Code: NANO:FP) and on the Nasdaq Global Select Market in the United States under the ticker symbol &#8220;NBTX&#8221; since December 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Group is the owner of more than 25 patent families associated with three nanotechnology platforms: 1) radioenhancer platform, from which JNJ-1900 (NBTXR3) is the first product candidate, designed to physically destroy tumor cells locally and prime immune response systemically; 2) Curadigm nanoprimer platform designed to redefine the design and application of therapeutic classes challenged by liver clearance; and 3) OOcuity neurological disease program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s efforts are concentrated on advancing JNJ-1900 (NBTXR3).</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant events of the period</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Amendment to the Janssen agreement</span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">An amendment of the Janssen Agreement has been signed as of March 17, 2025 with Janssen; this amendment of the global licensing agreement partially removes the Company&#8217;s funding obligation for NANORAY-312 and releases Janssen from select future milestone payments, while facilitating the Company&#8217;s path to sustainable cash flow through significant potential milestone payments over the next few years.</span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total expected payments under the agreement related to the Janssen Agreement is adjusted from approximately $2.7&#160;billion to approximately $2.6&#160;billion:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Revisions to potential future milestone payments in the amendment total $105&#160;million while maintaining eligibility to hundreds of millions in the next 2-3 years potential milestone payments related to the first two programs (cisplatin-ineligible head and neck cancer and stage 3 unresectable lung cancer), </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Beyond the hundreds of millions of the next 2-3 years potential milestone payments for the first two programs to the extent JNJ-1900 (NBTXR3) will hit the related milestone events , the remainder of the $2.6&#160;billion is related to medium-to-long-term potential development, regulatory, and sales milestones for the first two programs and potential payments for new indications that may be developed by Janssen, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">There are no changes to the potential $220&#160;million per new indication that may be developed by Nanobiotix, and potential royalties expected from commercial sales of JNJ-1900 (NBTXR3) remain in the low 10s to low 20s. Potential payments for new indications that may be developed by the Company are in addition to the $2.6&#160;billion deal value, next to potential related royalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The amendment provides that Janssen will assume almost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">full financial responsibility for NANORAY-312, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">the ongoing pivotal Phase 3 trial through completion,, less a small portion of costs that will remain covered by the Company, allowing the Company to strengthen its financial position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For further details, see Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenues and other Income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Information Related To The Company [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfInformationRelatedToTheCompanyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of notes and other explanatory information as part of a complete set of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General information, statement of compliance and basis of presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract', window );"><strong>General Information, Statement of Compliance and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General information, statement of compliance and basis of presentation</a></td>
<td class="text">General information, statement of compliance and basis of presentation<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements as of June&#160;30, 2025 and for the six-month period ended June&#160;30, 2025 were prepared under the supervision of the management of the Company and were submitted by the Executive Board to the review of the Supervisory Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All amounts in the unaudited interim condensed consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated  financial statements of the Company have been prepared in compliance with IAS 34 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Interim Financial Reporting&#8221; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which provides for the presentation of selected explanatory notes. As they are unaudited interim condensed consolidated  financial statements, the accompanying notes do not contain all the disclosures required for annual consolidated financial statements and should therefore be read in conjunction with the Company&#8217;s consolidated financial statements prepared in accordance with IFRS &#174; Accounting Standards, as of and for the year ended December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of the unaudited interim condensed consolidated financial statements in accordance with IAS 34 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Interim Financial Reporting&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> requires the use of estimates and assumptions that affect the amounts and information disclosed in the condensed consolidated financial statements. See Note 3.2 Use of judgement, estimates and assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June&#160;30, 2025 are identical to those used for the year ended December&#160;31, 2024 except for the standards listed below that required adoption in 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2025 in the European Union primarily concern:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.47pt">Amendment to IAS 21 Lack of Exchangeability, the Effects of Changes in Foreign Exchange Rates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">This amendment had no material impact on the Company&#8217;s unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable are:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">Amendments to IFRS 9 and IFRS 7 &#8211; Classification and Measurement of Financial Instruments &#8211; as of January 1, 2026</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">Amendments to IFRS 9 and IFRS 7 &#8211; Contracts Referencing Nature-dependent Electricity &#8211; as of January 1, 2026</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">Annual Improvements to IFRS Accounting Standards, as of January 1, 2026&#8211; Amendments to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 1 First-time Adoption of International Financial Reporting Standards;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 9 Financial Instruments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 10 Consolidated Financial Statements; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IAS 7 Statement of Cash flows</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">New standard &#8211; IFRS 18 &#8211; Presentation and Disclosure in Financial Statements &#8211; as of January 1, 2027</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">New standard &#8211; IFRS 19 &#8211; Subsidiaries without Public Accountability: Disclosures&#8211; as of January 1, 2027</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company is currently assessing the applicability and impact of these new standards, interpretations and amendments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Seasonality of the Company&#8217;s activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">According to IAS 34 &#8211; &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;, an entity whose business is highly seasonal should present financial information for the twelve months up to the end of the interim period and additional comparative information for the prior twelve-month period in the interim condensed consolidated financial statements in order to provide a better understanding and comparison of its interim consolidated financial statements. </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As mentioned in Note 16 Revenue and other income, as most of the income from the Company is generated by ongoing contracts that primarily depend on performance obligations not correlated to seasonal trends, it is considered that the Company activities are not seasonal. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Therefore, the following unaudited interim condensed consolidated financial statements and corresponding notes will not include comparative information other than that mentioned in IAS 34.20.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and payment of research tax credit (CIR) receivables. The Company continues to pursue its research and development activities for its product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning multiple years. The Company does not expect to generate revenue from product sales in the near future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In March 2025, the Company and Janssen executed an amendment to the License Agreement. The amendment provides that Janssen will assume almost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">full financial responsibility for NANORAY-312</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, the ongoing pivotal Phase 3 trial through completion, less a small portion of costs that will remain covered by the Company, allowing the Company to extend its cash runway and to reduce its operating cash outflows post this amendment, including the period beyond mid-2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of June 30, 2025, the Company had &#8364;28.8&#160;million of available cash and cash equivalents, consisting of cash and short-term bank deposits that are liquid and easily convertible within 3 months without penalty or risk of change in value (see Note 9. &#8211; Cash and cash equivalents).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of the date of authorization of the issuance of these interim condensed consolidated financial statements, the Company estimates, given its current cost structure and its projected expenditure commitments, that it should have sufficient funds to finance its activities into mid-2026. Accordingly, the Company&#8217;s current cash and cash equivalents will not be sufficient to cover its operating needs for at least the next 12 months following the date of the issuance of these financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on its current business plan, the Company estimates that to meet its obligations over the next 12 months, it will require additional liquidity in the range of &#8364;8 to &#8364;10&#160;million. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company&#8217;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This estimate is based on the Company&#8217;s current business plan and excludes (i) other expenses resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing. The Company may have based this estimate on incorrect assumptions and may have to use its resources sooner than anticipated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">To finance its activities beyond mid-2026, the Co</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">mpany needs to raise additional funds and is in active discussions regarding non-dilutive financing, intended to meaningfully extend its c</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">ash runway beyond the 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In addition, further to the current discussions, the Company may seek to raise additional funds to achieve its development goals for its research and development programs through: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">other potential public or private securities offerings, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">potential strategic transactions such as business development partnerships; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">R&amp;D project subsidies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on the above, the interim condensed consolidated financial statements as of and for the six-month period ended June 30, 2025, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future and to address its liquidity challenges by pursuing activities to generate additional cash inflows and by closely managing its operating expenditures. As such, they do not include any adjustments related to the value or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company cannot guarantee that it will be able to obtain the necessary financing, through any of the foregoing measures or otherwise, to meet its needs or to obtain funds at acceptable terms and conditions, on a timely basis, or at all, especially considering the generally challenging environment for financing of biotech companies. If the Company is unable to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any approved product or be unable </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">to expand its operations or otherwise capitalize on its business opportunities, as desired, which would impair the Company&#8217;s prospects and business operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 128<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_128&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General Information, Statement of Compliance and Basis of Presentation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated principles and methods<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">Consolidated principles and methods</a></td>
<td class="text">Consolidated principles and methods<div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">3.1 BASIS OF CONSOLIDATION</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Consolidated entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the consolidation scope is comprised of one parent entity and is similar to that of December&#160;31, 2024 as Nanobiotix S.A. has three wholly owned subsidiaries: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Nanobiotix Corp., incorporated in the State of Delaware in September 2014 and located in the USA,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Nanobiotix Germany GmbH, created in October 2017 and located in Germany,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Nanobiotix Spain S.L.U., created in December 2017 and located in Spain.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accordingly, the unaudited interim condensed consolidated financial statements as of June&#160;30, 2025 include the operations of each of these subsidiaries, to the extent applicable, from the date of their incorporation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements are presented in thousands of euros, which is the Group&#8217;s presentation currency and the functional currency of the parent company, Nanobiotix S.A. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate for the statement of financial position, whereas, items of the statement of operations, statement of comprehensive loss and statement of cash flow are converted at the average exchange rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The dollar-to-euro exchange rate used in the unaudited interim condensed consolidated financial statements to convert the Group transactions denominated in US dollars were a closing of $1.1720 as of June&#160;30, 2025 and an average of $1.0930 for the six-month period ended June&#160;30, 2025 compared with $1.0705 and $1.0812 respectively, as of and for the six-month period ended June&#160;30, 2024 (source: Banque de France).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">3.2. USE OF JUDGEMENT, ESTIMATES AND ASSUMPTIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed consolidated financial statements in accordance with IAS 34 requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. A sensitivity analysis may be presented if the results differ materially based on the application of different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the measurement of financial instruments (fair value and amortized costs).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Measurement of share-based payments </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures the fair value of stock options (OSA), founders&#8217; warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Executive and Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., option vesting terms) and market data (e.g., to determine expected share volatility) (See Note 18 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-based payments</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Deferred tax assets </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company&#8217;s assets and liabilities that appear in its financial statements. The primary source of deferred tax assets are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow for sufficiently reliable income projections to be made, the Company has not recognized deferred tax assets in relation to tax losses carry forwards in the statements of consolidated financial position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial accruals </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clinical trial expenses, although not yet billed in full, are estimated quarterly for each study and a provision is recognized accordingly. (See Note 14.1 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Trade and other payables</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for information regarding the clinical trial accruals as of June 30, 2025 and December 31, 2024).</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to determine the amount and timing of revenue under the contract with customers, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company, determining the stand alone selling price of the performance obligations, the transaction price allocation and the timing of satisfaction of support services provided to customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Determining the distinctiveness of performance obligations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; A promised good or service will need to be recognized separately in revenue if it is distinct as defined in IFRS 15. In determining whether the performance obligation is separate, the Company analyses if (i) the good or service is distinct in absolute terms, i.e. it can be useful to the customer, either on its own or in combination with resources that the customer can obtain separately; and if (ii) the good or service is distinct in the context of the contract, i.e. it can be identified separately from the other goods and services in the contract because there is not a high degree of interdependence or integration between this element and the other goods or services promised in the contract. If either of these two conditions is not met, the good or service is not distinct, and the Company must group it with other promised goods or services until it becomes a distinct group of goods or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Allocation of transaction price to performance obligations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For contracts with multiple performance obligations, the Company allocates the contract&#8217;s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable consideration</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; Due to the nature of the work required to be performed on many of the Company&#8217;s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration and license agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals). The Company includes the related amounts in the estimated transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue on a cumulative catch&#8209;up basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognized over time and input method</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; Some of the Company&#8217;s performance obligations are satisfied over time as work progresses, thus revenue is recognized over time, using an input measure of progress as it best depicts the transfer of control to the customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contract modification</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. The effect that the contract modification has on the transaction price, and on the entity's measure of progress towards complete satisfaction of the performance obligation, is recognized as an adjustment to revenue at the date of the contract modification (i.e. on a cumulative catch-up basis). The Company is required to use significant judgments with respect to identifying and determining the amended standalone selling price of the performance obligations, the transaction price allocation and the adjusted timing of satisfaction of the remaining services provided to customers.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 16 - to the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2024 for additional detail regarding the Company&#8217;s accounting policies and specific judgments made with regard to revenue recognition, and for its additional sources of revenue and other income.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Measurement of financial assets and liabilities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At the renegotiation date in October 2022, the fair value measurement of the EIB loan required the Company to determine:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">the discount rate of the new liability executed in October 2022. The discount rate reflects the company&#8217;s credit risk at the Amendment Agreement date as well as a premium to reflect uncertainties associated with the timing and the amount of the royalties&#8217; payment. The Company involved external financial instruments valuation specialists to support in determining the average discount rate;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">the amount of additional interest (&#8220;royalties&#8221;, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing upon commercialization. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to annual sales turnover relating to JNJ-1900 (NBTXR3) through specific Company&#8217;s license agreement. For the purpose of measuring the fair value of the EIB loan, the Company forecasts expected sales relating to JNJ-1900 (NBTXR3) during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see Notes 4.4 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financing Agreement with the European Investment Bank (&#8220;EIB&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2024, for details about this loan and the accounting treatment applied).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Subsequent to the estimate of the fair value of the EIB loan performed at the renegotiation date, the debt has been measured at amortized cost based on the revised best estimate of the future cash flows related to the debt at each closing date. Accordingly, the Company determines the amount of additional interest as described above. Any subsequent adjustment of flows indexed to turnover are discounted at the original effective interest rate and the adjustment is recognized in profit or loss under the &#8220;catch-up&#8221; method. As of June 30, 2025, the fair value measurement of the EIB loan has been reassessed by the Company for disclosure purpose.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfSignificantTransactionsTextBlock', window );">Significant transactions</a></td>
<td class="text">Significant transactions<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The significant transactions are those described in the consolidated financial statements prepared in accordance with IFRS &#174; Accounting Standards for the year ended December 31, 2024, except regarding the Janssen Amendment Agreement which was signed on March 17, 2025 and described in Note 1 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Company Information</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues and Other Income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfSignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Significant Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfSignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible assets</a></td>
<td class="text">Intangible assets<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in intangible assets breaks down as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:39.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">734</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">742</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of intangible assets (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(727)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt">Expenses for the period are detailed in Note 17.4 Depreciation, amortization and provisions expenses</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No impairment losses were recognized in application of IAS 36 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Assets</span> in the period presented.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in property, plant and equipment is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">movements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&amp; transfer.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments on tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16,559</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">150</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(108)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(92)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16,504</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,582)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(134)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,716)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,945)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(90)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,035)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of tangible assets(1)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11,021)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(798)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">108</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">65</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11,641)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,538</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(647)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(27)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,863</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.59pt">Expenses for the period are detailed in Note 17.4 Depreciation, amortization and provisions expenses </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No impairment losses were recognized in application of IAS 36 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Assets</span> in the period presented.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Disclosure of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock', window );">Non-current financial assets</a></td>
<td class="text">Non-current financial assets <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in non-current financial assets breaks down as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.122%"><tr><td style="width:1.0%"></td><td style="width:73.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Security <br/>deposits paid</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of Net book value as of December 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">406</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reclassification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">409</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Non-current Financial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and other current assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock', window );">Trade receivables and other current assets</a></td>
<td class="text">Trade receivables and other current assets<div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">8.1 TRADE RECEIVABLES</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,837</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,977</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, trade receivables balance mainly relates to Janssen revenue not yet collected, which is comprised of product supplies for 1.7&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">8.2 OTHER CURRENT ASSETS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets break down as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit receivable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,753</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, &#8364;1.9 million prepaid expenses mainly relate to research agreements with MD Anderson for &#8364;1.1&#160;million as compared to &#8364;1.2&#160;million as of December 31, 2024, &#8364;0.8&#160;million related to invoices received for third party services beyond the current closing period, mainly related to IT, insurance and other invoices related to annual administrative contracts as compared to &#8364;1.1&#160;million as of December 31, 2024, and &#8364;46&#160;thousand related to purchases of clinical product not yet consumed as of closing date as compared to &#8364;0.6&#160;million as of December 31, 2024, this significant decrease is explained by the sales dynamics of clinical products sold.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Other receivables increased by &#8364;0.2&#160;million and mainly comprised of advance payments to suppliers amounting of &#8364;1.3&#160;million as of June&#160;30, 2025, as compared to &#8364;1.1&#160;million as of December&#160;31, 2024. Most of these advance payments have been made to Contract Research Organization (CRO) and to Clinical Services Providers in connection with the execution of the clinical trial NANORAY-312.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research tax credit </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is eligible for the Research Tax Credit - CIR (Cr&#233;dit d&#8217;Imp&#244;t Recherche) issued by the French and U.S. tax authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in research tax credit receivables breaks down as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:84.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,369</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 research tax credit &#8211; Nanobiotix S.A. (1)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,616&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 research tax credit &#8211; Nanobiotix Corp (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receipt of 2024 research tax credit - Nanobiotix Corp</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,792</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See Note 16 - Revenue and other income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Trade Receivables And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text">Cash and cash equivalents<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalent break down as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and bank accounts</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term bank deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net Cash and cash equivalents</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">28,818</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">49,737</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, net cash and cash equivalents decreased by &#8364;20.9&#160;million as compared to December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The short-term bank deposits correspond exclusively to term deposit transactions that have been settled in July 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text">Share Capital<div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">10.1 CAPITAL ISSUED</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Detail of share capital transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands or number of shares)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nature of transaction</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Premiums related to share capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,423</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">312,743</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">47,426,851</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 27, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase AGA 2023-P1 and AGA 2023-P2</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">809,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,447</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">312,743</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">48,236,671</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the share capital was &#8364;1,447&#160;thousand divided into 48,236,671</span><span style="background-color:#ffffff;color:#202124;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">fully paid up ordinary shares, each with a par value of &#8364;0.03.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Allocation of prior period (loss)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The negative net result for the year 2023 of &#8364;68.1&#160;million has been fully allocated to reserves.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">10.2 FOUNDER&#8217;S WARRANTS, WARRANTS, STOCK OPTIONS AND FREE SHARES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, there are three different types of securities and other valid instruments entitling their holders to a stake in the Company's share capital: warrant (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">bons de souscription d&#8217;actions</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> or BSA), founders&#8217; warrant (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">bons de souscription de parts de cr&#233;ateur d&#8217;entreprise</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> or BSPCE) and stock option (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">options de souscription ou d&#8217;achat d&#8217;actions</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> or OSA).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At a meeting on February 18, 2025, the Executive Board, acting pursuant to delegations granted by the Company&#8217;s shareholders&#8217; meeting held on May 28, 2024, granted to certain employees of the Group 8,000 stock options, each giving its holder the right to subscribe one ordinary share, each with a par value of &#8364;0.03 and at a price of &#8364;3.36 (share premium included). Such stock options are governed by the 2025 stock option plan, adopted by the Executive Board on February 18, 2025 (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025 Stock Option Plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ordinary stock options are exercisable as follows:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt">up to one-third of the ordinary stock options as from February 18, 2026;</span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;      an additional one-third of the ordinary stock options as from February 18, 2027,</span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;      the balance, i.e., one-third of the ordinary stock options as from February 18, 2028,</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">subject to, for each increment, a continued service condition, and in any case, no later than 10 years after the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At a meeting on May 16, 2025, the Executive Board, acting pursuant to delegations granted by the Company&#8217;s shareholders&#8217; meeting held on May 28, 2024,, granted to certain employees of the Group and members of the Executive Board 1,241,005 stock options, each giving its holder the right to subscribe one ordinary share, each with a par value of &#8364;0.03 and at a price of &#8364;2.97 (share premium included). Such stock options are governed by the 2025 Stock Option Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ordinary stock options are exercisable as follows:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt">up to one-third of the ordinary stock options as from May 16, 2026;</span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;      an additional one-third of the ordinary stock options as from May 16, 2027,</span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;      the balance, i.e., one-third of the ordinary stock options as from May 16, 2028,</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">subject to, for each increment, a continued service condition, and in any case, no later than 10 years after the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Free Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No free shares were granted in the first half of 2025.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the assumptions related to the estimated vesting of the founders&#8217; warrants, the warrants and performance stock options have been updated (See Note 18 Share-based payments).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Obligations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_RetirementObligationAbstract', window );"><strong>Retirement Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Retirement Obligations</a></td>
<td class="text">Retirement Obligations<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:25.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lump-sum retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Non-current provisions</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">432</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">47</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">479</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assumptions used to measure lump-sum retirement benefits as of June 30, 2025 remain unchanged from the assumptions used as of December 31, 2024. See Note 11 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Retirement Obligations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the consolidated financial statements as of and for the period ended December 31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_RetirementObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retirement Obligation [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_RetirementObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionsExplanatory', window );">Provisions</a></td>
<td class="text">Provisions<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:29.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(230)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(90)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current provisions </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">438</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">49</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(320)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt">See Note 17.4 Depreciation, amortization and provision expenses for the nature of these decreases </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes exclusively include ongoing employee disputes. The &#8364;0.2&#160;million net decrease recorded in the first half of 2025 resulted from the settlement of disputes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock', window );">Financial liabilities</a></td>
<td class="text">Financial liabilities <div style="padding-left:72pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">13.1 DETAILS OF FINANCIAL LIABILITIES </span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Short term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE loans *</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,735</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,924</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Long term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE loans *</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">46,505</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">45,978</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">51,240</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">50,902</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(*)&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">The table below shows the detail of changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.434%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands of euros)</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Liabilities</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Repayable BPI Loan Advances</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PGE Loans</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EIB Loan</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance advance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Curadigm Bpi advance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HSBC<br/>&#8220;PGE&#8221;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance<br/>&#8220;PGE&#8221;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,230</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">342</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,891</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,198</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">40,635</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">50,902</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal received</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in loans and conditional advances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,927)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows used in<br/>financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(637)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(600)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(75)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(638)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(233)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indexation effect on current lease commitment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of discounting and catch-up</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,031)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash from financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">38</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,083</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,169</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,632</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,019</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">275</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,260</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,569</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">43,484</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">51,240</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Of which Current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,247</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">438</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">97</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,260</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,262</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">430</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,735</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Of which Non-Current</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,385</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">581</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">178</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">307</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">43,054</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">46,505</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lease Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities correspond to the discounted amount of the rentals to be paid over the lease terms for all outstanding contracts falling within the scope of IFRS 16. For the period presented, the main contracts relate to the buildings rented in Paris and in Villejuif</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Repayable BPI loan advances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company received repayable advance from Banque Publique d&#8217;Investissement (&#8220;Bpifrance&#8221;, formerly known as &#8220;OSEO Innovation&#8221;). The advance bears 1.56% interest. The repayment of the period amounts to &#8364;0.6&#160;million while the amount to be reimbursed corresponds to &#8364;1.0&#160;million (as detailed in table Note 13.2 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Due dates of the financial liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below)</span><span style="background-color:#ffffff;color:#ff0090;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2020, the Company obtained a &#8364;0.5&#160;million conditional advance from Bpifrance, &#8364;0.4&#160;million of which was received at the signature date. The advance is interest-free. The repayment of the period amounts to &#8364;0.1&#160;million while the amount to be reimbursed corresponds to &#8364;0.3&#160;million (as detailed in table Note 13.2 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Due dates of the financial liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">PGE loan (&#8220;Pr&#234;ts Garantis par l&#8217;Etat&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company announced in June 2020 that it has received approval for financing from both HSBC and Bpifrance for &#8364;5&#160;million each in the form of state-guaranteed loans (&#8220;Pr&#234;ts Garantis par l&#8217;Etat&#8221;, or &#8220;PGE&#8221; in France).</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This loan is booked at amortized cost using an effective interest rate of 0.31%. Reimbursement of the loan started in September 2022 and will continue through mid-2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2025, &#8364;0.6&#160;million was repaid on the HSBC PGE loan.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 10, 2020, the Company entered into the second &#8364;5&#160;million PGE loan with Bpifrance (the &#8216;&#8216;Bpifrance PGE Loan&#8217;&#8217;). The Bpifrance PGE loan has a 6-year term and is 90% guaranteed by the French State. Starting after its first year anniversary, the Bpifrance PGE loan bears an interest rate of 2.25% per annum, inclusive of an annual State guarantee fee of 1.61% per annum. The principal and interest of the Bpifrance PGE loan is being reimbursed in 20 quarterly installments as from October 31, 2021 through July 26, 2026. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2025, &#8364;0.6&#160;million was repaid on the Bpifrance PGE loan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">EIB loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the Company accounted for the debt at amortized cost using the original  effective interest rate (&#8220;EIR&#8221;) of 21.3% and adjusting the estimated debt outflows in accordance with the revised forecasts of annual sales turnover relating to JNJ-1900 (NBTXR3) through specific Company&#8217;s license agreement (value and timing).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The EIB loan amounts to &#8364;43.5&#160;million as of June 30, 2025 compared to &#8364;40.6&#160;million as of December 31, 2024. The increase of &#8364;2.8&#160;million over the six months ended June 30 2024 comprises:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Fixed and variable interest expenses accrual for an amount of &#8364;4.1&#160;million which are partially offset by</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the interest repayments of  &#8364;0.2&#160;million in accordance with the repayment schedule </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the P&amp;L net positive impact of accretion and discounting on EIB loan of &#8364;1.0&#160;million corresponding to : </span></div><div style="padding-left:36pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(i) the decrease in estimated debt outflows beyond 2024 - before discounting effect - for &#8364;2.4&#160;million positive P&amp;L effect</span></div><div style="padding-left:36pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(ii) partially offset by - &#8364;1.4&#160;million of discounting negative effect). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025 the fair value of the debt is estimated at &#8364;46.5&#160;million</span><span style="background-color:#ffffff;color:#2d2d2d;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company estimated the fair value of the debt using the same methodology as the one performed at renegotiation date. In doing so, the Company kept the same assumption of CCC credit rating. However, essentially because of a increase in spreads observed as of June 30, 2025 (compared to December 2024), the estimated fair market rate was estimated at 19.2%.</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">13.2 DUE DATES OF THE FINANCIAL LIABILITIES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The due dates for repayment of the financial liabilities at their nominal value and including fixed rate interests and future variable interest payments have been estimated based on the milestone and royalties forecasts at the reporting date are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:28.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1&#160;year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and <br/>3&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 3 and <br/>5&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5 years</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curadigm interest-free Bpifrance advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HSBC &#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance &#8220;PGE&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">314&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,589&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB fixed rate loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,707&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,831</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">24,843</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">45,781</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">30,366</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">105,822</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Company plans according to contractual terms to reimburse the two &#8220;PGE&#8221; (&#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; or state-guaranteed loans) from HSBC and BPI over 5 years with a deferral of 1 year (last reimbursement being in 2026).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:28.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1&#160;year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and <br/>3&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 3 and <br/>5&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5 years</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curadigm interest-free Bpifrance advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HSBC &#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance &#8220;PGE&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,289&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB fixed rate loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,210</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">24,689</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">41,725</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">39,412</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">111,036</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Company plans according to contractual terms to reimburse the two &#8220;PGE&#8221; (&#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; or state-guaranteed loans) from HSBC and BPI over five years with a deferral of 1 year (last reimbursement being in 2026).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The debt obligations indicated above relate to the fixed and variable rate interests and principal payable on repayable advances, the interest-free Bpifrance loan, EIB loan, PGE loans and the lease liabilities. These amounts reflect the committed amounts under those contracts as of June&#160;30, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the table above indicates that the EIB loan's total expected cash outflows (undiscounted) is &#8364;97.8 million, which includes :</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">&#8364;33.7&#160;million for the principal and fixed rate interest to be paid over the term of the loan,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">&#8364;19.0&#160;million remaining milestones to be prepaid under the following mechanisms: </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">should the company secure future non-dilutive capital through the execution of any business development deal, an accelerated redemption of this milestone payment would be triggered resulting in a prorated payment amount not exceeding 10% of any upfront or milestone payment received by the Company; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">should the Company contract future equity or debt financing transactions which will require prepayments equal to a tiered low single digit percentage of raising up to an aggregate of &#8364;100&#160;million, on a cumulative basis, increasing to a mid-single digit percentage for such financings greater than &#8364;100&#160;million.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">&#8364;45.1&#160;million for the estimated royalty payments to be made in the future, based on the forecasted sales expected to be generated by the Company&#8217;s partners during the six-year period beginning upon JNJ-1900 (NBTXR3) commercialization. (See Notes 4.4 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financing Agreement with the European Investment Bank (&#8220;EIB&#8221;) and 13.1 - Conditional advance, bank loan and loans from government and public authorities in the consolidated financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2024).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Financial Liabilities Footnote</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock', window );">Trade payables and other current liabilities</a></td>
<td class="text">Trade payables and other current liabilities<div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">14.1 TRADE AND OTHER PAYABLES</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses - clinical trials</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total trade and other payables</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11,639</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">20,036</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables are not discounted, as none of the amounts has a maturity date above one year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accrued Expenses related to clinical trials balance decreased by &#8364;8.1&#160;million between December 31, 2024 and June 30, 2025. This decrease is mainly explained by (i) the NANORAY-312 development in 2025, amounting to a &#8364;1.8&#160;million accrual as of June 30, 2025, compared to the 11.1&#160;million accrual as of December 31, 2024. This reduction reflects  the amendment letter signed in March 2025, removing the Company&#8217;s funding obligations for the 312 study in the frame of the transfer of sponsorship to Janssen; partially offset by (ii) the study 1100 development, increasing to a &#8364;5.3&#160;million accrual as of June 30, 2025, compared to the 4.4&#160;million accrual as of December 31, 2024.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The trade payables and other accruals are quite stable between December 2024 and June 2025. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">14.2 OTHER CURRENT LIABILITIES</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll tax and other payroll liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,543</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll tax and other payroll liabilities primarily consist of payroll taxes and social charges, namely the employer withholdings relating to free shares, as well as accrued bonuses, vacation day accruals and related social charges. Payroll tax and other payroll liabilities have decreased by &#8364;0.5&#160;million during the first half of 2025, mainly due to the payment in the first half of bonuses payable accrued at the previous year-end for &#8364;0.9&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">14.3 DEFERRED INCOME AND CONTRACT LIABILITIES</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities - Current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred income and current contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">36,222</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18,161</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The current contract liabilities are accounted for in accordance with IFRS 15.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current contract liabilities increased by &#8364;18.1&#160;million to &#8364;36.2&#160;million as of June 30, 2025. The initial payment received in 2021 from LianBio was &#8364;16.5&#160;million was recognized as a contract liability since the delivery of the related performance obligation has not yet commenced. The increase of &#8364;18.1&#160;million results from the combined effects of the amendments on the Janssen License Agreement and the Asia Licensing Agreement (formerly Lianbio) in the allocation of the constrained transaction price (See Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues and other income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">14.4 REFUND LIABILITIES</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current refund liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current refund liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Refund liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,378</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">35,613</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The refund liability, recognized as of December 2024, reflects the refund obligation related to the amendments of the Janssen Agreement, signed in the fourth quarter of 2024.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the refund liabilities decreased by &#8364;28.2&#160;million according to the amendment of the Janssen Agreement, signed on March 17, 2025.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These amendments were accounted for as a contract modification under IFRS 15, and resulted in a change in the transaction price, as well as a change in scope of the performance obligations, recorded as a cumulative catch-up in the statement of consolidated operations and refund liabilities in the consolidated statement of financial position. (Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues and other income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Trade Payables And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments included in the statement of financial position and impact on income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial instruments included in the statement of financial position and impact on income</a></td>
<td class="text">Financial instruments included in the statement of financial position and impact on income<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Detail of financial instruments included in the statements of financial position and impact on income</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,753&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Total liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62,879</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62,879</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">65,900</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Total liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70,936</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70,936</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">73,402</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Management of financial risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The principal financial instruments held by the Company are instruments classified as cash and cash equivalents. These instruments are managed with the objective of enabling the Company to finance its business activities. The Company's policy is to not use financial instruments for speculative purposes. It does not use derivative financial instruments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The principal financial risks faced by the Company are liquidity, foreign currency exchange, interest rate and credit risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Liquidity risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Liquidity risk arises from the Company&#8217;s financial liabilities and significant expenses related to development and manufacturing of nanotechnology products and conducting clinical studies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company&#8217;s operations have consumed substantial amounts of cash since its inception. Developing pharmaceutical product candidates, including conducting clinical trials, is expensive, lengthy and risky, and the Company expects to continue to incur significant losses in the near term. Accordingly, the Company will continue to </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">require substantial additional capital to continue its clinical development activities and potentially engage in commercialization activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Liquidity risk management aims to ensure that the Company has access to sufficient liquidity and financial resources to be able to meet present and future obligations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company prepares short&#8209;term cash forecasts and annual operating cash flow forecasts as part of its budget procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Prudent liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate credit facilities and being able to unwind market positions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">At the date of these consolidated financial statements, the Company estimates, given its current cost structure and its projected expenditure commitments, to be able to finance its activities into mid-2026 (see Note 2. &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">General information, statement of compliance and basis of presentation</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> for more details).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The functional currency of Nanobiotix S.A. is the euro. Exposure to foreign currency exchange risk is mainly derived from certain of its revenue and bank accounts denominated in U.S dollars. Under the global license Agreement  with Janssen, and the Asia Licensing Agreement (former LianBio contract) the Company has received payments in U.S dollars. Additionally, the Company is also exposed through intragroup transactions between Nanobiotix S.A. and its U.S. subsidiary for which the functional currency is the U.S. dollar, as well as trade relations with customers and suppliers outside the euro zone. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At this stage of its development, the Company does not use hedging to protect its business against exchange rate fluctuations. However, a significant increase in its business activity outside the euro zone could lead to a greater exposure to foreign currency exchange risk as the Company&#8217;s operating capital requirements are mainly denominated in euro. If this occurs, the Company may implement a suitable hedging policy for these risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Credit risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The credit risk related to cash and cash equivalents and to current financial instruments is not material given the rating and size of the relevant financial institutions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s exposure to credit risk chiefly stems from trade receivables related to its customer (Janssen) as of June 30, 2025. Due to the limited number of customers, the Company appropriately monitors its receivables and their payment and clearance. The Company enters into such transactions only with highly reputable, financially sound counterparts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest rate risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's exposure to interest rate risk is primarily related to cash equivalents and investment securities, which consist of term deposits. Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, loans issued by the Company are exclusively fixed rate loans and thus our exposure to interest rate and market risk is deemed low. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable interests on the EIB loan are royalty-based and are not subject to market rate risks.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue and other income</a></td>
<td class="text">Revenue and other income <div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The revenue recognition accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June&#160;30, 2025, are identical to those used for the year ended December&#160;31, 2024, as completed below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Further to the agreements signed during the fourth quarter of 2024 detailing the terms for the transfer of the sponsorship of the ongoing NANORAY-312 Phase 3 pivotal trial in head and neck cancer to Janssen (See Note 16 &#8211; </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenues and other income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> to the consolidated financial statements as of and for the year ended December 31, 2024), the Company signed an amendment letter with Janssen BV on March 17, 2025. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The amendment letter provides that Janssen will ultimately assume nearly all remaining costs for the ongoing pivotal Phase 3 trial through completion, except for a limited portion of costs that will continue to be covered by the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This amendment aims to improve the Company&#8217;s short-term cash runway by:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">reducing its obligation to make payments that were probable in the short term for the ongoing NANORAY-312 Phase 3 pivotal trial development costs; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">revising potential future milestone payments for a total of $105&#160;million under both the Janssen License Agreement and the Asia Licensing Agreement, </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This amendment letter has been considered and accounted for as a contract modification under IFRS 15, which modifies the remaining transaction prices of both Janssen License Agreement and Asia Licensing Agreement, originally treated as separate contracts for IFRS 15 purposes. As there are price interdependencies between the two effects of the amendment as described above, the contract modification has been applied to both agreements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The amendment does not change the scope of the initial contracts but the overall impact of the contract modification is a significant increase in the remaining constrained transaction price of the combined agreements (Janssen Agreement and Asia Licensing Agreement) while the constraint continues to apply to milestone payments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The net positive impact on the constrained transaction price on the Janssen Agreement was recognized as a cumulative catch-up adjustment, as the remaining goods or services under the license agreement are not distinct. As a result, revenue for the six-month period ended June 30, 2025, included a one-off positive impact of &#8364;21.2&#160;million, directly attributable to the contract modification as described above.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 15, the funding obligation towards Janssen was reduced to a net refund liability amounting to &#8364;7.4&#160;million as of June 30, 2025. See Note 14.4 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Refund liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The combined effects of the amendment on the two license agreements resulted also in the allocation of &#8364;18.1&#160;million of the constrained transaction price to the Asia Licensing Agreement, which was recognized as the related contract liability since the delivery of the related performance obligation has not yet commenced. See Note 14.3 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Deferred income and Contract liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Detail of revenue and other income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s revenue and other income per category for the six-month period ended June 30, 2025 and 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">24,928</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,163</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,710</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,126</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenue and other income</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">26,638</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,289</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Revenues</span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the Total Revenue reached &#8364;24.9&#160;million, composed of:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the line &#8216;Services&#8217; includes (i) a one-off positive revenue of &#8364;21.2&#160;million recognized over the six-month period ended June 30, 2025 directly attributable to the contract modification impact occurred during the first half of 2025, that counterbalances the negative revenue impact recognized in fiscal year 2024 : the amendments signed during the last quarter of 2024 had significantly reduced the transaction price of the license agreement as the R&amp;D service performance obligation was replaced with a funding obligation for the Company towards Janssen, while the amendment letter executed in March 2025 did not impact the scope of the Company's performance obligations but increased the remaining transaction price of the global </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">license agreement, (ii) and other &#8216;Services&#8217; revenue linked to technology transfer and technical assistance recharge to Janssen for &#8364;0.4&#160;million. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">&#8364;3.4&#160;million of &#8216;Other Sales&#8217; related to products clinical supplies to Janssen for the six-month period ended June 30, 2025.</span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2024, the &#8364;6.2&#160;million Total Revenue mainly includes (i) &#8216;Services&#8217; revenue linked to the assignment of the license to Janssen and the rendered R&amp;D services in proportion of the completion of the ongoing studies, totaling &#8364;2.7&#160;million; (ii) &#8216;Services&#8217; revenue linked to technology transfer and technical assistance recharge for &#8364;1.1&#160;million; (iii) and &#8364;2.4&#160;million of &#8216;Other Sales&#8217; related to products clinical supplies to Janssen.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research tax credit</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit decreased from &#8364;2.3&#160;million in 2024 to &#8364;1.6&#160;million in 2025 due mainly due to the exclusion of a major vendor from the CIR scope in 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subsidies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidies include the Bpifrance Deep Tech Grant received by the Company, &#8364;67&#160;thousand recognized as other income for the half-year ended June 30, 2025, as compared to &#8364;36&#160;thousand for the half-year ended June 30, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other</span></div>The line item &#8216;Other&#8217; mainly includes income for services recharge, in the framework of the &#8216;GTCA&#8217; totaling &#8364;26 thousand as of June 30, 2025 compared to &#8364;0.5&#160;million for services recharge and &#8364;0.2&#160;million for supply services as of June 30, 2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">Operating expenses</a></td>
<td class="text">Operating expenses<div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">17.1 RESEARCH AND DEVELOPMENT EXPENSES</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month  period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, sub-contracting and other expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,489)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(14,529)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(21,987)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt">see Note 17.4 Depreciation, amortization and provision expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, sub-contracting and other expenses decreased by &#8364;7.6&#160;million for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024. This favorable variance is mainly related to the transfer of sponsorship of the 312 study to Janssen, including the amendment of the Janssen Agreement signed in March 2025, resulting in the removal of funding obligations on the 312 study.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D Payroll costs increased by &#8364;0.2&#160;million, or by 3.7% for the six-month period ended June&#160;30, 2025 as compared with the same period in 2024, which is mainly due to the phasing of social charges expenses related to stock options granted between 2025 and 2024 for &#8364;0.2&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">17.2 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, fees and other expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,183)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total SG&amp;A expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11,294)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(10,819)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt">see Note 17.4 Depreciation, amortization and provision expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, fees and other expenses increased by &#8364;0.2&#160;million for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024, as SG&amp;A expenses were closely monitored and remained overall in line with prior year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SG&amp;A payroll costs increased by &#8364;0.7&#160;million, or 11.1%, for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024. This variation is mainly due to the phasing of social charges expenses related to stock options granted for &#8364;0.3&#160;million, and severance expenses following some resources reallocation for &#8364;0.2&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SG&amp;A depreciation expenses decreased by &#8364;0.4&#160;million following reversal of provision recorded during the first half off 2025 due to litigation settlement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">17.3 PAYROLL COSTS </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Wages and salaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,238)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement benefit obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total payroll costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(13,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(12,535)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average headcount</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End-of-period headcount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had 103 employees, including 72 in R&amp;D and 31 in selling, general and administrative expenses, compared to 110 as of June&#160;30, 2024,  including 77 in R&amp;D and 33 in selling, general and administrative expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Wages and salaries remained stable for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first half of 2025, related payroll taxes increased by 22.9%, or by &#8364;0.8&#160;million, mainly due to the phasing of social charges expenses related to stock options granting for &#8364;0.5 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In accordance with IFRS 2 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-based Payment</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, the share-based payment expense recognized in the statement of consolidated operations reflects the amortization of the fair value of the granted awards over the service period. The share-based payment expenses amounted to &#8364;2.2&#160;million for the period ended June&#160;30, 2025, as compared with &#8364;1.9&#160;million as of  June&#160;30, 2024 (see Note 18 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-based payments</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">17.4 DEPRECIATION, AMORTIZATION AND PROVISION EXPENSES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses by function are detailed as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six month period ended June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reversal of provision for disputes and charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for disputes and charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses (except IAS 19)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(610)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">80</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(529)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Provision for retirement benefit obligations&#160;(IAS 19) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(40)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(637)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">68</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(569)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six month period ended June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reversal of provision for disputes and charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for disputes and charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total depreciation, amortization and provision expenses (except IAS 19)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(682)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(301)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(983)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Provision for retirement benefit obligations&#160;(IAS 19) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(705)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,016)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Details of the provision for retirement benefit obligations are provided in note 11</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">17.5 OTHER OPERATING INCOME AND EXPENSES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non recurring expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non recurring  income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other operating income and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(134)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company has not recorded any material other operating income and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2024, the other non recurring expenses mainly relates to some employment termination indemnities for &#8364;129 thousand.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text">Share-based payments<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Detail of share-based payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has granted stock options (OSA), founders&#8217; warrants (BSPCE), warrants (BSA), and free shares (AGA) to corporate officers, employees, members of the Executive and Supervisory Board and consultants of the Group. In certain cases, exercise of the stock options, founders&#8217; warrants and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of stock options, founders&#8217; warrants, warrants and free shares outstanding on June&#160;30, 2025 and their main characteristics, are detailed below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Founders&#8217; warrants outstanding as of June 30, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.070%"><tr><td style="width:1.0%"></td><td style="width:45.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2015-1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2015-3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2016 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2016 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2017 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSCPE 2017</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders' meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Feb-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Jun-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-Feb-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-Feb-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7-Jan-17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7-Jan-17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSPCEs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSPCEs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,650</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,050</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,400</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117,650</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the BSPCE were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,650</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,050</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,250</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117,650</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number of which that may be subscribed by corporate officers:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,400</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the BSPCE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/10/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSPCE expiry date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/10/2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSPCE exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;18.57</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;20.28</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;14.46</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;14.46</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;15.93</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;15.93</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSPCEs lapsed or cancelled as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,650</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,050</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,250</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,150</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,600</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of BSPCEs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96,817</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98,100</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">97,050</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares available for subscription as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,817</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,100</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,050</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of the related BSPCEs are met)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,817</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,100</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,050</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000</span></td></tr></table></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Warrants outstanding as of June 30, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"></td><td style="width:43.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.187%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2015-1 </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2015-2 (a) </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2018-2</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2019-1</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2020</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2021 (a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-18</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-18</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Apr-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Feb-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jul-18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29-Mar-19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17-Mar-20</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Apr-21</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum number of BSAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650,000</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSAs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,820</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,103</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares to which the BSA were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,820</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,103</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the total number of shares that may subscribed by the corporate officers of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,700</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relevant officers:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anne-Marie GRAFFIN</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,900</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,843</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enno SPILLNER</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,829</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alain HERRERA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,900</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,195</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gary PHILLIPS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the BSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/25/2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">07/27/18</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/29/19</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/17/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/21</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSA expiry date (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/25/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">07/27/28</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/29/29</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/17/30</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSA issue price</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;4.87</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;5.00</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;2.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;1.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;0.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;2.95</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise price per BSA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;17.67</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;19.54</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;16.10</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;11.66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;6.59</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;13.47</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of forfeited or cancelled BSAs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,672</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of BSAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,820</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,431</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares available for subscription as of June&#160;30, 2025 (considering the conditions of exercise of the BSAs)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,820</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,431</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> outstanding </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">as of June 30, 2025</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"></td><td style="width:25.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.079%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2016-1 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2016-2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2017 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2018 </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2019-1 </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2019 LLY </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2020</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-04 O</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14-Jun-17</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-18</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Apr-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Apr-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02-Feb-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03-Nov-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">07-Jan-17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6-Mar-18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29-Mar-19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24-Oct-19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Mar-20</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Apr-21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526,800</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">648,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407,972</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,200</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the OSAs were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407,972</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,200</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the number that may be subscribed or purchased by corporate officers:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Anne-Juliette HERMANT</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Bart VAN RHIJN</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Louis KAYITALIRE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/03/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/08/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/07/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/30/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/24/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/11/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/22</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSA expiry date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/03/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/06/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/29/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/24/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/11/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise price per OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;13.05</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;14.26</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;14.97</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;12.87</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;11.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;6.41</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;13.74</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of lapsed or cancelled OSAs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,750</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,265</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104,668</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of OSAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24,750</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">360,707</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,532</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum number of shares available for subscription as of June&#160;30, 2025 (given the vesting conditions of the OSAs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,750</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360,707</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,532</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,750</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360,707</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,532</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"></td><td style="width:19.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-04 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-06 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-06 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2022-06 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2022-06 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2023-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2024-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2025-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2025-02 O</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-Apr-21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-Apr-21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-jun-2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Jul-23</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-May-2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-May-2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Apr-21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21-Jun-21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21-Jun-21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22-Jun-22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22-Jun-22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Jul-23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-24</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18-Feb-25</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16-May-25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,700,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,700,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,700,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,700,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338,860</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,224,780</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,005</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the OSAs were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338,860</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,224,780</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,005</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the number that may be subscribed or purchased by corporate officers:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298,860</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">930,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,116</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Anne-Juliette HERMANT</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,354</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Bart VAN RHIJN</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,390</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Louis KAYITALIRE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/20/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/23/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/18/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/16/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSA expiry date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/32</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/32</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/20/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/23/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/18/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/16/2035</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise price per OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;13.74</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;12.99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;12.99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;5.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;5.81</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;3.36</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;2.97</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of lapsed or cancelled OSAs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,620</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,250</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of OSAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">340,600</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123,780</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">380,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">318,860</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,219,530</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,241,004</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum number of shares available for subscription as of June&#160;30, 2025 (given the vesting conditions of the OSAs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106,288</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406,510</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340,600</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123,780</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318,860</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219,530</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,004</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Free shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> outstanding </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">as at June 30, 2025</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"></td><td style="width:48.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA 2023 - P1</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA 2023 - P2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of AGAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,200,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,200,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of AGAs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427,110</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">439,210</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the AGAs were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427,110</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">439,210</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the number that can be subscribed by corporate officers:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298,860</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293,470</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,116</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,116</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Anne-Juliette HERMANT</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,354</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,354</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Bart VAN RHIJN</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,390</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,390</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of acquisition (end of the acquisition period)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/27/25</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/27/25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392,060</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417,760</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of AGAs lapsed or cancelled as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,050</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,450</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of AGAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares that may be subscribed</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Duration of the holding period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 year</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.139%"><tr><td style="width:1.0%"></td><td style="width:48.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">371,967</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,251</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,730,663</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,158,881</span></td></tr></table></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The measurement methods used to estimate the fair value of stock options and warrants are described below:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The exercise price is based on the share price at the grant date;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The risk-free rate was determined based on the average life of the instruments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Volatility was determined based on a sample of listed companies in the biotechnology sector at the grant date and for a period equal to the life of the warrant or option.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The performance conditions for all of the plans were assessed as follows:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Performance conditions unrelated to the market were analyzed to determine the likely exercise date of the warrants and options and expense was recorded accordingly based on the probability these conditions would be met; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Market-related performance conditions were directly included in the calculation of the fair value of the instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of June&#160;30, 2025, the details of active share-based payment plans with remaining IFRS 2 expense are presented in the tables below, reflecting the assumptions related to the probability that the non-market performance conditions will be  and the ongoing accounting impact for the period:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"></td><td style="width:11.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2025</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 O</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38.9% - 37.8% - 38.3%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.38% / 0.33% / 0.28%</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 P</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.03</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 O</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.2% - 37.9% - 38.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.35% / 0.30% / 0.26%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 P</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.13</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2022-06 P </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.4008</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.0228</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2022-06 O </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">42.06% - 41.21% - 40.65%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.83% / 1.87% / 1.90%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">580&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2023-01 O</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">45.07% - 44.11% - 43.41% </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.85% /2.83% / 2.82%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2024-01 O</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">53.30% - 51.90% - 50.70%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 / 5.9 / 6.4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.00% / 3.02% / 3.02%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">194&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2025-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.65</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.36</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47.18% / 47.43% / 47.57%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 / 5.9 / 6.4</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.83% / 2.91% / 2.98%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2025-02 O</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.74</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.97</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47.56% / 47.32% / 47.43%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 / 5.9 / 6.4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.53% / 2.61% / 2.70%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total OSA</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;n.a. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,273</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">708</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.823%"><tr><td style="width:1.0%"></td><td style="width:10.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2025</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2023 - P1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.87</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3% / 3.2%</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2023 - P2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.87</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3% /3.2%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total AGA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">888</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,232</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"><tr><td style="width:1.0%"></td><td style="width:38.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,273</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">888</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,161</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"><tr><td style="width:1.0%"></td><td style="width:38.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">708</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,232</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,940</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income (loss)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NetFinancialIncomeLossAbstract', window );"><strong>Net Financial Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Net financial income (loss)</a></td>
<td class="text">Net financial income (loss)<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the six month period ended June 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">598&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">645</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,386</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest costs </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,174)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,772)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net impact of accretion, discounting and catch-up on EIB loan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease debt interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,463)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net financial income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,186)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,924</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from cash and cash equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">For the six month period ended June 30, 2025, the &#8364;0.6&#160;million income  from cash and cash equivalents was related to short-term deposits compared to &#8364;1.5&#160;million for the six month period ended June&#160;30, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interests costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2025, total interest costs amount to &#8364;4.2&#160;million, mainly due to interest costs on the EIB loan (see Note 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) which consists of fixed and variable rate interests of &#8364;4.1&#160;million. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2024, total interest costs amount to &#8364;3.8&#160;million, mainly due to interest costs on the EIB loan which consists of fixed and variable rate interests of &#8364;3.7&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net impact of accretion and discounting and catch-up on EIB loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2025, the P&amp;L net positive impact of accretion and discounting on EIB loan of &#8364;1.0&#160;million corresponding to (i) the decrease in estimated debt outflows beyond 2024 - before discounting effect - resulting in a &#8364;2.4&#160;million positive P&amp;L effect, (ii) partially offset by -&#8364;1.4&#160;million of discounting negative effect (See Note 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Liabilitie</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">s).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six month period ended June 30, 2024, the P&amp;L net positive impact of accretion and discounting on EIB loan of &#8364;2.7&#160;million corresponding to &#8364;13.5&#160;million discounting positive effect, partially offset by the increase in estimated debt outflows beyond 2023 - before discounting effect - resulting in a &#8364;10.8&#160;million negative P&amp;L effect, due to the revised forecasts of net sales and the revised forecasts of the upfront and milestone payments related to the consideration of the license agreement signed with Janssen signed on July 7, 2023. (See Note 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">Foreign exchange gains and losses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">For the six month period ended June 30, 2025, the company incurred net foreign exchange exchange loss of &#8364;3.6&#160;million, mainly related to the EUR conversion impact on short term USD deposits for &#8364;3.5&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">For the six month period ended June 30, 2024, the Company incurred net foreign exchange gains of &#8364;1.6&#160;million mainly related to the short term USD deposits for &#8364;1.1 million, and to the appreciation of the USD on HSBC bank current account denominated in U.S. dollars for &#8364;0.5 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NetFinancialIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Financial Income (Loss) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NetFinancialIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment reporting<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Segment reporting</a></td>
<td class="text">Segment reporting<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In accordance with IFRS 8 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Operating Segments</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, reporting by operating segment is derived from the internal organization of the Company&#8217;s activities; it reflects management&#8217;s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company&#8217;s Chairman and the members of the Executive and Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">cancer treatment. The positive net revenue, as disclosed in the &#8216;Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue and other Income</span>&#8217;, is primarily recognized by the Company towards one principal customer, Janssen, located in Belgium. The assets, liabilities and operating loss realized are primarily located in France.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text">Loss per share <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the six month period ended June 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss for the period (in thousands of euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(21,872)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average number of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47,418,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47,124,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basic loss per share (in euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diluted loss per share (in euros)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instruments providing deferred access to the capital (stock options, founders' warrants and warrants) are considered to be anti-dilutive because they result in a decrease in the loss per share. Therefore, diluted loss per share is identical to basic loss per share as all equity instruments issued, representing a total of 5,158,881 potential additional ordinary shares, have been considered antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalCommitmentsAbstract', window );"><strong>Capital commitments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Commitments</a></td>
<td class="text">Commitments <div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The off-balance sheet commitments have not changed significantly since December, 31, 2024, except for the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commitments related to the master services agreement with Janssen dedicated to the clinical manufacturing of JNJ-1900 (NBTXR3)</span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 22, 2023, the Company entered into a master services agreement (&#8220;MSA&#8221;) with Janssen which includes the clinical manufacturing and the supply of products to be provided by the Company, as well as technical expertise and development services in the field of the territory, as defined in the global  licensing, co-development, and commercialization agreement signed in July 2023.</span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under this MSA, the Company already received as of June 30, 2025 purchase orders from Janssen (a) for the delivery of raw materials and JNJ-1900 (NBTXR3) clinical and technical batches planned to be delivered during the second half of 2025 amounting to &#8364;6.1&#160;million and (b) for the technology transfer and related technical assistance services amounting to &#8364;0.2&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related parties</a></td>
<td class="text">Related parties <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Key management personnel compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the six-month period ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supervisory Board&#8217;s fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total compensation to related parties</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,094</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,722</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The methods used to measure share-based payments are presented in Note 18 -</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-based payments </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Related parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of June 30, 2025, Johnson &amp; Johnson Innovation &#8211; JJDC, an affiliate of Janssen, beneficially owns approximately 11.66% of the outstanding ordinary shares of Nanobiotix. Nanobiotix and Janssen are parties to the Janssen Agreement, the &#8220;TSA&#8221; and the &#8220;AAA&#8221;, each as described in the consolidated financial statements prepared for the year ended December 31, 2024). Accordingly Janssen may be considered a related party of Nanobiotix.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">For the six month period ended June 30, 2025, the Company continued to support Janssen in execution of NANORAY-312 clinical study during the transition process and following the sponsorship transfer and conducted transactions with Janssen (see Note 16 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">Revenues and other income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">). The payments between the two companies as well as the liabilities and receivables are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:54.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets/(Liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Collection (Janssen towards Nanobiotix SA) / Receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments (Nanobiotix SA towards Janssen) / Payables</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,905)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,387</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,068)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory', window );">Subsequent events</a></td>
<td class="text">Subsequent events <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2025-01-01<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 190<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_190&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 190<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_190&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated principles and methods (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">General principles and statement of compliance and basis of presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements as of June&#160;30, 2025 and for the six-month period ended June&#160;30, 2025 were prepared under the supervision of the management of the Company and were submitted by the Executive Board to the review of the Supervisory Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All amounts in the unaudited interim condensed consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated  financial statements of the Company have been prepared in compliance with IAS 34 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Interim Financial Reporting&#8221; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which provides for the presentation of selected explanatory notes. As they are unaudited interim condensed consolidated  financial statements, the accompanying notes do not contain all the disclosures required for annual consolidated financial statements and should therefore be read in conjunction with the Company&#8217;s consolidated financial statements prepared in accordance with IFRS &#174; Accounting Standards, as of and for the year ended December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of the unaudited interim condensed consolidated financial statements in accordance with IAS 34 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Interim Financial Reporting&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> requires the use of estimates and assumptions that affect the amounts and information disclosed in the condensed consolidated financial statements. See Note 3.2 Use of judgement, estimates and assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June&#160;30, 2025 are identical to those used for the year ended December&#160;31, 2024 except for the standards listed below that required adoption in 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2025 in the European Union primarily concern:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.47pt">Amendment to IAS 21 Lack of Exchangeability, the Effects of Changes in Foreign Exchange Rates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">This amendment had no material impact on the Company&#8217;s unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable are:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">Amendments to IFRS 9 and IFRS 7 &#8211; Classification and Measurement of Financial Instruments &#8211; as of January 1, 2026</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">Amendments to IFRS 9 and IFRS 7 &#8211; Contracts Referencing Nature-dependent Electricity &#8211; as of January 1, 2026</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">Annual Improvements to IFRS Accounting Standards, as of January 1, 2026&#8211; Amendments to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 1 First-time Adoption of International Financial Reporting Standards;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 9 Financial Instruments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IFRS 10 Consolidated Financial Statements; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">IAS 7 Statement of Cash flows</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">New standard &#8211; IFRS 18 &#8211; Presentation and Disclosure in Financial Statements &#8211; as of January 1, 2027</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#9632;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt">New standard &#8211; IFRS 19 &#8211; Subsidiaries without Public Accountability: Disclosures&#8211; as of January 1, 2027</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company is currently assessing the applicability and impact of these new standards, interpretations and amendments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Seasonality of the Company&#8217;s activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">According to IAS 34 &#8211; &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;, an entity whose business is highly seasonal should present financial information for the twelve months up to the end of the interim period and additional comparative information for the prior twelve-month period in the interim condensed consolidated financial statements in order to provide a better understanding and comparison of its interim consolidated financial statements. </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As mentioned in Note 16 Revenue and other income, as most of the income from the Company is generated by ongoing contracts that primarily depend on performance obligations not correlated to seasonal trends, it is considered that the Company activities are not seasonal. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Therefore, the following unaudited interim condensed consolidated financial statements and corresponding notes will not include comparative information other than that mentioned in IAS 34.20.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and payment of research tax credit (CIR) receivables. The Company continues to pursue its research and development activities for its product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning multiple years. The Company does not expect to generate revenue from product sales in the near future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In March 2025, the Company and Janssen executed an amendment to the License Agreement. The amendment provides that Janssen will assume almost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">full financial responsibility for NANORAY-312</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, the ongoing pivotal Phase 3 trial through completion, less a small portion of costs that will remain covered by the Company, allowing the Company to extend its cash runway and to reduce its operating cash outflows post this amendment, including the period beyond mid-2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of June 30, 2025, the Company had &#8364;28.8&#160;million of available cash and cash equivalents, consisting of cash and short-term bank deposits that are liquid and easily convertible within 3 months without penalty or risk of change in value (see Note 9. &#8211; Cash and cash equivalents).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of the date of authorization of the issuance of these interim condensed consolidated financial statements, the Company estimates, given its current cost structure and its projected expenditure commitments, that it should have sufficient funds to finance its activities into mid-2026. Accordingly, the Company&#8217;s current cash and cash equivalents will not be sufficient to cover its operating needs for at least the next 12 months following the date of the issuance of these financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on its current business plan, the Company estimates that to meet its obligations over the next 12 months, it will require additional liquidity in the range of &#8364;8 to &#8364;10&#160;million. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company&#8217;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This estimate is based on the Company&#8217;s current business plan and excludes (i) other expenses resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing. The Company may have based this estimate on incorrect assumptions and may have to use its resources sooner than anticipated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">To finance its activities beyond mid-2026, the Co</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">mpany needs to raise additional funds and is in active discussions regarding non-dilutive financing, intended to meaningfully extend its c</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">ash runway beyond the 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In addition, further to the current discussions, the Company may seek to raise additional funds to achieve its development goals for its research and development programs through: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">other potential public or private securities offerings, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">potential strategic transactions such as business development partnerships; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">R&amp;D project subsidies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on the above, the interim condensed consolidated financial statements as of and for the six-month period ended June 30, 2025, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future and to address its liquidity challenges by pursuing activities to generate additional cash inflows and by closely managing its operating expenditures. As such, they do not include any adjustments related to the value or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company cannot guarantee that it will be able to obtain the necessary financing, through any of the foregoing measures or otherwise, to meet its needs or to obtain funds at acceptable terms and conditions, on a timely basis, or at all, especially considering the generally challenging environment for financing of biotech companies. If the Company is unable to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any approved product or be unable </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">to expand its operations or otherwise capitalize on its business opportunities, as desired, which would impair the Company&#8217;s prospects and business operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text">BASIS OF CONSOLIDATION<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Consolidated entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the consolidation scope is comprised of one parent entity and is similar to that of December&#160;31, 2024 as Nanobiotix S.A. has three wholly owned subsidiaries: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Nanobiotix Corp., incorporated in the State of Delaware in September 2014 and located in the USA,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Nanobiotix Germany GmbH, created in October 2017 and located in Germany,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Nanobiotix Spain S.L.U., created in December 2017 and located in Spain.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accordingly, the unaudited interim condensed consolidated financial statements as of June&#160;30, 2025 include the operations of each of these subsidiaries, to the extent applicable, from the date of their incorporation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements are presented in thousands of euros, which is the Group&#8217;s presentation currency and the functional currency of the parent company, Nanobiotix S.A. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate for the statement of financial position, whereas, items of the statement of operations, statement of comprehensive loss and statement of cash flow are converted at the average exchange rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The dollar-to-euro exchange rate used in the unaudited interim condensed consolidated financial statements to convert the Group transactions denominated in US dollars were a closing of $1.1720 as of June&#160;30, 2025 and an average of $1.0930 for the six-month period ended June&#160;30, 2025 compared with $1.0705 and $1.0812 respectively, as of and for the six-month period ended June&#160;30, 2024 (source: Banque de France).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock', window );">Use of judgement, estimates and assumptions</a></td>
<td class="text">USE OF JUDGEMENT, ESTIMATES AND ASSUMPTIONS<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed consolidated financial statements in accordance with IAS 34 requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. A sensitivity analysis may be presented if the results differ materially based on the application of different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the measurement of financial instruments (fair value and amortized costs).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Measurement of share-based payments </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures the fair value of stock options (OSA), founders&#8217; warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Executive and Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., option vesting terms) and market data (e.g., to determine expected share volatility) (See Note 18 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-based payments</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Deferred tax assets </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company&#8217;s assets and liabilities that appear in its financial statements. The primary source of deferred tax assets are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow for sufficiently reliable income projections to be made, the Company has not recognized deferred tax assets in relation to tax losses carry forwards in the statements of consolidated financial position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial accruals </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clinical trial expenses, although not yet billed in full, are estimated quarterly for each study and a provision is recognized accordingly. (See Note 14.1 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Trade and other payables</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for information regarding the clinical trial accruals as of June 30, 2025 and December 31, 2024).</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to determine the amount and timing of revenue under the contract with customers, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company, determining the stand alone selling price of the performance obligations, the transaction price allocation and the timing of satisfaction of support services provided to customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Determining the distinctiveness of performance obligations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; A promised good or service will need to be recognized separately in revenue if it is distinct as defined in IFRS 15. In determining whether the performance obligation is separate, the Company analyses if (i) the good or service is distinct in absolute terms, i.e. it can be useful to the customer, either on its own or in combination with resources that the customer can obtain separately; and if (ii) the good or service is distinct in the context of the contract, i.e. it can be identified separately from the other goods and services in the contract because there is not a high degree of interdependence or integration between this element and the other goods or services promised in the contract. If either of these two conditions is not met, the good or service is not distinct, and the Company must group it with other promised goods or services until it becomes a distinct group of goods or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Allocation of transaction price to performance obligations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For contracts with multiple performance obligations, the Company allocates the contract&#8217;s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable consideration</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; Due to the nature of the work required to be performed on many of the Company&#8217;s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration and license agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals). The Company includes the related amounts in the estimated transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue on a cumulative catch&#8209;up basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognized over time and input method</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; Some of the Company&#8217;s performance obligations are satisfied over time as work progresses, thus revenue is recognized over time, using an input measure of progress as it best depicts the transfer of control to the customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contract modification</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212; The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. The effect that the contract modification has on the transaction price, and on the entity's measure of progress towards complete satisfaction of the performance obligation, is recognized as an adjustment to revenue at the date of the contract modification (i.e. on a cumulative catch-up basis). The Company is required to use significant judgments with respect to identifying and determining the amended standalone selling price of the performance obligations, the transaction price allocation and the adjusted timing of satisfaction of the remaining services provided to customers.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 16 - to the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2024 for additional detail regarding the Company&#8217;s accounting policies and specific judgments made with regard to revenue recognition, and for its additional sources of revenue and other income.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Measurement of financial assets and liabilities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At the renegotiation date in October 2022, the fair value measurement of the EIB loan required the Company to determine:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">the discount rate of the new liability executed in October 2022. The discount rate reflects the company&#8217;s credit risk at the Amendment Agreement date as well as a premium to reflect uncertainties associated with the timing and the amount of the royalties&#8217; payment. The Company involved external financial instruments valuation specialists to support in determining the average discount rate;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">the amount of additional interest (&#8220;royalties&#8221;, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing upon commercialization. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to annual sales turnover relating to JNJ-1900 (NBTXR3) through specific Company&#8217;s license agreement. For the purpose of measuring the fair value of the EIB loan, the Company forecasts expected sales relating to JNJ-1900 (NBTXR3) during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see Notes 4.4 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financing Agreement with the European Investment Bank (&#8220;EIB&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and 13 - </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2024, for details about this loan and the accounting treatment applied).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Subsequent to the estimate of the fair value of the EIB loan performed at the renegotiation date, the debt has been measured at amortized cost based on the revised best estimate of the future cash flows related to the debt at each closing date. Accordingly, the Company determines the amount of additional interest as described above. Any subsequent adjustment of flows indexed to turnover are discounted at the original effective interest rate and the adjustment is recognized in profit or loss under the &#8220;catch-up&#8221; method. As of June 30, 2025, the fair value measurement of the EIB loan has been reassessed by the Company for disclosure purpose.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenues and other income</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The revenue recognition accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June&#160;30, 2025, are identical to those used for the year ended December&#160;31, 2024, as completed below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Further to the agreements signed during the fourth quarter of 2024 detailing the terms for the transfer of the sponsorship of the ongoing NANORAY-312 Phase 3 pivotal trial in head and neck cancer to Janssen (See Note 16 &#8211; </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenues and other income</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> to the consolidated financial statements as of and for the year ended December 31, 2024), the Company signed an amendment letter with Janssen BV on March 17, 2025. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The amendment letter provides that Janssen will ultimately assume nearly all remaining costs for the ongoing pivotal Phase 3 trial through completion, except for a limited portion of costs that will continue to be covered by the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This amendment aims to improve the Company&#8217;s short-term cash runway by:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">reducing its obligation to make payments that were probable in the short term for the ongoing NANORAY-312 Phase 3 pivotal trial development costs; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">revising potential future milestone payments for a total of $105&#160;million under both the Janssen License Agreement and the Asia Licensing Agreement, </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This amendment letter has been considered and accounted for as a contract modification under IFRS 15, which modifies the remaining transaction prices of both Janssen License Agreement and Asia Licensing Agreement, originally treated as separate contracts for IFRS 15 purposes. As there are price interdependencies between the two effects of the amendment as described above, the contract modification has been applied to both agreements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The amendment does not change the scope of the initial contracts but the overall impact of the contract modification is a significant increase in the remaining constrained transaction price of the combined agreements (Janssen Agreement and Asia Licensing Agreement) while the constraint continues to apply to milestone payments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The net positive impact on the constrained transaction price on the Janssen Agreement was recognized as a cumulative catch-up adjustment, as the remaining goods or services under the license agreement are not distinct. As a result, revenue for the six-month period ended June 30, 2025, included a one-off positive impact of &#8364;21.2&#160;million, directly attributable to the contract modification as described above.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 15, the funding obligation towards Janssen was reduced to a net refund liability amounting to &#8364;7.4&#160;million as of June 30, 2025. See Note 14.4 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Refund liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The combined effects of the amendment on the two license agreements resulted also in the allocation of &#8364;18.1&#160;million of the constrained transaction price to the Asia Licensing Agreement, which was recognized as the related contract liability since the delivery of the related performance obligation has not yet commenced. See Note 14.3 &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Deferred income and Contract liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Basis Of Consolidation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in intangible assets breaks down as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:39.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">734</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">742</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of intangible assets (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(727)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt">Expenses for the period are detailed in Note 17.4 Depreciation, amortization and provisions expenses</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in property, plant and equipment is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">movements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&amp; transfer.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments on tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16,559</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">150</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(108)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(92)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16,504</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,582)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(134)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,716)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,945)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(90)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,035)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of tangible assets(1)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11,021)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(798)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">108</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">65</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11,641)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,538</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(647)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(27)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,863</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span>Expenses for the period are detailed in Note 17.4 Depreciation, amortization and provisions expenses<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Disclosure of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock', window );">Schedule of Changes in Non-current Financial Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in non-current financial assets breaks down as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.122%"><tr><td style="width:1.0%"></td><td style="width:73.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Security <br/>deposits paid</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of Net book value as of December 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">406</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reclassification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">409</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Non-Current Financial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock', window );">Schedule of Trade Receivables</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,837</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,977</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets break down as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit receivable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,753</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock', window );">Schedule of Changes in Research Tax Credit Receivables</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in research tax credit receivables breaks down as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:84.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,369</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 research tax credit &#8211; Nanobiotix S.A. (1)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,616&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 research tax credit &#8211; Nanobiotix Corp (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receipt of 2024 research tax credit - Nanobiotix Corp</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,792</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See Note 16 - Revenue and other income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Changes In Research Tax Credit Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Other Current Assets Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Trade Receivables Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalent break down as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and bank accounts</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term bank deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net Cash and cash equivalents</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">28,818</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">49,737</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Cash And Cash Equivalents Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of Share Capital Transactions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Detail of share capital transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands or number of shares)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nature of transaction</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Premiums related to share capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,423</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">312,743</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">47,426,851</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 27, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase AGA 2023-P1 and AGA 2023-P2</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">809,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,447</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">312,743</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">48,236,671</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_RetirementObligationAbstract', window );"><strong>Retirement Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory', window );">Schedule of Changes in Provisions</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:25.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lump-sum retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Non-current provisions</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">432</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">47</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">479</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:29.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(230)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(90)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current provisions </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">438</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">49</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(320)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span>See Note 17.4 Depreciation, amortization and provision expenses for the nature of these decreases<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_RetirementObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retirement Obligation [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_RetirementObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory', window );">Schedule of Changes in Provisions</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:25.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lump-sum retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Non-current provisions</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">432</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">47</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">479</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:29.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(230)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(90)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current provisions </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">438</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">49</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(320)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span>See Note 17.4 Depreciation, amortization and provision expenses for the nature of these decreases<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Schedule of Changes in Financial Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Short term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE loans *</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,735</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,924</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Long term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE loans *</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">46,505</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">45,978</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">51,240</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">50,902</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(*)&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Detail of financial instruments included in the statements of financial position and impact on income</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,753&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Total liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62,879</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62,879</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">65,900</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Total liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70,936</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70,936</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">73,402</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory', window );">Schedule of Changes in Lease Liabilities</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">The table below shows the detail of changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.434%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands of euros)</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Liabilities</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Repayable BPI Loan Advances</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PGE Loans</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EIB Loan</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance advance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Curadigm Bpi advance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HSBC<br/>&#8220;PGE&#8221;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance<br/>&#8220;PGE&#8221;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,230</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">342</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,891</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,198</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">40,635</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">50,902</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal received</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in loans and conditional advances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,927)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows used in<br/>financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(637)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(600)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(75)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(638)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(233)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indexation effect on current lease commitment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of discounting and catch-up</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,031)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash from financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">38</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,083</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,169</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,632</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,019</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">275</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,260</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,569</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">43,484</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">51,240</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Of which Current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,247</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">438</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">97</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,260</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,262</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">430</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,735</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Of which Non-Current</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,385</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">581</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">178</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">307</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">43,054</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">46,505</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock', window );">Schedule of Advances Loans and Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The due dates for repayment of the financial liabilities at their nominal value and including fixed rate interests and future variable interest payments have been estimated based on the milestone and royalties forecasts at the reporting date are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:28.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1&#160;year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and <br/>3&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 3 and <br/>5&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5 years</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curadigm interest-free Bpifrance advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HSBC &#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance &#8220;PGE&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">314&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,589&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB fixed rate loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,707&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,831</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">24,843</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">45,781</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">30,366</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">105,822</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Company plans according to contractual terms to reimburse the two &#8220;PGE&#8221; (&#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; or state-guaranteed loans) from HSBC and BPI over 5 years with a deferral of 1 year (last reimbursement being in 2026).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:28.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1&#160;year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and <br/>3&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 3 and <br/>5&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5 years</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curadigm interest-free Bpifrance advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HSBC &#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance &#8220;PGE&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,289&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB fixed rate loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,210</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">24,689</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">41,725</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">39,412</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">111,036</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Company plans according to contractual terms to reimburse the two &#8220;PGE&#8221; (&#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; or state-guaranteed loans) from HSBC and BPI over five years with a deferral of 1 year (last reimbursement being in 2026).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Advances Loans And Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock', window );">Schedule of Trade and Other Payables</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses - clinical trials</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total trade and other payables</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11,639</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">20,036</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll tax and other payroll liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,543</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock', window );">Schedule of Deferred Income and Contract Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities - Current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred income and current contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">36,222</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18,161</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock', window );">Schedule of Detailed Information About Refund Liabilities</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current refund liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current refund liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Refund liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,378</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">35,613</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Information About Deferred Income And Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Information About Other Current Liabilities Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Information About Refund Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Trade And Other Payables Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments included in the statement of financial position and impact on income (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Schedule of Financial Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Detail of financial instruments included in the statements of financial position and impact on income</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,753&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Total liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62,879</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62,879</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">65,900</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Total liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70,936</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70,936</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">73,402</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Schedule of Financial Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Short term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE loans *</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,735</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,924</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Long term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE loans *</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">46,505</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">45,978</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">51,240</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">50,902</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(*)&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Detail of financial instruments included in the statements of financial position and impact on income</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,753&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Total liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62,879</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62,879</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">65,900</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,120</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Total liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70,936</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70,936</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">73,402</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock', window );">Schedule of Revenues and Other Income</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s revenue and other income per category for the six-month period ended June 30, 2025 and 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">24,928</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,163</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,710</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,126</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenue and other income</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">26,638</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,289</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosur Of Disaggregation Of Revenues And Other Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock', window );">Schedule of Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month  period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, sub-contracting and other expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,489)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(14,529)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(21,987)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt">see Note 17.4 Depreciation, amortization and provision expenses</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock', window );">Schedule of Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, fees and other expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,183)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total SG&amp;A expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11,294)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(10,819)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt">see Note 17.4 Depreciation, amortization and provision expenses</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock', window );">Schedule of Payroll Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Wages and salaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,238)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement benefit obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total payroll costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(13,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(12,535)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average headcount</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End-of-period headcount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock', window );">Schedule of Depreciation, Amortization and Provision Expenses</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses by function are detailed as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six month period ended June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reversal of provision for disputes and charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for disputes and charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses (except IAS 19)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(610)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">80</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(529)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Provision for retirement benefit obligations&#160;(IAS 19) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(40)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(637)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">68</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(569)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six month period ended June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reversal of provision for disputes and charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for disputes and charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total depreciation, amortization and provision expenses (except IAS 19)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(682)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(301)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(983)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Provision for retirement benefit obligations&#160;(IAS 19) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(705)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,016)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Details of the provision for retirement benefit obligations are provided in note 11</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Operating Income (Expenses)</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the six-month period ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non recurring expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non recurring  income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other operating income and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(134)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Employee Benefits Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Research And Development Expense Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Other Operating Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock', window );">Schedule of Changes in Founders' Warrants, Warrants and Free Shares</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of stock options, founders&#8217; warrants, warrants and free shares outstanding on June&#160;30, 2025 and their main characteristics, are detailed below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Founders&#8217; warrants outstanding as of June 30, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.070%"><tr><td style="width:1.0%"></td><td style="width:45.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2015-1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2015-3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2016 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2016 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2017 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSCPE 2017</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders' meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Feb-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Jun-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-Feb-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-Feb-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7-Jan-17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7-Jan-17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSPCEs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSPCEs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,650</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,050</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,400</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117,650</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the BSPCE were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,650</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,050</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,250</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117,650</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number of which that may be subscribed by corporate officers:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,400</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the BSPCE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/10/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSPCE expiry date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/10/2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSPCE exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;18.57</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;20.28</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;14.46</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;14.46</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;15.93</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;15.93</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSPCEs lapsed or cancelled as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,650</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,050</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,250</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,150</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,600</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of BSPCEs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96,817</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98,100</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">97,050</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares available for subscription as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,817</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,100</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,050</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of the related BSPCEs are met)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,817</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,100</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,050</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,000</span></td></tr></table></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Warrants outstanding as of June 30, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"></td><td style="width:43.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.187%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2015-1 </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2015-2 (a) </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2018-2</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2019-1</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2020</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2021 (a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18-Jun-14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-18</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-18</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Apr-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Feb-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jul-18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29-Mar-19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17-Mar-20</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Apr-21</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum number of BSAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650,000</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of BSAs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,820</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,103</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares to which the BSA were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,820</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,103</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the total number of shares that may subscribed by the corporate officers of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,700</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relevant officers:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anne-Marie GRAFFIN</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,900</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,843</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enno SPILLNER</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,829</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alain HERRERA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,900</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,195</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gary PHILLIPS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the BSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/25/2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">07/27/18</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/29/19</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/17/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/21</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSA expiry date (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/25/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">07/27/28</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/29/29</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/17/30</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BSA issue price</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;4.87</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;5.00</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;2.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;1.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;0.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;2.95</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise price per BSA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;17.67</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;19.54</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;16.10</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;11.66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;6.59</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;13.47</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of forfeited or cancelled BSAs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,672</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of BSAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,820</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,431</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares available for subscription as of June&#160;30, 2025 (considering the conditions of exercise of the BSAs)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,820</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,431</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Free shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> outstanding </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">as at June 30, 2025</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"></td><td style="width:48.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA 2023 - P1</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA 2023 - P2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27-Jun-23</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of AGAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,200,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,200,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of AGAs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427,110</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">439,210</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the AGAs were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427,110</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">439,210</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the number that can be subscribed by corporate officers:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298,860</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293,470</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,116</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,116</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Anne-Juliette HERMANT</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,354</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,354</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Bart VAN RHIJN</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,390</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,390</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of acquisition (end of the acquisition period)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/27/25</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/27/25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392,060</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417,760</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of AGAs lapsed or cancelled as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,050</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,450</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of AGAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares that may be subscribed</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Duration of the holding period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 year</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.139%"><tr><td style="width:1.0%"></td><td style="width:48.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">371,967</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,251</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,730,663</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,158,881</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of Changes in Share Options</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> outstanding </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">as of June 30, 2025</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"></td><td style="width:25.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.079%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2016-1 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2016-2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2017 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2018 </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2019-1 </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2019 LLY </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2020</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-04 O</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25-Jun-15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-Jun-16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14-Jun-17</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-18</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Apr-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Apr-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02-Feb-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03-Nov-16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">07-Jan-17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6-Mar-18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29-Mar-19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24-Oct-19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11-Mar-20</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Apr-21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526,800</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">648,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407,972</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,200</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the OSAs were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407,972</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,200</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the number that may be subscribed or purchased by corporate officers:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Anne-Juliette HERMANT</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Bart VAN RHIJN</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Louis KAYITALIRE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/03/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/08/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/07/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/30/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/24/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/11/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/22</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSA expiry date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/03/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01/07/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/06/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/29/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/24/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03/11/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise price per OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;13.05</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;14.26</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;14.97</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;12.87</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;11.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;6.41</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;13.74</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of lapsed or cancelled OSAs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,750</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,265</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104,668</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of OSAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24,750</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">360,707</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,532</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum number of shares available for subscription as of June&#160;30, 2025 (given the vesting conditions of the OSAs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,750</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360,707</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,532</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,750</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360,707</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,532</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"><tr><td style="width:1.0%"></td><td style="width:19.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-04 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-06 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-06 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2022-06 P</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2022-06 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2023-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2024-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2025-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2025-02 O</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-Apr-21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-Nov-20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-Apr-21</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-jun-2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Jul-23</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-May-2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28-May-2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of grant by the Executive Board </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Apr-21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21-Jun-21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21-Jun-21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22-Jun-22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22-Jun-22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-Jul-23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23-May-24</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18-Feb-25</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16-May-25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,700,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,700,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,700,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,700,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of OSAs granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338,860</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,224,780</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,005</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of shares to which the OSAs were likely to give right on the date of their grant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,400</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338,860</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,224,780</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,005</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">including the number that may be subscribed or purchased by corporate officers:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298,860</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">930,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Laurent LEVY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,116</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Anne-Juliette HERMANT</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,354</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Bart VAN RHIJN</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,390</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">the number that can be subscribed by Louis KAYITALIRE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of beneficiaries who are not corporate officers </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Starting date for the exercise of the OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/20/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/23/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/18/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/16/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSA expiry date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04/20/31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/21/31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/32</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06/22/32</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/20/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/23/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/18/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/16/2035</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise price per OSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;13.74</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;12.99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;12.99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;5.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;5.81</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;3.36</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;2.97</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of shares subscribed as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total number of lapsed or cancelled OSAs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,620</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,250</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number of OSAs outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">340,600</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123,780</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">380,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">318,860</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,219,530</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,241,004</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum number of shares available for subscription as of June&#160;30, 2025 (given the vesting conditions of the OSAs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106,288</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406,510</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340,600</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123,780</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318,860</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219,530</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,004</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.139%"><tr><td style="width:1.0%"></td><td style="width:48.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">371,967</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,251</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,730,663</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,158,881</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory', window );">Schedule of Number of Founders' Warrants, Warrants and Free Shares Outstanding and Their Characteristics</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of June&#160;30, 2025, the details of active share-based payment plans with remaining IFRS 2 expense are presented in the tables below, reflecting the assumptions related to the probability that the non-market performance conditions will be  and the ongoing accounting impact for the period:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.823%"><tr><td style="width:1.0%"></td><td style="width:10.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2025</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2023 - P1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.87</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3% / 3.2%</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2023 - P2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.87</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3% /3.2%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total AGA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">888</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,232</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"><tr><td style="width:1.0%"></td><td style="width:38.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,273</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">888</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,161</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"><tr><td style="width:1.0%"></td><td style="width:38.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">708</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,232</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,940</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Schedule of Number of Shares Options Outstanding and Their Characteristics</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"><tr><td style="width:1.0%"></td><td style="width:11.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2025</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the first half of 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 O</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38.9% - 37.8% - 38.3%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.38% / 0.33% / 0.28%</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 P</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.03</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 O</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.2% - 37.9% - 38.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.35% / 0.30% / 0.26%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 P</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.13</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2022-06 P </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.4008</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.0228</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2022-06 O </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">42.06% - 41.21% - 40.65%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.83% / 1.87% / 1.90%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">580&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2023-01 O</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">45.07% - 44.11% - 43.41% </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.85% /2.83% / 2.82%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2024-01 O</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">53.30% - 51.90% - 50.70%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 / 5.9 / 6.4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.00% / 3.02% / 3.02%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">194&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2025-01 O</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.65</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.36</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47.18% / 47.43% / 47.57%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 / 5.9 / 6.4</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.83% / 2.91% / 2.98%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2025-02 O</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.74</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.97</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47.56% / 47.32% / 47.43%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4 / 5.9 / 6.4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.53% / 2.61% / 2.70%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total OSA</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;n.a. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,273</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">708</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"><tr><td style="width:1.0%"></td><td style="width:38.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,273</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">888</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,161</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"><tr><td style="width:1.0%"></td><td style="width:38.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">708</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,232</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,940</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income (loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NetFinancialIncomeLossAbstract', window );"><strong>Net Financial Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock', window );">Schedule of Net Financial Income (Loss)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the six month period ended June 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">598&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">645</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,386</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest costs </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,174)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,772)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net impact of accretion, discounting and catch-up on EIB loan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease debt interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,463)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net financial income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,186)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,924</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Information About Finance Income (Cost)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NetFinancialIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Financial Income (Loss) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NetFinancialIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Schedule of Basic and Diluted Loss Per Share</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the six month period ended June 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss for the period (in thousands of euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(21,872)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average number of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47,418,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47,124,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basic loss per share (in euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diluted loss per share (in euros)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of Key Management Personnel Compensation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the six-month period ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supervisory Board&#8217;s fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total compensation to related parties</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,094</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,722</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div>The payments between the two companies as well as the liabilities and receivables are as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:54.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets/(Liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Collection (Janssen towards Nanobiotix SA) / Receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments (Nanobiotix SA towards Janssen) / Payables</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,905)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,387</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,068)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Company information (Details) - Janssen Pharmaceutica NV<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 17, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 07, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 07, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems', window );"><strong>Disclosure Of Information Related To The Company [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementTotalConsideration', window );">Deal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember', window );">Nanobiotix Corp. | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems', window );"><strong>Disclosure Of Information Related To The Company [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication', window );">Collaboration agreement, compensation per indication | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember', window );">Major ordinary share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems', window );"><strong>Disclosure Of Information Related To The Company [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementTotalConsideration', window );">Deal value</a></td>
<td class="nump">&#8364; 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived', window );">Collaboration agreement, potential development and commercial milestones payments</a></td>
<td class="nump">&#8364; 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Potential Milestones Payments To Be Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Potential Milestones Payments To Be Received Per Indication</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementTotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Total Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementTotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Information Related To The Company</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfInformationRelatedToTheCompanyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbx_NanobiotixCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbx_NanobiotixCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General information, statement of compliance and basis of presentation (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 28,818<span></span>
</td>
<td class="nump">&#8364; 49,737<span></span>
</td>
<td class="nump">&#8364; 66,335<span></span>
</td>
<td class="nump">&#8364; 75,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdditionalLiquidityBusinessObligations', window );">Additional liquidity business obligations</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdditionalLiquidityBusinessObligations', window );">Additional liquidity business obligations</a></td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdditionalLiquidityBusinessObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Liquidity Business Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdditionalLiquidityBusinessObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated principles and methods (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>subsidiary</div>
</th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSubsidiaries', window );">Number of subsidiaries</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing foreign exchange rate</a></td>
<td class="nump">1.1720<span></span>
</td>
<td class="nump">1.0705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average foreign exchange rate</a></td>
<td class="nump">1.0930<span></span>
</td>
<td class="nump">1.0812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Schedule of Intangible Assets (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">&#8364; 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="num">(727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets | Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="num">(662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="num">&#8364; (663)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss recognised in profit or loss, intangible assets other than goodwill</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">&#8364; 5,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">4,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">16,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">16,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Fixtures, fittings and installations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">3,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">3,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Right of use &#8211; Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">9,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">8,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Technical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">2,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">2,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Office and IT equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Tangible assets in progress</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Prepayments on tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(11,021)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(11,641)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets | Fixtures, fittings and installations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(2,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(2,716)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets | Right of use &#8211; Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(5,473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(5,929)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets | Technical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(1,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(2,035)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets | Office and IT equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(1,021)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Other movements &amp; transfer.</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(961)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nbx_NettingMember', window );">Netting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_PrepaymentsOnTangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_PrepaymentsOnTangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nbx_NettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nbx_NettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial assets - Schedule of Changes in Non-current Financial Assets (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_SecurityDepositsRollForward', window );"><strong>Security deposits paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at beginning of period</a></td>
<td class="nump">&#8364; 406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at end of period</a></td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentLiquidityContractMember', window );">Security deposits paid</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_SecurityDepositsRollForward', window );"><strong>Security deposits paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at beginning of period</a></td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets', window );">Additions</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughDerecognitionFinancialAssets', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets', window );">Reclassification</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Currency translation adjustments</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at end of period</a></td>
<td class="nump">&#8364; 409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughDerecognitionFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in financial assets resulting from derecognition. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35I<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35I_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph IG20B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughDerecognitionFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph IG20B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets resulting from other movements. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph IG20B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in financial assets resulting from origination or purchase. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph IG20B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35I<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35I_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SecurityDepositsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Security Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SecurityDepositsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentLiquidityContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentLiquidityContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables and other current assets - Schedule of Trade Receivables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 1,837<span></span>
</td>
<td class="nump">&#8364; 2,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and other current assets - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 1,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">1,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables', window );">Adjustments for decrease (increase) in other receivables</a></td>
<td class="num">(620)<span></span>
</td>
<td class="nump">&#8364; 157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Current advances to suppliers</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nbx_JanssenPharmaceuticaNVMember', window );">Janssen Pharmaceutica NV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nbx_SuppliersMember', window );">Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables', window );">Adjustments for decrease (increase) in other receivables</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nbx_ThirdPartyServicesMember', window );">Third party services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">&#8364; 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nbx_ClinicalProductsMember', window );">Clinical products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member', window );">MD Anderson Cancer Center, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">&#8364; 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Decrease (Increase) In Other Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Trade Receivables and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbx_JanssenPharmaceuticaNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbx_JanssenPharmaceuticaNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbx_SuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbx_SuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_ThirdPartyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_ThirdPartyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_ClinicalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_ClinicalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables and other current assets - Schedule of Other Current Assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Research tax credit receivable</a></td>
<td class="nump">&#8364; 4,792<span></span>
</td>
<td class="nump">&#8364; 3,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">VAT receivable</a></td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">1,925<span></span>
</td>
<td class="nump">3,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">1,332<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">&#8364; 9,234<span></span>
</td>
<td class="nump">&#8364; 8,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and other current assets - Schedule of Changes in Research Tax Credit Receivables (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Research tax credit receivable at beginning of period</a></td>
<td class="nump">&#8364; 3,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Research tax credit receivable at end of period</a></td>
<td class="nump">4,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nbx_NanobiotixSAMember', window );">Nanobiotix S.A. | 2025 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit', window );">2025 research tax credit</a></td>
<td class="nump">1,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nbx_NanobiotixCorpMember', window );">Nanobiotix Corp. | 2025 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit', window );">2025 research tax credit</a></td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nbx_NanobiotixCorpMember', window );">Nanobiotix Corp. | 2024 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ProceedsFromIncomeTaxCredit', window );">Receipt of 2024 research tax credit - Nanobiotix Corp</a></td>
<td class="num">&#8364; (124)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Receivables From Taxes Other Than Income Tax, Income Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Trade Receivables and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ProceedsFromIncomeTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Income Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ProceedsFromIncomeTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nbx_NanobiotixSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nbx_NanobiotixSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OpenTaxYearAxis=nbx_A2025TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OpenTaxYearAxis=nbx_A2025TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nbx_NanobiotixCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nbx_NanobiotixCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OpenTaxYearAxis=nbx_A2024TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OpenTaxYearAxis=nbx_A2024TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash and bank accounts</a></td>
<td class="nump">&#8364; 4,693<span></span>
</td>
<td class="nump">&#8364; 5,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term bank deposits</a></td>
<td class="nump">24,125<span></span>
</td>
<td class="nump">44,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Net Cash and cash equivalents</a></td>
<td class="nump">&#8364; 28,818<span></span>
</td>
<td class="nump">&#8364; 49,737<span></span>
</td>
<td class="nump">&#8364; 66,335<span></span>
</td>
<td class="nump">&#8364; 75,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net decrease in cash and cash equivalents</a></td>
<td class="nump">&#8364; 20,919<span></span>
</td>
<td class="nump">&#8364; 8,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital Transactions (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 27, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (65,704)<span></span>
</td>
<td class="num">&#8364; (1,843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Allocation of loss 12/31/2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,952)<span></span>
</td>
<td class="num">(21,777)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Allocation of loss 12/31/2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,447<span></span>
</td>
<td class="nump">&#8364; 1,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,426,851<span></span>
</td>
<td class="nump">47,133,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Capital increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">809,820<span></span>
</td>
<td class="nump">293,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,236,671<span></span>
</td>
<td class="nump">47,426,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Premiums related to share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 312,743<span></span>
</td>
<td class="nump">&#8364; 312,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 312,743<span></span>
</td>
<td class="nump">&#8364; 312,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Member', window );">AGA 2023 | Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Allocation of loss 12/31/2024</a></td>
<td class="nump">&#8364; 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Capital increase (in shares)</a></td>
<td class="nump">809,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Capital Issued (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Share capital</a></td>
<td class="num">&#8364; (68,952)<span></span>
</td>
<td class="num">&#8364; (65,704)<span></span>
</td>
<td class="num">&#8364; (21,777)<span></span>
</td>
<td class="num">&#8364; (1,843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share)</a></td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Share capital</a></td>
<td class="nump">&#8364; 1,447<span></span>
</td>
<td class="nump">&#8364; 1,423<span></span>
</td>
<td class="nump">&#8364; 1,423<span></span>
</td>
<td class="nump">&#8364; 1,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="nump">48,236,671<span></span>
</td>
<td class="nump">47,426,851<span></span>
</td>
<td class="nump">47,426,851<span></span>
</td>
<td class="nump">47,133,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Founder's Warrants, Warrants, Stock Options and Free Shares (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>security</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes', window );">Number of security types (security) | security</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period | &#8364;</a></td>
<td class="num">&#8364; (5,383)<span></span>
</td>
<td class="num">&#8364; (21,872)<span></span>
</td>
<td class="nump">&#8364; 68,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share-Based Payment Arrangement, Number Of Security Types</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Stock Option Plans (Details)<br></strong></div></th>
<th class="th">
<div>May 16, 2025 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 18, 2025 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember', window );">Executive Board and Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares) | shares</a></td>
<td class="nump">1,241,005<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euro per share)</a></td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="nump">&#8364; 2.97<span></span>
</td>
<td class="nump">&#8364; 3.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedPaymentArrangementStockOptionTerm', window );">Maximum term of options granted for share-based payment arrangement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember', window );">Executive Board and Employees | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedPaymentArrangementStockOptionTerm', window );">Maximum term of options granted for share-based payment arrangement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ShareBasedPaymentArrangementStockOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Stock Option Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ShareBasedPaymentArrangementStockOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Obligations - Disclosure of Changes in Provisions (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_LumpSumRetirementBenefitsMember', window );">Lump-sum retirement benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherProvisionsRollForward', window );"><strong>Other Provisions [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">&#8364; 432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_NonCurrentOtherProvisionsMember', window );">Total Non-current provisions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherProvisionsRollForward', window );"><strong>Other Provisions [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">&#8364; 479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OtherProvisionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OtherProvisionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision Used And Unused Provision Reversed, Other Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_LumpSumRetirementBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_LumpSumRetirementBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_NonCurrentOtherProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_NonCurrentOtherProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Schedule of Changes in Provisions (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_CurrentOtherProvisionsMember', window );">Total current provisions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherProvisionsRollForward', window );"><strong>Other Provisions [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">&#8364; 438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember', window );">Provisions for disputes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherProvisionsRollForward', window );"><strong>Other Provisions [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForChargesMember', window );">Provisions for charges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherProvisionsRollForward', window );"><strong>Other Provisions [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">&#8364; 49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OtherProvisionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OtherProvisionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision Used And Unused Provision Reversed, Other Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_CurrentOtherProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_CurrentOtherProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Additional Information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember', window );">Provisions for disputes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Provisions</a></td>
<td class="nump">&#8364; 230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision Used And Unused Provision Reversed, Other Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial liabilities - Schedule of Changes in Financial Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Changes In Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Total current financial liabilities</a></td>
<td class="nump">&#8364; 4,735<span></span>
</td>
<td class="nump">&#8364; 4,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Total non-current financial liabilities</a></td>
<td class="nump">46,505<span></span>
</td>
<td class="nump">45,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">51,240<span></span>
</td>
<td class="nump">50,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Changes In Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Total current financial liabilities</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Total non-current financial liabilities</a></td>
<td class="nump">2,385<span></span>
</td>
<td class="nump">2,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=nbx_ConditionalAdvancesMember', window );">Conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Changes In Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Total current financial liabilities</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Total non-current financial liabilities</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember', window );">PGE loans | Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Changes In Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Total current financial liabilities</a></td>
<td class="nump">2,522<span></span>
</td>
<td class="nump">2,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Total non-current financial liabilities</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Changes In Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Total current financial liabilities</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Total non-current financial liabilities</a></td>
<td class="nump">&#8364; 43,054<span></span>
</td>
<td class="nump">&#8364; 40,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nbx_ConditionalAdvancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nbx_ConditionalAdvancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_LongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_LongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Narrative (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 10, 2020 </div>
<div>EUR (&#8364;) </div>
<div>quarterly_installment</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 12, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Jul. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings, classified as financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,926<span></span>
</td>
<td class="nump">&#8364; 1,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Increase in loans and conditional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,174<span></span>
</td>
<td class="nump">3,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC &#8220;PGE&#8221;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowing, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings, classified as financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance &#8220;PGE&#8221;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowing, interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings, classified as financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Increase in loans and conditional advances</a></td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_BorrowingMaturityTerm', window );">Borrowing, maturity</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_BorrowingPercentageOfStateGuaranteedLoan', window );">Percentage of state-guaranteed loan</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_BorrowingGuaranteeFee', window );">Borrowing, guarantee fee</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_BorrowingNumberOfQuarterlyInstallments', window );">Number of quarterly instalments | quarterly_installment</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowing, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings, classified as financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseInOutstandingLoans', window );">Increase in outstanding loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of accretion and discounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows', window );">Adjustment to debt financing related to estimated debt outflows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections', window );">Increase (decrease) related to adjustments for income forecast projections</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,400<span></span>
</td>
<td class="nump">&#8364; 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse', window );">Market rate estimated percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 97,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_BorrowingsCumulativeMilestonePrepaymentAmount', window );">Borrowings, cumulative milestone prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_EstimatedRoyaltyPayments', window );">Estimated royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 45,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ConsolidatedForecastedSalesPeriod', window );">Consolidated forecasted sales, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Principal and Fixed Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | At fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nbx_BanquePubliqueDInvestissementMember', window );">Banque Publique d&#8217;Investissement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdvancesReceivedInterestRate', window );">Advances, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfCurrentBorrowings', window );">Repayments of current borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ReimbursedAmountOfCorresponds', window );">Reimbursed amount of corresponds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nbx_BPIFranceMember', window );">Bpifrance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfCurrentBorrowings', window );">Repayments of current borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ReimbursedAmountOfCorresponds', window );">Reimbursed amount of corresponds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdvancesAuthorizedAmountToBeAdvanced', window );">Authorized amount to be advanced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Advances', window );">Advances received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Advances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of advances received representing contract liabilities for performance obligations satisfied at a point in time. [Refer: Contract liabilities; Performance obligations satisfied at point in time [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Advances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate used in the current estimate of the present value of the future cash flows expected to be derived from an asset or cash-generating unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 130<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_130_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Debt Financing Related to Estimated Debt Outflows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdvancesAuthorizedAmountToBeAdvanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances, Authorized Amount To Be Advanced</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdvancesAuthorizedAmountToBeAdvanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdvancesReceivedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances Received, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdvancesReceivedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingGuaranteeFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Guarantee Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingGuaranteeFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Maturity Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingNumberOfQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Number Of Quarterly Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingNumberOfQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingPercentageOfStateGuaranteedLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Percentage Of State-Guaranteed Loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingPercentageOfStateGuaranteedLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingsCumulativeMilestonePrepaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Cumulative Milestone Prepayment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingsCumulativeMilestonePrepaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ConsolidatedForecastedSalesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated Forecasted Sales, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ConsolidatedForecastedSalesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_EstimatedRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_EstimatedRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInOutstandingLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Outstanding Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInOutstandingLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Related To Adjustments For Income Forecast Projections</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ReimbursedAmountOfCorresponds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursed Amount of Corresponds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ReimbursedAmountOfCorresponds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DebtDetailsAxis=nbx_PrincipalAndFixedRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DebtDetailsAxis=nbx_PrincipalAndFixedRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DebtDetailsAxis=nbx_MilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DebtDetailsAxis=nbx_MilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbx_BanquePubliqueDInvestissementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbx_BanquePubliqueDInvestissementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbx_BPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbx_BPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Schedule of Changes in Liabilities Arising from Financing Activities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward', window );"><strong>Liabilities Arising From Financing Activities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">&#8364; (336)<span></span>
</td>
<td class="num">&#8364; (609)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="num">(568)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows used in financing activities</a></td>
<td class="num">(2,830)<span></span>
</td>
<td class="num">(2,655)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=nbx_LiabilitiesRelatedToFinancingActivitiesMember', window );">Liabilities Related to Financing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward', window );"><strong>Liabilities Arising From Financing Activities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities', window );">Decrease in loans and conditional advances</a></td>
<td class="num">(1,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="num">(568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows used in financing activities</a></td>
<td class="num">(2,831)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities', window );">Indexation effect on current lease commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and catch-up</a></td>
<td class="num">(1,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">3,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CashFlowsFromUsedInNonFinancingActivities', window );">Non-cash from financing activities</a></td>
<td class="nump">3,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">51,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent', window );">Of which Current</a></td>
<td class="nump">4,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent', window );">Of which Non-Current</a></td>
<td class="nump">46,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward', window );"><strong>Liabilities Arising From Financing Activities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities', window );">Decrease in loans and conditional advances</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="num">(568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows used in financing activities</a></td>
<td class="num">(637)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities', window );">Indexation effect on current lease commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and catch-up</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CashFlowsFromUsedInNonFinancingActivities', window );">Non-cash from financing activities</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">3,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent', window );">Of which Current</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent', window );">Of which Non-Current</a></td>
<td class="nump">2,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceAdvanceMember', window );">Bpifrance advance | Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward', window );"><strong>Liabilities Arising From Financing Activities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities', window );">Decrease in loans and conditional advances</a></td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows used in financing activities</a></td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities', window );">Indexation effect on current lease commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and catch-up</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CashFlowsFromUsedInNonFinancingActivities', window );">Non-cash from financing activities</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent', window );">Of which Current</a></td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent', window );">Of which Non-Current</a></td>
<td class="nump">581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_ConditionalAdvanceBPIFranceMember', window );">Curadigm Bpi advance | Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward', window );"><strong>Liabilities Arising From Financing Activities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities', window );">Decrease in loans and conditional advances</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows used in financing activities</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities', window );">Indexation effect on current lease commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and catch-up</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CashFlowsFromUsedInNonFinancingActivities', window );">Non-cash from financing activities</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent', window );">Of which Current</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent', window );">Of which Non-Current</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC &#8220;PGE&#8221; | Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward', window );"><strong>Liabilities Arising From Financing Activities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities', window );">Decrease in loans and conditional advances</a></td>
<td class="num">(626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows used in financing activities</a></td>
<td class="num">(638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities', window );">Indexation effect on current lease commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and catch-up</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CashFlowsFromUsedInNonFinancingActivities', window );">Non-cash from financing activities</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent', window );">Of which Current</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent', window );">Of which Non-Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance &#8220;PGE&#8221; | Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward', window );"><strong>Liabilities Arising From Financing Activities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities', window );">Decrease in loans and conditional advances</a></td>
<td class="num">(626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows used in financing activities</a></td>
<td class="num">(648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities', window );">Indexation effect on current lease commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and catch-up</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CashFlowsFromUsedInNonFinancingActivities', window );">Non-cash from financing activities</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent', window );">Of which Current</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent', window );">Of which Non-Current</a></td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward', window );"><strong>Liabilities Arising From Financing Activities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities', window );">Decrease in loans and conditional advances</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows used in financing activities</a></td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities', window );">Indexation effect on current lease commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and catch-up</a></td>
<td class="num">(1,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">3,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CashFlowsFromUsedInNonFinancingActivities', window );">Non-cash from financing activities</a></td>
<td class="nump">3,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">43,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent', window );">Of which Current</a></td>
<td class="nump">430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent', window );">Of which Non-Current</a></td>
<td class="nump">&#8364; 43,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CashFlowsFromUsedInNonFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flows From (Used In) Non Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CashFlowsFromUsedInNonFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Decrease In Loans And Conditional Advances, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Impact Of Discounting And Catch up, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Indexation Effect On Current Lease Commitment, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_LiabilitiesArisingFromFinancingActivitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities Arising from Financing Activities Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_LiabilitiesArisingFromFinancingActivitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities Arising from Financing Activities Non Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_LiabilitiesArisingFromFinancingActivitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_LiabilitiesArisingFromFinancingActivitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=nbx_LiabilitiesRelatedToFinancingActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=nbx_LiabilitiesRelatedToFinancingActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_ConditionalAdvanceBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_ConditionalAdvanceBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Schedule of Maturity Analysis for Advances Loans and Lease Liabilities (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2020</div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>loan</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>loan</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 105,822<span></span>
</td>
<td class="nump">&#8364; 111,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,831<span></span>
</td>
<td class="nump">5,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,843<span></span>
</td>
<td class="nump">24,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,781<span></span>
</td>
<td class="nump">41,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,366<span></span>
</td>
<td class="nump">39,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember', window );">Bpifrance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember', window );">Bpifrance | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember', window );">Bpifrance | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember', window );">Bpifrance | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember', window );">Bpifrance | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember', window );">Curadigm interest-free Bpifrance advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember', window );">Curadigm interest-free Bpifrance advance | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember', window );">Curadigm interest-free Bpifrance advance | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember', window );">Curadigm interest-free Bpifrance advance | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember', window );">Curadigm interest-free Bpifrance advance | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC "PGE"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC "PGE" | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">1,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC "PGE" | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC "PGE" | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC "PGE" | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance "PGE"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_BorrowingMaturityTerm', window );">Borrowing, maturity</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance "PGE" | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance "PGE" | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance "PGE" | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance "PGE" | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,751<span></span>
</td>
<td class="nump">100,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,027<span></span>
</td>
<td class="nump">19,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,891<span></span>
</td>
<td class="nump">40,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,366<span></span>
</td>
<td class="nump">39,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,855<span></span>
</td>
<td class="nump">4,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember', window );">HSBC "PGE" and Bpifrance "PGE"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_BorrowingScheduledForReimbursementNumber', window );">Borrowing, number of PGE | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_BorrowingMaturityTerm', window );">Borrowing, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriod', window );">Borrowing, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankBorrowingsUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph IG31A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IG31A&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph B11D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B11D&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankBorrowingsUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 58<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 72<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_72_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 72<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_72_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingDefermentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Deferment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingDefermentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Maturity Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingScheduledForReimbursementNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing Scheduled For Reimbursement, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingScheduledForReimbursementNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade payables and other current liabilities - Schedule of Trade and Other Payables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses - clinical trials</a></td>
<td class="nump">&#8364; 7,413<span></span>
</td>
<td class="nump">&#8364; 15,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables and other accruals</a></td>
<td class="nump">4,226<span></span>
</td>
<td class="nump">4,484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total trade and other payables</a></td>
<td class="nump">&#8364; 11,639<span></span>
</td>
<td class="nump">&#8364; 20,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and other current liabilities - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Disclosure of Trade Payables and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Change in accrued expenses</a></td>
<td class="nump">&#8364; 7,413<span></span>
</td>
<td class="nump">&#8364; 15,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent', window );">Decrease in payroll tax and other payroll liabilities</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseInBonusAccrual', window );">Decrease in bonus accrual</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities', window );">Adjustments for increase (decrease) in contract liabilities</a></td>
<td class="nump">18,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current contract liabilities</a></td>
<td class="nump">36,172<span></span>
</td>
<td class="nump">18,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseRefundLiabilities', window );">Decrease in refund liabilities</a></td>
<td class="nump">28,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ClinicalStudiesAxis=nbx_A1100StudyMember', window );">1100 study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Disclosure of Trade Payables and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Change in accrued expenses</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ClinicalStudiesAxis=nbx_NANORAY312Member', window );">NANORAY-312</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Disclosure of Trade Payables and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses', window );">Decrease in accrued expenses</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Change in accrued expenses</a></td>
<td class="nump">&#8364; 1,800<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseInOtherCurrentPayables', window );">Increase of other trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Increase (Decrease) In Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Trade Payables and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInBonusAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Bonus Accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInBonusAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Other Current Payables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseRefundLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Refund Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseRefundLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ClinicalStudiesAxis=nbx_A1100StudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ClinicalStudiesAxis=nbx_A1100StudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ClinicalStudiesAxis=nbx_NANORAY312Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ClinicalStudiesAxis=nbx_NANORAY312Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade payables and other current liabilities - Schedule of Other Current Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Tax liabilities</a></td>
<td class="nump">&#8364; 415<span></span>
</td>
<td class="nump">&#8364; 537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Payroll tax and other payroll liabilities</a></td>
<td class="nump">5,872<span></span>
</td>
<td class="nump">6,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherMiscellaneousCurrentLiabilities', window );">Other payables</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">&#8364; 7,000<span></span>
</td>
<td class="nump">&#8364; 7,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OtherMiscellaneousCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Miscellaneous Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OtherMiscellaneousCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities', window );">Deferred income</a></td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="nump">&#8364; 61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities - Current</a></td>
<td class="nump">36,172<span></span>
</td>
<td class="nump">18,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities', window );">Deferred income and current contract liabilities</a></td>
<td class="nump">&#8364; 36,222<span></span>
</td>
<td class="nump">&#8364; 18,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current refund liabilities</a></td>
<td class="nump">&#8364; 4,105<span></span>
</td>
<td class="nump">&#8364; 27,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Current refund liabilities</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">7,835<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RefundsProvision', window );">Refund liabilities</a></td>
<td class="nump">&#8364; 7,378<span></span>
</td>
<td class="nump">&#8364; 35,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for refunds. [Refer: Refunds provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for refunds to be made by the entity to its customers. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments included in the statement of financial position and impact on income - Schedule of Financial Asset and Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">&#8364; 31,064<span></span>
</td>
<td class="nump">&#8364; 53,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets, at fair value</a></td>
<td class="nump">31,064<span></span>
</td>
<td class="nump">53,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">62,879<span></span>
</td>
<td class="nump">70,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue', window );">Total financial liabilities, at fair value</a></td>
<td class="nump">65,900<span></span>
</td>
<td class="nump">73,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial liabilities at amortised cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">62,879<span></span>
</td>
<td class="nump">70,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">Financial liabilities at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_NonCurrentFinancialLiabilitiesMember', window );">Non-current financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">46,505<span></span>
</td>
<td class="nump">45,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue', window );">Total financial liabilities, at fair value</a></td>
<td class="nump">49,508<span></span>
</td>
<td class="nump">48,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_NonCurrentFinancialLiabilitiesMember', window );">Non-current financial liabilities | Financial liabilities at amortised cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">46,505<span></span>
</td>
<td class="nump">45,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_NonCurrentFinancialLiabilitiesMember', window );">Non-current financial liabilities | Financial liabilities at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_CurrentFinancialLiabilitiesMember', window );">Current financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">4,735<span></span>
</td>
<td class="nump">4,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue', window );">Total financial liabilities, at fair value</a></td>
<td class="nump">4,753<span></span>
</td>
<td class="nump">4,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_CurrentFinancialLiabilitiesMember', window );">Current financial liabilities | Financial liabilities at amortised cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">4,735<span></span>
</td>
<td class="nump">4,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_CurrentFinancialLiabilitiesMember', window );">Current financial liabilities | Financial liabilities at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_TradeAndOtherPayablesMember', window );">Trade payables and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">11,639<span></span>
</td>
<td class="nump">20,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue', window );">Total financial liabilities, at fair value</a></td>
<td class="nump">11,639<span></span>
</td>
<td class="nump">20,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_TradeAndOtherPayablesMember', window );">Trade payables and other payables | Financial liabilities at amortised cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">11,639<span></span>
</td>
<td class="nump">20,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_TradeAndOtherPayablesMember', window );">Trade payables and other payables | Financial liabilities at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember', window );">Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Assets and liabilities carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">31,064<span></span>
</td>
<td class="nump">53,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_NonCurrentFinancialAssetsMember', window );">Non-current financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets, at fair value</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_NonCurrentFinancialAssetsMember', window );">Non-current financial assets | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_NonCurrentFinancialAssetsMember', window );">Non-current financial assets | Assets and liabilities carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets, at fair value</a></td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables | Assets and liabilities carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_CashAndCashEquivalents1Member', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">28,818<span></span>
</td>
<td class="nump">49,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets, at fair value</a></td>
<td class="nump">28,818<span></span>
</td>
<td class="nump">49,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_CashAndCashEquivalents1Member', window );">Cash and cash equivalents | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_CashAndCashEquivalents1Member', window );">Cash and cash equivalents | Assets and liabilities carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">&#8364; 28,818<span></span>
</td>
<td class="nump">&#8364; 49,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 71<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_71&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 71<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_71&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Financial Liabilities Including Trade Payables And Other Payables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_NonCurrentFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_NonCurrentFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_CurrentFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_CurrentFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_NonCurrentFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=nbx_NonCurrentFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_CashAndCashEquivalents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=nbx_CashAndCashEquivalents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments included in the statement of financial position and impact on income - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 28,818<span></span>
</td>
<td class="nump">&#8364; 49,737<span></span>
</td>
<td class="nump">&#8364; 66,335<span></span>
</td>
<td class="nump">&#8364; 75,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 17, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">&#8364; 24,928<span></span>
</td>
<td class="nump">&#8364; 6,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current refund liabilities</a></td>
<td class="nump">4,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 27,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities', window );">Adjustments for increase (decrease) in contract liabilities</a></td>
<td class="nump">18,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ResearchAndDevelopmentTaxCredit', window );">Research tax credit</a></td>
<td class="nump">1,616<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance &#8220;PGE&#8221;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nbx_OtherSalesMember', window );">Other sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">3,406<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nbx_ServicesMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">21,522<span></span>
</td>
<td class="nump">3,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdjustmentsToRevenueFromContractsWithCustomers', window );">Contract modification adjustment</a></td>
<td class="nump">21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nbx_ServiceRechargeMember', window );">Service Recharge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nbx_SupplyServicesMember', window );">Supply Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_NANORAY312Member', window );">NANORAY-312</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived', window );">Collaboration agreement, potential development and commercial milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaBVMember', window );">Janssen Pharmaceutica BV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current refund liabilities</a></td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaBVMember', window );">Janssen Pharmaceutica BV | Other sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaBVMember', window );">Janssen Pharmaceutica BV | Recharge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">&#8364; 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember', window );">Janssen Pharmaceutica NV | Other sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember', window );">Janssen Pharmaceutica NV | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember', window );">Janssen Pharmaceutica NV | Technology Transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdjustmentsToRevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Revenue From Contracts With Customers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdjustmentsToRevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Potential Milestones Payments To Be Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_OtherSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_OtherSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_ServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_ServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_ServiceRechargeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_ServiceRechargeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_SupplyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_SupplyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_NANORAY312Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_NANORAY312Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_RechargeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_RechargeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_TechnologyTransferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_TechnologyTransferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income - Schedule of Revenues and Other Income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">&#8364; 24,928<span></span>
</td>
<td class="nump">&#8364; 6,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ResearchAndDevelopmentTaxCredit', window );">Research tax credit</a></td>
<td class="nump">1,616<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Total other income</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">3,126<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenues and other income</a></td>
<td class="nump">26,638<span></span>
</td>
<td class="nump">9,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nbx_ServicesMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">21,522<span></span>
</td>
<td class="nump">3,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nbx_OtherSalesMember', window );">Other sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">&#8364; 3,406<span></span>
</td>
<td class="nump">&#8364; 2,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_ServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_ServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_OtherSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_OtherSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Schedule of Research and Development Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses', window );">Purchases, sub-contracting and other expenses</a></td>
<td class="num">&#8364; (7,489)<span></span>
</td>
<td class="num">&#8364; (15,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ResearchAndDevelopmentExpensePayrollCosts', window );">Payroll costs (including share-based payments)</a></td>
<td class="num">(6,430)<span></span>
</td>
<td class="num">(6,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense', window );">Depreciation, amortization, and provision expenses</a></td>
<td class="num">(610)<span></span>
</td>
<td class="num">(682)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="num">&#8364; (14,529)<span></span>
</td>
<td class="num">&#8364; (21,987)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Depreciation, Amortization And Provision Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchAndDevelopmentExpensePayrollCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Payroll Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchAndDevelopmentExpensePayrollCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Sub-Contracting And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Narrative (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreasePayrollExpense', window );">Increase (decrease) in employee benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreasePayrollExpensePercentage', window );">Percentage change in employee benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="nump">&#8364; 3,094<span></span>
</td>
<td class="nump">&#8364; 2,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_SeveranceExpenses', window );">Severance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseInDepreciationExpense', window );">Decrease in depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage', window );">Percentage of increase in employee benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseInEmployeeBenefitExpense', window );">Increase in employee benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense from share-based payment transactions with employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">&#8364; 1,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherNonrecurringExpenses', window );">Other non recurring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">&#8364; 137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OperatingExpenseAxis=nbx_ResearchAndDevelopmentMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OperatingExpenseAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">SG&amp;A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NonRecurringExpenseTypeAxis=nbx_EmploymentTerminationIndemnitiesMember', window );">Employment Termination Indemnities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherNonrecurringExpenses', window );">Other non recurring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentArrangement1Member', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses', window );">Increase in purchases, sub-contracting and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">SG&amp;A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreasePayrollExpense', window );">Increase (decrease) in employee benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreasePayrollExpensePercentage', window );">Percentage change in employee benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses', window );">Decrease in purchases, fees, and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 227<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_227&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 227<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_227&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfOperatingExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfOperatingExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Depreciation Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInEmployeeBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Employee Benefit Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInEmployeeBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Employee Benefit Expense, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Purchases, Fees, And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreasePayrollExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Payroll Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreasePayrollExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreasePayrollExpensePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Payroll Expense, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreasePayrollExpensePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OtherNonrecurringExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Nonrecurring Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OtherNonrecurringExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SeveranceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SeveranceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OperatingExpenseAxis=nbx_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OperatingExpenseAxis=nbx_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OperatingExpenseAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OperatingExpenseAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NonRecurringExpenseTypeAxis=nbx_EmploymentTerminationIndemnitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NonRecurringExpenseTypeAxis=nbx_EmploymentTerminationIndemnitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentArrangement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentArrangement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Schedule of Selling, General and Administrative Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense', window );">Purchases, fees and other expenses</a></td>
<td class="num">&#8364; (4,334)<span></span>
</td>
<td class="num">&#8364; (4,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts', window );">Payroll costs (including share-based payments)</a></td>
<td class="num">(7,040)<span></span>
</td>
<td class="num">(6,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense', window );">Depreciation, amortization and provision expenses</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(301)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Total SG&amp;A expenses</a></td>
<td class="num">&#8364; (11,294)<span></span>
</td>
<td class="num">&#8364; (10,819)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling General And Administrative Expense, Payroll Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SellingGeneralAndAdministrativeExpensePayrollCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling General And Administrative Expense, Purchases, Fees And Other Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Schedule of Payroll Costs (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="num">&#8364; (7,182)<span></span>
</td>
<td class="num">&#8364; (7,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Payroll taxes</a></td>
<td class="num">(4,088)<span></span>
</td>
<td class="num">(3,324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments</a></td>
<td class="num">(2,161)<span></span>
</td>
<td class="num">(1,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss', window );">Retirement benefit obligations</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total payroll costs</a></td>
<td class="num">&#8364; (13,470)<span></span>
</td>
<td class="num">&#8364; (12,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageNumberOfEmployees', window );">Average headcount | employee</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">End-of-period headcount | employee</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of personnel employed by the entity during a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 133<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_133_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 141<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_141&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Schedule of Depreciation, Amortization and Provision Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Amortization expense of intangible assets</a></td>
<td class="num">&#8364; (2)<span></span>
</td>
<td class="num">&#8364; (2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Amortization expense of tangible assets</a></td>
<td class="num">(798)<span></span>
</td>
<td class="num">(785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LitigationExpense', window );">Reversal of provision for disputes and charges</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provision for disputes and charges</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19', window );">Total depreciation, amortization and provision expenses (except IAS 19)</a></td>
<td class="num">(529)<span></span>
</td>
<td class="num">(983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ProvisionForRetirementBenefitObligationsNet', window );">Total Provision for retirement benefit obligations (IAS 19)</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DepreciationAmortizationAndProvisionExpenses', window );">Total depreciation, amortization and provision expenses</a></td>
<td class="num">(569)<span></span>
</td>
<td class="num">(1,016)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentArrangement1Member', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Amortization expense of intangible assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Amortization expense of tangible assets</a></td>
<td class="num">(645)<span></span>
</td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LitigationExpense', window );">Reversal of provision for disputes and charges</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provision for disputes and charges</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19', window );">Total depreciation, amortization and provision expenses (except IAS 19)</a></td>
<td class="num">(610)<span></span>
</td>
<td class="num">(682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ProvisionForRetirementBenefitObligationsNet', window );">Total Provision for retirement benefit obligations (IAS 19)</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DepreciationAmortizationAndProvisionExpenses', window );">Total depreciation, amortization and provision expenses</a></td>
<td class="num">(637)<span></span>
</td>
<td class="num">(705)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">SG&amp;A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Amortization expense of intangible assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Amortization expense of tangible assets</a></td>
<td class="num">(152)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_LitigationExpense', window );">Reversal of provision for disputes and charges</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provision for disputes and charges</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19', window );">Total depreciation, amortization and provision expenses (except IAS 19)</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ProvisionForRetirementBenefitObligationsNet', window );">Total Provision for retirement benefit obligations (IAS 19)</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DepreciationAmortizationAndProvisionExpenses', window );">Total depreciation, amortization and provision expenses</a></td>
<td class="nump">&#8364; 68<span></span>
</td>
<td class="num">&#8364; (311)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DepreciationAmortizationAndProvisionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Amortization And Provision Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DepreciationAmortizationAndProvisionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Amortization And Provision Expenses Excluding IAS 19</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfOperatingExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfOperatingExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_LitigationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_LitigationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ProvisionForRetirementBenefitObligationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for Retirement Benefit Obligations&#160;Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ProvisionForRetirementBenefitObligationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentArrangement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentArrangement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Schedule of Other Operating Income (Expenses) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherNonrecurringExpenses', window );">Other non recurring expenses</a></td>
<td class="num">&#8364; (12)<span></span>
</td>
<td class="num">&#8364; (137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_OtherNonrecurringsIncome', window );">Other non recurring income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Total other operating income and expenses</a></td>
<td class="num">&#8364; (7)<span></span>
</td>
<td class="num">&#8364; (134)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OtherNonrecurringExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Nonrecurring Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OtherNonrecurringExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OtherNonrecurringsIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Nonrecurrings Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OtherNonrecurringsIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-based payments - Schedule of Changes in Founder's Warrant (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 07, 2017 </div>
<div>shares </div>
<div>benefeciary</div>
</th>
<th class="th">
<div>Feb. 02, 2016 </div>
<div>shares </div>
<div>benefeciary</div>
</th>
<th class="th">
<div>Jun. 10, 2015 </div>
<div>shares </div>
<div>benefeciary</div>
</th>
<th class="th">
<div>Feb. 10, 2015 </div>
<div>shares </div>
<div>benefeciary</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">5,158,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">71,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of shares available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1 | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1 | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">53,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of shares available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">29,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">96,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of shares available for subscription (in shares)</a></td>
<td class="nump">96,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">96,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 O | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 O | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 O | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember', window );">BSPCE 2016 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">31,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">98,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of shares available for subscription (in shares)</a></td>
<td class="nump">98,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">98,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember', window );">BSPCE 2016 P | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember', window );">BSPCE 2016 P | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember', window );">BSPCE 2016 P | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">97,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of shares available for subscription (in shares)</a></td>
<td class="nump">97,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">97,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 O | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 O | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 O | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member', window );">BSCPE 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of shares available for subscription (in shares)</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member', window );">BSCPE 2017 | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member', window );">BSCPE 2017 | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member', window );">BSCPE 2017 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Share-based Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Other Equity Instruments That May Be Subscribed In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Beneficiaries Of Other Equity Instruments, Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Equity Instruments Authorised In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares To Which Other Equity Instruments Were Likely To Give Right In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_CorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_CorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_LaurentLevyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_LaurentLevyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_BeneficiariesOtherThanCorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_BeneficiariesOtherThanCorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-based payments - Schedule of Warrants Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 17, 2020 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 27, 2018 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 25, 2015 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 10, 2015 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">5,158,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">BSA issue price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of awards available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of awards that may be subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1 | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1 | Corporate officers | Anne-Marie GRAFFIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1 | Corporate officers | Enno SPILLNER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1 | Corporate officers | Alain HERRERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152Member', window );">BSA 2015-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">BSA issue price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of awards available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of awards that may be subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152Member', window );">BSA 2015-2 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member', window );">BSA 2018-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">BSA issue price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">5,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of awards available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of awards that may be subscribed (in shares)</a></td>
<td class="nump">5,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member', window );">BSA 2018-2 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">BSA issue price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of awards available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of awards that may be subscribed (in shares)</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1 | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1 | Corporate officers | Anne-Marie GRAFFIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1 | Corporate officers | Enno SPILLNER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1 | Corporate officers | Alain HERRERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">BSA issue price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of awards available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of awards that may be subscribed (in shares)</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020 | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020 | Corporate officers | Anne-Marie GRAFFIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020 | Corporate officers | Enno SPILLNER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020 | Corporate officers | Alain HERRERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021Member', window );">BSA 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">BSA issue price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">33,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">14,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Total number of awards available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of awards that may be subscribed (in shares)</a></td>
<td class="nump">14,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021Member', window );">BSA 2021 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Share-based Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Other Equity Instruments That May Be Subscribed In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Beneficiaries Of Other Equity Instruments, Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Equity Instruments Authorised In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares To Which Other Equity Instruments Were Likely To Give Right In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_CorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_CorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OfficersNameAxis=nbx_AnneMarieGraffinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OfficersNameAxis=nbx_AnneMarieGraffinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OfficersNameAxis=nbx_EnnoSpillnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OfficersNameAxis=nbx_EnnoSpillnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OfficersNameAxis=nbx_AlainHerreraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OfficersNameAxis=nbx_AlainHerreraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_BeneficiariesOtherThanCorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_BeneficiariesOtherThanCorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Schedule of Changes in Share Options (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 23, 2024 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 20, 2023 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 22, 2022 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2019 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 06, 2018 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 07, 2017 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 03, 2016 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 02, 2016 </div>
<div>shares </div>
<div>benefeciary </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember', window );">OSA 2016-1 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember', window );">OSA 2016-1 P | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 O | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member', window );">OSA 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member', window );">OSA 2018 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member', window );">OSA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">12,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">24,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">24,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">24,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member', window );">OSA 2019-1 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member', window );">OSA 2019 LLY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member', window );">OSA 2019 LLY | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member', window );">OSA 2019 LLY | Corporate officers | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">47,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">360,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">360,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">360,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020 | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020 | Corporate officers | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020 | Corporate officers | Anne-Juliette HERMANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">104,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">38,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">38,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">38,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember', window );">OSA 2021-04 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">87,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">340,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">340,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember', window );">OSA 2021-04 P | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember', window );">OSA 2021-04 P | Corporate officers | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember', window );">OSA 2021-04 P | Corporate officers | Anne-Juliette HERMANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember', window );">OSA 2021-04 P | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember', window );">OSA 2021-06 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember', window );">OSA 2021-06 P | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember', window );">OSA 2021-06 P | Corporate officers | Bart VAN RHIJN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Corporate officers | Bart VAN RHIJN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206PerformanceMember', window );">OSA 2022-06 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">46,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">123,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">123,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206PerformanceMember', window );">OSA 2022-06 P | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Corporate officers | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Corporate officers | Anne-Juliette HERMANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Corporate officers | Bart VAN RHIJN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember', window );">OSA 2023-01 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">318,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">106,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">318,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember', window );">OSA 2023-01 O | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember', window );">OSA 2023-01 O | Corporate officers | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember', window );">OSA 2023-01 O | Corporate officers | Anne-Juliette HERMANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember', window );">OSA 2023-01 O | Corporate officers | Bart VAN RHIJN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember', window );">OSA 2023-01 O | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">1,219,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,219,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">406,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">1,219,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,219,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Corporate officers | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Corporate officers | Anne-Juliette HERMANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Corporate officers | Bart VAN RHIJN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Corporate officers | Louis Kayitalire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember', window );">OSA 2025-01 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember', window );">OSA 2025-01 O | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember', window );">OSA 2025-01 O | Corporate officers | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember', window );">OSA 2025-01 O | Corporate officers | Anne-Juliette HERMANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember', window );">OSA 2025-01 O | Corporate officers | Bart VAN RHIJN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember', window );">OSA 2025-01 O | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement', window );">Total number of share options authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of share options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,241,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,241,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Total number of share options lapsed or cancelled (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">1,241,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,241,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Maximum number of shares available for subscription (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Maximum total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">1,241,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,241,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O | Corporate officers | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O | Corporate officers | Anne-Juliette HERMANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O | Corporate officers | Bart VAN RHIJN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O | Corporate officers | Louis Kayitalire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the share options were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Share-based Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Share Options That May Be Subscribed In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Beneficiaries Of Share Options, Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Authorised In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares To Which Options Were Likely To Give Right In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_BeneficiariesOtherThanCorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_BeneficiariesOtherThanCorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_CorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_CorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OfficersNameAxis=nbx_LaurentLevyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OfficersNameAxis=nbx_LaurentLevyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OfficersNameAxis=nbx_AnneJulietteHermantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OfficersNameAxis=nbx_AnneJulietteHermantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OfficersNameAxis=nbx_BartVanRhijnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OfficersNameAxis=nbx_BartVanRhijnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OfficersNameAxis=nbx_LouisKayitalireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OfficersNameAxis=nbx_LouisKayitalireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-based payments - Schedule of Free Shares Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2023 </div>
<div>shares </div>
<div>benefeciary</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">5,158,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P1Member', window );">AGA 2023 - P1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">392,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">35,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod', window );">Duration of the holding period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P1Member', window );">AGA 2023 - P1 | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P1Member', window );">AGA 2023 - P1 | Corporate officers | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P1Member', window );">AGA 2023 - P1 | Corporate officers | Anne-Juliette HERMANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P1Member', window );">AGA 2023 - P1 | Corporate officers | Bart VAN RHIJN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P1Member', window );">AGA 2023 - P1 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P2Member', window );">AGA 2023 - P2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement', window );">Total number of awards authorised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of shares subscribed (in shares)</a></td>
<td class="nump">417,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Total number of awards lapsed, cancelled or forfeited (in shares)</a></td>
<td class="nump">21,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement', window );">Total number of shares that may be subscribed (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod', window );">Duration of the holding period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P2Member', window );">AGA 2023 - P2 | Corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P2Member', window );">AGA 2023 - P2 | Corporate officers | Laurent LEVY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P2Member', window );">AGA 2023 - P2 | Corporate officers | Anne-Juliette HERMANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P2Member', window );">AGA 2023 - P2 | Corporate officers | Bart VAN RHIJN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement', window );">Total number of shares to which the awards were likely to give right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P2Member', window );">AGA 2023 - P2 | Beneficiaries other than corporate officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement', window );">Number of beneficiaries who are not corporate officers | benefeciary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Share-based Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Other Equity Instruments That May Be Subscribed In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Beneficiaries Of Other Equity Instruments, Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Equity Instruments Authorised In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares To Which Other Equity Instruments Were Likely To Give Right In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Holding Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_CorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_CorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OfficersNameAxis=nbx_LaurentLevyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OfficersNameAxis=nbx_LaurentLevyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OfficersNameAxis=nbx_AnneJulietteHermantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OfficersNameAxis=nbx_AnneJulietteHermantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OfficersNameAxis=nbx_BartVanRhijnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OfficersNameAxis=nbx_BartVanRhijnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_BeneficiariesOtherThanCorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_BeneficiariesOtherThanCorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-based payments - Schedule of Number and Weighted Average Remaining Contractual Life of Outstanding Other Equity Instruments (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">5,158,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember', window );">BSPCE</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">371,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember', window );">BSA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Total number of awards outstanding (in shares)</a></td>
<td class="nump">56,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Total number of share options outstanding (in shares)</a></td>
<td class="nump">4,730,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Schedule of Share Based Assumptions (Details)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 23, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 20, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 22, 2022 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 17, 2020 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 27, 2018 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 06, 2018 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 07, 2017 </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 03, 2016 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 02, 2016 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 25, 2015 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 10, 2015 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 10, 2015 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,161<span></span>
</td>
<td class="nump">&#8364; 1,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember', window );">BSPCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember', window );">BSPCE 2016 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member', window );">BSCPE 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember', window );">BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152Member', window );">BSA 2015-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member', window );">BSA 2018-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember', window );">OSA 2016-1 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member', window );">OSA 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member', window );">OSA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember', window );">OSA 2021-04 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember', window );">OSA 2021-06 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206PerformanceMember', window );">OSA 2022-06 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember', window );">OSA 2022-06 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember', window );">OSA 2023-01 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember', window );">OSA 2023-01 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember', window );">OSA 2023-01 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember', window );">OSA 2023-01 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="nump">&#8364; 5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember', window );">OSA 2024-01 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember', window );">OSA 2025-01 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember', window );">OSA 2025-01 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember', window );">OSA 2025-01 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember', window );">OSA 2025-01 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 186<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="nump">&#8364; 2.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember', window );">OSA 2025-02 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember', window );">AGA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 888<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance1Member', window );">AGA 2023 - P1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance1Member', window );">AGA 2023 - P1 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance1Member', window );">AGA 2023 - P1 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance2Member', window );">AGA 2023 - P2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 442<span></span>
</td>
<td class="nump">&#8364; 507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance2Member', window );">AGA 2023 - P2 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance2Member', window );">AGA 2023 - P2 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ExercisePriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ExercisePriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Dividend As Percentage, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Share Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingPeriodAxis=nbx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingPeriodAxis=nbx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingPeriodAxis=nbx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingPeriodAxis=nbx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingPeriodAxis=nbx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingPeriodAxis=nbx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Schedule of Expense from Equity (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="nump">&#8364; 2,161<span></span>
</td>
<td class="nump">&#8364; 1,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember', window );">BSPCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember', window );">BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember', window );">AGA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="nump">&#8364; 888<span></span>
</td>
<td class="nump">&#8364; 1,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Share-based Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income (loss) - Schedule of Net Financial Income (Loss) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NetFinancialIncomeLossAbstract', window );"><strong>Net Financial Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks', window );">Income from cash and cash equivalents</a></td>
<td class="nump">&#8364; 598<span></span>
</td>
<td class="nump">&#8364; 1,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Total financial income</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">3,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest costs</a></td>
<td class="num">(4,174)<span></span>
</td>
<td class="num">(3,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_DebtAccretionAndDiscountingImpact', window );">Net impact of accretion, discounting and catch-up on EIB loan</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">2,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Lease debt interests</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Foreign exchange losses</a></td>
<td class="num">(3,624)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Total financial expenses</a></td>
<td class="num">(6,831)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Financial income (loss)</a></td>
<td class="num">&#8364; (6,186)<span></span>
</td>
<td class="nump">&#8364; 1,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DebtAccretionAndDiscountingImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt (Accretion) And Discounting Impact</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DebtAccretionAndDiscountingImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NetFinancialIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Financial Income (Loss) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NetFinancialIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income (loss) - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Interest income on cash and cash equivalents</a></td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest costs</a></td>
<td class="nump">4,174<span></span>
</td>
<td class="nump">3,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Net foreign exchange loss</a></td>
<td class="nump">3,624<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term bank deposits</a></td>
<td class="nump">24,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 44,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Net foreign exchange loss</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term bank deposits</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD | HSBC Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest costs</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of accretion and discounting</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections', window );">Increase (decrease) related to adjustments for income forecast projections</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows', window );">Adjustment to debt financing related to estimated debt outflows</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Fixed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Interest expense</a></td>
<td class="nump">&#8364; 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Debt Financing Related to Estimated Debt Outflows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Related To Adjustments For Income Forecast Projections</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=nbx_HSBCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=nbx_HSBCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share - Schedule of Basic and Diluted Loss Per Share (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Net loss for the period (in thousands of euros)</a></td>
<td class="num">&#8364; (5,383)<span></span>
</td>
<td class="num">&#8364; (21,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares (in shares)</a></td>
<td class="nump">47,418,155<span></span>
</td>
<td class="nump">47,124,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share (in euro per share)</a></td>
<td class="num">&#8364; (0.11)<span></span>
</td>
<td class="num">&#8364; (0.46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share (in euro per share)</a></td>
<td class="num">&#8364; (0.11)<span></span>
</td>
<td class="num">&#8364; (0.46)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented', window );">Potential additional ordinary shares that are considered antidilutive (in shares)</a></td>
<td class="nump">5,158,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of potential ordinary shares that are antidilutive in the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 1,837<span></span>
</td>
<td class="nump">&#8364; 2,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember', window );">Janssen Pharmaceutica NV | NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember', window );">Janssen Pharmaceutica NV | Technology Transfer and Technical Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbx_NBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbx_NBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbx_TechnologyTransferAndTechnicalAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbx_TechnologyTransferAndTechnicalAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties - Schedule of Key Management Personnel Compensation (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Salaries, wages and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,159<span></span>
</td>
<td class="nump">&#8364; 1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Supervisory Board&#8217;s fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total compensation to related parties</a></td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="nump">&#8364; 3,094<span></span>
</td>
<td class="nump">&#8364; 2,722<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DirectorsRemunerationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DirectorsRemunerationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 227<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_227&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 227<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_227&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=nbx_NanobiotixCorpMember', window );">Nanobiotix Corp. | Johnson &amp; Johnson Innovations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="nump">11.66%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nbx_NanobiotixCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nbx_NanobiotixCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nbx_JohnsonJohnsonInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nbx_JohnsonJohnsonInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties - Schedule of Disclosure of Transactions Between Liabilities and Receivables (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties', window );">Collections</a></td>
<td class="nump">&#8364; 7,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NetCollectionsPaymentsFromRelatedParty', window );">Net collections</a></td>
<td class="nump">7,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">1,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Liabilities</a></td>
<td class="num">(7,905)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbx_NetAmountsReceivablePayableRelatedPartyTransactions', window );">Net receivables (liabilities)</a></td>
<td class="num">&#8364; (6,068)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loans and advances made to related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAdvancesAndLoansMadeToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from repayment to the entity of loans and advances made to related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NetAmountsReceivablePayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Amounts Receivable Payable Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NetAmountsReceivablePayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NetCollectionsPaymentsFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Collections (Payments) From Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NetCollectionsPaymentsFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>594</ContextCount>
  <ElementCount>339</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>150</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION</Role>
      <ShortName>INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS</Role>
      <ShortName>INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS</Role>
      <ShortName>INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - INTERIM CONDENSED STATEMENT OF CONSOLIDATED CHANGES IN SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>INTERIM CONDENSED STATEMENT OF CONSOLIDATED CHANGES IN SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS</Role>
      <ShortName>INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Company information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Companyinformation</Role>
      <ShortName>Company information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - General information, statement of compliance and basis of presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Generalinformationstatementofcomplianceandbasisofpresentation</Role>
      <ShortName>General information, statement of compliance and basis of presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Consolidated principles and methods</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Consolidatedprinciplesandmethods</Role>
      <ShortName>Consolidated principles and methods</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Significant transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Significanttransactions</Role>
      <ShortName>Significant transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Intangibleassets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Propertyplantandequipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Non-current financial assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Noncurrentfinancialassets</Role>
      <ShortName>Non-current financial assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Trade receivables and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Tradereceivablesandothercurrentassets</Role>
      <ShortName>Trade receivables and other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Cashandcashequivalents</Role>
      <ShortName>Cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Retirement Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RetirementObligations</Role>
      <ShortName>Retirement Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Provisions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Provisions</Role>
      <ShortName>Provisions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Financial liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Financialliabilities</Role>
      <ShortName>Financial liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Trade payables and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities</Role>
      <ShortName>Trade payables and other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Financial instruments included in the statement of financial position and impact on income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome</Role>
      <ShortName>Financial instruments included in the statement of financial position and impact on income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Revenue and other income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Revenueandotherincome</Role>
      <ShortName>Revenue and other income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Operating expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Operatingexpenses</Role>
      <ShortName>Operating expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Sharebasedpayments</Role>
      <ShortName>Share-based payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Net financial income (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Netfinancialincomeloss</Role>
      <ShortName>Net financial income (loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Segment reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Segmentreporting</Role>
      <ShortName>Segment reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Losspershare</Role>
      <ShortName>Loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Relatedparties</Role>
      <ShortName>Related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952179 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Subsequentevents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Consolidated principles and methods (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsPolicies</Role>
      <ShortName>Consolidated principles and methods (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/IntangibleassetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Intangibleassets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/PropertyplantandequipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Propertyplantandequipment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Non-current financial assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NoncurrentfinancialassetsTables</Role>
      <ShortName>Non-current financial assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Noncurrentfinancialassets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Trade receivables and other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables</Role>
      <ShortName>Trade receivables and other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Tradereceivablesandothercurrentassets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/CashandcashequivalentsTables</Role>
      <ShortName>Cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Cashandcashequivalents</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/ShareCapital</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Retirement Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RetirementObligationsTables</Role>
      <ShortName>Retirement Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/RetirementObligations</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Provisions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ProvisionsTables</Role>
      <ShortName>Provisions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Provisions</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Financial liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesTables</Role>
      <ShortName>Financial liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Financialliabilities</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Trade payables and other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables</Role>
      <ShortName>Trade payables and other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Financial instruments included in the statement of financial position and impact on income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables</Role>
      <ShortName>Financial instruments included in the statement of financial position and impact on income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Revenue and other income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RevenueandotherincomeTables</Role>
      <ShortName>Revenue and other income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Revenueandotherincome</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Operating expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesTables</Role>
      <ShortName>Operating expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Operatingexpenses</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Share-based payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsTables</Role>
      <ShortName>Share-based payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Sharebasedpayments</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Net financial income (loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NetfinancialincomelossTables</Role>
      <ShortName>Net financial income (loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Netfinancialincomeloss</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/LosspershareTables</Role>
      <ShortName>Loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Losspershare</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Related parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RelatedpartiesTables</Role>
      <ShortName>Related parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Relatedparties</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Company information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/CompanyinformationDetails</Role>
      <ShortName>Company information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Companyinformation</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - General information, statement of compliance and basis of presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails</Role>
      <ShortName>General information, statement of compliance and basis of presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Generalinformationstatementofcomplianceandbasisofpresentation</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Consolidated principles and methods (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsDetails</Role>
      <ShortName>Consolidated principles and methods (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsPolicies</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Intangible assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Intangible assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/IntangibleassetsNarrativeDetails</Role>
      <ShortName>Intangible assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Property, plant and equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/PropertyplantandequipmentNarrativeDetails</Role>
      <ShortName>Property, plant and equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Non-current financial assets - Schedule of Changes in Non-current Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails</Role>
      <ShortName>Non-current financial assets - Schedule of Changes in Non-current Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Trade receivables and other current assets - Schedule of Trade Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofTradeReceivablesDetails</Role>
      <ShortName>Trade receivables and other current assets - Schedule of Trade Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Trade receivables and other current assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails</Role>
      <ShortName>Trade receivables and other current assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Trade receivables and other current assets - Schedule of Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails</Role>
      <ShortName>Trade receivables and other current assets - Schedule of Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Trade receivables and other current assets - Schedule of Changes in Research Tax Credit Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails</Role>
      <ShortName>Trade receivables and other current assets - Schedule of Changes in Research Tax Credit Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails</Role>
      <ShortName>Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Cash and cash equivalents - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/CashandcashequivalentsNarrativeDetails</Role>
      <ShortName>Cash and cash equivalents - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Share Capital - Schedule of Share Capital Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Share Capital - Capital Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails</Role>
      <ShortName>Share Capital - Capital Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Share Capital - Founder's Warrants, Warrants, Stock Options and Free Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails</Role>
      <ShortName>Share Capital - Founder's Warrants, Warrants, Stock Options and Free Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Share Capital - Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails</Role>
      <ShortName>Share Capital - Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Retirement Obligations - Disclosure of Changes in Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails</Role>
      <ShortName>Retirement Obligations - Disclosure of Changes in Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Provisions - Schedule of Changes in Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails</Role>
      <ShortName>Provisions - Schedule of Changes in Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Provisions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails</Role>
      <ShortName>Provisions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Financial liabilities - Schedule of Changes in Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails</Role>
      <ShortName>Financial liabilities - Schedule of Changes in Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Financial liabilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails</Role>
      <ShortName>Financial liabilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Financial liabilities - Schedule of Changes in Liabilities Arising from Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails</Role>
      <ShortName>Financial liabilities - Schedule of Changes in Liabilities Arising from Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Financial liabilities - Schedule of Maturity Analysis for Advances Loans and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails</Role>
      <ShortName>Financial liabilities - Schedule of Maturity Analysis for Advances Loans and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Trade payables and other current liabilities - Schedule of Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails</Role>
      <ShortName>Trade payables and other current liabilities - Schedule of Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Trade payables and other current liabilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails</Role>
      <ShortName>Trade payables and other current liabilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Trade payables and other current liabilities - Schedule of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Trade payables and other current liabilities - Schedule of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails</Role>
      <ShortName>Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1</Role>
      <ShortName>Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Schedule of Financial Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails</Role>
      <ShortName>Financial instruments included in the statement of financial position and impact on income - Schedule of Financial Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeNarrativeDetails</Role>
      <ShortName>Financial instruments included in the statement of financial position and impact on income - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Revenue and other income - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails</Role>
      <ShortName>Revenue and other income - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Revenue and other income - Schedule of Revenues and Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails</Role>
      <ShortName>Revenue and other income - Schedule of Revenues and Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Operating expenses - Schedule of Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails</Role>
      <ShortName>Operating expenses - Schedule of Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Operating expenses - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesNarrativeDetails</Role>
      <ShortName>Operating expenses - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Operating expenses - Schedule of Selling, General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails</Role>
      <ShortName>Operating expenses - Schedule of Selling, General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Operating expenses - Schedule of Payroll Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails</Role>
      <ShortName>Operating expenses - Schedule of Payroll Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Operating expenses - Schedule of Depreciation, Amortization and Provision Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails</Role>
      <ShortName>Operating expenses - Schedule of Depreciation, Amortization and Provision Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Operating expenses - Schedule of Other Operating Income (Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails</Role>
      <ShortName>Operating expenses - Schedule of Other Operating Income (Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Share-based payments - Schedule of Changes in Founder's Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails</Role>
      <ShortName>Share-based payments - Schedule of Changes in Founder's Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Share-based payments - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails</Role>
      <ShortName>Share-based payments - Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Share-based payments - Schedule of Changes in Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails</Role>
      <ShortName>Share-based payments - Schedule of Changes in Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Share-based payments - Schedule of Free Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails</Role>
      <ShortName>Share-based payments - Schedule of Free Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Share-based payments - Schedule of Number and Weighted Average Remaining Contractual Life of Outstanding Other Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails</Role>
      <ShortName>Share-based payments - Schedule of Number and Weighted Average Remaining Contractual Life of Outstanding Other Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Share-based payments - Schedule of Share Based Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails</Role>
      <ShortName>Share-based payments - Schedule of Share Based Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Share-based payments - Schedule of Expense from Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails</Role>
      <ShortName>Share-based payments - Schedule of Expense from Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Net financial income (loss) - Schedule of Net Financial Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails</Role>
      <ShortName>Net financial income (loss) - Schedule of Net Financial Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/NetfinancialincomelossTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Net financial income (loss) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails</Role>
      <ShortName>Net financial income (loss) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/NetfinancialincomelossTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails</Role>
      <ShortName>Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955579 - Disclosure - Loss per share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/LosspershareNarrativeDetails</Role>
      <ShortName>Loss per share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Commitments</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Related parties - Schedule of Key Management Personnel Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails</Role>
      <ShortName>Related parties - Schedule of Key Management Personnel Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Related parties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RelatedpartiesNarrativeDetails</Role>
      <ShortName>Related parties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="nbx-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Related parties - Schedule of Disclosure of Transactions Between Liabilities and Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails</Role>
      <ShortName>Related parties - Schedule of Disclosure of Transactions Between Liabilities and Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="nbx-20250630.htm">nbx-20250630.htm</File>
    <File>nbx-20250630.xsd</File>
    <File>nbx-20250630_cal.xml</File>
    <File>nbx-20250630_def.xml</File>
    <File>nbx-20250630_lab.xml</File>
    <File>nbx-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="1134">https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>116
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nbx-20250630.htm": {
   "nsprefix": "nbx",
   "nsuri": "http://nanobiotix.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "nbx-20250630.htm"
     ]
    },
    "schema": {
     "local": [
      "nbx-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "nbx-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nbx-20250630_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nbx-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbx-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 226,
   "keyCustom": 113,
   "axisStandard": 28,
   "axisCustom": 9,
   "memberStandard": 32,
   "memberCustom": 105,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2025": 6
   },
   "contextCount": 594,
   "entityCount": 1,
   "segmentCount": 150,
   "elementCount": 650,
   "unitCount": 12,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 1134,
    "http://xbrl.sec.gov/dei/2025": 14
   },
   "report": {
    "R1": {
     "role": "http://nanobiotix.com/role/Coverpage",
     "longName": "0000001 - Document - Cover page",
     "shortName": "Cover page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
     "longName": "9952151 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION",
     "shortName": "INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NoncurrentAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
     "longName": "9952152 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS",
     "shortName": "INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS",
     "longName": "9952153 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS",
     "shortName": "INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
     "longName": "9952154 - Statement - INTERIM CONDENSED STATEMENT OF CONSOLIDATED CHANGES IN SHAREHOLDERS\u2019 EQUITY",
     "shortName": "INTERIM CONDENSED STATEMENT OF CONSOLIDATED CHANGES IN SHAREHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-21",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-23",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS",
     "longName": "9952155 - Statement - INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS",
     "shortName": "INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://nanobiotix.com/role/Companyinformation",
     "longName": "9952156 - Disclosure - Company information",
     "shortName": "Company information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfNotesAndOtherExplanatoryInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfNotesAndOtherExplanatoryInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://nanobiotix.com/role/Generalinformationstatementofcomplianceandbasisofpresentation",
     "longName": "9952157 - Disclosure - General information, statement of compliance and basis of presentation",
     "shortName": "General information, statement of compliance and basis of presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://nanobiotix.com/role/Consolidatedprinciplesandmethods",
     "longName": "9952158 - Disclosure - Consolidated principles and methods",
     "shortName": "Consolidated principles and methods",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://nanobiotix.com/role/Significanttransactions",
     "longName": "9952159 - Disclosure - Significant transactions",
     "shortName": "Significant transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfSignificantTransactionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfSignificantTransactionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://nanobiotix.com/role/Intangibleassets",
     "longName": "9952160 - Disclosure - Intangible assets",
     "shortName": "Intangible assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://nanobiotix.com/role/Propertyplantandequipment",
     "longName": "9952161 - Disclosure - Property, plant and equipment",
     "shortName": "Property, plant and equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://nanobiotix.com/role/Noncurrentfinancialassets",
     "longName": "9952162 - Disclosure - Non-current financial assets",
     "shortName": "Non-current financial assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://nanobiotix.com/role/Tradereceivablesandothercurrentassets",
     "longName": "9952163 - Disclosure - Trade receivables and other current assets",
     "shortName": "Trade receivables and other current assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://nanobiotix.com/role/Cashandcashequivalents",
     "longName": "9952164 - Disclosure - Cash and cash equivalents",
     "shortName": "Cash and cash equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://nanobiotix.com/role/ShareCapital",
     "longName": "9952165 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://nanobiotix.com/role/RetirementObligations",
     "longName": "9952166 - Disclosure - Retirement Obligations",
     "shortName": "Retirement Obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://nanobiotix.com/role/Provisions",
     "longName": "9952167 - Disclosure - Provisions",
     "shortName": "Provisions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://nanobiotix.com/role/Financialliabilities",
     "longName": "9952168 - Disclosure - Financial liabilities",
     "shortName": "Financial liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfFinancialLiabilitiesFootnoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfFinancialLiabilitiesFootnoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities",
     "longName": "9952169 - Disclosure - Trade payables and other current liabilities",
     "shortName": "Trade payables and other current liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome",
     "longName": "9952170 - Disclosure - Financial instruments included in the statement of financial position and impact on income",
     "shortName": "Financial instruments included in the statement of financial position and impact on income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://nanobiotix.com/role/Revenueandotherincome",
     "longName": "9952171 - Disclosure - Revenue and other income",
     "shortName": "Revenue and other income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://nanobiotix.com/role/Operatingexpenses",
     "longName": "9952172 - Disclosure - Operating expenses",
     "shortName": "Operating expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://nanobiotix.com/role/Sharebasedpayments",
     "longName": "9952173 - Disclosure - Share-based payments",
     "shortName": "Share-based payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://nanobiotix.com/role/Netfinancialincomeloss",
     "longName": "9952174 - Disclosure - Net financial income (loss)",
     "shortName": "Net financial income (loss)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://nanobiotix.com/role/Segmentreporting",
     "longName": "9952175 - Disclosure - Segment reporting",
     "shortName": "Segment reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://nanobiotix.com/role/Losspershare",
     "longName": "9952176 - Disclosure - Loss per share",
     "shortName": "Loss per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://nanobiotix.com/role/Commitments",
     "longName": "9952177 - Disclosure - Commitments",
     "shortName": "Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://nanobiotix.com/role/Relatedparties",
     "longName": "9952178 - Disclosure - Related parties",
     "shortName": "Related parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://nanobiotix.com/role/Subsequentevents",
     "longName": "9952179 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsPolicies",
     "longName": "9955511 - Disclosure - Consolidated principles and methods (Policies)",
     "shortName": "Consolidated principles and methods (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://nanobiotix.com/role/IntangibleassetsTables",
     "longName": "9955512 - Disclosure - Intangible assets (Tables)",
     "shortName": "Intangible assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://nanobiotix.com/role/PropertyplantandequipmentTables",
     "longName": "9955513 - Disclosure - Property, plant and equipment (Tables)",
     "shortName": "Property, plant and equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://nanobiotix.com/role/NoncurrentfinancialassetsTables",
     "longName": "9955514 - Disclosure - Non-current financial assets (Tables)",
     "shortName": "Non-current financial assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables",
     "longName": "9955515 - Disclosure - Trade receivables and other current assets (Tables)",
     "shortName": "Trade receivables and other current assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://nanobiotix.com/role/CashandcashequivalentsTables",
     "longName": "9955516 - Disclosure - Cash and cash equivalents (Tables)",
     "shortName": "Cash and cash equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://nanobiotix.com/role/ShareCapitalTables",
     "longName": "9955517 - Disclosure - Share Capital (Tables)",
     "shortName": "Share Capital (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://nanobiotix.com/role/RetirementObligationsTables",
     "longName": "9955518 - Disclosure - Retirement Obligations (Tables)",
     "shortName": "Retirement Obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://nanobiotix.com/role/ProvisionsTables",
     "longName": "9955519 - Disclosure - Provisions (Tables)",
     "shortName": "Provisions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://nanobiotix.com/role/FinancialliabilitiesTables",
     "longName": "9955520 - Disclosure - Financial liabilities (Tables)",
     "shortName": "Financial liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables",
     "longName": "9955521 - Disclosure - Trade payables and other current liabilities (Tables)",
     "shortName": "Trade payables and other current liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables",
     "longName": "9955522 - Disclosure - Financial instruments included in the statement of financial position and impact on income (Tables)",
     "shortName": "Financial instruments included in the statement of financial position and impact on income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://nanobiotix.com/role/RevenueandotherincomeTables",
     "longName": "9955523 - Disclosure - Revenue and other income (Tables)",
     "shortName": "Revenue and other income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://nanobiotix.com/role/OperatingexpensesTables",
     "longName": "9955524 - Disclosure - Operating expenses (Tables)",
     "shortName": "Operating expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://nanobiotix.com/role/SharebasedpaymentsTables",
     "longName": "9955525 - Disclosure - Share-based payments (Tables)",
     "shortName": "Share-based payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://nanobiotix.com/role/NetfinancialincomelossTables",
     "longName": "9955526 - Disclosure - Net financial income (loss) (Tables)",
     "shortName": "Net financial income (loss) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://nanobiotix.com/role/LosspershareTables",
     "longName": "9955527 - Disclosure - Loss per share (Tables)",
     "shortName": "Loss per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://nanobiotix.com/role/RelatedpartiesTables",
     "longName": "9955528 - Disclosure - Related parties (Tables)",
     "shortName": "Related parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://nanobiotix.com/role/CompanyinformationDetails",
     "longName": "9955529 - Disclosure - Company information (Details)",
     "shortName": "Company information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "nbx:CollaborationAgreementTotalConsideration",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-40",
      "name": "nbx:CollaborationAgreementTotalConsideration",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails",
     "longName": "9955530 - Disclosure - General information, statement of compliance and basis of presentation (Details)",
     "shortName": "General information, statement of compliance and basis of presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-44",
      "name": "nbx:AdditionalLiquidityBusinessObligations",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsDetails",
     "longName": "9955531 - Disclosure - Consolidated principles and methods (Details)",
     "shortName": "Consolidated principles and methods (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "nbx:NumberOfSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "nbx:NumberOfSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails",
     "longName": "9955532 - Disclosure - Intangible assets - Schedule of Intangible Assets (Details)",
     "shortName": "Intangible assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://nanobiotix.com/role/IntangibleassetsNarrativeDetails",
     "longName": "9955533 - Disclosure - Intangible assets - Narrative (Details)",
     "shortName": "Intangible assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
     "longName": "9955534 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)",
     "shortName": "Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://nanobiotix.com/role/PropertyplantandequipmentNarrativeDetails",
     "longName": "9955535 - Disclosure - Property, plant and equipment - Narrative (Details)",
     "shortName": "Property, plant and equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails",
     "longName": "9955536 - Disclosure - Non-current financial assets - Schedule of Changes in Non-current Financial Assets (Details)",
     "shortName": "Non-current financial assets - Schedule of Changes in Non-current Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:NoncurrentFinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-94",
      "name": "ifrs-full:NoncurrentFinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofTradeReceivablesDetails",
     "longName": "9955537 - Disclosure - Trade receivables and other current assets - Schedule of Trade Receivables (Details)",
     "shortName": "Trade receivables and other current assets - Schedule of Trade Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails",
     "longName": "9955538 - Disclosure - Trade receivables and other current assets - Narrative (Details)",
     "shortName": "Trade receivables and other current assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentAdvancesToSuppliers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails",
     "longName": "9955539 - Disclosure - Trade receivables and other current assets - Schedule of Other Current Assets (Details)",
     "shortName": "Trade receivables and other current assets - Schedule of Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentValueAddedTaxReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails",
     "longName": "9955540 - Disclosure - Trade receivables and other current assets - Schedule of Changes in Research Tax Credit Receivables (Details)",
     "shortName": "Trade receivables and other current assets - Schedule of Changes in Research Tax Credit Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-105",
      "name": "nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails",
     "longName": "9955541 - Disclosure - Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details)",
     "shortName": "Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Cash",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Cash",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://nanobiotix.com/role/CashandcashequivalentsNarrativeDetails",
     "longName": "9955542 - Disclosure - Cash and cash equivalents - Narrative (Details)",
     "shortName": "Cash and cash equivalents - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails",
     "longName": "9955543 - Disclosure - Share Capital - Schedule of Share Capital Transactions (Details)",
     "shortName": "Share Capital - Schedule of Share Capital Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-108",
      "name": "ifrs-full:IssueOfEquity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
     "longName": "9955544 - Disclosure - Share Capital - Capital Issued (Details)",
     "shortName": "Share Capital - Capital Issued (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://nanobiotix.com/role/ShareCapitalFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
     "longName": "9955545 - Disclosure - Share Capital - Founder's Warrants, Warrants, Stock Options and Free Shares (Details)",
     "shortName": "Share Capital - Founder's Warrants, Warrants, Stock Options and Free Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "nbx:NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes",
      "unitRef": "security",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "nbx:NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes",
      "unitRef": "security",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
     "longName": "9955546 - Disclosure - Share Capital - Stock Option Plans (Details)",
     "shortName": "Share Capital - Stock Option Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails",
     "longName": "9955547 - Disclosure - Retirement Obligations - Disclosure of Changes in Provisions (Details)",
     "shortName": "Retirement Obligations - Disclosure of Changes in Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-116",
      "name": "ifrs-full:OtherProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "ifrs-full:OtherProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails",
     "longName": "9955548 - Disclosure - Provisions - Schedule of Changes in Provisions (Details)",
     "shortName": "Provisions - Schedule of Changes in Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-128",
      "name": "ifrs-full:OtherProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-128",
      "name": "ifrs-full:OtherProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
     "longName": "9955549 - Disclosure - Provisions - Additional Information (Details)",
     "shortName": "Provisions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-123",
      "name": "nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails",
     "longName": "9955550 - Disclosure - Financial liabilities - Schedule of Changes in Financial Liabilities (Details)",
     "shortName": "Financial liabilities - Schedule of Changes in Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentFinancialLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
     "longName": "9955551 - Disclosure - Financial liabilities - Narrative (Details)",
     "shortName": "Financial liabilities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-163",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails",
     "longName": "9955552 - Disclosure - Financial liabilities - Schedule of Changes in Liabilities Arising from Financing Activities (Details)",
     "shortName": "Financial liabilities - Schedule of Changes in Liabilities Arising from Financing Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestPaidClassifiedAsFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-145",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
     "longName": "9955553 - Disclosure - Financial liabilities - Schedule of Maturity Analysis for Advances Loans and Lease Liabilities (Details)",
     "shortName": "Financial liabilities - Schedule of Maturity Analysis for Advances Loans and Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails",
     "longName": "9955554 - Disclosure - Trade payables and other current liabilities - Schedule of Trade and Other Payables (Details)",
     "shortName": "Trade payables and other current liabilities - Schedule of Trade and Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails",
     "longName": "9955555 - Disclosure - Trade payables and other current liabilities - Narrative (Details)",
     "shortName": "Trade payables and other current liabilities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails",
     "longName": "9955556 - Disclosure - Trade payables and other current liabilities - Schedule of Other Current Liabilities (Details)",
     "shortName": "Trade payables and other current liabilities - Schedule of Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentTaxLiabilitiesCurrent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentTaxLiabilitiesCurrent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails",
     "longName": "9955557 - Disclosure - Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details)",
     "shortName": "Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1",
     "longName": "9955558 - Disclosure - Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details)",
     "shortName": "Trade payables and other current liabilities - Schedule of Deferred Income and Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NoncurrentContractLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DetailedInformationAboutRefundLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:RefundsProvision",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DetailedInformationAboutRefundLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails",
     "longName": "9955559 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Schedule of Financial Asset and Liabilities (Details)",
     "shortName": "Financial instruments included in the statement of financial position and impact on income - Schedule of Financial Asset and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeNarrativeDetails",
     "longName": "9955560 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Narrative (Details)",
     "shortName": "Financial instruments included in the statement of financial position and impact on income - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R81": {
     "role": "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
     "longName": "9955561 - Disclosure - Revenue and other income - Narrative (Details)",
     "shortName": "Revenue and other income - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-168",
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails",
     "longName": "9955562 - Disclosure - Revenue and other income - Schedule of Revenues and Other Income (Details)",
     "shortName": "Revenue and other income - Schedule of Revenues and Other Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R83": {
     "role": "http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails",
     "longName": "9955563 - Disclosure - Operating expenses - Schedule of Research and Development Expenses (Details)",
     "shortName": "Operating expenses - Schedule of Research and Development Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
     "longName": "9955564 - Disclosure - Operating expenses - Narrative (Details)",
     "shortName": "Operating expenses - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:IncreaseDecreasePayrollExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:IncreaseDecreasePayrollExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails",
     "longName": "9955565 - Disclosure - Operating expenses - Schedule of Selling, General and Administrative Expenses (Details)",
     "shortName": "Operating expenses - Schedule of Selling, General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails",
     "longName": "9955566 - Disclosure - Operating expenses - Schedule of Payroll Costs (Details)",
     "shortName": "Operating expenses - Schedule of Payroll Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails",
     "longName": "9955567 - Disclosure - Operating expenses - Schedule of Depreciation, Amortization and Provision Expenses (Details)",
     "shortName": "Operating expenses - Schedule of Depreciation, Amortization and Provision Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AmortisationExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AmortisationExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails",
     "longName": "9955568 - Disclosure - Operating expenses - Schedule of Other Operating Income (Expenses) (Details)",
     "shortName": "Operating expenses - Schedule of Other Operating Income (Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbx:OtherNonrecurringExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbx:OtherNonrecurringsIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
     "longName": "9955569 - Disclosure - Share-based payments - Schedule of Changes in Founder's Warrant (Details)",
     "shortName": "Share-based payments - Schedule of Changes in Founder's Warrant (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-320",
      "name": "nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails",
     "longName": "9955570 - Disclosure - Share-based payments - Schedule of Warrants Outstanding (Details)",
     "shortName": "Share-based payments - Schedule of Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-354",
      "name": "nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
     "longName": "9955571 - Disclosure - Share-based payments - Schedule of Changes in Share Options (Details)",
     "shortName": "Share-based payments - Schedule of Changes in Share Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-390",
      "name": "nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-390",
      "name": "nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
     "longName": "9955572 - Disclosure - Share-based payments - Schedule of Free Shares Outstanding (Details)",
     "shortName": "Share-based payments - Schedule of Free Shares Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-489",
      "name": "nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails",
     "longName": "9955573 - Disclosure - Share-based payments - Schedule of Number and Weighted Average Remaining Contractual Life of Outstanding Other Equity Instruments (Details)",
     "shortName": "Share-based payments - Schedule of Number and Weighted Average Remaining Contractual Life of Outstanding Other Equity Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-505",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails",
     "longName": "9955574 - Disclosure - Share-based payments - Schedule of Share Based Assumptions (Details)",
     "shortName": "Share-based payments - Schedule of Share Based Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-320",
      "name": "ifrs-full:ExercisePriceShareOptionsGranted2019",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails",
     "longName": "9955575 - Disclosure - Share-based payments - Schedule of Expense from Equity (Details)",
     "shortName": "Share-based payments - Schedule of Expense from Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R96": {
     "role": "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails",
     "longName": "9955576 - Disclosure - Net financial income (loss) - Schedule of Net Financial Income (Loss) (Details)",
     "shortName": "Net financial income (loss) - Schedule of Net Financial Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails",
     "longName": "9955577 - Disclosure - Net financial income (loss) - Narrative (Details)",
     "shortName": "Net financial income (loss) - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails",
     "longName": "9955578 - Disclosure - Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)",
     "shortName": "Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://nanobiotix.com/role/LosspershareNarrativeDetails",
     "longName": "9955579 - Disclosure - Loss per share - Narrative (Details)",
     "shortName": "Loss per share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://nanobiotix.com/role/CommitmentsDetails",
     "longName": "9955580 - Disclosure - Commitments (Details)",
     "shortName": "Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-592",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails",
     "longName": "9955581 - Disclosure - Related parties - Schedule of Key Management Personnel Compensation (Details)",
     "shortName": "Related parties - Schedule of Key Management Personnel Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://nanobiotix.com/role/RelatedpartiesNarrativeDetails",
     "longName": "9955582 - Disclosure - Related parties - Narrative (Details)",
     "shortName": "Related parties - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-594",
      "name": "ifrs-full:ProportionOfOwnershipInterestInAssociate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-594",
      "name": "ifrs-full:ProportionOfOwnershipInterestInAssociate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails",
     "longName": "9955583 - Disclosure - Related parties - Schedule of Disclosure of Transactions Between Liabilities and Receivables (Details)",
     "shortName": "Related parties - Schedule of Disclosure of Transactions Between Liabilities and Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbx-20250630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "nbx_A1100StudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "A1100StudyMember",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1100 study",
        "label": "1100 Study [Member]",
        "documentation": "1100 Study"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_A2024TaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "A2024TaxYearMember",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Tax Year",
        "label": "2024 Tax Year [Member]",
        "documentation": "2024 Tax Year"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_A2025TaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "A2025TaxYearMember",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Tax Year",
        "label": "2025 Tax Year [Member]",
        "documentation": "2025 Tax Year"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_A312StudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "A312StudyMember",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "312 study",
        "label": "312 Study [Member]",
        "documentation": "312 Study"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AGA2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AGA2023Member",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA 2023",
        "label": "AGA 2023 [Member]",
        "documentation": "AGA 2023"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AGA2023P1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AGA2023P1Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA 2023 - P1",
        "label": "AGA 2023 - P1 [Member]",
        "documentation": "AGA 2023 - P1"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AGA2023P2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AGA2023P2Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA 2023 - P2",
        "label": "AGA 2023 - P2 [Member]",
        "documentation": "AGA 2023 - P2"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AGA2023Performance1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AGA2023Performance1Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA 2023 - P1",
        "label": "AGA 2023 Performance1 [Member]",
        "documentation": "AGA 2023 Performance1"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AGA2023Performance2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AGA2023Performance2Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA 2023 - P2",
        "label": "AGA 2023 Performance2 [Member]",
        "documentation": "AGA 2023 Performance2"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AGAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AGAMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA",
        "label": "AGA [Member]",
        "documentation": "AGA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation of intangible assets",
        "label": "Accumulated depreciation and amortisation [member]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r327",
      "r336",
      "r339",
      "r340"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "nbx_AdditionalLiquidityBusinessObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AdditionalLiquidityBusinessObligations",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional liquidity business obligations",
        "label": "Additional Liquidity Business Obligations",
        "documentation": "Additional Liquidity Business Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionalProvisionsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails",
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases",
        "verboseLabel": "Increases",
        "label": "Additional provisions, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r34",
      "r182"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r187"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r170"
     ]
    },
    "nbx_AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to debt financing related to estimated debt outflows",
        "label": "Adjustment To Debt Financing Related to Estimated Debt Outflows",
        "documentation": "Adjustment To Debt Financing Related to Estimated Debt Outflows"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase) / Decrease in other receivables",
        "verboseLabel": "Adjustments for decrease (increase) in other receivables",
        "label": "Adjustments For Decrease (Increase) In Other Receivables",
        "documentation": "Adjustments For Decrease (Increase) In Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receipt of research tax credit receivable",
        "label": "Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax",
        "documentation": "Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase) / Decrease in trade receivables",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForFinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of net debt",
        "label": "Adjustments for finance costs"
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal",
        "label": "Adjustments for gain (loss) on disposals, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "nbx_AdjustmentsForIncreaseDecreaseInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AdjustmentsForIncreaseDecreaseInAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in accrued expenses",
        "label": "Adjustments For Increase (Decrease) In Accrued Expenses",
        "documentation": "Adjustments For Increase (Decrease) In Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for increase (decrease) in contract liabilities",
        "label": "Adjustments for increase (decrease) in contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in deferred revenues and contract liabilities",
        "label": "Adjustments for increase (decrease) in deferred income including contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of discounting financial liabilities and amortized cost",
        "label": "Adjustments for increase (decrease) in derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in derivative financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase / (Decrease) in other current liabilities",
        "label": "Adjustments for increase (decrease) in other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase / (Decrease) in trade and other payables",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Adjustments for provisions"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elimination of other non-cash, non-operating income and expenses",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses related to share-based payments",
        "label": "Adjustments for share-based payments"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "nbx_AdjustmentsToRevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AdjustmentsToRevenueFromContractsWithCustomers",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract modification adjustment",
        "label": "Adjustments To Revenue From Contracts With Customers",
        "documentation": "Adjustments To Revenue From Contracts With Customers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Advances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Advances",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances received",
        "label": "Advances received, representing contract liabilities for performance obligations satisfied at point in time"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of advances received representing contract liabilities for performance obligations satisfied at a point in time. [Refer: Contract liabilities; Performance obligations satisfied at point in time [member]]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r362"
     ]
    },
    "nbx_AdvancesAuthorizedAmountToBeAdvanced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AdvancesAuthorizedAmountToBeAdvanced",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized amount to be advanced",
        "label": "Advances, Authorized Amount To Be Advanced",
        "documentation": "Advances, Authorized Amount To Be Advanced"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AdvancesReceivedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AdvancesReceivedInterestRate",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances, interest rate",
        "label": "Advances Received, Interest Rate",
        "documentation": "Advances Received, Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AlainHerreraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AlainHerreraMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alain HERRERA",
        "label": "Alain Herrera [Member]",
        "documentation": "Alain Herrera"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails": {
       "parentTag": "nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization expense of intangible assets",
        "label": "Amortisation expense"
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AmountsPayableRelatedPartyTransactions",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": {
       "parentTag": "nbx_NetAmountsReceivablePayableRelatedPartyTransactions",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liabilities",
        "label": "Amounts payable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r21",
      "r176"
     ]
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": {
       "parentTag": "nbx_NetAmountsReceivablePayableRelatedPartyTransactions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Amounts receivable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r21",
      "r176"
     ]
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AnneJulietteHermantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AnneJulietteHermantMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anne-Juliette HERMANT",
        "label": "Anne-Juliette Hermant [Member]",
        "documentation": "Anne-Juliette Hermant"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_AnneMarieGraffinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "AnneMarieGraffinMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anne-Marie GRAFFIN",
        "label": "Anne-Marie Graffin [Member]",
        "documentation": "Anne-Marie Graffin"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r133",
      "r136",
      "r222",
      "r223",
      "r245"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At fair value",
        "label": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r50",
      "r65",
      "r75",
      "r196",
      "r221",
      "r222"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [axis]",
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      }
     },
     "auth_ref": [
      "r353",
      "r356"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line items by function",
        "label": "Attribution of expenses by nature to their function [domain]"
       }
      }
     },
     "auth_ref": [
      "r353",
      "r356"
     ]
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AverageForeignExchangeRate",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average foreign exchange rate",
        "label": "Average foreign exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_AverageNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AverageNumberOfEmployees",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average headcount",
        "label": "Average number of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The average number of personnel employed by the entity during a period."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "nbx_BPIFranceAdvanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BPIFranceAdvanceMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bpifrance advance",
        "label": "BPI France Advance [Member]",
        "documentation": "BPI France Advance"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BPIFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BPIFranceMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bpifrance",
        "label": "BPI France [Member]",
        "documentation": "BPI France"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSA20151Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSA20151Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2015-1",
        "label": "BSA 2015-1 [Member]",
        "documentation": "BSA 2015-1"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSA20152Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSA20152Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2015-2",
        "label": "BSA 2015-2 [Member]",
        "documentation": "BSA 2015-2"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSA20182Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSA20182Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2018-2",
        "label": "BSA 2018-2 [Member]",
        "documentation": "BSA 2018-2"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSA20191Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSA20191Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2019-1",
        "label": "BSA 2019-1 [Member]",
        "documentation": "BSA 2019-1"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSA2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSA2020Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2020",
        "label": "BSA 2020 [Member]",
        "documentation": "BSA 2020"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSA2021AMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSA2021AMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2021",
        "label": "BSA 2021 (a) [Member]",
        "documentation": "BSA 2021 (a)"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSA2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSA2021Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2021",
        "label": "BSA 2021 [Member]",
        "documentation": "BSA 2021"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSAMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA",
        "label": "BSA [Member]",
        "documentation": "BSA"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSPCE20151Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSPCE20151Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSPCE 2015-1",
        "label": "BSPCE 2015-1 [Member]",
        "documentation": "BSPCE 2015-1"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSPCE20153Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSPCE20153Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSPCE 2015-3",
        "label": "BSPCE 2015-3 [Member]",
        "documentation": "BSPCE 2015-3"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSPCE2016OrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSPCE2016OrdinaryMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSPCE 2016 O",
        "label": "BSPCE 2016 Ordinary [Member]",
        "documentation": "BSPCE 2016 Ordinary"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSPCE2016PerformanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSPCE2016PerformanceMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSPCE 2016 P",
        "label": "BSPCE 2016 Performance [Member]",
        "documentation": "BSPCE 2016 Performance"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSPCE2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSPCE2017Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSCPE 2017",
        "label": "BSPCE 2017 [Member]",
        "documentation": "BSPCE 2017"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSPCE2017OrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSPCE2017OrdinaryMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSPCE 2017 O",
        "label": "BSPCE 2017 Ordinary [Member]",
        "documentation": "BSPCE 2017 Ordinary"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BSPCEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BSPCEMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSPCE",
        "label": "BSPCE [Member]",
        "documentation": "BSPCE"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BankBorrowingsUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BankBorrowingsUndiscountedCashFlows",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Bank borrowings, undiscounted cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r300",
      "r306"
     ]
    },
    "nbx_BanquePubliqueDInvestissementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BanquePubliqueDInvestissementMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Banque Publique d\u2019Investissement",
        "label": "Banque Publique d\u2019Investissement [Member]",
        "documentation": "Banque Publique d\u2019Investissement"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BartVanRhijnMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BartVanRhijnMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bart VAN RHIJN",
        "label": "Bart Van Rhijn [Member]",
        "documentation": "Bart Van Rhijn"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share (in euro per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29"
     ]
    },
    "nbx_BeneficiariesOtherThanCorporateOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BeneficiariesOtherThanCorporateOfficersMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beneficiaries other than corporate officers",
        "label": "Beneficiaries Other Than Corporate Officers [Member]",
        "documentation": "Beneficiaries Other Than Corporate Officers"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BorrowingDefermentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BorrowingDefermentPeriod",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, deferment period",
        "label": "Borrowing, Deferment Period",
        "documentation": "Borrowing, Deferment Period"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BorrowingGuaranteeFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BorrowingGuaranteeFee",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, guarantee fee",
        "label": "Borrowing, Guarantee Fee",
        "documentation": "Borrowing, Guarantee Fee"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BorrowingMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BorrowingMaturityTerm",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, maturity",
        "label": "Borrowing, Maturity Term",
        "documentation": "Borrowing, Maturity Term"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BorrowingNumberOfQuarterlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BorrowingNumberOfQuarterlyInstallments",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of quarterly instalments",
        "label": "Borrowing, Number Of Quarterly Installments",
        "documentation": "Borrowing, Number Of Quarterly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BorrowingPercentageOfStateGuaranteedLoan": {
     "xbrltype": "pureItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BorrowingPercentageOfStateGuaranteedLoan",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of state-guaranteed loan",
        "label": "Borrowing, Percentage Of State-Guaranteed Loan",
        "documentation": "Borrowing, Percentage Of State-Guaranteed Loan"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_BorrowingScheduledForReimbursementNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BorrowingScheduledForReimbursementNumber",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, number of PGE",
        "label": "Borrowing Scheduled For Reimbursement, Number",
        "documentation": "Borrowing Scheduled For Reimbursement, Number"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [axis]",
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ifrs-full_BorrowingsByNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsByNameDomain",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name",
        "label": "Borrowings by name [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "nbx_BorrowingsCumulativeMilestonePrepaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "BorrowingsCumulativeMilestonePrepaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, cumulative milestone prepayment amount",
        "label": "Borrowings, Cumulative Milestone Prepayment Amount",
        "documentation": "Borrowings, Cumulative Milestone Prepayment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, interest rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r79",
      "r90",
      "r100",
      "r163",
      "r288",
      "r289",
      "r351"
     ]
    },
    "ifrs-full_CapitalCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CapitalCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital commitments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CapitalReserveMember",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve",
        "label": "Capital reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing capital reserves."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r10",
      "r38",
      "r42",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r106",
      "r112",
      "r113",
      "r169",
      "r173",
      "r186",
      "r190",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r207",
      "r216",
      "r217"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [member]",
        "label": "Carrying amount [member]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r42",
      "r47",
      "r49",
      "r50",
      "r106",
      "r112",
      "r113",
      "r173",
      "r190",
      "r193",
      "r195",
      "r196",
      "r207",
      "r216",
      "r217"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and bank accounts",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "ifrs-full_CashAdvancesAndLoansMadeToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAdvancesAndLoansMadeToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": {
       "parentTag": "nbx_NetCollectionsPaymentsFromRelatedParty",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments",
        "label": "Cash advances and loans made to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for loans and advances made to related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails",
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeNarrativeDetails",
      "http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Net cash and cash equivalents at beginning of period",
        "periodEndLabel": "Net cash and cash equivalents at end of period",
        "totalLabel": "Net Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r58",
      "r72",
      "r164",
      "r241"
     ]
    },
    "nbx_CashAndCashEquivalents1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CashAndCashEquivalents1Member",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash And Cash Equivalents1 [Member]",
        "documentation": "Cash And Cash Equivalents1"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from (used in) operating activities after tax and before changes in working capital",
        "label": "Cash Flow From Operating Activities After Tax And Before Change In Working Capital Requirement",
        "documentation": "Cash Flow From Operating Activities After Tax And Before Change In Working Capital Requirement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows from (used in) financing activities",
        "terseLabel": "Cash flows used in financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r59"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) financing activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows from (used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r59"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) investing activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_CashFlowsFromUsedInNonFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CashFlowsFromUsedInNonFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash from financing activities",
        "label": "Cash Flows From (Used In) Non Financing Activities",
        "documentation": "Cash Flows From (Used In) Non Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows from (used in) operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      }
     },
     "auth_ref": [
      "r52",
      "r59"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in operating activities",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows from (used in) operations, before tax and changes in working capital",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r346"
     ]
    },
    "ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": {
       "parentTag": "nbx_NetCollectionsPaymentsFromRelatedParty",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collections",
        "label": "Cash receipts from repayment of advances and loans made to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from repayment to the entity of loans and advances made to related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAxis",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial assets [axis]",
        "label": "Categories of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r213"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsDomain",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, category",
        "label": "Categories of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r213"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [axis]",
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r213"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, category [member]",
        "label": "Categories of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r213"
     ]
    },
    "ifrs-full_ChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ChangesInEquityAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in equity",
        "label": "Changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets [axis]",
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r120",
      "r121",
      "r142",
      "r143",
      "r231"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsDomain",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, class",
        "label": "Classes of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r92",
      "r120",
      "r121",
      "r142",
      "r143",
      "r231"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [axis]",
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r114",
      "r116",
      "r117",
      "r216",
      "r219"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments, class [member]",
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r112",
      "r114",
      "r116",
      "r117",
      "r216",
      "r219"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial liabilities [axis]",
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r142",
      "r143"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, class [member]",
        "label": "Classes of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r142",
      "r143"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [axis]",
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r191"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [domain]",
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r191"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities [axis]",
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r224"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesDomain",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities [member]",
        "label": "Classes of liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r224"
     ]
    },
    "ifrs-full_ClassesOfOtherProvisionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfOtherProvisionsDomain",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails",
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions [member]",
        "label": "Classes of other provisions [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r36",
      "r184"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r174"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [domain]",
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r174"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails",
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of other provisions [axis]",
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r184"
     ]
    },
    "nbx_ClinicalProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ClinicalProductsMember",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical products",
        "label": "Clinical Products [Member]",
        "documentation": "Clinical Products"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ClinicalStudiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ClinicalStudiesAxis",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Studies [Axis]",
        "label": "Clinical Studies [Axis]",
        "documentation": "Clinical Studies"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ClinicalStudiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ClinicalStudiesDomain",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Studies [Domain]",
        "label": "Clinical Studies [Domain]",
        "documentation": "Clinical Studies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClosingForeignExchangeRate",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing foreign exchange rate",
        "label": "Closing foreign exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "nbx_CollaborationAgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CollaborationAgreementAxis",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreement [Axis]",
        "label": "Collaboration Agreement [Axis]",
        "documentation": "Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_CollaborationAgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CollaborationAgreementDomain",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreement [Domain]",
        "label": "Collaboration Agreement [Domain]",
        "documentation": "Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CollaborationAgreementPotentialMilestonesPaymentsToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, potential development and commercial milestones payments",
        "label": "Collaboration Agreement, Potential Milestones Payments To Be Received",
        "documentation": "Collaboration Agreement, Potential Milestones Payments To Be Received"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, compensation per indication",
        "label": "Collaboration Agreement, Potential Milestones Payments To Be Received Per Indication",
        "documentation": "Collaboration Agreement, Potential Milestones Payments To Be Received Per Indication"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_CollaborationAgreementTotalConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CollaborationAgreementTotalConsideration",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deal value",
        "label": "Collaboration Agreement, Total Consideration",
        "documentation": "Collaboration Agreement, Total Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [member]",
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r70",
      "r180",
      "r199",
      "r233",
      "r258",
      "r287"
     ]
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "nbx_ConditionalAdvanceBPIFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ConditionalAdvanceBPIFranceMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Curadigm Bpi advance",
        "label": "Conditional Advance, BPI France [Member]",
        "documentation": "Conditional Advance, BPI France"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ConditionalAdvancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ConditionalAdvancesMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conditional advances",
        "label": "Conditional Advances [Member]",
        "documentation": "Conditional Advances"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ConsolidatedForecastedSalesPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ConsolidatedForecastedSalesPeriod",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated forecasted sales, period",
        "label": "Consolidated Forecasted Sales, Period",
        "documentation": "Consolidated Forecasted Sales, Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tangible assets in progress",
        "label": "Construction in progress [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "nbx_CorporateOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CorporateOfficersMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate officers",
        "label": "Corporate Officers [Member]",
        "documentation": "Corporate Officers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [axis]",
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [axis]",
        "label": "Counterparties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses - clinical trials",
        "verboseLabel": "Change in accrued expenses",
        "label": "Current accrued expenses and other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAdvancesToSuppliers",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current advances to suppliers",
        "label": "Current advances to suppliers"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r248",
      "r287"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails": {
       "parentTag": "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contract liabilities",
        "verboseLabel": "Contract liabilities - Current",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentDeferredIncomeIncludingCurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred income and current contract liabilities",
        "label": "Current deferred income including current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r362"
     ]
    },
    "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails": {
       "parentTag": "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred income",
        "terseLabel": "Deferred income",
        "label": "Current deferred income other than current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r362"
     ]
    },
    "ifrs-full_CurrentDepositsFromCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentDepositsFromCustomers",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current deposits from customers",
        "label": "Current deposits from customers"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current deposits from customers. [Refer: Deposits from customers]"
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ifrs-full_CurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current financial liabilities",
        "verboseLabel": "Total current financial liabilities",
        "label": "Current financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "nbx_CurrentFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CurrentFinancialLiabilitiesMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current financial liabilities",
        "label": "Current Financial Liabilities [Member]",
        "documentation": "Current Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r249",
      "r287"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_CurrentOtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CurrentOtherProvisionsMember",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total current provisions",
        "label": "Current Other Provisions [Member]",
        "documentation": "Current Other Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll tax and other payroll liabilities",
        "label": "Current payables on social security and taxes other than income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]"
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current provisions",
        "label": "Current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit receivable",
        "periodStartLabel": "Research tax credit receivable at beginning of period",
        "periodEndLabel": "Research tax credit receivable at end of period",
        "label": "Current receivables from taxes other than income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]"
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 research tax credit",
        "label": "Current Receivables From Taxes Other Than Income Tax, Income Tax Credit",
        "documentation": "Current Receivables From Taxes Other Than Income Tax, Income Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentRefundsProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentRefundsProvision",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1": {
       "parentTag": "ifrs-full_RefundsProvision",
       "weight": 1.0,
       "order": 2.0
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current refund liabilities",
        "label": "Current refunds provision"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provision for refunds. [Refer: Refunds provision]"
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax liabilities",
        "label": "Current tax liabilities, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofTradeReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r319",
      "r321"
     ]
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VAT receivable",
        "label": "Current value added tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "nbx_DebtAccretionAndDiscountingImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DebtAccretionAndDiscountingImpact",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net impact of accretion, discounting and catch-up on EIB loan",
        "label": "Debt (Accretion) And Discounting Impact",
        "documentation": "Debt (Accretion) And Discounting Impact"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DebtDetailsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DebtDetailsAxis",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Details [Axis]",
        "label": "Debt Details [Axis]",
        "documentation": "Debt Details"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DebtDetailsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DebtDetailsDomain",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Details [Domain]",
        "label": "Debt Details [Domain]",
        "documentation": "Debt Details [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DecreaseThroughDerecognitionFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DecreaseThroughDerecognitionFinancialAssets",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decreases",
        "label": "Decrease through derecognition, financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in financial assets resulting from derecognition. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r293",
      "r295",
      "r305",
      "r311",
      "r313"
     ]
    },
    "nbx_DepreciationAmortizationAndProvisionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DepreciationAmortizationAndProvisionExpenses",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total depreciation, amortization and provision expenses",
        "label": "Depreciation, Amortization And Provision Expenses",
        "documentation": "Depreciation, Amortization And Provision Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DepreciationAmortizationAndProvisionExpensesExcludingIAS19",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails": {
       "parentTag": "nbx_DepreciationAmortizationAndProvisionExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total depreciation, amortization and provision expenses (except IAS 19)",
        "label": "Depreciation, Amortization And Provision Expenses Excluding IAS 19",
        "documentation": "Depreciation, Amortization And Provision Expenses Excluding IAS 19"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails": {
       "parentTag": "nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization expense of tangible assets",
        "label": "Depreciation expense"
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of consolidation",
        "label": "Description Of Accounting Policy For Basis Of Consolidation [Policy Text Block]",
        "documentation": "Description Of Accounting Policy For Basis Of Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues and other income",
        "label": "Description of accounting policy for recognition of revenue [text block]"
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of judgement, estimates and assumptions",
        "label": "Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions [Policy Text Block]",
        "documentation": "Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market rate estimated percent",
        "label": "Discount rate used in current estimate of value in use"
       }
      },
      "en": {
       "role": {
        "documentation": "The discount rate used in the current estimate of the present value of the future cash flows expected to be derived from an asset or cash-generating unit."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity (in years)",
        "label": "Option life, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Income and Contract Liabilities",
        "label": "Detailed Information About Deferred Income And Contract Liabilities [Table Text Block]",
        "documentation": "Detailed Information About Deferred Income And Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DetailedInformationAboutFinanceIncomeCostTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Financial Income (Loss)",
        "label": "Detailed Information About Finance Income (Cost) [Table Text Block]",
        "documentation": "Detailed Information About Finance Income (Cost)"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Liabilities",
        "label": "Detailed Information About Other Current Liabilities Explanatory [Table Text Block]",
        "documentation": "Detailed Information About Other Current Liabilities Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DetailedInformationAboutRefundLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DetailedInformationAboutRefundLiabilitiesTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Detailed Information About Refund Liabilities",
        "label": "Detailed Information About Refund Liabilities [Table Text Block]",
        "documentation": "Detailed Information About Refund Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share (in euro per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29"
     ]
    },
    "ifrs-full_DirectorsRemunerationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DirectorsRemunerationExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supervisory Board\u2019s fees",
        "label": "Directors' remuneration expense"
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues and Other Income",
        "label": "Disclosur Of Disaggregation Of Revenues And Other Income [Table Text Block]",
        "documentation": "Disclosur Of Disaggregation Of Revenues And Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Advances Loans and Lease Liabilities",
        "label": "Disclosure Of Advances Loans And Lease Liabilities [Table Text Block]",
        "documentation": "Disclosure Of Advances Loans And Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfConsolidationExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Consolidatedprinciplesandmethods"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated principles and methods",
        "label": "Disclosure of basis of consolidation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for consolidation."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Cashandcashequivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Cash And Cash Equivalents Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Research Tax Credit Receivables",
        "label": "Disclosure Of Changes In Research Tax Credit Receivables [Table Text Block]",
        "documentation": "Disclosure Of Changes In Research Tax Credit Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital Transactions",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r227",
      "r255"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r227",
      "r255"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments",
        "label": "Disclosure of commitments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesLineItems",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of contingent liabilities",
        "label": "Disclosure of contingent liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesTable",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of contingent liabilities [table]",
        "label": "Disclosure of contingent liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to contingent liabilities."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r185"
     ]
    },
    "nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation, Amortization and Provision Expenses",
        "label": "Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Payroll Costs",
        "label": "Disclosure Of Detailed Information About Employee Benefits Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Employee Benefits Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Financial Liabilities [Line Items]",
        "label": "Disclosure Of Detailed Information About Financial Liabilities [Line Items]",
        "documentation": "Disclosure Of Detailed Information About Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Financial Liabilities [Table]",
        "label": "Disclosure Of Detailed Information About Financial Liabilities [Table]",
        "documentation": "Disclosure Of Detailed Information About Financial Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Non-current Financial Assets",
        "label": "Disclosure Of Detailed Information About Non-Current Financial Assets [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Non-Current Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Assets",
        "label": "Disclosure Of Detailed Information About Other Current Assets Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Other Current Assets Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r174"
     ]
    },
    "nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Expenses",
        "label": "Disclosure Of Detailed Information About Research And Development Expense Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Research And Development Expense Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Selling, General and Administrative Expenses",
        "label": "Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Share-based Payments [Line Items]",
        "label": "Disclosure Of Detailed Information About Share-based Payments [Line Items]",
        "documentation": "Disclosure Of Detailed Information About Share-based Payments"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentsTable",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Share-based Payments [Table]",
        "label": "Disclosure Of Detailed Information About Share-based Payments [Table]",
        "documentation": "Disclosure Of Detailed Information About Share-based Payments"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade and Other Payables",
        "label": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade Receivables",
        "label": "Disclosure Of Detailed Information About Trade Receivables Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Trade Receivables Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r145"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Losspershare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/RetirementObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Obligations",
        "label": "Disclosure of employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Netfinancialincomeloss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net financial income (loss)",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets",
        "label": "Disclosure of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r208"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial assets",
        "label": "Disclosure of financial assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsTable",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial assets [table]",
        "label": "Disclosure of financial assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r208"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial instruments by type of interest rate [line items]",
        "label": "Disclosure of financial instruments by type of interest rate [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of financial instruments by type of interest rate [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial instruments, by type of interest rate."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments included in the statement of financial position and impact on income",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r114",
      "r122",
      "r208"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables",
      "http://nanobiotix.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Financial Liabilities",
        "verboseLabel": "Schedule of Financial Liabilities",
        "label": "Disclosure of financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r208"
     ]
    },
    "nbx_DisclosureOfFinancialLiabilitiesFootnoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfFinancialLiabilitiesFootnoteTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/Financialliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "label": "Disclosure Of Financial Liabilities Footnote [Text Block]",
        "documentation": "Disclosure Of Financial Liabilities Footnote"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Changes In Financial Liabilities",
        "label": "Disclosure of financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesTable",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Changes In Financial Liabilities [Table]",
        "label": "Disclosure of financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r208"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Generalinformationstatementofcomplianceandbasisofpresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General information, statement of compliance and basis of presentation",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r238"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of Founders' Warrants, Warrants and Free Shares Outstanding and Their Characteristics",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of Shares Options Outstanding and Their Characteristics",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "nbx_DisclosureOfInformationRelatedToTheCompanyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfInformationRelatedToTheCompanyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Information Related To The Company [Abstract]",
        "label": "Disclosure Of Information Related To The Company [Abstract]",
        "documentation": "Disclosure Of Information Related To The Company [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfInformationRelatedToTheCompanyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfInformationRelatedToTheCompanyLineItems",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Information Related To The Company [Line Items]",
        "label": "Disclosure Of Information Related To The Company [Line Items]",
        "documentation": "Disclosure Of Information Related To The Company"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfInformationRelatedToTheCompanyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfInformationRelatedToTheCompanyTable",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Information Related To The Company [Table]",
        "label": "Disclosure Of Information Related To The Company [Table]",
        "documentation": "Disclosure Of Information Related To The Company [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Intangibleassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r191"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Maturity Analysis for Advances Loans and Lease Liabilities",
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Table]",
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r220"
     ]
    },
    "nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfNonCurrentFinancialAssetsTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/Noncurrentfinancialassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets",
        "label": "Disclosure Of Non-current Financial Assets [Text Block]",
        "documentation": "Disclosure Of Non-current Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Subsequentevents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent events",
        "label": "Disclosure of non-adjusting events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]"
       }
      }
     },
     "auth_ref": [
      "r0",
      "r165"
     ]
    },
    "nbx_DisclosureOfNotesAndOtherExplanatoryInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/Companyinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company information",
        "label": "Disclosure of notes and other explanatory information [Text Block]",
        "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding",
        "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding [Line Items]",
        "documentation": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding",
        "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding [Table]",
        "documentation": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Founders' Warrants, Warrants and Free Shares",
        "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of outstanding other equity Instruments [Table Text Block]",
        "documentation": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Share Options",
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "nbx_DisclosureOfOperatingExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfOperatingExpensesLineItems",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Operating Expenses",
        "label": "Disclosure Of Operating Expenses [Line Items]",
        "documentation": "Disclosure Of Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfOperatingExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfOperatingExpensesTable",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Operating Expenses [Table]",
        "label": "Disclosure Of Operating Expenses [Table]",
        "documentation": "Disclosure Of Operating Expenses [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Segmentreporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment reporting",
        "label": "Disclosure of operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Operatingexpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Disclosure of other operating expense [text block]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "nbx_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfOtherOperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Operating Income (Expenses)",
        "label": "Disclosure Of Other Operating Income (Expense) [Table Text Block]",
        "documentation": "Disclosure Of Other Operating Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsTables",
      "http://nanobiotix.com/role/RetirementObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Provisions",
        "label": "Disclosure of other provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r36",
      "r184"
     ]
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails",
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of other provisions",
        "label": "Disclosure of other provisions [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsTable",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails",
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of other provisions [table]",
        "label": "Disclosure of other provisions [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r184"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Propertyplantandequipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfProvisionsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Provisions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Disclosure of provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Lease Liabilities",
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r284"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Relatedparties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Revenueandotherincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue and other income",
        "label": "Disclosure of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital [Abstract]",
        "label": "Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "documentation": "Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r228",
      "r256"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/Sharebasedpayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "nbx_DisclosureOfSignificantTransactionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfSignificantTransactionsTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/Significanttransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant transactions",
        "label": "Disclosure Of Significant Transactions [Text Block]",
        "documentation": "Disclosure Of Significant Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [abstract]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [Table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r206"
     ]
    },
    "nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Trade Payables and Other Current Liabilities [Line Items]",
        "label": "Disclosure of Trade Payables and Other Current Liabilities [Line Items]",
        "documentation": "Disclosure of Trade Payables and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Trade Payables and Other Current Liabilities [Table]",
        "label": "Disclosure of Trade Payables and Other Current Liabilities [Table]",
        "documentation": "Disclosure of Trade Payables and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and other current liabilities",
        "label": "Disclosure Of Trade Payables And Other Current Liabilities [Text Block]",
        "documentation": "Disclosure Of Trade Payables And Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Trade Receivables and Other Current Assets",
        "label": "Disclosure of Trade Receivables and Other Current Assets [Line Items]",
        "documentation": "Disclosure of Trade Receivables and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Trade Receivables and Other Current Assets [Table]",
        "label": "Disclosure of Trade Receivables and Other Current Assets [Table]",
        "documentation": "Disclosure of Trade Receivables and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://nanobiotix.com/role/Tradereceivablesandothercurrentassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables and other current assets",
        "label": "Disclosure Of Trade Receivables And Other Current Assets [Text Block]",
        "documentation": "Disclosure Of Trade Receivables And Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [abstract]",
        "label": "Disclosure of transactions between related parties [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Key Management Personnel Compensation",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r177"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [line items]",
        "label": "Disclosure of transactions between related parties [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [table]",
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r178"
     ]
    },
    "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisposalsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decreases",
        "label": "Disposals, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r188"
     ]
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decreases",
        "label": "Disposals, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r171"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://nanobiotix.com/role/LosspershareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Loss Per Share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates changes on cash",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total payroll costs",
        "label": "Employee benefits expense"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r232",
      "r267",
      "r317"
     ]
    },
    "nbx_EmploymentTerminationIndemnitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "EmploymentTerminationIndemnitiesMember",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employment Termination Indemnities",
        "label": "Employment Termination Indemnities [Member]",
        "documentation": "Employment Termination Indemnities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_EnnoSpillnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "EnnoSpillnerMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enno SPILLNER",
        "label": "Enno Spillner [Member]",
        "documentation": "Enno Spillner"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Equity at beginning of period",
        "periodEndLabel": "Equity at end of period",
        "terseLabel": "Share capital",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r75",
      "r76",
      "r77",
      "r179",
      "r198",
      "r222",
      "r223",
      "r230",
      "r245",
      "r252"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDER\u2019S EQUITY",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_EstimatedRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "EstimatedRoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated royalty payments",
        "label": "Estimated Royalty Payments",
        "documentation": "Estimated Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_EuropeanInvestmentBankLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "EuropeanInvestmentBankLoanAgreementMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EIB Loan",
        "verboseLabel": "EIB fixed rate loan",
        "label": "European Investment Bank Loan Agreement [Member]",
        "documentation": "European Investment Bank Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ExecutiveBoardAndEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ExecutiveBoardAndEmployeesMember",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Board and Employees",
        "label": "Executive Board And Employees [Member]",
        "documentation": "Executive Board And Employees"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ExercisePriceOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ExercisePriceOtherEquityInstrumentsGranted",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in euro per share)",
        "label": "Exercise Price, Other Equity Instruments Granted",
        "documentation": "Exercise Price, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in euros per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ExpectedDividendAsPercentageOtherEquityInstrumentsGranted",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yield",
        "label": "Expected Dividend As Percentage, Other Equity Instruments Granted",
        "documentation": "Expected Dividend As Percentage, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yield",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense for the year",
        "label": "Expense from equity-settled share-based payment transactions"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense from share-based payment transactions with employees",
        "negatedTerseLabel": "Share-based payments",
        "label": "Expense from share-based payment transactions with employees"
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      },
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Financial expenses",
        "negatedTotalLabel": "Total financial expenses",
        "label": "Finance costs"
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial income",
        "totalLabel": "Total financial income",
        "label": "Finance income"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial income (loss)",
        "label": "Finance income (cost)"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial assets",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r109",
      "r112",
      "r113",
      "r116",
      "r216",
      "r217",
      "r219",
      "r297"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and liabilities carried at amortized cost",
        "label": "Financial assets at amortised cost, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r211"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial assets, at fair value",
        "label": "Financial assets, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets carried at fair value through profit or loss",
        "label": "Financial assets at fair value through profit or loss, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r209"
     ]
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at amortised cost",
        "label": "Financial liabilities at amortised cost, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r212"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at fair value through profit or loss, category",
        "label": "Financial liabilities at fair value through profit or loss, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r124",
      "r210"
     ]
    },
    "ifrs-full_FixedInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FixedInterestRateMember",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed interest rate",
        "label": "Fixed interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ifrs-full_FixturesAndFittingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FixturesAndFittingsMember",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixtures, fittings and installations",
        "label": "Fixtures and fittings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "ifrs-full_FloatingInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FloatingInterestRateMember",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable interest rate",
        "label": "Floating interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a non-fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustment",
        "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Information, Statement of Compliance and Basis of Presentation [Abstract]",
        "label": "General Information, Statement of Compliance and Basis of Presentation [Abstract]",
        "documentation": "General Information, Statement of Compliance and Basis of Presentation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross book value of intangible assets",
        "label": "Gross carrying amount [member]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r38",
      "r48",
      "r51",
      "r106",
      "r113",
      "r116",
      "r169",
      "r186",
      "r194",
      "r197",
      "r217",
      "r219",
      "r297"
     ]
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GrossLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Gross lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r148",
      "r299"
     ]
    },
    "nbx_HSBCBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "HSBCBankMember",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HSBC Bank",
        "label": "HSBC Bank [Member]",
        "documentation": "HSBC Bank"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ImpactOfAmendmentOnProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ImpactOfAmendmentOnProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of the Janssen amendment on profit or loss",
        "label": "Impact of Amendment on Profit or Loss",
        "documentation": "Impact of Amendment on Profit or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss, intangible assets other than goodwill",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r189"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r172",
      "r266"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax",
        "terseLabel": "Income tax expense",
        "label": "Tax expense (income)"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r3",
      "r4",
      "r24",
      "r74",
      "r132",
      "r166",
      "r167",
      "r168",
      "r262"
     ]
    },
    "ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax impact",
        "label": "Income tax relating to exchange differences on translation of foreign operations included in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to exchange differences on the translation of financial statements of foreign operations. [Refer: Other comprehensive income; Reserve of exchange differences on translation]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r263"
     ]
    },
    "ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax impact",
        "label": "Income tax relating to remeasurements of defined benefit plans included in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to remeasurements of defined benefit plans. [Refer: Other comprehensive income; Reserve of remeasurements of defined benefit plans; Defined benefit plans [domain]]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r263"
     ]
    },
    "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax Paid",
        "label": "Income taxes paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for income taxes paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "nbx_IncreaseDecreaseInBonusAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseInBonusAccrual",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in bonus accrual",
        "label": "Increase (Decrease) In Bonus Accrual",
        "documentation": "Increase (Decrease) In Bonus Accrual"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsNarrativeDetails",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "negatedLabel": "Net decrease in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r58",
      "r164"
     ]
    },
    "nbx_IncreaseDecreaseInDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseInDepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in depreciation expense",
        "label": "Increase (Decrease) in Depreciation Expense",
        "documentation": "Increase (Decrease) in Depreciation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseInEmployeeBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseInEmployeeBenefitExpense",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in employee benefit expense",
        "label": "Increase (Decrease) In Employee Benefit Expense",
        "documentation": "Increase (Decrease) In Employee Benefit Expense"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseInEmployeeBenefitExpensePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseInEmployeeBenefitExpensePercentage",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of increase in employee benefit expense",
        "label": "Increase (Decrease) In Employee Benefit Expense, Percentage",
        "documentation": "Increase (Decrease) In Employee Benefit Expense, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retirement benefit obligations",
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss"
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "nbx_IncreaseDecreaseInOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseInOtherCurrentPayables",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of other trade payables",
        "label": "Increase (Decrease) In Other Current Payables",
        "documentation": "Increase (Decrease) In Other Current Payables"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseInOutstandingLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseInOutstandingLoans",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in outstanding loans",
        "label": "Increase (Decrease) In Outstanding Loans",
        "documentation": "Increase (Decrease) In Outstanding Loans"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in payroll tax and other payroll liabilities",
        "label": "Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current",
        "documentation": "Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseInPurchasesFeesAndOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in purchases, fees, and other expenses",
        "label": "Increase (Decrease) In Purchases, Fees, And Other Expenses",
        "documentation": "Increase (Decrease) In Purchases, Fees, And Other Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in purchases, sub-contracting and other expenses",
        "label": "Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses",
        "documentation": "Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseInSocialTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseInSocialTax",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in social tax",
        "label": "Increase (Decrease) In Social Tax",
        "documentation": "Increase (Decrease) In Social Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInWorkingCapital",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Changes in operating working capital",
        "label": "Increase (decrease) in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "nbx_IncreaseDecreasePayrollExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreasePayrollExpense",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in employee benefit expense",
        "label": "Increase (Decrease) Payroll Expense",
        "documentation": "Increase (Decrease) Payroll Expense"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreasePayrollExpensePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreasePayrollExpensePercentage",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage change in employee benefit expense",
        "label": "Increase (Decrease) Payroll Expense, Percentage",
        "documentation": "Increase (Decrease) Payroll Expense, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseRefundLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseRefundLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in refund liabilities",
        "label": "Increase (Decrease) Refund Liabilities",
        "documentation": "Increase (Decrease) Refund Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) related to adjustments for income forecast projections",
        "label": "Increase (Decrease) Related To Adjustments For Income Forecast Projections",
        "documentation": "Increase (Decrease) Related To Adjustments For Income Forecast Projections"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated fixed interest expense accrual",
        "label": "Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated variable interest expense accrual",
        "label": "Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocation of prior period loss",
        "label": "Increase (decrease) through appropriation of retained earnings, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "nbx_IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in loans and conditional advances",
        "label": "Increase (Decrease) Through Decrease In Loans And Conditional Advances, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Decrease In Loans And Conditional Advances, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal received",
        "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r161"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustments",
        "label": "Increase (decrease) through foreign exchange, financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r293",
      "r305",
      "r311"
     ]
    },
    "nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of accretion and discounting",
        "label": "Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of discounting and catch-up",
        "label": "Increase (Decrease) Through Impact Of Discounting And Catch up, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Impact Of Discounting And Catch up, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indexation effect on current lease commitment",
        "label": "Increase (Decrease) Through Indexation Effect On Current Lease Commitment, Liabilities Arising From Financing Activities",
        "documentation": "Increase (Decrease) Through Indexation Effect On Current Lease Commitment, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails",
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustments",
        "label": "Increase (decrease) through net exchange differences, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation",
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughOtherMovementsFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughOtherMovementsFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification",
        "label": "Increase (decrease) through other movements, financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in financial assets resulting from other movements. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r293",
      "r296",
      "r305",
      "r311",
      "r314"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription of warrants",
        "label": "Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity",
        "documentation": "Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other movements &amp; transfer.",
        "label": "Increase (decrease) through transfers and other changes, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer",
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseThroughOriginationOrPurchaseFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Increase through origination or purchase, financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in financial assets resulting from origination or purchase. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r305",
      "r311",
      "r312"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "periodStartLabel": "Intangible assets at beginning of period",
        "periodEndLabel": "Intangible assets at end of period",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r42",
      "r190",
      "r240"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets other than goodwill [member]",
        "label": "Intangible assets other than goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r291",
      "r308",
      "r310"
     ]
    },
    "nbx_IntellectualPropertyServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "IntellectualPropertyServicesMember",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual Property Services",
        "label": "Intellectual Property Services [Member]",
        "documentation": "Intellectual Property Services"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest costs",
        "negatedLabel": "Interest costs",
        "label": "Interest expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r131",
      "r138"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lease debt interests",
        "label": "Interest expense on lease liabilities"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r147"
     ]
    },
    "nbx_InterestFreeAdvanceToCuradigmBPIFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "InterestFreeAdvanceToCuradigmBPIFranceMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Curadigm interest-free Bpifrance advance",
        "label": "Interest-free Advance To Curadigm, BPI France [Member]",
        "documentation": "Interest-free Advance To Curadigm, BPI France"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestIncomeOnCashAndBankBalancesAtCentralBanks",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from cash and cash equivalents",
        "label": "Interest income on cash and bank balances at central banks"
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_InterestIncomeOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestIncomeOnCashAndCashEquivalents",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income on cash and cash equivalents",
        "label": "Interest income on cash and cash equivalents"
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest paid",
        "label": "Interest paid, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_InterestRevenueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestRevenueExpense",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest income (expense)"
       }
      }
     },
     "auth_ref": [
      "r133",
      "r138",
      "r363"
     ]
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital increase",
        "verboseLabel": "Allocation of loss 12/31/2024",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r322"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital Ordinary shares",
        "verboseLabel": "Share Capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "nbx_JanssenPharmaceuticaBVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "JanssenPharmaceuticaBVMember",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen Pharmaceutica BV",
        "label": "Janssen Pharmaceutica BV [Member]",
        "documentation": "Janssen Pharmaceutica BV"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_JanssenPharmaceuticaNVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "JanssenPharmaceuticaNVMember",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen Pharmaceutica NV",
        "label": "Janssen Pharmaceutica NV [Member]",
        "documentation": "Janssen Pharmaceutica NV"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_JohnsonJohnsonInnovationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "JohnsonJohnsonInnovationsMember",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Johnson &amp; Johnson Innovations",
        "label": "Johnson &amp; Johnson Innovations [Member]",
        "documentation": "Johnson &amp; Johnson Innovations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
      "http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key management personnel compensation",
        "totalLabel": "Total compensation to related parties",
        "label": "Key management personnel compensation"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r175"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Key management personnel compensation, share-based payment"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesScheduleofKeyManagementPersonnelCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries, wages and benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than 5 years",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r91",
      "r150",
      "r153",
      "r298",
      "r303",
      "r306"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Between 1 and 3\u00a0years",
        "label": "Later than one year and not later than three years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r301",
      "r306"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Between 3 and 5\u00a0years",
        "label": "Later than three years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r302",
      "r306"
     ]
    },
    "nbx_LaurentLevyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "LaurentLevyMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laurent LEVY",
        "label": "Laurent Levy [Member]",
        "documentation": "Laurent Levy"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_LeaseDebtInterestPaidClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "LeaseDebtInterestPaidClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r286"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r133",
      "r137",
      "r222",
      "r223",
      "r245"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Liabilities arising from financing activities at beginning of period",
        "periodEndLabel": "Liabilities arising from financing activities at end of period",
        "label": "Liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r284"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities [axis]",
        "label": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r284"
     ]
    },
    "nbx_LiabilitiesArisingFromFinancingActivitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "LiabilitiesArisingFromFinancingActivitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails": {
       "parentTag": "ifrs-full_LiabilitiesArisingFromFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Of which Current",
        "label": "Liabilities Arising from Financing Activities Current",
        "documentation": "Liabilities Arising from Financing Activities Current"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesDomain",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities [member]",
        "label": "Liabilities arising from financing activities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r284"
     ]
    },
    "nbx_LiabilitiesArisingFromFinancingActivitiesNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "LiabilitiesArisingFromFinancingActivitiesNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails": {
       "parentTag": "ifrs-full_LiabilitiesArisingFromFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Of which Non-Current",
        "label": "Liabilities Arising from Financing Activities Non Current",
        "documentation": "Liabilities Arising from Financing Activities Non Current"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_LiabilitiesArisingFromFinancingActivitiesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "LiabilitiesArisingFromFinancingActivitiesRollForward",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities Arising From Financing Activities [Roll Forward]",
        "label": "Liabilities Arising From Financing Activities [Roll Forward]",
        "documentation": "Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_LiabilitiesRelatedToFinancingActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "LiabilitiesRelatedToFinancingActivitiesMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities Related to Financing Activities",
        "label": "Liabilities Related To Financing Activities [Member]",
        "documentation": "Liabilities Related To Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_LianBioNBTXR3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "LianBioNBTXR3Member",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LianBio, NBTXR3",
        "label": "LianBio, NBTXR3 [Member]",
        "documentation": "LianBio, NBTXR3"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_LitigationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "LitigationExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails": {
       "parentTag": "nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reversal of provision for disputes and charges",
        "label": "Litigation Expense",
        "documentation": "Litigation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LongtermBorrowingsMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term borrowings",
        "label": "Long-term borrowings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r286"
     ]
    },
    "nbx_LouisKayitalireMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "LouisKayitalireMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Louis Kayitalire",
        "label": "Louis Kayitalire [Member]",
        "documentation": "Louis Kayitalire"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_LumpSumRetirementBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "LumpSumRetirementBenefitsMember",
     "presentation": [
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lump-sum retirement benefits",
        "label": "Lump-Sum Retirement Benefits [Member]",
        "documentation": "Lump-Sum Retirement Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_MDAndersonCancerCenterNBTXR3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "MDAndersonCancerCenterNBTXR3Member",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MD Anderson Cancer Center, NBTXR3",
        "label": "MD Anderson Cancer Center, NBTXR3 [Member]",
        "documentation": "MD Anderson Cancer Center, NBTXR3"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MachineryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MachineryMember",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technical equipment",
        "label": "Machinery [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing long-lived, depreciable machinery used in operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MajorOrdinaryShareTransactionsMember",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major ordinary share transactions",
        "label": "Major ordinary share transactions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r309"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r108",
      "r119",
      "r144",
      "r146",
      "r151",
      "r154",
      "r214",
      "r247",
      "r272",
      "r298"
     ]
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated time bands [member]",
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r108",
      "r144",
      "r146",
      "r151",
      "r154",
      "r214",
      "r247",
      "r272",
      "r298",
      "r304"
     ]
    },
    "nbx_MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum total number of shares that may be subscribed (in shares)",
        "terseLabel": "Maximum total number of awards that may be subscribed (in shares)",
        "netLabel": "Total number of shares that may be subscribed (in shares)",
        "label": "Maximum Number Of Other Equity Instruments That May Be Subscribed In Share-Based Payment Arrangement",
        "documentation": "Maximum Number Of Other Equity Instruments That May Be Subscribed In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum total number of shares that may be subscribed (in shares)",
        "label": "Maximum Number Of Share Options That May Be Subscribed In Share-Based Payment Arrangement",
        "documentation": "Maximum Number Of Share Options That May Be Subscribed In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement [axis]",
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r50",
      "r75",
      "r196",
      "r222"
     ]
    },
    "ifrs-full_MeasurementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MeasurementDomain",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated measurement [member]",
        "label": "Measurement [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r50",
      "r75",
      "r196",
      "r222"
     ]
    },
    "nbx_MilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "MilestonePaymentMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment",
        "label": "Milestone Payment [Member]",
        "documentation": "Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Miscellaneous other operating income"
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "nbx_NANORAY312Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NANORAY312Member",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NANORAY-312",
        "label": "NANORAY-312 [Member]",
        "documentation": "NANORAY-312"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NBTXR3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NBTXR3Member",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NBTXR3",
        "label": "NBTXR3 [Member]",
        "documentation": "NBTXR3"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NanobiotixCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NanobiotixCorpMember",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RelatedpartiesNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nanobiotix Corp.",
        "label": "Nanobiotix Corp. [Member]",
        "documentation": "Nanobiotix Corp."
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NanobiotixSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NanobiotixSAMember",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nanobiotix S.A.",
        "label": "Nanobiotix S.A. [Member]",
        "documentation": "Nanobiotix S.A."
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NetAmountsReceivablePayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NetAmountsReceivablePayableRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net receivables (liabilities)",
        "label": "Net Amounts Receivable Payable Related Party Transactions",
        "documentation": "Net Amounts Receivable Payable Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NetCollectionsPaymentsFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NetCollectionsPaymentsFromRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesScheduleofDisclosureofTransactionsBetweenLiabilitiesandReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net collections",
        "label": "Net Collections (Payments) From Related Party",
        "documentation": "Net Collections (Payments) From Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NetFinancialIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NetFinancialIncomeLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Financial Income (Loss) [Abstract]",
        "documentation": "Net Financial Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetForeignExchangeGain",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange gains",
        "label": "Net foreign exchange gain"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r358"
     ]
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetForeignExchangeLoss",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossScheduleofNetFinancialIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange losses",
        "terseLabel": "Net foreign exchange loss",
        "label": "Net foreign exchange loss"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r358"
     ]
    },
    "nbx_NetLossForThePeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NetLossForThePeriodMember",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss for the period",
        "label": "Net Loss For The Period [Member]",
        "documentation": "Net Loss For The Period"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NettingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NettingMember",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Netting",
        "label": "Netting [Member]",
        "documentation": "Netting"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NonCurrentFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NonCurrentFinancialAssetsMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets",
        "label": "Non-Current Financial Assets [Member]",
        "documentation": "Non-Current Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NonCurrentFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NonCurrentFinancialLiabilitiesMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial liabilities",
        "label": "Non Current Financial Liabilities [Member]",
        "documentation": "Non Current Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NonCurrentLiquidityContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NonCurrentLiquidityContractMember",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposits paid",
        "label": "Non-current, Liquidity Contract [Member]",
        "documentation": "Non-current, Liquidity Contract"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NonCurrentOtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NonCurrentOtherProvisionsMember",
     "presentation": [
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Non-current provisions",
        "label": "Non-Current Other Provisions [Member]",
        "documentation": "Non-Current Other Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NonDilutiveFinancingAgreementBPIFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NonDilutiveFinancingAgreementBPIFranceMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bpifrance \u201cPGE\u201d",
        "verboseLabel": "Bpifrance \"PGE\"",
        "label": "Non-Dilutive Financing Agreement, BPI France [Member]",
        "documentation": "Non-Dilutive Financing Agreement, BPI France"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HSBC \"PGE\" and Bpifrance \"PGE\"",
        "label": "Non-Dilutive Financing Agreement, HSBC France And BPI France [Member]",
        "documentation": "Non-Dilutive Financing Agreement, HSBC France And BPI France"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NonDilutiveFinancingAgreementHSBCFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NonDilutiveFinancingAgreementHSBCFranceMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HSBC \u201cPGE\u201d",
        "verboseLabel": "HSBC \"PGE\"",
        "label": "Non-Dilutive Financing Agreement, HSBC France [Member]",
        "documentation": "Non-Dilutive Financing Agreement, HSBC France"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NonRecurringExpenseTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NonRecurringExpenseTypeAxis",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Recurring Expense Type [Axis]",
        "label": "Non-Recurring Expense Type [Axis]",
        "documentation": "Non-Recurring Expense Type"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NonRecurringExpenseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NonRecurringExpenseTypeDomain",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Recurring Expense Type [Domain]",
        "label": "Non-Recurring Expense Type [Domain]",
        "documentation": "Non-Recurring Expense Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r165"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [member]",
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r165"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r248",
      "r287"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1": {
       "parentTag": "ifrs-full_RefundsProvision",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current refund liabilities",
        "terseLabel": "Non-current refund liabilities",
        "label": "Non-current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets",
        "periodStartLabel": "Non-current financial assets at beginning of period",
        "periodEndLabel": "Non-current financial assets at end of period",
        "label": "Non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_NoncurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial liabilities",
        "verboseLabel": "Total non-current financial liabilities",
        "label": "Non-current financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r69",
      "r249",
      "r287"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current provisions",
        "label": "Non-current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Non-derivative financial liabilities, undiscounted cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r220"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 1\u00a0year",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r91",
      "r149",
      "r152",
      "r246",
      "r298",
      "r306"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "nbx_NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of beneficiaries who are not corporate officers",
        "label": "Number Of Beneficiaries Of Other Equity Instruments, Share-Based Payment Arrangement",
        "documentation": "Number Of Beneficiaries Of Other Equity Instruments, Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of beneficiaries who are not corporate officers",
        "label": "Number Of Beneficiaries Of Share Options, Share-Based Payment Arrangement",
        "documentation": "Number Of Beneficiaries Of Share Options, Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfEmployees",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of employees",
        "terseLabel": "End-of-period headcount",
        "label": "Number of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total number of awards granted (in shares)",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r349"
     ]
    },
    "nbx_NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of awards authorised (in shares)",
        "label": "Number Of Other Equity Instruments Authorised In Share-Based Payment Arrangement",
        "documentation": "Number Of Other Equity Instruments Authorised In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Total number of shares available for subscription (in shares)",
        "terseLabel": "Total number of awards available for subscription (in shares)",
        "label": "Number of other equity instruments exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Number of shares subscribed (in shares)",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of awards lapsed, cancelled or forfeited (in shares)",
        "label": "Number of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of awards outstanding (in shares)",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of share options outstanding (in shares)",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r98",
      "r100",
      "r200",
      "r204"
     ]
    },
    "ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented",
     "presentation": [
      "http://nanobiotix.com/role/LosspershareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential additional ordinary shares that are considered antidilutive (in shares)",
        "label": "Number of potential ordinary shares that are antidilutive in period presented"
       }
      },
      "en": {
       "role": {
        "documentation": "Number of potential ordinary shares that are antidilutive in the period presented."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "nbx_NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes": {
     "xbrltype": "integerItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of security types (security)",
        "label": "Number Of Share-Based Payment Arrangement, Number Of Security Types",
        "documentation": "Number Of Share-Based Payment Arrangement, Number Of Security Types"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of share options authorised (in shares)",
        "label": "Number Of Share Options Authorised In Share-Based Payment Arrangement",
        "documentation": "Number Of Share Options Authorised In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares available for subscription (in shares)",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r205"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares subscribed (in shares)",
        "label": "Number of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r203"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of share options lapsed or cancelled (in shares)",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r202"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of share options granted (in shares)",
        "label": "Number of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r201"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Capital increase (in shares)",
        "terseLabel": "Capital increase (in shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares outstanding at beginning of period (in shares)",
        "periodEndLabel": "Number of shares outstanding at end of period (in shares)",
        "terseLabel": "Number of shares outstanding (in shares)",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r226",
      "r254"
     ]
    },
    "nbx_NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of shares to which the share options were likely to give right (in shares)",
        "label": "Number Of Shares To Which Options Were Likely To Give Right In Share-Based Payment Arrangement",
        "documentation": "Number Of Shares To Which Options Were Likely To Give Right In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of shares to which the awards were likely to give right (in shares)",
        "label": "Number Of Shares To Which Other Equity Instruments Were Likely To Give Right In Share-Based Payment Arrangement",
        "documentation": "Number Of Shares To Which Other Equity Instruments Were Likely To Give Right In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_NumberOfSubsidiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "NumberOfSubsidiaries",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of subsidiaries",
        "label": "Number Of Subsidiaries",
        "documentation": "Number Of Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA20161PerformanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA20161PerformanceMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2016-1 P",
        "label": "OSA 2016-1 Performance [Member]",
        "documentation": "OSA 2016-1 Performance"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA20162Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA20162Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2016-2",
        "label": "OSA 2016-2 [Member]",
        "documentation": "OSA 2016-2"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA2017OrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA2017OrdinaryMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2017 O",
        "label": "OSA 2017 Ordinary [Member]",
        "documentation": "OSA 2017 Ordinary"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA2018Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2018",
        "label": "OSA 2018 [Member]",
        "documentation": "OSA 2018"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA20191Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA20191Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2019-1",
        "label": "OSA 2019-1 [Member]",
        "documentation": "OSA 2019-1"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA20192Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA20192Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2019-2",
        "label": "OSA 2019-2 [Member]",
        "documentation": "OSA 2019-2"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA2020Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2020",
        "label": "OSA 2020 [Member]",
        "documentation": "OSA 2020"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA202104OrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA202104OrdinaryMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2021-04 O",
        "label": "OSA 2021-04 Ordinary [Member]",
        "documentation": "OSA 2021-04 Ordinary"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA202104PerformanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA202104PerformanceMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2021-04 P",
        "label": "OSA 2021-04 Performance [Member]",
        "documentation": "OSA 2021-04 Performance"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA202106OrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA202106OrdinaryMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2021-06 O",
        "label": "OSA 2021-06 Ordinary [Member]",
        "documentation": "OSA 2021-06 Ordinary"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA202106PerformanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA202106PerformanceMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2021-06 P",
        "label": "OSA 2021-06 Performance [Member]",
        "documentation": "OSA 2021-06 Performance"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA202206OrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA202206OrdinaryMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2022-06 O",
        "label": "OSA 2022-06 Ordinary [Member]",
        "documentation": "OSA 2022-06 Ordinary"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA202206PerformanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA202206PerformanceMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2022-06 P",
        "label": "OSA 2022-06 Performance [Member]",
        "documentation": "OSA 2022-06 Performance"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA202301OrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA202301OrdinaryMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2023-01 O",
        "label": "OSA 2023-01 Ordinary [Member]",
        "documentation": "OSA 2023-01 Ordinary"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA202401OrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA202401OrdinaryMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2024-01 O",
        "label": "OSA 2024-01 Ordinary [Member]",
        "documentation": "OSA 2024-01 Ordinary"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA202501OrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA202501OrdinaryMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2025-01 O",
        "label": "OSA 2025-01 Ordinary [Member]",
        "documentation": "OSA 2025-01 Ordinary"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSA202502OrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSA202502OrdinaryMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2025-02 O",
        "label": "OSA 2025-02 Ordinary [Member]",
        "documentation": "OSA 2025-02 Ordinary"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSALLY2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSALLY2019Member",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA 2019 LLY",
        "label": "OSA LLY 2019 [Member]",
        "documentation": "OSA LLY 2019"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OSAMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSA",
        "label": "OSA [Member]",
        "documentation": "OSA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and IT equipment",
        "label": "Office equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "nbx_OfficersNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OfficersNameAxis",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officers Name [Axis]",
        "label": "Officers Name [Axis]",
        "documentation": "Officers Name"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OfficersNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OfficersNameDomain",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officers Name [Domain]",
        "label": "Officers Name [Domain]",
        "documentation": "Officers Name"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OpenTaxYearAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OpenTaxYearAxis",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open Tax Year [Axis]",
        "label": "Open Tax Year [Axis]",
        "documentation": "Open Tax Year"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OpenTaxYearDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OpenTaxYearDomain",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open Tax Year [Domain]",
        "label": "Open Tax Year [Domain]",
        "documentation": "Open Tax Year [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating expense"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "nbx_OperatingExpenseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OperatingExpenseAxis",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense [Axis]",
        "label": "Operating Expense [Axis]",
        "documentation": "Operating Expense"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OperatingExpenseDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OperatingExpenseDomain",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense [Domain]",
        "label": "Operating Expense [Domain]",
        "documentation": "Operating Expense [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAdjustmentsForNoncashItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherAdjustmentsForNoncashItems",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non cash income and expenses",
        "label": "Other adjustments for non-cash items"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "nbx_OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Actuarial gains and losses (IAS 19)",
        "label": "Other Comprehensive Income, Before Tax, Gains (Losses) on Actuarial Gains and Losses on Retirement Benefit Obligations",
        "documentation": "Other Comprehensive Income, Before Tax, Gains (Losses) on Actuarial Gains and Losses on Retirement Benefit Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains and losses on retirement benefit obligations (IAS 19)",
        "label": "Other comprehensive income, before tax, gains (losses) on remeasurements of defined benefit plans"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, before tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r265",
      "r329"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustments",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r264"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive loss that may be reclassified subsequently to loss",
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive loss that will not be reclassified subsequently to income or loss",
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324"
     ]
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "totalLabel": "Other current assets",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other current liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r321"
     ]
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "totalLabel": "Total other income",
        "label": "Other income"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r317",
      "r318"
     ]
    },
    "nbx_OtherMiscellaneousCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OtherMiscellaneousCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Other Miscellaneous Current Liabilities",
        "documentation": "Other Miscellaneous Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OtherNonrecurringExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OtherNonrecurringExpenses",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails": {
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non recurring expenses",
        "negatedTerseLabel": "Other non recurring expenses",
        "label": "Other Nonrecurring Expenses",
        "documentation": "Other Nonrecurring Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_OtherNonrecurringsIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OtherNonrecurringsIncome",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails": {
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non recurring income",
        "label": "Other Nonrecurrings Income",
        "documentation": "Other Nonrecurrings Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofOtherOperatingIncomeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other operating incomes and expenses",
        "totalLabel": "Total other operating income and expenses",
        "label": "Other operating income (expense)"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ifrs-full_OtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails",
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Other provisions at beginning of period",
        "periodEndLabel": "Other provisions at end of period",
        "label": "Other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r33",
      "r181",
      "r229",
      "r251"
     ]
    },
    "nbx_OtherProvisionsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OtherProvisionsRollForward",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails",
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Provisions [Roll Forward]",
        "label": "Other Provisions [Roll Forward]",
        "documentation": "Other Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve",
        "label": "Other reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r322"
     ]
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "label": "Other revenue"
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "nbx_OtherSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "OtherSalesMember",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other sales",
        "label": "Other Sales [Member]",
        "documentation": "Other Sales"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "PGELoanAgreementBPIFranceAndHSBCFranceMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PGE loans",
        "label": "PGE Loan Agreement, BPI France And HSBC France [Member]",
        "documentation": "PGE Loan Agreement, BPI France And HSBC France"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value per share (in euro per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r225",
      "r253"
     ]
    },
    "nbx_PaymentOfAdvisoryFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "PaymentOfAdvisoryFees",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of advisory fees",
        "label": "Payment Of Advisory Fees",
        "documentation": "Payment Of Advisory Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesScheduleofChangesinLiabilitiesArisingfromFinancingActivitiesDetails",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "nbx_PrepaymentsOnTangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "PrepaymentsOnTangibleAssetsMember",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments on tangible assets",
        "label": "Prepayments On Tangible Assets [Member]",
        "documentation": "Prepayments On Tangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_PrincipalAndFixedRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "PrincipalAndFixedRateMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal and Fixed Rate",
        "label": "Principal And Fixed Rate [Member]",
        "documentation": "Principal And Fixed Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in loans and conditional advances",
        "label": "Proceeds from borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "nbx_ProceedsFromIncomeTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ProceedsFromIncomeTaxCredit",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsScheduleofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receipt of 2024 research tax credit - Nanobiotix Corp",
        "label": "Proceeds From Income Tax Credit",
        "documentation": "Proceeds From Income Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [axis]",
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r290",
      "r307"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [member]",
        "label": "Products and services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r290",
      "r307"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS_1": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/ShareCapitalFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss for the period",
        "terseLabel": "Net loss for the period",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r133",
      "r135",
      "r180",
      "r199",
      "r234",
      "r257",
      "r287",
      "r292"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss for the period (in thousands of euros)",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income (loss)",
        "label": "Profit (loss) from operating activities"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r363"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "periodStartLabel": "Property, plant and equipment at beginning of period",
        "periodEndLabel": "Property, plant and equipment at end of period",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r173",
      "r239"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [abstract]",
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in associate",
        "label": "Proportion of ownership interest in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r64"
     ]
    },
    "nbx_ProvisionForRetirementBenefitObligationsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ProvisionForRetirementBenefitObligationsNet",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails": {
       "parentTag": "nbx_DepreciationAmortizationAndProvisionExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Total Provision for retirement benefit obligations (IAS 19)",
        "label": "Provision for Retirement Benefit Obligations\u00a0Net",
        "documentation": "Provision for Retirement Benefit Obligations\u00a0Net"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ProvisionUsedAndUnusedProvisionReversedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails",
      "http://nanobiotix.com/role/RetirementObligationsDisclosureofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decreases",
        "verboseLabel": "Provisions",
        "label": "Provision Used And Unused Provision Reversed, Other Provisions",
        "documentation": "Provision Used And Unused Provision Reversed, Other Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProvisionUsedOtherProvisions",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails": {
       "parentTag": "nbx_DepreciationAmortizationAndProvisionExpensesExcludingIAS19",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Provision for disputes and charges",
        "label": "Provision used, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r183"
     ]
    },
    "ifrs-full_ProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProvisionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions [abstract]",
        "label": "Provisions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ProvisionsForChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ProvisionsForChargesMember",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for charges",
        "label": "Provisions For Charges [Member]",
        "documentation": "Provisions For Charges"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ProvisionsForDisputesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ProvisionsForDisputesMember",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsScheduleofChangesinProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for disputes",
        "label": "Provisions For Disputes [Member]",
        "documentation": "Provisions For Disputes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of intangible assets",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Increase) / Decrease in non-current financial assets",
        "label": "Purchase of other long-term assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r79",
      "r90",
      "r100",
      "r163",
      "r288",
      "r289",
      "r351"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges [member]",
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r79",
      "r90",
      "r100",
      "r163",
      "r288",
      "r289",
      "r351"
     ]
    },
    "nbx_RechargeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "RechargeMember",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recharge",
        "label": "Recharge [Member]",
        "documentation": "Recharge"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]",
        "label": "Reconciliation of changes in property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReconciliationOfNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Reconciliation of number of shares outstanding [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RefundsProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RefundsProvision",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofDeferredIncomeandContractLiabilitiesDetails_1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Refund liabilities",
        "label": "Refunds provision"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of provision for refunds to be made by the entity to its customers. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "nbx_ReimbursedAmountOfCorresponds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ReimbursedAmountOfCorresponds",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursed amount of corresponds",
        "label": "Reimbursed Amount of Corresponds",
        "documentation": "Reimbursed Amount of Corresponds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transactions [abstract]",
        "label": "Related party transactions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loans repayments",
        "terseLabel": "Repayments of borrowings, classified as financing activities",
        "label": "Repayments of borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "ifrs-full_RepaymentsOfCurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RepaymentsOfCurrentBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of current borrowings",
        "label": "Repayments of current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesNarrativeDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ResearchAndDevelopmentArrangement1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ResearchAndDevelopmentArrangement1Member",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D",
        "label": "Research And Development Arrangement1 [Member]",
        "documentation": "Research And Development Arrangement1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development expenses",
        "negatedTotalLabel": "Total research and development expenses",
        "label": "Research and development expense"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r192"
     ]
    },
    "nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation, amortization, and provision expenses",
        "label": "Research And Development Expense, Depreciation, Amortization And Provision Expense",
        "documentation": "Research And Development Expense, Depreciation, Amortization And Provision Expense"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ResearchAndDevelopmentExpensePayrollCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ResearchAndDevelopmentExpensePayrollCosts",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payroll costs (including share-based payments)",
        "label": "Research And Development Expense, Payroll Costs",
        "documentation": "Research And Development Expense, Payroll Costs"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofResearchandDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases, sub-contracting and other expenses",
        "label": "Research And Development Expense, Sub-Contracting And Other Expenses",
        "documentation": "Research And Development Expense, Sub-Contracting And Other Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ResearchAndDevelopmentMember",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research And Development [Member]",
        "documentation": "Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ResearchAndDevelopmentTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ResearchAndDevelopmentTaxCredit",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit",
        "label": "Research And Development, Tax Credit",
        "documentation": "Research And Development, Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsProfitLossForReportingPeriod",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss for the period",
        "label": "Retained earnings, profit (loss) for reporting period"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "nbx_RetirementObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "RetirementObligationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Obligation [Abstract]",
        "label": "Retirement Obligation [Abstract]",
        "documentation": "Retirement Obligation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenues and other income",
        "label": "Revenue"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r107",
      "r130",
      "r134",
      "r139",
      "r140",
      "r141",
      "r260",
      "r287",
      "r317",
      "r318"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues and other income",
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from contracts with customers"
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r145"
     ]
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidies",
        "label": "Income from government grants"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "nbx_RightOfUseBuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "RightOfUseBuildingsMember",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use \u2013 Buildings",
        "label": "Right Of Use, Buildings [Member]",
        "documentation": "Right Of Use, Buildings"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Risk Free Interest Rate, Other Equity Instruments Granted",
        "documentation": "Risk Free Interest Rate, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_SecurityDepositsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "SecurityDepositsRollForward",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsScheduleofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposits paid",
        "label": "Security Deposits [Roll Forward]",
        "documentation": "Security Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDOPERATIONS",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Selling, general and administrative expenses",
        "negatedTotalLabel": "Total SG&amp;A expenses",
        "label": "Selling, general and administrative expense"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation, amortization and provision expenses",
        "label": "Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense",
        "documentation": "Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails",
      "http://nanobiotix.com/role/OperatingexpensesScheduleofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SG&amp;A",
        "label": "Selling, general and administrative expense [member]"
       }
      }
     },
     "auth_ref": [
      "r353",
      "r356"
     ]
    },
    "nbx_SellingGeneralAndAdministrativeExpensePayrollCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "SellingGeneralAndAdministrativeExpensePayrollCosts",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payroll costs (including share-based payments)",
        "label": "Selling General And Administrative Expense, Payroll Costs",
        "documentation": "Selling General And Administrative Expense, Payroll Costs"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases, fees and other expenses",
        "label": "Selling General And Administrative Expense, Purchases, Fees And Other Expense",
        "documentation": "Selling General And Administrative Expense, Purchases, Fees And Other Expense"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ServiceRechargeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ServiceRechargeMember",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Recharge",
        "label": "Service Recharge [Member]",
        "documentation": "Service Recharge"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ServicesMember",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails",
      "http://nanobiotix.com/role/RevenueandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services",
        "label": "Services [Member]",
        "documentation": "Services"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_SeveranceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "SeveranceExpenses",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance expenses",
        "label": "Severance Expenses",
        "documentation": "Severance Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of initial plan",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ShareBasedPaymentArrangementStockOptionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ShareBasedPaymentArrangementStockOptionTerm",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum term of options granted for share-based payment arrangement",
        "label": "Share-Based Payment Arrangement, Stock Option Term",
        "documentation": "Share-Based Payment Arrangement, Stock Option Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums related to share capital",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r322"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums related to share capital",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsScheduleofCashandCashEquivalentsDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term bank deposits",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments, classified as cash equivalents",
        "label": "Short-term investments, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "nbx_SignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "SignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]",
        "documentation": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SocialSecurityContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SocialSecurityContributions",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payroll taxes",
        "label": "Social security contributions"
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfIFRSCompliance",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidatedprinciplesandmethodsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General principles and statement of compliance and basis of presentation",
        "label": "Statement of IFRS compliance [text block]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "nbx_StockOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "StockOptionsGranted",
     "crdr": "debit",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted",
        "label": "Stock Options Granted",
        "documentation": "Stock Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_SuppliersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "SuppliersMember",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suppliers",
        "label": "Suppliers [Member]",
        "documentation": "Suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_SupplyServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "SupplyServicesMember",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply Services",
        "label": "Supply Services [Member]",
        "documentation": "Supply Services"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_TechnologyTransferAndTechnicalAssistanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TechnologyTransferAndTechnicalAssistanceMember",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology Transfer and Technical Assistance",
        "label": "Technology Transfer And Technical Assistance [Member]",
        "documentation": "Technology Transfer And Technical Assistance"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_TechnologyTransferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TechnologyTransferMember",
     "presentation": [
      "http://nanobiotix.com/role/RevenueandotherincomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology Transfer",
        "label": "Technology Transfer [Member]",
        "documentation": "Technology Transfer"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_ThirdPartyServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "ThirdPartyServicesMember",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third party services",
        "label": "Third Party Services [Member]",
        "documentation": "Third Party Services"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/GeneralinformationstatementofcomplianceandbasisofpresentationDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r79",
      "r90",
      "r100",
      "r163",
      "r288",
      "r289",
      "r351"
     ]
    },
    "nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial liabilities",
        "label": "Total Financial Liabilities Including Trade Payables And Other Payables",
        "documentation": "Total Financial Liabilities Including Trade Payables And Other Payables"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial liabilities, at fair value",
        "label": "Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value",
        "documentation": "Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and other payables",
        "totalLabel": "Total trade and other payables",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesScheduleofTradeandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and other accruals",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r320",
      "r362"
     ]
    },
    "nbx_TradeAndOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TradeAndOtherPayablesMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and other payables",
        "label": "Trade And Other Payables [Member]",
        "documentation": "Trade And Other Payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeReceivablesMember",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeScheduleofFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Trade receivables [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r111",
      "r115",
      "r215",
      "r218",
      "r297",
      "r356"
     ]
    },
    "nbx_TrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TrancheFourMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche four",
        "label": "Tranche Four [Member]",
        "documentation": "Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche one",
        "label": "Tranche One [Member]",
        "documentation": "Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_TrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TrancheThreeMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche three",
        "label": "Tranche Three [Member]",
        "documentation": "Tranche Three"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche two",
        "label": "Tranche Two [Member]",
        "documentation": "Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_TranchesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TranchesAxis",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranches [Axis]",
        "label": "Tranches [Axis]",
        "documentation": "Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_TranchesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "TranchesDomain",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranches [Domain]",
        "label": "Tranches [Domain]",
        "documentation": "Tranches [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TreasuryShares",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury shares",
        "label": "Treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r316",
      "r322"
     ]
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://nanobiotix.com/role/INTERIMCONDENSEDSTATEMENTOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares",
        "label": "Treasury shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates [axis]",
        "label": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ifrs-full_TypesOfInterestRatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesDomain",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate types [member]",
        "label": "Types of interest rates [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r206"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalScheduleofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinFoundersWarrantDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofChangesinShareOptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofExpensefromEquityDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofNumberandWeightedAverageRemainingContractualLifeofOutstandingOtherEquityInstrumentsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangements [member]",
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r206"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "USD",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USD",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_VestingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "VestingPeriodAxis",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting Period [Axis]",
        "documentation": "Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_VestingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "VestingPeriodDomain",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting Period [Domain]",
        "documentation": "Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofFreeSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duration of the holding period",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Holding Period",
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Holding Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesScheduleofPayrollCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Wages and salaries",
        "label": "Wages and salaries"
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA issue price (in euro per share)",
        "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://nanobiotix.com/20250630",
     "localname": "WeightedAverageSharePriceOtherEquityInstrumentsGranted",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in euros per share)",
        "label": "Weighted Average Share Price, Other Equity Instruments Granted",
        "documentation": "Weighted Average Share Price, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsScheduleofShareBasedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in euros per share)",
        "label": "Weighted average share price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2025-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2025-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2025-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2025-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "130",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "84",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2025-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2025-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2025-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2026-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "30A",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "128",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "133",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "166",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "166",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "168",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "169",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "190",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "192",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_v&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "227",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "230",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "230",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "231",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "257",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "257",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "257",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "257",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "259",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "266",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "269",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "271",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "271",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "273",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "274",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "43",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "64A",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "71",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "71",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "72",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "88",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2026-01-01",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.49",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_l&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "90",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_90&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "87",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_87&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Section": "Example 4 Refunds policy",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex4_TI",
   "URIDate": "2025-03-27"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2025-03-27"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2025-03-27"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35I",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35I",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG20B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "191",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_191_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "251",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_251&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "141",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard",
   "URIDate": "2025-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>117
<FILENAME>0001628280-25-043232-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-043232-xbrl.zip
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M.:5KWQ9>W.F-0VJ!&M VDC]Q?:?WKKX-G+G3/[=Y1Z!=V6M0NX:_4V8DP[]
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M+YD@*TT@<,B_F0DN?*Q@1*PKZY&Z'F,#8OU<X NI.6"O:D!@^*'D@$QT@,!
M2'+%'8BAK?&E8T^#PBK6N*]YQF/^<4ASC]1H"8QX;);'V QS7WA_PO=V#LA6
M(O?* P*C+YMY8#4BBKBB9(=WL8/ F-!F=KBQK7/#9)F_,7E"XYR&JWZ0K"$P
M:O5&UBB5QGXX0V!D+4V_7B *"(RR[2@1+%$Z?N2>LO*N WO- \4AC\#XE\!A
MCPB[PJU"HE8'&B,)P3"%!+G*@$H(WA$8'BNCK^+P4;N0P%X9JHG&1H7$!G.)
MZX0@E\#879&"0"%H*3#8)G#$F-+&=;N0 ->!!H%I\8# $%L9UV7/#@)#>F6H
MEB]K%!(R+*.O##BCD-A@WAME>Z6 P A;D6*DE,C3$0ZX>KEM PC"7SZ]\X>F
M ?]]SB7$<-T,4 ;U9.O(%&[=7U';CG"@T"LDVM)TO4\(ZOL4 N%PG-Q6> &*
M86N\'113WR,4TQ$8BDG;TQ=(* H)P>S%J1:("(7$0'(3A07MU=H>2&[M4WO)
MAU-D:&^Z5;6^I;U)WOH^BATN?/!N39<DPOLT72$C=2'$)J<=LX[ D;VPV H&
MD=U]9;EVA0O>"T"!O1ZO[ H7FPMWP/8[):[O)-I7QY?ZWB4QG-^)Z:=KI_8)
MF'6%PPIVVIG>(UV)YSMK6FC=V-XUV!1G,"'6K473:<27%G$+B3QD2-QERO8M
M/4GOP034!_Y>' "\6TB8(P^2Q\1=HOHE>+\%(WHA894\B%Y VA82?\DF8-_K
M.A<2-;G"+15P>B]!EP7Y60/[S'>(;HRGI9>T'>4+"=6(0GD)7:A" D'"\8-$
M_M5)(8$IX3BB@(0O)!ZV%\(+1(1"0E299TK+Z)J=%!+ $H;T\OEF)X6$M\1C
M")F<LT*"7^*Q1 $I7TAH3(3$RKU2H9# 6=:GE:3TS@H)G(E">0F=LT("9\+Q
M@T2^6:^0P)EP'%% PA<2.!,@!WFO1"@D<)9M-I^$;EFOD*"9$&27SR?K%1(P
M$XL99'+("@F6B<4.!:1ZX8"R-]=\.W3;7S@P+D]*2VCN"P?)"4%_F2Q\X4 X
M(3B@<(1NU N'K16_D&NC+C"N):$_ V\KWGI+YU4TZ@(C2@=DVQMU@<$<&2UL
M(<&2+?-+0!CD+NC1J!<.]9#\:/L>*U4TZH4#.@[R:/M>25XX;.- C[;OE>B%
M@S/D/MJ^3]JJA4,PLCO:OM=U%ABT$/_X8I&])%5@^$1\RLOG0JD" SD%X@>)
M_"M58$BI0!Q10,(7$MP2X&C[7HE02(A*F+.+A7;-"@E@"4-Z"7VS0L);XC&$
M3,Y9(<$O\5BB>)1O%!(:$^%H^UZI4$C@3)3CBT7VSAJ%!,Y$H;Q\SEFCD,"9
M</P@D6_6*"1P)AQ'%)#PA03.!#C:OE<B%!(X$^(<8Z'=LD*"9D*074*?K)"
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M\?,O\/\85QBDV]":];;:&78[K8;>'O;J)\-6LZ>U6\->J]/Y-QKQ^!G7FYO
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M8<MAA$*2W@#>NLX9"/!ZA(^H@ZN4@+]88#*#6S%N"(,9>& ADH6@*42F$NW
MDX0.>WYCO!L $9&2M&<(.OH6LW05U)\08>#<PZ-.3PS!PO,JAK,VPH-QL1T$
MSA6)%X=C20'K66R#V@2I"W[!X]7-EU+8\T_*FR%+!,F:(Y]AAR%3.HF-/:X
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M!5.+M\H.XL!-H;J>6[ IK8]M/WUVT!AJ [G?CR:]E#_4E D0%3#*S@W9:3V
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M(VO1V+"\*ZO^1!P/=;7II]@M;O#-F>4X*KL<@APKWVUKX:72._\VW+=K,'*
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MLDE<V.1QE9L9IA0S V&AG%C,?*?)[ 2A%ZMU#AK#?CL:4CE].R,!D.-(D'6
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M=;0UDGJ9H;-5WBE;Q@B77]Y5U#XZ(G</]529V=9"^L([JWSU6JN _2I+8P*
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MJUHHPO%"Z@<53#99ZI^T-*WV+GA%$PV)3N&%?_(A]C#;DVOLSJ]MTXY$ [6
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M)L$.K+2DVI6P/[P;]%]55 _X@>$;WKGXC<HV";1F\/Y&!S=9Z^#RG=-869\
M2NZ P0:L.&8']RCDT5EOAN_O"_7C<$%-ZQ/#CFC&VE!]X6JM33D4[-,>8J&M
MQ<L%;- X\I_YPWOD-_[&#\$[Q F!06,8E0!(A'U6V,Z_PFPR#!M,*3OZ@5(-
MV/$["3/'C\E6XWB]-@F71T$%T0K]%M@) 7:/UE"$>G%.\(R&QRC@C.3$:B,]
M:-CMV=7HF=0EW\N('A(VVLU=]W9Y&.4-0%=LI -5X.#@_<U9&:CP_,6P(OM-
MMU_9%W.#/=H(V55(7HR0@$U/@>@=C+-A#[1PS#OS: V//7ZQC=>O\0^FJ_RD
M_D%'^F)\Y<Y *J <VB?#0<L8-I>-A,")<W[#4L.\".:,(-.?P'E@(14JBP/V
M$6/ 8]S*&T5%A_[11AR?X<E587M]$T/,E2/#FHVO&\N*Z>H=[CUK\_Z]^,"E
M;D1:T.+'_KU"[\!%D?FZ[AW N[(*)#YF+[PIM+2;.F?AY<.-"9#N_I5P"K"3
M 7=+ : G0!_'LDS/+:MC;;J!,[[.HED40W>BEK-AI7G\Y>AF/MM_IO,@(],-
M9TUF,FV-:G^\4PAU;2%G6SEL8H1-7G6;^^S-BZDQ9]W#?*BQM!%:C$FEN8[.
M*K2</M?,XO+X$$(&^CAHSN_K&&>#WKN@A[7L=W;EGBV/$X> $)618/']N055
M.,9F\F:0=W8ZPISRU<(F99[O.MD!ZH\U8"Z=R[K-L:A0-B\3NJ$1!BQ5#R61
M#:88"!*' &H8^[-F,SKOU:G=Y)$*[5BP5PX=</@*VP5_,1VFM^.$5SQS3J!N
MK9T]W79!N#MOQC)+(KW8R.(W\NF_],7RZL9SSGB3><\HQ/<M;#7H8^N=6VS[
MMVM-V9LUY&N.:>Z(0>$-NY)U J9J]&:<@/HM?)L4I"-S2I%@;(R%DI!0JY./
MYN(1!( %&V)-[4S/S>&/?770/J#6!DUX"]30<!@PG+*'*I!ALM #[5\,-\/>
M8O-/UE,6;[/N-@NY UF#1&0>,FN3R'L9>CD<U$*B4_IBYUTQ=S&.U%VO@L=-
M"6SKL#6];AGQOE3&>NM-VNP65^'9[%N,_[,Y-FM)!KJ)Y'E=X51@EQ#?CTMA
M.28^X:PQ[4C)G&\8J,8$^Y"V[X77J!TZ\X'+*+Q@;0RHZ>RWL977W'S,&+'L
MT+.X%8*)#1AR9RLA]F+3?R2S$X=ULH!4>M283>YB9 Z[V"T)'G<6U:"97MXA
M9,> ?L-/#46U^6[8EDD%'IY"_S6ILX8-L^=C[)'=2G?KH*.CRC?HYL\FC:[4
MB*(84]4"SQ:N;H5NL#EFH,QU:NBC"NYA&1T&\!$=J\T367WE&7\:ISMSYA),
MT@E%'NA17=*2\JGO ($+ N]7FN37Q"$%9Y3^VB]5^FMR&NOVA-72IZ:R23$8
M<%]Z(:M0WDZ8Z7A97>BWY>$)7\^UEI@"@,YUZM73'3IO'<ZCEZ'S04-;6"UC
MV+&>2C@KR&NXL K=V%O+SED>!YGNL=\P[IQC)[3$L1,GFC&AY9LQ\0VY]<,L
M*"^&W8F;)M&+20GO*='!"6MURJ&^HM2_2MPW:^KL'!61.6.=+21F>1M3&3(;
M;P?8S(RIKEI32;F_& J[@<VP#>K2?I@%G5(>84<FG]\M.VZWV9<O<,=O<VOR
M9[#C,0G]/36ZX]]&SW?/TL-WZ?KA_OGAQ]W-Z.7NX?X FXS/SL:Q#[97\4=Q
M#?NT@.F<"N02!H/(7OOF '$2Z'A+PDH4%L CJ+D[DUB B'IB>?47=]4[!BQ2
MY^Y:G28>)_3\!>$6C%V4GINC)DV238PT.UY=[N?63*F[^^_A4P:8AD<_S,)5
MO6OA92#A!$/,'Y8]=8CI1Y=;P>'2< :<34@T0/[Q9J'F;GU@PK\3>D3M',(5
MFH,:0M6U92^;,@LC+BU6V<--2%KFS^ YUS_XZ,QG,/)8BW^UI;29O6]-PI?]
M\3R2Q=:68&M_)5AO]2G]NAC_4\9Z!F^7'B:NQ7>PM[F#_"*Q@V78P><ENB6>
MFS^:?S37=M"?LQ&WA?2JC$V,3T^-4%&ZET]XH-E>GK.3IJ.'+-"91'1TQGC)
M@6%I)6^,9P\:OLI!F60HU]"P0RRU9J-&,^J17I-M%I>>?*X%LFI$ED./JDLS
MC(RY0 PVON17>,MER.T1ZN[C[X7.4RAF?*X01AB\[[SJ*)UG'?-"BDV5])RV
M,&F2V/KV<< [:VUR:.N'.#+S1MV4N< NTHVF1V3.&3KZS'![J9M[;91E=*0Q
MFP,G\?IH](NP"!!/^5^+6>VX%:*)8%&ES&_*\;!V6< _8Z9LVN0-L_?>"2WB
M8U4.:[_QROCH._-B!JS7XM-TX)_Z*TE8/8_W^4="]D:DT%6S1#GFHO'B)V/>
M5@=3_U@4+YR9NO&4.6;7<\DP7?FQB%"C;[: \\+_%*MJ[0O7NJ!07:?9*C3@
M*!^O8S% 1$/ R-;S'^!6U@(NY;SPCV>^-(=%$W4?^@"S_YUH,)O4]-UJ++=C
MJHK8K;E<\V9'X.B(.-.XW1@J3:6G1I.OMT\?Q;Q,?@#V> =EQSN,V*U3OD,'
MWZ$UT&+>(?L\)-8G +ZC\\RROI@V*'1WNO3->JU.S.[ )F1=7;M0LO?HXOI8
MQ+FY.)O&2S$0A\IRIKR(M>UH2U]81O"E]$TW_P*V"(HQ/,:<D+.H\_(Y6Y")
MOJZGSGD#@5!2! HKFZ"MPI@/2Z];%WB\@\H7%'Q?61[#9+58S7G]^O9'I!DF
MOR>]URQS[)QZ<J,A*5"0>MIXFDC!'PYYF/WFS<QS;KU*II$Y'05I\XFQ@WY,
M[* ?C1W\\7R+D8/?_KCY]?;WV_L76;I]?KG[??1R^RR-[F^DT?/S'[\_8CSA
M^0 !A7YLU*A?H5G>&_,S#S4[\T@S'N,[DN%[KC\,1SFR)5,%:OP9G@V.O,:O
MNP&5UK5L.D8P_&2==5AB;&@&$L*RG7 %.NLKX?6%'&-1,$]1XY5>X=9*%A\X
MB\V34,MEY:?4F#!L8&'8FVW"NZ XX5?QTV/>:03$T\(WKL.%,B/5]:;TLM=C
MDO!L1 X&UP"&M/6GC&E_*];) 600(^6[3N?:A?.+/#_3&MG9D/FI,:/#1=:K
M@#!1ST_ :DHCR4'I1#,,T?+7YY^8\,@W+N1;8':>MQIV;[_>C^5$A5(ZU^?]
MI5H)'@+:K(%;J_1T!3T;HF<28.*\P7\OV*.]PBM,M8*G4>#J/WD.H@RZOV&R
M89NX8-JSWP;ZPC=>/Q44WZ^FX1\??.IB?8Q/N/5B,,;GRPS32E@>)&NQB@TI
M_J8<R:E9;7Q&/]_&&*2X_8K:RB4GP4Z1Y=?4>,F3E/,'&*$3,"T<3,A/PI>'
MY]%7&?1TUNF2N^>D#]W&W$[X_MOSX_4M_"+\R>@K4^YMPL\!?#KZ%3Y]I0FA
ME&V3Q7)N?1)T52]H;,!WV-S2/CBH=^)-GE=@$0"/QKF9WRQL\\P3-?&TTP?Z
MQYNR)5KCN["F9.XS_<W/_8KN2&,^/,F\.EB" SE9>;INB#=0T<SM&6KYPPO"
M$V!+8*LG_EN\<FJ0YFM3YN24W@EKI$$S3K_RLD?[3^*B+U[W?@PWG1+\"6PA
MEX88C$9"2N\6+@G+CK]*7_Q)RTI?NBCU;.WGF--5EKA68QC#!DM^T#/RNINH
MV!'IMBG3;0>E2K?=T]2*RR;KTQS<Y*2^N&N4\N?M1@!/ A<(Z%!_>V/,00!9
M-FJMG@HXH3\T'+^\G\9(_2^QY?,'X<8%GB->?\/5L=! =_9%4O/V+84GH)MB
M>SR#Y1 G&V2L82WHV]051M78F /.7GJM( :_Y0T*Z0-!4T==>@*RVV!T^4 )
MBVGYL&WX=YGWQ.5U!GB3_ZR 2%.#>O::TJVI4_&$M[9][=<;9,_UC+7UU6AB
M<1!H2*1_X'<+H03MROGG1HS>JY(Q:,[WF!5[>!H*MX#ABYGA-2**-"%"5FJ/
MZ>^S[7*33CCRBECP 0"Y5XXLO]##B]?Z'2!ICSH6YO/7 :\%H#/HZKE7D1<3
M,O<$-=@7^I1$>ZCB+4.G-(ZF0$8F8A"+5AC/^':?WKOY;5&VA3TC$<3*P3)K
MANR:G>F;F?6R<C9>TFO=@@T5,0/A]<T?@@R\=\Y.)L8Z9'I>/1M^*OT%)@,(
M\CGK4$DS;1QW-64I"#IKM^GPP=4AT.I!4E SK*"WFTK)5?076Y^&>ZV#FDX;
M")='36=='$*>Q*!?",L>B(=W$+:4UB*6?E*:E\!<H#?DU%L<SP">HNZD6IW]
MN]"HCL""#KS@3%DS%CS0[GG7F$^2)\K3P0#,R)_ JX'\LC?ZD1C.6E$E^@S"
MB1F^?URF/L/Y9\1C8& T"VA&^\HFS!E8UQYE_W4\L-.9(\#3,&W?(?,YO9=M
M3((FT?$W9J\2RDW@5Z$H#\T(IS_R">7 %\Z,_Q[_O:)5;?!@^]U M9DW'Z;T
M\*EV%K[%)/-C?;>FM($JC7^SXKU9TOZ4B-M2DT6]DD:XO0L:)7FU+*HW\HWG
M_3!)*!#C"T*'Q<:P)IDJ;>RH&3.O53FG"*N(!%V,SU>@H]LZ30F.<ACR'V^$
M]0Q*1#8M5>'/W.RQC9$#;)4WHSW=J'=NXT7"*\)('/=),$>=+!E-TL2%<TT:
MCCRH#$$#(P9X62(&722O ;4^D!U)M,?S8FRPX<H^,^!]S7P%W[L+?08O\ YH
M>,7B=S/6X"W%&WC<#'M:<H[@,;?(ZW!^9*SOFF\",W4 G\=SXKQ3'WH,99IC
M,M&1&])>AUZ>H$YG1L%F8N-R6DF.+AQODOR$,!*Y\#6C3V!E8^>X.0\K<I84
M7DKP[DX T(TET3)Z;U>\/&GWPUIK%,G6N2"NG$18_-XCKNPOQO>EP\[AR(?5
MDO4X@/WE&E3XV*PO&#T%<_PYT QV'?,M_-UCMX+E1BX[8XXZ"N03;F1$?N$X
MBPIQ5 ^@OELH^D;H6YI[91(8,$$3Q =) A-$;(:M$<?GO,!!3=;!@NL 6]@H
M%?? #IK2=Q8)Y=.2*+;]V1!;-0R?^?)7<-;.Y9;7]MXT87DKEB6YPL81<.R"
MUI*S0"U*T(K6"1@YYAN<XWR/VK\P5D:;PG.?D!XV%$ITC&Z"62GK U(^+/O/
M-1U][*.510H7H8XRD7X+VV#-\>:Q(3H2P@Z-*:.]SG4W-!#"*[2=DY\RIMC_
MAQL!= GOG-0./[@\T2?.G !1QN>*+1:AD8>IY@;Q'D4Z[: ?M[F!G] ;3!1O
M)C0E!@[6]Y@?F1AC JN*G?!<-;93,:UHF:9#O9+A-NB\FZ,?G,=F.T"0X Y^
M9-6A7D?ZI9<!@J,#R"O&;C%H3#F8UY"&MZ#1Y\[7];ZUO,C*X:DDS&ONY4[Q
M%PV<0S&OS%K4XI^LG(KVU5VZH:&9GE.7)U6Q%*U@@ATC._]W] &;)'0"&FYX
MH!R:B^UG9[*NT@RBM%-0.+%3=R=OB/S6X IT#AJX.&/.M^$?06JR[O#&@L\M
M,)<KEY=IE) A/J.W/1M;8[E*GL /OZ[#V"AM[D0<ZD)UWU:!0K&..O]"F8MH
MRDL8M5@("&U>?B^\.=5]@5F")6"P28P<]3.FJU-!;$6,K'.&Y[5G:"VLJ=_,
MKH0P#/-5/^!%QV $MF+X%2@<J&. %\-@0U /Q[1%?WAH9Y#OA^XU_"9J7GE3
M-0,OPT8/?CP*_F-TG,+VFJC1\L"<0W_/,@J# \.M]_#8CMAW7&/Z@=$?2PZ,
MA5D)LE7VTF<I;6BCCO_7B3UCKL4B85P5(1$O7K(1(&<0*6D)('VA7H=8"73A
MR9Y-H9S2T[K5P\HZ/:_[X^CD*S+=:BX4XT1E1"/3+=[4=3!G\JD>J=?7&67[
MX-"1$J7[)&?T;,_=J4:63A >[4H7GJ2/3.K8H\TNCJWD)621*!^31$&'6N -
MNC'?B"5&LG:"[)XE5MT8W&3S#9. %V%N@\>0\)9A9AD*O,G^@ND\AV ]GF<X
M%*#:'(!=]T2%WY-2VQ.2IVJD$FYW@KI<6)CDU0)5A!7RT'$WX2XYJBIOYG5O
M% O0-.N[;]+<TLV0B V)WG $];)P^E:\*8^BE+4ICX94XA%'RK%8J3O?<I-\
M^.?F,Y@WNP$>IH.MWP#TYCGQS+3))H=FHZ?IN$:N#H[\N;3^P%H&5#0K"9U)
M2Y-HR,)8+1B'I \(3>>B+#:8?D0Y:B@L[2M8+++OZ5'6IS['2[U"!>XDV73V
MO%OS=SIY$" >FF:T43V#9X?WS&/=GMFT,,L/@!MF5+7D1?!K]+L2)ZAR)R@
M5D@XT^ ENBV^T.9<K:LUP*G*E1P.://Z,/:;S\ CR\ ,#/BK%,P#'C,?GY]
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M@];?;0RI.AB[BDPUG?%I)ZP1OZ<&'-F[FG+H03=QZ,%16^=O]=BT,W6_"4U
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M"88FZ-D16 96EW3;A4EDY"%1+2@"]M*_R A-IS8-"E,+B6;RHBT'9^RFYX.
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M,W]M6 U].XU/.,Y3D9;:F&''((PI^^WU6@-5D6L_<99C(04+O30L7*TO&C:
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MOGHW<VRLGH!(+IDKG0ZQ@G7^%-Y?,WT663$)TR)H8"5LG-$;'NFK\#RU'4\
M_LQY-4N>FXK4%E:L#MB+,Y6RQ=!"5QHZ&V-_=B5K>]41AUT,[%*+8\N$78_"
M3J]_'6VS#:>4=EQ+\X-Z.]\>[X2938>=O^$$SM)T^'DG[RJI=8=[128J%49K
MH"E:33)YRW2L+A@CJ66$.3'2;PUT@V=[5U\X^-L-U8FN\+^*F*_G"NO4:L$2
MK04)J^3;FES6%+2&F:+G"J'4VJ@R(211"*E*32!TQF;ES=TW9DQR&S*+%*06
M@.6S#R0Z.2::3\UMR 9C)+4H*B=&E#IAY"QLR"P5@Y.XJ^S+"8T63^(^9H1*
MPOX&[5Z,-]ZT;&\>BVT:SHN%E7+B7$.<]_&^BN/\@JSTY&N['_;BM;"UWBR1
M/<JMW;V]&)4HMSHZM(I15K3X](=%23[ Y2$OU2PJ&7D]1%Y?+RL&72/U74?/
MXO"[NV**_,R#CZDV5IK01.7": UZ6ED#KAMFHI\K3%)O[TK6K7V:%Z&5U3*4
M&\"5W>^=><@Q]7XOMWZ4L=.'6#C1C$>FZP23U#N\<O6C+*%^U(JG*_+8=>YK
M/&Y.%KG%*UD.Z"U?6]2B83MN;C881JD7?27#""\"Q;8LU@5&9V%O[KL+!!)W
MRK\/;&3HZPCW@25+"UX)ZFU-;.*=( _S-AOKA>-5.;&.UX):N]]K8AM='E@N
M>DQ5E:K"NQ%F.[A*$6&]-="PMB^:Z%5_$:Y1K\WC);APZ<AVU)4B'3V0#K'=
M%Z-%!5PZ\K?SC.^RHL/F"_7R+)<%>=M(_*_/&/N2I:^/O]WX/]D.M@Z\Q4;(
M4QH9D\6OC\Y__H>LJ%\]5W@U'7/A6:ZP-!UA1B-GO:\WGNGY'Q=,!WO+F![I
MO*[H>PD9LVN(:#O!<'^C BV-#NW$\T3@[2,0+]H,Z6$2$K8KQW*!I[>./?=E
M<?%Z!<+SEMBN!^<Z[+;KD8WX=CTG;JY)6R)A5TS6"6A(9O:[X$[M=Y=V@QP3
MS[1FV%6$-<9V$1#A/"J3$8?UCYP$Y!',-7W:?EM.?!5D=[I^T-8G1Z8[%28S
M_%IL>DH#!_B2_^:8]I-;_;#VM=>=!IJZ:_100B/M9_TN/"+5W*$/^II&W'S$
M'()>67G)'XDTZZBF;62\!-]V)'V'3J&_ITZPB*7Y2CI#AY@_.^8$UOC%G+V;
M'R[JNK!B ZVV0[K=72<+8K:N60GMQZ*-B_%5);&K+A,M_^N:T-!*UKI*7RVE
M=U2_*_9*:HT%OY#TM$?%V(D!+4$@2?E?F.E11E?K*R4]J:>5PQFCVR]M=ZJR
M?TV^A[ZC\6216A4[7'- QQYR\9#!@V>B<4)#1CRP'U9)-*E/?R:6[_PC0S1#
M/Y,=;Z<(_L"KW"L_1?#L]X[)/3^VK.I+P#A>V>.N+VK3-& 9UVQM5_?K<;J_
MM-J2>A+GVQ)\.Q3Y(#LX0^^_&.OE@BAVO7+,L?4Z%X!T.8AVKN3XV_.W:^JJ
M!+&.=23D@HFREJH,E#E21D-%AF82&<1UEUEA?^-+?JN;DO&3.IHM<]@M=P0<
MYTJVY9@^ /4/@!\UFX'C-HI;-76<6F6X543, =9%G>,VZ\7E/I..HSL&W:G%
MO#G0'06PU!HH:A/O';G:/34P4S-'JE.[./RR;?2C+7LY;CENTW";FM-1'6X5
M+%>7^CR1D>,V/VY3ZW^KPZU*:S/T1G:@XL ]-7!3ZW>K Z[6X,RZ<TD=KS8>
M&'_-_.A8 )VE.<,QN\1Z(^/+:6Y80O&?FEI+?;=@8XR_^^.,7Z9 N-?I6F:O
M37=ZBQEC!\KVQ/I%QIT_B6/'B;7>HJ%N2?Y:^Z$='&HI4$LM5SXMU'K-A%KQ
M@-O% C*U\/FT@#2:"4@.M1BHI=ZXG19J?0ZU<X&:EGI)=E*HJ2*'VME +?7&
MZK10DSC4S@9JJ7=0IX6:W!RHG45R6'PP*. ]K8ZC;1:QB@V@-*:%8^9LW:^6
M=U_,' I:#'\E"5?PS[L%S7N_6HRO-[0.\OXKD3>E-'FKH+7C66'H4\$@CPL+
MAY].@*8H:M360!>CJ8>1HJ1C@J6TA*FSA50D3%,G2&G8?[M>B+IDK$3B+'7"
MB@[J1XYFD'*PG 8LT4A)G<#2XV"ID7&<%.JHI7%<WL4!QU"I"B<2Q#B=PLF7
M7J/2$1%].=H"_>CZZ(QS6>ZPUI"XGK TK4)I+.<J0%FR51@)'X&"US/3=:V)
M1<97;K9#%RR"0<R(J>P8KZ"Q^5FQN_2$D1S<SGQ^:J7?&]0K7G#FJ,F0U5$)
M:DJ_ N!:I**80,F'A@*V4;1 B1\:=?'J2V:WVAK(T2QSSNX3L3M##D(A=FO
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M#L@"L:!"@)1;@Z@]RP') 5D@J%0(D%@R$1W[SA')$5D@/)4#D;EB KJH8DQ
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MQ)!:<0>Z*K8&_6BH^B]"R(@;?E \WCID 28??7 7_P-V"]HJJ G 7G?!+'?
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M2!4=*D".OT;A3ZH0?]@-I=]-ZE<7X,\A<]-:H*T#KP#,[ 5Q ZCA80QH"XY
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MBLV^$6!YHVEGM0R^V/5 Z .>8HX#JFBJ!^!K'']B%%M]!/S^([8^M?6\B;6
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M%<3<S[7!O(R-Y@[4<J"" Y7,5'%P7^<?FS0S /PMLO3H \QUN&EI.U04:;(
M/I\N+Y+O.D3\O(%#LNO)10_B9G,.+S[7K L2_JPY<H_$7AK15+3.)@G-62U
MX0*5OB1NWJ]I[&!_%>JBQ!0>;KDQ'<F(^#&G(1 M=]._UD6[?=TBI:1V#0T)
M!3!=C5 X,"BZ29ID/O%/LKD09V '6*-X#GV_FQE"R%862-J5N'1#*)QX2Z7J
M*VI5CH?3X>'-<MDMJY_V'&34PM<2U\-KY34FF'[T*#M!*_X_^7HH;!>0Z^$"
M\FO,8AC:K.1BG=#Q&"SI]V I[J._E!?[&WGRDSBRU8SK&U\9?%I)3&I.!=N>
ML;U@?@K8PBP/(SB5?D2R5-+24MKG=H)OG0/^$8Y)-4/,<J&AYC$]#6GHC3G@
MOD^+2>#KK!QA;H\WY;^,W*PV6 OBUNP=Q/5OZ(+3/GQO"FX]9LP"&BFK]K,I
MF46V8[U:--D'GDZH'0B+=3$^0)-O_34S$?!7&2JYO*)+Q(Q0JB^MD1^D'!-,
M!R5@3I)-(A!U+M]M@4PFM"C'=R9#9RM&:C$8-,1E#.TWOW0[GG)KTILTIX=&
M-B@M-@[QN5DB86*M<W+\+!9Z0HWLY?IFU\)8D#D+\7"X8GG":+6A'1E<;DSV
M4!E!GYBCLPU/% %X@H4V?P2JFV^9#^D[0F&+X$8T(VH_HY3,R-J#H=_IK6U3
M:IXA)F@A<E2;GQ\H%NND=\SYV+JQ2N')8DO';\C_SG(%,9[X)U,)H+]6\Z#F
M&K QFG962\$<(RV8*C%WU=6K;8]!RAT!^R10;;5:YSX&28_FAN/^9<78 N(N
M1AY5+B86!X OU%Y'.3-$'$/W3:RL$'< >R4=>S*)$FJ"02=%5[_F.]6WA]UH
MT;BV'P>X=>SY=2""_P2W]SJXP\]]?BNM@2QUHQU?M@[PMG]UB;ZB![;GD%W+
MAUS^&"F/:M[SDI([%A)WQC3OG08?UD>NGVU*BT^W'(-WTP'\KMUR*A+@1! _
MR1"ESB'XR77I\H=?&NNG1QZ$*RT-5_?VPL\!"F 5:CR4&U-J:]#K)O6+#VS"
MV$253=A6[:JGJ=/('9G;XE9H%,WI$7I>\O82/ND3[3U[8Q-&S@/7U_RHCS#K
MW+<VP&RQ?9UUF.*6TL3K:GVDN;>V<^=;.]\)^^_=H@RAT\ 1,[I2BM1M[+(]
M1[BOUI,M?.911 ]T/_F/FOSK0V&CR%A-/ZTJ(S,X+IV/4,8@_1"<NW3;^+Z0
MWD2S',_Q#^*QXF'X_7A;6RB-T!;?R80X#KT8I9?E:))>[Q*JSCKD(EI%?:<W
MF8A-)R'+X8A)#1C26>=N/$S@1_,5))%)QCIY8=T'\(ZN[P7-LQ=XVC=0;3\W
M2D*/Y##46N]O:K-LT-'OU 2BAJ>[FF,NWY\DOL(BB6VH7]#1(*^V\Y'+[*>/
MPNNHY'![J,F?)"=U^?.7'UP.TW:$(PS8+5WR)?CA*_@KRYGY\<5:4'+0#WWU
MG^_?*&O1OGST"]FO_6O6?K_;-[#D,>C8[G^Q?PG;!?+^-?JZKG2E?B_V5V)7
MBGT]Z5&2WI4,+=>CDE_O*_%?<M"BC+V/*MKE/G9J=K]0EWR6"U"'1J>WV>1F
MJW5GL\<&Y,S)_D0-2WL%#QU3$Q4+M]S/6P3)28?,G4OK"1E4H=5N/V5._1D3
M5BTF:,V9F_;LA_R*C$=K5J/I,@8?)<P++3VFN.DCK?4PIMC6Y*2H8MZ9-<=I
M8IY#2&*5#4=?#/H2)IA6B3ZC-5#:/:-7>_ UVR;:"Q+JB@JN>>@PRYB=GI-4
M)(P:JU(J^B@5JA@=='%8G_UC*=XL?M4% REAYF6%0-)%.-S;2J\N0#H+>S?>
MMF>3Z/Q8UN48O<6GJR1,V*I2*B20"IR2;31P= JWLIL-=_7X<)=; [TMZ0I'
M^T69]4_$);2BQC-_^<U+2AB.VA!!+6ZO[9G\&%#V:C'^OLGJ?S%_L69-N054
M:0VDMBZ59:6=_FPHR1&X-,@EG U50$ZECH&2E/=5'\B=A<N0$")GK2^+Q<C/
M4Q+R. 6_83;[ L7A-YS:YL;!70,3J*P88\,,[/,$2!XS.@M ]-8@9J[L:0!R
MQC8I#37S('-N=?>[Y8[(;&8NB+UR*1$?@KZT+(<L#M-XLU>7R!\/(1]#Z1T$
M$QRKK=4%)V=A[NV+$,<FIO(P<7$5&4JHS>T-]=$![TDBCY"=W%R]-%RGZO0"
MN.Z)>(\LQ1@!'-?G865GN(M,+H<X/ CLI[4K2ZQ"7V&2/&7)I<ENUBA%;KG%
M"TJ]K2M-O* L$2D-<#2X0!P2E<DM$')KT&_+1I_+0\G'7%"\!#3=(SY5OHLN
M\*^T:BI<M[C3V[,>I8D93MV@Q"]+Y9F25'AV^CJ^V.;M6$>TM4NP,<S1E(PK
MJ<,NO7U&#]MGJ-VH$MEIGX']$>F ,WN2J8 0V<C;M57<KHWUC $XTKI1_6M0
M7^*7D0:-7ESAD_4YKME+8 T?VNU%CX<KWLV&&@:\V.6C5LW2]"5<VX_7'=EK
M90]H%A,TSAG1-B3;[:8MQ_6$J3F;^*VFJ=HPO6 "S-"<8;\ 5@F\H(71(>;X
M#P[MQ5K (Y$FK.TL[5W]9;N+1%S7ZYD)J]CM>3TUQ^%&5G2VB-_.)>AZ'=>P
M*J93$5O^TW^:\^77[T%WHZ1^"*SS IQY^$VT\XP9UVXF*' .>N?NM)]IAWI>
M19K0D5]DM/+GSK$NNCYKQ[03@T_62(.PS4"6^*6SAF%!OZ]Q6C.ZX+'^6,L<
MO0@NJ6.WTI".W4ILQVZU5?04K,69%Y'I-IP;>'"L8R4)QTR@J>"1/UD?*(^,
MI@M8Z^O'IG$^[8R)K],1!Z:+,XBH;(%FFP+)2+C]/0K^ 4>2(HK'MZ"TUD!,
M:Q:U9V(<-YJ.:S0=!*L3&.:8?9':@XQ9;BB4K&#M&0O6-G*YGA*V=&PXU7'@
M'E")"J _]-?=E;JL-E+R8)&LSER*X]H,GS#42D)((9G*G,4#\'?\KHJ]7FN@
MI]K7VWZO/_)WR^G(?F*@">>B)<J:H&V;F2&,!@V6'20P&MH[%B>=7H>#'S?]
M^OT.JWY__]UQ+:ZW&M/I>+23-;YRD(:0C\\C YR@;E(&G\^CK^P,K_CD/OBX
M5HY/-;S73NLR1ZGFFSX'[>OX$FM@6>-QSXNL1T!#YDK%1S#W58S4;@N9BUX0
MG;X#2\=UEG<HE9:8'X(V7OUUHZ5:V] &M4\C&H>UF$TP\*K8#0X<Z";EEFWO
M1A/&FX-UO)F![$\$90)MPAO^!0H8%,H8_A.,7Q6N[Y[\T(;_L#.<!1<OL]$B
M@K/9<$K51&!]40!\6\)Y0P_J[X0LA1<XK06:[>W/OX[,*&H?)#EZGF80T;SS
M?+>>AK*G:B%H6;;3U'6K@6+@XV XMA,:V[5SK>-/4C0==AX>9 1HQZ2+NB=9
M?TV7+)M7+T9-;"?>5]<=MAF>[)ZPI\IZF-*K)LLC\RT;,K >=]V_D+RM7;/
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MX_)L7)Z-R[-QZT+8B\G&_:?YZ@>9P( #'X^W"BWW#HK2]VHQ?O:IFSMHCY7
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M,_**]JI#I0E-E17^<YTO1Y]F?C![S6< 6_JT) /VH'PL>#NPY&HQ_B?%#Z@
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ML3T[Z+-SCYY,R\9,_1X_#:BZ-I=?K#FTW'E5]'<KEF]_83K9IN_ P( M0G+
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M= U6!O?.,=T9U_*4@GP<W_1]ME/*']:CX[L.:[]K?^&X^"$SYKS9=]XD=4L
MY\VV]@*+!O?V?]>6O_ED>[Z[!F^,-PYHZA7OMI&(VX9GP0P* (U3.1J7 E"F
M!I#2UFF0J'D,YJ50L&D+N3%1G!SGW.TP8CQ[AH-GTG,?C)03M;Z0+;.UA:@D
MRH@J48'9<I+1%\^AT@VM),I\=+B7A35=$.6;B(\7Y")N:?U$RPV\"Z5UG L/
MXIR@Q&[V:L5:;B!MV)687J<A%Y[WX/P%Y(]G];\P%%\($@_.[QB'>UA3T5>E
MEDM8=0E6*DVG+K#JQ4B[>@LURYXNU[,@[1I%PHUD8$_Q"O:3N2<;O#]WY;B!
M^)I;4^1ZUQV]CT^EY-:-DXW>2#0RIR2U$;U3R;@U0T^!Z8R&U)>U3FI=5&+I
MB[EV,6VY+[=__LVNW'U6/Y6S7#=6%Z =,8\UJ8(&P[88UE-9S'6#5:2$M=&:
M%)6@&MOX:Y_72POY6(?ZX_;^Z_C;0T?OX%,IW'7C8.AT)_4EY4P*8G? .Y6Z
M73?P9#KP6M'@.8=L>F>Z/O?G^!MW_\>GS]]:UMJY(+8_E>I>-[:'TDRE+QG,
M*W4.U5/9[W5#5:5#M9T)+]^VSO<)LM'<FEJF:R&/>UDXI & [?@Q+JJVI\ D
M\CLA$@(B;8Z9GL;#_FZ7RDDQZ-/\'</"6F_$N@W1@*3P-/[R<D#285QAC12F
MRI/JS"FF85"%P[U!]BQ*.]U]?85_P9FUO><(KUZ)VM5.O4&'MMGB!K+?#B/9
M.^8 FS1+KS\J?(J1(K'">3M7^<[]$WG%3PM3H";=$/M\437I+<8RQ022BV"I
M\KV1+&A][1R6+79GQ";MQ4W-[LC<JIJ(L;*&':H"%E]*GR]JVF&+(<PKO4J#
M$$) 0E\^!V$KU"VZ(7M$:)4\9*^.]W0A8R<4/L4PJEA.WQE&45R/4)6V1R@#
MD$\QKZI" .5.-WE-2G&.;>[*[EXZB1330R>>HW-VTSG#V4K!HJG%2*;H$'@)
M)-6R9%0C8D ?UF[0%R?TQT(' %"? E]L:V[9DZR,N0]_?1I7-?'*J7\&@YSN
M$>9.%T7J_2DN_",@Y7="R3V6Q,N=7L_6[@:9[@XG:CM3L\,UC3CX3*=A@"J'
M2F'0J6#(WQ^M2WW-#IO/'#09 ]I;IB9.)5X1U(FFRN),F1B\/I$E8ZK($T-6
MU?\18*Y\+;JA%=*U#'J-Q74@TQ*[E@F"+)]L:A:T/#NWT(I[52E#0<K2JTJ5
ME50-II)?-W2]D%95 C\4-;:HPA85<X]%7(=E+TKUJ4ML\/2CBNE:EO)CI5WS
M[_'7)JY%>1'$=]U[]^/[^]L4*;[MV/.X8SN^H]IQYH/><NH1I]$EG&,7V^RQ
MAPSO!;G+#=BAI)P_R;-_W+LSA\LE=??(R_=W.PW!64^SF,F=0S]SL5!/,TU8
M#!(S-*%OJ&=2[0I'F/$.'>_0SWRLFG<TOC=2U+ZH"(QU:LDZ]",G=YADM[M^
M>I: @:!]#=\QJBIEX8HB51S&825S6-Y<CQ)%DXA%4U]0]+ZNGY%.^9V29_O;
ME]91_J0+\6$!\RA-;QWX?&$VY<*984T1DM1\AP.O\!.DFD,,8VY:+O=L+M?!
M4$O?F?[DG$ (<!@A[L5T ZT2BEQF:%NTAY;.R_6^[VZ',B'3#T!WOI;4V$;P
MP4L65E]M_WH@8$:M!?4@OB6JV\GOEU[0S1XI!7FH*T"HA]UII"O7FB+.\CAR
MBJ)67^3HAN^9/GDIZ-8+/<!N&'27A,ZUO)^#.8RC(.5B+]A,FR%\%SSA1\SV
M833Q]6 ^0E>W^;;_N/4J2F_@E#(P+P7FGP[$GY;X>DL$T>0\\VFU). M+<C+
MQK?I$]X.E ]: <@3R_'1=&'C]3]N. ]-?<<]/K1$(,,L8C,,.7/H?]?F$F0Z
M?'"70T*Q#3G)@30?)O)(UNDT-;[],'6(WF!/C\8XDPG0 8VP)FF'+1--ST.>
M%Z1MSYTEOML\=KE=[%!]CX=O;9-H;Z#$ (!/IOL3^2&"MKG<_"=X;WL*PV-!
MVF%N;\N=%I@[V@U4V>VH/>C7"ME>()E=- 7M'C/'%/Z"UXL?MR>C5ZXS,2>!
M&,#_]O:6_>*LEZ P@1[&I/5%&>LK89A!Q$8)8H+PT\S"L/L8Z*!-(?YT**JQ
MR3%=+_?R@/9UZ(,+NB#!>RKM0SBVOSY8WG3I@ D 77F#S7Q]M0GNYA_QFO^$
M)=_-?W>P=7#G_D#N,]85O7LT1=8SFIWLX/MA[6[S1&Y_@20U\96UV3'$I*-X
M/;P(:\5&A+F"_;MK%)<+7SG#""),M4G(@>\'?7.1;UI++ZC.)2,NB'H]",3
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MT)Q<+*=?(\;PH0RLINA'(CG1UHJX[AX](WN-LC*?R@/S';O+]IAOR*63*'7
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MTHN\Y'V5&73P[(+'!3]\JC\)E$37M"=A]LTMZ?3!#%H0/1 6DV?,BOR3)7X
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MSN_^TRKP.?43/U]U=HF&)Q8#<:H,C@ZL7 X&3YP'I5+(0C:L*[Q+W; \OWY
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M;:FVQ,FL2 Q42IYRR4COH+(>7&!@]X^U@'"O+5OGS:W7C^\F*8O-NS#%6&"
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MCT\[L;<E,0?,\-V!( -F^'9 ]4>&[]'YT#'#=P]E#D>U$"QW.AOPCH6:^U?
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M'63/E!*.]AX]7/.ZIWI:O)/6'@UY[B+RHX4\A7&,&R4AI\AKN!_!R]K Q9K
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M-<(!/@NR*S%:QR0S93W.U"/I-B%\&L< C;APCV\'ZZ07!VX=U:KL3 =<@Q\
M;,9Z+,?_<'T^2I$#E#$D643*@94*:'%&%F0 QUP&Z0W+3F<IU'!7Y(8DR:/>
M_7 <V44'K5WZO[[Z=1+&+SY-\;HLS;O7OTQI"47R//[UPT\OKW]9NJ9>LJ*S
M8N!3=7*3YN1M% T2?4@V)V?6,ZHV.WH[C'D,]ZZ%EB8#B+BQ]__J:CJYQ#!^
M/?Z"L_D":1C_]S?0;[(Y58R6H.6$M6H*C^"+B%#["@7F.!K7)<>Y\X G0()^
MA-OOL? =&VJQ]DEE>-;>$K*:ZY"*AQ!JNR#+N9#T-YN/<""\AO*T[= FNNFE
MY](F9,MWI@NVXP6D[N$]>C#J(-UVHLP!BAELR5G='>(^,JD]N%"+I3FG(6IG
M0(O@6(J.B7*$V[T#D:9[!&HPSNRBCUZX\FO-T;N#:[EM%BUTJAT23/ "E.82
M0I0"T*,VU@>!\:'&H&UYLAGC40-8!VKR'D4:J*&Q_7K3AR&<O\A?JDV] L4S
M<XDH#SS52EJUWX(31@ 7)@>5D)?$.]BK6P<X <6V$V _+_UD_&F.TXM;JWP5
M+669^Q0<Z,P)F:^M-!09Y2%XYQ)BBFFX OW;4)X /QJKHA\3]/I2XR;;^RP:
M%HV4%IRM<R:<X+)3P'7V.LG$]("-'!X >NQP=I]!FU;ZZ:>)X&2<'L!G"P93
M6V1J6NI 9<D@D*]?0_I%8- \NN'2ZA_&>LH4:JBE7O:IC:A<K0N/9 YQK*D9
MGGOP3ENPJ0BBM^3>#6>:/C?&'*R1K5M5S\DR;\)T&FHO]K;I,/<>VTO"R\/@
M#TQIJ;;J7?I<CU&;?MY<G'D1)U<;EXA;6FDR6W,F_\1Z#.0A\TS+1 XU/TM+
MQAQ:VZ6BP\% #G%Y]AW\^B@R9HZEU#HLWBZ.(A/MOIJ#=D&A=%P597N4P""I
M*<-SY:Y'-9Q^CIV^,IO.R7^\HF=.+\-T?ALP#:P0>F&@Y%IA/S,-KM ZKJ,D
MES)J6H8?"AJ4,(L+;=, BWWO1SR?S^IO"R(N2+AM[*%# 0-K?-)0\@V-H8KG
M/5Y>3=/G,,.;Z-8ZQ*4OV@5DA]A 5YIT!C9L$*"-#B=#*>!H;,G."LM$!&9,
MM>]+O6U-;XHK!7.-CUM\R(O_3EBRY=3_B"391>Z-$U1^"N/_N<)W5_%\1/_]
M^3I^/IK-[H;,)?ILHV/ 92T[@Y$$D+4&'RS'D!@:VR4OI<-0PWE*/2IHTI]T
M&Q_IWZ3*K+ID>85&60?>> =*6U;[92G(RC+R)Z*R07=1]+>//3FE'B"U05(/
MKR.446;'LP-4$FND2("O13N"C#864:(<L#[X4\AH/H[YV%!+O1SJ;\G#ZH+K
MCQSG _79-7]U'V4,F>.<+.=*.@\%ZU4\[R0X80TX'6S(V:8A;^P\_1SG7CBR
MBPX:FY!O)N.?1^=7]3ARN7:./]WLO?<R<#,R+Z.6P#2)0 DOP-4BF9E;2U"C
M%:Y+:].=!GU"":X[Z6DRA)#;MSO=#G3==++1>%;3_4D:BJ2A6;W)3V\&0\M#
M];?6JQ_M3H:C6:/'X<(A(FZ\,'1/RJXI+S:3%9YL$*"<08BL&M/)6>:M1O*(
M3C3C?5\2]"/<7FS,OV&H)G>%M-@ $W,6E3)@L@H54('HLP",N4BI,V$:KK[7
M&KCGYI4<HIM>:G_> ;1Z0SI &MP7N0?S6&[(00I\B X'2+\7Y^,^M.@4^F R
M8-*)EC/KR,I!#J7DK*631;#ARK<-1(A'78Z^^;"+T/NI03[_)8RF_PCG5RL3
M)Q2=#-,1/#JL?3$S^.0C""Y92CZAE</=8;@'[QBVQH%JNU]<_""9-_8P?L8X
M7^:]+!CN)0JCR*IACA1"/P2(JI"YH[- K;PHH4N;B;7'/@]#X%!Y-JRYO 9E
MR=LN8#9O_H\I^1C;]L'BWJRV V35V.6[#XI+;3 C@DZ807%)_DT*'% 709Y/
M<B&(IZ.X+=MKOWK;143-2PZ.:#&Y#.<OQOF7T>^8WX?Y:HEW+FK&@X7L"_F-
MS"8(GO[QV5F./$43NC13>V"(82O<'RCX27NI-=X8_T;[Q6P^&>.[\/6._Z^+
MU)'^#XQFM4MW) L0>0;#K+.9-FNCNKR!FY_^O:JP@:P:OXJK.V'O,>'H2]WX
MYS@EC)5;9U$[*[B)4)0A7-DB>$83YK3#A^RXQ4Y]4!X:8V!-'BUIM)F<>[DG
M\QXOKPDY>UN6%WIN#P[/HHQ<.NO!6D5[CB)X@0>YJ(JJR.)&%M?.27OT=!Z$
M^AS8U(?6&B\J[W%T$:]J0=,7%S4+AN 1+IQ=3L9Y=N:8DM$J)&#.$=N=H4EC
M 9/1IR BBZ5+9=D'!WD.1&@KZ<:=MU;KW8NK^>?)=/1_5P _3G["Y=_R66T5
MZW(J@,@262TL@T/!@1N3E3:&<9MVV%\>&NNY$**YW'LY;E^A/.,,O2^2@Q".
M#"E3%/C%'706I'<,N7##!656J)X#5P[412]=K]Y,EG4*%HP]4R@]:D^F=681
M:/^R$ J!*E:8X,G796RXRE3?8GM>##E +_=YHELFA'UC12LDOTOD M[6P^$8
M'/A:P9^,:RL8K7<Y#+>6;,;XO'C30$_W^6/:>CNW&!>U-49E1#OF[#;!)<U'
M7ZZO%VLA"F-!0#9U>8R>8*.JJB<+"TWV,0W7>7BO*3PO]O6OY?ODM(>3\]UT
MDA#S[!<29G?826.RN3#PSI"HBF40:XVP8H.-J1A/(AN,G'M-X7F1LW\MWR>G
M.^C2S@KDW\+\:CJ:?_V(TXLSHP4Z7S+HP@HHEPQX8SEDGE,43+%HN[CR&Q_^
M' C11K+W5>V;J/H=3A.MG^$3R>3#G+;NOUZ%::"M''/-^#LC,B:M= 91:Q(J
M\AT@")J[-2QEE8MFHDM2==?QGATA6LI_PPG?89?X5B!O,/V">,:," EUC4!A
M J5*@<B3!B=*O63 5$Z=KO)M>OBS4__>DMV@Z\-NZZX0O;FJ GM;_@\A(X/^
M_.OK\6P>SL\75M:9U%@\"PC!U+YIW)%?F&V]5RJUDU866L5V4?Z#HST[-K23
M_09Z''34N]YJ_?7X[=6<L(TSP:X+U>S,1,ZMC31G5DM->L$A!*4 G8LVA\2Q
M4Z;]XR,]%UHTEOD&2C0XY5UY_:]^O\3QC-8PJVWD9,3(4CB9KZ) <%F <\ZP
M@LYD/5P'LC5PSX$X;32S@2L'9=^M4_GCY^GDZM/GUQ>7(<U)/"2J>NQ8/:%Q
M?I'H2]>US&Y+8T]',_IK=:4V.4VT/;(<(];#['S=+SJ*$  CTZ%8P[GH4A"K
M9YC/@7]/3=L;F+SWZ?1U[.V_KJXO17V<U)RA&WSO\9RL]_QQ\FHV'UW4'^N?
M:<4NYY/?:IE4AZ&6>M$^*<)LR*V//D.)+!1:I>G5+!T8NN?PSX5Y0VAG Z/V
M/J_>]+;<0+V=3&TV3%^;7"#]@"G,YN^FD__"-%\TD$W%Q*)J.Q+NZZUODR 6
M6N=3*D'RK)/R78KH'(KCN7!L4'UM(%N#\^>?<9:FH\L*YW8YKG&;66U=_'J\
M3#1:O2MOR^)^QNO:V/@L.1N*M@%\[86C?#'@+,D.<_'(8B["#==V[H")/ >Z
M#J_Q#7S=^TAZ4Y#QK(1B/ H/(I*?HX+($'0T())7RF>;'!O.OWBN28E[ZF,#
M.=H<8L]>7EU<G2_*%M]F7T]7L<%E2D/RF%4.!K!6C59."@@H&62F>!".*V:[
M6& [#?H<:-&O)C:D+![6*W%E_[V?? WG\Z_+)/W96;4 2U$TUYJGH)"1>ZS)
M1T;!2HS%1QZ[!#JV/?^Y,*&)?#<H_:##[9=D=DW.1[GB6EEDF#\$(N@[G(XF
M^8PL?&F4I$UM<9 6-#F7L5YGI3^H2-,MG0XO'QWHN="@K<0W\&&84OX?TF?,
M5^<X*2\_A_$GG(TV'%.4S<<4;:O_MT#22\. YB)Z$CT&F*Q>FG&@K:4M"JV!
M&!G6VUHL"^YJEE"']> [[C' =<K>T/LI8DU.2"&"YT@[M4K61B.T*WUV6?B.
M>@SLPI5V/09VT<^Q>PP\5K;0.9LD>F"9U;9F8G%504#B@:FD?/+Y>%4>O\^*
M#3NQHV-!V1VT-&2-T"ZX_B@H>Z ^.Q>4W4,90Y(%E5"A, 9:>5W[81;PBA2(
M62A&KF<)8;AN<-]!0=D^.+*+#EKW)%B5L%Q>B%K>S8\%BXZ% ?DZY.6@LS4A
M7 .!S/3_/JEN1T,;G_Z$*D+N)/E-=>GW%UOO+8/7JY/RHES6];Y]J%&6>@FR
M)DK5Y@>^()><X7ZM@Y]NU==]U=M6F$>M 5V8TH87!($EDPCJA7A=#+ 4;<Y(
MDA!=*LM\KS6@]V5 ?T)N?.5\IP+%I=0&D63_)A,2*!X%N!(D6">M<T;PF+HX
M\=]I#>A>N'"(B!O>,A_O5*8X,L\+2P5L4;7-DG(0@U3 N"G%IY#1G6H-Z'U)
MT(]P>[E1WCEO;&'1(L^D4ZWJ]2JL%YLE>"$1R%F.'D-!)P9L.[\+].=V"-&?
M7GLI1=X9[NK-[ !X\&.+'2=QK/.,'JFQ/PT/T&LO)R"[ N<Y:F29@^&B%JCC
M$:*GEY?Q9!@6Z6@&SXN(CYZ9/&4>[J+.QB[;':@WR9$;@"X-",$(H4T>#-D*
M-?=60=1: P;I":;B"KM<*=MIT&-8:+TJ<#*$]'LI2_AKS:&]@WF)BT467:Q=
M41/Y%"H1+A^4!RZM<3)QKWD:;C7:B''87(X>U7I_K3E<)_UL:9/QISE.[U13
M6")+.?'BJ]^I:AW$),C(-.2)I(A2AZ0S^N%:4FY#><)\::&7QB=%G9?;]Y/S
M\U\FT]_"-)\I:[(-DH%,MMXLXAX<%^31&F^MPR12Z!((V&?L[RTS;-^LA][U
MTL\NU?ER6HE29[4(BD2B?' )'"*]3BD'PX)GH@Q7I>>)7DWLGP/[F\\[*;"7
M76[+]<D;K"_#[/,O]=I:]SDQ'U!4V?':$U3%L.@)RL$F)F-),BL]7-B[_?Q.
MGKU'ID3CK7G+;&[K'"R*&[P8Y_N!R1TFR'41RA8!Z&I:<2P</"8'**56BMNH
MS3[7(GL!>Z($?IK*[J7:\:K:PKLPRH^5>,.@1>2!@;'2@?*Y@)-<0Z"WL+#H
MN3,XX&K<&?B)LK1_)?82]WIW4_ERW5U_M,1@8MJJK&BQ\R0DC.3')V[ B9A=
M9M)E,=P5WKVG<?)L'$;!O51OOK%'JI"N;QAO-+7)!.%9>I!&<U"&7A^/Y$UZ
M:1):H;-P<3 B=L-\\JSK074-"SP_5%YFG/'WQ>G%JU(PS=^N+K4OWIZ7DXN+
MT2*1H;M1H:2,KM#TA"RUP;D@01::*"^V=K:V.?,N*81#X3U1:CY9E3<L#;US
MU:2789X^__URAYI)JH2"P0%GKA8/S/2^^E) !I%8DMR5TJ65::\@GR&!AU=N
MXYK16R;V(J7K0@!XW<9PK1A=+?IU]<W!\B,SC$46%D0$IZ.M]Y 1HI(%"H^V
MWB+.,76YC3@,VN?'XV.JNW%E[,=G^(\P'=7\MD,G&7B,+$<$IFI=G:@R&>B^
M@$X^)B%5"IUNG0P&^%G3^AA*;UW/>X-I_V:RT;K7(0@90VW?PB4H%ADXICPD
M]*I6^TE&=BJ'T77 $Z96/T)O6?Y[GR 9<U%KZ2TD6>N">.4@,!$@*>XSBR6)
M,MR5[3U7L)[R"98NR!FS(MEZ9TKDZB'SH"%8VLVD1>ZUUAQ#E[X9NX[[1QY!
M WWTEQ#Y,%9:&59P9?!1A9 @1$,;!1.T&LB8 5/16"_=619:TN=VZ#\8U$8K
M6Z.F@Q4M6G6;>3$.YU]GHQE)]2:T5J-N89S7CY;[JEIT )2>RQ:U$M*!=8ON
MU.J\\T:L@R-KA-A(9!I]"7=NZ&UY,WQP+""+D!(3H#*R&@(PP I#SK5VR0S7
M+;'9M!K4OST0RO)Z$R>3SY%%:!/9\RI8![Z044__N"(QY5"&:Q;89$I]UULZ
M-L<WU,4=G E/O193XB5XXP%M+=.8=(' ZQ6^6I?:DK"M'R[O_BG48CHJ5SI6
M9MI!9X-69NJ ZX_*3 ?JLW-EICV4,219%#,N*ND@U1XU*I%1[15&<#9Q[T3F
M)@]W,?L[J,S4!T=VT4%?E9F6-T>\D"$Q$P Y>79*" $^(VDK<^=ERCR'+K4[
MGFYYCIUDO:D6TQZ":ER$:746_LL45Y6A/D[(4PYY].EB'2?JHCC3'D1MM:Q*
MK DCTH,E=YH+M%GJ+N<9NXQY MKN3<1'K=(4T$9OL1[1L'K2S15$+@VXZ*1W
M.O/HNB36?*]5FO8E0W]"/F:5IEH_B/GB07%C0-F:NITLF<9.94)=$IHNO=N^
MTRI-O7#A$!$?K4J35B4G40)HD@)!*PF\*QF*R#)$2Z15G1HP?(=5FO8E03_"
M[:=*T^8KY3'FA%E+\#Z3]6(U@QAH\R)<(=8> YD-6'3DR-?\>^%)4Q4T3!;?
M84-[,<[K*UK26J/A JS1E<\RD?M3-+B:!I>S+9(UK/-X'\!W3HKAA-\P]_M6
M$C>G;]433M(S;Z4 $U4B!XAI"-DIR%XG0QL;RV:X5(2[R)[W2>7>.NJE.ML*
MS?*=Z8)G\)/);S$>ZT1R?[UMI< !0N_E!'(-%ZU8(1HD7"PS4 H]N*"0]D,?
M!$^.>#[<R>,0)'CTQ+$_#NPBZUYT_V8R_S7,<?KQ<QB_'>-_8IBNJAMYPPE9
M ,RTTBE7JQIGPB=8MC9)I0P;KH;05IC',#P.T>$]0K110#]%7M9PD>ES%^U'
MTOKB\Y7EK)#QF(4'R2S90;&6-F6. 1>Y^)R4I5^&<UYV __=\ZA/9?53O.P^
MM#7,OY Y=A=RE+RV5^40I F@&))L2K%0C/ ,25[)#UA*:%?XI\.P7A363Q'B
M;<AT$B(:<NVSKR7[4_(0LW>TP-K,LF-&\P'/64Z>,8>(OY?R)/5<\/;\X._C
MO+QPB/GF?L*9Y#D[801D[FGN+C*(EBF(@0>!]%3DPRTW'0 ?@RY/)6^MM3Y[
ML:?^.IW,9NNGCF<I9>:CM&"E(W\B2 E!&P0;=/;*.1+*<-5O-D)\SL0Z7&<]
MN6V/S'_S*^"983IF#5(%4?N7%?")'%AN4M'<.7.O"52O/MT^<WC.9!Q ZXTC
MWS=K\NI^0>U^_1Y'%_%J.EN<K+^Y6E@$DB6E9.&@9'5VD7R2D**%2'9!<;:@
M36N^X^;\IH[C/3\6]::-Q@'R&XPK$7W$Z<69\-98X0/P7+.Z.&$)-3+''2]%
M)9\S=KF N_'ASYP+>\NY85S\&T _8R$H1,9W)())/N.T8&E.GH?TOMXQ<P:"
M)R]2EJ2]SHYG[)(0L^WYSUS]ATA[:_B[X8V^C].0\3)\K2&X>O=L,O]<0W^+
MZX=W[J^]"=/I0ES[7]C;=Z2#[^,UF>*!U^W6KYXN,+U;8GHQSF\KIE4UJ4U$
MU$S[6&J)DI0DK1R>M@Q-+CT:8:1 %Z3O4I'F$ R'K#Y[C'L=%;;6)1FR I.5
MJ#?_)7A&+V V5C*=HB'[JI]Y#W)%;5!>W%V@!E'(L2^?+0IBT(>C%,X_S*_R
M:-D:*7I-ZVWFP%3M+&(RB2\F!!G)+M.%"[U>D71SO9'[CSYVU[S^5#EI)]+&
MR>!K<)9'JUT ;<ZYZ*+K8R1--!']=C4>(+=!%(K&YBP"6<RR7D'2,4!,.H"M
M;K:UFFN5GY8BMR0^#*/'7<356'\O)!<5S-=E.,(6QIRW&:S7M0@53=$+'FJA
M-8'>T,*CNY2F67OLL'5#&@AYTD9"C6]5O>"<L;M8M N"N<#!)$5SRN2A^)0U
M,,YX<):S'+M87.O/_:[5=8B,6E]]>O'F[?L7_TD$6G$GV^@Y"[2+>[( /<W,
M"Z4@,<WI$QEY[-+0</VYW[.^#I)1XR/:EY-S^F0RO2XOM$IXODYUX['&S J$
ME.FM%R9"K!74-;W[2F!1+'<YE-T^PO.P1ML(>!"UKU)3.^#:Q39]8*PCF*B-
M]/&HB@\09FN#]4%\JB@>LH"$TM B9@Q$S1F$G*-'@=J(+N>KPROY(?-U:!WO
M(,/&NOVW,)[-</SN<YA>A(17<]JFWOQC=06:9ZY<\>!5RO5^(X=@"ZV1F0?A
MB'/:=O%)'AICX'VXF18F/8BPL>E+6]#XI]'DS4\?_^.]7%D*(JNDR30P.M8Y
M>B*R)7-<&&.55E9EV\7ZW?#H$U#DH0)K[6?F_[JZOH=:HSKK195?CQ?5DC$O
M:R?/SD0Q.9E:MUZ*6E/7T(SKTI193%[(ND)U\D-W&_9X]2T'.TSN4Q&]I(HM
MA;"&:[N(SNCUP%P(;-0):5<C7R\8KXCO,A>9.<]EN-L:NZ(_<08.I-;&B]?]
MM^0NR)7,S@KG7*540,=<SX-HC_3.:Q*(EX[,*6G6&]-WJMJ_>;03)TI/8N^Y
M7>GK\0K5V_&'2<U4^(!IF=*0/X;?Z?,Z@YH'3O_3R0729S=%J*/7Q9D$VE;C
M2B3:Z$LA[SHYYGD,5G:J?-,0TK.DV# *;)PI=G\:/TW&5[-E"XHS&61F)=):
MJ0SAD80LA"#!Z@I*9%I:]Z/6W5&>)5OV%G,OE50>L^U>3L;S:4C?;*M&(6&,
M$IPMZ;I9J<\Z 6HG@[(9(^;!K*4])G#BM!M.N?UT^[P6QR9LTN;"N!:@F2!L
M+G%P#,F\HR6':<:]C\/5R-Z.\]GPJY&J>N[H^1[+U3C?!8?:RAP$31@E;;NV
M.JBR5CIT0A6?&$;1Y:3@T8%.G CMA;VU"68?32Y&X]E\>K58'4?C='Z5,9/4
M/^-L'N:+X[1)*:OO7DYFBV'#F)12NRQ.QJ.%,7?;^>'FN2]F,YR';X30H _&
M$="V:Y5Q;%'WTDWC!L7KV]G=OE#,:H>J]@:JZ1Y*BD N)MEX)7&===2T# Y7
M^KXS[+;=,#8-=1T-QN2=TV1;H V&EAMFJG1JV+[DK*T6O@QW;;,3Y.-TLVC'
ML8>[5;31U+$3@N]8)K6G/7G>:TO%=29>=LD1< 03(]DF20F(46?0QB/M>5JS
M <GW$-*G4?.M$3?N6X^M=-3+'>%MZ%:E'3K@&[SFV\.8CU4#KIV>.U/H "4=
M@TPIZ41O$'G:NM0@JRP0>?$@E1%.(2NL^),FT:,UY(['H5UTT[X,_M)E6X.V
MC,T+%"YDSR!*:T'1[,E[RQ:R=BE&)H()'0O?/S3,,6YXMM3)I!^!]A*X7KCM
M[S'AZ,O"<U]5@N*I</0&3,GD1V=3<R=U HE!%J=%$.L7FGI<'S9C/!&6-%5%
MZS3$,/O\8KRH3/'J?ZX(UGFUQ/C-'0,3F&&T]'&#H)1RX(T3-'F..7+/0^R4
M;?S0(">BY+;"[*7TVLLPQT^3Z6C;EB>D9DD8"\E)6\MT1_#%RZI/5HJ5)ND!
M3\(?!GOB7DQ#30U-I>4[U 7B\+[,8["/YLZT5/@N=#I 6_TX-8]"-249IR0#
M6J5Y+?2%$).4D&7(K$@52WH2J]1Q79LC\VD7)?7"H_5)SW\)H^D_POD5?OP\
MG5Q]^OQN.BFC^=OIKY/9;#F?FYMZ,OF210#NLP95-&W4TM,_GL44-+>1#><Y
M'S"1HUA6;:EQCWI#Z;473^P>^!<7D^E\-,/\<C*;KZ$-F"07B4Q/R3TH+_BU
MG)CEW"H,NJCA_+-=D#\+VK72W$ G@W=BF==U TPN2F5:^EDVM6Z  I]= HSH
M)#?.D(".>#BX!O?$C?VFVNJE-O.#$%=%0#J ? +!BWO GTX$XR"U[T:K W0V
M_(JU:@\NE!1<&$C*$>*L/83:2E9:8VD+#TXD<_K$VB.J,3RO=E%5__&-#0T%
M,Z),"4$$#&0,H(404H2DR0Q$DR5C'1NZ/CK6TSC>/%!%#X<[#I-OXPNZ'<#Y
MG!E+#+*NZ?$Y</"(!3CSB0?IF%F_E[?Y4/NY:;ZM9!N_]HO(RBHG=96CNH1E
M&&,NT4(>529[O'J ,0?ZE4<A2*71K1N[&Q7^P!"GINI6TASN['E]CS.82HQ%
M0='UNC R#]&;6*L"Q<A4$)P-YSUW07SB/DYKG?5R;^DQE*NCA XXGT9HX^DX
M.\WUOS/%#E#><)&.^WC1*,N43\"U8[7\NP'G@P+4T@JRLY)0]EF0;+^8QU$X
MMHO.^HU^W)W^PV>6GBO'":TLC"!K:R"22, K%H,007M]A)A'5_A/YLCY0"YL
M/W?N19']!CF^@;Q#F ;IK8R)K%3C!!F8Q67PW"$4590B#Y()'.Z<Y]#9/#-F
M]J3F(4+$9]+D+&H+.NUKQJ\.2&\.&;S<!"%MD-&JX9H+KH$[=D>4/J\,':*'
M8<*T-ZP^"YISEA#!H$3"EBPXZS24[*R7R=K A[OELQWG,Z++OMII??XTF8?S
M36OBZ\75U-'XT\;;TS?%@Z2LZ9_!@> H:364M:H4+R23C-)+SG()WQ)K\QG5
M83!.CS=#ZZ9Q8:<#H=]].42PJ3#%J[@,*"<51%?='Q,=%N1%N$ZGH,T0_4&V
MAAK;&O9O6.3@/7[!\16NVF%=7Z!OT.6KVW,/+ARP!_Q>KOC3S^'3IRE^6M19
M?5N6N'XANJZ*GLS^?33__/)J-B>$T[ND],PYS *L00LJ^ (>=:9?<V:(9++C
M<"4EV\RI;7& G7%<'VYS9DRI-65"4237*.A-8\)!B*($Q14/)GP?<CUB68&!
M>/UPS8$!"'#L@@2/%%,7Q2DL+  Z2VZ])]_>J20@T0R#UZ6@>VQ!?EH=(HZG
MZ&X=(W81^)!-!+K@.L6.$3OIHVLW@7V$.:2RG?'*:<^ 1WJ;5%3$<*S9Q\+Q
MPIVPGHDGJ>3].D;THN-=9-A[AR9A%=)L0*')H#0YGM$;FFK*A5OG?%&J@SZ/
MW*&IF;0?;-2T@Z@:)YMMZE+QTTV7"I]MU"R#QD#3"J5 C3$"+U;'Y(ODTG=0
MX4-CG( ZFXEPR!XNGK3DK*E%''S-@:HEEC/7U6A-Y)O7?[I46/].>KBT5.U>
M(NPEC>S==)*OR$A\,<X?</IEE)89 M[(R.I$T=5NBN@1:/(1HF2*&6%26J_C
MV:,ON 7DLS/!VZIM*#XMWY\NT ;/%]L*]U@I8DT4VX4N!VBEESCT=HA1*<^E
M3*!#[9-DM 5OE:2%5\MBK&$R#%<3?6#"/)KN-31?=E%&8UMD$2'X$&YSL%7@
MF#EMGC+F2(:N#^!KE](HDLW!!4%_[&!_K#_W&!&91@*?-))68P=A-:65/2N=
M]QH=I)A"#5#7LM7, <LID ^3@L N7MVW3ST-K1T@J=:A?$R?QY/SR:>O'Z=D
MP1:<KC"9')-" 4Q+,EF95N"329"-"@$-T:A3U^1MSS\-/3:17N,H^G)J[PE:
MF'["U;*03 Z"6;":U0;JN@8=. <FO&2V&&9=EY2+C0\_#5T>+K?&_84^7%U>
MGG]=6RI\HD$M%L",#%3M,.)KI4Y:0A@SSN24.^EQP[-/1(V'2JWA99N*9XU/
MMJ!*ZO]O[]V:VTB2-<'W_15C^^[3<;^,S:Z9ZGIJIKJDJ=+IWGVBQ<5#PCD4
MH %(==7^^O4 "9(" 3(3&9D@0'5;JR2Q.M/#/\\(=P_WSX.E5Z.NS:(,O):5
M_3 %KE%8J;MLJ^?X 0[0U"AC=+Y;+)>+?\WF'U;?_?5;^(0W#G?,Y$TQBN)M
M%"25JG7$V=-Y'0UM$\+Z[9'T(T8INR1\Q=F2P8"-0B>R+=4F(N\@U^1YDMVR
M'BM),AS/9TUD !BCI$?VR(=T=HDZ !B+4Z <81=5R6 SX^2),(]ANH:E*8WD
MV<3(=#;2!X/V-!\_S"ZO:^7>;;'E_,/=O<5W[W[YB8*/M#DWF8VA!"X@J)H
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M-@!+XZUP+D!,M6ZCT!GLD[<@>+31!^1!R-%6?S(-P'ULI%4#<!]D3K !V&%
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MKXS(*,%),C^9I.$E*RE[ ?WX#6<.]$"5-JZPN)-J:Y,))CB5<H%DB@ 5=:'
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M9PWP,&7N +A!"DLSL1VS8Y92D\OG5&77M"Z SQ2]1R3Q7)%&\,ZYY<>//W.
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MN$'PKJSLN[_N_Y5-T=F_PC+_(UQ>DUY_J9"'RW>787ZA,L<<,L4%7@MR75T
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M H\Q2>DT8VDZTLRN4A\[(3Q9!F44&/MFBV__NOY29Z3]W__'_P]02P,$%
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MBB014/ XAHAR[=]RK1)H1E5 .%*9)&Z*P)[XQ(KAP A8*\#WK(#E@1=7O>"
MK*V>F 8O-[UA Q7XHL>2(#><M-LQ'IK$'8#)-8L#2S-K&G>P3C6/QQB^FNAJ
MI1>NW&S??WN4JXVV.S**$",I1#AA4/^((6-9"@,I,Q&Q- UCZ:9N7E"86*?L
MJ.DULMDZ:X^7:&!"4)"@#"8RU9 @H?5N2 *H?PBS-"-"8;5HNLX3X=$;!I@-
M$5NE.6#6W33C7CQ941I3\;4(,;EV>TEW9A76(O:IGFI[T%<9_?YDW*IK=;/>
M:GVG+:_K0F@CK/C^^9YJ.K?W='M9R$O])Y$OG[;YL[Q:53&V&_UG_8H4"R73
M,.,X@#R(]4(E@D(:QR&D@8R$$&$<IX&; AN!JXF5WIXS0(7(33A _[BNN02;
MDDVPU7P"_9.Q'C:YGA8I &TP#7[.5_6SO[AJB3$FSE:SS#P=;MJH8L[8:(_[
M.6F=B"/T-?B/)9?@<<?FF*IL1-0F5W]C\#JSRAP1WE,U.^;@;JK9A+[>?+YY
M^SX*PE0/:<YOS7EE'>SD 4Y%1BAD..40Q8'^2844H@C%2EN1B@96NK:;S,3*
MLR0,#&5P8Q_][4"E/]@]CJQNFJDIYH&J1]R[0W+[X/<X"/A%P,\C,4X<O%^N
MCF!XQ\NS1<3[!6B&Q2V>=E<X;Y^*0D_J]?9>%C?%^CDW.2B;^A-+!%&))!$,
M VW4H81($PFC4$9AFE 6Z_]G?;+616B6F#BO&- [_HZX_3+L1*E?!8TENYL2
MJJF"DBPXT/500YWRVRNBL7#P4T5M>(RCC&QDZU!'G:_/II!LA&BJ)*OGW952
M,R17FEUOZ:,Y#/RD#:SB66XN5Z(D^?Z_GO+M]YUC?,DVVX+R[0+C-,@XP3!2
M3'NEB<(0IW$"4:K-I QQ@1)JJ[:&L3*Q8BL9 C5'X,N.JL/"'HATO^J;#S_O
M&/^U D= 7H =<T!S5ZN+BC^P#X"] MCV>G8^T/TT\0S@.^GN<?#JT.X#"<RF
M_\<!HKE#C#2B^QYRM>*%I!OY3E;_>[5Z)Q\+R?/R4]U%V&,6*QRC4%NX,H)(
MX0RR2%)(30ITQ),HY>'B)"^R<_%9$?8XB&C+_NQ:9S4+)MXE&DSTAN\]T>S?
M#L8#Q_/\H@;DYQT#OQALFCR ]]-@8Z^]1\?(3TF/@963%G:2NT/9VHTSFTYU
M$JNI.MU>'*XA;^AW+=-R]\%F,8]#*3$4"5$018F"A"484D41QAE"61C96M'=
MI"8_I=Y]R*+Y(<N'Q^7ZNY2 R954>?^9IBN [MK0'Y;A:K"F/5S]O4#!7^_Y
MHS&>PK-%99"B.R^H@X9[,<"KJ;;S@G3IM)8WAH4,JB,<;5G^59HK;U)</LN"
MWLE/\H'FJWQU9])\C'GY1)<?<Z7?.#)!M>E9?CV;ZZ>MN3%FKN'=4K;4*C$0
M02C2! :$28B$E)!J2Q$F8<P#2H@,>.836)B*X5E3"E?5::PF#[[68@!:R0&*
MG2!E-ETM"5AJ4<R;Z]+)DY63EQ_$ >N#/'Y>]F1?@EO@XT>8WR'AD?J@W3CD
M.PE +0+8RP :0@ CA7GSA?]^F-J&*.!+*8QG(&6R*?8+M_P(4SU&4&;:*1\_
M;#,U[I;!G<G8>)40T-2@M@6*)J<[S+YX)[<T7TIQM2J/8<TJNV1ZKRJ9J(]$
MJFL,VJ[1:\Q\PM]+!F[EM^T;C?3?%RF/0L734'M7(H8H1!3B%"LH."91&*.8
M<Z\SBA%XF_K0@M]+\;0L=_Y*5^P.YBJ^_+:!,>;$;5.?&>DA^_>.5=#@%93,
MGIT!T&"XWIR!X1F43'ONTV-,D-^6//-$C;'[#IBP\;?6$?&SW$7'H/@J&^:(
M4+7MC6.2\$T=O]$?\;WVWJ_53;%^E,7V^XVFM-4;MMF"'\W7_W9)-YM<Y7KO
MWERMGN7&W*NYY-O\N;Q3LV )"K0GS:! DD-$LQ#B(# 7[Q+)A:*"1)G#P<N8
MO,US-G/)-3N;,G]\4Z8PU]Q> #-KV]*/ECN.75/$1YB@[LUP=KR]=L$=;[WX
M7@"^YQ'0#<AW7 *Z9W/,!/'Q0)L\/WP$5F=.#Q\/W-/L\!''=O=!2A7_^WI5
M2)/+J$?5X_/U@UQ0$JE$_Q^,)2*F HJ C(L0\BQ0) V#B)+$UIEH(S*Q5U"9
M-2MMYNP)ZU5H"-N;FZWX]!OV8TCMIILJ@8](@JNQ!+8WE,<0W,_B]0# R83M
MDZS#%FU]=3:CLH_YIG78^ZR[IKGY[?W'-5U=WA52FIE]<W/UH3#YYEK1_?OG
M-V^K?]3YOUG,.,]"K7APJO\3,@9)%**R/&"2L#1D4BV>9<'6-OK'A;3+1]ID
MP-Z ^.T]6&IN'((23M#U*Z:IX' TI#0.A@VPY^,":$Y 1;V,$AMF=O]V3S!W
M0LU>NTV%GI_&<T-Q'"WH@T"'9G0:;C9MZ2-D4X-ZO3]&2N*;]>II<\EY\427
M"QY0D8I,N\088XBXML99EF8PBK0&C0(N!$6#<Q&;%.=/0F2&NO:I2O)#,NR.
M@.O7HB/@,%JBS=4*E,3!Y<@P#,DP](5CO$P;:U@&YA2>D]0IF?!H@%?,(CPG
M2'?ZX-DWAJNQ3W)9U0>]%'][VFS+D[</ZZ(R0O4/DM/-5KO+?Y.\C'8MI#8/
M92(%#%"<:7>5,ZWH6 )3J4*%49K%L56YO3&8>87<PZ)B$6S7@!Z8!&I=U!ZO
M^;'DTP2M=HSZJPGG^7'7IU.B/ESCUMR!VS5H\ <T7[7#"78L@IM7 =Q?<T\)
M_'BZ?>0)&+0#^"+FL$<XDWBU7<07C*Y]QGM,W].HO]*[\A[19[JDA3FZD&%J
MVA%$,%,DUH9TJ" A(8<Q2^.(Q6'(P]CK;.DEI7D,Z))J>5ZQJ>FZ'@>=(&1[
MN.,EL)?>=A#2X[RE38[)3T].",]\%M(F^.G)1NN3;LM2R'SQ?K7-M]\_Y$M9
M)7(M,,FP"AB%"4U#;?"%(:09$Y#0..61-OHHL<J;/C?XQ 9<10X8>G5.I-WB
M.XM#][(;*IW;@G,0S'K!=4EP9JEM)/_3W?KY5_U:N<C,#^7N6BZBLX/-LGRZ
MQ-@MG,YG?'>R1M'1RR+?Y*N[#YJINC1R\Q#Q\EN^6;! +Z*((BBS)-6KBNEM
M+A0<,HV@PJD*9>I8K-B)_L0+K\$+H!4SP$S1KK;YT=D\^$(U1Y;Q9E^\;3?-
MR5!T6^"C NBQYWK!,/F&[,;5S+NU%V2G6[G?,-Y%C1\>:5X8,__C>K/Y)/GZ
M;I5O3(*:-O)5OKTNS.^OM!^YNLO94E;):>6AY>T]7?VV7HNON1XGIBH-!5$P
M$UQ;[8B&D$B,M4[C4D5QG''.'(LAC\/9U"&B/9=@J=DQ^0\UGV69RI)3/27E
M'R_TKW;<UDT-ZMM36\TPN*LY=JX[/-(4VFK(5Y@8QRC2C'/B4RIY7/RF+[$\
M$K]SEV8>%^8S)9U')N"1Z$&_&_+7ZE(\YYMU\?V#E)L%B1130@4P")GVUR1G
M$ =9 F5,A(ABGJ3"2A6W4IA8I=8T3=HGK:D")6WC)NVX] ?&!TOKIJ=V@EXK
ML",(/HP@J$.&Q5"!/5,I7 5W2YKH$JHK.^+L>_.E072Q?93OT/F@KR%X_2@+
M:I)=]^TMF H";<C!C"4"HBRA$,N(PB2E0<HD22,F%B?=!2WLAY>4?.*P+4T3
M>\N(KG>T=_5"G*.Q)SC9FDU>8OLEI[X4<DSKI4V,R<V0$\(SVQ-M@I\:!JU/
M^G>>.3ZDN;TOUD]W]Y>/YEI$4544NE:?S-VBE13O:6%NV6X6*"*,2B$A966#
MFBR&3*$,,A[$"J.8,^;8&,^/D8GMA<OELNX#7=T4R;5I7_<',!:^>QL7+["M
MO:?)(71TEL[D.&PKG@!M,F7 +6JV@*SYNJ@+?XS;2F8(0C-TG/%B;_;&-$-
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M*!&F4J=)Y,$R51E)H]CN2,N)ZL3Z4!.%7//2?E?'WO.Q1[+?"YP$'S<]8%@
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M_VCW-(,,I002Q8.,14I%$GD9/0Y,S&,,[1@"IO&Y>S$;>TAM3:&Q$?(L5=-
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MN]:J"F83)/B"VI\<)UGC<S-QCN,]^T[E@PJOMO;(DD>2O9+SZR_ %YFR1!(
M 3KWP\IR'!'=_5!XT&@TNLV><XB=U<T ;P13&YF[M@X98DQM)[#:7U"4U5VL
M,&0()#DK*$DQ8>:%4,]*"#SCVWZ2K5"+J,E9/ R"4E.MM POO3+0(9/WO*46
MD9ZI%CO&;$Q?K5VL9<B8H:C)V>?FBW\,J7T4R1C\H(_+<75#""'>B[60RWW;
M3(DF,F-Q H&^] M0D5% <AH#F1#"2<E$&AM'*DR%!B:7PW6=Y3H2C0(1K348
M;<WDCN0X!X7 QXZ6>FXRM6I$C1YM'[D *$VY(C8=+:_WOZQ1FWBG:]A\JPM;
M/4.]X6VL8>.&KUJ-/.LC<'.U;AO9U7Y=-PH!,8D+22$HL*  "<(!(2P!,2YQ
M7B9(^6B6NS%#R<%Y=&KS/D, 7<(XGF"9$LI9OL9GEG".@>&SAG2&]'G#L(X!
M3,.A'9,!W%N"[MAV^:@7H6MYL]S]\]-6B+9;S@W9B^K4ZKKZP.Z/+5'_PA>"
MXYB6.09YK+L[9[P$.(<0E$F:PD**F)MY:M/4"!TT5EH J=2(MDJ^?;=0!UR-
MV2<P6G94I!6(*J"6;5LMC=B[:%>=A6]J-:*[6@^_G4C=<9BA5:F#<K/W,G4'
M\%RSTPFCN1)85>!+.]**)S_=?-.G[ZNEKG.[*.."YQFC@.>< P0AUB7&&<@4
M1<5ECJC$1OVW#&0%IJ(_E#>YU:E6V^6:+1]UH0=]E737JJ-= '90IKEFNEM6
M =Q'W=.GV6;8DE@_MJ9,Y04QRWA7%Q4MM M-*+=HU,[@=-.OP<R<,@K%*7&,
M/V(?=OHB]H< >%W7XO-F9YHC/3Y N.^ODAN]'$,UA5I^T[)_C[Y?V-UI-0#"
M/ KB#Q"WV,=$8*Q"'F:V#@0Z1@:8+;QA9D@WJ&'XA/-Y<EU:IDI[N^!<Z!(T
M51NZYZI&S4)RE.<,$I!D^J)(G I <B)!D3&>9ARQ.+8]4!Z6&'CM_OO%;;0]
M2+,^2!Y!RW0=]HB!'9NU%8R?J^17HD57I=Q>(/':6]?0SO!'R2-ZS'V6; ;+
MF<-DPP>G-NUN J77Z]=-*18((:QFO0 %BZ'RXK$ 99%S(!5-H)2@,D-B4JON
M7M%&DV)RK<.ZCPH7='_8/EM'-\=1-.4)/Z!,Z\G=G(M%FW6TJL Q*?(XH0_W
MJ*VS==_NU^2->FZ/0M/?:7O\4?<J-]H.-1JI(PU?GO0)];6LH@N[ZZ>]VA>O
MN;XYUOJX.<<I2BD"*6.ZIBHL02EY"5!>QC(3N(R9923 6H? 7D8M7^]XJZ";
M-8/88VK**$&1L@Q4'JFBP5J_@BW:O.@3K%".(QXS5,ZQU6SV4CJ.T)VKK>,Z
ME+NG<WQ6?'N_W3S=W5<":>=24+?2SZ(@19KE. 5IJ0]:XCP&I* ","@3%F>$
M*U:S(RX7-4)GX%7'!)5P7=?YP;AF\$1PS7VBL)#9NDEM!@@_9(#L:XUJ$@-'
M2![5_GH7B7\]+?<>2EGZ06<&Q\I!N=E]+7< S[E?$T:SC[+J8=B]N/USTR2%
MBI2SO"@Q(#!F *&B!(2F"< ((YK! N:E<7W?UX,'YJ%&7+3_<V,>73T!8#RP
M/,4L.ZYH+5*B'+)^3TPS#Q5/,=$M.-PQU4\$N,^$@9COR2.S17G[E.W&=7L_
MXR,I[7#IH"*:ID=\U5!T4<94$@H1R!$2:O.EV[=3D8%"""%35":<6I8/-!,<
MF"V.$[#8RXV9.NN!U9I$W_=:%^LB@H;8FKHP_A&S(R)/8$W,5QNW?-9TM0%U
MWC!;;1RDX60U@^==":?J4Z /A[?B7JQWRV=1GT]]$?MK>4M^?/S![G6YA0]+
M*85N7J9;'E2.SJI>LC!D4N24 (91 A C&. \*4#!*1+*,Q&$8CLJFJI28)*Z
M;)JXU;N 6F1$^/\\[?9ZB;4.$TU^ Z:$-2>N=E16-U%A7=6B9:7;NV@MJJ23
MO>ZJ(AH-(_ZBH@YI=]^$OE^YV8KEG?KQ46RK7WH-<?N",3@O3E9T9L;T!>PI
MEWH;V95EOR@,ZE._.MMXD>4Y+CEBH(Q3") N"T%%7.BVI65"&10D(8O]1M&\
M*6N^%F'%@@=!YGL#_4BTWJQ!(]7Q$L$),J9L-L5>.W;Z8FZD YWTV1&<'DX$
MSSS=^PP_G;Z]GW2=CE^WF\?-MHY27_^Y5C[ _?*Q/62[6BLINJ?37BP24M*<
MY!@(S+#:9^$"8$9+D$HF4DQSS!*CR(N]Z,!.S(L:>L'<M(J\9)LOU_J[7NMB
M.Z>-X36=ZR% L^, /W@YT(.MZ<%IPUBAF>G$%JA3FK$>P:7<0]TE[H-XW.R6
M^]W-9K7ZM-GJFG4+R6"2L$0 G.B6$%PHYX#%#*2L9 RB+$ZDT;G4B)S0!T]M
MBT3>B(X>R=*B(?$00N-A8$]VVW'#P>16:O1=RXT:P58U(?J-MZD,X04$U_H0
MK\#P52!BU*;!,A']3\]8+&+4A..2$>,?=RAF66^)UW=-*E%3/ F2M"AE*0!B
M90I0+B$@DL8@AGE>$(HS0HEQ0<NS(@+3SD%H>TO?I>[C>6S&66>ZQ9;ADG#&
M6A2ZG&RT8[%+>^/M*E\.VC54_?+\@_-5P!Q4_*@*YO G)U>UTXZ4V.Y_ZL*[
M^XLU__BOI^5C59SWQW*W(#)+"J1V4@6BF2Z>BT$I$ 8\1DE<",Y)9ADP-A,<
M.BS\<@#SV*CQKJKCOJ_N#HI6E>@[4<K8=\ R ]=T1^4?,CL*\X76E,)X1J;/
M5R!O6)VW*I1G!-) P3RSYWT<EZN?R=W=5E\:J"]+BV>Q?A*Z^\7E9ETE'.[^
M>[F_OWS:[3</:H)_7J[%U5X\[!9QDL0Y+W+ <T:4^R-20%.8Z=-UEDF4<$@M
M<YG]*#;K<3L_4K,N9ELI6C>08:VJT9]*UXBURDXYA9_PRDR);OX784>$7MY!
M]%T)$]%2JQKLI'\Z>K-F DQ0]PTS!::#/)Q)X&'\<.YALP?)N2QX+CE@0M].
M*PL,*,H3D.6<YIE /).6#0Q-1?\R+N)8/>"I$/MS$V<LFSP1LR"NXEM54QY3
MZ)=S%XTK+)N.8$=#7"P7']?[Y?[G!>?JZ[:[W#PINONY0&G&"B@(8*R( 8HE
M4[M1F8(\QKR$RA.DA=$)7Y^ P)12BXP:F>^B1JH9<?2",DP//DRU(P%;*XVG
M^I@I9R;T3K"_W&V>_T,]6DUE_4,5#*JF:N^ LTS(,7/::3?Z.?O \HW8"?7
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MBT>Q76[XMSW9[M\<W]>Z>$(Y(ON(BKOE>JUC@KIL:24G+/@I+"1+" =QGL4
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M\W5]]0[046]7_Z-/N+%7U[45NZ]DR2^;2VJ"7^S.=GND/$[+M "%OJ*,BJP
M&*4(P*(@,8K5"I=QBSV]JQ[S;/-U($DKXW!7SP;3X<4G*$2NV_ZF_+5:+QZ5
M)N\B=M E(KO@#1_=@)CC1IZ-6O/?Q7, [>PM/)=Q)C:O.'=,NN \8911!)C
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M3O_MI=_HN1%GF8(#IK0S:^@C]J[42TCLTV:K)NSCTUZTG2$3PCB1) ,D*05
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MJ)%@C<R(5$+'F]@Z\,2H<<&9H5^#F;E@%(K3V3_^2(B+_8L"0E8D.CZ;9RE
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MT/F4Y8CS'5ZYF7ITLN4XA#TSW]XOM_PKV>Y_?A/;YR4[M#H@(HLQ*PG@,L<
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M[:BR$3-FFH-/=M: X"[5L=29/:*S)I\Z-.<_YI@* ?.DC6NG19KCF(*$E@5
M5#DD%.K]("LIRS*H6,FHWMGIT+.D/, <)):'_B^VC_L?[A;93:@78UQ3&5ZL
MLDQ?<+)N2LK"X"NSSU(XT7\L,^'E@7FS$4X4/<E ./V$JV]QJ=-&Q:Y3/ZR;
M,?ICN5M0B'-)A%0K:Z+F/4]24&*< Z@V(I!B3@BQ#/R,R@Q,"(W\XPI[W8#H
M=Z*4L+X=,@ZEZ>+L%2 [?IF*C<-*;FQM\-5]7).95WQC:$Z] /-'@U!'TPQ'
M4IHB7:FCH 4%ND('H(AS4/(<%K1D.99&%U^MI,ZVA3E*4:X2\*/O#S:+LAV8
M7N@C=*NA<0+AOIH/.5G\MB0R9^LB)W@LB612<R/MSOQ=GTRO[[Z*[7+#JT6R
MC*&@ZC]%&6D"$$2ZS5BL]O24%(+$7/#2Z&[(V=$#4T,C+_I^8>Y G$=A?,<Q
MR3:[.=V:5<OR8)WYSF.2E6Z;CV-K_6Q >LT8V(.</C/;-J17W>Y.I/]#7AH3
MZ).50ROQ3M$I3'$,89P#)G3\D_($8(@D*#B#&L"4$^Y^K[U/;&#B>-7%H#K.
M?#QH,>6>>B^.IMZ$;W3LJ&<8F%G*<HT9/6]WASYEWK*YPPA ([T=QIX.P";=
MYO.QB!-8L!20#!* XIB LLAR !'F#)4RX\3R+JJ9X,",\HW="_ZTJJ;-Y4O+
M^:\A2*4+IP=:<03)+['LQ8]]1-67_I]S$<L9L]^26KKJ_#KD<JY/O0V]3.]S
MW\D<>19;<B>^/.D=_[7\^/"XVOP40KFWDLL<)A1 HD.F*94 YT0 K(BEP%DJ
MDAQ:YLKUB I,(HW8Z%X07EVRM<Y^ZX/(E"9\&&Y'#*W-ZTJD)@?1"O6:4S9B
M6/CLL#X%YL[S&@'B3,;6V!/.%68V.KSQ3;"G[7+_LVI?N*1/5>+7 N(4(<$(
M@#)C !6X )1F&,0YA;),:<E$[E2(<T"HT9=\<D'.IEM\I+Y5]NFM0Y"9SO&I
M"+B5UJF$1KM&:IT9WXKU6C9GW+KPE7$&=)B[^,TX'&?JVQ@\Y'#ONNEDUKDS
M>*'[F-T(^;3FG2AG=6WP5CF$[[4_N$ (,YE("/(RU<M[*@&A<0*X*$@F"64T
M-[KQ,D&'&3</K89'EV K':-:R:BCI<5=8D?PQP.C,T!JN=6P0;"Y2!QIO:+W
MP_L/;Z!:7-0.#Z[CA6TO7U.[6]K3L!BZK>TX\GRWMJ>9?G1[>^)0$^IM]':O
MUK72JHUCG43W:K;$,H^9VL8!C'56OH@U_RM7D,*<TI1CCJ!Q->>)NLRX#K3J
M5*4&*X6B*XN$51_ &W#_?' ZAIMT.8ECU?1O#N!>O )WVG(P$6^'^AWA<9]8
MS\,2?\_U/*;!8U+?PU'"_/4^ID%QMO['Q"&]]I"N[X=-*@+=,]9<,?&7])WF
MEF7X\LXC%K]-,^%7NOP*;8//PV/8(+CG8:=NCI=/VZWBXL_+?STM>;LU5Z.V
M)1-)@@5%L?*/]%D]2]1/4FV7"Y0*D4B,68(LNC8.2POM"[61(BX>-[NEF@^/
M9&E8,\(,K7'WQBL&=MR@Z[2R6O:[Z" ]:L6[-5(< <2J8:(_8-P;(PX Y*WW
MH9F=PST.1\:8LY>AF3FO>A8:/N1\#G!/MN+K5CPLGQZ:KV+!)2<TSD%.<0J0
MY )@(1'(,<PX(R7/"\LL@5,A@0FLD;4[M&W8;Z*=5B)BY''I4*GZ#$S&(?])
MQEM&^BL;'VMAXPG:+B'^7FO"1_9/1<\=T.\U_DP<O_^S$RK0-ZS[<LB_R$H*
M"X%U<52H_ Z>98 4:K:F1$K!*.<%,ZJ;,"PF\'SM+"@3<@'/XF,Z3:=:[>QB
MF!CL5N.]UYXY*KB?"I^_/GLO &>KK_=_>D)M]5>MT42AYF-:4I S#@$JDE+M
M%U .9 (3!/,,,6*4+C,@(_!4[9;8MNZ.=PK(^$; @YEV<_/(PJG=\4XM=JBD
M_D;=\8X0\%Q#W;$[WNF3\U=/-^V.U_]1>SZY6*_%W\AV*?[8JG5]V9;2H0)*
M!G,!"I(K5SUG!:!IDH,B+4L"12F$-*:3\R("LXD6"BJIT1\W%Y\^75D43^K!
M9)Q1IEMJ1RA=(VN)#G328ZTYFTRWVHU,3JWW0R7#]@PP2<^#LQ')L.)='AGY
MI.L^HGL[>JM<G?7=)Z5@$S1=WUVP_?*Y>QDW*U*:IJ4$6,158VX&*%8LDPM>
MLJ+4O[ ,"%AJ$)B$NBDII%8GTJ^L/190?R4'C9RO/=NB;KIQ"8BE'<U9PAC@
M;K0C%,&W0[9ZS;Q3<H3M=!/E.I KD;65:C^(^O]--<NJ3Z=4/#!>8S8K$!&$
M8^4V,45MB,= ^4UJ/X9@F<*,8)8:-;KRJ%-@LFL5L:6OZ5B;$MJL"-I17*M:
M]!MOE/O]4,%WW^KW!E5[O4$6G JG:SHS.7J#]I0N_0WMP1-<B!+%A: $$)$I
M*B2%^BDN"E!DB&"$,9>ZN8%-@<G.Z%:DYEI>TCHY^SP0#H[7+$Y5($_I+;R@
M-_1PC+R7Z9[);O>DNW16AXT+61)(95:"G"<4($$8(#GARNDH((O+C+ BM?0R
MNN.'S@:9<G!Z#(2Q"^!JGN5R7HD9-<UE03YG0/C%]4CJW OE.9//+'IG/^:0
MD476&[K<[)<_+C?;QR8:EB)(<EI*H*95K!N2J3F6IS$HLQ03(G+,"J."T7T"
M0A^#'D1&6N9?+!*,SJ$Q'@F=:J/=='MMGDLBU3D[+7*G)MKKF"YE^EKM\J,&
M;!E*B3KWV'Q94 -*'R4^#7W.=5&^EG+)Q,=_/2T?.VWFRB3/DCR&.E-3+<ZR
MS'2<DP%6E@S&7$HJ+"L8G)43^EBVDEE=6+FZC40KVW:Y/@^1Z;(]V7 [/FEL
M/A@;).%IT*;@*_IYZ3.O[(,0G*[PPQ^W7^F_[3?LG]>/U17H/]3>>"_X(J>0
MI<I[!BC'A?*HU<RE,2D!1VKEYPRA%!E7:#\S?FB/6DN,-K7(Z*Z6:;X(G@-D
M?*V?:*;=U*PM;*1%?_BPT'R5GVBIVR)O9['52C]@S\!"?^ZIV=;Y 96[R_S0
MQR8<"E3WGGY439&7Z[O;S<<?K"H+]F$II=@*W7/P>EV%V5;-Y:DJM*8[)V_%
MO5COEL]MDQ'!,)64(5 0Q@#*%,=@G19=IAPQD3.6,.Q4"\6KFD9?[\G54Y2R
MT?+A<2C#?Y9W8G&0,#/$KH<*^O:K\A?J='5]4+K?1*)1->(OND:;=7W.4&M;
M75W;;,7R3OWX*+9-(]/EFJV>N."Z"%Y]\,"Z]@3H4!,$Z3G.(CQJ/?^YA'_(
MSYY1!!#CT#%PL]UN_E3R_W@BU4(A/@FQH'DI(20IP"S/='D" HC:M@%<%#A.
MU-XM2XT+:)^5$-@1/,A\%]VU4B,I+.H,G,=EW!N<;*T=QW4,/0B,/DTWU**7
MX%2#'=L)VAINUUAPR*BAWH)GGYNOO>"0VD<=!@<_Z, B=6+N1=OG2TA1Y(D
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M65%U9OU$M56]]O05676_.%^U5:_B)V57_4^.Y1WZY?'I8?6B]>8.P0KQ$C-
MA&M_6N8YX PAH)F02!J,.%%W/_1:K,+96_920GYJQ[*\?VD'JA*]DQE+T7*
MANL*R;+4P#I8"K" '% M76,?4W$FN*@DBZ.UB0(FAN-SJ<#*@);[Y[OF2JZ>
MP[LXGT/CF\X:97"8JPWY"8P@J3FS9#9RFH/D*Y'2G)E^F8SF_-%8C_5^L9$/
MJ\WS6A\U[3BZW/KVY:L=VO&,V_FA-]O/?*M_M3O"CUO]N+DKB:#*."HJ8SC
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M^ D^9V! <>4O&=6B.BW(,S2S3F3 [&VOTWZ(K@;9B26&GV>_OOV)E$)Y@3!
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MT.B@2*W/HIZ J_.UV>*F/J6/PY_>YZ*CF#57CK9 +WZXU,"F/8@L>5[E")?
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M^.4J4D(9E:8X@/D_+(S_(Q& PTMJ*E#"UD_'Y[93(]OKD>T5>9.-ZJ82A%E
MC5TB["*+ZP(PG*B>+L+^OD*ZD.'FJZ"+,/*D="[F_8B]CAOFNUWS7-5*J;6&
MBG# JU( C" &7'$!*&>N@)D5BI7>&Y>C@5/O0EI1V;<;_Q*>,^,]MA&1)@7N
M"2:Q)B!0C[0J,NINI4T4-G?HWA<#'S\^7T#;H>1)=-KU[^.XE7];;0]A[%%^
M]H@'\T *J[E!!A4&($05P"6U$YY6%6!(TTK+G"/HG:Z(56*&@C^^?,D6!]%Q
M!+Q!P Y[E#G@&I-)73J=ZCO\JWK3JP]J'6.9?1O-;!P$;!R-<2J (QWA=UTW
M%PL'FV^R)[ZNNY/Q3-I?]H/>ZFRCMZ>Y[XU5J"'0^M?IJ8UCL/3D,0X:^BJD
MQ3'&7V(HCAHKHC..&_X+/S#TY))QC<L<*(8DP!J)IF2"(\Q+P>W?(N]0[_7@
MB9UYDW_;\*#$YQD P\YYC%EA3K>QJ!85TR/GM6D!77)&F!C9)^=@ZD2-<BZ8
MT-<JY_4K\S7+N:#L2;N<2\]$W^5X<%5ZFUMSW++>[1$*Q+50);0^ !< &U("
M5I0*5()!(4M%11%(NWI)5.KPKA'KUK^3$]^X&QV7X.KW&-."$.8_XNR/N=<Q
M8%KZFQV7%)C[;L< $!VW.X;>B+^J]>P*S5U(:(=L*7\-S V7E08%M-LYS%P+
M2HTJ0!6URSX1I)!>1PG]8I+OVHY%1E_0ZH#'>RJ/-#IP&K^R-P'!<9]!,US+
MZA ^^Z6LRP!T7<GJ>3J>4E1S&_R_-&SK;<Q62%5P8X'CFI< YU@"+E4)5%DJ
MC;46H@R\J]PE)GDBMA'9D*5$D(EV .,[5<>:&YJD/;$T$8WH98MF(!'M$#X[
MA>AE +H(1'N>CCJY_ZQ=2[7%\M[NR_5RHQU9>1T)BIQ+IK "!<<,8&1G+$=Y
M#D19&DQ4H6CA==]@0$[BV>H._O:BLU9VYH0''SWT@36\T9X(@K 9/)/U0:?"
M4Z 0?PC<C<9D1[Y#QO6?\%Y\>\X#W2$37IW?#CZ>LK5*_>N#E&/.90D*;0,*
MK)  0E $<B,5E=3&%51-WUAECB-?_S8A4;L&;X2]PY,$N 6&+%-!EJBORJQY
M!&^%?L*>*OUYAN 18IW0S>%J]8?5^KU^6FNY:%HL+M7-X\INF3;U?[;>[XXJ
MHAB3'*@JQP!;#P2H+ PPB%"58XJ1#+RE&:I"8J=TK$!]CL=K%?X[X+QY!+R^
MGB@E:&$>Z4@3=\D\4]WX-=JXXU"GSI1N*1:*Y.XI6+&9W50L<.?N*GJD*6X8
MUDYRSX*]T>L?1V>Q-0//CL/C^+*N$E5%2BX L3$JP,;=/"3<%<UI6!E4$BB\
M.D=-J%-BQU;KM*.6'W/A, YP7\\V*XQAKNZTK*;A$FZ;7[S)UJU^Q[4?#3/7
MGN%GCOO4HR";]5)CG*97O.PX"MK^2Y#CAAY79GBIO?:)&S^*@:Q>G]:K'XO-
MP9^_[E!?0&(WIE #Q(H"X#+7@"$N 8/85*K"$&D34XPXO:JI?>X1'\6QDF^R
M8S5KE[%7=)>X":B+2?PYAY-_/\]'BO;HM^X+-9IG1ZIGM>Y]'^^F\^-EWVH;
MLM$UE0F^9USEY76_:UQ&--WWG;X:,QV^GC6;"12X2F5G.B OU7\FE!A1)?KE
MILAA=;M6BR5?O[0GL-1^>JTK#(2INW-+#+@L-5#80 &)A!!Y=\KME)!X);4R
M,R<TNPVHJ>Q$8G@U&VU?V")T,*T5&%,^VFEJ0 WI6),C"TE?FSY1.6F?-7TU
MI9WOS5=8VJ?V275I[X/1O*2;S;/>L1;?05Y496[=A.8R![B"'%!3<""J$IK<
M%)4A7K7E%\9/7776=M!;M+2'P;RA)UA024HF$ :,*^L\L4" :Z3J38T6186X
M*D)I\Z+1B+IQ?O-0SQ@7P;CZTM5FD\'BWQ!TNWD\#AS?Q$ZTP6'>M!9SX$6?
ME-6TRX+T;*4G4N=F(>TRN8-=M/.Q6$=4IST:)N!MR\BK!%8%*BJ C*JL-V(&
M<%1 8%B98Z)8B65@E?NYD-013)T3E(W$(<Y=?V2@$D)*^\,I,8< *TH U5H
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M/FRA";<[(M[M-RIY3'M!_,QQ:S\(Y['IP/.Q_N[3>J6>Y=;QP7S1ZQ\+N2?
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M001\E],),8/%^J\O6[LZN_/_6]-FZCXNFPN!7UT[R+M"09US60!8\1)@Q2O
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MXS(7PVJOWYM,U!IF=EO>--D[I!%&UGN-^$B^F9=YH _TK!ZH[T"/ 'L:9HQ
ME*[!EN&KXO49- +!]&+5"!TS/,A[Q3%7GZPU!'.=]')_6_.E??J.Y%51*<R
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MQOQ<@*?3WV>/[NZD-\\J)/Z9E-MB^U#]LJNJ6U$VHN\IEQP+DH*8L00@P7*
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MD?(<%"0F-^/Y].<%TO4[21ZAH-/D$1&N([,>F# AHS=&Y] @'I:K[@4&^U+
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M6OK]#S@1V4=MN88LN0>E+)+A-@EB8C8EM('^T1FLME'9-\!.T?XC*#6BBD&
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MQWGJVPMO\9 [0O:#\+]7= >Z8YK(R7(&TJ*RS(+GP0 O+!M74(G4W4OG,)X
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MHX$N+%YRVCV2=?=\^B2)?3]R=0.R8W4RB/O J^WRT44@8S8#NMH=O<HGA&1
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MJ-Y[MS9]M^A/98,X/+>Q7YF*]._\,?RL-Z;%NP#)>7%70A:MR2Q ,HF!4KR
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MXF:HV0^>+S9FU9/:!@[4!7<;;%^0(V1S*@%R),NG1(C@>4Z@5)+&<LVYL0U
M\N&Z^X'OQ8:>6E?% (_VQQ&'I=T?+YO%?PP_5VS&G&W(%F16 >K[+CC++<24
M7%#"!)>[:TA[% O[@?>_04CI= 6_"!PO.R#=3*MR-D-F12$W19#S[2TC1GD
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MAD+NHU(^":Z["X\_(*Z1!]3S0G\-7[].\6NXUXKP-HWYW9W4-\ITF<SDG%M
M#!I488KDHC@PGB(W1F2;#TJ5/XZ,OH_14]#RY(MG!]H8YJ7F=F0E+L?N'A])
MVO9)#9BCO8ALS!2=C</EST7;YMN'EM5,XKM0IHZ^D())V]:"<G1Y]K55$_)D
MK.,Z:XF=6:?=]+8=\5F7O-+*KVG;7$[6S:P>#')^L'N"RREJ@T#.)H(*@CS/
MPCDDHVT.'"/G[A!;UCB%?9NYAI%X:*RG [7V_>:XAQ0^XR7]ZM>_X)B,T&7M
M?YVO1N-1E?]\]'T]KOR9, (3+#J1+' 6%*CL71W\ZP!3BB0+IM+#-.ZC87XJ
MK7W?/7H&?*>J?@'0?T/'_N0GXF\DD#)ZKH"7><ZM+(;VO."U6Y@ [UF$8HR+
MSF>!3#:$\;V)ZCMNU#.8VU'>"T#M:R3*TC)U\>RJ#J;Z?Y=_'^?;HH4WFX[D
M1KJ"S-&(4GM]6KG($J/]ZR0$#*9.056:A89@?#R5?8><>L9U1^H=$- 7]\_;
M.]!2Z"L.'S!8G"(Y9P$Z2UE[-]1*0V? L:BX$Q*E.!2_>R^^%RSUBX=E.\H8
MYN/ HKP]AED=)_SSZJ3./EL_JJD&%SO);"5Z^ 6G5[-E)D8>K<+O=^1\7))S
M-IW6WE#WFDRGB-PH+:%(4_.198%8VP18Q8,C1U&2\]A+=.)8CIHR=A]NKB).
MB8"_X>CKMSGFL^^TU[X29J\"^>+CK^NDEYL:+BAU1][,9[7?/7WO7ON'VXC%
M(W>GD!]N(TCC-3GI+H$3GD%(UAJN93!YKP2G+HGN^R6B<\QO,[_#@L?@@J(G
MB6>AQ//E9*_-\%OVVKB0(UAFZQCL$&L2+X+AGGMIE<*>(JEM<-OW$TAO.VV@
M@!K<%GM'K-$%9/X[AOJ%Y9S1MV$T_;=P>4/?KQ-Q9N?3SSC]/DHX6W9_Q/RT
M[?D+Z8Z$^OIF^N3T9,V2S1D]Q.+)A62Q@/-*@'6^,*LCZM)/766'0NC[&6=@
M&W*H\/M[V:>;-FN'>#BS,M32@**0D:<@$@2C$Y@Z6+@8D5CJ)_^M==;[?H+Z
M^]B3+4%MF&\)'_!NH,XRGXBD=\(DH.<^KHDQ0'N3VT!/.5IL(].N+O:>%KL%
MJG/!<JLM2*RUR\Y:\/61G@=CI5,B>K;/ )OG5VFC=&.Y'"X7>S69S1]&B@U*
M FZJC3-J7I_BX&N+-&:%E^0%:AY.*37:L7Q_W>(:U/<^I1E-JF&8QJ6*[YH6
MJ ;U:)/RQ(<T8$AVD=;8L^2;,*WWL1D='HN#Y2XYSGIN'/.@DZ3;EI *"& "
MM G>*N-*?#@<H$4W91N5I_M^#S]Y\_A,DL=0LB'W-;I:AHS@4@H0O+?1H[5T
MOO8F@@&5)S2"H<>^4E.J&:;Q^82785YC#].3.G$\^3&-Y'+O(J_!).[%4A]I
MJ9]?R*&=$73N]R!417-2*GG;VM#)YNAJF0+M$9&LE=PR65B'6=W/4]OL=71S
MA=]P_@?B>(. !P4/4:!'QR5H9C,HKS2$' .(H#Q=R;5GI9_F<(=PT;<Q:Q2-
MSU\ 6U/N,"W>J\G5=1C_'-WYF4O7\ZB1+UL_JXEY+_L1VO $A W_>X6"+Y,O
MWW!%S"W\(B;G<Y3DYMO:D)5G<!H#>(%)99U*M(>F/^^W<E.AVN=76YPT%\4X
M3):N%8))#TK5:%IQ# KW/GF=BU9[5><?MNPP9A2T@(-M8=&F5=%S]M.KR25]
M93)=JNSK%)<O=S]&LPN1A#/"*<@AD[]HK8%(3B)D9YC')(0K^Z0X;5_A)6#G
M"(5.&I?N(#'R>E+CDA>Z/I7$J,"&$D'EI"!8+2$I)S-+/,E8CD;)<HW^<-*4
M_G9"X@AA]@R*?R4_C/3PD6Z95R'AS7R4PH=_^QUK$/O"&*8LH[NEEJD6+-<J
M0<W)T/(@G9.)1</V ,5S:PP-%,=H<-*". <1'?PP&8?\'S>SFKCYYONBEKW0
MYW_"ZYI%O Z[+/91<F@S:1ZDUH'N!X:#4ZSF# N1.19%AW-G%[#]Z>XG>:6K
MLZMU3;X@E*XVMM/6<[0"C*Y=E8JNL7I=9]P&R9E$'OS0<-KGZ=D^@HZ$ZA'J
M' 18?P__,9F>3_-H'*8_%V^[FT\AZX,B9T_;V=*-)C*@(T="9$;0D9$%YX4Q
MHTQG(-V'XI<!SF,P\PB>C2NP1UC.IG-R@V[JW+_ZVOWS0[C"I5=< @O,6LA<
MZ_K0YR"D3!=NY;!DK7E^-E&GA%E<$$L+++#W*U[.9_5?"^=P ;!M:_>3O=;5
MB=R(Q'M&#.VJFVGZ%F9XZS4_9&FUTXQ*6*S(X*W/H-"3PTNL0<[9%.\Q6)L:
M@-'>!/5CIIK1^:1M!?1\$?UP^QK]:C*]7ME1S1V&D!$BW8](0G1M\BXXL.1"
M"$?7IN+V&0_YU&?WAX66U#=I4):#<)4^U03$Q4;)7%EN0VU41+ZD*IX.UD 2
M*2PH$T4I6+H;_7M+5C\YG=W?'8_3PW @M-I,F9OBZ H"7GM>6TUD<$8HV@3"
MDU.FF'\8/6H;1,.XV!VIWJ=A<H2L!P&4+Y/K\[+@8&4M&==9!"Z@>*);:?HC
M)!D!2\@F.<M4[@XM#ZD;!&2.4?4CT)PD]P%U''C>"K\?C?'='*]F%YB-X3(@
M!.&1KH/&0S"* 4<LQAMT4NP39CEBZ7ZZ#709I6M;'X,,WWV9S,/EJ\EX-LJX
M_-9%SIY'5!&,8XD<O:C!,<N!><-R\3%KM\\XE7W7>PGAWR,5OC/>=Z+T!XFH
MCY,Y_3D*E[^/+G$VGXQQ]G'=)6+R&ZYK<2ZT8Y),/@=-)P!=3I*J61C$-Q/&
M../(7!^?5[ G$2\A?-,6]MK0TTL&Y,?:<C:OAGI<^*PD[<(ZQX4DK")Q'77A
MX)+*4I8@M=GGY: YBE["NV;/4#U>@\/,^ERU1=Q(IMR8Z$$_=7TYJF5&89QC
MF(UFD[*Y[/$)HHTLVT N:?/L-Y!VNB)J8Q]\7A-U7E[=$G4VSK^%16^LCYL[
M];:3OV(L><M VU+;5I8 (><,*$,4+#FMPS[6I1%BFLVZ?U5G(^&Z(OA5N!Z1
MA[/TR[GSV4AKP*L8Z&KF:^$)_<%S0B$5%IFZBTKN1W-_OFGW.'L^X;XAO0[B
ML>;NQ<IK61*+#GA4#A33$>@O&G)&PUUD$D6'Y3$'/0QWU'NJ*;T_\RI\B!*&
M@Y_5\Y5UL>9X<A E>%"%]IIS)0/CAIE(5[B<9;<(&MJK\$'J??95^!!9#P(H
MCUXGG4=FZ_@_F>H$G^#))[7<TM^BS9R)P$QWX\V&_"I\D*IWOPH?(O=!(.>W
MR7P^N;K/A!*R2!,UF%"',B%F\,('B,++.O^)E=1=ZN$3!/;=R*TY_)PJ_4%
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M^NC<:DE7DNWK7[EB0$BT4Z1,9LJM\_07P60.8C(S-S?W$)2]>K7FVA$ OD
M" P^H15<B&=?N$;!ZU.;G3NQ8EZ$#B+"EC"Y[P2:S&L.+ME"Q9(3:(4'I[,
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ML/WM@Z0FV'D="'DQUQY(HC;"YPD\LX'5W'1,SU5"#MX,8V]_$SQK.^]C9*&
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M0!>Y):A'&^B&C\Z6PEQ0;KHX9===#WN)'UKIYLX16AKM7(' ><UF('LG,,.
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MGPJD/EIH\*31>7!T"KOGCM]W;@P?F>>%I0*VJ#I&3CF(02I@W)3B4\CHIN_
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MWQ4X74B>LQ-&0.:>5(F+#*)E"F+@02!]%?ET5D"'#<_M&<T$I\=Y00/+M@G
M_FV]VFSVP_$7*67FH[1@I4MT_J6$H V"#3I[Y1PQ<;K.:0>W.+>KU HH3Y=?
M$S!\D5^'CYMGANF8-4@51!UA2U=48AJX245SY\RCV9RCAI;ZT'#N!L-00)X
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MGUMCGK>$T: P&#L;A,7;6SH\2=A94SNVU-Z6.1F(F6LRTG2*;OM#Z@F+M\?
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M;"U=R"SG')CPDMEBF'5=DI\.?GSN3)'1=,$)/)P;!-??OEW^V%-I/M$F+1;
MC R4+770M,Y JHXQXTQ.N1,&#GQ[[OSP$2!P*@=G1L >=FU!E52PM%74M<\
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M<U?X9$ ]I22OU4?)'GCI7))WC/!:1>'M('>M1$PUW27& HIA+0,BWTTPQ:)
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MSPR\\/IBCK2M9 ?9LD+&:;1:=;E4^/,AZ@0,G_PAZA@R-&&Y=+Y1SKY(]-I
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ML@S.L/OM!Z;;AAY.=[Z<VRDWIH$PM43 A[9?5=L%LHP>%8*MG=J43+5)7Y#
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M;WY0?ZG!Z?_[?_Q_4$L! A0#%     @ <((^6[O/ODZ#F0$ YYH: !
M         ( !     &YB>"TR,#(U,#8S,"YH=&U02P$"% ,4    " !P@CY;
MVU,\8VXB  "AR $ $               @ &QF0$ ;F)X+3(P,C4P-C,P+GAS
M9%!+ 0(4 Q0    ( '""/ELYER_TNB8  +.. 0 4              "  4V\
M 0!N8G@M,C R-3 V,S!?8V%L+GAM;%!+ 0(4 Q0    ( '""/EOX5^HJ9XP
M *94!@ 4              "  3GC 0!N8G@M,C R-3 V,S!?9&5F+GAM;%!+
M 0(4 Q0    ( '""/ENB=MTLW"T! /$=#  4              "  =)O @!N
M8G@M,C R-3 V,S!?;&%B+GAM;%!+ 0(4 Q0    ( '""/EMQ0E$DS],  "_$
M"0 4              "  >"= P!N8G@M,C R-3 V,S!?<')E+GAM;%!+!08
1    !@ & (0!  #A<00    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>nbx-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:currency="http://xbrl.sec.gov/currency/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nbx="http://nanobiotix.com/20250630"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nbx-20250630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-17</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:NanobiotixCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nbx:NettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ThirdPartyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ThirdPartyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ClinicalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ClinicalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:SuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2025TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2025TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2024TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-27</startDate>
            <endDate>2025-06-27</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-27</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-18</startDate>
            <endDate>2025-02-18</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-18</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-16</startDate>
            <endDate>2025-05-16</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-16</startDate>
            <endDate>2025-05-16</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-16</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nbx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nbx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:PGELoanAgreementBPIFranceAndHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:PGELoanAgreementBPIFranceAndHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:LiabilitiesRelatedToFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:LiabilitiesRelatedToFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:LiabilitiesRelatedToFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BanquePubliqueDInvestissementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-10</startDate>
            <endDate>2020-07-10</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-10</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:DebtDetailsAxis">nbx:PrincipalAndFixedRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:DebtDetailsAxis">nbx:MilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-12</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:ClinicalStudiesAxis">nbx:NANORAY312Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:ClinicalStudiesAxis">nbx:NANORAY312Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:ClinicalStudiesAxis">nbx:NANORAY312Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:ClinicalStudiesAxis">nbx:NANORAY312Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:ClinicalStudiesAxis">nbx:A1100StudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:NANORAY312Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-17</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:RechargeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:TechnologyTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServiceRechargeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:SupplyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentArrangement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OperatingExpenseAxis">nbx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OperatingExpenseAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentArrangement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentArrangement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentArrangement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:NonRecurringExpenseTypeAxis">nbx:EmploymentTerminationIndemnitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-10</startDate>
            <endDate>2015-06-10</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-10</startDate>
            <endDate>2015-06-10</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-27</startDate>
            <endDate>2018-07-27</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneMarieGraffinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneMarieGraffinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneMarieGraffinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:EnnoSpillnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:EnnoSpillnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:EnnoSpillnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AlainHerreraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AlainHerreraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AlainHerreraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-27</startDate>
            <endDate>2018-07-27</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-03</startDate>
            <endDate>2016-11-03</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-06</startDate>
            <endDate>2018-03-06</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-24</startDate>
            <endDate>2019-10-24</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-24</startDate>
            <endDate>2019-10-24</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-24</startDate>
            <endDate>2019-10-24</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-03</startDate>
            <endDate>2016-11-03</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-06</startDate>
            <endDate>2018-03-06</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LouisKayitalireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LouisKayitalireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:LaurentLevyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:CorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:OfficersNameAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BeneficiariesOtherThanCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023P2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202206OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202301OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingPeriodAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202401OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202501OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202502OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2023Performance2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">nbx:HSBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbx:NBTXR3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbx:TechnologyTransferAndTechnicalAssistanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nbx:NanobiotixCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:JohnsonJohnsonInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="subsidiary">
        <measure>nbx:subsidiary</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>nbx:security</measure>
    </unit>
    <unit id="quarterly_installment">
        <measure>nbx:quarterly_installment</measure>
    </unit>
    <unit id="loan">
        <measure>nbx:loan</measure>
    </unit>
    <unit id="employee">
        <measure>nbx:employee</measure>
    </unit>
    <unit id="benefeciary">
        <measure>nbx:benefeciary</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-9">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-10">0001760854</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-11">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-12">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-13">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-14">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="c-1" id="f-1">6-K</dei:DocumentType>
    <dei:EntityFileNumber contextRef="c-1" id="f-2">001-39777</dei:EntityFileNumber>
    <dei:EntityFileNumber contextRef="c-1" id="f-3">001-39777</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-4">NANOBIOTIX S.A.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-5">60 rue de Wattignies</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-6">75012</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-7">Paris</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-8">FR</dei:EntityAddressCountry>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-3" id="f-15" unitRef="eur">13000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-3" id="f-16" unitRef="eur">7000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2" decimals="-3" id="f-17" unitRef="eur">4863000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-18" unitRef="eur">5538000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-2" decimals="-3" id="f-19" unitRef="eur">409000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-3" decimals="-3" id="f-20" unitRef="eur">406000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-2" decimals="-3" id="f-21" unitRef="eur">5284000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-3" decimals="-3" id="f-22" unitRef="eur">5951000</ifrs-full:NoncurrentAssets>
    <ifrs-full:CurrentTradeReceivables contextRef="c-2" decimals="-3" id="f-23" unitRef="eur">1837000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-3" id="f-24" unitRef="eur">2977000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentAssets contextRef="c-2" decimals="-3" id="f-25" unitRef="eur">9234000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-3" decimals="-3" id="f-26" unitRef="eur">8753000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-3" id="f-27" unitRef="eur">28818000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-28" unitRef="eur">49737000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets contextRef="c-2" decimals="-3" id="f-29" unitRef="eur">39889000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-3" decimals="-3" id="f-30" unitRef="eur">61466000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="c-2" decimals="-3" id="f-31" unitRef="eur">45174000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-3" decimals="-3" id="f-32" unitRef="eur">67418000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital contextRef="c-2" decimals="-3" id="f-33" unitRef="eur">1447000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-3" decimals="-3" id="f-34" unitRef="eur">1423000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium contextRef="c-2" decimals="-3" id="f-35" unitRef="eur">312743000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c-3" decimals="-3" id="f-36" unitRef="eur">312743000</ifrs-full:SharePremium>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-2" decimals="-3" id="f-37" unitRef="eur">686000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-3" decimals="-3" id="f-38" unitRef="eur">712000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:TreasuryShares contextRef="c-2" decimals="-3" id="f-39" unitRef="eur">228000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares contextRef="c-3" decimals="-3" id="f-40" unitRef="eur">228000</ifrs-full:TreasuryShares>
    <ifrs-full:OtherReserves contextRef="c-2" decimals="-3" id="f-41" unitRef="eur">-378217000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c-3" decimals="-3" id="f-42" unitRef="eur">-312221000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod contextRef="c-2" decimals="-3" id="f-43" unitRef="eur">-5383000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod contextRef="c-3" decimals="-3" id="f-44" unitRef="eur">-68132000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:Equity contextRef="c-2" decimals="-3" id="f-45" unitRef="eur">-68952000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-46" unitRef="eur">-65704000</ifrs-full:Equity>
    <ifrs-full:NoncurrentProvisions contextRef="c-2" decimals="-3" id="f-47" unitRef="eur">479000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-3" decimals="-3" id="f-48" unitRef="eur">432000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-2" decimals="-3" id="f-49" unitRef="eur">46505000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-3" decimals="-3" id="f-50" unitRef="eur">45978000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-2" decimals="-3" id="f-51" unitRef="eur">4105000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-52" unitRef="eur">27778000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-2" decimals="-3" id="f-53" unitRef="eur">51089000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-3" decimals="-3" id="f-54" unitRef="eur">74187000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:CurrentProvisions contextRef="c-2" decimals="-3" id="f-55" unitRef="eur">167000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c-3" decimals="-3" id="f-56" unitRef="eur">438000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-2" decimals="-3" id="f-57" unitRef="eur">4735000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-3" decimals="-3" id="f-58" unitRef="eur">4924000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-2" decimals="-3" id="f-59" unitRef="eur">11639000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-3" decimals="-3" id="f-60" unitRef="eur">20036000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-2" decimals="-3" id="f-61" unitRef="eur">7000000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-3" decimals="-3" id="f-62" unitRef="eur">7543000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities contextRef="c-2" decimals="-3" id="f-63" unitRef="eur">50000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-64" unitRef="eur">61000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-2" decimals="-3" id="f-65" unitRef="eur">36172000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-66" unitRef="eur">18100000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentRefundsProvision contextRef="c-2" decimals="-3" id="f-67" unitRef="eur">3273000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision contextRef="c-3" decimals="-3" id="f-68" unitRef="eur">7835000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentLiabilities contextRef="c-2" decimals="-3" id="f-69" unitRef="eur">63037000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-3" decimals="-3" id="f-70" unitRef="eur">58935000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c-2" decimals="-3" id="f-71" unitRef="eur">114126000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c-3" decimals="-3" id="f-72" unitRef="eur">133122000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-2" decimals="-3" id="f-73" unitRef="eur">45174000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-3" decimals="-3" id="f-74" unitRef="eur">67418000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-3" id="f-75" unitRef="eur">24928000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-4" decimals="-3" id="f-76" unitRef="eur">6163000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:OtherIncome contextRef="c-1" decimals="-3" id="f-77" unitRef="eur">1710000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c-4" decimals="-3" id="f-78" unitRef="eur">3126000</ifrs-full:OtherIncome>
    <ifrs-full:Revenue contextRef="c-1" decimals="-3" id="f-79" unitRef="eur">26638000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-4" decimals="-3" id="f-80" unitRef="eur">9289000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-81" unitRef="eur">14529000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-4" decimals="-3" id="f-82" unitRef="eur">21987000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-83" unitRef="eur">11294000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-4" decimals="-3" id="f-84" unitRef="eur">10819000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-85" unitRef="eur">-7000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-4" decimals="-3" id="f-86" unitRef="eur">-134000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OperatingExpense contextRef="c-1" decimals="-3" id="f-87" unitRef="eur">25829000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c-4" decimals="-3" id="f-88" unitRef="eur">32941000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-3" id="f-89" unitRef="eur">808000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-4" decimals="-3" id="f-90" unitRef="eur">-23652000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-3" id="f-91" unitRef="eur">645000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-3" id="f-92" unitRef="eur">3386000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-93" unitRef="eur">6831000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-3" id="f-94" unitRef="eur">1463000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost contextRef="c-1" decimals="-3" id="f-95" unitRef="eur">-6186000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-4" decimals="-3" id="f-96" unitRef="eur">1924000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-97" unitRef="eur">6000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-4" decimals="-3" id="f-98" unitRef="eur">144000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-99" unitRef="eur">-5383000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-3" id="f-100" unitRef="eur">-21872000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-101"
      unitRef="eurPerShare">-0.11</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-102"
      unitRef="eurPerShare">-0.46</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-103"
      unitRef="eurPerShare">-0.11</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-104"
      unitRef="eurPerShare">-0.46</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-105" unitRef="eur">-5383000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-3" id="f-106" unitRef="eur">-21872000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-1" decimals="-3" id="f-107" unitRef="eur">0</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-4" decimals="-3" id="f-108" unitRef="eur">0</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome contextRef="c-1" decimals="-3" id="f-109" unitRef="eur">0</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome contextRef="c-4" decimals="-3" id="f-110" unitRef="eur">0</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-3" id="f-111" unitRef="eur">0</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-4" decimals="-3" id="f-112" unitRef="eur">0</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-1" decimals="-3" id="f-113" unitRef="eur">-26000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-4" decimals="-3" id="f-114" unitRef="eur">-2000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome contextRef="c-1" decimals="-3" id="f-115" unitRef="eur">0</ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome contextRef="c-4" decimals="-3" id="f-116" unitRef="eur">0</ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-3" id="f-117" unitRef="eur">-26000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-4" decimals="-3" id="f-118" unitRef="eur">-2000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-119" unitRef="eur">-5409000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-4" decimals="-3" id="f-120" unitRef="eur">-21874000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c-5" decimals="INF" id="f-121" unitRef="shares">47426851</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-122" unitRef="eur">1423000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-123" unitRef="eur">312743000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-3" id="f-124" unitRef="eur">712000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-3" id="f-125" unitRef="eur">-228000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-9" decimals="-3" id="f-126" unitRef="eur">-312221000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-3" id="f-127" unitRef="eur">-68132000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-128" unitRef="eur">-65704000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-11" decimals="-3" id="f-129" unitRef="eur">-5383000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-130" unitRef="eur">-5383000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-12" decimals="-3" id="f-131" unitRef="eur">-26000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-132" unitRef="eur">-26000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <nbx:OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations contextRef="c-1" decimals="-3" id="f-133" unitRef="eur">0</nbx:OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations>
    <ifrs-full:ComprehensiveIncome contextRef="c-12" decimals="-3" id="f-134" unitRef="eur">-26000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-11" decimals="-3" id="f-135" unitRef="eur">-5383000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-136" unitRef="eur">-5409000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-13" decimals="-3" id="f-137" unitRef="eur">-68132000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-11" decimals="-3" id="f-138" unitRef="eur">68132000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-1" decimals="-3" id="f-139" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-14"
      decimals="INF"
      id="f-140"
      unitRef="shares">809820</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssueOfEquity contextRef="c-15" decimals="-3" id="f-141" unitRef="eur">24000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-13" decimals="-3" id="f-142" unitRef="eur">-24000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-1" decimals="-3" id="f-143" unitRef="eur">0</ifrs-full:IssueOfEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity contextRef="c-1" decimals="-3" id="f-144" unitRef="eur">0</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-13" decimals="-3" id="f-145" unitRef="eur">2161000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-1" decimals="-3" id="f-146" unitRef="eur">2161000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-147"
      unitRef="shares">48236671</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-14" decimals="-3" id="f-148" unitRef="eur">1447000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-16" decimals="-3" id="f-149" unitRef="eur">312743000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-17" decimals="-3" id="f-150" unitRef="eur">686000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-18" decimals="-3" id="f-151" unitRef="eur">-228000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-19" decimals="-3" id="f-152" unitRef="eur">-378217000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-20" decimals="-3" id="f-153" unitRef="eur">-5383000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-2" decimals="-3" id="f-154" unitRef="eur">-68952000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-155"
      unitRef="shares">47133328</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-21" decimals="-3" id="f-156" unitRef="eur">1414000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-22" decimals="-3" id="f-157" unitRef="eur">312742000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-3" id="f-158" unitRef="eur">738000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-3" id="f-159" unitRef="eur">-228000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-25" decimals="-3" id="f-160" unitRef="eur">-276810000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-26" decimals="-3" id="f-161" unitRef="eur">-39700000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-27" decimals="-3" id="f-162" unitRef="eur">-1843000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-28" decimals="-3" id="f-163" unitRef="eur">-21872000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-3" id="f-164" unitRef="eur">-21872000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-29" decimals="-3" id="f-165" unitRef="eur">-2000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-4" decimals="-3" id="f-166" unitRef="eur">-2000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <nbx:OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations contextRef="c-4" decimals="-3" id="f-167" unitRef="eur">0</nbx:OtherComprehensiveIncomeBeforeTaxGainsLossesOnActuarialGainsAndLossesOnRetirementBenefitObligations>
    <ifrs-full:ComprehensiveIncome contextRef="c-29" decimals="-3" id="f-168" unitRef="eur">-2000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-28" decimals="-3" id="f-169" unitRef="eur">-21872000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-4" decimals="-3" id="f-170" unitRef="eur">-21874000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-30" decimals="-3" id="f-171" unitRef="eur">-39700000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-28" decimals="-3" id="f-172" unitRef="eur">39700000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-4" decimals="-3" id="f-173" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-31"
      decimals="INF"
      id="f-174"
      unitRef="shares">293523</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssueOfEquity contextRef="c-32" decimals="-3" id="f-175" unitRef="eur">9000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-30" decimals="-3" id="f-176" unitRef="eur">-9000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-4" decimals="-3" id="f-177" unitRef="eur">0</ifrs-full:IssueOfEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity contextRef="c-33" decimals="-3" id="f-178" unitRef="eur">0</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity contextRef="c-30" decimals="-3" id="f-179" unitRef="eur">0</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity contextRef="c-4" decimals="-3" id="f-180" unitRef="eur">0</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-30" decimals="-3" id="f-181" unitRef="eur">1940000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-4" decimals="-3" id="f-182" unitRef="eur">1940000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-31"
      decimals="INF"
      id="f-183"
      unitRef="shares">47426851</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-31" decimals="-3" id="f-184" unitRef="eur">1423000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-34" decimals="-3" id="f-185" unitRef="eur">312743000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-35" decimals="-3" id="f-186" unitRef="eur">736000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-36" decimals="-3" id="f-187" unitRef="eur">-228000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-37" decimals="-3" id="f-188" unitRef="eur">-314578000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-38" decimals="-3" id="f-189" unitRef="eur">-21872000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-39" decimals="-3" id="f-190" unitRef="eur">-21777000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-191" unitRef="eur">-5383000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-3" id="f-192" unitRef="eur">-21872000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-1" decimals="-3" id="f-193" unitRef="eur">800000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-4" decimals="-3" id="f-194" unitRef="eur">786000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForProvisions contextRef="c-1" decimals="-3" id="f-195" unitRef="eur">-231000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions contextRef="c-4" decimals="-3" id="f-196" unitRef="eur">-115000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-3" id="f-197" unitRef="eur">2161000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-4" decimals="-3" id="f-198" unitRef="eur">1940000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-1" decimals="-3" id="f-199" unitRef="eur">842000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-4" decimals="-3" id="f-200" unitRef="eur">1101000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-201" unitRef="eur">0</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-202" unitRef="eur">-8000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities contextRef="c-1" decimals="-3" id="f-203" unitRef="eur">2365000</ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities contextRef="c-4" decimals="-3" id="f-204" unitRef="eur">37000</ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-205" unitRef="eur">6000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-4" decimals="-3" id="f-206" unitRef="eur">144000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-1" decimals="-3" id="f-207" unitRef="eur">392000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-4" decimals="-3" id="f-208" unitRef="eur">0</ifrs-full:OtherAdjustmentsForNoncashItems>
    <nbx:ImpactOfAmendmentOnProfitOrLoss contextRef="c-1" decimals="-3" id="f-209" unitRef="eur">-19823000</nbx:ImpactOfAmendmentOnProfitOrLoss>
    <nbx:ImpactOfAmendmentOnProfitOrLoss contextRef="c-4" decimals="-3" id="f-210" unitRef="eur">0</nbx:ImpactOfAmendmentOnProfitOrLoss>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-3" id="f-211" unitRef="eur">-18873000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-4" decimals="-3" id="f-212" unitRef="eur">-17970000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities contextRef="c-1" decimals="-3" id="f-213" unitRef="eur">205000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities contextRef="c-4" decimals="-3" id="f-214" unitRef="eur">114000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <nbx:CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement contextRef="c-1" decimals="-3" id="f-215" unitRef="eur">-19077000</nbx:CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement>
    <nbx:CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement contextRef="c-4" decimals="-3" id="f-216" unitRef="eur">-18084000</nbx:CashFlowFromOperatingActivitiesAfterTaxAndBeforeChangeInWorkingCapitalRequirement>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-1" decimals="-3" id="f-217" unitRef="eur">1139000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-4" decimals="-3" id="f-218" unitRef="eur">-2214000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax contextRef="c-1" decimals="-3" id="f-219" unitRef="eur">124000</nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax>
    <nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax contextRef="c-4" decimals="-3" id="f-220" unitRef="eur">0</nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax>
    <nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables contextRef="c-1" decimals="-3" id="f-221" unitRef="eur">-620000</nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables>
    <nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables contextRef="c-4" decimals="-3" id="f-222" unitRef="eur">157000</nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-1" decimals="-3" id="f-223" unitRef="eur">1293000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-4" decimals="-3" id="f-224" unitRef="eur">1070000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="c-1" decimals="-3" id="f-225" unitRef="eur">-260000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="c-4" decimals="-3" id="f-226" unitRef="eur">-436000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities contextRef="c-1" decimals="-3" id="f-227" unitRef="eur">-11000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities contextRef="c-4" decimals="-3" id="f-228" unitRef="eur">13671000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-1" decimals="-3" id="f-229" unitRef="eur">-1666000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-4" decimals="-3" id="f-230" unitRef="eur">-12248000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-231" unitRef="eur">-17411000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-4" decimals="-3" id="f-232" unitRef="eur">-5836000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-233" unitRef="eur">8000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-4" decimals="-3" id="f-234" unitRef="eur">2000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-235" unitRef="eur">150000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-4" decimals="-3" id="f-236" unitRef="eur">489000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-237" unitRef="eur">3000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="c-4" decimals="-3" id="f-238" unitRef="eur">9000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-239" unitRef="eur">-162000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-4" decimals="-3" id="f-240" unitRef="eur">-500000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-241" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-4" decimals="-3" id="f-242" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-243" unitRef="eur">1926000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-4" decimals="-3" id="f-244" unitRef="eur">1525000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-245" unitRef="eur">568000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-4" decimals="-3" id="f-246" unitRef="eur">521000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-247" unitRef="eur">336000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-4" decimals="-3" id="f-248" unitRef="eur">609000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-249" unitRef="eur">-2830000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-4" decimals="-3" id="f-250" unitRef="eur">-2655000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-251" unitRef="eur">-515000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-252" unitRef="eur">43000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-253" unitRef="eur">-20919000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-254" unitRef="eur">-8948000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-255" unitRef="eur">49737000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-27" decimals="-3" id="f-256" unitRef="eur">75283000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-3" id="f-257" unitRef="eur">28818000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-39" decimals="-3" id="f-258" unitRef="eur">66335000</ifrs-full:CashAndCashEquivalents>
    <nbx:DisclosureOfNotesAndOtherExplanatoryInformationTextBlock contextRef="c-1" id="f-259">COMPANY INFORMATION &lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Nanobiotix, a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;soci&#xe9;t&#xe9; anonyme&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; registered with the Paris registry of trade and companies under number 447 521 600 and having its registered office at 60 rue de Wattignies, 75012, Paris (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nanobiotix&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x201d; or the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x201d; and, with its subsidiaries, the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Group&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x201d;), is a late-stage clinical biotechnology company pioneering disruptive, nanophysics-based therapeutic approaches to the treatment of cancer and other major diseases with the express intent of favorably  impacting the lives of millions of patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The Company also has subsidiaries in Cambridge, Massachusetts (United States), Spain, and Germany. The Group has been listed on Euronext: Paris under the ticker symbol &#x201c;NANO&#x201d; since 2012 (ISIN: FR0011341205, Bloomberg Code: NANO:FP) and on the Nasdaq Global Select Market in the United States under the ticker symbol &#x201c;NBTX&#x201d; since December 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Group is the owner of more than 25 patent families associated with three nanotechnology platforms: 1) radioenhancer platform, from which JNJ-1900 (NBTXR3) is the first product candidate, designed to physically destroy tumor cells locally and prime immune response systemically; 2) Curadigm nanoprimer platform designed to redefine the design and application of therapeutic classes challenged by liver clearance; and 3) OOcuity neurological disease program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s efforts are concentrated on advancing JNJ-1900 (NBTXR3).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Significant events of the period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Amendment to the Janssen agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;An amendment of the Janssen Agreement has been signed as of March 17, 2025 with Janssen; this amendment of the global licensing agreement partially removes the Company&#x2019;s funding obligation for NANORAY-312 and releases Janssen from select future milestone payments, while facilitating the Company&#x2019;s path to sustainable cash flow through significant potential milestone payments over the next few years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total expected payments under the agreement related to the Janssen Agreement is adjusted from approximately $2.7&#160;billion to approximately $2.6&#160;billion:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Revisions to potential future milestone payments in the amendment total $105&#160;million while maintaining eligibility to hundreds of millions in the next 2-3 years potential milestone payments related to the first two programs (cisplatin-ineligible head and neck cancer and stage 3 unresectable lung cancer), &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Beyond the hundreds of millions of the next 2-3 years potential milestone payments for the first two programs to the extent JNJ-1900 (NBTXR3) will hit the related milestone events , the remainder of the $2.6&#160;billion is related to medium-to-long-term potential development, regulatory, and sales milestones for the first two programs and potential payments for new indications that may be developed by Janssen, and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;There are no changes to the potential $220&#160;million per new indication that may be developed by Nanobiotix, and potential royalties expected from commercial sales of JNJ-1900 (NBTXR3) remain in the low 10s to low 20s. Potential payments for new indications that may be developed by the Company are in addition to the $2.6&#160;billion deal value, next to potential related royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The amendment provides that Janssen will assume almost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;full financial responsibility for NANORAY-312, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;the ongoing pivotal Phase 3 trial through completion,, less a small portion of costs that will remain covered by the Company, allowing the Company to strengthen its financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;For further details, see Note 16 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenues and other Income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfNotesAndOtherExplanatoryInformationTextBlock>
    <nbx:CollaborationAgreementTotalConsideration contextRef="c-40" decimals="-8" id="f-260" unitRef="eur">2700000000</nbx:CollaborationAgreementTotalConsideration>
    <nbx:CollaborationAgreementTotalConsideration contextRef="c-41" decimals="-8" id="f-261" unitRef="eur">2600000000</nbx:CollaborationAgreementTotalConsideration>
    <nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived contextRef="c-41" decimals="-6" id="f-262" unitRef="eur">105000000</nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived>
    <nbx:CollaborationAgreementTotalConsideration contextRef="c-41" decimals="-8" id="f-263" unitRef="eur">2600000000</nbx:CollaborationAgreementTotalConsideration>
    <nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication contextRef="c-42" decimals="-6" id="f-264" unitRef="usd">220000000</nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication>
    <nbx:CollaborationAgreementTotalConsideration contextRef="c-41" decimals="-8" id="f-265" unitRef="eur">2600000000</nbx:CollaborationAgreementTotalConsideration>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c-1" id="f-266">General information, statement of compliance and basis of presentation&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements as of June&#160;30, 2025 and for the six-month period ended June&#160;30, 2025 were prepared under the supervision of the management of the Company and were submitted by the Executive Board to the review of the Supervisory Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;All amounts in the unaudited interim condensed consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated  financial statements of the Company have been prepared in compliance with IAS 34 &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Interim Financial Reporting&#x201d; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which provides for the presentation of selected explanatory notes. As they are unaudited interim condensed consolidated  financial statements, the accompanying notes do not contain all the disclosures required for annual consolidated financial statements and should therefore be read in conjunction with the Company&#x2019;s consolidated financial statements prepared in accordance with IFRS &#xae; Accounting Standards, as of and for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of the unaudited interim condensed consolidated financial statements in accordance with IAS 34 &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Interim Financial Reporting&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; requires the use of estimates and assumptions that affect the amounts and information disclosed in the condensed consolidated financial statements. See Note 3.2 Use of judgement, estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June&#160;30, 2025 are identical to those used for the year ended December&#160;31, 2024 except for the standards listed below that required adoption in 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2025 in the European Union primarily concern:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.47pt"&gt;Amendment to IAS 21 Lack of Exchangeability, the Effects of Changes in Foreign Exchange Rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;This amendment had no material impact on the Company&#x2019;s unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable are:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt"&gt;Amendments to IFRS 9 and IFRS 7 &#x2013; Classification and Measurement of Financial Instruments &#x2013; as of January 1, 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt"&gt;Amendments to IFRS 9 and IFRS 7 &#x2013; Contracts Referencing Nature-dependent Electricity &#x2013; as of January 1, 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt"&gt;Annual Improvements to IFRS Accounting Standards, as of January 1, 2026&#x2013; Amendments to:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;IFRS 1 First-time Adoption of International Financial Reporting Standards;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;IFRS 9 Financial Instruments;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;IFRS 10 Consolidated Financial Statements; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;IAS 7 Statement of Cash flows&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt"&gt;New standard &#x2013; IFRS 18 &#x2013; Presentation and Disclosure in Financial Statements &#x2013; as of January 1, 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt"&gt;New standard &#x2013; IFRS 19 &#x2013; Subsidiaries without Public Accountability: Disclosures&#x2013; as of January 1, 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company is currently assessing the applicability and impact of these new standards, interpretations and amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Seasonality of the Company&#x2019;s activities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;According to IAS 34 &#x2013; &#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Financial Reporting&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x201d;, an entity whose business is highly seasonal should present financial information for the twelve months up to the end of the interim period and additional comparative information for the prior twelve-month period in the interim condensed consolidated financial statements in order to provide a better understanding and comparison of its interim consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As mentioned in Note 16 Revenue and other income, as most of the income from the Company is generated by ongoing contracts that primarily depend on performance obligations not correlated to seasonal trends, it is considered that the Company activities are not seasonal. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Therefore, the following unaudited interim condensed consolidated financial statements and corresponding notes will not include comparative information other than that mentioned in IAS 34.20.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and payment of research tax credit (CIR) receivables. The Company continues to pursue its research and development activities for its product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning multiple years. The Company does not expect to generate revenue from product sales in the near future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In March 2025, the Company and Janssen executed an amendment to the License Agreement. The amendment provides that Janssen will assume almost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;full financial responsibility for NANORAY-312&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;, the ongoing pivotal Phase 3 trial through completion, less a small portion of costs that will remain covered by the Company, allowing the Company to extend its cash runway and to reduce its operating cash outflows post this amendment, including the period beyond mid-2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As of June 30, 2025, the Company had &#x20ac;28.8&#160;million of available cash and cash equivalents, consisting of cash and short-term bank deposits that are liquid and easily convertible within 3 months without penalty or risk of change in value (see Note 9. &#x2013; Cash and cash equivalents).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As of the date of authorization of the issuance of these interim condensed consolidated financial statements, the Company estimates, given its current cost structure and its projected expenditure commitments, that it should have sufficient funds to finance its activities into mid-2026. Accordingly, the Company&#x2019;s current cash and cash equivalents will not be sufficient to cover its operating needs for at least the next 12 months following the date of the issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Based on its current business plan, the Company estimates that to meet its obligations over the next 12 months, it will require additional liquidity in the range of &#x20ac;8 to &#x20ac;10&#160;million. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company&#x2019;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;This estimate is based on the Company&#x2019;s current business plan and excludes (i) other expenses resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing. The Company may have based this estimate on incorrect assumptions and may have to use its resources sooner than anticipated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;To finance its activities beyond mid-2026, the Co&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;mpany needs to raise additional funds and is in active discussions regarding non-dilutive financing, intended to meaningfully extend its c&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;ash runway beyond the 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In addition, further to the current discussions, the Company may seek to raise additional funds to achieve its development goals for its research and development programs through: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;other potential public or private securities offerings, &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;potential strategic transactions such as business development partnerships; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;R&amp;amp;D project subsidies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Based on the above, the interim condensed consolidated financial statements as of and for the six-month period ended June 30, 2025, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future and to address its liquidity challenges by pursuing activities to generate additional cash inflows and by closely managing its operating expenditures. As such, they do not include any adjustments related to the value or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company cannot guarantee that it will be able to obtain the necessary financing, through any of the foregoing measures or otherwise, to meet its needs or to obtain funds at acceptable terms and conditions, on a timely basis, or at all, especially considering the generally challenging environment for financing of biotech companies. If the Company is unable to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any approved product or be unable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;to expand its operations or otherwise capitalize on its business opportunities, as desired, which would impair the Company&#x2019;s prospects and business operations.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:StatementOfIFRSCompliance contextRef="c-1" id="f-267">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements as of June&#160;30, 2025 and for the six-month period ended June&#160;30, 2025 were prepared under the supervision of the management of the Company and were submitted by the Executive Board to the review of the Supervisory Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;All amounts in the unaudited interim condensed consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated  financial statements of the Company have been prepared in compliance with IAS 34 &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Interim Financial Reporting&#x201d; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which provides for the presentation of selected explanatory notes. As they are unaudited interim condensed consolidated  financial statements, the accompanying notes do not contain all the disclosures required for annual consolidated financial statements and should therefore be read in conjunction with the Company&#x2019;s consolidated financial statements prepared in accordance with IFRS &#xae; Accounting Standards, as of and for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of the unaudited interim condensed consolidated financial statements in accordance with IAS 34 &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Interim Financial Reporting&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; requires the use of estimates and assumptions that affect the amounts and information disclosed in the condensed consolidated financial statements. See Note 3.2 Use of judgement, estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June&#160;30, 2025 are identical to those used for the year ended December&#160;31, 2024 except for the standards listed below that required adoption in 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2025 in the European Union primarily concern:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.47pt"&gt;Amendment to IAS 21 Lack of Exchangeability, the Effects of Changes in Foreign Exchange Rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;This amendment had no material impact on the Company&#x2019;s unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable are:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt"&gt;Amendments to IFRS 9 and IFRS 7 &#x2013; Classification and Measurement of Financial Instruments &#x2013; as of January 1, 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt"&gt;Amendments to IFRS 9 and IFRS 7 &#x2013; Contracts Referencing Nature-dependent Electricity &#x2013; as of January 1, 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt"&gt;Annual Improvements to IFRS Accounting Standards, as of January 1, 2026&#x2013; Amendments to:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;IFRS 1 First-time Adoption of International Financial Reporting Standards;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;IFRS 9 Financial Instruments;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;IFRS 10 Consolidated Financial Statements; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;IAS 7 Statement of Cash flows&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt"&gt;New standard &#x2013; IFRS 18 &#x2013; Presentation and Disclosure in Financial Statements &#x2013; as of January 1, 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#x25a0;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.47pt"&gt;New standard &#x2013; IFRS 19 &#x2013; Subsidiaries without Public Accountability: Disclosures&#x2013; as of January 1, 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company is currently assessing the applicability and impact of these new standards, interpretations and amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Seasonality of the Company&#x2019;s activities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;According to IAS 34 &#x2013; &#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Financial Reporting&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x201d;, an entity whose business is highly seasonal should present financial information for the twelve months up to the end of the interim period and additional comparative information for the prior twelve-month period in the interim condensed consolidated financial statements in order to provide a better understanding and comparison of its interim consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As mentioned in Note 16 Revenue and other income, as most of the income from the Company is generated by ongoing contracts that primarily depend on performance obligations not correlated to seasonal trends, it is considered that the Company activities are not seasonal. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Therefore, the following unaudited interim condensed consolidated financial statements and corresponding notes will not include comparative information other than that mentioned in IAS 34.20.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and payment of research tax credit (CIR) receivables. The Company continues to pursue its research and development activities for its product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning multiple years. The Company does not expect to generate revenue from product sales in the near future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In March 2025, the Company and Janssen executed an amendment to the License Agreement. The amendment provides that Janssen will assume almost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;full financial responsibility for NANORAY-312&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;, the ongoing pivotal Phase 3 trial through completion, less a small portion of costs that will remain covered by the Company, allowing the Company to extend its cash runway and to reduce its operating cash outflows post this amendment, including the period beyond mid-2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As of June 30, 2025, the Company had &#x20ac;28.8&#160;million of available cash and cash equivalents, consisting of cash and short-term bank deposits that are liquid and easily convertible within 3 months without penalty or risk of change in value (see Note 9. &#x2013; Cash and cash equivalents).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As of the date of authorization of the issuance of these interim condensed consolidated financial statements, the Company estimates, given its current cost structure and its projected expenditure commitments, that it should have sufficient funds to finance its activities into mid-2026. Accordingly, the Company&#x2019;s current cash and cash equivalents will not be sufficient to cover its operating needs for at least the next 12 months following the date of the issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Based on its current business plan, the Company estimates that to meet its obligations over the next 12 months, it will require additional liquidity in the range of &#x20ac;8 to &#x20ac;10&#160;million. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company&#x2019;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;This estimate is based on the Company&#x2019;s current business plan and excludes (i) other expenses resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing. The Company may have based this estimate on incorrect assumptions and may have to use its resources sooner than anticipated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;To finance its activities beyond mid-2026, the Co&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;mpany needs to raise additional funds and is in active discussions regarding non-dilutive financing, intended to meaningfully extend its c&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;ash runway beyond the 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In addition, further to the current discussions, the Company may seek to raise additional funds to achieve its development goals for its research and development programs through: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;other potential public or private securities offerings, &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;potential strategic transactions such as business development partnerships; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;R&amp;amp;D project subsidies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Based on the above, the interim condensed consolidated financial statements as of and for the six-month period ended June 30, 2025, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future and to address its liquidity challenges by pursuing activities to generate additional cash inflows and by closely managing its operating expenditures. As such, they do not include any adjustments related to the value or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company cannot guarantee that it will be able to obtain the necessary financing, through any of the foregoing measures or otherwise, to meet its needs or to obtain funds at acceptable terms and conditions, on a timely basis, or at all, especially considering the generally challenging environment for financing of biotech companies. If the Company is unable to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any approved product or be unable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;to expand its operations or otherwise capitalize on its business opportunities, as desired, which would impair the Company&#x2019;s prospects and business operations.&lt;/span&gt;&lt;/div&gt;</ifrs-full:StatementOfIFRSCompliance>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-5" id="f-268" unitRef="eur">28800000</ifrs-full:CashAndCashEquivalents>
    <nbx:AdditionalLiquidityBusinessObligations contextRef="c-43" decimals="-5" id="f-269" unitRef="eur">8000000</nbx:AdditionalLiquidityBusinessObligations>
    <nbx:AdditionalLiquidityBusinessObligations contextRef="c-44" decimals="-5" id="f-270" unitRef="eur">10000000</nbx:AdditionalLiquidityBusinessObligations>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="c-1" id="f-271">Consolidated principles and methods&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;3.1 BASIS OF CONSOLIDATION&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidated entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the consolidation scope is comprised of one parent entity and is similar to that of December&#160;31, 2024 as Nanobiotix S.A. has three wholly owned subsidiaries: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Nanobiotix Corp., incorporated in the State of Delaware in September 2014 and located in the USA,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Nanobiotix Germany GmbH, created in October 2017 and located in Germany,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Nanobiotix Spain S.L.U., created in December 2017 and located in Spain.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accordingly, the unaudited interim condensed consolidated financial statements as of June&#160;30, 2025 include the operations of each of these subsidiaries, to the extent applicable, from the date of their incorporation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign currency transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements are presented in thousands of euros, which is the Group&#x2019;s presentation currency and the functional currency of the parent company, Nanobiotix S.A. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate for the statement of financial position, whereas, items of the statement of operations, statement of comprehensive loss and statement of cash flow are converted at the average exchange rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The dollar-to-euro exchange rate used in the unaudited interim condensed consolidated financial statements to convert the Group transactions denominated in US dollars were a closing of $1.1720 as of June&#160;30, 2025 and an average of $1.0930 for the six-month period ended June&#160;30, 2025 compared with $1.0705 and $1.0812 respectively, as of and for the six-month period ended June&#160;30, 2024 (source: Banque de France).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:72pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;3.2. USE OF JUDGEMENT, ESTIMATES AND ASSUMPTIONS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited interim condensed consolidated financial statements in accordance with IAS 34 requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. A sensitivity analysis may be presented if the results differ materially based on the application of different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the measurement of financial instruments (fair value and amortized costs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Measurement of share-based payments &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of stock options (OSA), founders&#x2019; warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Executive and Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., option vesting terms) and market data (e.g., to determine expected share volatility) (See Note 18 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred tax assets &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company&#x2019;s assets and liabilities that appear in its financial statements. The primary source of deferred tax assets are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow for sufficiently reliable income projections to be made, the Company has not recognized deferred tax assets in relation to tax losses carry forwards in the statements of consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical trial accruals &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses, although not yet billed in full, are estimated quarterly for each study and a provision is recognized accordingly. (See Note 14.1 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade and other payables&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for information regarding the clinical trial accruals as of June 30, 2025 and December 31, 2024).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In order to determine the amount and timing of revenue under the contract with customers, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company, determining the stand alone selling price of the performance obligations, the transaction price allocation and the timing of satisfaction of support services provided to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Determining the distinctiveness of performance obligations&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014; A promised good or service will need to be recognized separately in revenue if it is distinct as defined in IFRS 15. In determining whether the performance obligation is separate, the Company analyses if (i) the good or service is distinct in absolute terms, i.e. it can be useful to the customer, either on its own or in combination with resources that the customer can obtain separately; and if (ii) the good or service is distinct in the context of the contract, i.e. it can be identified separately from the other goods and services in the contract because there is not a high degree of interdependence or integration between this element and the other goods or services promised in the contract. If either of these two conditions is not met, the good or service is not distinct, and the Company must group it with other promised goods or services until it becomes a distinct group of goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allocation of transaction price to performance obligations&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014; A contract&#x2019;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For contracts with multiple performance obligations, the Company allocates the contract&#x2019;s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable consideration&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014; Due to the nature of the work required to be performed on many of the Company&#x2019;s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration and license agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals). The Company includes the related amounts in the estimated transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue on a cumulative catch&#x2011;up basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue recognized over time and input method&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014; Some of the Company&#x2019;s performance obligations are satisfied over time as work progresses, thus revenue is recognized over time, using an input measure of progress as it best depicts the transfer of control to the customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract modification&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. The effect that the contract modification has on the transaction price, and on the entity's measure of progress towards complete satisfaction of the performance obligation, is recognized as an adjustment to revenue at the date of the contract modification (i.e. on a cumulative catch-up basis). The Company is required to use significant judgments with respect to identifying and determining the amended standalone selling price of the performance obligations, the transaction price allocation and the adjusted timing of satisfaction of the remaining services provided to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note 16 - to the Company&#x2019;s consolidated financial statements as of and for the year ended December 31, 2024 for additional detail regarding the Company&#x2019;s accounting policies and specific judgments made with regard to revenue recognition, and for its additional sources of revenue and other income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Measurement of financial assets and liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At the renegotiation date in October 2022, the fair value measurement of the EIB loan required the Company to determine:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;the discount rate of the new liability executed in October 2022. The discount rate reflects the company&#x2019;s credit risk at the Amendment Agreement date as well as a premium to reflect uncertainties associated with the timing and the amount of the royalties&#x2019; payment. The Company involved external financial instruments valuation specialists to support in determining the average discount rate;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;the amount of additional interest (&#x201c;royalties&#x201d;, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing upon commercialization. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to annual sales turnover relating to JNJ-1900 (NBTXR3) through specific Company&#x2019;s license agreement. For the purpose of measuring the fair value of the EIB loan, the Company forecasts expected sales relating to JNJ-1900 (NBTXR3) during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see Notes 4.4 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financing Agreement with the European Investment Bank (&#x201c;EIB&#x201d;)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and 13 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to the Company&#x2019;s consolidated financial statements as of and for the year ended December 31, 2024, for details about this loan and the accounting treatment applied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;Subsequent to the estimate of the fair value of the EIB loan performed at the renegotiation date, the debt has been measured at amortized cost based on the revised best estimate of the future cash flows related to the debt at each closing date. Accordingly, the Company determines the amount of additional interest as described above. Any subsequent adjustment of flows indexed to turnover are discounted at the original effective interest rate and the adjustment is recognized in profit or loss under the &#x201c;catch-up&#x201d; method. As of June 30, 2025, the fair value measurement of the EIB loan has been reassessed by the Company for disclosure purpose.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <nbx:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock contextRef="c-1" id="f-272">BASIS OF CONSOLIDATION&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidated entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the consolidation scope is comprised of one parent entity and is similar to that of December&#160;31, 2024 as Nanobiotix S.A. has three wholly owned subsidiaries: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Nanobiotix Corp., incorporated in the State of Delaware in September 2014 and located in the USA,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Nanobiotix Germany GmbH, created in October 2017 and located in Germany,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Nanobiotix Spain S.L.U., created in December 2017 and located in Spain.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accordingly, the unaudited interim condensed consolidated financial statements as of June&#160;30, 2025 include the operations of each of these subsidiaries, to the extent applicable, from the date of their incorporation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign currency transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements are presented in thousands of euros, which is the Group&#x2019;s presentation currency and the functional currency of the parent company, Nanobiotix S.A. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate for the statement of financial position, whereas, items of the statement of operations, statement of comprehensive loss and statement of cash flow are converted at the average exchange rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The dollar-to-euro exchange rate used in the unaudited interim condensed consolidated financial statements to convert the Group transactions denominated in US dollars were a closing of $1.1720 as of June&#160;30, 2025 and an average of $1.0930 for the six-month period ended June&#160;30, 2025 compared with $1.0705 and $1.0812 respectively, as of and for the six-month period ended June&#160;30, 2024 (source: Banque de France).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.&lt;/span&gt;&lt;/div&gt;</nbx:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock>
    <nbx:NumberOfSubsidiaries
      contextRef="c-2"
      decimals="INF"
      id="f-273"
      unitRef="subsidiary">3</nbx:NumberOfSubsidiaries>
    <ifrs-full:ClosingForeignExchangeRate contextRef="c-2" decimals="4" id="f-274" unitRef="number">1.1720</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="c-1" decimals="4" id="f-275" unitRef="number">1.0930</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate contextRef="c-39" decimals="4" id="f-276" unitRef="number">1.0705</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="c-4" decimals="4" id="f-277" unitRef="number">1.0812</ifrs-full:AverageForeignExchangeRate>
    <nbx:DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock contextRef="c-1" id="f-278">USE OF JUDGEMENT, ESTIMATES AND ASSUMPTIONS&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited interim condensed consolidated financial statements in accordance with IAS 34 requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. A sensitivity analysis may be presented if the results differ materially based on the application of different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the measurement of financial instruments (fair value and amortized costs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Measurement of share-based payments &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of stock options (OSA), founders&#x2019; warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Executive and Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., option vesting terms) and market data (e.g., to determine expected share volatility) (See Note 18 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred tax assets &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company&#x2019;s assets and liabilities that appear in its financial statements. The primary source of deferred tax assets are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow for sufficiently reliable income projections to be made, the Company has not recognized deferred tax assets in relation to tax losses carry forwards in the statements of consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical trial accruals &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses, although not yet billed in full, are estimated quarterly for each study and a provision is recognized accordingly. (See Note 14.1 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade and other payables&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for information regarding the clinical trial accruals as of June 30, 2025 and December 31, 2024).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In order to determine the amount and timing of revenue under the contract with customers, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company, determining the stand alone selling price of the performance obligations, the transaction price allocation and the timing of satisfaction of support services provided to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Determining the distinctiveness of performance obligations&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014; A promised good or service will need to be recognized separately in revenue if it is distinct as defined in IFRS 15. In determining whether the performance obligation is separate, the Company analyses if (i) the good or service is distinct in absolute terms, i.e. it can be useful to the customer, either on its own or in combination with resources that the customer can obtain separately; and if (ii) the good or service is distinct in the context of the contract, i.e. it can be identified separately from the other goods and services in the contract because there is not a high degree of interdependence or integration between this element and the other goods or services promised in the contract. If either of these two conditions is not met, the good or service is not distinct, and the Company must group it with other promised goods or services until it becomes a distinct group of goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allocation of transaction price to performance obligations&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014; A contract&#x2019;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For contracts with multiple performance obligations, the Company allocates the contract&#x2019;s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable consideration&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014; Due to the nature of the work required to be performed on many of the Company&#x2019;s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration and license agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals). The Company includes the related amounts in the estimated transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue on a cumulative catch&#x2011;up basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue recognized over time and input method&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014; Some of the Company&#x2019;s performance obligations are satisfied over time as work progresses, thus revenue is recognized over time, using an input measure of progress as it best depicts the transfer of control to the customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract modification&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. The effect that the contract modification has on the transaction price, and on the entity's measure of progress towards complete satisfaction of the performance obligation, is recognized as an adjustment to revenue at the date of the contract modification (i.e. on a cumulative catch-up basis). The Company is required to use significant judgments with respect to identifying and determining the amended standalone selling price of the performance obligations, the transaction price allocation and the adjusted timing of satisfaction of the remaining services provided to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note 16 - to the Company&#x2019;s consolidated financial statements as of and for the year ended December 31, 2024 for additional detail regarding the Company&#x2019;s accounting policies and specific judgments made with regard to revenue recognition, and for its additional sources of revenue and other income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Measurement of financial assets and liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At the renegotiation date in October 2022, the fair value measurement of the EIB loan required the Company to determine:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;the discount rate of the new liability executed in October 2022. The discount rate reflects the company&#x2019;s credit risk at the Amendment Agreement date as well as a premium to reflect uncertainties associated with the timing and the amount of the royalties&#x2019; payment. The Company involved external financial instruments valuation specialists to support in determining the average discount rate;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;the amount of additional interest (&#x201c;royalties&#x201d;, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing upon commercialization. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to annual sales turnover relating to JNJ-1900 (NBTXR3) through specific Company&#x2019;s license agreement. For the purpose of measuring the fair value of the EIB loan, the Company forecasts expected sales relating to JNJ-1900 (NBTXR3) during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see Notes 4.4 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financing Agreement with the European Investment Bank (&#x201c;EIB&#x201d;)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and 13 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to the Company&#x2019;s consolidated financial statements as of and for the year ended December 31, 2024, for details about this loan and the accounting treatment applied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;Subsequent to the estimate of the fair value of the EIB loan performed at the renegotiation date, the debt has been measured at amortized cost based on the revised best estimate of the future cash flows related to the debt at each closing date. Accordingly, the Company determines the amount of additional interest as described above. Any subsequent adjustment of flows indexed to turnover are discounted at the original effective interest rate and the adjustment is recognized in profit or loss under the &#x201c;catch-up&#x201d; method. As of June 30, 2025, the fair value measurement of the EIB loan has been reassessed by the Company for disclosure purpose.&lt;/span&gt;&lt;/div&gt;</nbx:DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock>
    <nbx:DisclosureOfSignificantTransactionsTextBlock contextRef="c-1" id="f-279">Significant transactions&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The significant transactions are those described in the consolidated financial statements prepared in accordance with IFRS &#xae; Accounting Standards for the year ended December 31, 2024, except regarding the Janssen Amendment Agreement which was signed on March 17, 2025 and described in Note 1 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Company Information&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and Note 16 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues and Other Income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfSignificantTransactionsTextBlock>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c-1" id="f-280">Intangible assets&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in intangible assets breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.126%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Transfer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;734&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;742&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of intangible assets (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt"&gt;Expenses for the period are detailed in Note 17.4 Depreciation, amortization and provisions expenses&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;No impairment losses were recognized in application of IAS 36 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Assets&lt;/span&gt; in the period presented.</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory contextRef="c-1" id="f-281">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in intangible assets breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.126%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Transfer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;734&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;742&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of intangible assets (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt"&gt;Expenses for the period are detailed in Note 17.4 Depreciation, amortization and provisions expenses&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-45" decimals="-3" id="f-282" unitRef="eur">65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-46" decimals="-3" id="f-283" unitRef="eur">7000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-46" decimals="-3" id="f-284" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-46" decimals="-3" id="f-285" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-47" decimals="-3" id="f-286" unitRef="eur">72000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-48" decimals="-3" id="f-287" unitRef="eur">669000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-49" decimals="-3" id="f-288" unitRef="eur">1000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-49" decimals="-3" id="f-289" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-49" decimals="-3" id="f-290" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-50" decimals="-3" id="f-291" unitRef="eur">669000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-51" decimals="-3" id="f-292" unitRef="eur">734000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-52" decimals="-3" id="f-293" unitRef="eur">8000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-52" decimals="-3" id="f-294" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-52" decimals="-3" id="f-295" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-53" decimals="-3" id="f-296" unitRef="eur">742000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-54" decimals="-3" id="f-297" unitRef="eur">-65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-55" decimals="-3" id="f-298" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-55" decimals="-3" id="f-299" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-55" decimals="-3" id="f-300" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-56" decimals="-3" id="f-301" unitRef="eur">-65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-57" decimals="-3" id="f-302" unitRef="eur">-662000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-58" decimals="-3" id="f-303" unitRef="eur">-2000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-58" decimals="-3" id="f-304" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-58" decimals="-3" id="f-305" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-59" decimals="-3" id="f-306" unitRef="eur">-663000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-60" decimals="-3" id="f-307" unitRef="eur">-727000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-61" decimals="-3" id="f-308" unitRef="eur">-2000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-61" decimals="-3" id="f-309" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-61" decimals="-3" id="f-310" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-62" decimals="-3" id="f-311" unitRef="eur">-729000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-3" id="f-312" unitRef="eur">7000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-313" unitRef="eur">6000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-314" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-315" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-3" id="f-316" unitRef="eur">13000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="INF" id="f-317" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-318">Property, plant and equipment&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in property, plant and equipment is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.725%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;movements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&amp;amp; transfer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tangible assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepayments on tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;16,559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;16,504&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of tangible assets(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(11,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(11,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,863&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.59pt"&gt;Expenses for the period are detailed in Note 17.4 Depreciation, amortization and provisions expenses &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;No impairment losses were recognized in application of IAS 36 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Assets&lt;/span&gt; in the period presented.</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-319">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in property, plant and equipment is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.725%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;movements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&amp;amp; transfer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tangible assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepayments on tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;16,559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;16,504&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of tangible assets(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(11,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(11,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,863&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;Expenses for the period are detailed in Note 17.4 Depreciation, amortization and provisions expenses</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-63" decimals="-3" id="f-320" unitRef="eur">3390000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-64" decimals="-3" id="f-321" unitRef="eur">65000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-64" decimals="-3" id="f-322" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-64" decimals="-3" id="f-323" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-64" decimals="-3" id="f-324" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-65" decimals="-3" id="f-325" unitRef="eur">3455000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-66" decimals="-3" id="f-326" unitRef="eur">9026000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-67" decimals="-3" id="f-327" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-67" decimals="-3" id="f-328" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-67" decimals="-3" id="f-329" unitRef="eur">-92000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-67" decimals="-3" id="f-330" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-68" decimals="-3" id="f-331" unitRef="eur">8934000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-69" decimals="-3" id="f-332" unitRef="eur">2492000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-70" decimals="-3" id="f-333" unitRef="eur">61000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-70" decimals="-3" id="f-334" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-70" decimals="-3" id="f-335" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-70" decimals="-3" id="f-336" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-71" decimals="-3" id="f-337" unitRef="eur">2553000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-72" decimals="-3" id="f-338" unitRef="eur">1258000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-73" decimals="-3" id="f-339" unitRef="eur">25000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-73" decimals="-3" id="f-340" unitRef="eur">105000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-73" decimals="-3" id="f-341" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-73" decimals="-3" id="f-342" unitRef="eur">-5000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-74" decimals="-3" id="f-343" unitRef="eur">1173000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-75" decimals="-3" id="f-344" unitRef="eur">141000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-76" decimals="-3" id="f-345" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-76" decimals="-3" id="f-346" unitRef="eur">3000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-76" decimals="-3" id="f-347" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-76" decimals="-3" id="f-348" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-77" decimals="-3" id="f-349" unitRef="eur">138000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-78" decimals="-3" id="f-350" unitRef="eur">250000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-79" decimals="-3" id="f-351" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-79" decimals="-3" id="f-352" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-79" decimals="-3" id="f-353" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-79" decimals="-3" id="f-354" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-80" decimals="-3" id="f-355" unitRef="eur">250000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-51" decimals="-3" id="f-356" unitRef="eur">16559000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-52" decimals="-3" id="f-357" unitRef="eur">150000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-52" decimals="-3" id="f-358" unitRef="eur">108000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-52" decimals="-3" id="f-359" unitRef="eur">-92000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-52" decimals="-3" id="f-360" unitRef="eur">-5000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-53" decimals="-3" id="f-361" unitRef="eur">16504000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-81" decimals="-3" id="f-362" unitRef="eur">-2582000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-82" decimals="-3" id="f-363" unitRef="eur">-134000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-82" decimals="-3" id="f-364" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-82" decimals="-3" id="f-365" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-82" decimals="-3" id="f-366" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-83" decimals="-3" id="f-367" unitRef="eur">-2716000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-84" decimals="-3" id="f-368" unitRef="eur">-5473000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-85" decimals="-3" id="f-369" unitRef="eur">-522000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-85" decimals="-3" id="f-370" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-85" decimals="-3" id="f-371" unitRef="eur">65000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-85" decimals="-3" id="f-372" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-86" decimals="-3" id="f-373" unitRef="eur">-5929000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-87" decimals="-3" id="f-374" unitRef="eur">-1945000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-88" decimals="-3" id="f-375" unitRef="eur">-90000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-88" decimals="-3" id="f-376" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-88" decimals="-3" id="f-377" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-88" decimals="-3" id="f-378" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-89" decimals="-3" id="f-379" unitRef="eur">-2035000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-90" decimals="-3" id="f-380" unitRef="eur">-1021000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-91" decimals="-3" id="f-381" unitRef="eur">-52000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-91" decimals="-3" id="f-382" unitRef="eur">-108000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-91" decimals="-3" id="f-383" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-91" decimals="-3" id="f-384" unitRef="eur">4000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-92" decimals="-3" id="f-385" unitRef="eur">-961000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-60" decimals="-3" id="f-386" unitRef="eur">-11021000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-61" decimals="-3" id="f-387" unitRef="eur">-798000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-61" decimals="-3" id="f-388" unitRef="eur">-108000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-61" decimals="-3" id="f-389" unitRef="eur">65000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-61" decimals="-3" id="f-390" unitRef="eur">4000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-62" decimals="-3" id="f-391" unitRef="eur">-11641000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-392" unitRef="eur">5538000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-93" decimals="-3" id="f-393" unitRef="eur">-647000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-93" decimals="-3" id="f-394" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-395" unitRef="eur">-27000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-396" unitRef="eur">-1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2" decimals="-3" id="f-397" unitRef="eur">4863000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-1" decimals="INF" id="f-398" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock contextRef="c-1" id="f-399">Non-current financial assets &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in non-current financial assets breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.517%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Security &lt;br/&gt;deposits paid&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value as of Net book value as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;406&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock>
    <nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock contextRef="c-1" id="f-400">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in non-current financial assets breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.517%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Security &lt;br/&gt;deposits paid&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value as of Net book value as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;406&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-94" decimals="-3" id="f-401" unitRef="eur">406000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets contextRef="c-95" decimals="-3" id="f-402" unitRef="eur">3000</ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets contextRef="c-95" decimals="-3" id="f-403" unitRef="eur">0</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughOtherMovementsFinancialAssets contextRef="c-95" decimals="-3" id="f-404" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughOtherMovementsFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets contextRef="c-95" decimals="-3" id="f-405" unitRef="eur">-1000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-96" decimals="-3" id="f-406" unitRef="eur">409000</ifrs-full:NoncurrentFinancialAssets>
    <nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock contextRef="c-1" id="f-407">Trade receivables and other current assets&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;8.1 TRADE RECEIVABLES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,837&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,977&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, trade receivables balance mainly relates to Janssen revenue not yet collected, which is comprised of product supplies for 1.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;8.2 OTHER CURRENT ASSETS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current assets break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research tax credit receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;9,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, &#x20ac;1.9 million prepaid expenses mainly relate to research agreements with MD Anderson for &#x20ac;1.1&#160;million as compared to &#x20ac;1.2&#160;million as of December 31, 2024, &#x20ac;0.8&#160;million related to invoices received for third party services beyond the current closing period, mainly related to IT, insurance and other invoices related to annual administrative contracts as compared to &#x20ac;1.1&#160;million as of December 31, 2024, and &#x20ac;46&#160;thousand related to purchases of clinical product not yet consumed as of closing date as compared to &#x20ac;0.6&#160;million as of December 31, 2024, this significant decrease is explained by the sales dynamics of clinical products sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Other receivables increased by &#x20ac;0.2&#160;million and mainly comprised of advance payments to suppliers amounting of &#x20ac;1.3&#160;million as of June&#160;30, 2025, as compared to &#x20ac;1.1&#160;million as of December&#160;31, 2024. Most of these advance payments have been made to Contract Research Organization (CRO) and to Clinical Services Providers in connection with the execution of the clinical trial NANORAY-312.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research tax credit &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is eligible for the Research Tax Credit - CIR (Cr&#xe9;dit d&#x2019;Imp&#xf4;t Recherche) issued by the French and U.S. tax authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in research tax credit receivables breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receivable as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,369&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025 research tax credit &#x2013; Nanobiotix S.A. (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025 research tax credit &#x2013; Nanobiotix Corp (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receipt of 2024 research tax credit - Nanobiotix Corp&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receivable as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,792&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;See Note 16 - Revenue and other income.&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock>
    <nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,837&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,977&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock>
    <ifrs-full:CurrentTradeReceivables contextRef="c-2" decimals="-3" id="f-409" unitRef="eur">1837000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-3" id="f-410" unitRef="eur">2977000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-2" decimals="-3" id="f-411" unitRef="eur">1837000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-3" id="f-412" unitRef="eur">2977000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-97" decimals="-5" id="f-413" unitRef="eur">1700000</ifrs-full:CurrentTradeReceivables>
    <nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock contextRef="c-1" id="f-414">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current assets break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research tax credit receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;9,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax contextRef="c-2" decimals="-3" id="f-415" unitRef="eur">4792000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax contextRef="c-3" decimals="-3" id="f-416" unitRef="eur">3369000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentValueAddedTaxReceivables contextRef="c-2" decimals="-3" id="f-417" unitRef="eur">1185000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables contextRef="c-3" decimals="-3" id="f-418" unitRef="eur">1104000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-2" decimals="-3" id="f-419" unitRef="eur">1925000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-3" decimals="-3" id="f-420" unitRef="eur">3195000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables contextRef="c-2" decimals="-3" id="f-421" unitRef="eur">1332000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c-3" decimals="-3" id="f-422" unitRef="eur">1085000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentAssets contextRef="c-2" decimals="-3" id="f-423" unitRef="eur">9234000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-3" decimals="-3" id="f-424" unitRef="eur">8753000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-2" decimals="-5" id="f-425" unitRef="eur">1900000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-98" decimals="-5" id="f-426" unitRef="eur">1100000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-99" decimals="-5" id="f-427" unitRef="eur">1200000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-100" decimals="-5" id="f-428" unitRef="eur">800000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-101" decimals="-5" id="f-429" unitRef="eur">1100000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-102" decimals="-3" id="f-430" unitRef="eur">46000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-103" decimals="-5" id="f-431" unitRef="eur">600000</ifrs-full:CurrentPrepaidExpenses>
    <nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables contextRef="c-104" decimals="-5" id="f-432" unitRef="eur">200000</nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables>
    <ifrs-full:CurrentAdvancesToSuppliers contextRef="c-2" decimals="-5" id="f-433" unitRef="eur">1300000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers contextRef="c-3" decimals="-5" id="f-434" unitRef="eur">1100000</ifrs-full:CurrentAdvancesToSuppliers>
    <nbx:DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock contextRef="c-1" id="f-435">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in research tax credit receivables breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receivable as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,369&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025 research tax credit &#x2013; Nanobiotix S.A. (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025 research tax credit &#x2013; Nanobiotix Corp (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receipt of 2024 research tax credit - Nanobiotix Corp&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receivable as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,792&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;See Note 16 - Revenue and other income.&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax contextRef="c-3" decimals="-3" id="f-436" unitRef="eur">3369000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit contextRef="c-105" decimals="-3" id="f-437" unitRef="eur">1616000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit contextRef="c-106" decimals="-3" id="f-438" unitRef="eur">-69000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit>
    <nbx:ProceedsFromIncomeTaxCredit contextRef="c-107" decimals="-3" id="f-439" unitRef="eur">-124000</nbx:ProceedsFromIncomeTaxCredit>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax contextRef="c-2" decimals="-3" id="f-440" unitRef="eur">4792000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c-1" id="f-441">Cash and cash equivalents&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalent break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and bank accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;28,818&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;49,737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, net cash and cash equivalents decreased by &#x20ac;20.9&#160;million as compared to December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The short-term bank deposits correspond exclusively to term deposit transactions that have been settled in July 2025.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock contextRef="c-1" id="f-442">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalent break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and bank accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;28,818&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;49,737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock>
    <ifrs-full:Cash contextRef="c-2" decimals="-3" id="f-443" unitRef="eur">4693000</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c-3" decimals="-3" id="f-444" unitRef="eur">5309000</ifrs-full:Cash>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-2" decimals="-3" id="f-445" unitRef="eur">24125000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-3" decimals="-3" id="f-446" unitRef="eur">44427000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-3" id="f-447" unitRef="eur">28818000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-448" unitRef="eur">49737000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-5" id="f-449" unitRef="eur">-20900000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-450">Share Capital&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;10.1 CAPITAL ISSUED&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Detail of share capital transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.672%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.731%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands or number of shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nature of transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Share Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Premiums related to share capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;312,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;47,426,851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 27, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital increase AGA 2023-P1 and AGA 2023-P2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;809,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;312,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;48,236,671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, the share capital was &#x20ac;1,447&#160;thousand divided into 48,236,671&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#202124;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;fully paid up ordinary shares, each with a par value of &#x20ac;0.03.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allocation of prior period (loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The negative net result for the year 2023 of &#x20ac;68.1&#160;million has been fully allocated to reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;10.2 FOUNDER&#x2019;S WARRANTS, WARRANTS, STOCK OPTIONS AND FREE SHARES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, there are three different types of securities and other valid instruments entitling their holders to a stake in the Company's share capital: warrant (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;bons de souscription d&#x2019;actions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; or BSA), founders&#x2019; warrant (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;bons de souscription de parts de cr&#xe9;ateur d&#x2019;entreprise&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; or BSPCE) and stock option (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;options de souscription ou d&#x2019;achat d&#x2019;actions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; or OSA).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At a meeting on February 18, 2025, the Executive Board, acting pursuant to delegations granted by the Company&#x2019;s shareholders&#x2019; meeting held on May 28, 2024, granted to certain employees of the Group 8,000 stock options, each giving its holder the right to subscribe one ordinary share, each with a par value of &#x20ac;0.03 and at a price of &#x20ac;3.36 (share premium included). Such stock options are governed by the 2025 stock option plan, adopted by the Executive Board on February 18, 2025 (the &#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025 Stock Option Plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The ordinary stock options are exercisable as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt"&gt;up to one-third of the ordinary stock options as from February 18, 2026;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x25aa;      an additional one-third of the ordinary stock options as from February 18, 2027,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x25aa;      the balance, i.e., one-third of the ordinary stock options as from February 18, 2028,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;subject to, for each increment, a continued service condition, and in any case, no later than 10 years after the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At a meeting on May 16, 2025, the Executive Board, acting pursuant to delegations granted by the Company&#x2019;s shareholders&#x2019; meeting held on May 28, 2024,, granted to certain employees of the Group and members of the Executive Board 1,241,005 stock options, each giving its holder the right to subscribe one ordinary share, each with a par value of &#x20ac;0.03 and at a price of &#x20ac;2.97 (share premium included). Such stock options are governed by the 2025 Stock Option Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The ordinary stock options are exercisable as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt"&gt;up to one-third of the ordinary stock options as from May 16, 2026;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x25aa;      an additional one-third of the ordinary stock options as from May 16, 2027,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x25aa;      the balance, i.e., one-third of the ordinary stock options as from May 16, 2028,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;subject to, for each increment, a continued service condition, and in any case, no later than 10 years after the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Free Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;No free shares were granted in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, the assumptions related to the estimated vesting of the founders&#x2019; warrants, the warrants and performance stock options have been updated (See Note 18 Share-based payments).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-451">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Detail of share capital transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.672%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.731%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands or number of shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nature of transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Share Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Premiums related to share capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;312,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;47,426,851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 27, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital increase AGA 2023-P1 and AGA 2023-P2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;809,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;312,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;48,236,671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-452" unitRef="eur">1423000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-453" unitRef="eur">312743000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c-5" decimals="INF" id="f-454" unitRef="shares">47426851</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:IssueOfEquity contextRef="c-108" decimals="-3" id="f-455" unitRef="eur">24000</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-109"
      decimals="INF"
      id="f-456"
      unitRef="shares">809820</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-14" decimals="-3" id="f-457" unitRef="eur">1447000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-16" decimals="-3" id="f-458" unitRef="eur">312743000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-459"
      unitRef="shares">48236671</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-14" decimals="-3" id="f-460" unitRef="eur">1447000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-461"
      unitRef="shares">48236671</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="c-2"
      decimals="2"
      id="f-462"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:ProfitLoss contextRef="c-110" decimals="-5" id="f-463" unitRef="eur">68100000</ifrs-full:ProfitLoss>
    <nbx:NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes
      contextRef="c-2"
      decimals="INF"
      id="f-464"
      unitRef="security">3</nbx:NumberOfShareBasedPaymentArrangementNumberOfSecurityTypes>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-111"
      decimals="INF"
      id="f-465"
      unitRef="shares">8000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ParValuePerShare
      contextRef="c-112"
      decimals="INF"
      id="f-466"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-111"
      decimals="2"
      id="f-467"
      unitRef="eurPerShare">3.36</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <nbx:ShareBasedPaymentArrangementStockOptionTerm contextRef="c-113" id="f-468">P10Y</nbx:ShareBasedPaymentArrangementStockOptionTerm>
    <nbx:ShareBasedPaymentArrangementStockOptionTerm contextRef="c-114" id="f-469">P10Y</nbx:ShareBasedPaymentArrangementStockOptionTerm>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-114"
      decimals="INF"
      id="f-470"
      unitRef="shares">1241005</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ParValuePerShare
      contextRef="c-115"
      decimals="INF"
      id="f-471"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-114"
      decimals="2"
      id="f-472"
      unitRef="eurPerShare">2.97</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <nbx:ShareBasedPaymentArrangementStockOptionTerm contextRef="c-113" id="f-473">P10Y</nbx:ShareBasedPaymentArrangementStockOptionTerm>
    <nbx:ShareBasedPaymentArrangementStockOptionTerm contextRef="c-114" id="f-474">P10Y</nbx:ShareBasedPaymentArrangementStockOptionTerm>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="c-1" id="f-475">Retirement Obligations&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lump-sum retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total Non-current provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The assumptions used to measure lump-sum retirement benefits as of June 30, 2025 remain unchanged from the assumptions used as of December 31, 2024. See Note 11 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retirement Obligations&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to the consolidated financial statements as of and for the period ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <ifrs-full:DisclosureOfOtherProvisionsExplanatory contextRef="c-1" id="f-476">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lump-sum retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total Non-current provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provisions for disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provisions for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current provisions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;See Note 17.4 Depreciation, amortization and provision expenses for the nature of these decreases</ifrs-full:DisclosureOfOtherProvisionsExplanatory>
    <ifrs-full:OtherProvisions contextRef="c-116" decimals="-3" id="f-477" unitRef="eur">432000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c-117" decimals="-3" id="f-478" unitRef="eur">47000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions contextRef="c-117" decimals="-3" id="f-479" unitRef="eur">0</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-117" decimals="-3" id="f-480" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-118" decimals="-3" id="f-481" unitRef="eur">479000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-119" decimals="-3" id="f-482" unitRef="eur">432000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c-120" decimals="-3" id="f-483" unitRef="eur">47000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions contextRef="c-120" decimals="-3" id="f-484" unitRef="eur">0</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-120" decimals="-3" id="f-485" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-121" decimals="-3" id="f-486" unitRef="eur">479000</ifrs-full:OtherProvisions>
    <ifrs-full:DisclosureOfProvisionsExplanatory contextRef="c-1" id="f-487">Provisions&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provisions for disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provisions for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current provisions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt"&gt;See Note 17.4 Depreciation, amortization and provision expenses for the nature of these decreases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provisions for disputes exclusively include ongoing employee disputes. The &#x20ac;0.2&#160;million net decrease recorded in the first half of 2025 resulted from the settlement of disputes.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfProvisionsExplanatory>
    <ifrs-full:OtherProvisions contextRef="c-122" decimals="-3" id="f-488" unitRef="eur">341000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c-123" decimals="-3" id="f-489" unitRef="eur">7000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions contextRef="c-123" decimals="-3" id="f-490" unitRef="eur">230000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-123" decimals="-3" id="f-491" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-124" decimals="-3" id="f-492" unitRef="eur">118000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-125" decimals="-3" id="f-493" unitRef="eur">96000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c-126" decimals="-3" id="f-494" unitRef="eur">42000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions contextRef="c-126" decimals="-3" id="f-495" unitRef="eur">90000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-126" decimals="-3" id="f-496" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-127" decimals="-3" id="f-497" unitRef="eur">49000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-128" decimals="-3" id="f-498" unitRef="eur">438000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c-129" decimals="-3" id="f-499" unitRef="eur">49000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions contextRef="c-129" decimals="-3" id="f-500" unitRef="eur">320000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-129" decimals="-3" id="f-501" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-130" decimals="-3" id="f-502" unitRef="eur">167000</ifrs-full:OtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions contextRef="c-123" decimals="-5" id="f-503" unitRef="eur">200000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <nbx:DisclosureOfFinancialLiabilitiesFootnoteTextBlock contextRef="c-1" id="f-504">Financial liabilities &lt;div style="padding-left:72pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"&gt;13.1 DETAILS OF FINANCIAL LIABILITIES &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayable BPI loan advances &#x2013; Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PGE loans *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB loan &#x2013; Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,735&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,924&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayable BPI loan advances &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PGE loans *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB loan &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;46,505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;45,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;51,240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;50,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(*)&#x201d;PGE&#x201d;or in French &#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; are state-guaranteed loans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;The table below shows the detail of changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.593%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.916%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Repayable BPI Loan Advances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PGE Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;EIB Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Curadigm Bpi advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;HSBC&lt;br/&gt;&#x201c;PGE&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bpifrance&lt;br/&gt;&#x201c;PGE&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;342&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;40,635&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;50,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease in loans and conditional advances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash flows used in&lt;br/&gt;financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indexation effect on current lease commitment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impact of discounting and catch-up&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated fixed interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated variable interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-cash from financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,083&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,169&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,632&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;43,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;51,240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,262&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;430&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,735&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which Non-Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;43,054&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;46,505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities correspond to the discounted amount of the rentals to be paid over the lease terms for all outstanding contracts falling within the scope of IFRS 16. For the period presented, the main contracts relate to the buildings rented in Paris and in Villejuif&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Repayable BPI loan advances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company received repayable advance from Banque Publique d&#x2019;Investissement (&#x201c;Bpifrance&#x201d;, formerly known as &#x201c;OSEO Innovation&#x201d;). The advance bears 1.56% interest. The repayment of the period amounts to &#x20ac;0.6&#160;million while the amount to be reimbursed corresponds to &#x20ac;1.0&#160;million (as detailed in table Note 13.2 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Due dates of the financial liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; below)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#ff0090;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company obtained a &#x20ac;0.5&#160;million conditional advance from Bpifrance, &#x20ac;0.4&#160;million of which was received at the signature date. The advance is interest-free. The repayment of the period amounts to &#x20ac;0.1&#160;million while the amount to be reimbursed corresponds to &#x20ac;0.3&#160;million (as detailed in table Note 13.2 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Due dates of the financial liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; below).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;PGE loan (&#x201c;Pr&#xea;ts Garantis par l&#x2019;Etat&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company announced in June 2020 that it has received approval for financing from both HSBC and Bpifrance for &#x20ac;5&#160;million each in the form of state-guaranteed loans (&#x201c;Pr&#xea;ts Garantis par l&#x2019;Etat&#x201d;, or &#x201c;PGE&#x201d; in France).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;This loan is booked at amortized cost using an effective interest rate of 0.31%. Reimbursement of the loan started in September 2022 and will continue through mid-2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the six month period ended June 30, 2025, &#x20ac;0.6&#160;million was repaid on the HSBC PGE loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On July 10, 2020, the Company entered into the second &#x20ac;5&#160;million PGE loan with Bpifrance (the &#x2018;&#x2018;Bpifrance PGE Loan&#x2019;&#x2019;). The Bpifrance PGE loan has a 6-year term and is 90% guaranteed by the French State. Starting after its first year anniversary, the Bpifrance PGE loan bears an interest rate of 2.25% per annum, inclusive of an annual State guarantee fee of 1.61% per annum. The principal and interest of the Bpifrance PGE loan is being reimbursed in 20 quarterly installments as from October 31, 2021 through July 26, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the six month period ended June 30, 2025, &#x20ac;0.6&#160;million was repaid on the Bpifrance PGE loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;EIB loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, the Company accounted for the debt at amortized cost using the original  effective interest rate (&#x201c;EIR&#x201d;) of 21.3% and adjusting the estimated debt outflows in accordance with the revised forecasts of annual sales turnover relating to JNJ-1900 (NBTXR3) through specific Company&#x2019;s license agreement (value and timing).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The EIB loan amounts to &#x20ac;43.5&#160;million as of June 30, 2025 compared to &#x20ac;40.6&#160;million as of December 31, 2024. The increase of &#x20ac;2.8&#160;million over the six months ended June 30 2024 comprises:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Fixed and variable interest expenses accrual for an amount of &#x20ac;4.1&#160;million which are partially offset by&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;the interest repayments of  &#x20ac;0.2&#160;million in accordance with the repayment schedule &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;the P&amp;amp;L net positive impact of accretion and discounting on EIB loan of &#x20ac;1.0&#160;million corresponding to : &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(i) the decrease in estimated debt outflows beyond 2024 - before discounting effect - for &#x20ac;2.4&#160;million positive P&amp;amp;L effect&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(ii) partially offset by - &#x20ac;1.4&#160;million of discounting negative effect). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025 the fair value of the debt is estimated at &#x20ac;46.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#2d2d2d;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company estimated the fair value of the debt using the same methodology as the one performed at renegotiation date. In doing so, the Company kept the same assumption of CCC credit rating. However, essentially because of a increase in spreads observed as of June 30, 2025 (compared to December 2024), the estimated fair market rate was estimated at 19.2%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"&gt;13.2 DUE DATES OF THE FINANCIAL LIABILITIES &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The due dates for repayment of the financial liabilities at their nominal value and including fixed rate interests and future variable interest payments have been estimated based on the milestone and royalties forecasts at the reporting date are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.959%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Less than 1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 1 and &lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 3 and &lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;More than &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Curadigm interest-free Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;HSBC &#x201c;PGE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance &#x201c;PGE&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB fixed rate loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,831&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;24,843&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;45,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;30,366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;105,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company plans according to contractual terms to reimburse the two &#x201c;PGE&#x201d; (&#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; or state-guaranteed loans) from HSBC and BPI over 5 years with a deferral of 1 year (last reimbursement being in 2026).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.959%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Less than 1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 1 and &lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 3 and &lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;More than &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Curadigm interest-free Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;HSBC &#x201c;PGE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance &#x201c;PGE&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB fixed rate loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;24,689&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;41,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;39,412&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;111,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company plans according to contractual terms to reimburse the two &#x201c;PGE&#x201d; (&#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; or state-guaranteed loans) from HSBC and BPI over five years with a deferral of 1 year (last reimbursement being in 2026).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The debt obligations indicated above relate to the fixed and variable rate interests and principal payable on repayable advances, the interest-free Bpifrance loan, EIB loan, PGE loans and the lease liabilities. These amounts reflect the committed amounts under those contracts as of June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, the table above indicates that the EIB loan's total expected cash outflows (undiscounted) is &#x20ac;97.8 million, which includes :&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;&#x20ac;33.7&#160;million for the principal and fixed rate interest to be paid over the term of the loan,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;&#x20ac;19.0&#160;million remaining milestones to be prepaid under the following mechanisms: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;should the company secure future non-dilutive capital through the execution of any business development deal, an accelerated redemption of this milestone payment would be triggered resulting in a prorated payment amount not exceeding 10% of any upfront or milestone payment received by the Company; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;should the Company contract future equity or debt financing transactions which will require prepayments equal to a tiered low single digit percentage of raising up to an aggregate of &#x20ac;100&#160;million, on a cumulative basis, increasing to a mid-single digit percentage for such financings greater than &#x20ac;100&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;&#x20ac;45.1&#160;million for the estimated royalty payments to be made in the future, based on the forecasted sales expected to be generated by the Company&#x2019;s partners during the six-year period beginning upon JNJ-1900 (NBTXR3) commercialization. (See Notes 4.4 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financing Agreement with the European Investment Bank (&#x201c;EIB&#x201d;) and 13.1 - Conditional advance, bank loan and loans from government and public authorities in the consolidated financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2024).&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfFinancialLiabilitiesFootnoteTextBlock>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c-1" id="f-505">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayable BPI loan advances &#x2013; Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PGE loans *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB loan &#x2013; Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,735&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,924&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayable BPI loan advances &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PGE loans *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB loan &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;46,505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;45,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;51,240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;50,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(*)&#x201d;PGE&#x201d;or in French &#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; are state-guaranteed loans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Detail of financial instruments included in the statements of financial position and impact on income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets carried at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities carried at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;62,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;62,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;65,900&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets carried at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities carried at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;53,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;53,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;53,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;70,936&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;70,936&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;73,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-131" decimals="-3" id="f-506" unitRef="eur">1247000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-132" decimals="-3" id="f-507" unitRef="eur">1261000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-133" decimals="-3" id="f-508" unitRef="eur">535000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-134" decimals="-3" id="f-509" unitRef="eur">689000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-135" decimals="-3" id="f-510" unitRef="eur">2522000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-136" decimals="-3" id="f-511" unitRef="eur">2543000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-137" decimals="-3" id="f-512" unitRef="eur">430000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-138" decimals="-3" id="f-513" unitRef="eur">430000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-2" decimals="-3" id="f-514" unitRef="eur">4735000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-3" decimals="-3" id="f-515" unitRef="eur">4924000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-131" decimals="-3" id="f-516" unitRef="eur">2385000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-132" decimals="-3" id="f-517" unitRef="eur">2969000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-133" decimals="-3" id="f-518" unitRef="eur">759000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-134" decimals="-3" id="f-519" unitRef="eur">1258000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-135" decimals="-3" id="f-520" unitRef="eur">307000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-136" decimals="-3" id="f-521" unitRef="eur">1547000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-137" decimals="-3" id="f-522" unitRef="eur">43054000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-138" decimals="-3" id="f-523" unitRef="eur">40204000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-2" decimals="-3" id="f-524" unitRef="eur">46505000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-3" decimals="-3" id="f-525" unitRef="eur">45978000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-2" decimals="-3" id="f-526" unitRef="eur">51240000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-3" decimals="-3" id="f-527" unitRef="eur">50902000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory contextRef="c-1" id="f-528">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;The table below shows the detail of changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.593%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.916%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Repayable BPI Loan Advances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PGE Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;EIB Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Curadigm Bpi advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;HSBC&lt;br/&gt;&#x201c;PGE&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bpifrance&lt;br/&gt;&#x201c;PGE&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;342&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;40,635&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;50,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease in loans and conditional advances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash flows used in&lt;br/&gt;financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indexation effect on current lease commitment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impact of discounting and catch-up&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated fixed interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated variable interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-cash from financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,083&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,169&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,632&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;43,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;51,240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,262&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;430&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,735&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which Non-Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;43,054&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;46,505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-139" decimals="-3" id="f-529" unitRef="eur">4230000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-140" decimals="-3" id="f-530" unitRef="eur">1606000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-141" decimals="-3" id="f-531" unitRef="eur">342000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-142" decimals="-3" id="f-532" unitRef="eur">1891000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-143" decimals="-3" id="f-533" unitRef="eur">2198000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-144" decimals="-3" id="f-534" unitRef="eur">40635000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-145" decimals="-3" id="f-535" unitRef="eur">50902000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-146" decimals="-3" id="f-536" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-147" decimals="-3" id="f-537" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-148" decimals="-3" id="f-538" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-149" decimals="-3" id="f-539" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-150" decimals="-3" id="f-540" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-151" decimals="-3" id="f-541" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-152" decimals="-3" id="f-542" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities contextRef="c-146" decimals="-3" id="f-543" unitRef="eur">0</nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities contextRef="c-147" decimals="-3" id="f-544" unitRef="eur">-600000</nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities contextRef="c-148" decimals="-3" id="f-545" unitRef="eur">-75000</nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities contextRef="c-149" decimals="-3" id="f-546" unitRef="eur">-626000</nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities contextRef="c-150" decimals="-3" id="f-547" unitRef="eur">-626000</nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities contextRef="c-151" decimals="-3" id="f-548" unitRef="eur">0</nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities contextRef="c-152" decimals="-3" id="f-549" unitRef="eur">-1927000</nbx:IncreaseDecreaseThroughDecreaseInLoansAndConditionalAdvancesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-146" decimals="-3" id="f-550" unitRef="eur">69000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-147" decimals="-3" id="f-551" unitRef="eur">0</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-148" decimals="-3" id="f-552" unitRef="eur">0</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-149" decimals="-3" id="f-553" unitRef="eur">11000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-150" decimals="-3" id="f-554" unitRef="eur">22000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-151" decimals="-3" id="f-555" unitRef="eur">233000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c-152" decimals="-3" id="f-556" unitRef="eur">335000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-146" decimals="-3" id="f-557" unitRef="eur">568000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-147" decimals="-3" id="f-558" unitRef="eur">0</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-148" decimals="-3" id="f-559" unitRef="eur">0</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-149" decimals="-3" id="f-560" unitRef="eur">0</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-150" decimals="-3" id="f-561" unitRef="eur">0</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-151" decimals="-3" id="f-562" unitRef="eur">0</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-152" decimals="-3" id="f-563" unitRef="eur">568000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-146" decimals="-3" id="f-564" unitRef="eur">-637000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-147" decimals="-3" id="f-565" unitRef="eur">-600000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-148" decimals="-3" id="f-566" unitRef="eur">-75000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-149" decimals="-3" id="f-567" unitRef="eur">-638000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-150" decimals="-3" id="f-568" unitRef="eur">-648000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-151" decimals="-3" id="f-569" unitRef="eur">-233000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-152" decimals="-3" id="f-570" unitRef="eur">-2831000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities contextRef="c-146" decimals="-3" id="f-571" unitRef="eur">0</nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities contextRef="c-147" decimals="-3" id="f-572" unitRef="eur">0</nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities contextRef="c-148" decimals="-3" id="f-573" unitRef="eur">0</nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities contextRef="c-149" decimals="-3" id="f-574" unitRef="eur">0</nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities contextRef="c-150" decimals="-3" id="f-575" unitRef="eur">0</nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities contextRef="c-151" decimals="-3" id="f-576" unitRef="eur">0</nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities contextRef="c-152" decimals="-3" id="f-577" unitRef="eur">0</nbx:IncreaseDecreaseThroughIndexationEffectOnCurrentLeaseCommitmentLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities contextRef="c-146" decimals="-3" id="f-578" unitRef="eur">0</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities contextRef="c-147" decimals="-3" id="f-579" unitRef="eur">3000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities contextRef="c-148" decimals="-3" id="f-580" unitRef="eur">8000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities contextRef="c-149" decimals="-3" id="f-581" unitRef="eur">-4000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities contextRef="c-150" decimals="-3" id="f-582" unitRef="eur">-1000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities contextRef="c-151" decimals="-3" id="f-583" unitRef="eur">-1036000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities contextRef="c-152" decimals="-3" id="f-584" unitRef="eur">-1031000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndCatchUpLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-146" decimals="-3" id="f-585" unitRef="eur">38000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-147" decimals="-3" id="f-586" unitRef="eur">10000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-148" decimals="-3" id="f-587" unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-149" decimals="-3" id="f-588" unitRef="eur">11000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-150" decimals="-3" id="f-589" unitRef="eur">21000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-151" decimals="-3" id="f-590" unitRef="eur">742000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-152" decimals="-3" id="f-591" unitRef="eur">822000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-146" decimals="-3" id="f-592" unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-147" decimals="-3" id="f-593" unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-148" decimals="-3" id="f-594" unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-149" decimals="-3" id="f-595" unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-150" decimals="-3" id="f-596" unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-151" decimals="-3" id="f-597" unitRef="eur">3377000</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities contextRef="c-152" decimals="-3" id="f-598" unitRef="eur">3377000</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:CashFlowsFromUsedInNonFinancingActivities contextRef="c-146" decimals="-3" id="f-599" unitRef="eur">38000</nbx:CashFlowsFromUsedInNonFinancingActivities>
    <nbx:CashFlowsFromUsedInNonFinancingActivities contextRef="c-147" decimals="-3" id="f-600" unitRef="eur">13000</nbx:CashFlowsFromUsedInNonFinancingActivities>
    <nbx:CashFlowsFromUsedInNonFinancingActivities contextRef="c-148" decimals="-3" id="f-601" unitRef="eur">8000</nbx:CashFlowsFromUsedInNonFinancingActivities>
    <nbx:CashFlowsFromUsedInNonFinancingActivities contextRef="c-149" decimals="-3" id="f-602" unitRef="eur">7000</nbx:CashFlowsFromUsedInNonFinancingActivities>
    <nbx:CashFlowsFromUsedInNonFinancingActivities contextRef="c-150" decimals="-3" id="f-603" unitRef="eur">19000</nbx:CashFlowsFromUsedInNonFinancingActivities>
    <nbx:CashFlowsFromUsedInNonFinancingActivities contextRef="c-151" decimals="-3" id="f-604" unitRef="eur">3083000</nbx:CashFlowsFromUsedInNonFinancingActivities>
    <nbx:CashFlowsFromUsedInNonFinancingActivities contextRef="c-152" decimals="-3" id="f-605" unitRef="eur">3169000</nbx:CashFlowsFromUsedInNonFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-153" decimals="-3" id="f-606" unitRef="eur">3632000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-154" decimals="-3" id="f-607" unitRef="eur">1019000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-155" decimals="-3" id="f-608" unitRef="eur">275000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-156" decimals="-3" id="f-609" unitRef="eur">1260000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-157" decimals="-3" id="f-610" unitRef="eur">1569000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-158" decimals="-3" id="f-611" unitRef="eur">43484000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-159" decimals="-3" id="f-612" unitRef="eur">51240000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <nbx:LiabilitiesArisingFromFinancingActivitiesCurrent contextRef="c-153" decimals="-3" id="f-613" unitRef="eur">1247000</nbx:LiabilitiesArisingFromFinancingActivitiesCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesCurrent contextRef="c-154" decimals="-3" id="f-614" unitRef="eur">438000</nbx:LiabilitiesArisingFromFinancingActivitiesCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesCurrent contextRef="c-155" decimals="-3" id="f-615" unitRef="eur">97000</nbx:LiabilitiesArisingFromFinancingActivitiesCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesCurrent contextRef="c-156" decimals="-3" id="f-616" unitRef="eur">1260000</nbx:LiabilitiesArisingFromFinancingActivitiesCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesCurrent contextRef="c-157" decimals="-3" id="f-617" unitRef="eur">1262000</nbx:LiabilitiesArisingFromFinancingActivitiesCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesCurrent contextRef="c-158" decimals="-3" id="f-618" unitRef="eur">430000</nbx:LiabilitiesArisingFromFinancingActivitiesCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesCurrent contextRef="c-159" decimals="-3" id="f-619" unitRef="eur">4735000</nbx:LiabilitiesArisingFromFinancingActivitiesCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent contextRef="c-153" decimals="-3" id="f-620" unitRef="eur">2385000</nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent contextRef="c-154" decimals="-3" id="f-621" unitRef="eur">581000</nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent contextRef="c-155" decimals="-3" id="f-622" unitRef="eur">178000</nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent contextRef="c-156" decimals="-3" id="f-623" unitRef="eur">0</nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent contextRef="c-157" decimals="-3" id="f-624" unitRef="eur">307000</nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent contextRef="c-158" decimals="-3" id="f-625" unitRef="eur">43054000</nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent>
    <nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent contextRef="c-159" decimals="-3" id="f-626" unitRef="eur">46505000</nbx:LiabilitiesArisingFromFinancingActivitiesNonCurrent>
    <nbx:AdvancesReceivedInterestRate contextRef="c-160" decimals="4" id="f-627" unitRef="number">0.0156</nbx:AdvancesReceivedInterestRate>
    <ifrs-full:RepaymentsOfCurrentBorrowings contextRef="c-160" decimals="-5" id="f-628" unitRef="eur">600000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <nbx:ReimbursedAmountOfCorresponds contextRef="c-160" decimals="-5" id="f-629" unitRef="eur">1000000</nbx:ReimbursedAmountOfCorresponds>
    <nbx:AdvancesAuthorizedAmountToBeAdvanced contextRef="c-161" decimals="-5" id="f-630" unitRef="eur">500000</nbx:AdvancesAuthorizedAmountToBeAdvanced>
    <ifrs-full:Advances contextRef="c-161" decimals="-5" id="f-631" unitRef="eur">400000</ifrs-full:Advances>
    <ifrs-full:RepaymentsOfCurrentBorrowings contextRef="c-162" decimals="-5" id="f-632" unitRef="eur">100000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <nbx:ReimbursedAmountOfCorresponds contextRef="c-162" decimals="-5" id="f-633" unitRef="eur">300000</nbx:ReimbursedAmountOfCorresponds>
    <ifrs-full:NotionalAmount contextRef="c-163" decimals="-6" id="f-634" unitRef="eur">5000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-164" decimals="-6" id="f-635" unitRef="eur">5000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate contextRef="c-163" decimals="4" id="f-636" unitRef="number">0.0031</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-165" decimals="-5" id="f-637" unitRef="eur">600000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-166" decimals="-6" id="f-638" unitRef="eur">5000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <nbx:BorrowingMaturityTerm contextRef="c-166" id="f-639">P6Y</nbx:BorrowingMaturityTerm>
    <nbx:BorrowingPercentageOfStateGuaranteedLoan contextRef="c-167" decimals="2" id="f-640" unitRef="number">0.90</nbx:BorrowingPercentageOfStateGuaranteedLoan>
    <ifrs-full:BorrowingsInterestRate contextRef="c-167" decimals="4" id="f-641" unitRef="number">0.0225</ifrs-full:BorrowingsInterestRate>
    <nbx:BorrowingGuaranteeFee contextRef="c-167" decimals="4" id="f-642" unitRef="number">0.0161</nbx:BorrowingGuaranteeFee>
    <nbx:BorrowingNumberOfQuarterlyInstallments
      contextRef="c-166"
      decimals="INF"
      id="f-643"
      unitRef="quarterly_installment">20</nbx:BorrowingNumberOfQuarterlyInstallments>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-168" decimals="-5" id="f-644" unitRef="eur">600000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:BorrowingsInterestRate contextRef="c-169" decimals="3" id="f-645" unitRef="number">0.213</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-158" decimals="-5" id="f-646" unitRef="eur">43500000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-170" decimals="-5" id="f-647" unitRef="eur">40600000</ifrs-full:NotionalAmount>
    <nbx:IncreaseDecreaseInOutstandingLoans contextRef="c-151" decimals="-5" id="f-648" unitRef="eur">2800000</nbx:IncreaseDecreaseInOutstandingLoans>
    <ifrs-full:InterestExpense contextRef="c-151" decimals="-5" id="f-649" unitRef="eur">4100000</ifrs-full:InterestExpense>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-151" decimals="-5" id="f-650" unitRef="eur">200000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities contextRef="c-151" decimals="-5" id="f-651" unitRef="eur">1000000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows contextRef="c-151" decimals="-5" id="f-652" unitRef="eur">2400000</nbx:AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows>
    <nbx:IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections contextRef="c-151" decimals="-5" id="f-653" unitRef="eur">1400000</nbx:IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections>
    <ifrs-full:NotionalAmount contextRef="c-171" decimals="-5" id="f-654" unitRef="eur">46500000</ifrs-full:NotionalAmount>
    <ifrs-full:DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse contextRef="c-158" decimals="3" id="f-655" unitRef="number">0.192</ifrs-full:DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse>
    <nbx:DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock contextRef="c-1" id="f-656">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The due dates for repayment of the financial liabilities at their nominal value and including fixed rate interests and future variable interest payments have been estimated based on the milestone and royalties forecasts at the reporting date are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.959%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Less than 1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 1 and &lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 3 and &lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;More than &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Curadigm interest-free Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;HSBC &#x201c;PGE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance &#x201c;PGE&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB fixed rate loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,831&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;24,843&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;45,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;30,366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;105,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company plans according to contractual terms to reimburse the two &#x201c;PGE&#x201d; (&#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; or state-guaranteed loans) from HSBC and BPI over 5 years with a deferral of 1 year (last reimbursement being in 2026).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.959%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Less than 1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 1 and &lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 3 and &lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;More than &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Curadigm interest-free Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;HSBC &#x201c;PGE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance &#x201c;PGE&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB fixed rate loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;24,689&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;41,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;39,412&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;111,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company plans according to contractual terms to reimburse the two &#x201c;PGE&#x201d; (&#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; or state-guaranteed loans) from HSBC and BPI over five years with a deferral of 1 year (last reimbursement being in 2026).&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfAdvancesLoansAndLeaseLiabilitiesTableTextBlock>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-172" decimals="-3" id="f-657" unitRef="eur">442000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-173" decimals="-3" id="f-658" unitRef="eur">595000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-174" decimals="-3" id="f-659" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-175" decimals="-3" id="f-660" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-176" decimals="-3" id="f-661" unitRef="eur">1037000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-177" decimals="-3" id="f-662" unitRef="eur">100000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-178" decimals="-3" id="f-663" unitRef="eur">200000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-179" decimals="-3" id="f-664" unitRef="eur">25000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-180" decimals="-3" id="f-665" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-181" decimals="-3" id="f-666" unitRef="eur">325000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-182" decimals="-3" id="f-667" unitRef="eur">1266000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-183" decimals="-3" id="f-668" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-184" decimals="-3" id="f-669" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-185" decimals="-3" id="f-670" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-186" decimals="-3" id="f-671" unitRef="eur">1266000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-187" decimals="-3" id="f-672" unitRef="eur">1275000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-188" decimals="-3" id="f-673" unitRef="eur">314000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-189" decimals="-3" id="f-674" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-190" decimals="-3" id="f-675" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-191" decimals="-3" id="f-676" unitRef="eur">1589000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-192" decimals="-3" id="f-677" unitRef="eur">467000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-193" decimals="-3" id="f-678" unitRef="eur">22027000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-194" decimals="-3" id="f-679" unitRef="eur">44891000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-195" decimals="-3" id="f-680" unitRef="eur">30366000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-158" decimals="-3" id="f-681" unitRef="eur">97751000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-196" decimals="-3" id="f-682" unitRef="eur">1282000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-197" decimals="-3" id="f-683" unitRef="eur">1707000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-198" decimals="-3" id="f-684" unitRef="eur">866000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-199" decimals="-3" id="f-685" unitRef="eur">0</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-200" decimals="-3" id="f-686" unitRef="eur">3855000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-201" decimals="-3" id="f-687" unitRef="eur">4831000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-202" decimals="-3" id="f-688" unitRef="eur">24843000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-203" decimals="-3" id="f-689" unitRef="eur">45781000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-204" decimals="-3" id="f-690" unitRef="eur">30366000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-2" decimals="-3" id="f-691" unitRef="eur">105822000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <nbx:BorrowingScheduledForReimbursementNumber contextRef="c-205" decimals="INF" id="f-692" unitRef="loan">2</nbx:BorrowingScheduledForReimbursementNumber>
    <nbx:BorrowingMaturityTerm contextRef="c-205" id="f-693">P5Y</nbx:BorrowingMaturityTerm>
    <nbx:BorrowingDefermentPeriod contextRef="c-205" id="f-694">P1Y</nbx:BorrowingDefermentPeriod>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-206" decimals="-3" id="f-695" unitRef="eur">800000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-207" decimals="-3" id="f-696" unitRef="eur">837000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-208" decimals="-3" id="f-697" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-209" decimals="-3" id="f-698" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-210" decimals="-3" id="f-699" unitRef="eur">1637000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-211" decimals="-3" id="f-700" unitRef="eur">100000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-212" decimals="-3" id="f-701" unitRef="eur">200000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-213" decimals="-3" id="f-702" unitRef="eur">75000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-214" decimals="-3" id="f-703" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-215" decimals="-3" id="f-704" unitRef="eur">375000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-216" decimals="-3" id="f-705" unitRef="eur">1272000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-217" decimals="-3" id="f-706" unitRef="eur">631000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-218" decimals="-3" id="f-707" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-219" decimals="-3" id="f-708" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-220" decimals="-3" id="f-709" unitRef="eur">1903000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-221" decimals="-3" id="f-710" unitRef="eur">1289000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-222" decimals="-3" id="f-711" unitRef="eur">948000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-223" decimals="-3" id="f-712" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-224" decimals="-3" id="f-713" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-225" decimals="-3" id="f-714" unitRef="eur">2237000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-226" decimals="-3" id="f-715" unitRef="eur">467000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-227" decimals="-3" id="f-716" unitRef="eur">19942000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-228" decimals="-3" id="f-717" unitRef="eur">40784000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-229" decimals="-3" id="f-718" unitRef="eur">39196000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-170" decimals="-3" id="f-719" unitRef="eur">100389000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-230" decimals="-3" id="f-720" unitRef="eur">1282000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-231" decimals="-3" id="f-721" unitRef="eur">2131000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-232" decimals="-3" id="f-722" unitRef="eur">866000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-233" decimals="-3" id="f-723" unitRef="eur">216000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-234" decimals="-3" id="f-724" unitRef="eur">4495000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-235" decimals="-3" id="f-725" unitRef="eur">5210000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-236" decimals="-3" id="f-726" unitRef="eur">24689000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-237" decimals="-3" id="f-727" unitRef="eur">41725000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-238" decimals="-3" id="f-728" unitRef="eur">39412000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-3" decimals="-3" id="f-729" unitRef="eur">111036000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <nbx:BorrowingScheduledForReimbursementNumber contextRef="c-239" decimals="INF" id="f-730" unitRef="loan">2</nbx:BorrowingScheduledForReimbursementNumber>
    <nbx:BorrowingMaturityTerm contextRef="c-239" id="f-731">P5Y</nbx:BorrowingMaturityTerm>
    <nbx:BorrowingDefermentPeriod contextRef="c-239" id="f-732">P1Y</nbx:BorrowingDefermentPeriod>
    <ifrs-full:Borrowings contextRef="c-158" decimals="-5" id="f-733" unitRef="eur">97800000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-240" decimals="-5" id="f-734" unitRef="eur">33700000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-241" decimals="-5" id="f-735" unitRef="eur">19000000</ifrs-full:Borrowings>
    <nbx:BorrowingsCumulativeMilestonePrepaymentAmount contextRef="c-242" decimals="-6" id="f-736" unitRef="eur">100000000</nbx:BorrowingsCumulativeMilestonePrepaymentAmount>
    <nbx:BorrowingsCumulativeMilestonePrepaymentAmount contextRef="c-242" decimals="-6" id="f-737" unitRef="eur">100000000</nbx:BorrowingsCumulativeMilestonePrepaymentAmount>
    <nbx:EstimatedRoyaltyPayments contextRef="c-158" decimals="-5" id="f-738" unitRef="eur">45100000</nbx:EstimatedRoyaltyPayments>
    <nbx:ConsolidatedForecastedSalesPeriod contextRef="c-151" id="f-739">P6Y</nbx:ConsolidatedForecastedSalesPeriod>
    <nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock contextRef="c-1" id="f-740">Trade payables and other current liabilities&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;14.1 TRADE AND OTHER PAYABLES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued expenses - clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;11,639&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;20,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables are not discounted, as none of the amounts has a maturity date above one year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accrued Expenses related to clinical trials balance decreased by &#x20ac;8.1&#160;million between December 31, 2024 and June 30, 2025. This decrease is mainly explained by (i) the NANORAY-312 development in 2025, amounting to a &#x20ac;1.8&#160;million accrual as of June 30, 2025, compared to the 11.1&#160;million accrual as of December 31, 2024. This reduction reflects  the amendment letter signed in March 2025, removing the Company&#x2019;s funding obligations for the 312 study in the frame of the transfer of sponsorship to Janssen; partially offset by (ii) the study 1100 development, increasing to a &#x20ac;5.3&#160;million accrual as of June 30, 2025, compared to the 4.4&#160;million accrual as of December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The trade payables and other accruals are quite stable between December 2024 and June 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;14.2 OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll tax and other payroll liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,543&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll tax and other payroll liabilities primarily consist of payroll taxes and social charges, namely the employer withholdings relating to free shares, as well as accrued bonuses, vacation day accruals and related social charges. Payroll tax and other payroll liabilities have decreased by &#x20ac;0.5&#160;million during the first half of 2025, mainly due to the payment in the first half of bonuses payable accrued at the previous year-end for &#x20ac;0.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;14.3 DEFERRED INCOME AND CONTRACT LIABILITIES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contract liabilities - Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Deferred income and current contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;36,222&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;18,161&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The current contract liabilities are accounted for in accordance with IFRS 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current contract liabilities increased by &#x20ac;18.1&#160;million to &#x20ac;36.2&#160;million as of June 30, 2025. The initial payment received in 2021 from LianBio was &#x20ac;16.5&#160;million was recognized as a contract liability since the delivery of the related performance obligation has not yet commenced. The increase of &#x20ac;18.1&#160;million results from the combined effects of the amendments on the Janssen License Agreement and the Asia Licensing Agreement (formerly Lianbio) in the allocation of the constrained transaction price (See Note 16 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues and other income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;14.4 REFUND LIABILITIES&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current refund liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Current refund liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Refund liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;35,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The refund liability, recognized as of December 2024, reflects the refund obligation related to the amendments of the Janssen Agreement, signed in the fourth quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, the refund liabilities decreased by &#x20ac;28.2&#160;million according to the amendment of the Janssen Agreement, signed on March 17, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;These amendments were accounted for as a contract modification under IFRS 15, and resulted in a change in the transaction price, as well as a change in scope of the performance obligations, recorded as a cumulative catch-up in the statement of consolidated operations and refund liabilities in the consolidated statement of financial position. (Note 16 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues and other income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock>
    <nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock contextRef="c-1" id="f-741">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued expenses - clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;11,639&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;20,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-2" decimals="-3" id="f-742" unitRef="eur">7413000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-3" decimals="-3" id="f-743" unitRef="eur">15550000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-2" decimals="-3" id="f-744" unitRef="eur">4226000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-3" decimals="-3" id="f-745" unitRef="eur">4484000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-2" decimals="-3" id="f-746" unitRef="eur">11639000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-3" decimals="-3" id="f-747" unitRef="eur">20036000</ifrs-full:TradeAndOtherCurrentPayables>
    <nbx:AdjustmentsForIncreaseDecreaseInAccruedExpenses contextRef="c-243" decimals="-5" id="f-748" unitRef="eur">-8100000</nbx:AdjustmentsForIncreaseDecreaseInAccruedExpenses>
    <nbx:AdjustmentsForIncreaseDecreaseInAccruedExpenses contextRef="c-244" decimals="-5" id="f-749" unitRef="eur">-8100000</nbx:AdjustmentsForIncreaseDecreaseInAccruedExpenses>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-245" decimals="-5" id="f-750" unitRef="eur">1800000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-246" decimals="-5" id="f-751" unitRef="eur">11100000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-247" decimals="-5" id="f-752" unitRef="eur">5300000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <nbx:IncreaseDecreaseInOtherCurrentPayables contextRef="c-243" decimals="-5" id="f-753" unitRef="eur">4400000</nbx:IncreaseDecreaseInOtherCurrentPayables>
    <nbx:DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-754">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll tax and other payroll liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,543&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-2" decimals="-3" id="f-755" unitRef="eur">415000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-756" unitRef="eur">537000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-2" decimals="-3" id="f-757" unitRef="eur">5872000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-3" decimals="-3" id="f-758" unitRef="eur">6334000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <nbx:OtherMiscellaneousCurrentLiabilities contextRef="c-2" decimals="-3" id="f-759" unitRef="eur">714000</nbx:OtherMiscellaneousCurrentLiabilities>
    <nbx:OtherMiscellaneousCurrentLiabilities contextRef="c-3" decimals="-3" id="f-760" unitRef="eur">672000</nbx:OtherMiscellaneousCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-2" decimals="-3" id="f-761" unitRef="eur">7000000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-3" decimals="-3" id="f-762" unitRef="eur">7543000</ifrs-full:OtherCurrentLiabilities>
    <nbx:IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent contextRef="c-1" decimals="-5" id="f-763" unitRef="eur">-500000</nbx:IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent>
    <nbx:IncreaseDecreaseInBonusAccrual contextRef="c-1" decimals="-5" id="f-764" unitRef="eur">-900000</nbx:IncreaseDecreaseInBonusAccrual>
    <nbx:DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock contextRef="c-1" id="f-765">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contract liabilities - Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Deferred income and current contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;36,222&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;18,161&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities contextRef="c-2" decimals="-3" id="f-766" unitRef="eur">50000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-767" unitRef="eur">61000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-2" decimals="-3" id="f-768" unitRef="eur">36172000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-769" unitRef="eur">18100000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities contextRef="c-2" decimals="-3" id="f-770" unitRef="eur">36222000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-771" unitRef="eur">18161000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities contextRef="c-1" decimals="-5" id="f-772" unitRef="eur">18100000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-2" decimals="-5" id="f-773" unitRef="eur">36200000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities contextRef="c-248" decimals="-5" id="f-774" unitRef="eur">16500000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities contextRef="c-1" decimals="-5" id="f-775" unitRef="eur">18100000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <nbx:DetailedInformationAboutRefundLiabilitiesTableTextBlock contextRef="c-1" id="f-776">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current refund liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Current refund liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Refund liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;35,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DetailedInformationAboutRefundLiabilitiesTableTextBlock>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-2" decimals="-3" id="f-777" unitRef="eur">4105000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-778" unitRef="eur">27778000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:CurrentRefundsProvision contextRef="c-2" decimals="-3" id="f-779" unitRef="eur">3273000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision contextRef="c-3" decimals="-3" id="f-780" unitRef="eur">7835000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:RefundsProvision contextRef="c-2" decimals="-3" id="f-781" unitRef="eur">7378000</ifrs-full:RefundsProvision>
    <ifrs-full:RefundsProvision contextRef="c-3" decimals="-3" id="f-782" unitRef="eur">35613000</ifrs-full:RefundsProvision>
    <nbx:IncreaseDecreaseRefundLiabilities contextRef="c-1" decimals="-5" id="f-783" unitRef="eur">-28200000</nbx:IncreaseDecreaseRefundLiabilities>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c-1" id="f-784">Financial instruments included in the statement of financial position and impact on income&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Detail of financial instruments included in the statements of financial position and impact on income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets carried at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities carried at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;62,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;62,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;65,900&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets carried at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities carried at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;53,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;53,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;53,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;70,936&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;70,936&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;73,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Management of financial risks&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The principal financial instruments held by the Company are instruments classified as cash and cash equivalents. These instruments are managed with the objective of enabling the Company to finance its business activities. The Company's policy is to not use financial instruments for speculative purposes. It does not use derivative financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The principal financial risks faced by the Company are liquidity, foreign currency exchange, interest rate and credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Liquidity risk arises from the Company&#x2019;s financial liabilities and significant expenses related to development and manufacturing of nanotechnology products and conducting clinical studies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s operations have consumed substantial amounts of cash since its inception. Developing pharmaceutical product candidates, including conducting clinical trials, is expensive, lengthy and risky, and the Company expects to continue to incur significant losses in the near term. Accordingly, the Company will continue to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;require substantial additional capital to continue its clinical development activities and potentially engage in commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Liquidity risk management aims to ensure that the Company has access to sufficient liquidity and financial resources to be able to meet present and future obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company prepares short&#x2011;term cash forecasts and annual operating cash flow forecasts as part of its budget procedures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Prudent liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate credit facilities and being able to unwind market positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;At the date of these consolidated financial statements, the Company estimates, given its current cost structure and its projected expenditure commitments, to be able to finance its activities into mid-2026 (see Note 2. &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"&gt;General information, statement of compliance and basis of presentation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt; for more details).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Exchange Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The functional currency of Nanobiotix S.A. is the euro. Exposure to foreign currency exchange risk is mainly derived from certain of its revenue and bank accounts denominated in U.S dollars. Under the global license Agreement  with Janssen, and the Asia Licensing Agreement (former LianBio contract) the Company has received payments in U.S dollars. Additionally, the Company is also exposed through intragroup transactions between Nanobiotix S.A. and its U.S. subsidiary for which the functional currency is the U.S. dollar, as well as trade relations with customers and suppliers outside the euro zone. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At this stage of its development, the Company does not use hedging to protect its business against exchange rate fluctuations. However, a significant increase in its business activity outside the euro zone could lead to a greater exposure to foreign currency exchange risk as the Company&#x2019;s operating capital requirements are mainly denominated in euro. If this occurs, the Company may implement a suitable hedging policy for these risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The credit risk related to cash and cash equivalents and to current financial instruments is not material given the rating and size of the relevant financial institutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s exposure to credit risk chiefly stems from trade receivables related to its customer (Janssen) as of June 30, 2025. Due to the limited number of customers, the Company appropriately monitors its receivables and their payment and clearance. The Company enters into such transactions only with highly reputable, financially sound counterparts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's exposure to interest rate risk is primarily related to cash equivalents and investment securities, which consist of term deposits. Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, loans issued by the Company are exclusively fixed rate loans and thus our exposure to interest rate and market risk is deemed low. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Variable interests on the EIB loan are royalty-based and are not subject to market rate risks.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="c-1" id="f-785">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Detail of financial instruments included in the statements of financial position and impact on income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets carried at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities carried at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;62,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;62,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;65,900&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets carried at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities carried at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;53,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;53,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;53,120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;70,936&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;70,936&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;73,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:FinancialAssets contextRef="c-249" decimals="-3" id="f-786" unitRef="eur">409000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-250" decimals="-3" id="f-787" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-251" decimals="-3" id="f-788" unitRef="eur">409000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-249" decimals="-3" id="f-789" unitRef="eur">409000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-252" decimals="-3" id="f-790" unitRef="eur">1837000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-253" decimals="-3" id="f-791" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-254" decimals="-3" id="f-792" unitRef="eur">1837000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-252" decimals="-3" id="f-793" unitRef="eur">1837000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-255" decimals="-3" id="f-794" unitRef="eur">28818000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-256" decimals="-3" id="f-795" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-257" decimals="-3" id="f-796" unitRef="eur">28818000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-255" decimals="-3" id="f-797" unitRef="eur">28818000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-2" decimals="-3" id="f-798" unitRef="eur">31064000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-258" decimals="-3" id="f-799" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-259" decimals="-3" id="f-800" unitRef="eur">31064000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-2" decimals="-3" id="f-801" unitRef="eur">31064000</ifrs-full:FinancialAssetsAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-260" decimals="-3" id="f-802" unitRef="eur">46505000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-261" decimals="-3" id="f-803" unitRef="eur">0</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-262" decimals="-3" id="f-804" unitRef="eur">46505000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue contextRef="c-260" decimals="-3" id="f-805" unitRef="eur">49508000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-263" decimals="-3" id="f-806" unitRef="eur">4735000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-264" decimals="-3" id="f-807" unitRef="eur">0</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-265" decimals="-3" id="f-808" unitRef="eur">4735000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue contextRef="c-263" decimals="-3" id="f-809" unitRef="eur">4753000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-266" decimals="-3" id="f-810" unitRef="eur">11639000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-267" decimals="-3" id="f-811" unitRef="eur">0</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-268" decimals="-3" id="f-812" unitRef="eur">11639000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue contextRef="c-266" decimals="-3" id="f-813" unitRef="eur">11639000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-2" decimals="-3" id="f-814" unitRef="eur">62879000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-269" decimals="-3" id="f-815" unitRef="eur">0</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-270" decimals="-3" id="f-816" unitRef="eur">62879000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue contextRef="c-2" decimals="-3" id="f-817" unitRef="eur">65900000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-271" decimals="-3" id="f-818" unitRef="eur">406000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-272" decimals="-3" id="f-819" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-273" decimals="-3" id="f-820" unitRef="eur">406000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-271" decimals="-3" id="f-821" unitRef="eur">406000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-274" decimals="-3" id="f-822" unitRef="eur">2977000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-275" decimals="-3" id="f-823" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-276" decimals="-3" id="f-824" unitRef="eur">2977000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-274" decimals="-3" id="f-825" unitRef="eur">2977000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-277" decimals="-3" id="f-826" unitRef="eur">49737000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-278" decimals="-3" id="f-827" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-279" decimals="-3" id="f-828" unitRef="eur">49737000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-277" decimals="-3" id="f-829" unitRef="eur">49737000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-3" decimals="-3" id="f-830" unitRef="eur">53120000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-280" decimals="-3" id="f-831" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-281" decimals="-3" id="f-832" unitRef="eur">53120000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-3" decimals="-3" id="f-833" unitRef="eur">53120000</ifrs-full:FinancialAssetsAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-282" decimals="-3" id="f-834" unitRef="eur">45978000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-283" decimals="-3" id="f-835" unitRef="eur">0</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-284" decimals="-3" id="f-836" unitRef="eur">45978000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue contextRef="c-282" decimals="-3" id="f-837" unitRef="eur">48443000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-285" decimals="-3" id="f-838" unitRef="eur">4924000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-286" decimals="-3" id="f-839" unitRef="eur">0</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-287" decimals="-3" id="f-840" unitRef="eur">4924000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue contextRef="c-285" decimals="-3" id="f-841" unitRef="eur">4924000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-288" decimals="-3" id="f-842" unitRef="eur">20035000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-289" decimals="-3" id="f-843" unitRef="eur">0</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-290" decimals="-3" id="f-844" unitRef="eur">20035000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue contextRef="c-288" decimals="-3" id="f-845" unitRef="eur">20035000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-3" decimals="-3" id="f-846" unitRef="eur">70936000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-291" decimals="-3" id="f-847" unitRef="eur">0</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables contextRef="c-292" decimals="-3" id="f-848" unitRef="eur">70936000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue contextRef="c-3" decimals="-3" id="f-849" unitRef="eur">73402000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="c-1" id="f-850">Revenue and other income &lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The revenue recognition accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June&#160;30, 2025, are identical to those used for the year ended December&#160;31, 2024, as completed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Further to the agreements signed during the fourth quarter of 2024 detailing the terms for the transfer of the sponsorship of the ongoing NANORAY-312 Phase 3 pivotal trial in head and neck cancer to Janssen (See Note 16 &#x2013; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenues and other income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; to the consolidated financial statements as of and for the year ended December 31, 2024), the Company signed an amendment letter with Janssen BV on March 17, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The amendment letter provides that Janssen will ultimately assume nearly all remaining costs for the ongoing pivotal Phase 3 trial through completion, except for a limited portion of costs that will continue to be covered by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;This amendment aims to improve the Company&#x2019;s short-term cash runway by:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;reducing its obligation to make payments that were probable in the short term for the ongoing NANORAY-312 Phase 3 pivotal trial development costs; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;revising potential future milestone payments for a total of $105&#160;million under both the Janssen License Agreement and the Asia Licensing Agreement, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;This amendment letter has been considered and accounted for as a contract modification under IFRS 15, which modifies the remaining transaction prices of both Janssen License Agreement and Asia Licensing Agreement, originally treated as separate contracts for IFRS 15 purposes. As there are price interdependencies between the two effects of the amendment as described above, the contract modification has been applied to both agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The amendment does not change the scope of the initial contracts but the overall impact of the contract modification is a significant increase in the remaining constrained transaction price of the combined agreements (Janssen Agreement and Asia Licensing Agreement) while the constraint continues to apply to milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The net positive impact on the constrained transaction price on the Janssen Agreement was recognized as a cumulative catch-up adjustment, as the remaining goods or services under the license agreement are not distinct. As a result, revenue for the six-month period ended June 30, 2025, included a one-off positive impact of &#x20ac;21.2&#160;million, directly attributable to the contract modification as described above.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In accordance with IFRS 15, the funding obligation towards Janssen was reduced to a net refund liability amounting to &#x20ac;7.4&#160;million as of June 30, 2025. See Note 14.4 &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Refund liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The combined effects of the amendment on the two license agreements resulted also in the allocation of &#x20ac;18.1&#160;million of the constrained transaction price to the Asia Licensing Agreement, which was recognized as the related contract liability since the delivery of the related performance obligation has not yet commenced. See Note 14.3 &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Deferred income and Contract liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Detail of revenue and other income&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s revenue and other income per category for the six-month period ended June 30, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six-month period ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;24,928&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subsidies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total revenue and other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;26,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;9,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, the Total Revenue reached &#x20ac;24.9&#160;million, composed of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the line &#x2018;Services&#x2019; includes (i) a one-off positive revenue of &#x20ac;21.2&#160;million recognized over the six-month period ended June 30, 2025 directly attributable to the contract modification impact occurred during the first half of 2025, that counterbalances the negative revenue impact recognized in fiscal year 2024 : the amendments signed during the last quarter of 2024 had significantly reduced the transaction price of the license agreement as the R&amp;amp;D service performance obligation was replaced with a funding obligation for the Company towards Janssen, while the amendment letter executed in March 2025 did not impact the scope of the Company's performance obligations but increased the remaining transaction price of the global &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;license agreement, (ii) and other &#x2018;Services&#x2019; revenue linked to technology transfer and technical assistance recharge to Janssen for &#x20ac;0.4&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;&#x20ac;3.4&#160;million of &#x2018;Other Sales&#x2019; related to products clinical supplies to Janssen for the six-month period ended June 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the six month period ended June 30, 2024, the &#x20ac;6.2&#160;million Total Revenue mainly includes (i) &#x2018;Services&#x2019; revenue linked to the assignment of the license to Janssen and the rendered R&amp;amp;D services in proportion of the completion of the ongoing studies, totaling &#x20ac;2.7&#160;million; (ii) &#x2018;Services&#x2019; revenue linked to technology transfer and technical assistance recharge for &#x20ac;1.1&#160;million; (iii) and &#x20ac;2.4&#160;million of &#x2018;Other Sales&#x2019; related to products clinical supplies to Janssen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Research tax credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research tax credit decreased from &#x20ac;2.3&#160;million in 2024 to &#x20ac;1.6&#160;million in 2025 due mainly due to the exclusion of a major vendor from the CIR scope in 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subsidies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subsidies include the Bpifrance Deep Tech Grant received by the Company, &#x20ac;67&#160;thousand recognized as other income for the half-year ended June 30, 2025, as compared to &#x20ac;36&#160;thousand for the half-year ended June 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;The line item &#x2018;Other&#x2019; mainly includes income for services recharge, in the framework of the &#x2018;GTCA&#x2019; totaling &#x20ac;26 thousand as of June 30, 2025 compared to &#x20ac;0.5&#160;million for services recharge and &#x20ac;0.2&#160;million for supply services as of June 30, 2024</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c-1" id="f-851">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The revenue recognition accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June&#160;30, 2025, are identical to those used for the year ended December&#160;31, 2024, as completed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Further to the agreements signed during the fourth quarter of 2024 detailing the terms for the transfer of the sponsorship of the ongoing NANORAY-312 Phase 3 pivotal trial in head and neck cancer to Janssen (See Note 16 &#x2013; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenues and other income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; to the consolidated financial statements as of and for the year ended December 31, 2024), the Company signed an amendment letter with Janssen BV on March 17, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The amendment letter provides that Janssen will ultimately assume nearly all remaining costs for the ongoing pivotal Phase 3 trial through completion, except for a limited portion of costs that will continue to be covered by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;This amendment aims to improve the Company&#x2019;s short-term cash runway by:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;reducing its obligation to make payments that were probable in the short term for the ongoing NANORAY-312 Phase 3 pivotal trial development costs; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;revising potential future milestone payments for a total of $105&#160;million under both the Janssen License Agreement and the Asia Licensing Agreement, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;This amendment letter has been considered and accounted for as a contract modification under IFRS 15, which modifies the remaining transaction prices of both Janssen License Agreement and Asia Licensing Agreement, originally treated as separate contracts for IFRS 15 purposes. As there are price interdependencies between the two effects of the amendment as described above, the contract modification has been applied to both agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The amendment does not change the scope of the initial contracts but the overall impact of the contract modification is a significant increase in the remaining constrained transaction price of the combined agreements (Janssen Agreement and Asia Licensing Agreement) while the constraint continues to apply to milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The net positive impact on the constrained transaction price on the Janssen Agreement was recognized as a cumulative catch-up adjustment, as the remaining goods or services under the license agreement are not distinct. As a result, revenue for the six-month period ended June 30, 2025, included a one-off positive impact of &#x20ac;21.2&#160;million, directly attributable to the contract modification as described above.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In accordance with IFRS 15, the funding obligation towards Janssen was reduced to a net refund liability amounting to &#x20ac;7.4&#160;million as of June 30, 2025. See Note 14.4 &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Refund liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The combined effects of the amendment on the two license agreements resulted also in the allocation of &#x20ac;18.1&#160;million of the constrained transaction price to the Asia Licensing Agreement, which was recognized as the related contract liability since the delivery of the related performance obligation has not yet commenced. See Note 14.3 &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Deferred income and Contract liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived contextRef="c-293" decimals="-6" id="f-852" unitRef="eur">105000000</nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-294" decimals="-5" id="f-853" unitRef="eur">21200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-295" decimals="-5" id="f-854" unitRef="eur">7400000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities contextRef="c-1" decimals="-5" id="f-855" unitRef="eur">18100000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock contextRef="c-1" id="f-856">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s revenue and other income per category for the six-month period ended June 30, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six-month period ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;24,928&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subsidies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total revenue and other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;26,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;9,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-296" decimals="-3" id="f-857" unitRef="eur">21522000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-297" decimals="-3" id="f-858" unitRef="eur">3787000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-298" decimals="-3" id="f-859" unitRef="eur">3406000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-299" decimals="-3" id="f-860" unitRef="eur">2376000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-3" id="f-861" unitRef="eur">24928000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-4" decimals="-3" id="f-862" unitRef="eur">6163000</ifrs-full:RevenueFromContractsWithCustomers>
    <nbx:ResearchAndDevelopmentTaxCredit contextRef="c-1" decimals="-3" id="f-863" unitRef="eur">1616000</nbx:ResearchAndDevelopmentTaxCredit>
    <nbx:ResearchAndDevelopmentTaxCredit contextRef="c-4" decimals="-3" id="f-864" unitRef="eur">2334000</nbx:ResearchAndDevelopmentTaxCredit>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c-1" decimals="-3" id="f-865" unitRef="eur">67000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c-4" decimals="-3" id="f-866" unitRef="eur">36000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-3" id="f-867" unitRef="eur">26000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-4" decimals="-3" id="f-868" unitRef="eur">756000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:OtherIncome contextRef="c-1" decimals="-3" id="f-869" unitRef="eur">1710000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c-4" decimals="-3" id="f-870" unitRef="eur">3126000</ifrs-full:OtherIncome>
    <ifrs-full:Revenue contextRef="c-1" decimals="-3" id="f-871" unitRef="eur">26638000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-4" decimals="-3" id="f-872" unitRef="eur">9289000</ifrs-full:Revenue>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-5" id="f-873" unitRef="eur">24900000</ifrs-full:RevenueFromContractsWithCustomers>
    <nbx:AdjustmentsToRevenueFromContractsWithCustomers contextRef="c-296" decimals="-5" id="f-874" unitRef="eur">21200000</nbx:AdjustmentsToRevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-300" decimals="-5" id="f-875" unitRef="eur">400000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-301" decimals="-5" id="f-876" unitRef="eur">3400000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-4" decimals="-5" id="f-877" unitRef="eur">6200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-302" decimals="-5" id="f-878" unitRef="eur">2700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-303" decimals="-5" id="f-879" unitRef="eur">1100000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-304" decimals="-5" id="f-880" unitRef="eur">2400000</ifrs-full:RevenueFromContractsWithCustomers>
    <nbx:ResearchAndDevelopmentTaxCredit contextRef="c-4" decimals="-5" id="f-881" unitRef="eur">2300000</nbx:ResearchAndDevelopmentTaxCredit>
    <nbx:ResearchAndDevelopmentTaxCredit contextRef="c-1" decimals="-5" id="f-882" unitRef="eur">1600000</nbx:ResearchAndDevelopmentTaxCredit>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c-168" decimals="-3" id="f-883" unitRef="eur">67000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c-305" decimals="-3" id="f-884" unitRef="eur">36000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-3" id="f-885" unitRef="eur">26000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:OtherRevenue contextRef="c-306" decimals="-5" id="f-886" unitRef="eur">500000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-307" decimals="-5" id="f-887" unitRef="eur">200000</ifrs-full:OtherRevenue>
    <ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory contextRef="c-1" id="f-888">Operating expenses&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;17.1 RESEARCH AND DEVELOPMENT EXPENSES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six-month  period ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchases, sub-contracting and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll costs (including share-based payments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and provision expenses(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(14,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(21,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt"&gt;see Note 17.4 Depreciation, amortization and provision expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchases, sub-contracting and other expenses decreased by &#x20ac;7.6&#160;million for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024. This favorable variance is mainly related to the transfer of sponsorship of the 312 study to Janssen, including the amendment of the Janssen Agreement signed in March 2025, resulting in the removal of funding obligations on the 312 study.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D Payroll costs increased by &#x20ac;0.2&#160;million, or by 3.7% for the six-month period ended June&#160;30, 2025 as compared with the same period in 2024, which is mainly due to the phasing of social charges expenses related to stock options granted between 2025 and 2024 for &#x20ac;0.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;17.2 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six-month period ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchases, fees and other expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll costs (including share-based payments) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and provision expenses (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total SG&amp;amp;A expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(11,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(10,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt"&gt;see Note 17.4 Depreciation, amortization and provision expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchases, fees and other expenses increased by &#x20ac;0.2&#160;million for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024, as SG&amp;amp;A expenses were closely monitored and remained overall in line with prior year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A payroll costs increased by &#x20ac;0.7&#160;million, or 11.1%, for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024. This variation is mainly due to the phasing of social charges expenses related to stock options granted for &#x20ac;0.3&#160;million, and severance expenses following some resources reallocation for &#x20ac;0.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A depreciation expenses decreased by &#x20ac;0.4&#160;million following reversal of provision recorded during the first half off 2025 due to litigation settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;17.3 PAYROLL COSTS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six-month period ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Wages and salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Retirement benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total payroll costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(13,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(12,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Average headcount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;End-of-period headcount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company had 103 employees, including 72 in R&amp;amp;D and 31 in selling, general and administrative expenses, compared to 110 as of June&#160;30, 2024,  including 77 in R&amp;amp;D and 33 in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Wages and salaries remained stable for the six-month period ended June&#160;30, 2025 as compared to the same period in 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In the first half of 2025, related payroll taxes increased by 22.9%, or by &#x20ac;0.8&#160;million, mainly due to the phasing of social charges expenses related to stock options granting for &#x20ac;0.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 2 &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-based Payment&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, the share-based payment expense recognized in the statement of consolidated operations reflects the amortization of the fair value of the granted awards over the service period. The share-based payment expenses amounted to &#x20ac;2.2&#160;million for the period ended June&#160;30, 2025, as compared with &#x20ac;1.9&#160;million as of  June&#160;30, 2024 (see Note 18 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;17.4 DEPRECIATION, AMORTIZATION AND PROVISION EXPENSES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and provision expenses by function are detailed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.735%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six month period ended June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reversal of provision for disputes and charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for disputes and charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses (except IAS 19)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total Provision for retirement benefit obligations&#160;(IAS 19) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.735%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six month period ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reversal of provision for disputes and charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for disputes and charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total depreciation, amortization and provision expenses (except IAS 19)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total Provision for retirement benefit obligations&#160;(IAS 19) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Details of the provision for retirement benefit obligations are provided in note 11&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;17.5 OTHER OPERATING INCOME AND EXPENSES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six-month period ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other non recurring expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other non recurring  income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company has not recorded any material other operating income and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, the other non recurring expenses mainly relates to some employment termination indemnities for &#x20ac;129 thousand.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory>
    <nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock contextRef="c-1" id="f-889">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six-month  period ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchases, sub-contracting and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll costs (including share-based payments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and provision expenses(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(14,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(21,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt"&gt;see Note 17.4 Depreciation, amortization and provision expenses&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock>
    <nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses contextRef="c-1" decimals="-3" id="f-890" unitRef="eur">7489000</nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses>
    <nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses contextRef="c-4" decimals="-3" id="f-891" unitRef="eur">15105000</nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses>
    <nbx:ResearchAndDevelopmentExpensePayrollCosts contextRef="c-1" decimals="-3" id="f-892" unitRef="eur">6430000</nbx:ResearchAndDevelopmentExpensePayrollCosts>
    <nbx:ResearchAndDevelopmentExpensePayrollCosts contextRef="c-4" decimals="-3" id="f-893" unitRef="eur">6199000</nbx:ResearchAndDevelopmentExpensePayrollCosts>
    <nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense contextRef="c-1" decimals="-3" id="f-894" unitRef="eur">610000</nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense>
    <nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense contextRef="c-4" decimals="-3" id="f-895" unitRef="eur">682000</nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-896" unitRef="eur">14529000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-4" decimals="-3" id="f-897" unitRef="eur">21987000</ifrs-full:ResearchAndDevelopmentExpense>
    <nbx:IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses contextRef="c-308" decimals="-5" id="f-898" unitRef="eur">7600000</nbx:IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses>
    <nbx:IncreaseDecreasePayrollExpense contextRef="c-1" decimals="-5" id="f-899" unitRef="eur">200000</nbx:IncreaseDecreasePayrollExpense>
    <nbx:IncreaseDecreasePayrollExpensePercentage contextRef="c-1" decimals="3" id="f-900" unitRef="number">0.037</nbx:IncreaseDecreasePayrollExpensePercentage>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-309" decimals="-5" id="f-901" unitRef="eur">200000</ifrs-full:KeyManagementPersonnelCompensation>
    <nbx:DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock contextRef="c-1" id="f-902">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six-month period ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchases, fees and other expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll costs (including share-based payments) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and provision expenses (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total SG&amp;amp;A expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(11,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(10,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:7.08pt;text-align:justify;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.32pt"&gt;see Note 17.4 Depreciation, amortization and provision expenses&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock>
    <nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense contextRef="c-1" decimals="-3" id="f-903" unitRef="eur">4334000</nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense>
    <nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense contextRef="c-4" decimals="-3" id="f-904" unitRef="eur">4183000</nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense>
    <nbx:SellingGeneralAndAdministrativeExpensePayrollCosts contextRef="c-1" decimals="-3" id="f-905" unitRef="eur">7040000</nbx:SellingGeneralAndAdministrativeExpensePayrollCosts>
    <nbx:SellingGeneralAndAdministrativeExpensePayrollCosts contextRef="c-4" decimals="-3" id="f-906" unitRef="eur">6336000</nbx:SellingGeneralAndAdministrativeExpensePayrollCosts>
    <nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense contextRef="c-1" decimals="-3" id="f-907" unitRef="eur">-80000</nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense>
    <nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense contextRef="c-4" decimals="-3" id="f-908" unitRef="eur">301000</nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-909" unitRef="eur">11294000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-4" decimals="-3" id="f-910" unitRef="eur">10819000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <nbx:IncreaseDecreaseInPurchasesFeesAndOtherExpenses contextRef="c-310" decimals="-5" id="f-911" unitRef="eur">-200000</nbx:IncreaseDecreaseInPurchasesFeesAndOtherExpenses>
    <nbx:IncreaseDecreasePayrollExpense contextRef="c-310" decimals="-5" id="f-912" unitRef="eur">700000</nbx:IncreaseDecreasePayrollExpense>
    <nbx:IncreaseDecreasePayrollExpensePercentage contextRef="c-310" decimals="3" id="f-913" unitRef="number">0.111</nbx:IncreaseDecreasePayrollExpensePercentage>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-311" decimals="-5" id="f-914" unitRef="eur">300000</ifrs-full:KeyManagementPersonnelCompensation>
    <nbx:SeveranceExpenses contextRef="c-1" decimals="-5" id="f-915" unitRef="eur">200000</nbx:SeveranceExpenses>
    <nbx:IncreaseDecreaseInDepreciationExpense contextRef="c-1" decimals="-5" id="f-916" unitRef="eur">-400000</nbx:IncreaseDecreaseInDepreciationExpense>
    <nbx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock contextRef="c-1" id="f-917">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six-month period ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Wages and salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Retirement benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total payroll costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(13,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(12,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Average headcount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;End-of-period headcount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock>
    <ifrs-full:WagesAndSalaries contextRef="c-1" decimals="-3" id="f-918" unitRef="eur">7182000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c-4" decimals="-3" id="f-919" unitRef="eur">7238000</ifrs-full:WagesAndSalaries>
    <ifrs-full:SocialSecurityContributions contextRef="c-1" decimals="-3" id="f-920" unitRef="eur">4088000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions contextRef="c-4" decimals="-3" id="f-921" unitRef="eur">3324000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-1" decimals="-3" id="f-922" unitRef="eur">2161000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-4" decimals="-3" id="f-923" unitRef="eur">1940000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss contextRef="c-1" decimals="-3" id="f-924" unitRef="eur">-40000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss contextRef="c-4" decimals="-3" id="f-925" unitRef="eur">-33000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-1" decimals="-3" id="f-926" unitRef="eur">13470000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-4" decimals="-3" id="f-927" unitRef="eur">12535000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:AverageNumberOfEmployees contextRef="c-1" decimals="0" id="f-928" unitRef="employee">104</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:AverageNumberOfEmployees contextRef="c-4" decimals="0" id="f-929" unitRef="employee">105</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-2"
      decimals="INF"
      id="f-930"
      unitRef="employee">103</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-39"
      decimals="INF"
      id="f-931"
      unitRef="employee">110</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-2"
      decimals="INF"
      id="f-932"
      unitRef="employee">103</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-312"
      decimals="INF"
      id="f-933"
      unitRef="employee">72</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-313"
      decimals="INF"
      id="f-934"
      unitRef="employee">31</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-39"
      decimals="INF"
      id="f-935"
      unitRef="employee">110</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-314"
      decimals="INF"
      id="f-936"
      unitRef="employee">77</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-315"
      decimals="INF"
      id="f-937"
      unitRef="employee">33</ifrs-full:NumberOfEmployees>
    <nbx:IncreaseDecreaseInEmployeeBenefitExpensePercentage contextRef="c-1" decimals="3" id="f-938" unitRef="number">0.229</nbx:IncreaseDecreaseInEmployeeBenefitExpensePercentage>
    <nbx:IncreaseDecreaseInEmployeeBenefitExpense contextRef="c-1" decimals="-5" id="f-939" unitRef="eur">800000</nbx:IncreaseDecreaseInEmployeeBenefitExpense>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-316" decimals="-5" id="f-940" unitRef="eur">500000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-1" decimals="-5" id="f-941" unitRef="eur">2200000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-4" decimals="-5" id="f-942" unitRef="eur">1900000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock contextRef="c-1" id="f-943">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and provision expenses by function are detailed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.735%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six month period ended June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reversal of provision for disputes and charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for disputes and charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses (except IAS 19)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total Provision for retirement benefit obligations&#160;(IAS 19) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.735%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six month period ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reversal of provision for disputes and charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for disputes and charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total depreciation, amortization and provision expenses (except IAS 19)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total Provision for retirement benefit obligations&#160;(IAS 19) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Details of the provision for retirement benefit obligations are provided in note 11&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock>
    <ifrs-full:AmortisationExpense contextRef="c-308" decimals="-3" id="f-944" unitRef="eur">2000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense contextRef="c-310" decimals="-3" id="f-945" unitRef="eur">1000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense contextRef="c-1" decimals="-3" id="f-946" unitRef="eur">2000</ifrs-full:AmortisationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-308" decimals="-3" id="f-947" unitRef="eur">645000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-310" decimals="-3" id="f-948" unitRef="eur">152000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-1" decimals="-3" id="f-949" unitRef="eur">798000</ifrs-full:DepreciationExpense>
    <nbx:LitigationExpense contextRef="c-308" decimals="-3" id="f-950" unitRef="eur">-80000</nbx:LitigationExpense>
    <nbx:LitigationExpense contextRef="c-310" decimals="-3" id="f-951" unitRef="eur">-240000</nbx:LitigationExpense>
    <nbx:LitigationExpense contextRef="c-1" decimals="-3" id="f-952" unitRef="eur">-320000</nbx:LitigationExpense>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-308" decimals="-3" id="f-953" unitRef="eur">43000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-310" decimals="-3" id="f-954" unitRef="eur">7000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1" decimals="-3" id="f-955" unitRef="eur">49000</ifrs-full:ProvisionUsedOtherProvisions>
    <nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19 contextRef="c-308" decimals="-3" id="f-956" unitRef="eur">610000</nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19>
    <nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19 contextRef="c-310" decimals="-3" id="f-957" unitRef="eur">-80000</nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19>
    <nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19 contextRef="c-1" decimals="-3" id="f-958" unitRef="eur">529000</nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19>
    <nbx:ProvisionForRetirementBenefitObligationsNet contextRef="c-308" decimals="-3" id="f-959" unitRef="eur">27000</nbx:ProvisionForRetirementBenefitObligationsNet>
    <nbx:ProvisionForRetirementBenefitObligationsNet contextRef="c-310" decimals="-3" id="f-960" unitRef="eur">13000</nbx:ProvisionForRetirementBenefitObligationsNet>
    <nbx:ProvisionForRetirementBenefitObligationsNet contextRef="c-1" decimals="-3" id="f-961" unitRef="eur">40000</nbx:ProvisionForRetirementBenefitObligationsNet>
    <nbx:DepreciationAmortizationAndProvisionExpenses contextRef="c-308" decimals="-3" id="f-962" unitRef="eur">637000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DepreciationAmortizationAndProvisionExpenses contextRef="c-310" decimals="-3" id="f-963" unitRef="eur">-68000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DepreciationAmortizationAndProvisionExpenses contextRef="c-1" decimals="-3" id="f-964" unitRef="eur">569000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <ifrs-full:AmortisationExpense contextRef="c-317" decimals="-3" id="f-965" unitRef="eur">1000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense contextRef="c-318" decimals="-3" id="f-966" unitRef="eur">0</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense contextRef="c-4" decimals="-3" id="f-967" unitRef="eur">2000</ifrs-full:AmortisationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-317" decimals="-3" id="f-968" unitRef="eur">621000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-318" decimals="-3" id="f-969" unitRef="eur">164000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-4" decimals="-3" id="f-970" unitRef="eur">785000</ifrs-full:DepreciationExpense>
    <nbx:LitigationExpense contextRef="c-317" decimals="-3" id="f-971" unitRef="eur">0</nbx:LitigationExpense>
    <nbx:LitigationExpense contextRef="c-318" decimals="-3" id="f-972" unitRef="eur">-14000</nbx:LitigationExpense>
    <nbx:LitigationExpense contextRef="c-4" decimals="-3" id="f-973" unitRef="eur">-14000</nbx:LitigationExpense>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-317" decimals="-3" id="f-974" unitRef="eur">60000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-318" decimals="-3" id="f-975" unitRef="eur">150000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-4" decimals="-3" id="f-976" unitRef="eur">210000</ifrs-full:ProvisionUsedOtherProvisions>
    <nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19 contextRef="c-317" decimals="-3" id="f-977" unitRef="eur">682000</nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19>
    <nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19 contextRef="c-318" decimals="-3" id="f-978" unitRef="eur">301000</nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19>
    <nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19 contextRef="c-4" decimals="-3" id="f-979" unitRef="eur">983000</nbx:DepreciationAmortizationAndProvisionExpensesExcludingIAS19>
    <nbx:ProvisionForRetirementBenefitObligationsNet contextRef="c-317" decimals="-3" id="f-980" unitRef="eur">23000</nbx:ProvisionForRetirementBenefitObligationsNet>
    <nbx:ProvisionForRetirementBenefitObligationsNet contextRef="c-318" decimals="-3" id="f-981" unitRef="eur">10000</nbx:ProvisionForRetirementBenefitObligationsNet>
    <nbx:ProvisionForRetirementBenefitObligationsNet contextRef="c-4" decimals="-3" id="f-982" unitRef="eur">33000</nbx:ProvisionForRetirementBenefitObligationsNet>
    <nbx:DepreciationAmortizationAndProvisionExpenses contextRef="c-317" decimals="-3" id="f-983" unitRef="eur">705000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DepreciationAmortizationAndProvisionExpenses contextRef="c-318" decimals="-3" id="f-984" unitRef="eur">311000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DepreciationAmortizationAndProvisionExpenses contextRef="c-4" decimals="-3" id="f-985" unitRef="eur">1016000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock contextRef="c-1" id="f-986">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the six-month period ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other non recurring expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other non recurring  income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock>
    <nbx:OtherNonrecurringExpenses contextRef="c-1" decimals="-3" id="f-987" unitRef="eur">12000</nbx:OtherNonrecurringExpenses>
    <nbx:OtherNonrecurringExpenses contextRef="c-4" decimals="-3" id="f-988" unitRef="eur">137000</nbx:OtherNonrecurringExpenses>
    <nbx:OtherNonrecurringsIncome contextRef="c-1" decimals="-3" id="f-989" unitRef="eur">5000</nbx:OtherNonrecurringsIncome>
    <nbx:OtherNonrecurringsIncome contextRef="c-4" decimals="-3" id="f-990" unitRef="eur">3000</nbx:OtherNonrecurringsIncome>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-991" unitRef="eur">-7000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-4" decimals="-3" id="f-992" unitRef="eur">-134000</ifrs-full:OtherOperatingIncomeExpense>
    <nbx:OtherNonrecurringExpenses contextRef="c-319" decimals="-3" id="f-993" unitRef="eur">129000</nbx:OtherNonrecurringExpenses>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c-1" id="f-994">Share-based payments&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Detail of share-based payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has granted stock options (OSA), founders&#x2019; warrants (BSPCE), warrants (BSA), and free shares (AGA) to corporate officers, employees, members of the Executive and Supervisory Board and consultants of the Group. In certain cases, exercise of the stock options, founders&#x2019; warrants and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The number of stock options, founders&#x2019; warrants, warrants and free shares outstanding on June&#160;30, 2025 and their main characteristics, are detailed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Founders&#x2019; warrants outstanding as of June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.254%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSPCE 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSPCE 2015-3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSPCE 2016 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSPCE 2016 P&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSPCE 2017 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSCPE 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of the shareholders' meeting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18-Jun-14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18-Jun-14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25-Jun-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25-Jun-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-Jun-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-Jun-16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of grant by the Executive Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10-Feb-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10-Jun-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-Feb-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-Feb-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7-Jan-17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7-Jan-17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of BSPCEs authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of BSPCEs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares to which the BSPCE were likely to give right on the date of their grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number of which that may be subscribed by corporate officers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Laurent LEVY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of beneficiaries who are not corporate officers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Starting date for the exercise of the BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/10/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/10/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BSPCE expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/10/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/10/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/07/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/07/2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BSPCE exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;18.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;20.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;14.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;14.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;15.93&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of BSPCEs lapsed or cancelled as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total number of BSPCEs outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;97,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares available for subscription as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of the related BSPCEs are met)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants outstanding as of June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2015-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2015-2 (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2018-2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2019-1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2021 (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of the shareholders&#x2019; meeting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18-Jun-14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18-Jun-14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-May-18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-May-18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11-Apr-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30-Nov-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of grant by the Executive Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10-Feb-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25-Jun-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27-Jul-18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29-Mar-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17-Mar-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-Apr-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum number of BSAs authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;650,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of BSAs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,103&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares to which the BSA were likely to give right on the date of their grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,103&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;including the total number of shares that may subscribed by the corporate officers of the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relevant officers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Anne-Marie GRAFFIN&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,900&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,843&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Enno SPILLNER&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,829&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alain HERRERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,900&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,195&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gary PHILLIPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of beneficiaries who are not corporate officers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Starting date for the exercise of the BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/10/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;07/27/18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/29/19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/17/20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BSA expiry date (6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/10/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/25/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;07/27/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/29/29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/17/30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BSA issue price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;4.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;2.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;1.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;0.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;2.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercise price per BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;17.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;19.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;16.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;11.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;13.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of forfeited or cancelled BSAs as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total number of BSAs outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares available for subscription as of June&#160;30, 2025 (considering the conditions of exercise of the BSAs)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;as of June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.482%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2016-1 P&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2017 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2018 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2019-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2019 LLY &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2021-04 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of the shareholders&#x2019; meeting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25-Jun-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-Jun-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-Jun-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14-Jun-17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-May-18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11-Apr-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11-Apr-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30-Nov-20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of grant by the Executive Board &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02-Feb-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03-Nov-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;07-Jan-17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6-Mar-18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29-Mar-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24-Oct-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11-Mar-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-Apr-21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of OSAs authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;526,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;648,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of OSAs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares to which the OSAs were likely to give right on the date of their grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;including the number that may be subscribed or purchased by corporate officers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Laurent LEVY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Anne-Juliette HERMANT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Bart VAN RHIJN&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Louis KAYITALIRE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of beneficiaries who are not corporate officers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Starting date for the exercise of the OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/03/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/08/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/07/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/30/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10/24/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/11/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OSA expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/03/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/07/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/06/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/29/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10/24/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/11/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercise price per OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;13.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;14.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;14.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;12.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;11.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;6.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;13.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of lapsed or cancelled OSAs as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,265&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104,668&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total number of OSAs outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;360,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,532&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum number of shares available for subscription as of June&#160;30, 2025 (given the vesting conditions of the OSAs)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,532&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,532&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.866%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.866%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2021-04 P&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2021-06 P&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2021-06 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2022-06 P&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2022-06 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2023-01 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2024-01 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2025-01 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2025-02 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of the shareholders&#x2019; meeting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30-Nov-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30-Nov-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28-Apr-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30-Nov-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28-Apr-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-jun-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-Jul-23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28-May-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28-May-2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of grant by the Executive Board &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-Apr-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21-Jun-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21-Jun-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22-Jun-22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22-Jun-22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-Jul-23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-May-24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18-Feb-25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16-May-25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of OSAs authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,700,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,700,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,700,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,700,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of OSAs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;338,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,224,780&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241,005&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares to which the OSAs were likely to give right on the date of their grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;338,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,224,780&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241,005&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;including the number that may be subscribed or purchased by corporate officers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;930,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Laurent LEVY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Anne-Juliette HERMANT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,354&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Bart VAN RHIJN&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,390&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Louis KAYITALIRE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of beneficiaries who are not corporate officers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Starting date for the exercise of the OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/21/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/21/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/22/23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/22/23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7/20/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5/23/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2/18/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5/16/2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OSA expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/21/31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/21/31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/22/32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/22/32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7/20/2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5/23/2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2/18/2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5/16/2035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercise price per OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;13.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;12.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;12.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;5.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;2.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of lapsed or cancelled OSAs as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,620&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total number of OSAs outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;340,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;123,780&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;380,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;318,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,219,530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,241,004&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum number of shares available for subscription as of June&#160;30, 2025 (given the vesting conditions of the OSAs)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106,288&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406,510&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123,780&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,219,530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241,004&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Free shares&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;as at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.267%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.216%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.217%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AGA 2023 - P1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AGA 2023 - P2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of the shareholders&#x2019; meeting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27-Jun-23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27-Jun-23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of grant by the Executive Board &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27-Jun-23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27-Jun-23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of AGAs authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of AGAs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;427,110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;439,210&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares to which the AGAs were likely to give right on the date of their grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;427,110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;439,210&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;including the number that can be subscribed by corporate officers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293,470&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Laurent LEVY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Anne-Juliette HERMANT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,354&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,354&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Bart VAN RHIJN&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,390&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,390&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of beneficiaries who are not corporate officers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of acquisition (end of the acquisition period)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/27/25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/27/25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392,060&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;417,760&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of AGAs lapsed or cancelled as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,450&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total number of AGAs outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares that may be subscribed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Duration of the holding period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.139%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;371,967&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,730,663&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,158,881&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The measurement methods used to estimate the fair value of stock options and warrants are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;The exercise price is based on the share price at the grant date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;The risk-free rate was determined based on the average life of the instruments; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Volatility was determined based on a sample of listed companies in the biotechnology sector at the grant date and for a period equal to the life of the warrant or option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The performance conditions for all of the plans were assessed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Performance conditions unrelated to the market were analyzed to determine the likely exercise date of the warrants and options and expense was recorded accordingly based on the probability these conditions would be met; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;Market-related performance conditions were directly included in the calculation of the fair value of the instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As of June&#160;30, 2025, the details of active share-based payment plans with remaining IFRS 2 expense are presented in the tables below, reflecting the assumptions related to the probability that the non-market performance conditions will be  and the ongoing accounting impact for the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.008%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.308%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the first half of 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the first half of 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-04 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38.9% - 37.8% - 38.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.38% / 0.33% / 0.28%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-04 P&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.03&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-06 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.2% - 37.9% - 38.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.35% / 0.30% / 0.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-06 P&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2022-06 P &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.4008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.0228&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2022-06 O &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;42.06% - 41.21% - 40.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.83% / 1.87% / 1.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2023-01 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;45.07% - 44.11% - 43.41% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.85% /2.83% / 2.82%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2024-01 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;53.30% - 51.90% - 50.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.4 / 5.9 / 6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.00% / 3.02% / 3.02%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2025-01 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;47.18% / 47.43% / 47.57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.4 / 5.9 / 6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.83% / 2.91% / 2.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2025-02 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;47.56% / 47.32% / 47.43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.4 / 5.9 / 6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.53% / 2.61% / 2.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;n.a. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;708&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.823%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.770%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the first half of 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the first half of 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2023 - P1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3% / 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2023 - P2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3% /3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.781%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,161&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.781%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;708&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,232&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,940&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock contextRef="c-1" id="f-995">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The number of stock options, founders&#x2019; warrants, warrants and free shares outstanding on June&#160;30, 2025 and their main characteristics, are detailed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Founders&#x2019; warrants outstanding as of June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.254%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSPCE 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSPCE 2015-3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSPCE 2016 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSPCE 2016 P&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSPCE 2017 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSCPE 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of the shareholders' meeting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18-Jun-14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18-Jun-14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25-Jun-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25-Jun-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-Jun-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-Jun-16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of grant by the Executive Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10-Feb-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10-Jun-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-Feb-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-Feb-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7-Jan-17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7-Jan-17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of BSPCEs authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of BSPCEs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares to which the BSPCE were likely to give right on the date of their grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number of which that may be subscribed by corporate officers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Laurent LEVY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of beneficiaries who are not corporate officers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Starting date for the exercise of the BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/10/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/10/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BSPCE expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/10/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/10/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/07/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/07/2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BSPCE exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;18.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;20.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;14.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;14.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;15.93&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of BSPCEs lapsed or cancelled as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total number of BSPCEs outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;97,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares available for subscription as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of the related BSPCEs are met)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants outstanding as of June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2015-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2015-2 (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2018-2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2019-1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BSA 2021 (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of the shareholders&#x2019; meeting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18-Jun-14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18-Jun-14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-May-18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-May-18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11-Apr-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30-Nov-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of grant by the Executive Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10-Feb-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25-Jun-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27-Jul-18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29-Mar-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17-Mar-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-Apr-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum number of BSAs authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;650,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of BSAs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,103&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares to which the BSA were likely to give right on the date of their grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,103&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;including the total number of shares that may subscribed by the corporate officers of the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relevant officers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Anne-Marie GRAFFIN&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,900&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,843&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Enno SPILLNER&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,829&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alain HERRERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,900&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,195&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gary PHILLIPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of beneficiaries who are not corporate officers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Starting date for the exercise of the BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/10/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;07/27/18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/29/19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/17/20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BSA expiry date (6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/10/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/25/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;07/27/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/29/29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/17/30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BSA issue price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;4.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;2.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;1.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;0.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;2.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercise price per BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;17.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;19.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;16.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;11.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;13.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of forfeited or cancelled BSAs as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total number of BSAs outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares available for subscription as of June&#160;30, 2025 (considering the conditions of exercise of the BSAs)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Free shares&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;as at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.267%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.216%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.217%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AGA 2023 - P1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AGA 2023 - P2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of the shareholders&#x2019; meeting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27-Jun-23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27-Jun-23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of grant by the Executive Board &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27-Jun-23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27-Jun-23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of AGAs authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,200,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of AGAs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;427,110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;439,210&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares to which the AGAs were likely to give right on the date of their grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;427,110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;439,210&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;including the number that can be subscribed by corporate officers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293,470&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Laurent LEVY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Anne-Juliette HERMANT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,354&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,354&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Bart VAN RHIJN&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,390&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,390&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of beneficiaries who are not corporate officers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of acquisition (end of the acquisition period)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/27/25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/27/25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392,060&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;417,760&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of AGAs lapsed or cancelled as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,450&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total number of AGAs outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares that may be subscribed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Duration of the holding period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.139%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;371,967&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,730,663&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,158,881&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-320"
      decimals="INF"
      id="f-996"
      unitRef="shares">450000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-321"
      decimals="INF"
      id="f-997"
      unitRef="shares">450000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-322"
      decimals="INF"
      id="f-998"
      unitRef="shares">450000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-323"
      decimals="INF"
      id="f-999"
      unitRef="shares">450000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-324"
      decimals="INF"
      id="f-1000"
      unitRef="shares">450000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-325"
      decimals="INF"
      id="f-1001"
      unitRef="shares">450000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-320"
      decimals="INF"
      id="f-1002"
      unitRef="shares">71650</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-321"
      decimals="INF"
      id="f-1003"
      unitRef="shares">53050</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-322"
      decimals="INF"
      id="f-1004"
      unitRef="shares">126400</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-323"
      decimals="INF"
      id="f-1005"
      unitRef="shares">129250</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-324"
      decimals="INF"
      id="f-1006"
      unitRef="shares">117650</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-325"
      decimals="INF"
      id="f-1007"
      unitRef="shares">80000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-320"
      decimals="INF"
      id="f-1008"
      unitRef="shares">71650</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-321"
      decimals="INF"
      id="f-1009"
      unitRef="shares">53050</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-322"
      decimals="INF"
      id="f-1010"
      unitRef="shares">126400</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-323"
      decimals="INF"
      id="f-1011"
      unitRef="shares">129250</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-324"
      decimals="INF"
      id="f-1012"
      unitRef="shares">117650</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-325"
      decimals="INF"
      id="f-1013"
      unitRef="shares">80000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-326"
      decimals="INF"
      id="f-1014"
      unitRef="shares">24000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-327"
      decimals="INF"
      id="f-1015"
      unitRef="shares">23500</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-328"
      decimals="INF"
      id="f-1016"
      unitRef="shares">23500</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-329"
      decimals="INF"
      id="f-1017"
      unitRef="shares">26400</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-330"
      decimals="INF"
      id="f-1018"
      unitRef="shares">32000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-331"
      decimals="INF"
      id="f-1019"
      unitRef="shares">24000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-332"
      decimals="INF"
      id="f-1020"
      unitRef="shares">23500</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-333"
      decimals="INF"
      id="f-1021"
      unitRef="shares">23500</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-334"
      decimals="INF"
      id="f-1022"
      unitRef="shares">26400</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-335"
      decimals="INF"
      id="f-1023"
      unitRef="shares">32000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-336"
      decimals="INF"
      id="f-1024"
      unitRef="benefeciary">13</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-337"
      decimals="INF"
      id="f-1025"
      unitRef="benefeciary">42</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-338"
      decimals="INF"
      id="f-1026"
      unitRef="benefeciary">43</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-339"
      decimals="INF"
      id="f-1027"
      unitRef="benefeciary">50</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-340"
      decimals="INF"
      id="f-1028"
      unitRef="benefeciary">42</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-341"
      decimals="INF"
      id="f-1029"
      unitRef="benefeciary">3</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-320"
      decimals="2"
      id="f-1030"
      unitRef="eurPerShare">18.57</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-321"
      decimals="2"
      id="f-1031"
      unitRef="eurPerShare">20.28</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-322"
      decimals="2"
      id="f-1032"
      unitRef="eurPerShare">14.46</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-323"
      decimals="2"
      id="f-1033"
      unitRef="eurPerShare">14.46</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-324"
      decimals="2"
      id="f-1034"
      unitRef="eurPerShare">15.93</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-325"
      decimals="2"
      id="f-1035"
      unitRef="eurPerShare">15.93</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-342"
      decimals="INF"
      id="f-1036"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-343"
      decimals="INF"
      id="f-1037"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-344"
      decimals="INF"
      id="f-1038"
      unitRef="shares">333</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-345"
      decimals="INF"
      id="f-1039"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-346"
      decimals="INF"
      id="f-1040"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-347"
      decimals="INF"
      id="f-1041"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-342"
      decimals="INF"
      id="f-1042"
      unitRef="shares">71650</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-343"
      decimals="INF"
      id="f-1043"
      unitRef="shares">53050</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-344"
      decimals="INF"
      id="f-1044"
      unitRef="shares">29250</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-345"
      decimals="INF"
      id="f-1045"
      unitRef="shares">31150</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-346"
      decimals="INF"
      id="f-1046"
      unitRef="shares">20600</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-347"
      decimals="INF"
      id="f-1047"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-348"
      decimals="INF"
      id="f-1048"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-349"
      decimals="INF"
      id="f-1049"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-350"
      decimals="INF"
      id="f-1050"
      unitRef="shares">96817</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-351"
      decimals="INF"
      id="f-1051"
      unitRef="shares">98100</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-352"
      decimals="INF"
      id="f-1052"
      unitRef="shares">97050</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-353"
      decimals="INF"
      id="f-1053"
      unitRef="shares">80000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-348"
      decimals="INF"
      id="f-1054"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-349"
      decimals="INF"
      id="f-1055"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-350"
      decimals="INF"
      id="f-1056"
      unitRef="shares">96817</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-351"
      decimals="INF"
      id="f-1057"
      unitRef="shares">98100</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-352"
      decimals="INF"
      id="f-1058"
      unitRef="shares">97050</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-353"
      decimals="INF"
      id="f-1059"
      unitRef="shares">80000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-348"
      decimals="INF"
      id="f-1060"
      unitRef="shares">0</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-349"
      decimals="INF"
      id="f-1061"
      unitRef="shares">0</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-350"
      decimals="INF"
      id="f-1062"
      unitRef="shares">96817</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-351"
      decimals="INF"
      id="f-1063"
      unitRef="shares">98100</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-352"
      decimals="INF"
      id="f-1064"
      unitRef="shares">97050</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-353"
      decimals="INF"
      id="f-1065"
      unitRef="shares">80000</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-354"
      decimals="INF"
      id="f-1066"
      unitRef="shares">100000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-355"
      decimals="INF"
      id="f-1067"
      unitRef="shares">100000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-356"
      decimals="INF"
      id="f-1068"
      unitRef="shares">140000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-357"
      decimals="INF"
      id="f-1069"
      unitRef="shares">140000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-358"
      decimals="INF"
      id="f-1070"
      unitRef="shares">500000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-359"
      decimals="INF"
      id="f-1071"
      unitRef="shares">650000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-354"
      decimals="INF"
      id="f-1072"
      unitRef="shares">26000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-355"
      decimals="INF"
      id="f-1073"
      unitRef="shares">64000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-356"
      decimals="INF"
      id="f-1074"
      unitRef="shares">5820</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-357"
      decimals="INF"
      id="f-1075"
      unitRef="shares">18000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-358"
      decimals="INF"
      id="f-1076"
      unitRef="shares">18000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-359"
      decimals="INF"
      id="f-1077"
      unitRef="shares">48103</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-354"
      decimals="INF"
      id="f-1078"
      unitRef="shares">26000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-355"
      decimals="INF"
      id="f-1079"
      unitRef="shares">64000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-356"
      decimals="INF"
      id="f-1080"
      unitRef="shares">5820</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-357"
      decimals="INF"
      id="f-1081"
      unitRef="shares">18000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-358"
      decimals="INF"
      id="f-1082"
      unitRef="shares">18000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-359"
      decimals="INF"
      id="f-1083"
      unitRef="shares">48103</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-360"
      decimals="INF"
      id="f-1084"
      unitRef="shares">15000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-361"
      decimals="INF"
      id="f-1085"
      unitRef="shares">12700</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-362"
      decimals="INF"
      id="f-1086"
      unitRef="shares">14024</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-363"
      decimals="INF"
      id="f-1087"
      unitRef="shares">5000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-364"
      decimals="INF"
      id="f-1088"
      unitRef="shares">2900</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-365"
      decimals="INF"
      id="f-1089"
      unitRef="shares">3843</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-366"
      decimals="INF"
      id="f-1090"
      unitRef="shares">3000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-367"
      decimals="INF"
      id="f-1091"
      unitRef="shares">4000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-368"
      decimals="INF"
      id="f-1092"
      unitRef="shares">3829</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-369"
      decimals="INF"
      id="f-1093"
      unitRef="shares">5000</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-370"
      decimals="INF"
      id="f-1094"
      unitRef="shares">2900</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-371"
      decimals="INF"
      id="f-1095"
      unitRef="shares">3195</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-372"
      decimals="INF"
      id="f-1096"
      unitRef="benefeciary">2</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-373"
      decimals="INF"
      id="f-1097"
      unitRef="benefeciary">1</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-374"
      decimals="INF"
      id="f-1098"
      unitRef="benefeciary">1</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-375"
      decimals="INF"
      id="f-1099"
      unitRef="benefeciary">1</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-376"
      decimals="INF"
      id="f-1100"
      unitRef="benefeciary">1</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-377"
      decimals="INF"
      id="f-1101"
      unitRef="benefeciary">1</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="c-354"
      decimals="2"
      id="f-1102"
      unitRef="eurPerShare">4.87</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="c-355"
      decimals="2"
      id="f-1103"
      unitRef="eurPerShare">5.00</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="c-356"
      decimals="2"
      id="f-1104"
      unitRef="eurPerShare">2.36</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="c-357"
      decimals="2"
      id="f-1105"
      unitRef="eurPerShare">1.15</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="c-358"
      decimals="2"
      id="f-1106"
      unitRef="eurPerShare">0.29</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="c-359"
      decimals="2"
      id="f-1107"
      unitRef="eurPerShare">2.95</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-354"
      decimals="2"
      id="f-1108"
      unitRef="eurPerShare">17.67</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-355"
      decimals="2"
      id="f-1109"
      unitRef="eurPerShare">19.54</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-356"
      decimals="2"
      id="f-1110"
      unitRef="eurPerShare">16.10</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-357"
      decimals="2"
      id="f-1111"
      unitRef="eurPerShare">11.66</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-358"
      decimals="2"
      id="f-1112"
      unitRef="eurPerShare">6.59</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-359"
      decimals="2"
      id="f-1113"
      unitRef="eurPerShare">13.47</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-378"
      decimals="INF"
      id="f-1114"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-379"
      decimals="INF"
      id="f-1115"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-380"
      decimals="INF"
      id="f-1116"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-381"
      decimals="INF"
      id="f-1117"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-382"
      decimals="INF"
      id="f-1118"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-383"
      decimals="INF"
      id="f-1119"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-378"
      decimals="INF"
      id="f-1120"
      unitRef="shares">26000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-379"
      decimals="INF"
      id="f-1121"
      unitRef="shares">64000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-380"
      decimals="INF"
      id="f-1122"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-381"
      decimals="INF"
      id="f-1123"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-382"
      decimals="INF"
      id="f-1124"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-383"
      decimals="INF"
      id="f-1125"
      unitRef="shares">33672</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-384"
      decimals="INF"
      id="f-1126"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-385"
      decimals="INF"
      id="f-1127"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-386"
      decimals="INF"
      id="f-1128"
      unitRef="shares">5820</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-387"
      decimals="INF"
      id="f-1129"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-388"
      decimals="INF"
      id="f-1130"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-389"
      decimals="INF"
      id="f-1131"
      unitRef="shares">14431</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-384"
      decimals="INF"
      id="f-1132"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-385"
      decimals="INF"
      id="f-1133"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-386"
      decimals="INF"
      id="f-1134"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-387"
      decimals="INF"
      id="f-1135"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-388"
      decimals="INF"
      id="f-1136"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-389"
      decimals="INF"
      id="f-1137"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-384"
      decimals="INF"
      id="f-1138"
      unitRef="shares">0</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-385"
      decimals="INF"
      id="f-1139"
      unitRef="shares">0</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-386"
      decimals="INF"
      id="f-1140"
      unitRef="shares">5820</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-387"
      decimals="INF"
      id="f-1141"
      unitRef="shares">18000</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-388"
      decimals="INF"
      id="f-1142"
      unitRef="shares">18000</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-389"
      decimals="INF"
      id="f-1143"
      unitRef="shares">14431</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="c-1" id="f-1144">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;as of June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.482%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2016-1 P&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2017 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2018 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2019-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2019 LLY &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2021-04 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of the shareholders&#x2019; meeting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25-Jun-15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-Jun-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-Jun-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14-Jun-17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-May-18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11-Apr-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11-Apr-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30-Nov-20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of grant by the Executive Board &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02-Feb-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03-Nov-16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;07-Jan-17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6-Mar-18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29-Mar-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24-Oct-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11-Mar-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-Apr-21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of OSAs authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;526,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;648,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of OSAs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares to which the OSAs were likely to give right on the date of their grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;including the number that may be subscribed or purchased by corporate officers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Laurent LEVY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Anne-Juliette HERMANT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Bart VAN RHIJN&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Louis KAYITALIRE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of beneficiaries who are not corporate officers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Starting date for the exercise of the OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/03/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/08/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/07/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/30/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10/24/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/11/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OSA expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/03/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;01/07/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/06/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/29/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10/24/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;03/11/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercise price per OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;13.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;14.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;14.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;12.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;11.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;6.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;13.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of lapsed or cancelled OSAs as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,265&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104,668&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total number of OSAs outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;360,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,532&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum number of shares available for subscription as of June&#160;30, 2025 (given the vesting conditions of the OSAs)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,532&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,532&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.866%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.866%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2021-04 P&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2021-06 P&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2021-06 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2022-06 P&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2022-06 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2023-01 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2024-01 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2025-01 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;OSA 2025-02 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of the shareholders&#x2019; meeting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30-Nov-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30-Nov-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28-Apr-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30-Nov-20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28-Apr-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-jun-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-Jul-23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28-May-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28-May-2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Date of grant by the Executive Board &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-Apr-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21-Jun-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21-Jun-21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22-Jun-22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22-Jun-22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20-Jul-23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23-May-24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18-Feb-25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16-May-25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of OSAs authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,700,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,700,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,700,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,700,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of OSAs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;338,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,224,780&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241,005&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of shares to which the OSAs were likely to give right on the date of their grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;338,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,224,780&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241,005&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;including the number that may be subscribed or purchased by corporate officers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;930,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Laurent LEVY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Anne-Juliette HERMANT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,354&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Bart VAN RHIJN&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,390&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;the number that can be subscribed by Louis KAYITALIRE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of beneficiaries who are not corporate officers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Starting date for the exercise of the OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/21/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/21/22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/22/23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/22/23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7/20/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5/23/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2/18/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5/16/2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OSA expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;04/20/31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/21/31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/21/31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/22/32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;06/22/32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7/20/2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5/23/2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2/18/2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5/16/2035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercise price per OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;13.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;12.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;12.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;5.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x20ac;2.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total number of lapsed or cancelled OSAs as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,620&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total number of OSAs outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;340,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;123,780&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;380,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;318,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,219,530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,241,004&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum number of shares available for subscription as of June&#160;30, 2025 (given the vesting conditions of the OSAs)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106,288&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406,510&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123,780&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318,860&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,219,530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241,004&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.139%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;371,967&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,730,663&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,158,881&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-390"
      decimals="INF"
      id="f-1145"
      unitRef="shares">450000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-391"
      decimals="INF"
      id="f-1146"
      unitRef="shares">450000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-392"
      decimals="INF"
      id="f-1147"
      unitRef="shares">450000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-393"
      decimals="INF"
      id="f-1148"
      unitRef="shares">526800</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-394"
      decimals="INF"
      id="f-1149"
      unitRef="shares">648000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-395"
      decimals="INF"
      id="f-1150"
      unitRef="shares">500000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-396"
      decimals="INF"
      id="f-1151"
      unitRef="shares">500000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-397"
      decimals="INF"
      id="f-1152"
      unitRef="shares">850000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-390"
      decimals="INF"
      id="f-1153"
      unitRef="shares">6400</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-391"
      decimals="INF"
      id="f-1154"
      unitRef="shares">4000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-392"
      decimals="INF"
      id="f-1155"
      unitRef="shares">3500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-393"
      decimals="INF"
      id="f-1156"
      unitRef="shares">62000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-394"
      decimals="INF"
      id="f-1157"
      unitRef="shares">37500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-395"
      decimals="INF"
      id="f-1158"
      unitRef="shares">500000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-396"
      decimals="INF"
      id="f-1159"
      unitRef="shares">407972</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-397"
      decimals="INF"
      id="f-1160"
      unitRef="shares">143200</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-390"
      decimals="INF"
      id="f-1161"
      unitRef="shares">6400</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-391"
      decimals="INF"
      id="f-1162"
      unitRef="shares">4000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-392"
      decimals="INF"
      id="f-1163"
      unitRef="shares">3500</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-393"
      decimals="INF"
      id="f-1164"
      unitRef="shares">62000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-394"
      decimals="INF"
      id="f-1165"
      unitRef="shares">37500</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-395"
      decimals="INF"
      id="f-1166"
      unitRef="shares">500000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-396"
      decimals="INF"
      id="f-1167"
      unitRef="shares">407972</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-397"
      decimals="INF"
      id="f-1168"
      unitRef="shares">143200</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-398"
      decimals="INF"
      id="f-1169"
      unitRef="shares">500000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-399"
      decimals="INF"
      id="f-1170"
      unitRef="shares">180000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-400"
      decimals="INF"
      id="f-1171"
      unitRef="shares">500000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-401"
      decimals="INF"
      id="f-1172"
      unitRef="shares">120000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-402"
      decimals="INF"
      id="f-1173"
      unitRef="shares">60000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-403"
      decimals="INF"
      id="f-1174"
      unitRef="benefeciary">2</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-404"
      decimals="INF"
      id="f-1175"
      unitRef="benefeciary">1</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-405"
      decimals="INF"
      id="f-1176"
      unitRef="benefeciary">2</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-406"
      decimals="INF"
      id="f-1177"
      unitRef="benefeciary">5</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-407"
      decimals="INF"
      id="f-1178"
      unitRef="benefeciary">12</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-408"
      decimals="INF"
      id="f-1179"
      unitRef="benefeciary">104</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-409"
      decimals="INF"
      id="f-1180"
      unitRef="benefeciary">13</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-390"
      decimals="2"
      id="f-1181"
      unitRef="eurPerShare">13.05</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-391"
      decimals="2"
      id="f-1182"
      unitRef="eurPerShare">14.26</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-392"
      decimals="2"
      id="f-1183"
      unitRef="eurPerShare">14.97</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-393"
      decimals="2"
      id="f-1184"
      unitRef="eurPerShare">12.87</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-394"
      decimals="2"
      id="f-1185"
      unitRef="eurPerShare">11.08</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-395"
      decimals="2"
      id="f-1186"
      unitRef="eurPerShare">6.41</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-396"
      decimals="2"
      id="f-1187"
      unitRef="eurPerShare">6.25</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-397"
      decimals="2"
      id="f-1188"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-410"
      decimals="INF"
      id="f-1189"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-411"
      decimals="INF"
      id="f-1190"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-412"
      decimals="INF"
      id="f-1191"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-413"
      decimals="INF"
      id="f-1192"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-414"
      decimals="INF"
      id="f-1193"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-415"
      decimals="INF"
      id="f-1194"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-416"
      decimals="INF"
      id="f-1195"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-417"
      decimals="INF"
      id="f-1196"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-410"
      decimals="INF"
      id="f-1197"
      unitRef="shares">6000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-411"
      decimals="INF"
      id="f-1198"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-412"
      decimals="INF"
      id="f-1199"
      unitRef="shares">3000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-413"
      decimals="INF"
      id="f-1200"
      unitRef="shares">12000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-414"
      decimals="INF"
      id="f-1201"
      unitRef="shares">12750</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-415"
      decimals="INF"
      id="f-1202"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-416"
      decimals="INF"
      id="f-1203"
      unitRef="shares">47265</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-417"
      decimals="INF"
      id="f-1204"
      unitRef="shares">104668</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-418"
      decimals="INF"
      id="f-1205"
      unitRef="shares">400</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-419"
      decimals="INF"
      id="f-1206"
      unitRef="shares">4000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-420"
      decimals="INF"
      id="f-1207"
      unitRef="shares">500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-421"
      decimals="INF"
      id="f-1208"
      unitRef="shares">50000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-422"
      decimals="INF"
      id="f-1209"
      unitRef="shares">24750</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-423"
      decimals="INF"
      id="f-1210"
      unitRef="shares">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-424"
      decimals="INF"
      id="f-1211"
      unitRef="shares">360707</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-425"
      decimals="INF"
      id="f-1212"
      unitRef="shares">38532</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-418"
      decimals="INF"
      id="f-1213"
      unitRef="shares">400</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-419"
      decimals="INF"
      id="f-1214"
      unitRef="shares">4000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-420"
      decimals="INF"
      id="f-1215"
      unitRef="shares">500</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-421"
      decimals="INF"
      id="f-1216"
      unitRef="shares">50000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-422"
      decimals="INF"
      id="f-1217"
      unitRef="shares">24750</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-423"
      decimals="INF"
      id="f-1218"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-424"
      decimals="INF"
      id="f-1219"
      unitRef="shares">360707</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-425"
      decimals="INF"
      id="f-1220"
      unitRef="shares">38532</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-418"
      decimals="INF"
      id="f-1221"
      unitRef="shares">400</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-419"
      decimals="INF"
      id="f-1222"
      unitRef="shares">4000</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-420"
      decimals="INF"
      id="f-1223"
      unitRef="shares">500</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-421"
      decimals="INF"
      id="f-1224"
      unitRef="shares">50000</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-422"
      decimals="INF"
      id="f-1225"
      unitRef="shares">24750</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-423"
      decimals="INF"
      id="f-1226"
      unitRef="shares">500000</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-424"
      decimals="INF"
      id="f-1227"
      unitRef="shares">360707</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-425"
      decimals="INF"
      id="f-1228"
      unitRef="shares">38532</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-426"
      decimals="INF"
      id="f-1229"
      unitRef="shares">1000000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-427"
      decimals="INF"
      id="f-1230"
      unitRef="shares">1000000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-428"
      decimals="INF"
      id="f-1231"
      unitRef="shares">850000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-429"
      decimals="INF"
      id="f-1232"
      unitRef="shares">1000000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-430"
      decimals="INF"
      id="f-1233"
      unitRef="shares">850000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-431"
      decimals="INF"
      id="f-1234"
      unitRef="shares">1700000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-432"
      decimals="INF"
      id="f-1235"
      unitRef="shares">1700000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-433"
      decimals="INF"
      id="f-1236"
      unitRef="shares">1700000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-434"
      decimals="INF"
      id="f-1237"
      unitRef="shares">1700000</nbx:NumberOfShareOptionsAuthorisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-426"
      decimals="INF"
      id="f-1238"
      unitRef="shares">428000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-427"
      decimals="INF"
      id="f-1239"
      unitRef="shares">60000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-428"
      decimals="INF"
      id="f-1240"
      unitRef="shares">60000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-429"
      decimals="INF"
      id="f-1241"
      unitRef="shares">170400</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-430"
      decimals="INF"
      id="f-1242"
      unitRef="shares">410500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-431"
      decimals="INF"
      id="f-1243"
      unitRef="shares">338860</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-432"
      decimals="INF"
      id="f-1244"
      unitRef="shares">1224780</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-433"
      decimals="INF"
      id="f-1245"
      unitRef="shares">8000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-434"
      decimals="INF"
      id="f-1246"
      unitRef="shares">1241005</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-426"
      decimals="INF"
      id="f-1247"
      unitRef="shares">428000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-427"
      decimals="INF"
      id="f-1248"
      unitRef="shares">60000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-428"
      decimals="INF"
      id="f-1249"
      unitRef="shares">60000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-429"
      decimals="INF"
      id="f-1250"
      unitRef="shares">170400</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-430"
      decimals="INF"
      id="f-1251"
      unitRef="shares">410500</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-431"
      decimals="INF"
      id="f-1252"
      unitRef="shares">338860</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-432"
      decimals="INF"
      id="f-1253"
      unitRef="shares">1224780</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-433"
      decimals="INF"
      id="f-1254"
      unitRef="shares">8000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-434"
      decimals="INF"
      id="f-1255"
      unitRef="shares">1241005</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-435"
      decimals="INF"
      id="f-1256"
      unitRef="shares">240000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-436"
      decimals="INF"
      id="f-1257"
      unitRef="shares">60000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-437"
      decimals="INF"
      id="f-1258"
      unitRef="shares">60000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-438"
      decimals="INF"
      id="f-1259"
      unitRef="shares">245000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-439"
      decimals="INF"
      id="f-1260"
      unitRef="shares">298860</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-440"
      decimals="INF"
      id="f-1261"
      unitRef="shares">930000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-441"
      decimals="INF"
      id="f-1262"
      unitRef="shares">0</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-442"
      decimals="INF"
      id="f-1263"
      unitRef="shares">945000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-443"
      decimals="INF"
      id="f-1264"
      unitRef="shares">180000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-444"
      decimals="INF"
      id="f-1265"
      unitRef="shares">150000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-445"
      decimals="INF"
      id="f-1266"
      unitRef="shares">200116</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-446"
      decimals="INF"
      id="f-1267"
      unitRef="shares">500000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-447"
      decimals="INF"
      id="f-1268"
      unitRef="shares">0</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-448"
      decimals="INF"
      id="f-1269"
      unitRef="shares">505000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-449"
      decimals="INF"
      id="f-1270"
      unitRef="shares">60000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-450"
      decimals="INF"
      id="f-1271"
      unitRef="shares">35000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-451"
      decimals="INF"
      id="f-1272"
      unitRef="shares">33354</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-452"
      decimals="INF"
      id="f-1273"
      unitRef="shares">90000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-453"
      decimals="INF"
      id="f-1274"
      unitRef="shares">0</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-454"
      decimals="INF"
      id="f-1275"
      unitRef="shares">100000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-455"
      decimals="INF"
      id="f-1276"
      unitRef="shares">60000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-456"
      decimals="INF"
      id="f-1277"
      unitRef="shares">60000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-457"
      decimals="INF"
      id="f-1278"
      unitRef="shares">60000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-458"
      decimals="INF"
      id="f-1279"
      unitRef="shares">65390</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-459"
      decimals="INF"
      id="f-1280"
      unitRef="shares">180000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-460"
      decimals="INF"
      id="f-1281"
      unitRef="shares">0</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-461"
      decimals="INF"
      id="f-1282"
      unitRef="shares">190000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-462"
      decimals="INF"
      id="f-1283"
      unitRef="shares">160000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-463"
      decimals="INF"
      id="f-1284"
      unitRef="shares">150000</nbx:NumberOfSharesToWhichOptionsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-464"
      decimals="INF"
      id="f-1285"
      unitRef="benefeciary">14</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-465"
      decimals="INF"
      id="f-1286"
      unitRef="benefeciary">83</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-466"
      decimals="INF"
      id="f-1287"
      unitRef="benefeciary">49</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-467"
      decimals="INF"
      id="f-1288"
      unitRef="benefeciary">2</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-468"
      decimals="INF"
      id="f-1289"
      unitRef="benefeciary">107</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-469"
      decimals="INF"
      id="f-1290"
      unitRef="benefeciary">2</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement
      contextRef="c-470"
      decimals="INF"
      id="f-1291"
      unitRef="benefeciary">105</nbx:NumberOfBeneficiariesOfShareOptionsShareBasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-426"
      decimals="2"
      id="f-1292"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-427"
      decimals="2"
      id="f-1293"
      unitRef="eurPerShare">12.99</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-428"
      decimals="2"
      id="f-1294"
      unitRef="eurPerShare">12.99</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-429"
      decimals="2"
      id="f-1295"
      unitRef="eurPerShare">4.16</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-430"
      decimals="2"
      id="f-1296"
      unitRef="eurPerShare">4.16</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-431"
      decimals="2"
      id="f-1297"
      unitRef="eurPerShare">5.00</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-432"
      decimals="2"
      id="f-1298"
      unitRef="eurPerShare">5.81</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-433"
      decimals="2"
      id="f-1299"
      unitRef="eurPerShare">3.36</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-434"
      decimals="2"
      id="f-1300"
      unitRef="eurPerShare">2.97</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-471"
      decimals="INF"
      id="f-1301"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-472"
      decimals="INF"
      id="f-1302"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-473"
      decimals="INF"
      id="f-1303"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-474"
      decimals="INF"
      id="f-1304"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-475"
      decimals="INF"
      id="f-1305"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-476"
      decimals="INF"
      id="f-1306"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-477"
      decimals="INF"
      id="f-1307"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-478"
      decimals="INF"
      id="f-1308"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-479"
      decimals="INF"
      id="f-1309"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-471"
      decimals="INF"
      id="f-1310"
      unitRef="shares">87400</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-472"
      decimals="INF"
      id="f-1311"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-473"
      decimals="INF"
      id="f-1312"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-474"
      decimals="INF"
      id="f-1313"
      unitRef="shares">46620</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-475"
      decimals="INF"
      id="f-1314"
      unitRef="shares">30500</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-476"
      decimals="INF"
      id="f-1315"
      unitRef="shares">20000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-477"
      decimals="INF"
      id="f-1316"
      unitRef="shares">5250</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-478"
      decimals="INF"
      id="f-1317"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-479"
      decimals="INF"
      id="f-1318"
      unitRef="shares">1</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-480"
      decimals="INF"
      id="f-1319"
      unitRef="shares">340600</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-481"
      decimals="INF"
      id="f-1320"
      unitRef="shares">60000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-482"
      decimals="INF"
      id="f-1321"
      unitRef="shares">60000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-483"
      decimals="INF"
      id="f-1322"
      unitRef="shares">123780</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-484"
      decimals="INF"
      id="f-1323"
      unitRef="shares">380000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-485"
      decimals="INF"
      id="f-1324"
      unitRef="shares">318860</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-486"
      decimals="INF"
      id="f-1325"
      unitRef="shares">1219530</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-487"
      decimals="INF"
      id="f-1326"
      unitRef="shares">8000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-488"
      decimals="INF"
      id="f-1327"
      unitRef="shares">1241004</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-482"
      decimals="INF"
      id="f-1328"
      unitRef="shares">60000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-484"
      decimals="INF"
      id="f-1329"
      unitRef="shares">380000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-485"
      decimals="INF"
      id="f-1330"
      unitRef="shares">106288</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-486"
      decimals="INF"
      id="f-1331"
      unitRef="shares">406510</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-487"
      decimals="INF"
      id="f-1332"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-488"
      decimals="INF"
      id="f-1333"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-480"
      decimals="INF"
      id="f-1334"
      unitRef="shares">340600</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-481"
      decimals="INF"
      id="f-1335"
      unitRef="shares">60000</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-482"
      decimals="INF"
      id="f-1336"
      unitRef="shares">60000</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-483"
      decimals="INF"
      id="f-1337"
      unitRef="shares">123780</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-484"
      decimals="INF"
      id="f-1338"
      unitRef="shares">380000</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-485"
      decimals="INF"
      id="f-1339"
      unitRef="shares">318860</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-486"
      decimals="INF"
      id="f-1340"
      unitRef="shares">1219530</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-487"
      decimals="INF"
      id="f-1341"
      unitRef="shares">8000</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-488"
      decimals="INF"
      id="f-1342"
      unitRef="shares">1241004</nbx:MaximumNumberOfShareOptionsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-489"
      decimals="INF"
      id="f-1343"
      unitRef="shares">1200000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement
      contextRef="c-490"
      decimals="INF"
      id="f-1344"
      unitRef="shares">1200000</nbx:NumberOfOtherEquityInstrumentsAuthorisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-489"
      decimals="INF"
      id="f-1345"
      unitRef="shares">427110</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-490"
      decimals="INF"
      id="f-1346"
      unitRef="shares">439210</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-489"
      decimals="INF"
      id="f-1347"
      unitRef="shares">427110</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-490"
      decimals="INF"
      id="f-1348"
      unitRef="shares">439210</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-491"
      decimals="INF"
      id="f-1349"
      unitRef="shares">298860</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-492"
      decimals="INF"
      id="f-1350"
      unitRef="shares">293470</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-493"
      decimals="INF"
      id="f-1351"
      unitRef="shares">200116</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-494"
      decimals="INF"
      id="f-1352"
      unitRef="shares">200116</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-495"
      decimals="INF"
      id="f-1353"
      unitRef="shares">33354</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-496"
      decimals="INF"
      id="f-1354"
      unitRef="shares">33354</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-497"
      decimals="INF"
      id="f-1355"
      unitRef="shares">65390</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement
      contextRef="c-498"
      decimals="INF"
      id="f-1356"
      unitRef="shares">65390</nbx:NumberOfSharesToWhichOtherEquityInstrumentsWereLikelyToGiveRightInShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-499"
      decimals="INF"
      id="f-1357"
      unitRef="benefeciary">88</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement
      contextRef="c-500"
      decimals="INF"
      id="f-1358"
      unitRef="benefeciary">87</nbx:NumberOfBeneficiariesOfOtherEquityInstrumentsShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-501"
      decimals="INF"
      id="f-1359"
      unitRef="shares">392060</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-502"
      decimals="INF"
      id="f-1360"
      unitRef="shares">417760</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-501"
      decimals="INF"
      id="f-1361"
      unitRef="shares">35050</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-502"
      decimals="INF"
      id="f-1362"
      unitRef="shares">21450</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-503"
      decimals="INF"
      id="f-1363"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-504"
      decimals="INF"
      id="f-1364"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-503"
      decimals="INF"
      id="f-1365"
      unitRef="shares">0</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement
      contextRef="c-504"
      decimals="INF"
      id="f-1366"
      unitRef="shares">0</nbx:MaximumNumberOfOtherEquityInstrumentsThatMayBeSubscribedInShareBasedPaymentArrangement>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod contextRef="c-489" id="f-1367">P1Y</nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod contextRef="c-490" id="f-1368">P1Y</nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-505"
      decimals="INF"
      id="f-1369"
      unitRef="shares">371967</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-506"
      decimals="INF"
      id="f-1370"
      unitRef="shares">56251</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-507"
      decimals="INF"
      id="f-1371"
      unitRef="shares">4730663</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-2"
      decimals="INF"
      id="f-1372"
      unitRef="shares">5158881</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory contextRef="c-1" id="f-1373">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As of June&#160;30, 2025, the details of active share-based payment plans with remaining IFRS 2 expense are presented in the tables below, reflecting the assumptions related to the probability that the non-market performance conditions will be  and the ongoing accounting impact for the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.823%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.770%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the first half of 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the first half of 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2023 - P1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3% / 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2023 - P2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3% /3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.781%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,161&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.781%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;708&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,232&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,940&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c-1" id="f-1374">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.984%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.008%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.308%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the first half of 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the first half of 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-04 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38.9% - 37.8% - 38.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.38% / 0.33% / 0.28%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-04 P&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.03&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-06 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.2% - 37.9% - 38.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.35% / 0.30% / 0.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-06 P&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2022-06 P &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.4008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.0228&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2022-06 O &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;42.06% - 41.21% - 40.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.83% / 1.87% / 1.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2023-01 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;45.07% - 44.11% - 43.41% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.85% /2.83% / 2.82%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2024-01 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;53.30% - 51.90% - 50.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.4 / 5.9 / 6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.00% / 3.02% / 3.02%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2025-01 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;47.18% / 47.43% / 47.57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.4 / 5.9 / 6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.83% / 2.91% / 2.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2025-02 O&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;47.56% / 47.32% / 47.43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.4 / 5.9 / 6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.53% / 2.61% / 2.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;n.a. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;708&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.781%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,161&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.500%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.781%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;708&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,232&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,940&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-397"
      decimals="2"
      id="f-1375"
      unitRef="eurPerShare">13.60</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-397"
      decimals="2"
      id="f-1376"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-508"
      decimals="3"
      id="f-1377"
      unitRef="number">0.389</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-509"
      decimals="3"
      id="f-1378"
      unitRef="number">0.378</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-510"
      decimals="3"
      id="f-1379"
      unitRef="number">0.383</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-511" decimals="1" id="f-1380" unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-512" decimals="1" id="f-1381" unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-513" decimals="1" id="f-1382" unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-508"
      decimals="4"
      id="f-1383"
      unitRef="number">0.0038</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-509"
      decimals="4"
      id="f-1384"
      unitRef="number">0.0033</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-510"
      decimals="4"
      id="f-1385"
      unitRef="number">0.0028</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c-397"
      decimals="4"
      id="f-1386"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-397" decimals="-3" id="f-1387" unitRef="eur">684000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-514" decimals="-3" id="f-1388" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-515" decimals="-3" id="f-1389" unitRef="eur">-4000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-426"
      decimals="2"
      id="f-1390"
      unitRef="eurPerShare">13.60</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-426"
      decimals="2"
      id="f-1391"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-426"
      decimals="4"
      id="f-1392"
      unitRef="number">0.3910</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-426" decimals="1" id="f-1393" unitRef="y">10000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-426"
      decimals="4"
      id="f-1394"
      unitRef="number">0.0003</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c-426"
      decimals="4"
      id="f-1395"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-426" decimals="-3" id="f-1396" unitRef="eur">1816000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-516" decimals="-3" id="f-1397" unitRef="eur">48000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-517" decimals="-3" id="f-1398" unitRef="eur">77000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-428"
      decimals="2"
      id="f-1399"
      unitRef="eurPerShare">12.20</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-428"
      decimals="2"
      id="f-1400"
      unitRef="eurPerShare">12.99</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-518"
      decimals="3"
      id="f-1401"
      unitRef="number">0.392</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-519"
      decimals="3"
      id="f-1402"
      unitRef="number">0.379</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-520"
      decimals="3"
      id="f-1403"
      unitRef="number">0.381</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-521" decimals="1" id="f-1404" unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-522" decimals="1" id="f-1405" unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-523" decimals="1" id="f-1406" unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-518"
      decimals="4"
      id="f-1407"
      unitRef="number">0.0035</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-519"
      decimals="4"
      id="f-1408"
      unitRef="number">0.0030</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-520"
      decimals="4"
      id="f-1409"
      unitRef="number">0.0026</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c-428"
      decimals="4"
      id="f-1410"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-428" decimals="-3" id="f-1411" unitRef="eur">246000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-524" id="f-1412" unitRef="eur" xsi:nil="true"/>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-525" decimals="-3" id="f-1413" unitRef="eur">13000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-427"
      decimals="2"
      id="f-1414"
      unitRef="eurPerShare">12.20</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-427"
      decimals="2"
      id="f-1415"
      unitRef="eurPerShare">12.99</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-427"
      decimals="4"
      id="f-1416"
      unitRef="number">0.3910</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-427" decimals="1" id="f-1417" unitRef="y">10000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-427"
      decimals="4"
      id="f-1418"
      unitRef="number">0.0013</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c-427"
      decimals="4"
      id="f-1419"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-427" decimals="-3" id="f-1420" unitRef="eur">212000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-526" decimals="-3" id="f-1421" unitRef="eur">12000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-527" decimals="-3" id="f-1422" unitRef="eur">12000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-429"
      decimals="2"
      id="f-1423"
      unitRef="eurPerShare">3.68</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-429"
      decimals="2"
      id="f-1424"
      unitRef="eurPerShare">4.16</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-429"
      decimals="4"
      id="f-1425"
      unitRef="number">0.4008</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-429" decimals="1" id="f-1426" unitRef="y">10</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-429"
      decimals="4"
      id="f-1427"
      unitRef="number">0.0228</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c-429"
      decimals="4"
      id="f-1428"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-429" decimals="-3" id="f-1429" unitRef="eur">71000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-528" decimals="-3" id="f-1430" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-529" decimals="-3" id="f-1431" unitRef="eur">2000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-430"
      decimals="2"
      id="f-1432"
      unitRef="eurPerShare">3.68</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-430"
      decimals="2"
      id="f-1433"
      unitRef="eurPerShare">4.16</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-530"
      decimals="4"
      id="f-1434"
      unitRef="number">0.4206</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-531"
      decimals="4"
      id="f-1435"
      unitRef="number">0.4121</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-532"
      decimals="4"
      id="f-1436"
      unitRef="number">0.4065</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-533" decimals="1" id="f-1437" unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-534" decimals="1" id="f-1438" unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-535" decimals="1" id="f-1439" unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-530"
      decimals="4"
      id="f-1440"
      unitRef="number">0.0183</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-531"
      decimals="4"
      id="f-1441"
      unitRef="number">0.0187</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-532"
      decimals="4"
      id="f-1442"
      unitRef="number">0.0190</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c-430"
      decimals="4"
      id="f-1443"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-430" decimals="-3" id="f-1444" unitRef="eur">580000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-536" decimals="-3" id="f-1445" unitRef="eur">23000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-537" decimals="-3" id="f-1446" unitRef="eur">57000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-538"
      decimals="2"
      id="f-1447"
      unitRef="eurPerShare">6.75</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-538"
      decimals="2"
      id="f-1448"
      unitRef="eurPerShare">5.00</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-539"
      decimals="4"
      id="f-1449"
      unitRef="number">0.4507</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-540"
      decimals="4"
      id="f-1450"
      unitRef="number">0.4411</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-541"
      decimals="4"
      id="f-1451"
      unitRef="number">0.4341</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-542" decimals="1" id="f-1452" unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-543" decimals="1" id="f-1453" unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-544" decimals="1" id="f-1454" unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-539"
      decimals="4"
      id="f-1455"
      unitRef="number">0.0285</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-540"
      decimals="4"
      id="f-1456"
      unitRef="number">0.0283</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-541"
      decimals="4"
      id="f-1457"
      unitRef="number">0.0282</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c-538"
      decimals="4"
      id="f-1458"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-538" decimals="-3" id="f-1459" unitRef="eur">1255000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-545" decimals="-3" id="f-1460" unitRef="eur">164000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-546" decimals="-3" id="f-1461" unitRef="eur">357000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-547"
      decimals="2"
      id="f-1462"
      unitRef="eurPerShare">5.19</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-547"
      decimals="2"
      id="f-1463"
      unitRef="eurPerShare">5.81</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-548"
      decimals="4"
      id="f-1464"
      unitRef="number">0.5330</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-549"
      decimals="4"
      id="f-1465"
      unitRef="number">0.5190</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-550"
      decimals="4"
      id="f-1466"
      unitRef="number">0.5070</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-551" decimals="1" id="f-1467" unitRef="y">5.4</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-552" decimals="1" id="f-1468" unitRef="y">5.9</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-553" decimals="1" id="f-1469" unitRef="y">6.4</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-548"
      decimals="4"
      id="f-1470"
      unitRef="number">0.0300</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-549"
      decimals="4"
      id="f-1471"
      unitRef="number">0.0302</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-550"
      decimals="4"
      id="f-1472"
      unitRef="number">0.0302</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c-547"
      decimals="4"
      id="f-1473"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-547" decimals="-3" id="f-1474" unitRef="eur">3107000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-554" decimals="-3" id="f-1475" unitRef="eur">837000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-555" decimals="-3" id="f-1476" unitRef="eur">194000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-556"
      decimals="2"
      id="f-1477"
      unitRef="eurPerShare">3.65</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-556"
      decimals="2"
      id="f-1478"
      unitRef="eurPerShare">3.36</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-557"
      decimals="4"
      id="f-1479"
      unitRef="number">0.4718</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-558"
      decimals="4"
      id="f-1480"
      unitRef="number">0.4743</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-559"
      decimals="4"
      id="f-1481"
      unitRef="number">0.4757</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-557" decimals="1" id="f-1482" unitRef="y">5.4</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-558" decimals="1" id="f-1483" unitRef="y">5.9</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-559" decimals="1" id="f-1484" unitRef="y">6.4</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-557"
      decimals="4"
      id="f-1485"
      unitRef="number">0.0283</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-558"
      decimals="4"
      id="f-1486"
      unitRef="number">0.0291</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-559"
      decimals="4"
      id="f-1487"
      unitRef="number">0.0298</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c-556"
      decimals="4"
      id="f-1488"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-556" decimals="-3" id="f-1489" unitRef="eur">15000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-556" decimals="-3" id="f-1490" unitRef="eur">3000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-560" decimals="-3" id="f-1491" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-561"
      decimals="2"
      id="f-1492"
      unitRef="eurPerShare">3.74</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-561"
      decimals="2"
      id="f-1493"
      unitRef="eurPerShare">2.97</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-562"
      decimals="4"
      id="f-1494"
      unitRef="number">0.4756</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-563"
      decimals="4"
      id="f-1495"
      unitRef="number">0.4732</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-564"
      decimals="4"
      id="f-1496"
      unitRef="number">0.4743</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-562" decimals="1" id="f-1497" unitRef="y">5.4</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-563" decimals="1" id="f-1498" unitRef="y">5.9</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-564" decimals="1" id="f-1499" unitRef="y">6.4</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-562"
      decimals="4"
      id="f-1500"
      unitRef="number">0.0253</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-563"
      decimals="4"
      id="f-1501"
      unitRef="number">0.0261</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-564"
      decimals="4"
      id="f-1502"
      unitRef="number">0.0270</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c-561"
      decimals="4"
      id="f-1503"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-561" decimals="-3" id="f-1504" unitRef="eur">2523000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-561" decimals="-3" id="f-1505" unitRef="eur">186000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-565" decimals="-3" id="f-1506" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-566" decimals="-3" id="f-1507" unitRef="eur">1273000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-567" decimals="-3" id="f-1508" unitRef="eur">708000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="c-568"
      decimals="2"
      id="f-1509"
      unitRef="eurPerShare">4.87</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="c-568"
      decimals="2"
      id="f-1510"
      unitRef="eurPerShare">0.00</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="c-569"
      decimals="2"
      id="f-1511"
      unitRef="number">0.03</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="c-570"
      decimals="3"
      id="f-1512"
      unitRef="number">0.032</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="c-568"
      decimals="4"
      id="f-1513"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-568" decimals="-3" id="f-1514" unitRef="eur">2071000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-571" decimals="-3" id="f-1515" unitRef="eur">446000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-572" decimals="-3" id="f-1516" unitRef="eur">472000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="c-573"
      decimals="2"
      id="f-1517"
      unitRef="eurPerShare">4.87</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="c-573"
      decimals="2"
      id="f-1518"
      unitRef="eurPerShare">0</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="c-574"
      decimals="2"
      id="f-1519"
      unitRef="number">0.03</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="c-575"
      decimals="3"
      id="f-1520"
      unitRef="number">0.032</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="c-573"
      decimals="4"
      id="f-1521"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan contextRef="c-573" decimals="-3" id="f-1522" unitRef="eur">2130000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-576" decimals="-3" id="f-1523" unitRef="eur">442000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-577" decimals="-3" id="f-1524" unitRef="eur">507000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-578" decimals="-3" id="f-1525" unitRef="eur">888000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-579" decimals="-3" id="f-1526" unitRef="eur">1232000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-580" decimals="-3" id="f-1527" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-581" decimals="-3" id="f-1528" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-566" decimals="-3" id="f-1529" unitRef="eur">1273000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-578" decimals="-3" id="f-1530" unitRef="eur">888000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-1" decimals="-3" id="f-1531" unitRef="eur">2161000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-582" decimals="-3" id="f-1532" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-583" decimals="-3" id="f-1533" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-567" decimals="-3" id="f-1534" unitRef="eur">708000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-579" decimals="-3" id="f-1535" unitRef="eur">1232000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-4" decimals="-3" id="f-1536" unitRef="eur">1940000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c-1" id="f-1537">Net financial income (loss)&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the six month period ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income from cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign exchange gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,386&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net impact of accretion, discounting and catch-up on EIB loan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease debt interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net financial income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,924&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;For the six month period ended June 30, 2025, the &#x20ac;0.6&#160;million income  from cash and cash equivalents was related to short-term deposits compared to &#x20ac;1.5&#160;million for the six month period ended June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interests costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the six month period ended June 30, 2025, total interest costs amount to &#x20ac;4.2&#160;million, mainly due to interest costs on the EIB loan (see Note 13 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;) which consists of fixed and variable rate interests of &#x20ac;4.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the six month period ended June 30, 2024, total interest costs amount to &#x20ac;3.8&#160;million, mainly due to interest costs on the EIB loan which consists of fixed and variable rate interests of &#x20ac;3.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net impact of accretion and discounting and catch-up on EIB loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the six month period ended June 30, 2025, the P&amp;amp;L net positive impact of accretion and discounting on EIB loan of &#x20ac;1.0&#160;million corresponding to (i) the decrease in estimated debt outflows beyond 2024 - before discounting effect - resulting in a &#x20ac;2.4&#160;million positive P&amp;amp;L effect, (ii) partially offset by -&#x20ac;1.4&#160;million of discounting negative effect (See Note 13 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Liabilitie&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;s).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the six month period ended June 30, 2024, the P&amp;amp;L net positive impact of accretion and discounting on EIB loan of &#x20ac;2.7&#160;million corresponding to &#x20ac;13.5&#160;million discounting positive effect, partially offset by the increase in estimated debt outflows beyond 2023 - before discounting effect - resulting in a &#x20ac;10.8&#160;million negative P&amp;amp;L effect, due to the revised forecasts of net sales and the revised forecasts of the upfront and milestone payments related to the consideration of the license agreement signed with Janssen signed on July 7, 2023. (See Note 13 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"&gt;Foreign exchange gains and losses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;For the six month period ended June 30, 2025, the company incurred net foreign exchange exchange loss of &#x20ac;3.6&#160;million, mainly related to the EUR conversion impact on short term USD deposits for &#x20ac;3.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;For the six month period ended June 30, 2024, the Company incurred net foreign exchange gains of &#x20ac;1.6&#160;million mainly related to the short term USD deposits for &#x20ac;1.1 million, and to the appreciation of the USD on HSBC bank current account denominated in U.S. dollars for &#x20ac;0.5 million.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock contextRef="c-1" id="f-1538">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the six month period ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income from cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign exchange gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,386&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net impact of accretion, discounting and catch-up on EIB loan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease debt interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net financial income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,924&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock>
    <ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks contextRef="c-1" decimals="-3" id="f-1539" unitRef="eur">598000</ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks>
    <ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks contextRef="c-4" decimals="-3" id="f-1540" unitRef="eur">1499000</ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks>
    <ifrs-full:NetForeignExchangeGain contextRef="c-1" decimals="-3" id="f-1541" unitRef="eur">47000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain contextRef="c-4" decimals="-3" id="f-1542" unitRef="eur">1888000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-3" id="f-1543" unitRef="eur">645000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-3" id="f-1544" unitRef="eur">3386000</ifrs-full:FinanceIncome>
    <ifrs-full:InterestExpense contextRef="c-1" decimals="-3" id="f-1545" unitRef="eur">4174000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="c-4" decimals="-3" id="f-1546" unitRef="eur">3772000</ifrs-full:InterestExpense>
    <nbx:DebtAccretionAndDiscountingImpact contextRef="c-1" decimals="-3" id="f-1547" unitRef="eur">-1036000</nbx:DebtAccretionAndDiscountingImpact>
    <nbx:DebtAccretionAndDiscountingImpact contextRef="c-4" decimals="-3" id="f-1548" unitRef="eur">-2722000</nbx:DebtAccretionAndDiscountingImpact>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-3" id="f-1549" unitRef="eur">69000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-4" decimals="-3" id="f-1550" unitRef="eur">89000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:NetForeignExchangeLoss contextRef="c-1" decimals="-3" id="f-1551" unitRef="eur">3624000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss contextRef="c-4" decimals="-3" id="f-1552" unitRef="eur">324000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-1553" unitRef="eur">6831000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-3" id="f-1554" unitRef="eur">1463000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost contextRef="c-1" decimals="-3" id="f-1555" unitRef="eur">-6186000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-4" decimals="-3" id="f-1556" unitRef="eur">1924000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-1" decimals="-5" id="f-1557" unitRef="eur">600000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-4" decimals="-5" id="f-1558" unitRef="eur">1500000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestExpense contextRef="c-1" decimals="-5" id="f-1559" unitRef="eur">4200000</ifrs-full:InterestExpense>
    <ifrs-full:InterestRevenueExpense contextRef="c-584" decimals="-5" id="f-1560" unitRef="eur">-4100000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestExpense contextRef="c-4" decimals="-5" id="f-1561" unitRef="eur">3800000</ifrs-full:InterestExpense>
    <ifrs-full:InterestRevenueExpense contextRef="c-585" decimals="-5" id="f-1562" unitRef="eur">-3700000</ifrs-full:InterestRevenueExpense>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities contextRef="c-151" decimals="-5" id="f-1563" unitRef="eur">1000000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows contextRef="c-151" decimals="-5" id="f-1564" unitRef="eur">2400000</nbx:AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows>
    <nbx:IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections contextRef="c-151" decimals="-5" id="f-1565" unitRef="eur">1400000</nbx:IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities contextRef="c-586" decimals="-5" id="f-1566" unitRef="eur">2700000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections contextRef="c-586" decimals="-5" id="f-1567" unitRef="eur">13500000</nbx:IncreaseDecreaseRelatedToAdjustmentsForIncomeForecastProjections>
    <nbx:AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows contextRef="c-586" decimals="-5" id="f-1568" unitRef="eur">10800000</nbx:AdjustmentToDebtFinancingRelatedToEstimatedDebtOutflows>
    <ifrs-full:NetForeignExchangeLoss contextRef="c-587" decimals="-5" id="f-1569" unitRef="eur">3600000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-588" decimals="-5" id="f-1570" unitRef="eur">3500000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:NetForeignExchangeGain contextRef="c-589" decimals="-5" id="f-1571" unitRef="eur">1600000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-590" decimals="-5" id="f-1572" unitRef="eur">1100000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-591" decimals="-5" id="f-1573" unitRef="eur">500000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c-1" id="f-1574">Segment reporting&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 8 &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Segments&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, reporting by operating segment is derived from the internal organization of the Company&#x2019;s activities; it reflects management&#x2019;s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company&#x2019;s Chairman and the members of the Executive and Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;cancer treatment. The positive net revenue, as disclosed in the &#x2018;Note 16 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue and other Income&lt;/span&gt;&#x2019;, is primarily recognized by the Company towards one principal customer, Janssen, located in Belgium. The assets, liabilities and operating loss realized are primarily located in France.</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c-1" id="f-1575">Loss per share &lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the six month period ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss for the period (in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(21,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47,418,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47,124,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Basic loss per share (in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(0.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Diluted loss per share (in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(0.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Instruments providing deferred access to the capital (stock options, founders' warrants and warrants) are considered to be anti-dilutive because they result in a decrease in the loss per share. Therefore, diluted loss per share is identical to basic loss per share as all equity instruments issued, representing a total of 5,158,881 potential additional ordinary shares, have been considered antidilutive.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c-1" id="f-1576">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the six month period ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss for the period (in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(21,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47,418,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47,124,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Basic loss per share (in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(0.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Diluted loss per share (in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(0.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-3" id="f-1577" unitRef="eur">-5383000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-4" decimals="-3" id="f-1578" unitRef="eur">-21872000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-1579" unitRef="shares">47418155</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-4" decimals="0" id="f-1580" unitRef="shares">47124112</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-1581"
      unitRef="eurPerShare">-0.11</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-1582"
      unitRef="eurPerShare">-0.46</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-1583"
      unitRef="eurPerShare">-0.11</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-1584"
      unitRef="eurPerShare">-0.46</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented contextRef="c-1" decimals="0" id="f-1585" unitRef="shares">5158881</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ifrs-full:DisclosureOfCommitmentsExplanatory contextRef="c-1" id="f-1586">Commitments &lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The off-balance sheet commitments have not changed significantly since December, 31, 2024, except for the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Commitments related to the master services agreement with Janssen dedicated to the clinical manufacturing of JNJ-1900 (NBTXR3)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On December 22, 2023, the Company entered into a master services agreement (&#x201c;MSA&#x201d;) with Janssen which includes the clinical manufacturing and the supply of products to be provided by the Company, as well as technical expertise and development services in the field of the territory, as defined in the global  licensing, co-development, and commercialization agreement signed in July 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under this MSA, the Company already received as of June 30, 2025 purchase orders from Janssen (a) for the delivery of raw materials and JNJ-1900 (NBTXR3) clinical and technical batches planned to be delivered during the second half of 2025 amounting to &#x20ac;6.1&#160;million and (b) for the technology transfer and related technical assistance services amounting to &#x20ac;0.2&#160;million.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <ifrs-full:CurrentTradeReceivables contextRef="c-592" decimals="-5" id="f-1587" unitRef="eur">6100000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-593" decimals="-5" id="f-1588" unitRef="eur">200000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c-1" id="f-1589">Related parties &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Key management personnel compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the six-month period ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Salaries, wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Supervisory Board&#x2019;s fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total compensation to related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,722&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The methods used to measure share-based payments are presented in Note 18 -&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-based payments &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;of the Company&#x2019;s consolidated financial statements as of and for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related parties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of June 30, 2025, Johnson &amp;amp; Johnson Innovation &#x2013; JJDC, an affiliate of Janssen, beneficially owns approximately 11.66% of the outstanding ordinary shares of Nanobiotix. Nanobiotix and Janssen are parties to the Janssen Agreement, the &#x201c;TSA&#x201d; and the &#x201c;AAA&#x201d;, each as described in the consolidated financial statements prepared for the year ended December 31, 2024). Accordingly Janssen may be considered a related party of Nanobiotix.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;For the six month period ended June 30, 2025, the Company continued to support Janssen in execution of NANORAY-312 clinical study during the transition process and following the sponsorship transfer and conducted transactions with Janssen (see Note 16 - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"&gt;Revenues and other income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;). The payments between the two companies as well as the liabilities and receivables are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets/(Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Collection (Janssen towards Nanobiotix SA) / Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payments (Nanobiotix SA towards Janssen) / Payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-1590">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.197%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the six-month period ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Salaries, wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Supervisory Board&#x2019;s fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total compensation to related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,722&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The payments between the two companies as well as the liabilities and receivables are as follows:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets/(Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Collection (Janssen towards Nanobiotix SA) / Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payments (Nanobiotix SA towards Janssen) / Payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-1" decimals="-3" id="f-1591" unitRef="eur">1159000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-4" decimals="-3" id="f-1592" unitRef="eur">1120000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-1" decimals="-3" id="f-1593" unitRef="eur">1723000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-4" decimals="-3" id="f-1594" unitRef="eur">1517000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:DirectorsRemunerationExpense contextRef="c-1" decimals="-3" id="f-1595" unitRef="eur">212000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense contextRef="c-4" decimals="-3" id="f-1596" unitRef="eur">86000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-1" decimals="-3" id="f-1597" unitRef="eur">3094000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-4" decimals="-3" id="f-1598" unitRef="eur">2722000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="c-594"
      decimals="4"
      id="f-1599"
      unitRef="number">0.1166</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties contextRef="c-1" decimals="-3" id="f-1600" unitRef="eur">7387000</ifrs-full:CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-2" decimals="-3" id="f-1601" unitRef="eur">1837000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties contextRef="c-1" decimals="-3" id="f-1602" unitRef="eur">0</ifrs-full:CashAdvancesAndLoansMadeToRelatedParties>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-2" decimals="-3" id="f-1603" unitRef="eur">7905000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <nbx:NetCollectionsPaymentsFromRelatedParty contextRef="c-1" decimals="-3" id="f-1604" unitRef="eur">7387000</nbx:NetCollectionsPaymentsFromRelatedParty>
    <nbx:NetAmountsReceivablePayableRelatedPartyTransactions contextRef="c-2" decimals="-3" id="f-1605" unitRef="eur">-6068000</nbx:NetAmountsReceivablePayableRelatedPartyTransactions>
    <ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-1606">Subsequent events &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
